PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Burfoot, MS; Rogers, NC; Watling, D; Smith, JM; Pons, S; Paonessaw, G; Pellegrini, S; White, MF; Kerr, IM				Burfoot, MS; Rogers, NC; Watling, D; Smith, JM; Pons, S; Paonessaw, G; Pellegrini, S; White, MF; Kerr, IM			Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; SIGNAL-TRANSDUCTION PATHWAY; STIMULATED GENE FACTOR-3; GROWTH-FACTOR-I; TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; GAMMA RECEPTOR; JAK KINASES; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING	In addition to a role in response to insulin and insulinlike growth factors, insulin receptor substrate 1 (IRS-1) is phosphorylated in response to IL-4, the interferons (IFNs) and oncostatin M (OSM). Here mutant cell lines lacking JAK1, JAK2, or Tyk2 were used to determine the role(s) of the Janus kinase (JAK) family of protein-tyrosine kinases in IRS-1 phophorylation. 32D cells, which do not express IRS proteins, were analyzed for any requirement for these proteins in response to the IFNs. For the mutant human fibrosarcoma cell lines, phospho rylation of IRS-1 through the insulin-like growth factor receptor is independent of JAK1, JAK2, or Tyk2. In contrast, phosphorylation of IRS-1 mediated by the Type I IFNs, IL-4, and OSM is JAK-dependent. For the alpha beta-IFNs, activation of IRS-1 is dependent on JAK1 and Tyk2, consistent with the interdependence of these kinases in the IFN-alpha beta response. Neither IRS-1 nor IRS-2 was detectably activated by IFN-gamma. Consistent with this, activation of neither IRS proteins appears to be an absolute requirement for an antiproliferative or an antiviral response to the IFNs. For IL-4 and OSM phosphorylation of IRS-1 in the human fibrosarcoma cells is largely dependent on JAK1 but can also be mediated through Tyk2 or JAK2. Activation of phosphatidylinositol 3'-kinase in response to IL-4 and OSM, at least, was also JAK-dependent. The JAKs are, therefore, required not only for STAT activation but also for the activation through a variety of different types of cytokine receptor, of an additional signaling pathway(s) through IRS-1 and phosphatidylinositol S'-kinase.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; IRBM,I-00040 POMEZIA,ROMA,ITALY; INST PASTEUR,UNITE INSERM 276,F-75724 PARIS 15,FRANCE	Cancer Research UK; Harvard University; Joslin Diabetes Center, Inc.; Merck & Company; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Pellegrini, Sandra -/G-5546-2015; Pellegrini, Sandra/Y-6351-2019; PONS, SEBASTIAN/K-7794-2014	Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; Rogers, Neil/0000-0001-8977-7585; PONS, SEBASTIAN/0000-0003-1027-0621				AGUET G, 1988, CELL, V56, P273; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PAUL WE, 1991, BLOOD, V77, P1859; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PONS S, 1995, MOL CELL BIOL, V15, P4453; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schnyder B, 1996, BIOCHEM J, V315, P767, DOI 10.1042/bj3150767; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang HY, 1997, J IMMUNOL, V158, P1037; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	62	103	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24183	24190		10.1074/jbc.272.39.24183	http://dx.doi.org/10.1074/jbc.272.39.24183			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305869	hybrid			2022-12-25	WOS:A1997XY51500020
J	ElHadri, K; Courtalon, A; Gauthereau, X; ChambautGuerin, AM; Pairault, J; Feve, B				ElHadri, K; Courtalon, A; Gauthereau, X; ChambautGuerin, AM; Pairault, J; Feve, B			Differential regulation by tumor necrosis factor-alpha of beta(1)-, beta(2)-, and beta(3)-adrenoreceptor gene expression in 3T3-F442A adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; TYROSINE KINASE-ACTIVITY; MESSENGER-RNA CONTENT; ADIPOSE-TISSUE; 3T3-L1 CELLS; BETA-3-ADRENERGIC RECEPTOR; LIPOPROTEIN-LIPASE; BETA(3)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; GLYCEROPHOSPHATE DEHYDROGENASE	Modulation of beta-adrenoreceptor expression by tumor necrosis factor-alpha (TNF-alpha) was investigated in murine 3T3-F442A adipocytes. TNF-alpha treatment of mature adipocytes decreased beta(3)-adrenoreceptor mRNA content in a time-and concentration-dependent manner, with a 8.5-fold decrease observed after a 6-h exposure to 300 pM TNF-alpha. beta(1)-Adrenoreceptor mRNA abundance was slightly decreased by TNF-alpha treatment, while beta(2)-adrenoreceptor mRNA levels were potently induced (6-fold increase at 6 h), (-)-[I-125]Iodocyanopindolol saturation and competition binding experiments indicated that TNF-alpha induced a 2-fold decrease in beta(3)-adrenoreceptor number, a nonsignificant reduction in beta(1)-subtype population, and a similar to 4.5-fold increase in beta(2)-adrenoreceptor density, This correlated with a lower EC value measured for epinephrine in stimulating adenylyl cyclase, whereas the EC50 value for norepinephrine increased. Nuclear run-on assays on isolated nuclei and mRNA stability measurements showed that TNF-alpha increased both beta(2)-adrenoreceptor gene transcription and beta(2)-adrenoreceptor mRNA half-life, while beta(1)- and beta(3)-adrenoreceptor gene expression was modulated only at the transcriptional level by the cytokine. These findings demonstrate a differential modulation by TNF-alpha of the three beta-adrenoreceptor subtypes in adipocytes, which may contribute to metabolic disorders induced by the cytokine in the adipocyte.	HOP HENRI MONDOR,INSERM UNITE 282,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)				Feve, Bruno/0000-0001-6577-9009; EL HADRI, KHADIJA/0000-0002-1275-9861				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; Barbe P, 1996, BRIT J PHARMACOL, V117, P907, DOI 10.1111/j.1476-5381.1996.tb15279.x; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLIN N, 1993, MOL PHARMACOL, V44, P1094; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Charon C, 1995, BIOCHEM J, V312, P781, DOI 10.1042/bj3120781; CHAUDHRY A, 1994, J PHARMACOL EXP THER, V271, P1253; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; ElHadri K, 1996, EUR J BIOCHEM, V239, P519; ElHadri K, 1996, EUR J PHARMACOL, V297, P107, DOI 10.1016/0014-2999(95)00723-7; ENOCKSSON S, 1995, J CLIN INVEST, V95, P2239, DOI 10.1172/JCI117914; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1992, J BIOL CHEM, V267, P15909; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GRANNEMAN JG, 1994, ENDOCRINOLOGY, V135, P1025, DOI 10.1210/en.135.3.1025; GRANNEMAN JG, 1993, MOL PHARMACOL, V44, P264; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GRUNFELD C, 1991, TRENDS ENDOCRIN MET, V2, P213, DOI 10.1016/1043-2760(91)90027-K; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KRIEF S, 1994, J BIOL CHEM, V269, P6664; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LANG CH, 1993, AM J PHYSIOL, V264, pR984, DOI 10.1152/ajpregu.1993.264.5.R984; LIN ECC, 1960, J BIOL CHEM, V235, P1820; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053; NANTEL F, 1994, J BIOL CHEM, V269, P13148; PAIRAULT J, 1987, J CELL PHYSIOL, V132, P279, DOI 10.1002/jcp.1041320212; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; PETRUSCHKE T, 1993, J CLIN ENDOCR METAB, V76, P742, DOI 10.1210/jc.76.3.742; PRICE SR, 1986, BIOCHEM J, V240, P601, DOI 10.1042/bj2400601; REVELLI JP, 1993, J MOL ENDOCRINOL, V10, P193, DOI 10.1677/jme.0.0100193; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; STERN L, 1988, J BIOL CHEM, V263, P15876; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; WEINER FR, 1991, J BIOL CHEM, V266, P23525; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	71	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24514	24521		10.1074/jbc.272.39.24514	http://dx.doi.org/10.1074/jbc.272.39.24514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305915	hybrid			2022-12-25	WOS:A1997XY51500066
J	Masson, D; Duverger, N; Emmanuel, F; Lagrost, L				Masson, D; Duverger, N; Emmanuel, F; Lagrost, L			Differential interaction of the human cholesteryl ester transfer protein with plasma high density lipoproteins (HDLs) from humans, control mice, and transgenic mice to human HDL apolipoproteins - Lack of lipid transfer inhibitory activity in transgenic mice expressing human apoA-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; A-I; SIZE DISTRIBUTION; EXCHANGE; BINDING; ACYLTRANSFERASE; ATHEROGENESIS; TRIGLYCERIDE; METABOLISM; PARTICLES	Plasma high density lipoproteins (HDLs) from humans, from transgenic mice to human apolipoprotein A-I (HuAITg mice), from transgenic mice to human apolipoprotein A-II (HuAIITg mice), from transgenic mice to human apolipoproteins A-I and A-II (HuAIAIITg mice), and from C57BL/6 control mice were isolated, and their ability to interact with the human cholesteryl ester transfer protein (CETP) was studied, Whereas cholesteryl ester transfer rates were gradually enhanced by the addition of moderate amounts of HDL from the different sources, striking differences appeared when HDL levels kept increasing beyond a maximal transfer value. Indeed, while a plateau value corresponding to maximal CETP activity was maintained when raising the concentration of HuAITg HDL and HuAIAIITg HDL, inhibitions could be observed with the highest levels of human, control mouse, and HuAIITg mouse HDL. The concentration-dependent inhibition of CETP activity could be reproduced by the addition of delipidated HDL apolipoproteins from control mice, but it was abolished by a l-h preheating treatment at 56 degrees C, In contrast, no significant inhibition of CETP activity was observed with the delipidated protein moiety of HuAITg HDL, and cholesteryl ester transfer rates remained unchanged before and after a l-h, 56 degrees C preheating step. Finally, the CETP-mediated transfer of radiolabeled cholesteryl esters from human low density lipoprotein to human HDL was significantly higher in the presence of lipoprotein-deficient plasma from HuAITg mice than in the presence of lipoprotein-deficient plasma from control mice, Interestingly, cholesteryl ester transfer rates measured with both control and HuAITg lipoprotein deficient plasmas became remarkably similar following a 1-h, 56 degrees C preheating treatment. It is concluded that human, control mouse, and HuAIITg mouse HDL contain a heat-labile lipid transfer inhibitory activity that is absent from HDL of HuAITg and HuAIAIITg mice, Alterations in CETP-lipoprotein binding did not account for differential lipid transfer inhibitory activities.	FAC MED,INSERM CJF9310,LAB BIOCHIM LIPOPROT,F-21033 DIJON,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,GENCELL DIV,ATHEROSCLEROSIS DEPT,F-94403 VITRY SUR SEINE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Sanofi-Aventis; Sanofi France			Masson, David/R-6633-2019; MASSON, David/AAC-8896-2022; MASSON, David/R-4557-2017	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699				AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BARTER PJ, 1980, J LIPID RES, V21, P238; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V1085, P209; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BRUCE C, 1995, J BIOL CHEM, V270, P11532, DOI 10.1074/jbc.270.19.11532; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; CHAM BE, 1976, J LIPID RES, V17, P176; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; EPPS DE, 1995, BIOCHEMISTRY-US, V34, P12560, DOI 10.1021/bi00039a010; Florentin E, 1996, EUR J BIOCHEM, V240, P699, DOI 10.1111/j.1432-1033.1996.0699h.x; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; GONG EL, 1994, BBA-LIPID LIPID MET, V1213, P335, DOI 10.1016/0005-2760(94)00062-X; GUYARDDANGREMONT V, 1994, CLIN CHIM ACTA, V231, P147, DOI 10.1016/0009-8981(94)90199-6; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; IHM J, 1982, J LIPID RES, V23, P1328; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; JIANG XC, 1995, BIOCHEMISTRY-US, V34, P7258, DOI 10.1021/bi00021a042; KUSHWAHA RS, 1993, J LIPID RES, V34, P1285; LAGROST L, 1994, J BIOL CHEM, V269, P3189; Lagrost L, 1996, J BIOL CHEM, V271, P19058, DOI 10.1074/jbc.271.32.19058; LAGROST L, 1994, BBA-LIPID LIPID MET, V1215, P209, DOI 10.1016/0005-2760(94)90047-7; LAGROST L, 1991, BIOCHIM BIOPHYS ACTA, V1085, P209, DOI 10.1016/0005-2760(91)90096-Z; LAGROST L, 1994, J LIPID RES, V35, P825; Masson D, 1996, J LIPID RES, V37, P1579; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1994, J LIPID RES, V35, P836; MORTON RE, 1994, J LIPID RES, V35, P2094; MORTON RE, 1993, ARTERIOSCLER THROMB, V13, P1843, DOI 10.1161/01.ATV.13.12.1843; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MOULIN P, 1994, J LIPID RES, V35, P793; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NISHIDE T, 1989, J LIPID RES, V30, P149; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; Roy P, 1996, J LIPID RES, V37, P22; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RYE KA, 1992, J LIPID RES, V33, P215; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SON YSC, 1984, BIOCHIM BIOPHYS ACTA, V795, P473; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1989, J LIPID RES, V30, P1491; TALL AR, 1995, J INTERN MED, V237, P5, DOI 10.1111/j.1365-2796.1995.tb01133.x; TALL AR, 1993, J LIPID RES, V34, P1255; TALL AR, 1985, J BIOL CHEM, V259, P9587; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE984; TREMP GL, 1995, GENE, V156, P199, DOI 10.1016/0378-1119(95)00010-4; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	49	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24287	24293		10.1074/jbc.272.39.24287	http://dx.doi.org/10.1074/jbc.272.39.24287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305883	hybrid			2022-12-25	WOS:A1997XY51500034
J	Ng, J; Cantrell, D				Ng, J; Cantrell, D			STAT3 is a serine kinase target in T lymphocytes - Interleukin 2 and T cell antigen receptor signals converge upon serine 727	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC ANTIBODIES; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION STATE; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; ACTIVATION; TYROSINE; PROTEINS; DISTINCT	Interleukin 2 (IL-2) induces tyrosine phosphorylation of STATs 3 and 5 (signal transducer and activator of transcription). We now show that IL-2 regulation of STAT3 proteins in T cells is a complex response involving activation of two forms of STAT3: 90-kDa STAT3 alpha and an 83-kDa carboxyl-terminal truncated STAT3 beta. The phosphorylation of STAT proteins on serine residues is also required far competent STAT transcription, A critical serine phosphorylation site in STAT3 alpha is at position 727. In this study we have produced an antisera specific for STAT3 alpha proteins phosphorylated on serine 727 and used this to monitor the phosphorylation of this residue during T lymphocyte activation, Our results show that phosphorylation of STAT3 alpha on serine 727 is not constitutive in quiescent T cells but can be induced by the cytokine IL-2. Interestingly, triggering of the T cell antigen receptor complex or activation of protein kinase C with phorbol esters also induces phosphorylation of serine 727 but without simultaneously inducing STAT3 tyrosine phosphorylation or DNA binding, Hence, the present results show that STAT3 serine phosphorylation call be regulated independently of the tyrosine phosphorylation of this molecule, IL-2 and T cell antigen receptor complex induction of STAT3 alpha serine 727 phosphorylation is dependent; on the activity of the MEK/ERK pathway, Previous studies have identified H-7-sensitive kinase pathways that regulate STAT3 DNA binding, We show that H-7-sensitive pathways regulate STAT3 DNA binding in T cells. Nevertheless, we show that H-7-sensitive kinases do not regulate STAT3 tyrosine phosphorylation or phosphorylation of serine 727. These results thus show that STAT3 proteins are targets for multiple kinase pathways in T cells and can integrate signals from both cytokine receptors and antigen receptors.	IMPERIAL CANC RES FUND, LYMPHOCYTE ACTIVAT LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Ng, Julian/C-5747-2009	Ng, Julian/0000-0002-1908-4414				AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Cho SS, 1996, J IMMUNOL, V157, P4781; COGHLAN MP, 1994, BIOCHEM J, V303, P893, DOI 10.1042/bj3030893; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORI T, 1987, BLOOD, V70, P1069; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MERIDA I, 1991, J IMMUNOL, V147, P2202; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	44	129	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24542	24549		10.1074/jbc.272.39.24542	http://dx.doi.org/10.1074/jbc.272.39.24542			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305919	hybrid			2022-12-25	WOS:A1997XY51500070
J	Onions, J; Hermann, S; Grundstrom, T				Onions, J; Hermann, S; Grundstrom, T			Basic helix-loop-helix protein sequences determining differential inhibition by calmodulin and S-100 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; CALCIUM MESSENGER SYSTEM; KINASE-II; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; RAT S100-ALPHA; GENE FAMILY; MYOD FAMILY; PHOSPHORYLATION; E47	Basic helix-loop-helix (bHLH) proteins are a group of transcription factors that are involved in differentiation and numerous other cellular processes. The proteins include the widely expressed class A bHLH proteins (E proteins) and the tissue specific class E proteins. Previous studies have shown that calmodulin can inhibit the DNA binding activity of certain E proteins but not their heterodimers with class B proteins. Here we show that calmodulin binds to the DNA-interacting basic sequence within the bHLH domain of E proteins. The strength of the binding of bHLH proteins to calmodulin correlates directly with the calmodulin sensitivity of their DNA binding, The basic sequence of MyoD, a class B protein, can also interact with calmodulin. This interaction, however, is blocked by MyoD sequences directly N-terminal of the basic sequence. We further demonstrate that S-100 proteins can interact with and differentially inhibit the DNA binding of bHLH proteins through interaction with the basic sequence, Both the binding to the basic sequence and the effect of the directly N-terminal sequence vary for different 5-100 proteins and bHLH proteins, The results suggest the involvement of both calmodulin and S-100 proteins in the differential regulation of bHLH proteins.	UMEA UNIV,DEPT APPL CELL & MOL BIOL,DIV TUMOUR BIOL,S-90187 UMEA,SWEDEN	Umea University								ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BABIYCHUK EB, 1995, BIOCHEMISTRY-US, V34, P6366, DOI 10.1021/bi00019a015; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAUDIER J, 1982, FEBS LETT, V147, P165, DOI 10.1016/0014-5793(82)81033-8; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRODIN P, 1989, PROTEIN ENG, V2, P353, DOI 10.1093/protein/2.5.353; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EDMONDSON DG, 1990, GENE DEV, V4, P1450, DOI 10.1101/gad.4.8.1450; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; FARMER K, 1992, J BIOL CHEM, V267, P5631; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAIMOTO H, 1987, LAB INVEST, V57, P489; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOPAN R, 1994, DEVELOPMENT, V120, P2385; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAUE TM, 1995, P NATL ACAD SCI USA, V92, P11824, DOI 10.1073/pnas.92.25.11824; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MITSUI K, 1993, J BIOL CHEM, V268, P24415; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1094; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232; ZIMMER DB, 1987, AM J PHYSIOL, V252, pC285, DOI 10.1152/ajpcell.1987.252.3.C285; ZIMMER DB, 1991, BRAIN RES BULL, V27, P157, DOI 10.1016/0361-9230(91)90061-N	54	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23930	23937		10.1074/jbc.272.38.23930	http://dx.doi.org/10.1074/jbc.272.38.23930			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295343	hybrid			2022-12-25	WOS:A1997XX38100068
J	Vonakis, BM; Chen, HX; HaleemSmith, H; Metzger, H				Vonakis, BM; Chen, HX; HaleemSmith, H; Metzger, H			The unique domain as the site on Lyn kinase for its constitutive association with the high affinity receptor for IgE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BASOPHILIC LEUKEMIA-CELLS; ACTIVATION MOTIF ITAM; IMMUNOGLOBULIN-E; MAST-CELLS; 2-HYBRID SYSTEM; 2 FORMS; BINDING; HISTAMINE; SUBUNITS	Aggregation of the high affinity receptor for IgE (Fc epsilon RI) leads to the phosphorylation of tyrosines on the beta and gamma chains of the receptor by the Src family kinase Lyn. We have studied the interaction between Lyn and the Fc epsilon RI in vivo using a transfection-based approach. Fc epsilon RI were stably transfected into Chinese hamster ovary cells. The small amount of endogenous Src family kinase was sufficient to phosphorylate receptor tyrosines upon extensive aggregation of Fc epsilon RI but not after addition of dimers of IgE. Upon stable co-transfection of Lyn kinase into the cells, dimers were now able to stimulate receptor phosphorylation and the response to more extensive aggregation was enhanced. In contrast, co-transfection with catalytically inactive Lyn inhibited the aggregation-induced phosphorylation by the endogenous kinase, and a quantitatively similar inhibition was observed in cells transfected with the SH4-containing unique domain of Lyn. Consistent with the results of others using alternative approaches, our additional studies using a yeast two-hybrid system detected a direct interaction between intact Lyn or its unique domain and the C-terminal cytoplasmic domain of the beta chain but not with the receptor's other cytoplasmic domains.			Vonakis, BM (corresponding author), NIAMSD,ARTHRIT & RHEUMATISM BRANCH,NIH,BLDG 10-RM 9N-258,10 CTR DR MSC 1520,BETHESDA,MD 20892, USA.			Vonakis, Becky/0000-0003-4174-6514				ALBER G, 1992, J IMMUNOL, V149, P2428; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BAZIN H, 1974, IMMUNOLOGY, V26, P713; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; EISEMAN E, 1992, NATURE, V355, P78; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; LIU FT, 1980, J IMMUNOL, V124, P2728; MATTHYSSENS GE, 1975, MOL CELL BIOCHEM, V7, P119, DOI 10.1007/BF01792078; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RIDER LG, 1994, GENE, V138, P219, DOI 10.1016/0378-1119(94)90811-7; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SUMMERS MD, 1988, TEX AGR EXPT STN B, V1555; TAUROG JD, 1977, J IMMUNOL, V119, P1757; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	39	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24072	24080		10.1074/jbc.272.38.24072	http://dx.doi.org/10.1074/jbc.272.38.24072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295361	hybrid			2022-12-25	WOS:A1997XX38100086
J	Makino, Y; Yamano, K; Kanemaki, M; Morikawa, K; Kishimoto, T; Shimbara, N; Tanaka, K; Tamura, T				Makino, Y; Yamano, K; Kanemaki, M; Morikawa, K; Kishimoto, T; Shimbara, N; Tanaka, K; Tamura, T			SUG1, a component of the 26 S proteasome, is an ATPase stimulated by specific RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE; BINDING PROTEIN; HELICASE ACTIVITY; YEAST; DEGRADATION; EXPRESSION; UBIQUITIN; POLYMERASE; COMPLEX; CLONING	SUG1 is an integral component of the 26 S proteasome, Belonging to a novel putative ATPase family, it shares four conserved motifs characteristic of ATP-dependent DNA/RNA helicases, Recombinant rat SUG1 (rSUG1) produced in Escherichia coli was highly purified and characterized in terms of its biochemical properties. The rSUG1 exhibited a Mg2+-dependent ATPase activity. The K-m for ATP and V-max of rSUG1 were 35 mu M and 7 pmol of ATP/min/mu g of protein, respectively. Both ATPase activity to release [P-32]monophosphate and [P-32]ATP-labeling activity were coordinately affected by cold ATP severely, GTP and UTP moderately, and CTP little, Interestingly, the rSUG1 ATPase activity was stimulated by poly(U) and poly(C), but not by poly(A), poly(G), or by any forms of DNAs tested. A UV crosslinking assay also indicated poly(U)- and poly(C)-stimulated labeling of rSUG1 with [alpha-P-32]ATP. Moreover, the ATPase activity was facilitated by cellular poly(A)(+) RNA, but not by poly(A)(-) RNA. RNA transcribed in vitro from cDNA encoding a b-Zip protein could stimulate the ATPase activity, This is the first report to demonstrate a specific RNA requirement for ATPase with respect to the proteasomal ATPases. Our present work suggests that SUG1 can specifically interact with protein-coding RNA (mRNA) and play some roles in mRNA metabolism.	CHIBA UNIV, FAC SCI, DEPT BIOL, INAGE KU, CHIBA 263, JAPAN; SUMITOMO ELECT IND LTD, BIOMED R&D DEPT, SAKAE KU, YOKOHAMA, KANAGAWA 244, JAPAN; TOKYO METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN	Chiba University; Sumitomo Electric Industries; Tokyo Metropolitan Institute of Medical Science			Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556				AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; ARMON T, 1990, J BIOL CHEM, V265, P20723; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOYER C, 1992, DNA CELL BIOL, V11, P579, DOI 10.1089/dna.1992.11.579; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HIRTZLIN J, 1994, EUR J BIOCHEM, V226, P673, DOI 10.1111/j.1432-1033.1994.tb20095.x; Kishimoto T, 1996, BIOCHEM BIOPH RES CO, V223, P746, DOI 10.1006/bbrc.1996.0962; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LUCERO HA, 1995, J BIOL CHEM, V270, P9178, DOI 10.1074/jbc.270.16.9178; MA CP, 1994, J BIOL CHEM, V269, P3539; Makino Y, 1996, BIOCHEM BIOPH RES CO, V220, P1049, DOI 10.1006/bbrc.1996.0530; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	37	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23201	23205		10.1074/jbc.272.37.23201	http://dx.doi.org/10.1074/jbc.272.37.23201			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287326	hybrid			2022-12-25	WOS:A1997XV74400037
J	Sepp, A; Skacel, P; Lindstedt, R; Lechler, RI				Sepp, A; Skacel, P; Lindstedt, R; Lechler, RI			Expression of alpha-1,3-galactose and other type 2 oligosaccharide structures in a porcine endothelial cell line transfected with human alpha-1,2-fucosyltransferase cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOLICHOS-BIFLORUS AGGLUTININ; XENOREACTIVE NATURAL ANTIBODIES; HYPERACUTE XENOGRAFT REJECTION; COMPLEMENT-MEDIATED CYTOLYSIS; ALPHA-GALACTOSYL EPITOPES; COLLECTING DUCT CELLS; HAMSTER OVARY CELLS; ANTI-GAL ANTIBODY; LEWIS-Y ANTIGEN; DISCORDANT XENOGRAFTS	The binding of xenoreactive natural antibodies to the Gal alpha 1-3Gal beta 1-4GlcNAc (alpha-galactose) oligosaccharide epitope on pig cells activates the recipient's complement system in pig to primate xenotransplantation, Expression of human alpha-1,2-fucosyltransferase in pigs has been proposed as a strategy for reducing the expression level of the alpha-galactose epitope thereby rendering the pig organs more suitable for transplantation into humans. The aim of this study was to examine how the cell surface expression of alpha-galactose, H, and related fucosylated and sialylated structures on a pig liver endothelial cell line is affected by transfection of human alpha-1,2-fucosyltransferase cDNA. Nontransfected and mock-transfected cells expressed alpha-galactose, alpha-2,3-sialylated, and alpha-2,6-sialylated epitopes strongly, with low level expression of type 2 H and Lewis(X). By contrast, expression of the H epitope was increased 5-8-fold in transfected cells with a 40% reduction in the expression of alpha-galactose epitope and a 50% decrease in sialylation, as measured by binding of Maackia amurensis and Sambuccus nigra agglutinins. Lewis(X) expression was reduced to background levels, while the Lewis(Y) neoepitope was induced in human alpha-1,2-fucosyltransferase-expressing pig cells. The activities of endogenous alpha-1,3-galactosyltransferase, alpha-1,3-fucosyltransferases, and alpha-2,3- and alpha-2,6-sialyltransferases acting on lactosamine were unaffected, Our results show that a reduction in alpha-galactose epitope expression in porcine endothelial cells transfected with human alpha-1,2-fucosyltransferase cDNA may be achieved but at the expense of considerable distortion of the overall cell surface glycosylation profile, including the appearance of carbohydrate epitopes that are absent from the parent cells.	ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND; ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London								ASHFORD DA, 1993, J BIOL CHEM, V268, P3260; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; Cairns T, 1995, TRANSPLANTATION, V60, P1202; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cooper D K, 1993, Transpl Immunol, V1, P198, DOI 10.1016/0966-3274(93)90047-C; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; DARR D, 1990, J CUTAN PATHOL, V17, P9, DOI 10.1111/j.1600-0560.1990.tb01671.x; DELAU WBM, 1993, J IMMUNOL, V150, P4911; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GRUPP CT, 1990, KIDNEY INT, V37, P1163; HAYASHI S, 1994, TRANSPLANT P, V26, P1243; HecklOstreicher B, 1995, CLIN EXP IMMUNOL, V102, P589; HELLER D S, 1990, Pediatric Pathology, V10, P681; HENDRICKS SP, 1990, J BIOL CHEM, V265, P17621; HOKKE CH, 1994, EUR J BIOCHEM, V221, P491, DOI 10.1111/j.1432-1033.1994.tb18762.x; HOLTHOFER H, 1987, CELL TISSUE RES, V249, P481; HOLZKNECHT ZE, 1995, J IMMUNOL, V154, P4565; INOUE M, 1990, VIRCHOWS ARCH A, V416, P221, DOI 10.1007/BF01678981; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; KANEKO T, 1993, J BIOCHEM-TOKYO, V113, P114, DOI 10.1093/oxfordjournals.jbchem.a123993; KENNEDY SP, 1994, TRANSPLANTATION, V57, P1494; KIRK AD, 1992, TRANSPLANT P, V24, P602; KIRK AD, 1993, TRANSPLANTATION, V55, P924, DOI 10.1097/00007890-199304000-00043; KROSHUS TJ, 1995, J SURG RES, V59, P43, DOI 10.1006/jsre.1995.1130; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEVENTHAL JR, 1994, TRANSPLANTATION, V57, P974; Lowe J B, 1991, Semin Cell Biol, V2, P289; MARTENSSON S, 1995, HUM PATHOL, V26, P735, DOI 10.1016/0046-8177(95)90220-1; MCCORMACK KM, 1987, CLIN RES, V35, pA702; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; McKenzie I F, 1994, Transpl Immunol, V2, P81, DOI 10.1016/0966-3274(94)90032-9; MIYAGAWA S, 1994, TRANSPLANTATION, V58, P834, DOI 10.1097/00007890-199410150-00015; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MYERS RB, 1995, J UROLOGY, V153, P1572, DOI 10.1016/S0022-5347(01)67464-0; NEETHLING FA, 1994, TRANSPLANTATION, V57, P959, DOI 10.1097/00007890-199403270-00032; OGAWA J, 1995, ANN THORAC SURG, V59, P412, DOI 10.1016/0003-4975(94)00866-6; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PARKER W, 1994, J IMMUNOL, V153, P3791; PLATT JL, 1994, TRANSPLANTATION, V57, P327, DOI 10.1097/00007890-199402150-00003; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; PLATT JL, 1991, TRANSPLANTATION, V52, P1037, DOI 10.1097/00007890-199112000-00019; PLENDL J, 1992, ANAT HISTOL EMBRYOL, V21, P118, DOI 10.1111/j.1439-0264.1992.tb00328.x; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; ROSE AG, 1991, J HEART LUNG TRANSPL, V10, P223; ROSENGARD AM, 1995, TRANSPLANT P, V27, P326; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; Sepp A, 1996, J IMMUNOL METHODS, V196, P175, DOI 10.1016/0022-1759(96)00112-3; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; SHIOJIRI N, 1988, ANAT EMBRYOL, V178, P15, DOI 10.1007/BF00305009; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOARES M, 1994, TRANSPLANTATION, V57, P1003; TERADA T, 1995, AM J PATHOL, V146, P67; THALL A, 1991, ACTA ENDOCRINOL-COP, V124, P692, DOI 10.1530/acta.0.1240692; VAUGHAN HA, 1993, TRANSPLANT P, V25, P2919; WAKABAYASHI M, 1995, CANCER, V75, P2827, DOI 10.1002/1097-0142(19950615)75:12<2827::AID-CNCR2820751207>3.0.CO;2-Z; YANNOUTSOS N, 1995, TRANSPLANT P, V27, P324	63	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23104	23110		10.1074/jbc.272.37.23104	http://dx.doi.org/10.1074/jbc.272.37.23104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287311	hybrid			2022-12-25	WOS:A1997XV74400022
J	Vance, BA; Wu, WY; Ribaudo, RK; Segal, DM; Kearse, KP				Vance, BA; Wu, WY; Ribaudo, RK; Segal, DM; Kearse, KP			Multiple dimeric forms of human CD69 result from differential addition of N-glycans to typical (Asn-X-Ser/Thr) and atypical (Asn-X-Cys) glycosylation motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION ANTIGEN CD69; ASPARAGINE-LINKED OLIGOSACCHARIDES; NATURAL-KILLER-CELLS; LYMPHOCYTE-ACTIVATION; AMINO-ACID; ENDOPLASMIC-RETICULUM; PROTEIN-C; RECEPTOR; EXPRESSION; SEQUENCE	CD69 is expressed on the surface of all hematopoietically derived leukocytes and is suggested to function as a multipurpose cell-surface trigger molecule important in the development and activation of many different cell types. Human CD69 contains only a single consensus sequence for N-linked oligosaccharide addition within its extracellular domain (Asn-Val-Thr), yet exists as two distinct glycoforms that are assembled together into disulfide-linked homodimers and heterodimers. The molecular basis for human CD69 heterogeneity has remained elusive. In the current report we show that human CD69 glycoforms are generated before the egress of CD69 proteins from the endoplasmic reticulum to the Golgi and are synthesized under conditions where Golgi processing is inhibited, effectively ruling out the possibility that CD69 heterogeneity results from the differential processing of a single glycosylation site in the Golgi complex. Importantly, these data demonstrate that contrary to current belief, not one but two sites for N-glycan addition exist within the human CD69 extracellular do main and identify the second, ''cryptic'' CD69 N-glycan attachment site as the atypical Cys-containing glycosylation motif, Asn-Ala-Cys. The results in this study provide a molecular basis for human CD69 heterogeneity and show that multiple dimeric forms of human CD69 result from the variable addition of N-glycans to atypical and typical glycosylation motifs within the CD69 extracellular domain.	E CAROLINA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, GREENVILLE, NC 27858 USA; NCI, EXPT IMMUNOL BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, LAB IMMUNE CELL BIOL, NIH, BETHESDA, MD 20892 USA	University of North Carolina; East Carolina University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Ribaudo, Randall/AAH-7094-2021; Vance, Barbara/GYA-0940-2022					BAJORATH J, 1994, J BIOL CHEM, V269, P32457; Balow JP, 1996, J IMMUNOL METHODS, V189, P251, DOI 10.1016/0022-1759(95)00255-3; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; Bause E, 1995, BIOCHEM J, V312, P979, DOI 10.1042/bj3120979; BEZOUSKA K, 1995, BIOCHEM BIOPH RES CO, V208, P68, DOI 10.1006/bbrc.1995.1306; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FRANKLIN RA, 1994, J CLIN INVEST, V93, P2134, DOI 10.1172/JCI117209; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAMANN J, 1993, J IMMUNOL, V150, P4920; HART GW, 1979, J BIOL CHEM, V254, P9747; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; Marshall R D, 1974, Biochem Soc Symp, P17; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; MORETTA A, 1991, J EXP MED, V174, P1393, DOI 10.1084/jem.174.6.1393; SANCHEZMATEOS P, 1991, EUR J IMMUNOL, V21, P2317, DOI 10.1002/eji.1830211005; SANTIS AG, 1994, EUR J IMMUNOL, V24, P1692, DOI 10.1002/eji.1830240735; STENFLO J, 1982, J BIOL CHEM, V257, P2180; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TESTI R, 1990, J EXP MED, V172, P701, DOI 10.1084/jem.172.3.701; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; TESTI R, 1989, J IMMUNOL, V143, P1123; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZEIGLER SF, 1994, J IMMUNOL, V152, P1228; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502	34	61	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23117	23122		10.1074/jbc.272.37.23117	http://dx.doi.org/10.1074/jbc.272.37.23117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287313	hybrid			2022-12-25	WOS:A1997XV74400024
J	Waters, SB; DAuria, M; Martin, SS; Nguyen, C; Kozma, LM; Luskey, KL				Waters, SB; DAuria, M; Martin, SS; Nguyen, C; Kozma, LM; Luskey, KL			The amino terminus of insulin-responsive aminopeptidase causes Glut4 translocation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED MEMBRANE AMINOPEPTIDASE; GLUCOSE-TRANSPORTER; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; MAJOR PROTEIN; VESICLES; LOCALIZATION; FIBROBLASTS; TRAFFICKING; MUSCLE	The insulin-responsive aminopeptidase (IRAP) is a constituent of the vesicles that contain the insulin-regulated glucose transporter (Glut4). Like Glu4, IRAP translocates to the cell surface in response to insulin, Microinjection into 3T3-L1 adipocytes of a glutathione S-transferase (GST) fusion protein containing the cytosolic portion of IRAP (GST-IRAP-(1-109)), resulted in translocation of Glut4 to the cell surface, Immunostaining of 3T3-L1 adipocytes for Glut4 showed that the percentage of cells with substantial cell surface Glut4 was 10% in unstimulated cells, 8% following injection of GST, and 27% following injection of GST-IRAP-(1-109). Increased cell surface Glut4 occurred within 5-10 min following injection and was maintained for at least 4 h, A fusion protein containing only 28 amino acids from IRAP (GST-IRAP-(55-82)) was as effective in increasing cell surface Glut4 as stimulation with 100 nM insulin (44% versus 43%, respectively), In contrast to insulin-stimulated Glut4 translocation, the redistribution of Glut4 following injection of GST-IRAP-(55-82) was not blocked by wortmannin or co-injection with a SH2 domain from the regulatory subunit of phosphatidylinositol 3-kinase. These data suggest that the amino terminus of IRAP interacts with a retention/sorting protein that also regulates the distribution of Glut4 in insulin-responsive cells.	METABOLEX INC, HAYWARD, CA 94545 USA; UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018	24	102	105	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23323	23327		10.1074/jbc.272.37.23323	http://dx.doi.org/10.1074/jbc.272.37.23323			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287343	hybrid			2022-12-25	WOS:A1997XV74400054
J	Zhao, KW; Faull, KF; Kakkis, ED; Neufeld, EF				Zhao, KW; Faull, KF; Kakkis, ED; Neufeld, EF			Carbohydrate structures of recombinant human alpha-L-iduronidase secreted by Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; MUCOPOLYSACCHARIDOSIS-TYPE; ENZYME REPLACEMENT; MASS-SPECTROMETRY; PURIFIED ENZYME; CANINE MODEL; OVEREXPRESSION; GLUCOSIDASE; PROTEINS	alpha-L-Iduronidase is a lysosomal hydrolase that is deficient in Hurler syndrome and clinically milder variants. Recombinant human alpha-L-iduronidase, isolated from secretions of an overexpressing Chinese hamster ovary cell line, is potentially useful for replacement therapy of these disorders. Because of the importance of carbohydrate residues for endocytosis and lysosomal targeting, we examined the oligosaccharides of recombinant alpha-L-iduronidase at each of its six N-glycosylation sites. Biosynthetic radiolabeling showed that three or four of the six oligosaccharides of the secreted enzyme were cleaved by endo-beta-N-acetylglucosaminidase H, with phosphate present on the sensitive oligosaccharides and L-fucose on the resistant ones. For structural analysis, tryptic and chymotryptic glycopeptides were isolated by lectin binding and reverse phase high pressure liquid chromatography; their molecular mass was determined by matrix-assisted laser desorption-time of flight mass spectrometry before and after treatment with endo- or exoglycosidases or with alkaline phosphatase. Identification of the peptides was assisted by amino-or carboxyl-terminal sequence analysis. The major oligosaccharide structures found at each site were as follows: Asn-110, complex; Asn-190, complex; Asn-336, bisphosphorylated (P(2)Man(7)GlcNAc(2)); Asn-372, high mannose (mainly Man(9)GlcNAc(2), some of which was monoglucosylated); Asn-415, mixed high mannose and complex; Asn-451, bisphosphorylated (P(2)Man(7)GlcNAc(2)). The Asn-451 glycopeptide was unexpectedly resistant to digestion by N-glycanase unless first dephosphorylated, but it was sensitive to endo-beta-N-acetylglucosaminidase H and to glycopeptidase A. The heterogeneity of carbohydrate structures must represent the accessibility of the glycosylation sites as well as the processing capability of the overexpressing Chinese hamster ovary cells.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BEHAV SCI,CTR MOL & MED SCI MASS SPECTROMETRY,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,CTR MOL & MED SCI MASS SPECTROMETRY,LOS ANGELES,CA 90095; HARBOR UCLA MED CTR,DEPT PEDIAT,TORRANCE,CA 90502	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038857] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16042-20] Funding Source: Medline; NIDDK NIH HHS [DK38857] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; BIELICKI J, 1993, BIOCHEM J, V289, P241, DOI 10.1042/bj2890241; CALRKE LA, 1996, AM J HUM GENET, V59, pA196; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; Haskins M. E., 1995, American Journal of Human Genetics, V57, pA39; HUBERTY MC, 1993, ANAL CHEM, V65, P2791, DOI 10.1021/ac00068a015; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; Kakkis ED, 1996, BIOCHEM MOL MED, V58, P156, DOI 10.1006/bmme.1996.0044; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; KHANDKE KM, 1989, INT J PEPT PROT RES, V34, P118; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING P, 1993, BIOL REPROD, V49, P1317, DOI 10.1095/biolreprod49.6.1317; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; PATTERSON DH, ANAL CHEM, V67, P369; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PROIA RL, 1984, J BIOL CHEM, V259, P3350; SCOTT HS, 1991, P NATL ACAD SCI USA, V88, P9695, DOI 10.1073/pnas.88.21.9695; SCOTT HS, 1995, HUM MUTAT, V6, P288, DOI 10.1002/humu.1380060403; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; Starr CM, 1996, J CHROMATOGR A, V720, P295, DOI 10.1016/0021-9673(95)00749-0; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; SUTTON CW, 1994, ANAL BIOCHEM, V218, P34, DOI 10.1006/abio.1994.1138; TAYLOR JA, 1991, BIOCHEM J, V274, P263, DOI 10.1042/bj2740263; UNGER EG, 1994, BIOCHEM J, V304, P43, DOI 10.1042/bj3040043; VanHove JLK, 1996, P NATL ACAD SCI USA, V93, P65, DOI 10.1073/pnas.93.1.65; ZHAO KW, 1996, FASEB J, V10, pA1108	30	44	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22758	22765		10.1074/jbc.272.36.22758	http://dx.doi.org/10.1074/jbc.272.36.22758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278435	hybrid			2022-12-25	WOS:A1997XV49200056
J	Keynan, S; Asipu, A; Hooper, NM; Turner, AJ; Blair, GE				Keynan, S; Asipu, A; Hooper, NM; Turner, AJ; Blair, GE			Stable and temperature-sensitive transformation of baby rat kidney cells by SV40 suppresses expression of membrane dipeptidase	ONCOGENE			English	Article						SV40; adenoviruses; cell transformation; tumour cells; peptidases	PHOSPHATIDYLINOSITOL-ANCHORED ECTOENZYME; HUMAN RENAL DIPEPTIDASE; MOLECULAR-CLONING; MICROSOMAL DIPEPTIDASE; WILMS-TUMOR; GENE DPEP1; DNA; PURIFICATION; BINDING; 16Q24.3	Membrane dipeptidase (MDP) is a zinc metalloenzyme located in the lungs and on the brush border membranes of the kidney and intestine, The gene for MDP (also termed DPEP1) is both frequently lost in Wilm's tumours and is located on human chromosome 16q24.3, a region of the genome known to contain a tumour suppressor gene(s), We now report on the regulation of MDP gene expression in normal and transformed cells, MDP enzyme activity and mRNA was detected in primary baby rat kidney (BRK) cells maintained in culture for up to 4 weeks. In contrast all stable transformed cell lines that were tested, derived either by transformation with the DNA tumour viruses SV40 or adenovirus, or in human tumour cell lines, contained very low levels of or no detectable MDP mRNA or enzyme activity, In BRK cells transformed by the temperature-sensitive tsA58 mutant of SV40 T antigen, MDP activity was not detectable, in cell lines grown at the permissive temperature (33 degrees C) but after 5-14 days of incubation at the non-permissive temperature (39.5 degrees C), MDP protein and enzyme activity could be readily detected. Taken together, these results indicate that MDP expression is characteristic of differentiated kidney epithelial cells and is down-regulated in proliferating, transformed cells.	UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds			Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795; Hooper, Nigel/0000-0002-5811-3484	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADACHI H, 1992, BIOCHIM BIOPHYS ACTA, V1132, P311, DOI 10.1016/0167-4781(92)90167-X; ADACHI H, 1990, J BIOL CHEM, V265, P3992; AN SZ, 1994, BBA-MOL BASIS DIS, V1226, P337, DOI 10.1016/0925-4439(94)90046-9; AUSTRUY E, 1993, CANCER RES, V53, P2888; AUSTRUY E, 1993, GENOMICS, V15, P684, DOI 10.1006/geno.1993.1126; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; Fukuda S, 1996, HUM MUTAT, V7, P123, DOI 10.1002/(SICI)1098-1004(1996)7:2<123::AID-HUMU6>3.3.CO;2-V; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUENAL I, 1995, FEBS LETT, V374, P384, DOI 10.1016/0014-5793(95)01157-A; HABIB GB, 1996, J BIOL CHEM, V217, P16273; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGARASHI P, 1991, BIOCHEM J, V280, P71, DOI 10.1042/bj2800071; KAHAN FM, 1983, J ANTIMICROB CHEMOTH, V12, P1; KEYNAN S, 1994, FEBS LETT, V349, P50, DOI 10.1016/0014-5793(94)00637-7; Keynan S, 1996, ZINC METALLOPROTEASE, P285; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLEWOOD GM, 1989, BIOCHEM J, V257, P361, DOI 10.1042/bj2570361; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MAW MA, 1992, CANCER RES, V52, P3094; NAKAGAWA H, 1992, CYTOGENET CELL GENET, V59, P258, DOI 10.1159/000133263; NANUS DM, 1993, RENAL CELL CARCINOMA, P53; RACHED E, 1990, BIOCHEM J, V271, P755, DOI 10.1042/bj2710755; Sambrook J., 2002, MOL CLONING LAB MANU; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1163, P234, DOI 10.1016/0167-4838(93)90157-M; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P181, DOI 10.1016/0167-4781(93)90289-P; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; van der Eb A J, 1980, Methods Enzymol, V65, P826; VERITY AN, 1993, J NEUROCHEM, V60, P577, DOI 10.1111/j.1471-4159.1993.tb03188.x; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	32	7	7	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1241	1245		10.1038/sj.onc.1201297	http://dx.doi.org/10.1038/sj.onc.1201297			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294618				2022-12-25	WOS:A1997XU99100014
J	Halleck, MM; Liu, H; North, J; Stevens, JL				Halleck, MM; Liu, H; North, J; Stevens, JL			Reduction of trans-4,5-dihydroxy-1,2-dithiane by cellular oxidoreductases activates gadd153/chop and grp78 transcription and induces cellular tolerance in kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN (C/EBP)-RELATED GENE; CYSTEINE CONJUGATE TOXICITY; MESSENGER-RNA STABILITY; DNA-DAMAGE; ENDOPLASMIC-RETICULUM; LLC-PK1 CELLS; OXIDATIVE STRESS; REDOX REGULATION; C-FOS; LIPID-PEROXIDATION	Trans-4,5-Dihydroxy-1,2-dithiane, the intramolecular disulfide form of dithiothreitol (DTTox) transcription ally activates the stress-responsive genes gadd153(chop) and grp78, Herein, we used a renal epithelial cell line, LLC-PK1, to investigate the mechanism(s) whereby DTTox activates a molecular stress response, DTTox activated both grp78 and gadd153 transcriptionally, but gadd153 mRNA stability also increased suggesting that both transcriptional and posttranscriptional mechanisms are involved. DTTox did not activate hsp70 transcription indicating that a heat shock response was not induced. Structure-activity studies showed that DTTox analogues lacking the intramolecular disulfide were inactive, Furthermore, the ring-open intermolecular di sulfide form of DTTox, a-hydroxyethyl disulfide, was only a weak inducer of grp78 and gadd153 but was a strong inducer of hsp70 mRNA and a potent oxidant that lowered the NADPH/NADP(+) ratio and depleted reduced glutathione (GSH). DTTox had little effect on the overall GSH and NADPH levels; thus cells were not undergoing oxidative stress; however, the NADPH/NADP(+) ratio decreased slightly indicating that reducing equivalents were consumed. LLC-PK1 cells reduced DTTox to DTT, and the kinetics as well as the concentration dependence for reduction correlated with induction of both grp78 and gadd153 mRNA Prior treatment with DTTox rendered cells tolerant to the potent nephrotoxicant S-(1,1,2,2-tetrafluoroethyl)-L-cysteine. Bacitracin, an inhibitor of plasma membrane oxidoreductases, blocked DTTox reduction and gene activation as well as DTTox induced tolerance, Thus, activation of stress genes and induction of cellular tolerance by DTTox is mediated by a novel mechanism involving cellular oxidoreductases.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946						NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267, R29DK038965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005569] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38965, DK46267] Funding Source: Medline; NIEHS NIH HHS [ES05569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHEN Q, 1992, J BIOL CHEM, V267, P24322; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHEN Q, 1991, ARCH BIOCHEM BIOPHYS, V284, P422, DOI 10.1016/0003-9861(91)90318-D; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FREEMAN ML, 1995, J CELL PHYSIOL, V164, P356, DOI 10.1002/jcp.1041640216; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOMER CJ, 1991, CANCER RES, V51, P6574; GUY GR, 1993, J BIOL CHEM, V268, P2141; HAINAUT P, 1993, CANCER RES, V53, P4469; Halleck MM, 1997, CELL STRESS CHAPERON, V2, P31, DOI 10.1379/1466-1268(1997)002<0031:TMRTRS>2.3.CO;2; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, J BIOL CHEM, V266, P18415; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKMAN J, 1994, CANCER RES, V54, P5656; KIM YK, 1987, MOL CELL BIOL, V7, P2974, DOI 10.1128/MCB.7.8.2974; LEE AS, 1983, J BIOL CHEM, V258, P597; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1996, J BIOL CHEM, V271, P4805; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LUETHY JD, 1994, CANCER RES, V54, pS1902; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; MATSUOKA M, 1995, KIDNEY INT, V48, P383, DOI 10.1038/ki.1995.306; NAKAMURA K, 1993, ONCOGENE, V8, P3133; PASSONNEAU JV, 1974, METHOD ENZYMAT AN, P2059; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; PRICE BD, 1992, CANCER RES, V52, P3814; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTHWARF DM, 1992, P NATL ACAD SCI USA, V89, P7944, DOI 10.1073/pnas.89.17.7944; ROY B, 1995, MOL CELL BIOL, V15, P2263; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCOTTO CF, 1970, EXPERIENTIA, V26, P172; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; STEVENS J, 1986, J BIOL CHEM, V261, P3325; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUGAWARA S, 1993, CANCER RES, V53, P6001; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; UEDA N, 1992, AM J PHYSIOL, V263, pF214, DOI 10.1152/ajprenal.1992.263.2.F214; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; VAMVAKAS S, 1993, TOXICOL LETT, V67, P161, DOI 10.1016/0378-4274(93)90053-Z; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; YU KF, 1994, J CELL PHYSIOL, V161, P303, DOI 10.1002/jcp.1041610215	67	28	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21760	21766		10.1074/jbc.272.35.21760	http://dx.doi.org/10.1074/jbc.272.35.21760			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268305	hybrid			2022-12-25	WOS:A1997XT85000017
J	Kamitani, T; Nguyen, HP; Yeh, ETH				Kamitani, T; Nguyen, HP; Yeh, ETH			Activation-induced aggregation and processing of the human Fas antigen - Detection with cytoplasmic domain-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; POLY(ADP-RIBOSE) POLYMERASE; MEDIATED APOPTOSIS; TNF RECEPTOR; PROTEOLYTIC CLEAVAGE; SIGNALING COMPLEX; IL-6 RECEPTOR; DEATH DOMAIN; CELL-DEATH; IN-VITRO	Fas (APO1/CD95) is a type 1 transmembrane protein critically involved in receptor-mediated apoptosis. Previous studies have shown that Pas exists in monomeric form in resting cells and aggregates upon cross-linking to form a complex that serves to recruit additional signaling molecules to the cell membrane, To study the molecular fate of the Pas antigen following receptor activation, a monoclonal antibody specific for the cell death domain of Fas has been generated, This monoclonal antibody (3D5) could be used in Western blot analysis using total cell lysates to identify different forms of Fas antigens without immunoprecipitation. High molecular mass (>200 kDa), SDS- and beta-mercaptoethanol-resistant Fas aggregates were formed immediately following receptor cross-linking, and a 97-kDa band (p97) was detected about 2 h later, p97 could be detected by antibodies against either the death domain or the C terminus, However, p97 could not be precipitated by antiextracellular domain antibodies. Thus, p97 most likely represents a processed form of the high molecular weight Fas aggregates, Although p97 generation followed a similar time course as CPP32 activation and poly(ADP-ribose) polymerase cleavage, it could not be inhibited by cysteine protease, calpain, or proteasome inhibitors.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV MOL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,CARDIOVASC RES CTR,INST MOL MED PREVENT HUMAN DIS,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NHLBI NIH HHS [HL-45851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; FRASER A, 1996, CELL, V85, P784; Fujita E, 1996, BIOCHEM BIOPH RES CO, V224, P74, DOI 10.1006/bbrc.1996.0986; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Papoff G, 1996, J IMMUNOL, V156, P4622; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMAS LJ, 1992, J CLIN INVEST, V89, P1172, DOI 10.1172/JCI115700; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	29	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22307	22314		10.1074/jbc.272.35.22307	http://dx.doi.org/10.1074/jbc.272.35.22307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268381	hybrid			2022-12-25	WOS:A1997XT85000093
J	TonThat, H; Faull, KF; Schneewind, O				TonThat, H; Faull, KF; Schneewind, O			Anchor structure of staphylococcal surface proteins - A branched peptide that links the carboxyl terminus of proteins to the cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; PENICILLIN-BINDING PROTEINS; ESCHERICHIA-COLI; MUREIN-LIPOPROTEIN; MASS-SPECTROMETRY; PEPTIDOGLYCAN COMPOSITION; SEQUENCE-ANALYSIS; TEICHOIC-ACIDS; AUREUS STRAIN; IDENTIFICATION	Surface proteins of Staphylococcus aureus are anchored to the cell wall by a mechanism requiring a COOH-terminal sorting signal, Previous work demonstrated that the sorting signal is cleaved at the conserved LPXTG motif and that the carboxyl of threonine (T) is linked to the staphylococcal cell wall. By employing different cell wall lytic enzymes, surface proteins were released from the staphylococcal peptidoglycan and their COOH-terminal anchor structure was revealed by a combination of mass spectrometry and chemical analysis, The results demonstrate that surface proteins are linked to a branched peptide (NH2-Ala-gamma-Gln-Lys-(NH2-Gly(5))-Ala-COOH) by an amide bond be tween the carboxyl of threonine and the amino of the pentaglycine cross-bridge that is attached to the epsilon-amino of lysyl, This branched anchor peptide is amide-linked to the carboxyl of N-acetylmuramic acid, thereby tethering the COOH-terminal end of surface proteins to the staphylococcal peptidoglycan.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOL BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT & BIOBEHAV SCI, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Ton-That, Hung/AAB-6155-2020	Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI 33985, AI 38897] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985, R01AI038897] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JS, 1965, P NATL ACAD SCI USA, V53, P881, DOI 10.1073/pnas.53.4.881; ARAKI Y, 1989, CRIT REV MICROBIOL, V17, P121, DOI 10.3109/10408418909105745; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; BRAUN V, 1974, ANNU REV BIOCHEM, V43, P89, DOI 10.1146/annurev.bi.43.070174.000513; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; Braun V., 1994, BACTERIAL CELL WALL, P319, DOI 10.1016/S0167-7306(08)60417-2; CHOI DS, 1986, J BIOL CHEM, V261, P8953; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; ENDL J, 1983, ARCH MICROBIOL, V135, P215, DOI 10.1007/BF00414483; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FOLKENING WJ, 1987, J BACTERIOL, V169, P4223, DOI 10.1128/jb.169.9.4223-4227.1987; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; GHUYSEN J. M., 1965, BIOCHEMISTRY, V4, P2245, DOI 10.1021/bi00886a043; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GHUYSEN JM, 1965, BIOCHEMISTRY-US, V3, P474; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HANDWERGER S, 1994, J BACTERIOL, V176, P260, DOI 10.1128/JB.176.1.260-264.1994; HANDWERGER S, 1992, J BACTERIOL, V174, P5982, DOI 10.1128/jb.174.18.5982-5984.1992; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; KEHOE MA, 1994, BACTERIAL CELL WALL, P217; LEE SF, 1992, INFECT IMMUN, V60, P4032, DOI 10.1128/IAI.60.10.4032-4039.1992; MARTIN SA, 1987, J BIOL CHEM, V262, P7514; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; OSHIDA T, 1995, P NATL ACAD SCI USA, V92, P285, DOI 10.1073/pnas.92.1.285; PANCHOLI V, 1989, J EXP MED, V170, P2119, DOI 10.1084/jem.170.6.2119; PETIT JF, 1966, BIOCHEMISTRY-US, V5, P2764, DOI 10.1021/bi00872a037; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; STROMINGER JL, 1967, FED PROC, V26, P9; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TIPPER DJ, 1969, BIOCHEMISTRY-US, V8, P2183, DOI 10.1021/bi00833a060; TIPPER DJ, 1967, BIOCHEMISTRY-US, V6, P906, DOI 10.1021/bi00855a035; TIPPER DJ, 1965, BIOCHEMISTRY-US, V4, P468, DOI 10.1021/bi00879a015; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; WANG X, 1991, GENE, V102, P105; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; YOKOYAMA K, 1986, EUR J BIOCHEM, V161, P479, DOI 10.1111/j.1432-1033.1986.tb10469.x	53	98	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22285	22292		10.1074/jbc.272.35.22285	http://dx.doi.org/10.1074/jbc.272.35.22285			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268378	hybrid			2022-12-25	WOS:A1997XT85000090
J	Wang, AJ; Loo, R; Chen, ZL; Dennis, EA				Wang, AJ; Loo, R; Chen, ZL; Dennis, EA			Regiospecificity and catalytic triad of lysophospholipase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE P388D1; PHOSPHOLIPASE A(2); PURIFICATION; SPECIFICITY; LYSOPHOSPHATIDYLCHOLINE; ACETYLCHOLINESTERASE; IDENTIFICATION; DEMYELINATION; MACROPHAGES; HYDROLASE	A 25-kDa murine lysophospholipase (LysoPLA I) has been cloned and expressed, and Ser-119 has been shown to be essential for the enzyme activity (Wang, A., Deems, R. A., and Dennis, E. A. (1997) J. Biol, Chem, 272, 12723-12729). In the present study, we show that LysoPLA I represents a new member of the serine hydrolase family with Ser-119, Asp-174, and His-208 composing the catalytic triad, The Asp-174 and His-208 are conserved among several esterases and are demonstrated herein to be essential for LysoPLA I activity as the mutation of either residue to Ala abolished LysoPLA I activity, whereas the global conformation of the mutants remained unchanged, Furthermore, the predicted secondary structure of LysoPLA I resembles that of the alpha/beta-hydrolase fold, with Ser-119, Asp-174, and His-208 occupying the conserved topological location of the catalytic triad in the alpha/beta-hydrolases. Structural modeling of LysoPLA I also indicates that the above three residues orient in such a manner that they would comprise a charge-relay network necessary for catalysis, In addition, the regiospecificity of LysoPLA I was studied using P-31 NMR, and the result shows that LysoPLA I has similar LysoPLA(1) and LysoPLA(2) activity, This finding suggests that LysoPLA I may play an important role in removing lysophospholipids produced by both phospholipase A(1) and A(2) in vivo.	UNIV CALIF SAN DIEGO,DEPT BIOCHEM & CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NIGMS NIH HHS [GM 51606] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLT G, 1988, ACTA NEUROPATHOL, V75, P456, DOI 10.1007/BF00687132; AMBUDKAR IS, 1988, MOL CELL BIOCHEM, V79, P81, DOI 10.1007/BF00229401; ANTTINEN H, 1976, BIOCHEM J, V160, P29, DOI 10.1042/bj1600029; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P380; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; KELLY RA, 1986, J BIOL CHEM, V261, P1704; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO RW, 1997, J BIOL CHEM, V271, P19214; LOW PA, 1983, BIOCHIM BIOPHYS ACTA, V754, P298, DOI 10.1016/0005-2760(83)90146-7; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; PLUCKTHUN A, 1985, J BIOL CHEM, V260, P1099; SHAIKH NA, 1981, CIRC RES, V49, P316, DOI 10.1161/01.RES.49.2.316; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; SOBEL BE, 1978, J CLIN INVEST, V62, P546, DOI 10.1172/JCI109159; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STAFFORD RE, 1993, BIOCHIM BIOPHYS ACTA, V1167, P43, DOI 10.1016/0005-2760(93)90215-U; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; van den Boogaard M, 1988, SCRIPTA GEOLOGICA, V88, P1; Wallace AC, 1996, PROTEIN SCI, V5, P1001; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	31	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22030	22036		10.1074/jbc.272.35.22030	http://dx.doi.org/10.1074/jbc.272.35.22030			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268342	Green Published, hybrid			2022-12-25	WOS:A1997XT85000054
J	Barker, KT; Jackson, LE; Crompton, MR				Barker, KT; Jackson, LE; Crompton, MR			BRK tyrosine kinase expression in a high proportion of human breast carcinomas	ONCOGENE			English	Article						BRK; breast tumour kinase; non-receptor protein tyrosine kinase; breast cancer	GROWTH-FACTOR RECEPTOR; PP60C-SRC PROTEIN-KINASE; MAMMARY-TUMORS; NEU PROTOONCOGENE; TRANSGENIC MICE; PROGNOSTIC VALUE; CELL-LINES; CANCER; INDUCTION; ONCOGENE	BRK is a recently described non receptor protein tyrosine kinase whose mRNA was found to be expressed in human breast tumours and breast cancer cell lines, Expression of BRK in fibroblasts and mammary epithelial cells has been shown to enhance their ability to grow anchorage independently, and mammary epithelial cells expressing BRK acquire a potentiated mitogenic response to epidermal growth factor, In order to investigate further the expression of BRK in breast cancers, we have isolated monoclonal antibodies specifically recognising the protein, Whereas BRK expression was low or undetectable in normal mammary tissue and benign lesions, approximately two-thirds of breast tumours expressed appreciable levels, and 27% of tumours over expressed BRK by fivefold or more (up to 43x), This expression pattern was mirrored in a comparison of cell lines derived either from normal mammary epithelial cells or from carcinomas, BRK expression was found to be constant throughout the cell cycle, and did not vary with cell proliferation rate, A consideration of this expression data, in conjunction with BRK's demonstrated ability to deregulate the proliferation of mammary epithelial cells, supports the hypothesis that the over expression of BRK in a high proportion of breast carcinomas is a functionally important factor in their evolution.	INST CANC RES,SECT CELL BIOL & EXPT PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK								BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; Bosher JM, 1996, ONCOGENE, V13, P1701; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GRIMAUX M, 1989, BREAST CANCER RES TR, V14, P77, DOI 10.1007/BF01805978; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HENNIPMAN A, 1989, CANCER RES, V49, P516; JACOBS C, 1983, CANCER RES, V43, P1696; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KAMALATI T, 1996, MAMMARY TUMOUR CELL, P227; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; ORMEROD MG, 1994, FLOW CYTOMETRY PRACT, P122; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; ROMAIN S, 1994, BRIT J CANCER, V70, P304, DOI 10.1038/bjc.1994.297; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SAINSBURY JRC, 1987, LANCET, V1, P1398; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Taylor-Papadimitriou J., 1987, The mammary gland. Development, regulation, and function., P181; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WHITEHEAD RH, 1983, J NATL CANCER I, V70, P649	32	128	133	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					799	805		10.1038/sj.onc.1201241	http://dx.doi.org/10.1038/sj.onc.1201241			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266966				2022-12-25	WOS:A1997XQ11700006
J	Severinov, K; Mooney, R; Darst, SA; Landick, R				Severinov, K; Mooney, R; Darst, SA; Landick, R			Tethering of the large subunits of Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FUNCTIONAL TOPOGRAPHY; BETA-SUBUNIT; TRANSCRIPTION; ELONGATION; GENOME; PURIFICATION; TERMINATION; EXPRESSION; EVOLUTION	The rpoB and rpoC genes of eubacteria and archaea, coding, respectively, for the beta and beta'-like subunits of DNA-dependent RNA polymerase, are organized in an operon with rpoB always preceding rpoC, Here, we show that in Escherichia coli the two genes can be fused and that the resulting 2751-amino acid beta::beta' fusion polypeptide assembles into functional RNA polymerase in vivo and in vitro, The results establish that the C terminus of the beta subunit and the N terminus of the beta' subunit are in close proximity to each other on the surface of the assembled RNA polymerase during all phases of the transcription cycle and also suggest that RNA polymerase assembly in vivo may occur co-translationally.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	Rockefeller University; University of Wisconsin System; University of Wisconsin Madison			Severinov, Konstantin/C-8545-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759, R29GM038660, R01GM038660, R37GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38660, GM53759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Buhler J.M., 1987, RNA POLYM REGULATION, P25; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Dykxhoorn DM, 1996, MOL MICROBIOL, V19, P483, DOI 10.1046/j.1365-2958.1996.384913.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GODOVIKOVA TS, 1987, EUR J BIOCHEM, V166, P611, DOI 10.1111/j.1432-1033.1987.tb13557.x; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; Ishihama A, 1981, Adv Biophys, V14, P1; Jansma DB, 1996, NUCLEIC ACIDS RES, V24, P4543, DOI 10.1093/nar/24.22.4543; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; LANDICK R, 1990, J BACTERIOL, V172, P2844, DOI 10.1128/jb.172.6.2844-2854.1990; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; LU J, 1996, GENES CELLS, V1, P819; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; RIDLEY SP, 1982, J BACTERIOL, V152, P736; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WILSON DW, 1988, NUCLEIC ACIDS RES, V16, P8097; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	27	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24137	24140		10.1074/jbc.272.39.24137	http://dx.doi.org/10.1074/jbc.272.39.24137			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305860	hybrid			2022-12-25	WOS:A1997XY51500011
J	Culotta, VC; Klomp, LWJ; Strain, J; Casareno, RLB; Krems, B; Gitlin, JD				Culotta, VC; Klomp, LWJ; Strain, J; Casareno, RLB; Krems, B; Gitlin, JD			The copper chaperone for superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; SACCHAROMYCES-CEREVISIAE; CANDIDATE GENE; WILSON DISEASE; MENKES DISEASE; YEAST; ENCODES; PROTEIN; CLONING	Copper is distributed to distinct localizations in the cell through diverse pathways. We demonstrate here that the delivery of copper to copper/zinc superoxide dismutase (SOD1) is mediated through a soluble factor identified as Saccharomyces cerevisiae LYS7 and human CCS (copper chaperone for SOD). This factor is specific for SOD1 and does not deliver copper to proteins in the mitochondria, nucleus, or secretory pathway. Yeast cells containing a lys7 Delta null mutation have normal levels of SOD1 protein, but fail to incorporate copper into SOD1, which is therefore devoid of superoxide scavenging activity. LYS7 and CCS specifically restore the biosynthesis of holoSOD1 in vivo. Elucidation of the CCS copper delivery pathway may permit development of novel therapeutic approaches to human diseases that involve SOD1, including amyotrophic lateral sclerosis.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Culotta, VC (corresponding author), JOHNS HOPKINS UNIV, SCH PUBL HLTH,DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI,615 N WOLFE ST, RM 7032, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044464, R01DK044464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44464] Funding Source: Medline; NIGMS NIH HHS [GM 50016] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BEEM KM, 1974, J BIOL CHEM, V249, P7298; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1994, SCIENCE, V266, P1586, DOI 10.1126/science.7985031; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; NULPE C, 1993, NAT GENET, V3, P7; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHERMAN F, 1978, METHODS YEAST GENETI, P163; SIKORSKI RS, 1989, GENETICS, V122, P19; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	43	667	682	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23469	23472		10.1074/jbc.272.38.23469	http://dx.doi.org/10.1074/jbc.272.38.23469			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295278	hybrid			2022-12-25	WOS:A1997XX38100003
J	Matsunaga, I; Yokotani, N; Gotoh, O; Kusunose, E; Yamada, M; Ichihara, K				Matsunaga, I; Yokotani, N; Gotoh, O; Kusunose, E; Yamada, M; Ichihara, K			Molecular cloning and expression of fatty acid alpha-hydroxylase from Sphingomonas paucimobilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; OXIDATION; METABOLISM; SEQUENCE; SYNTHASE; LOCALIZATION; PEROXISOMES; PRODUCT; PROTEIN; SYSTEM	Fatty acid alpha-hydroxylase (FAAH) catalyzes the initial reaction in alpha-oxidation of fatty acid to produce 2-hydroxy fatty acid, FAAH activity has been detected in a wide range of organisms from prokaryotes to eukaryotes. Here, we describe cloning of the FAAH gene from Sphingomonas paucimobilis, a sphingolipid- and 2-hydroxyristic acid-rich bacterium, The isolated gene encoded 415 amino acids, A homology search revealed that amino acid sequences highly conserved in cytochrome P450 (P450) were present in FAAH, Although the heme-bindimg cysteine was recognizable at position 361, the consensus in the heme-binding region was modified by an insertion. Overall, FAAH has no significant identity to the known P450s, CO difference spectrum of recombinant FAAH showed the characteristic one of P450, except this peak was at 445 nm. These results suggest bacterial FAAH is a novel member of the P450 superfamily.	SAITAMA CANC CTR,RES INST,DEPT BIOCHEM,INA,SAITAMA 362,JAPAN		Matsunaga, I (corresponding author), OSAKA CITY UNIV,SCH MED,TONEYAMA INST TB RES,SECT MOL REGULAT,5-1-1 TONEYAMA,TOYONAKA,OSAKA 560,JAPAN.			Matsunaga, Isamu/0000-0001-9541-350X				AKANUMA H, 1978, J NEUROCHEM, V30, P1051, DOI 10.1111/j.1471-4159.1978.tb12398.x; AOYAMA T, 1989, J BIOL CHEM, V264, P10388; Borge GIA, 1997, BBA-LIPID LIPID MET, V1344, P47; CASTELFRANCO PAUL, 1955, JOUR BIOL CHEM, V214, P567; Croes K, 1996, EUR J BIOCHEM, V240, P674, DOI 10.1111/j.1432-1033.1996.0674h.x; Davis LG, 1994, BASIC METHODS MOL BI; FULCO AJ, 1967, J BIOL CHEM, V242, P3608; Gotoh O, 1996, J MOL BIOL, V264, P823, DOI 10.1006/jmbi.1996.0679; Gotoh O., 1993, CYTOCHROME P450, P255; HITCHCOC.C, 1966, BIOCHIM BIOPHYS ACTA, V116, P413, DOI 10.1016/0005-2760(66)90112-3; HORIUCHI T, 1993, CYTOCHROME P 450, P186; HOSHI M, 1973, J BIOL CHEM, V248, P4123; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARKOVETZ AJ, 1972, LIPIDS, V7, P159, DOI 10.1007/BF02533056; Matsui K, 1996, FEBS LETT, V394, P21, DOI 10.1016/0014-5793(96)00924-6; Matsunaga I, 1996, FEBS LETT, V386, P252, DOI 10.1016/0014-5793(96)00451-6; MATSUNAGA I, 1994, BIOCHEM BIOPH RES CO, V201, P1554, DOI 10.1006/bbrc.1994.1881; MIHALIK SJ, 1995, EUR J BIOCHEM, V232, P545, DOI 10.1111/j.1432-1033.1995.tb20842.x; MIYATA A, 1994, BIOCHEM BIOPH RES CO, V200, P1728, DOI 10.1006/bbrc.1994.1652; MURAD S, 1975, J BIOL CHEM, V250, P5841; MURALIDHARAN FN, 1987, INT J BIOCHEM, V19, P663, DOI 10.1016/0020-711X(87)90078-4; MURALIDHARAN VB, 1984, J BIOL CHEM, V259, P3021; NARHI LO, 1986, J BIOL CHEM, V261, P7160; OHASHI K, 1992, J BIOL CHEM, V267, P789; OMURA T, 1964, J BIOL CHEM, V239, P2379; Pahan K, 1995, FEBS LETT, V377, P213, DOI 10.1016/0014-5793(95)01341-5; PAHAN K, 1993, FEBS LETT, V333, P154, DOI 10.1016/0014-5793(93)80395-B; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; SAWAMURA A, 1993, BIOCHIM BIOPHYS ACTA, V1168, P30; SINGH I, 1979, J BIOL CHEM, V254, P7698; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Steinberg D, 1989, METABOLIC BASIS INHE, P1533; STUMPF PK, 1956, J BIOL CHEM, V223, P643; TSAI SC, 1969, J BIOL CHEM, V244, P2682; YABUUCHI E, 1990, MICROBIOL IMMUNOL, V34, P99, DOI 10.1111/j.1348-0421.1990.tb00996.x; YANO I, 1971, BIOCHIM BIOPHYS ACTA, V239, P513	36	57	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23592	23596		10.1074/jbc.272.38.23592	http://dx.doi.org/10.1074/jbc.272.38.23592			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295298	hybrid			2022-12-25	WOS:A1997XX38100023
J	Newlon, MG; Roy, M; Hausken, ZE; Scott, JD; Jennings, PA				Newlon, MG; Roy, M; Hausken, ZE; Scott, JD; Jennings, PA			The A-kinase anchoring domain of type II alpha cAMP-dependent protein kinase is highly helical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; FOLDING INITIATION SITES; GROUP HYDROGEN-EXCHANGE; CHEMICAL-SHIFT INDEX; NMR-SPECTROSCOPY; IMPROVED SENSITIVITY; SECONDARY STRUCTURE; LARGER PROTEINS; CIRCULAR-DICHROISM; LINEAR PEPTIDES	Subcellular localization of the type II cAMP-dependent protein kinase is controlled by interaction of the regulatory subunit with A-Kinase Anchoring Proteins (AKAPs). This contribution examines the solution structure of a 44-residue region that is sufficient for high affinity binding to AKAPs. The N-terminal dimerization domain of the type II alpha regulatory subunit of cAMP-dependent protein kinase was expressed to high levels on minimal media and uniformly isotopically enriched with N-15 and C-13 nuclei. Sequence-specific backbone and side chain resonance assignments have been made for greater than 95% of the amino acids in the free dimerization domain using high resolution multidimensional heteronuclear NMR techniques. Contrary to the results from secondary structure prediction algorithms, our analysis indicates that the domain is :highly helical with a single 3-5-residue sequence involved in a beta-strand. The assignments and secondary structure analysis provide the basis for analyzing the structure and dynamics of the dimerization domain both free and complexed with specific anchoring proteins.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; OREGON HLTH SCI UNIV, VOLLUM INST, HOWARD HUGHES MED INST, PORTLAND, OR 97201 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NCI NIH HHS [CA09523] Funding Source: Medline; NIDDK NIH HHS [DK44239] Funding Source: Medline; NIGMS NIH HHS [GM07313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURELL L, 1977, THROMB RES, V11, P595, DOI 10.1016/0049-3848(77)90018-4; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAHMACHARI SK, 1982, BIOPOLYMERS, V21, P1107, DOI 10.1002/bip.360210608; BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1991, J BIOMOL NMR, V1, P99; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MANNING MC, 1989, BIOCHEMISTRY-US, V28, P8609, DOI 10.1021/bi00447a051; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MCCOY MA, 1992, J MAGN RESON, V98, P674, DOI 10.1016/0022-2364(92)90023-Z; MCCOY MA, 1992, J AM CHEM SOC, V114, P2108, DOI 10.1021/ja00032a026; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; PATT SL, 1992, J MAGN RESON, V96, P94, DOI 10.1016/0022-2364(92)90289-J; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHLEUCHER J, 1993, ANGEW CHEM, V105, P1518; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6348, DOI 10.1021/bi00076a007; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6356, DOI 10.1021/bi00076a008; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; STARICH MR, 1996, J MOL BIOL, V33, P15036; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Venyaminov SY, 1996, DETERMINATION PROTEI; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAO J, 1994, J MOL BIOL, V243, P736, DOI 10.1016/0022-2836(94)90044-2	73	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23637	23644		10.1074/jbc.272.38.23637	http://dx.doi.org/10.1074/jbc.272.38.23637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295304	hybrid, Green Submitted			2022-12-25	WOS:A1997XX38100029
J	Owczarek, CM; Zhang, Y; Layton, MJ; Metcalf, D; Roberts, B; Nicola, NA				Owczarek, CM; Zhang, Y; Layton, MJ; Metcalf, D; Roberts, B; Nicola, NA			The unusual species cross-reactivity of the leukemia inhibitory factor receptor alpha-chain is determined primarily by the immunoglobulin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; MOLECULAR-CLONING; EXPRESSION CLONING; HUMAN HOMOLOG; GENE FAMILY; BINDING; MURINE; GP130; COMPLEX	Human leukemia inhibitory factor (hLIF) binds to both human and mouse LIF receptors (LIFRs), while mouse LIF (mLIF) binds only to mouse LIFRs. Furthermore, hLIF binds with much higher affinity to the mouse LIFR (mLIFR) alpha-chain than does mLIF itself. To define the structural elements of the mLIFR alpha-chain conferring high affinity binding of hLIF and the species-specific interaction with mLIF, we first constructed C-terminally truncated extracellular domains of both the mLIFR and the human LIFR (hLIFR) alpha-chains, which contained only the two hemopoietin domains separated by an immunoglobulin-like domain. These recombinant truncated LIFR alpha-chains had identical binding and biological characteristics to either their naturally occurring or transfected counterparts. On the basis of this, we have generated eight interspecies receptor chimeras by combining different regions of the mouse and human LIFR sequence. Surprisingly, the immunoglobulin-like domain of the mLIFR, alpha-chain played the predominant role in receptor-ligand interactions. Moreover, both high affinity binding for hLIF and the species-specific binding for mLIF mapped to the same domain of mLIFR molecule, These findings should enable the development of a ''humanized'' mouse LIFR that could act as a potent antagonist of hLIF biological activities in vivo.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; COOPERAT RES CTR CELLULAR GROWTH FACTORS, MELBOURNE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Layton, Meredith/E-9171-2014; Nicola, Nicos/D-2989-2011	Nicola, Nicos/0000-0003-1054-7889	NCI NIH HHS [CA22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TOMIDA M, 1993, FEBS LETT, V334, P193, DOI 10.1016/0014-5793(93)81710-H; TOMIDA M, 1994, J BIOCHEM-TOKYO, V115, P557, DOI 10.1093/oxfordjournals.jbchem.a124375; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348	47	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23976	23985		10.1074/jbc.272.38.23976	http://dx.doi.org/10.1074/jbc.272.38.23976			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295349	hybrid			2022-12-25	WOS:A1997XX38100074
J	Lee, J; Dawes, IW; Roe, JH				Lee, J; Dawes, IW; Roe, JH			Isolation, expression, and regulation of the pgr1(+) gene encoding glutathione reductase absolutely required for the growth of Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YAP-1 TRANSCRIPTIONAL REGULATION; YEAST SACCHAROMYCES-CEREVISIAE; FISSION YEAST; ESCHERICHIA-COLI; OXIDATIVE STRESS; DISULFIDE OXIDOREDUCTASES; RIBONUCLEOTIDE REDUCTASE; GLUTAREDOXIN SYSTEMS; TARGET GENE; THIOREDOXIN	The pgr1(+) C gene encoding glutathione reductase (GR, EC 1.6.4.2) was isolated from Schizosaccharomyces pombe using a polymerase chain reaction fragment as a probe. The gene consists of two exons and an intron of 55 nucleotides, encoding a polypeptide of 465 amino acids (50,238 Da) with conserved residues characteristic of GR. The transcriptional start site was localized at 239 nucleotides upstream from the ATG initiation codon. The level of transcript as well as the GR enzyme activity increased more than 11-fold when the cloned pgr1(+) gene was expressed on a multicopy plasmid. This overexpression conferred on S. pombe cells snore resistance against menadione, a redox cycling agent, but not against H2O2. The level of pgr1(+) transcripts increased by treatment with oxidants such as menadione, cumene hydroperoxide, and diamide. It also increased by treatment with high osmolarity, heat shock, or at the stationary growth phase. The deletion of the pap1(+) C gene encoding an AP-1 homolog in S. pombe caused reduction in tale pgr1(+) gene expression. Furthermore, Delta pap1 cells lost the inducibility of pgr1(+) gene expression by the above stresses, implying that Pap1 is involved in general stress-inducible gene expression. When the pgr1(+) gene was disrupted, the haploid spores were not viable. Repression of nmt1 promoter-driven pgr1(+) expression by thiamine caused cessation of growth, which was rescued by the episomal pgi-IC gene. These results indicate that GR activity, which efficiently reduces GSSG, is essentially required for the growth of S. pombe, unlike in Saccharomyces cerevisiae or Escherichia coli.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MICROBIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, RES CTR MOL MICROBIOL, SEOUL 151742, SOUTH KOREA; UNIV NEW S WALES, SCH BIOCHEM & MOL GENET, SYDNEY, NSW 2052, AUSTRALIA	Seoul National University (SNU); Seoul National University (SNU); University of New South Wales Sydney								ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; Chesney JA, 1996, J BACTERIOL, V178, P2131, DOI 10.1128/jb.178.7.2131-2135.1996; COLLINSON LP, 1995, GENE, V156, P123, DOI 10.1016/0378-1119(95)00026-3; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V22, P739, DOI 10.1046/j.1365-2958.1996.d01-1727.x; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; KISTLER M, 1990, MUTAGENESIS, V5, P39, DOI 10.1093/mutage/5.1.39; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Lee J, 1995, MICROBIOL-SGM, V141, P3127, DOI 10.1099/13500872-141-12-3127; LOPEZBAREA J, 1990, GLUTATHIONE METABOLI, P105; Manchenko GP., 1994, HDB DETECTION ENZYME, P82; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; MUTOH N, 1988, BIOCHEM BIOPH RES CO, V151, P32, DOI 10.1016/0006-291X(88)90555-4; NAKAGAWA CW, 1995, J BIOCHEM-TOKYO, V118, P109, DOI 10.1093/oxfordjournals.jbchem.a124864; Nasim A., 1989, MOL BIOL FISSION YEA; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSELL P, 1989, MOL BIOL FISSION YEA, P244; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SMITH IK, 1988, ANAL BIOCHEM, V175, P408, DOI 10.1016/0003-2697(88)90564-7; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	57	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23042	23049		10.1074/jbc.272.37.23042	http://dx.doi.org/10.1074/jbc.272.37.23042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287302	hybrid			2022-12-25	WOS:A1997XV74400013
J	Ohta, T; Kinoshita, T; Naito, M; Nozaki, T; Masutani, M; Tsuruo, T; Miyajima, A				Ohta, T; Kinoshita, T; Naito, M; Nozaki, T; Masutani, M; Tsuruo, T; Miyajima, A			Requirement of the caspase-3/CPP32 protease cascade for apoptotic death following cytokine deprivation in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; POLY(ADP-RIBOSE) POLYMERASE; ICE/CED-3 PROTEASE; EXPRESSION; FAS; ICE; RECEPTOR; ACTIVATION; SURVIVAL; IMMUNE	Hematopoietic cytokines transduce cell survival signals, which are distinct from the signals necessary for the stimulation of DNA synthesis, Recently, the Ras and phosphatidylinositol 3-kinase pathways have been shown to play important roles in preventing apoptosis in various cell types, e.g. hematopoietic cells and neuronal cells, Withdrawal of cytokine(s), in turn, results in rapid inactivation of these survival pathways and eventually leads to cell death accompanied by the hallmarks of apoptosis, However, the mechanism of cell death caused by cytokine deprivation has not been fully elucidated, In this study, we demonstrate that caspase-3/CPP32, a member of the caspase/interleukin-1 beta-converting enzyme family, is activated upon interleukin (IL)-3 deprivation in IL-3-dependent cells as well as IL-2 deprivation in IL-2-dependent cells, In addition, poly(ADP-ribose) polymerase, a cellular substrate for the caspase family proteases, was degraded into apoptotic fragments in both cell lines after cytokine removal, Furthermore, inhibition of a caspase family protease by synthetic peptides suppressed apoptotic death, These results indicate that the activation of a caspase-like protease(s) is required for the progression of apoptosis following cytokine deprivation. However, readdition of IL-3 did not restore the proliferative potential of the cells that survived in the presence of the peptide inhibitor after IL-3 depletion, Therefore, cellular commitment to apoptosis appears to precede the activation of a caspase-like protease(s).	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,LAB CELLULAR BIOSYNTH,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BIOMED RES LAB,BUNKYO KU,TOKYO 113,JAPAN; NATL CANC CTR,RES INST,DIV BIOCHEM,CHUO KU,TOKYO 104,JAPAN	University of Tokyo; University of Tokyo; National Cancer Center - Japan								ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDERSON MW, 1992, ENVIRON HEALTH PERSP, V98, P13, DOI 10.2307/3431243; ANDREA K, 1997, NATURE, V385, P544; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; IKEJIMA M, 1989, BIOCHEM BIOPH RES CO, V163, P739, DOI 10.1016/0006-291X(89)92285-7; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KINOSHITA T, 1997, IN PRESS ONCOGENE, V14; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VASILAKOS JP, 1995, J IMMUNOL, V155, P3433; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	39	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23111	23116		10.1074/jbc.272.37.23111	http://dx.doi.org/10.1074/jbc.272.37.23111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287312	hybrid			2022-12-25	WOS:A1997XV74400023
J	Jacobsen, R; Yoshikami, D; Ellison, M; Martinez, J; Gray, WR; Cartier, GE; Shon, KJ; Groebe, DR; Abramson, SN; Olivera, RM; McIntosh, JM				Jacobsen, R; Yoshikami, D; Ellison, M; Martinez, J; Gray, WR; Cartier, GE; Shon, KJ; Groebe, DR; Abramson, SN; Olivera, RM; McIntosh, JM			Differential targeting of nicotinic acetylcholine receptors by novel alpha A-conotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONUS PEPTIDES; LIGAND-BINDING; SITES; VENOM; SELECTIVITY; ANTAGONIST; SUBUNIT; PROBES; GI; MI	We describe the isolation and characterization of two peptide toxins from Conus ermimeus venom targeted to nicotinic acetylcholine receptors (nAChRs). The peptide structures have been confirmed by mass spectrometry and chemical synthesis, In contrast to the 12-18 residue, 4 Cys-containing alpha-conotoxins, the new toxins have 30 residues and 6 Cys residues. The toxins, named alpha A-conotoxins EIVA and EIVB, block both Torpedo and mouse alpha 1-containing muscle subtype nAChRs expressed in Xenopus oocytes at low nanomolar concentrations. In contrast to alpha-bungarotoxin, alpha A-EIVA is inactive at alpha 7-containing nAChRs even at micromolar concentrations. In this regard, alpha A-EIVA is similar to the previously described alpha-conotoxins (e.g. alpha-MI and alpha-GI) which also selectively target alpha 1- versus alpha 7-containing nAChRs, However, alpha-MI and alpha-GI discriminate between the alpha/delta versus alpha/gamma subunit interfaces of the mouse muscle nAChR with 10,000-fold selectivity. In contrast, alpha A-conotoxin EIVA blocks both the alpha/gamma site and alpha/delta site with equally high affinity but with distinct kinetics. The alpha A-conotoxins thus represent novel probes for the alpha/gamma as well as the alpha/delta binding sites of the nAChR.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT PSYCHIAT,SALT LAKE CITY,UT 84112; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NIGMS NIH HHS [P01 GM48677] Funding Source: Medline; NIMH NIH HHS [K20 MH0929, MH53631] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053631, K20MH000929, R29MH053631] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CHARNET P, 1992, MOL PHARMACOL, V41, P708; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; GRAY WR, 1983, J BIOL CHEM, V258, P2247; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; GROEBE DR, 1995, J BIOL CHEM, V270, P281, DOI 10.1074/jbc.270.1.281; Guddat LW, 1996, BIOCHEMISTRY-US, V35, P11329, DOI 10.1021/bi960820h; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; Hille B., 1992, IONIC CHANNELS EXCIT; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MYERS RA, 1991, BIOCHEMISTRY-US, V30, P9370, DOI 10.1021/bi00102a034; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; SEGUELA P, 1993, J NEUROSCI, V13, P596; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1991, J BIOL CHEM, V266, P13679; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; TAYLOR P, 1983, CURR TOP MEMBR TRANS, V18, P407; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	27	70	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22531	22537		10.1074/jbc.272.36.22531	http://dx.doi.org/10.1074/jbc.272.36.22531			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278406	hybrid			2022-12-25	WOS:A1997XV49200026
J	Jakobsson, PJ; Mancini, JA; Riendeau, D; FordHutchinson, AW				Jakobsson, PJ; Mancini, JA; Riendeau, D; FordHutchinson, AW			Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE C-4 SYNTHASE; GUINEA-PIG LUNG; S-TRANSFERASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; SUBSTRATE-SPECIFICITY; ARACHIDONIC-ACID; PURIFICATION; ACTIVATION; SEQUENCE; BINDING	5-Lipoxygenase activating protein (FLAP), leukotriene-C-4 (LTC4) synthase, and microsomal glutathione S-transferase II (microsomal GST-II) are all members of a common gene family that may also include microsomal GST-I; The present work describes the identification and characterization of a novel member of this family termed microsomal glutathione S-transferase III (microsomal GST-III). The open reading frame encodes a 16.5-kDa protein with a calculated pI of 10.2. Microsomal GST-III has 36, 27, 22, and 20% amino acid identity to microsomal GST-II, LTC, synthase, microsomal GST-I, and FLAP, respectively. Microsomal GST-III also has a similar hydrophobicity pattern to FLAP, LTC, synthase, and microsomal GST-I. Fluorescent in situ hybridization mapped microsomal GST-III to chromosomal localization 1q23. Like microsomal GST-II, microsomal GST-III has a wide tissue distribution (at the mRNA level) and is predominantly expressed in human heart, skeletal muscle, and adrenal cortex, and it is also found in brain, placenta, liver, and kidney tissues. Expression of microsomal GST-III mRNA was also detected in several glandular tissues such as pancreas, thyroid, testis, and ovary. In contrast, microsomal GST-III mRNA expression-was very low (if any) in lung, thymus, and peripheral blood leukocytes. Microsomal GST-III protein was expressed in a baculovirus insect cell system, and microsomes from Sf9 cells containing either microsomal GST-II or microsomal GST-III were both found to possess glutathione-dependent peroxidase activity as shown by their ability to reduce 5-HPETE to 5-HETE in the presence of reduced glutathione. The apparent K-m of 5-HPETE was determined to be approximately 7 mu M for microsomal GST-LI and 21 mu M for microsomal GST-III. Microsomal GST-III was also found to catalyze the production of LTC4 from LTA(4) and reduced glutathione. Based on these catalytic activities it is proposed that this novel membrane protein is a member of the microsomal glutathione S-transferase super family, which also includes microsomal GST-I, LTC4 synthase, FLAP, and microsomal GST-II.	MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company			Jakobsson, Per-Johan/ABC-5594-2021					ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; Andersson C, 1994, Adv Pharmacol, V27, P19, DOI 10.1016/S1054-3589(08)61028-5; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; DEJONG JL, 1990, GENOMICS, V6, P379, DOI 10.1016/0888-7543(90)90580-N; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HABIG WH, 1974, J BIOL CHEM, V249, P7130; IZUMI T, 1988, BIOCHIM BIOPHYS ACTA, V959, P305; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MANCINI JA, 1994, LIFE SCI, V54, P137; MANTLE TJ, 1995, BIOCHEM SOC T, V23, P423, DOI 10.1042/bst0230423; MCLELLAN LI, 1989, BIOCHEM J, V258, P87, DOI 10.1042/bj2580087; METTERS KM, 1994, J BIOL CHEM, V269, P12816; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MORGENSTERN R, 1979, BIOCHEM BIOPH RES CO, V87, P657, DOI 10.1016/0006-291X(79)92009-6; MORGENSTERN R, 1984, BIOCHEM PHARMACOL, V33, P3609, DOI 10.1016/0006-2952(84)90145-X; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; MORGENSTERN R, 1988, J BIOL CHEM, V263, P6671; MOSIALOU E, 1995, ARCH BIOCHEM BIOPHYS, V320, P210, DOI 10.1016/0003-9861(95)90002-0; MOSIALOU E, 1993, FEBS LETT, V315, P77, DOI 10.1016/0014-5793(93)81137-O; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; Otieno MA, 1997, DRUG METAB DISPOS, V25, P12; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scoggan KA, 1997, J BIOL CHEM, V272, P10182; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SINGHAL SS, 1992, ARCH BIOCHEM BIOPHYS, V299, P232, DOI 10.1016/0003-9861(92)90269-3; SODERSTROM M, 1988, BIOCHEM J, V250, P713, DOI 10.1042/bj2500713; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	36	121	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22934	22939		10.1074/jbc.272.36.22934	http://dx.doi.org/10.1074/jbc.272.36.22934			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278457	hybrid			2022-12-25	WOS:A1997XV49200079
J	Zhao, X; Gschwend, JE; Powell, CT; Foster, RG; Day, KC; Day, ML				Zhao, X; Gschwend, JE; Powell, CT; Foster, RG; Day, KC; Day, ML			Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for protein kinase c-signalled apoptosis of prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ALTERED EXPRESSION; CDK INHIBITORS; CYCLIN E-CDK2; ALLELIC LOSS; GENE; ACTIVATION; INDUCTION; DEATH; ALPHA	dBoth protein kinase C and the retinoblastoma tumor suppressor protein have been linked to the regulation of cell growth and bell death, suggesting the differential roles these factors play in mediating cell fate, In some cells, protein kinase C-induced activation of the retinoblastoma protein results in G(1) arrest, However, inducible overexpression and activation of the protein kinase C alpha isozyme or the addition of 12-O-tetradecanoylphorbol-13-acetate in the prostate epithelial cell line, LNCaP, resulted in apoptosis preceded by induction of p21 and dephosphorylation of the retinoblastoma protein, Consistent with a role for the retinoblastoma growth suppressor protein in protein kinase C-induced apoptosis, DU145 cells, which do not express functional retinoblastoma protein or LNCaP cells, which have been transfected with the retinoblastoma inhibitor, E1a, were resistant to apoptosis, LNCaP apoptosis was initiated by a unique conflict between the growth-suppressive activity of the retinoblastoma protein and growth-promoting mitogenic signals, Thus, when this conflict was prevented by serum depletion, apoptosis was suppressed, The caspase family of cysteine proteases is believed to encompass the execution machinery of mammalian apoptosis, and addition of the cell-permeable caspase inhibitor, Z-Val-Ala-Asp-fluoromethylketone, afforded nearly total protection from protein kinase C-signaled apoptosis, This protection correlated with the total loss of caspase activity as measured by the proteolytic cleavage of nuclear poly(ADP-ribose) polymerase, On the basis of these results, we propose that protein kinase C regulates a novel cell death pathway that is initiated by a cellular conflict between retinoblastoma growth-suppressive signals and serum mitogenic signals in proliferating prostate epithelial cells and that is executed by the caspase family of cysteine proteases.	DEPT SURG,UROL SECT,ANN ARBOR,MI 48109; UNIV MICHIGAN,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; WASHINGTON UNIV,SCH MED,DEPT MED & CELL BIOL,ST LOUIS,MO 63110	University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; Washington University (WUSTL)					NCI NIH HHS [P50 CA69568] Funding Source: Medline; NIDDK NIH HHS [DK/CA47650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; Blagosklonny MV, 1997, CANCER RES, V57, P320; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; CLEMENS MJ, 1992, J CELL SCI, V103, P881; Cooney KA, 1996, CANCER RES, V56, P1142; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; DAY ML, 1993, CANCER RES, V53, P5597; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Frey MR, 1997, J BIOL CHEM, V272, P9424; GAO X, 1995, ONCOGENE, V11, P1395; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; Ittmann MM, 1996, HUM PATHOL, V27, P28, DOI 10.1016/S0046-8177(96)90134-3; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; Livneh E, 1996, ONCOGENE, V12, P1545; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MICHIELI P, 1994, CANCER RES, V54, P3391; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; Wang H, 1996, ONCOGENE, V13, P373; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	42	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22751	22757		10.1074/jbc.272.36.22751	http://dx.doi.org/10.1074/jbc.272.36.22751			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278434	hybrid			2022-12-25	WOS:A1997XV49200055
J	Brownawell, AM; Creutz, CE				Brownawell, AM; Creutz, CE			Calcium-dependent binding of sorcin to the N-terminal domain of synexin (annexin VII)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; TYROSINE-PROTEIN-KINASE; CHROMAFFIN GRANULES; CHROMOSOMAL LOCALIZATION; ESCHERICHIA-COLI; LIGHT CHAIN; PURIFICATION; EXPRESSION; SEQUENCE; XI	The annexins are characterized by their ability to bind phospholipid membranes in a Ca2+-dependent manner. Sequence variability between the N-terminal domains of the family members may contribute to the specific cellular function of each annexin. To identify proteins that interact with the N-terminal domain of synexin (annexin VII), a fusion protein was constructed composed of glutathione S-transferase fused to amino acids 1-145 of human synexin, Affinity chromatography using this construct identified sorcin as a Ca2+-dependent synexin-binding protein. Overlay assays confirmed the interaction. The glutathione S-transferase construct associates with recombinant sorcin over the range of pCa(2+) = 4.7-3.1 with no binding observed at pCa(2+) = 5.4. Overlay assays using deletion constructs of the synexin N-terminal domain mapped the sorcin binding site to the N-terminal 31 amino acids of the synexin protein. Additionally, synexin forms a complex with sorcin and recruits this protein to chromaffin granule membranes in a Ca2+-dependent manner. Sorcin is able to inhibit synexin-mediated chromaffin granule aggregation in a manner saturable with increasing sorcin concentrations, but does not influence the Ca2+ sensitivity of synexin-mediated granule aggregation. Therefore, the interaction between sorcin and synexin may serve to regulate the functions of these proteins on membrane surfaces iri a Ca2+-dependent manner.			Brownawell, AM (corresponding author), UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053266] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CREUTZ CE, 1979, J BIOL CHEM, V254, P553; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; CREUTZ CE, 1992, J CELL SCI, V103, P1177; DORING V, 1991, J BIOL CHEM, V266, P17509; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Fernandez MP, 1996, GENOMICS, V37, P366, DOI 10.1006/geno.1996.0571; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; GREENWOOD M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P429, DOI 10.1016/0167-4781(91)90137-B; Gruenberg Jean, 1993, Trends in Cell Biology, V3, P224, DOI 10.1016/0962-8924(93)90116-I; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMADA H, 1988, CANCER RES, V48, P3173; JOHNSSON N, 1988, FEBS LETT, V236, P201, DOI 10.1016/0014-5793(88)80314-4; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JONGSMA APM, 1987, CANCER RES, V47, P2875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MAGENDZO K, 1991, J BIOL CHEM, V266, P3228; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; MATSUSHIMA N, 1990, PROTEINS, V7, P125, DOI 10.1002/prot.340070204; MEYERS MB, 1987, BIOCHEM PHARMACOL, V36, P2373, DOI 10.1016/0006-2952(87)90606-X; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 1997, BIOPHYS J, V72, pA333; MIZUTANI A, 1995, ARCH BIOCHEM BIOPHYS, V318, P157, DOI 10.1006/abbi.1995.1216; NAKA M, 1994, BBA-MOL CELL RES, V1223, P348, DOI 10.1016/0167-4889(94)90094-9; PAZOLES CJ, 1978, J BIOL CHEM, V253, P3962; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Srivastava M, 1996, BIOCHEM J, V316, P729, DOI 10.1042/bj3160729; TOKUMITSU H, 1993, ARCH BIOCHEM BIOPHYS, V303, P302, DOI 10.1006/abbi.1993.1287; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; WANG SL, 1995, BBA-GENE STRUCT EXPR, V1260, P285, DOI 10.1016/0167-4781(94)00206-I; WATANABE M, 1993, BIOCHEM BIOPH RES CO, V196, P1376, DOI 10.1006/bbrc.1993.2405; ZHANGKECK ZY, 1993, BIOCHEM J, V289, P735, DOI 10.1042/bj2890735	46	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22182	22190		10.1074/jbc.272.35.22182	http://dx.doi.org/10.1074/jbc.272.35.22182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268363	hybrid			2022-12-25	WOS:A1997XT85000075
J	Buchholz, CJ; Koller, D; Devaux, P; Mumenthaler, C; SchneiderSchaulies, J; Braun, W; Gerlier, D; Cattaneo, R				Buchholz, CJ; Koller, D; Devaux, P; Mumenthaler, C; SchneiderSchaulies, J; Braun, W; Gerlier, D; Cattaneo, R			Mapping of the primary binding site of measles virus to its receptor CD46	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COFACTOR PROTEIN CD46; EPSTEIN-BARR-VIRUS; AMINO-ACID-RESIDUES; POLIOVIRUS RECEPTOR; SCANNING MUTAGENESIS; CELLULAR RECEPTOR; ATOMIC-STRUCTURE; HUMAN BRAIN; DOMAINS; FUSION	The measles virus (Mn) hemagglutinin binds to the complement control protein (CCP) CD46 primarily through the two external modules, CCP-I and -II, To define the residues involved in binding, 40 amino acids predicted to be solvent-exposed on the CCP-I-II module surface were changed to either alanine or serine, Altered proteins were expressed on the cell surface, and their abilities to bind purified PUN particles, a soluble form of hemagglutinin (sH) and nine CD46-specific antibodies competing to different levels with sH attachment, were measured, All proteins retained, at least in part, PUN and sH binding, but some completely lost binding to certain antibodies. Amino acids essential for binding of antibodies weakly or moderately competing with sH attachment are situated in the membrane-distal tip of CCP-I, whereas residues involved in binding of strongly sH competing antibodies cluster in the center of CCP-I (Arg-25, Asp-27) or in CCP-II (Arg-69, Asp-70). Both clusters face the same side of CCP-I II and map close to amino acid exchanges impairing sH binding (E11A, R29A, P39A, and D70A) or MV binding (D70A and E84A) and to a six-amino acid loop, previously shown to be necessary for sH binding.	UCBI, IVMC, CNRS, UMR 5537, F-69372 LYON 08, FRANCE; ETH HONGGERBERG, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND; UNIV WURZBURG, INST IMMUNOL & VIROL, D-97078 WURZBURG, GERMANY; UNIV TEXAS, MED BRANCH, SEALY CTR STRUCT BIOL, GALVESTON, TX 77555 USA; UNIV ZURICH, INST MOL BIOL, ABT 1, CH-8093 ZURICH, SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Wurzburg; University of Texas System; University of Texas Medical Branch Galveston; University of Zurich			Braun, Werner/A-6642-2012; Gerlier, Denis/L-6094-2014	Gerlier, Denis/0000-0001-5539-456X; Devaux, Patricia/0000-0002-5345-8336; Buchholz, Christian/0000-0002-9837-7345				ADAMS EM, 1991, J IMMUNOL, V147, P3005; AOKI J, 1994, J BIOL CHEM, V269, P8431; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; BERNHARDT G, 1994, VIROLOGY, V203, P344, DOI 10.1006/viro.1994.1493; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Buchholz CJ, 1996, J VIROL, V70, P3716, DOI 10.1128/JVI.70.6.3716-3723.1996; Buchholz CJ, 1996, VIROLOGY, V217, P349, DOI 10.1006/viro.1996.0122; CATTANEO R, 1993, J VIROL, V67, P1493, DOI 10.1128/JVI.67.3.1493-1502.1993; CLARKSON NA, 1995, J VIROL, V69, P5497, DOI 10.1128/JVI.69.9.5497-5501.1995; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Devaux P, 1997, J VIROL, V71, P4157, DOI 10.1128/JVI.71.5.4157-4160.1997; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERLIER D, 1995, TRENDS MICROBIOL, V3, P338, DOI 10.1016/S0966-842X(00)88972-6; GREWE JM, 1994, CELLULAR RECEPTORS A, P195; HARRISON SC, 1994, COLD SPRING HARBOR M, P33; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; KOLLER D, 1996, THESIS SWISS I TECHN; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MARTIN DR, 1991, J EXP MED, V174, P1299, DOI 10.1084/jem.174.6.1299; MCCLURE JE, 1992, PROG MED VIROL, V39, P116; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; MOLINA H, 1991, J BIOL CHEM, V266, P12173; MOORE MD, 1991, J VIROL, V65, P3559, DOI 10.1128/JVI.65.7.3559-3565.1991; MORRISON ME, 1994, J VIROL, V68, P2578, DOI 10.1128/JVI.68.4.2578-2588.1994; Mumenthaler C, 1997, PROTEIN SCI, V6, P588; Murakami Y, 1996, BIOL PHARM BULL, V19, P1541; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SCHNEIDERSCHAULIES J, 1995, J VIROL, V69, P2248, DOI 10.1128/JVI.69.4.2248-2256.1995; SEYA T, 1990, J IMMUNOL, V145, P238; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILD TF, 1991, J GEN VIROL, V72, P439, DOI 10.1099/0022-1317-72-2-439; WIMMER E, 1994, COLD SPRING HARBOR M, P1; WIMMER E, 1994, COLD SPRING HARBOR M, P101; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150	43	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22072	22079		10.1074/jbc.272.35.22072	http://dx.doi.org/10.1074/jbc.272.35.22072			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268348	hybrid			2022-12-25	WOS:A1997XT85000060
J	KahnPerles, B; Lipcey, C; Lecine, P; Olive, D; Imbert, J				KahnPerles, B; Lipcey, C; Lecine, P; Olive, D; Imbert, J			Temporal and subunit-specific modulations of the Rel/NF-kappa B transcription factors through CD28 costimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; COLONY-STIMULATING FACTOR; ALPHA-CHAIN GENE; HTLV-I TAX; C-REL; ADHESION MOLECULES; INTERLEUKIN-2 GENE; RESPONSE ELEMENT; SIGNAL-TRANSDUCTION; DOWN-REGULATION	Stimulation of highly purified primary T lymphocytes through CD2 and CD28 adhesion molecules induces a long-term proliferation, dependent on persistent autocrine secretion of interleukin 2 (IL-2), high and prolonged expression of inducible CD25/IL-2 receptor (alpha chain (IL-2R alpha), and secretion of growth factors such as the granulocyte-macrophage colony-stimulating factor (GM-CSF). CD28 costimulation appears to activate cytokine gene expression through conserved KB-related CD28 response (CD28RE) or cytokine 1 (CK-1) elements in addition to canonical NF-KB-binding sites. In this report, we assess: 1) the evolution of the expression, over an 8-day time period, of the Rel/NF-KB family of proteins in costimulated versus TcR/CD3 stimulated primary T cells; 2) the impact of changes on the in vitro occupancy of GM-CSF KB and CK-1, as well as IL-2R alpha KB sites; and 3) the differential regulation of newly synthesized p65 and c-Rel by IKB proteins. We show that CD2 + CD28 stimulation specifically induces, at maximal T cell proliferation phase, sustained nuclear overexpression of NFKB2 p52 and c-Rel subunits which might rely on long-lasting processing of p100 precursor for p52 and increased neosynthesis of c-Rel. This up-regulation correlates with sustained occupancy of GM-CSF KB and CK-1 elements by both proteins. Conversely, these subunits do not appear to bind to the IL-2R alpha KB site. Costimulation, but not TcR/CD3 stimulation, appears supported by sustained down-regulation of both IKB alpha and -beta regulators. Furthermore, contrary to p65, c-Rel appears to display little affinity for p105, p100 and IKB alpha regulators.			KahnPerles, B (corresponding author), INSERM,U119,UNITE CANCEROL EXPT,27 BLVD LEI ROURE,F-13009 MARSEILLE,FRANCE.		Imbert, Jean/AAG-1165-2020; Imbert, Jean/G-3248-2013; Lecine, Patrick/H-9338-2016	Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Lecine, Patrick/0000-0002-8091-7286				ALGARTE M, 1995, EMBO J, V14, P5060, DOI 10.1002/j.1460-2075.1995.tb00188.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTTIER P, 1985, J IMMUNOL, V135, P1624; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Cantorna MT, 1996, J IMMUNOL, V156, P2674; CERDAN C, 1992, J IMMUNOL, V149, P2255; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; CIVIL A, 1992, EUR J IMMUNOL, V22, P3041, DOI 10.1002/eji.1830221142; COSTELLO R, 1993, EUR J IMMUNOL, V23, P608, DOI 10.1002/eji.1830230304; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P947; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghoshal K, 1996, BIOCHEM J, V317, P689, DOI 10.1042/bj3170689; Gilmore TD, 1996, ONCOGENE, V13, P1367; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRUTERS RA, 1991, EUR J IMMUNOL, V21, P167, DOI 10.1002/eji.1830210125; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HANNINK M, 1990, ONCOGENE, V5, P1843; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAI JH, 1994, J BIOL CHEM, V269, P30077; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LANOIX J, 1994, ONCOGENE, V9, P841; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P1601, DOI 10.1002/eji.1830181020; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; MASUDA ES, 1994, BIOCHEM BIOPH RES CO, V205, P1518, DOI 10.1006/bbrc.1994.2839; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PIERCE JW, 1995, J IMMUNOL, V155, P1972; PIERRES A, 1988, EUR J IMMUNOL, V18, P685, DOI 10.1002/eji.1830180505; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	64	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21774	21783		10.1074/jbc.272.35.21774	http://dx.doi.org/10.1074/jbc.272.35.21774			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268307	hybrid			2022-12-25	WOS:A1997XT85000019
J	Rameh, LE; Arvidsson, AK; Carraway, KL; Couvillon, AD; Rathbun, G; Crompton, A; VanRenterghem, B; Czech, MP; Ravichandran, KS; Burakoff, SJ; Wang, DS; Chen, CS; Cantley, LC				Rameh, LE; Arvidsson, AK; Carraway, KL; Couvillon, AD; Rathbun, G; Crompton, A; VanRenterghem, B; Czech, MP; Ravichandran, KS; Burakoff, SJ; Wang, DS; Chen, CS; Cantley, LC			A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PH DOMAIN; PHOSPHOLIPASE C-DELTA(1); INOSITOL PHOSPHATES; BILAYER-MEMBRANES; CRYSTAL-STRUCTURE; EXCHANGE FACTOR; DYNAMIN	Pleckstrin homology (PH) and phosphotyrosine binding (PTB) domains are structurally related regulatory modules that are present in a variety of proteins involved in signal transduction, such as kinases, phospholipases, GTP exchange proteins, and adapter proteins. Initially these domains were shown to mediate protein-protein interactions, but more recently they were also found to bind phosphoinositides. Most studies to date have focused on binding of PH domains to phosphatidylinositol (PtdIns)-4-P and PtdIns-4,5-P-2 and have not considered the lipid products of phosphoinositide 3-kinase: PtdIns-3-P, PtdIns-3,4-P-2, and PtdIns-3,4,5-P-3. Here we have compared the phosphoinositide specificity of six different PH domains and the She PTB domain using all five phosphoinositides. We show that the Bruton's tyrosine kinase PH domain binds to PtdIns-3,4,5-P-3 with higher affinity than to PtdIns-4,5-P-2, PtdIns-3,4-P-2 or inositol 1,3,4,5-tetrakisphosphate (Ins-1,3,4,5 P-4). This selectivity is decreased by the rid mutation (R28C). Selective binding of PtdIns-3,4,5 P-3 over PtdIns-4,5-P-2 or PtdIns-3,4-P-2 was also observed for the amino-terminal PH domain of T lymphoma invasion and metastasis protein (Tiam-1), the PH domains of Son-of-sevenless (Sos) and, to a lesser extent, the PH domain of the beta-adrenergic receptor kinase. The oxysterol binding protein and beta-spectrin PH domains bound PtdIns-3,4,5-P-3 and PtdIns-4,5-P-2 with similar affinities. PtdIns-3,4,5-P-3 and PtdIns-4,5-P-2 also bound to the PTB domain of She with similar affinities and lipid binding was competed with phosphotyrosine (Tyr(P)-containing peptides. These results indicate that distinct PH domains select for different phosphoinositides.	BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA; UNIV KENTUCKY, COLL PHARM, DIV MED CHEM PHARMACEUT, LEXINGTON, KY 40536 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, BEIRNE CARTER CTR IMMUNOL RES, CHARLOTTESVILLE, VA 22908 USA	Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Kentucky; University of Virginia; University of Virginia	Rameh, LE (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.		Ravichandran, Kattur Soundarapandian/AAG-7319-2019; Cantley, Lewis C/D-1800-2014	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X; Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [GM41890, GM36624, R01 GM041890, GM 53448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R01GM053448, R01GM036624, R37GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	42	412	417	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22059	22066		10.1074/jbc.272.35.22059	http://dx.doi.org/10.1074/jbc.272.35.22059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268346	hybrid			2022-12-25	WOS:A1997XT85000058
J	Uren, A; Jakus, J; deMora, JF; Yeudall, A; Santos, E; Gutkind, S; Heidaran, MA				Uren, A; Jakus, J; deMora, JF; Yeudall, A; Santos, E; Gutkind, S; Heidaran, MA			Carboxyl-terminal domain of p27(Kip1) activates CDC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; CDK INHIBITOR; P21; P21(CIP1); BINDING	A variant form of p27 was unexpectedly detected in a synchronized culture of NIH3T3 cells treated with serum. The expression levels of this form of p27 which lacked its amino (NH2)-terminal region reached maximum during G(2)/M phase. Since the appearance of the NH2-terminal truncated form of p27 coincided with increased expression of Cdc2, we hypothesized that p27 may play a role in regulating Cdc2 catalytic activity. To test this hypothesis, wild type p27, as well as the aminoterminal (Np27) and carboxyl-terminal (Cp27), were individually expressed, purified, and examined for their ability to regulate CDC2 kinase activity in vitro, Our data showed that both p27 and Np27 inhibited CDC2 kinase activity. However, in marked contrast, Cp27 enhanced the CDC2 kinase activity. In vitro kinase assays showed that Cp27 and p27 were phosphorylated by CDC2, whereas Np27 was not. In addition, we demonstrated that deletion of the putative CDC2 phosphorylation site in the carboxyl-terminal domain of Cp27 diminished activation of CDC2 kinase activity otherwise stimulated by Cp27. A similar deletion did not have any effect on the inhibitory function of p27. Together these results suggest that the carboxyl-terminal domain of p27 may activate CDC2 kinase activity in vivo during G(2)/M and that this effect may be regulated by serine/threonine phosphorylation.	NCI,NIH,BETHESDA,MD 20892; NIDR,ORAL & PHARYNGEAL CANC BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			de Mora, Jaime Font/H-6304-2015; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; de Mora, Jaime Font/AAK-7591-2021	de Mora, Jaime Font/0000-0002-6816-2095; Gutkind, J. Silvio/0000-0002-5150-4482; de Mora, Jaime Font/0000-0002-6816-2095				CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jakus J, 1996, ONCOGENE, V12, P2369; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nigg E A, 1991, Semin Cell Biol, V2, P261; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8	25	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21669	21672		10.1074/jbc.272.35.21669	http://dx.doi.org/10.1074/jbc.272.35.21669			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268291	hybrid			2022-12-25	WOS:A1997XT85000003
J	Desai, SD; Liu, LF; VazquezAbad, D; DArpa, P				Desai, SD; Liu, LF; VazquezAbad, D; DArpa, P			Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CLEAVABLE COMPLEXES; PROTEOLYTIC PATHWAY; REPLICATION FORKS; CELL-CYCLE; MULTIUBIQUITIN CHAIN; SCLERODERMA PATIENTS; CONJUGATING ENZYMES; PROTEASOME PATHWAY; ACTIVATING ENZYME; TRANSCRIPTION	y Topoisomerase I (TOP1) relaxes superhelical DNA through a breakage/rejoining reaction in which the active site tyrosine links covalently to a 3' phosphate at the break site as a transient intermediate, The antitumor drug camptothecin (CPT) and its analogs inhibit the rejoining step of the breakage/rejoining reaction, which traps the enzyme in covalent linkage with DNA (the cleavable complex), Little is known about the fate of cellular TOP1 trapped in the cleavable complex, We have analyzed TOP1 in mammalian cell lines treated with CPT, When CPT-treated cells were lysed with either SDS or alkali and analyzed by Western blotting, greater than 90% of the TOP1 was linked to DNA, Nuclease treatment of the cell lysate to remove the covalently linked DNA from TOP1 revealed a distinct ladder of higher molecular weight bands having properties indicative of multi-ubiquitin (Ub) conjugates of TOP1, Approximately 5-10% of TOP1 was present as these conjugates within minutes of CPT treatment. Consistent with ubiquitination, TOP1 was not modified in ts85 cells at the restrictive temperature for its thermolabile ubiquitin activating enzyme (El), Because conjugation with ubiquitin can mark proteins for destruction by the 26S proteasome, we analyzed TOP1 protein levels during prolonged CPT treatment, TOP1 protein levels were reduced to about 25% during CPT treatments of 2-4 h resulting from increased destruction, with the half-life dropping from 10-16 h down to 1-2 h. The destruction of TOP1, like the formation of Ub-TOP1 conjugates, was not observed in ts85 cells at the restrictive temperature, The destruction of TOP1 was also prevented in cells treated with MG-132 and lactacystin, specific inhibitors of the 26S proteasome. Finally, the multi-Ub conjugates of TOP1 were observed whether or not aphidicolin was included in cotreatment with CPT, indicating that replication fork activity was not involved in making TOP1 a substrate for ubiquitination, These results demonstrate that independent of DNA replication, the TOP1 cleavable complex is ubiquitinated and destroyed in cells treated with antitumor drugs that block the religation step of the TOP1 reaction.	UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM & MOL BIOL,BETHESDA,MD 20814; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854; CANC INST NEW JERSEY,NEW BRUNSWICK,NJ 08901; UNIV CONNECTICUT,SCH MED,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06030	Uniformed Services University of the Health Sciences - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Connecticut				D'Arpa, Peter/0000-0002-0562-0263; Liu, Leroy/0000-0001-9396-763X	NATIONAL CANCER INSTITUTE [R01CA059750, R01CA039662, R29CA059750] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662, CA59750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; BENDIXEN C, 1990, BIOCHEMISTRY-US, V29, P5613, DOI 10.1021/bi00475a028; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DARPA P, 1995, EXP CELL RES, V217, P125, DOI 10.1006/excr.1995.1071; DARPA P, 1990, CANCER RES, V50, P6919; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DARPA P, 1990, ARTHRITIS RHEUM-US, V33, P1501, DOI 10.1002/art.1780331007; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; ERICSSON C, 1986, EXP CELL RES, V167, P127, DOI 10.1016/0014-4827(86)90210-7; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; GILMOUR DS, 1987, MOL CELL BIOL, V7, P141, DOI 10.1128/MCB.7.1.141; GILMOUR DS, 1986, CELL, V44, P401, DOI 10.1016/0092-8674(86)90461-7; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; GRANT EP, 1995, J IMMUNOL, V155, P3750; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; LEE DH, 1996, J BIOL CHEM, V271, P23720; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Maniatis T., 1982, MOL CLONING; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; PORTER SE, 1989, MOL CELL BIOL, V9, P541, DOI 10.1128/MCB.9.2.541; RYAN AJ, 1994, CARCINOGENESIS, V15, P823, DOI 10.1093/carcin/15.5.823; SADIS S, 1995, MOL CELL BIOL, V15, P4086; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; SQUIRES S, 1993, CANCER RES, V53, P2012; TSAO YP, 1993, CANCER RES, V53, P5908; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU RS, 1971, P NATL ACAD SCI USA, V68, P3009, DOI 10.1073/pnas.68.12.3009; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	51	218	227	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24159	24164		10.1074/jbc.272.39.24159	http://dx.doi.org/10.1074/jbc.272.39.24159			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305865	hybrid			2022-12-25	WOS:A1997XY51500016
J	Mannick, JB; Miao, XQ; Stamler, JS				Mannick, JB; Miao, XQ; Stamler, JS			Nitric oxide inhibits Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1-BETA CONVERTING ENZYME; MEDIATED APOPTOSIS; T-CELLS; LYMPHOPROLIFERATIVE SYNDROME; MONOCLONAL-ANTIBODY; SIGNALING COMPLEX; HIV-INFECTION; LPR/LPR MICE	The Fas antigen (CD95, APO-1) is a transmembrane cell surface receptor that mediates apoptosis of many cell types when bound by Fas ligand or cross-linked by agonist antibody. The cellular factors regulating Fas-induced apoptosis have not been well defined. Here we show that basal nitric-oxide synthase (NOS) activity in human leukocytes inhibits Fas-induced apoptosis via a cGMP-independent mechanism. Further, NOS inhibits Fas-induced cleavage of poly(ADP-ribose) polymerase by members of the caspase family of cysteine proteases. These data suggest that Fas activity is under the control of the NO signaling pathway. NOS regulating the function of this member of the tumor necrosis factor receptor family suggests a new role for nitric oxide (or related molecules) in the human immune response.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DIV RESP,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DIV CARDIOVASC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University	Mannick, JB (corresponding author), DANA FARBER CANC INST,DIV INFECT DIS,JFB 422,44 BINNEY ST,BOSTON,MA 02115, USA.			Stamler, Jonathan/0000-0002-6866-1572				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALBINA JE, 1993, J IMMUNOL, V150, P5080; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BLANCO FJ, 1995, AM J PATHOL, V146, P75; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; EVANS TG, 1994, CLIN EXP IMMUNOL, V97, P83; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IZUI S, 1984, J IMMUNOL, V133, P227; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Kohno T, 1996, J IMMUNOL, V156, P4722; KONDO E, 1994, AM J PATHOL, V145, P330; MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NERI A, 1991, BLOOD, V77, P1092; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, BIOL NITRIC OXIDE, V1, P20; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TORRE D, 1995, AIDS, V9, P979, DOI 10.1097/00002030-199508000-00027; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANDENDOBBELSTE.DJ, 1996, J BIOL CHEM, V271, P14520; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	64	277	280	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24125	24128		10.1074/jbc.272.39.24125	http://dx.doi.org/10.1074/jbc.272.39.24125			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305857	hybrid			2022-12-25	WOS:A1997XY51500008
J	Tepper, AD; BoesendeCock, JGR; deVries, E; Borst, J; vanBlitterswijk, WJ				Tepper, AD; BoesendeCock, JGR; deVries, E; Borst, J; vanBlitterswijk, WJ			CD95/Fas-induced ceramide formation proceeds with slow kinetics and is not blocked by caspase-3/CPP32 inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CELL-DEATH; ICE/CED-3 PROTEASE; SIGNALING COMPLEX; SPHINGOMYELINASE; RECEPTOR; PATHWAY; CYTOTOXICITY; BIOSYNTHESIS; INVOLVEMENT	The current confusion regarding the relevance of endogenous ceramide in mediating GD95/Fas-induced apoptosis is based mainly on (i) discrepancies in kinetics of the ceramide response between different studies using the same apoptotic stimulus and (ii) the observation that late ceramide formation (hours) often parallels apoptosis onset, We investigated CD95-induced ceramide formation in Jurkat cells, using two methods (radiolabeling/thin layer chromatography and benzoylation/ high performance liquid chromatography), which, unlike the commonly used diglyceride kinase assay, discriminate between ceramide species and de novo formed dihydroceramide. We demonstrate that ceramide accumulates after several hours, reaching a I-fold increase after 8 h, kinetics closely paralleling apoptosis induction, No fast response was observed, not even in the presence of inhibitors of ceramide metabolism. The majority (similar to 70%) of the ceramide response remained unaffected when apoptosis was completely inhibited at the level of caspase-3/CPP32 processing by the inhibitor peptide DEVD-CHO. Exogenous cell-permeable C-2-ceramide induced the proteolytic processing of caspase-3, albeit viith somewhat slower kinetics than with CD95, DEVD-CHO dose-dependently inhibited C-2-ceramide- or exogenous sphingomyelinase-induced apoptosis, The results support the idea that ceramide acts in conjunction with the caspase cascade in CD95-induced apoptosis.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Borst, Jannie/0000-0002-8043-5009				Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cabot MC, 1996, FEBS LETT, V394, P129, DOI 10.1016/0014-5793(96)00942-8; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CIFONE MG, 1993, J EXP MED, V177, P1547; DHAIBO GS, 1997, J EXP MED, V185, P481; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; GOTTSCHALK AR, 1995, EUR J IMMUNOL, V25, P1032, DOI 10.1002/eji.1830250426; GROSS SK, 1980, ANAL BIOCHEM, V102, P429, DOI 10.1016/0003-2697(80)90178-5; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; IWAMORI M, 1974, J LIPID RES, V20, P86; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LOUIE K, 1988, BIOCHEMISTRY-US, V27, P9014, DOI 10.1021/bi00425a020; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Previati M, 1996, ANAL BIOCHEM, V233, P108, DOI 10.1006/abio.1996.0014; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	42	113	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24308	24312		10.1074/jbc.272.39.24308	http://dx.doi.org/10.1074/jbc.272.39.24308			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305886	hybrid			2022-12-25	WOS:A1997XY51500037
J	Lacorte, JM; Ktistaki, E; Beigneux, A; Zannis, VI; Chambaz, J; Talianidis, I				Lacorte, JM; Ktistaki, E; Beigneux, A; Zannis, VI; Chambaz, J; Talianidis, I			Activation of CAAT enhancer-binding protein delta (C/EBP delta) by interleukin-1 negatively influences apolipoprotein C-III expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-SPECIFIC EXPRESSION; HUMAN APOCIII GENE; ACUTE-PHASE GENES; NUCLEAR FACTOR; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; TRANSGENIC MICE; DNA-BINDING; I GENE	Tissue specific transcription of the apolipoprotein C-III (apoC-III) gene is mainly regulated by synergistic interactions between the liver-enriched transcription factor HNF-4, which binds to the proximal promoter, and ubiquitous factors, which bind to the upstream enhancer region, Here we show that apoC-III expression in HepG2 cells is negatively regulated in response to interleukin-1 (IL-1), and this inhibition is mainly due to transcriptional repression, CAAT enhancer-binding protein delta (C/EBP delta) was found to be the main mediator of IL-1-induced suppression. Analysis of the apoC-III promoter revealed two IL-1 response elements, The first is located in the proximal promoter region D and the second in the distal enhancer region I, Proximal element D is a high affinity binding site for C/EBP delta, while the enhancer element I is not directly recognized by this transcription factor, Functional analysis of different combinations of homologous and heterologous promoter constructs revealed that indirect interaction of C/EBP delta with site I, in the context of the full promoter, leads to repression. C/EBP delta is activated by phosphorylation during IL-1-induced signal transduction pathway, This modification is important for bath DNA binding activity and indirect transrepression of the apoC-III promoter.	FDN RES & TECHNOL HELLAS,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,CRETE,GREECE; INST BIOMED CORDELIERS,CNRS,URA 1283,F-75006 PARIS,FRANCE	Foundation for Research & Technology - Hellas (FORTH); Centre National de la Recherche Scientifique (CNRS)			Talianidis, Iannis/F-7556-2016	Talianidis, Iannis/0000-0002-1209-3609				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Aldred A.R., 1993, ACUTE PHASE PROTEINS, V1st ed., P21; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FEINGOLD KR, 1989, ENDOCRINOLOGY, V125, P267, DOI 10.1210/endo-125-1-267; FEY G, 1990, PROGR LIVER DIS, P89; FEY GH, 1987, MOL BIOL MED, V4, P323; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JOHNSON PF, 1994, TRANSCRIPTIONAL REGU, P143; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; LI XX, 1991, J BIOL CHEM, V266, P15192; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAJJELO B, 1990, EMBO J, V9, P457; MORRONE G, 1989, EMBO J, V8, P3767, DOI 10.1002/j.1460-2075.1989.tb08553.x; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; OGAMI K, 1990, J BIOL CHEM, V265, P9808; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; POLI V, 1994, TRANSCRIPTIONAL REGU, P84; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; WALSH A, 1993, J LIPID RES, V34, P617; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181	59	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23578	23584		10.1074/jbc.272.38.23578	http://dx.doi.org/10.1074/jbc.272.38.23578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295296	hybrid			2022-12-25	WOS:A1997XX38100021
J	Sano, T; Ohyama, K; Yamano, Y; Nakagomi, Y; Nakazawa, S; Kikyo, M; Shirai, H; Blank, JS; Exton, JH; Inagami, T				Sano, T; Ohyama, K; Yamano, Y; Nakagomi, Y; Nakazawa, S; Kikyo, M; Shirai, H; Blank, JS; Exton, JH; Inagami, T			A domain for G protein coupling in carboxyl-terminal tail of rat angiotensin II receptor type 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-2-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAINS; PHOSPHOLIPASE-C; IDENTIFICATION; BINDING; EXPRESSION; SEQUENCE; CELLS; INTERNALIZATION	To delineate domains essential for G(q) protein coupling in the C-terminal region (C-tail) of rat angiotensin II (Ang II) receptor type 1A (AT(1A)), we modified the putative cytosolic regions of the receptor by truncation or alanine substitution and determined resultant changes in the guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) effect on Ang II binding and inositol trisphosphate production by the agonist, Independently, we studied the effect of synthetic C-tail peptides (P-5) and its alanine substitution analogs on [S-35]GTP gamma S binding to G(q), Effects of GTP gamma S on Ang II binding (shift to a low affinity form) and inositol trisphosphate production in the deletional mutant receptor 1-317 AT(1A) was similar to wild type AT(1A), whereas in shorter C-terminal deletion mutants 1-309, 1-311, 1-312, 1-313 AT(1A), and substitutional mutants Y312A, F313A, and L314A these activities were markedly reduced. The binding of [S-35]GTP gamma S to G(q) was promoted by the synthetic C-terminal peptide P-5 but not when mutated at Tyr(312), Phe(313), or Leu(314). Results indicate that Tyr(312), Phe(313), and Leu(314) in cytosolic carboxyl-terminal region of rat AT(1A) are essential for coupling and activation of G(q).	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOL BIOPHYS,NASHVILLE,TN 37232; YAMANASHI MED COLL,DEPT PEDIAT,YAMANASHI 40938,JAPAN; TOTTORI UNIV,FAC AGR,DEPT MET BIOCHEM,TOTTORI 680,JAPAN	Vanderbilt University; Vanderbilt University; University of Yamanashi; Tottori University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL058205, R01HL058205, P50HL014192, R01HL035323] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14192, HL58205, HL-35323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAKI S, 1992, BIOCHEM BIOPH RES CO, V182, P388, DOI 10.1016/S0006-291X(05)80157-3; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CRAWFORD KW, 1992, MOL PHARMACOL, V41, P154; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HESCHELER J, 1988, EMBO J, V7, P619, DOI 10.1002/j.1460-2075.1988.tb02855.x; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; INAGAMI T, 1992, J HYPERTENS, V10, P713; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARIE J, 1994, J BIOL CHEM, V269, P20815; MITCHELL J, 1991, END SOC ABSTR, V199; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SHIRAI H, 1995, HYPERTENSION, V25, P726, DOI 10.1161/01.HYP.25.4.726; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677	27	102	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23631	23636		10.1074/jbc.272.38.23631	http://dx.doi.org/10.1074/jbc.272.38.23631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295303	hybrid			2022-12-25	WOS:A1997XX38100028
J	Vora, AC; Chiu, R; McCord, M; Goodarzi, G; Stahl, SJ; Mueser, TC; Hyde, CC; Grandgenett, DP				Vora, AC; Chiu, R; McCord, M; Goodarzi, G; Stahl, SJ; Mueser, TC; Hyde, CC; Grandgenett, DP			Avian retrovirus U3 and U5 DNA inverted repeats - Role of nonsymmetrical nucleotides in promoting full-site integration by purified virion and bacterial recombinant integrases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOBLASTOSIS VIRUS INTEGRASE; IN-VITRO; CONCERTED INTEGRATION; VIRAL-DNA; PROTEIN INVITRO; SEQUENCES; BINDING; WATER; CLEAVAGE; TERMINI	The U3 and U5 termini of linear retrovirus DNA contain imperfect inverted repeats that are necessary for the concerted insertion of the termini into the host chromosome by viral integrase. Avian myeloblastosis virus integrase can efficiently insert the termini of retrovirus-like DNA donor substrates (480 base pairs) by a concerted mechanism (full-site reaction) into circular target DNA in vitro. The specific activities of virion-derived avian myeloblastosis virus integrase and bacterial recombinant Rous sarcoma virus (Prague A strain) integrase (similar to 50 nM or less) appear similar upon catalyzing the full-site reaction with 3'-OH recessed wild type or mutant donor substrates, We examined the role of the three nonsymmetrical nucleotides located at the 5th, 8th, and 12th positions in the U3 and U5 15-base pair inverted repeats for their ability to modify the full-site and simultaneously, the half-site strand transfer reactions. Our data suggest that the nucleotide at the 5th position appears to be responsible for the 3-5-fold preference for wild type U3 ends over wild type U5 ends by integrase for concerted integration. Additional mutations at the 5th or 6th position, or both, of U3 or U5 termini significantly increased (similar to 3 fold) the full-site reactions of mutant donors over wild type donors.	ST LOUIS UNIV,HLTH SCI CTR,INST MOL VIROL,ST LOUIS,MO 63110; NIAMS,NIH,BETHESDA,MD 20892	Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)					NATIONAL CANCER INSTITUTE [R01CA016312] Funding Source: NIH RePORTER; NCI NIH HHS [CA16312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Balakrishnan M, 1997, J VIROL, V71, P1025, DOI 10.1128/JVI.71.2.1025-1035.1997; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; FITZGERALD ML, 1992, J VIROL, V66, P6257, DOI 10.1128/JVI.66.11.6257-6263.1992; FITZGERALD ML, 1994, J VIROL, V68, P4314, DOI 10.1128/JVI.68.7.4314-4321.1994; FITZGERALD ML, 1991, ANAL BIOCHEM, V196, P19, DOI 10.1016/0003-2697(91)90111-6; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; GRANDGENETT DP, 1993, J VIROL, V67, P1628; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10205, DOI 10.1021/bi00032a014; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; REICIN AS, 1995, J VIROL, V69, P5904, DOI 10.1128/JVI.69.9.5904-5907.1995; Robinson CR, 1996, PROTEIN SCI, V5, P2119, DOI 10.1002/pro.5560051019; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; Sidorova NY, 1996, P NATL ACAD SCI USA, V93, P12272, DOI 10.1073/pnas.93.22.12272; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VARMUS HE, 1983, MOBILE GENETIC ELEME, P411; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; VINK C, 1993, TRENDS GENET, V9, P4333; VORA AC, 1995, J VIROL, V69, P7483, DOI 10.1128/JVI.69.12.7483-7488.1995; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454	30	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23938	23945		10.1074/jbc.272.38.23938	http://dx.doi.org/10.1074/jbc.272.38.23938			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295344	hybrid			2022-12-25	WOS:A1997XX38100069
J	Zugaza, JL; Waldron, RT; SinnettSmith, J; Rozengurt, E				Zugaza, JL; Waldron, RT; SinnettSmith, J; Rozengurt, E			Bombesin, vasopressin, endothelin, bradykinin, and platelet-derived growth factor rapidly activate protein kinase D through a protein kinase C-dependent signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; FOCAL ADHESION KINASE; STRUCTURALLY RELATED PEPTIDES; TYROSINE PHOSPHORYLATION; PHORBOL ESTERS; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; RAT-BRAIN; D PKD; DIACYLGLYCEROL	Protein kinase D (PKD) is a serine/threonine protein kinase that is activated by phorbol esters via protein kinase C in intact cells. To assess the physiological significance of this putative pathway, we examined the regulation of PKD in living cells by mitogenic regulatory peptides and by platelet-derived growth factors (PDGF). Our results demonstrate that bombesin rapidly induces PKD activation in Swiss 3T3 cells, as shown by autophosphorylation and syntide-2 phosphorylation assays, Maximum PKD activation (14-fold above base-line levels) was obtained 90 s after bombesin stimulation, Bombesin also induced PBD activation in Rat-1 cells stably transfected with the bombesin/gastrin releasing peptide (GRP) receptor and in COS-7 cells transiently co-transfected with PKD and bombesin/GRP receptor expression constructs, No inducible kinase activity was demonstrated when COS-7 cells were transfected with a kinase-deficient PKD mutant. Bombesin-mediated PKD activation was prevented by treatment of Swiss 3T3 cells with the protein kinase C inhibitors GF 1092030X and Ro 31-8220. In contrast, these compounds did not inhibit PKD activity when added directly in vitro. Vasopressin, endothelin, and bradykinin also activated PKD in Swiss 3T3 cells through a PRC-dependent pathway. Platelet-derived growth factor-stimulated PKD activation in Swiss 3T3 cells and in porcine aortic endothelial cells stably transfected with PDGF-beta receptors. Treatment with GF 1092030X or ro 31-8220 inhibited PKD activation induced by PDGF. Thus, our results indicate that PKD is activated by multiple signaling peptides through a protein kinase C-dependent signal transduction pathway in a variety of cell types.	IMPERIAL CANC RES FUND, GROWTH REGULAT LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Waldron, Richard Taliesin/ABF-2773-2020; Bustelo, Xose R./A-9526-2010	Waldron, Richard Taliesin/0000-0003-3151-6002; Bustelo, Xose R./0000-0001-9398-6072; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Charlesworth A, 1996, ONCOGENE, V12, P1337; COY DH, 1992, PEPTIDES, V13, P775, DOI 10.1016/0196-9781(92)90186-7; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HUBBARD SR, 1991, SCIENCE, V254, P1776; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISSANDOU M, 1989, BIOCHEM BIOPH RES CO, V163, P201, DOI 10.1016/0006-291X(89)92121-9; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MORRIS C, 1988, FEBS LETT, V231, P311, DOI 10.1016/0014-5793(88)80840-8; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STADDON JM, 1991, J BIOL CHEM, V266, P4840; TAKUWA N, 1987, J BIOL CHEM, V262, P182; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; Withers DJ, 1997, J BIOL CHEM, V272, P2509; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	63	156	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23952	23960		10.1074/jbc.272.38.23952	http://dx.doi.org/10.1074/jbc.272.38.23952			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295346	hybrid			2022-12-25	WOS:A1997XX38100071
J	Davidson, D; Cloutier, JF; Gregorieff, A; Veillette, A				Davidson, D; Cloutier, JF; Gregorieff, A; Veillette, A			Inhibitory tyrosine protein kinase p50(csk) is associated with protein-tyrosine phosphatase PTP-PEST in hemopoietic and non-hemopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTES; SH2 DOMAIN; ZETA-CHAIN; C-SRC; V-SRC; CSK; ACTIVATION; CLONING; GENE; PHOSPHORYLATION	p50(csk) is a cytosolic tyrosine protein kinase expressed in all cell types, Accumulating data show that it inhibits multiple cellular processes, as a consequence of its ability to repress the enzymatic activity of Src family tyrosine protein kinases, We previously demonstrated that, via its Src homology 3 (SH3) domain, Csk is tightly bound to PEP, a protein-tyrosine phosphatase (PTP) exclusively expressed in hemopoietic cells, In this report, we have tested the possibility that Csk also interacts with PTP-PEST, a ubiquitous PTP sharing structural homology with PEP, Our studies revealed that Csk was associated with PTP-PEST in a variety of cell types, including non-hemopoietic cells, This interaction involved the SH3 region of p50(csk) and a proline-rich region (PPPLPERTPESFVLADM) outside the catalytic region of PTP-PEST. Even though both PTP PEST and PEP were associated with Csk, significant differences were noted between these two PTPs. PTP-PEST, but not PEP, was also complexed with She, an adaptor molecule implicated in the has pathway, Moreover, PTP-PEST and PEP were found to accumulate primarily in distinct intracellular compartments in cell fractionation studies, In combination, these findings indicated that, like PEP, PTP-PEST is probably involved in Csk-mediated functions in mammalian cells, Moreover, they suggested that the roles of Csk-PTP-PEST and Csk-PEP are likely to be different.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University			Cloutier, Jean-François/K-2003-2012					ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FLORES E, 1994, MOL CELL BIOL, V14, P4938, DOI 10.1128/MCB.14.7.4938; FORD CE, 1994, J BIOL CHEM, V269, P30378; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; HABIB T, 1994, J BIOL CHEM, V269, P25243; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Huang K, 1996, ONCOGENE, V13, P1567; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kim YW, 1996, ONCOGENE, V13, P2275; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NADA S, 1993, CELL, V73, P125; NEET K, 1995, MOL CELL BIOL, V15, P4908; OETKEN C, 1994, ONCOGENE, V9, P1625; PERI KG, 1993, ONCOGENE, V8, P2765; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; ROZDZIAL MM, 1994, J IMMUNOL, V153, P1563; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SupertiFurga G, 1996, NAT BIOTECHNOL, V14, P600, DOI 10.1038/nbt0596-600; Tobe K, 1996, MOL CELL BIOL, V16, P4765; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEIL R, 1994, J BIOL CHEM, V269, P22830; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; YANG Q, 1993, J BIOL CHEM, V268, P6622	44	94	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23455	23462		10.1074/jbc.272.37.23455	http://dx.doi.org/10.1074/jbc.272.37.23455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287362	hybrid			2022-12-25	WOS:A1997XV74400073
J	Kooijman, M; Bloemendal, M; Traub, P; vanGrondelle, R; vanAmerongen, H				Kooijman, M; Bloemendal, M; Traub, P; vanGrondelle, R; vanAmerongen, H			Transient electric birefringence study of intermediate filament formation from vimentin and glial fibrillary acidic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; COILED-COIL MOLECULES; INTEGRAL-EQUATIONS; KERATIN FILAMENTS; EPIDERMAL KERATIN; ROD DOMAIN; DESMIN; MOUSE; MECHANISM; INVITRO	Mg2+-induced polymerization of type III intermediate filament proteins vimentin and glial fibrillary acidic protein was studied by transient electric birefringence. In the absence of MgCl2 we found a net permanent dipole moment, similar to 45-nm-long dimers for vimentin, similar to 65-nm-long tetramers, hexamers, and possibly octamers for both proteins, and 100-nm aggregates for glial fibrillary acidic protein. Controlled oligomerization occurred after the addition of MgCl2. Although the solutions contained (small) aggregates of different sizes, more or less discrete steps in polymer formation were observed, and it was possible to discriminate between an increase in width and length. At the first stage of polymerization (in 0.3 mM MgCl2 for vimentin and 0.2 mM MgCl2 for glial fibrillary acidic protein), the permanent dipole moment disappeared without a change in length of the particles. At higher MgCl2 concentrations, structures of approximately 100 nm were formed, which strongly tended to laterally assemble into full-width intermediate filament structures consisting of about 32 monomers. This contrasts with previous models where first full-width (similar to 10-nm) aggregates are formed, which then increase in length. Subsequently, two discrete elongation steps of 35 nm are observed that increase the length to 135 and 170 nm, respectively. Possible structural models are suggested for the polymerization.	FREE UNIV AMSTERDAM,DEPT PHYS & ASTRON,NL-1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM,INST MOL BIOL SCI,NL-1081 HV AMSTERDAM,NETHERLANDS; MAX PLANCK INST CELL BIOL,D-68526 LADENBURG,GERMANY	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Max Planck Society			van Amerongen, Herbert/J-9483-2016	van Amerongen, Herbert/0000-0002-9783-2895				AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; BROERSMA S, 1981, J CHEM PHYS, V74, P6989, DOI 10.1063/1.441071; BROERSMA S, 1960, J CHEM PHYS, V32, P1626, DOI 10.1063/1.1730994; EICHNER R, 1985, ANN NY ACAD SCI, V455, P381, DOI 10.1111/j.1749-6632.1985.tb50424.x; FREDERICQ E, 1973, ELECTRIC DICHROISM E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1993, FEBS LETT, V323, P63, DOI 10.1016/0014-5793(93)81449-A; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; KOOIJMAN M, 1994, J MOL BIOL, V236, P1241, DOI 10.1016/0022-2836(94)90024-8; KOOIJMAN M, 1995, J BIOL CHEM, V270, P2931, DOI 10.1074/jbc.270.7.2931; KOOIJMAN M, 1995, FEBS LETT, V358, P185, DOI 10.1016/0014-5793(94)01419-2; MANDELKERN M, 1981, J MOL BIOL, V152, P153, DOI 10.1016/0022-2836(81)90099-1; PARRY DAD, 1995, PROTEINS, V22, P267, DOI 10.1002/prot.340220307; Parry DAD, 1996, INT J BIOL MACROMOL, V19, P45, DOI 10.1016/0141-8130(96)01099-9; POTSCHKA M, 1990, EUR J BIOCHEM, V190, P503, DOI 10.1111/j.1432-1033.1990.tb15602.x; Provencher S. W., 1976, Journal of Chemical Physics, V64, P2772, DOI 10.1063/1.432601; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1976, BIOPHYS J, V16, P27, DOI 10.1016/S0006-3495(76)85660-3; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; QUINLAN RA, 1982, P NATL ACAD SCI-BIOL, V79, P3452, DOI 10.1073/pnas.79.11.3452; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; STEINERT PM, 1993, J BIOL CHEM, V268, P2878; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; VANHAERINGEN B, 1992, J BIOMOL STRUCT DYN, V9, P991, DOI 10.1080/07391102.1992.10507972; VORGIAS CE, 1983, BIOCHEM BIOPH RES CO, V115, P68, DOI 10.1016/0006-291X(83)90969-5; Weast RC, 1971, HDB CHEM PHYS, pC528; YANG ZW, 1988, BIOCHEMISTRY-US, V27, P7045, DOI 10.1021/bi00418a056; ZAKFROFF RV, 1979, P NATL ACAD SCI USA, V76, P6226	41	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22548	22555		10.1074/jbc.272.36.22548	http://dx.doi.org/10.1074/jbc.272.36.22548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278408	hybrid, Green Published			2022-12-25	WOS:A1997XV49200028
J	Schreiber, M; Poirier, C; Franchi, A; Kurzbauer, R; Guenet, JL; Carle, GF; Wagner, EF				Schreiber, M; Poirier, C; Franchi, A; Kurzbauer, R; Guenet, JL; Carle, GF; Wagner, EF			Structure and chromosomal assignment of the mouse fra-1 gene, and its exclusion as a candidate gene for oc (osteosclerosis)	ONCOGENE			English	Article						AP-1 target gene; Fos gene family; Fos11 genomic locus; fra-1; MMU 19; osteosclerosis (oc)	TRANSCRIPTION FACTOR AP-1; FOS-TRANSGENIC MICE; LACKING C-FOS; REGULATORY FUNCTION; CELL-PROLIFERATION; MAP; TRANSFORMATION; EXPRESSION; REGION; BONE	We have determined the genomic structure of the mouse fra-1 gene, which consists of four exons and three introns at positions also found in the other members of the fos gene family, Fra-1 is expressed rather highly in the brain and testes of adult mice, and at low levels in most other tissues, Absence of c-Fos leads to significantly reduced serum stimulation of fra-1 expression in gene targeted mouse fibroblasts, demonstrating that mitogen induction of fra-1 is partially mediated by c-Fos/AP-1. A polymorphic (CA)(n) microsatellite marker was found in intron 2 of fra-1 and used to map the gene to the centromeric region of mouse chromosome 19, Since fra-1 maps to the same genomic region as oc (osteosclerosis), an autosomal recessive disorder leading to the bone remodelling disease osteopetrosis, we tested it as a candidate gene for oc, The segregation of fra-1 in two different crosses of mice carrying oc and an allelism test between oc and a targeted disruption of fra-1 demonstrate that fra-1 and oc are two distinct genes rather than oc being a mutant allele of fra-1.	RES INST MOL PATHOL, A-1030 VIENNA, AUSTRIA; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE; UNIV NICE, FAC MED, LAB ETUD GENOME MURIN, CNRS, UMR 6549, F-06107 NICE 2, FRANCE	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Martin, Schreiber/F-2175-2013; Carle, Georges/GWC-5240-2022	Martin, Schreiber/0000-0003-1102-7789; Wagner, Erwin F/0000-0001-7872-0196; Carle, Georges/0000-0002-3901-1052				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BROOKES S, 1992, GENE CHROMOSOME CANC, V4, P290, DOI 10.1002/gcc.2870040404; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1993, ONCOGENE, V8, P443; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DEUSTACHIO P, 1984, J EXP MED, V160, P827, DOI 10.1084/jem.160.3.827; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GACK S, 1994, J BIOL CHEM, V269, P10363; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROSKOPF JC, 1994, MOL CELL BIOL, V14, P6013, DOI 10.1128/MCB.14.9.6013; HSU JC, 1993, CANCER RES, V53, P3789; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MARKS SC, 1985, J HERED, V76, P171, DOI 10.1093/oxfordjournals.jhered.a110059; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; SCHREIBER M, 1996, THESIS VIENNA; Silver L. M., 1995, MOUSE GENETICS; SINKE RJ, 1993, GENOMICS, V18, P165, DOI 10.1006/geno.1993.1447; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TANIGAMI A, 1992, GENOMICS, V13, P16, DOI 10.1016/0888-7543(92)90195-X; UDAGAWA N, 1992, BIOCHEM BIOPH RES CO, V184, P67, DOI 10.1016/0006-291X(92)91158-M; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	40	36	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1171	1178		10.1038/sj.onc.1201460	http://dx.doi.org/10.1038/sj.onc.1201460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294610				2022-12-25	WOS:A1997XU99100006
J	Strauss, O; Mergler, S; Wiederholt, M				Strauss, O; Mergler, S; Wiederholt, M			Regulation of L-type calcium channels by protein tyrosine kinase and protein kinase C in cultured rat and human retinal pigment epithelial cells	FASEB JOURNAL			English	Article						retinal pigment epithelium; L-type-channel; patch-clamp recording; PKC	SMOOTH-MUSCLE CELLS; PHOSPHORYLATION; MODULATION; PEPTIDE; ACTIVATION; RECEPTORS; INHIBITOR	The effect of protein tyrosine kinases (PTKs) on L-type calcium channel currents was studied in cultured rat and human retinal pigment epithelial cells, Barium currents through L-type channels were measured in the perforated patch-clamp technique and identified by using the L-type calcium channel opener Bay K8644 (10(-6) M), Application of the PTK blockers genistein (5x10(-6) M) or lavendustin A (5x10(-6) M) led to a decrease of L-type currents, The inactive genistein analog daidzein (10(-5) M) showed no effect on calcium channels, Intracellular application of pp60(c-src) (30 U/ml) via the patch-pipette during the conventional whole-cell configuration led to an increase of L-type currents, The protein kinase A and protein kinase G blocker H9 (10(-6) M) showed no effect on L-type currents; genistein reduced the current in the presence of H9, The protein kinase C (PKC) blocker chelerythrine (10(-5) M) reduced the G type current; additional inhibition of PTK by lavendustin showed an additional reduction of currents, Intracellular application of myristoylated PKC substrate (5x10(-5) M) for PKC inhibition led to a fast rundown of L-type current amplitudes, Intracellularly applied myristoylated PKC substrate (10(-4) M) together with pp60(c-src) showed no effect on L-type current, Up-regulation of PKC by 10(-6) M phorbol-12-myristate-13-acetate (PMA) had no effect on the L-type current amplitude, However, genistein in cells pretreated with PIMA led to an increase of the L-type currents, Intracellular application of pp60(c-src) in PMA-treated cells led to a reduction of L-type currents, We conclude that in the resting cell, PTK and PKC regulate L-type calcium channels in an additive manner, L-type channels appeared as a site of integration of PTK activation and of PKC-dependent pathways, The activity of PKC determines whether PTK decreases or increases L-type channel activity.			Strauss, O (corresponding author), FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,INST KLIN PHYSIOL,HINDENBURGDAMM 30,D-12200 BERLIN,GERMANY.		Strauss, Olaf/AAA-6485-2019	Mergler, Stefan/0000-0001-8608-648X; Strauss, Olaf/0000-0002-6272-8596				BOST LM, 1992, EXP EYE RES, V55, P727, DOI 10.1016/0014-4835(92)90177-T; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; GALLIZI JP, 1987, J BIOL CHEM, V262, P6947; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Holmes TC, 1996, J NEUROSCI, V16, P1581; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUANG XY, 1993, CELL, V80, P225; KOH SWM, 1992, CELL BIOL INT REP, V16, P1003, DOI 10.1016/S0309-1651(06)80053-6; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; STEELE FR, 1992, P NATL ACAD SCI USA, V90, P1526; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; STRAUSS O, 1994, J CELL PHYSIOL, V160, P89, DOI 10.1002/jcp.1041600111; UEDA Y, 1993, INVEST OPHTH VIS SCI, V34, P3408; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; YOSHIDA M, 1992, BIOCHEM BIOPH RES CO, V189, P66, DOI 10.1016/0006-291X(92)91526-V; YOSHIMURA N, 1992, CURR EYE RES, V11, P997, DOI 10.3109/02713689209033498	23	71	74	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					859	867		10.1096/fasebj.11.11.9285484	http://dx.doi.org/10.1096/fasebj.11.11.9285484			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285484				2022-12-25	WOS:A1997XT79000005
J	Surya, A; Knox, BE				Surya, A; Knox, BE			Modulation of opsin apoprotein activity by retinal - Dark activity of rhodopsin formed at low temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PHOTORECEPTOR-MEMBRANES; TRANSDUCIN ACTIVATION; METARHODOPSIN-II; G-PROTEIN; CONFORMATIONAL-CHANGES; ROD PHOTORECEPTORS; BINDING-SITE; PHOTOTRANSDUCTION; ADAPTATION; ANALOGS	The bovine opsin apoprotein activates transducin, although at a much reduced level than light-activated rhodopsin (Surya, A., Foster, K., and Knox, B, (1995) J, Biol, Chem, 270, 5024-5031), The ability of retinal to modulate opsin apoprotein activity was investigated using a guanyl nucleotide exchange assay on transducin. 11-cis-Retinal reacted with opsin at 22 degrees C to (a) reform pigment having maximal absorbance at 500 nm and (b) reduce opsin activity by > 80%. Pigment formation also occurred at 0 degrees C with a t(1/2) of 260 min, However, unlike rhodopsin formed at 22 degrees C (R-22), th, rhodopsin formed at 0 degrees C (R-0) activated transducin with the same half saturating concentration as opsin in an exhaustive binding assay, Thus, the formation of a protonated Schiff base associated with 500 nm absorbance does not by itself lead to the inactivation of opsin. The R-0 conformation was partially inactivated by incubation at 22 degrees C (t(1/2) = 61 +/- 9 min), suggesting that it may be an intermediate conformation in the regeneration of rhodopsin.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT OPHTHALMOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NEI NIH HHS [EY09409, EY11256] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011256, R01EY009409, R55EY009409] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1994, J BIOL CHEM, V269, P23879; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BALOGHNAIR V, 1982, STEREOCHEMISTRY, P283; BARLOW HB, 1964, VISION RES, V4, P47, DOI 10.1016/0042-6989(64)90031-8; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BRIN KP, 1977, J GEN PHYSIOL, V69, P97, DOI 10.1085/jgp.69.1.97; BUBIS J, 1990, J BIOL CHEM, V265, P12995; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; CATT M, 1982, BIOCHEM SOC T, V10, P343, DOI 10.1042/bst0100343; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CORNWALL MC, 1990, J GEN PHYSIOL, V96, P345, DOI 10.1085/jgp.96.2.345; CORSON DW, 1990, P NATL ACAD SCI USA, V87, P6823, DOI 10.1073/pnas.87.17.6823; DAEMEN FJM, 1978, NATURE, V276, P847, DOI 10.1038/276847a0; DEGRIP WJ, 1973, BIOCHIM BIOPHYS ACTA, V325, P315, DOI 10.1016/0005-2728(73)90107-2; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HENSELMAN RA, 1976, BIOCHEMISTRY-US, V15, P5321, DOI 10.1021/bi00669a019; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; HUBBARD R, 1958, J GEN PHYSIOL, V42, P259, DOI 10.1085/jgp.42.2.259; JIN J, 1993, NEURON, V11, P513, DOI 10.1016/0896-6273(93)90155-K; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LAMB TD, 1980, NATURE, V287, P349, DOI 10.1038/287349a0; LEIBROCK CS, 1994, VISION RES, V34, P2787, DOI 10.1016/0042-6989(94)90048-5; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; MATSUMOTO H, 1975, NATURE, V258, P523, DOI 10.1038/258523a0; MATSUMOTO H, 1978, BIOCHIM BIOPHYS ACTA, V501, P257, DOI 10.1016/0005-2728(78)90031-2; OKADA D, 1989, PHOTOCHEM PHOTOBIOL, V49, P197, DOI 10.1111/j.1751-1097.1989.tb04096.x; OTTOLENGHI M, 1989, J MEMBRANE BIOL, V112, P193, DOI 10.1007/BF01870951; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PEPPERBERG DR, 1978, J GEN PHYSIOL, V71, P369, DOI 10.1085/jgp.71.4.369; PEPPERBERG DR, 1987, EXP EYE RES, V45, P41; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RUSHTON WAH, 1961, J PHYSL, V156, P195; SAKAMOTO T, 1995, P NATL ACAD SCI USA, V92, P249, DOI 10.1073/pnas.92.1.249; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; SURYA A, 1994, BIOPHYS J, V66, pA47; THORGEIRSSON TE, 1993, BIOCHEMISTRY-US, V32, P13861, DOI 10.1021/bi00213a015; TOWNER P, 1981, EUR J BIOCHEM, V117, P353, DOI 10.1111/j.1432-1033.1981.tb06345.x; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YOSHIZAWA T, 1983, BIOPHYS STRUCT MECH, V9, P245, DOI 10.1007/BF00535660; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	54	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21745	21750		10.1074/jbc.272.35.21745	http://dx.doi.org/10.1074/jbc.272.35.21745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268303	hybrid			2022-12-25	WOS:A1997XT85000015
J	Thomas, D; Bradshaw, RA				Thomas, D; Bradshaw, RA			Differential utilization of ShcA tyrosine residues and functional domains in the transduction of epidermal growth factor-induced mitogen-activated protein kinase activation in 293T cells and nerve growth factor-induced neurite outgrowth in PC12 cells - Identification of a new Grb2 center dot Sos1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SIGNAL-TRANSDUCTION; FACTOR-RECEPTOR; ADAPTER PROTEIN; SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; PHOSPHOTYROSINE-BINDING; INSULIN-RECEPTOR; TERMINAL DOMAIN; SRC HOMOLOGY-2	By transient expression of both truncated forms of p52(SHCA) and those with point mutations in 293T cells, it has been shown that, in addition to Tyr-317, Tyr-239/240 is a major site of phosphorylation that serves as a docking site for Grb2.Sos1 complexes, In addition, analysis of epidermal growth factor (EGF)-induced activation of mitogen-activated protein kinase in 293T cells showed that the overexpression Shc SH2 or phosphotyrosine binding (PTB) domains of ShcA alone has a more potent negative effect than the overexpression of the forms of ShcA lacking Tyr-317 or Tyr 239/240 or both. In transiently transfected PC12 cells, the ShcA PTB domain and tyrosine phosphorylation in the CH1 domain, especially on Tyr-239/240, are crucial for mediating nerve growth factor (NGF)-induced neurite outgrowth, These findings suggest that the EGF and NGF (TrkA) receptor can utilize Shc in different ways to promote their activity, For EGF-induced mitogen-activated protein kinase activation in 293T cells, both Shc PTB and SH2 domains are essential for optimal activation, indicating that a mechanism independent of Grb2 engagement with Shc may exist, For NGF-induced neurite outgrowth in PC12 cells, Shc PTB plays an essential role, and phosphorylation on Tyr-239/240, but not on Tyr-317, is required.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92697	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NIA NIH HHS [AG09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROWE AJ, 1994, ONCOGENE, V9, P537; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEPRONK GJ, 1994, MOL CELL BIOL, V14, P1575; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1995, ONCOGENE, V11, P2525; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; Nakamura T, 1996, ONCOGENE, V13, P1111; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; ROZAKIS AM, 1993, NATURE, V363, P83; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLER C, 1994, ONCOGENE, V9, P2207; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509	51	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22293	22299		10.1074/jbc.272.35.22293	http://dx.doi.org/10.1074/jbc.272.35.22293			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268379	hybrid			2022-12-25	WOS:A1997XT85000091
J	Flajolet, M; Gegonne, A; Ghysdael, J; Tiollais, P; Buendia, MA; Fourel, G				Flajolet, M; Gegonne, A; Ghysdael, J; Tiollais, P; Buendia, MA; Fourel, G			Cellular and viral trans-acting factors modulate N-myc2 promoter activity in woodchuck liver tumors	ONCOGENE			English	Article						N-myc2; woodchucks; IL-6	INTERLEUKIN-6 RESPONSE ELEMENT; HEPATITIS-VIRUS; HEPADNAVIRUS INSERTION; MYC; EXPRESSION; ACTIVATION; PROTEIN; FAMILY; CELLS; GENE	Activation of the N-myc2 oncogene by integration of woodchuck hepatitis virus (WHV) DNA is a central event in woodchuck liver oncogenesis, In this study, we have evaluated the influence of several cellular and viral tr ans-acting factors and mediators of inflammation on N-myc2 promoter activity in hepatoma cell lines, Ets oncoproteins, including Ets1, Ets2 and PEA3 efficiently activated a chimeric N-myc2 promoter/luciferase reporter gene, By electrophoretic mobility shift assays, we show that Ets1 and Ets2 proteins can efficiently bind two consensus Ets sites located within a 59 bp sequence upstream of the N-myc2 transcription start site, Site-directed mutagenesis of these Ets-binding motifs abolished transactivation of the N-myc2 promoter by Ets proteins, Addition of interleukin-6 (IL-6) induced a weak but reproducible activation of the N-myc2 promoter, while IL-1 was ineffective, We further show that the N-myc2 promoter can be transactivated by the hepadnavirus X protein, and that distal promoter sequences are required for both IL-6 and X responsiveness, Similar effects of these factors were observed in the context of the N-myc2 promoter activated by WHV cis-regulatory elements, In view of the high-level expression of the N-myc2 oncogene in most woodchuck liver tumors, the Ets oncoproteins, inflammation-associated cytokine IL-6 and the viral X transactivator might play important roles in hepadnavirus-associated tumorigenesis.	CTR UNIV ORSAY, CNRS URA 1443, F-91405 ORSAY, FRANCE	UDICE-French Research Universities; Universite Paris Saclay	Flajolet, M (corresponding author), INST PASTEUR, INSERM U163, UNITE RECOMBINAISON & EXPRESS GENET, F-75724 PARIS, FRANCE.		GHYSDAEL, Jacques/F-3377-2013					BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FLAJOLET M, 1997, IN PRESS VIRAL HEPAT; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; Fourel G, 1996, J VIROL, V70, P8571, DOI 10.1128/JVI.70.12.8571-8583.1996; FOUREL G, 1994, LIVER GENE EXPRESSIO, P297; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; POLI V, 1994, LIVER GENE EXPRESSIO, P131; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; STEMMER WPC, 1992, BIOTECHNIQUES, V13, P214; TOSHKOV I, 1990, J CANCER RES CLIN, V116, P581, DOI 10.1007/BF01637078; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; Ueda K, 1996, J VIROL, V70, P4714, DOI 10.1128/JVI.70.7.4714-4723.1996; Ueda K, 1996, VIROLOGY, V217, P413, DOI 10.1006/viro.1996.0133; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; YANG D, 1993, CANCER RES, V53, P2020; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	41	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1103	1110		10.1038/sj.onc.1201257	http://dx.doi.org/10.1038/sj.onc.1201257			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285565				2022-12-25	WOS:A1997XT16100012
J	Narducci, MG; Virgilio, L; Engiles, JB; Buchberg, AM; Billips, L; Facchiano, A; Croce, CM; Russo, G; Rothstein, JL				Narducci, MG; Virgilio, L; Engiles, JB; Buchberg, AM; Billips, L; Facchiano, A; Croce, CM; Russo, G; Rothstein, JL			The murine Tcl1 oncogene: embryonic and lymphoid cell expression	ONCOGENE			English	Article						ATM; ataxia-telangiectasia; TCL1; chronic lymphocytic leukemia; MTCP1; T-PLL	T-PROLYMPHOCYTIC LEUKEMIA; ATAXIA-TELANGIECTASIA; MOLECULAR ANALYSIS; CHROMOSOME; GENE; TRANSLOCATIONS; LOCUS; BREAKPOINT; RECEPTOR; PATIENT	In human leukemias and lymphomas nonrandom chromosomal rearrangements cause changes in cell growth and/or survival in such a way as to promote malignancy, The detailed study of the biochemical and genetic pathways altered in human cancer requires the identification or development of models to allow the study and manipulation of cancer gene function, Recently, the breakpoint gene TCL1, involved in chromosome translocations observed mostly in mature T-cell proliferations and chronic lymphocytic leukemias (CLL), was isolated and characterized, and showed to be part of a new gene family of proteins involved in these tumors, The murine Tcl1 gene, is similar in sequence to the murine and human MTCP1 gene also involved in T cell leukemias, The murine Tcl1 gene was shown to reside on mouse chromosome 12 in a region syntenic to human chromosome 14, Furthermore, we show that the murine Tcl1 gene is expressed early in mouse embryonic development and demonstrates expression in fetal hematopoietic organs as well as in immature T and B cells, Characterization of the murine Tcl1 gene will help in developing a mouse model of CLL and would provide the best opportunity to study and decipher the role of TCL1 in malignant transformation.	THOMAS JEFFERSON MED COL,KIMMEL CANC INST,DEPT MICROBIOL IMMUNOL,PHILADELPHIA,PA 19107; IRCCS,IST DERMOPAT IMMACOLATA,I-00167 ROME,ITALY; THOMAS JEFFERSON MED COL,KIMMEL CANC INST,DEPT OTOLARYNGOL HEAD & NECK SURG,PHILADELPHIA,PA 19107; UNIV ALABAMA,HOWARD HUGHES MED INST,BIRMINGHAM,AL 35294	Jefferson University; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Jefferson University; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham			Engiles, Julie/K-1916-2015; Facchiano, Antonio/K-5984-2016; Facchiano, Antonio/J-4744-2012; Young, Richard A/F-6495-2012; Russo, Giandomenico/K-9566-2016; Narducci, Maria Grazia/L-3093-2018	Engiles, Julie/0000-0001-9057-2093; Facchiano, Antonio/0000-0002-4243-2392; Facchiano, Antonio/0000-0002-4243-2392; Young, Richard A/0000-0001-8855-8647; Russo, Giandomenico/0000-0002-7718-9687; Narducci, Maria Grazia/0000-0002-9066-186X; Narducci, Maria Grazia/0000-0002-8877-4611; Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [CA-56336, CA-39869, CA-21124] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; BRUNNING RD, 1991, BLOOD, V78, P3111; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CIMINO G, 1991, CANCER RES, V51, P6712; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; CROCE CM, 1991, ORIGINS OF HUMAN CANCER, P527; DIETRICH W, 1992, GENETICS, V131, P423; Freeman SJ, 1990, POSTIMPLANTATION MAM, P249; FU TB, 1994, CANCER RES, V54, P6297; Green MC., 1989, GENETIC VARIANTS STR, P12; HEIM S, 1987, CANC CYTOGENETICS; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Innis MA, 1990, PCR PROTOCOLS GUIDE; ISOBE M, 1985, SCIENCE, V228, P580, DOI 10.1126/science.3983641; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Madani A, 1996, BLOOD, V87, P1923; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; NAGASAKA M, 1983, BLOOD, V61, P1174; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; ROTHSTEIN JL, 1993, METHOD ENZYMOL, V225, P587; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Sambrook J., 2002, MOL CLONING LAB MANU; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; STAATS J, 1981, MOUSE BIOCH RES, P177; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AM, 1992, ATAXIA TELANGIECTASI, P53; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P925; WEI S, 1990, CANCER GENET CYTOGEN, V46, P1, DOI 10.1016/0165-4608(90)90002-R; WOLF FW, 1994, J BIOL CHEM, V269, P3633	42	32	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					919	926		10.1038/sj.onc.1201246	http://dx.doi.org/10.1038/sj.onc.1201246			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285687				2022-12-25	WOS:A1997XR76700005
J	Ogris, E; Gibson, DM; Pallas, DC				Ogris, E; Gibson, DM; Pallas, DC			Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen	ONCOGENE			English	Article						phosphatase; PP2A; polyomavirus middle tumor antigen	SMALL-T-ANTIGEN; A-SUBUNIT; TYROSINE PHOSPHORYLATION; REGULATORY SUBUNITS; DNA-REPLICATION; TYPE-2A; IDENTIFICATION; KINASE; GROWTH; FORMS	The carboxy terminus of protein phosphatase 2A (PP2A) catalytic subunit is highly conserved. Seven out of the last nine residues, including two potential in vivo phosphorylation sites, threonine 304 and tyrosine 307, are completely invariant in all known PP2As, Mutational analysis of the carboxy terminus in vivo was facilitated by efficient immunoprecipitation of trimeric PP2A holoenzyme via an epitope-tagged catalytic subunit, The results indicate that the catalytic submit carboxy terminus is important for complex formation with the PP2A 55 kDa regulatory B subunit, but not with polyomavirus oncogene, middle tumor antigen (MT), a viral B-type regulatory subunit, Replacing catalytic subunit threonine 304 or tyrosine 307 with a negatively charged amino acid abolished binding of the B subunit to the dimeric enzyme core and altered substrate specificity, Certain other amino acid substitutions of different size and/or charge also abolished or greatly reduced B subunit binding, Substitution of alanine at position 304 or phenylalanine at position 307 did not dramatically reduce B subunit binding or phosphatase activity in vitro, yet the latter substitutions are not found in naturally occurring PP2As, Thus, the wild-type residues are important for a yet unknown function in vivo, Additionally, deleting the carboxy terminal nine amino acids inhibited binding of the B subunit to the dimeric enzyme core, indicating a requirement for one or more of these amino acids for complex formation, MT interaction with the dimeric PP2A enzyme core was not inhibited by any of these mutations, Finally, unlike B subunit, MT does not activate the phosphatase activity of the PP2A heterodimer towards cdc2-phosphorylated histone HI.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Ogris, Egon/0000-0001-5950-9264	NCI NIH HHS [CA57327, R01 CA057327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Harlow E., 1988, ANTIBODIES LAB MANUA; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1993, J BIOL CHEM, V268, P19192; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; Sambrook J., 2002, MOL CLONING LAB MANU; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; USUI H, 1988, J BIOL CHEM, V263, P3752; XIE HY, 1994, J BIOL CHEM, V269, P1981	45	109	111	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					911	917		10.1038/sj.onc.1201259	http://dx.doi.org/10.1038/sj.onc.1201259			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285686				2022-12-25	WOS:A1997XR76700004
J	Zong, WX; Farrell, M; Bash, J; Gelinas, C				Zong, WX; Farrell, M; Bash, J; Gelinas, C			v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNF alpha-induced cell death	ONCOGENE			English	Article						v-Rel; apoptosis; cell transformation; tetracycline-regulation	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; RECEPTOR FUSION PROTEIN; CHICKEN SPLEEN-CELLS; RETICULOENDOTHELIOSIS VIRUS; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; GENE-EXPRESSION; FAMILY; DNA	The v-Rel oncoprotein belongs to the Rel/NF-kappa B family of transcription factors, It transforms chicken lymphoid cells in vitro and induces fatal lymphomas in vivo, In this study, we used a tetracycline-regulated system to characterize the role of v-Rel in cell transformation. We show that the continued expression of v-Rel is necessary to maintain the viability of transformed lymphoid cells and enables primary spleen cells to escape apoptosis in vitro culture. In agreement with a possible role for v-Rel in the inhibition of programmed cell death, its inducible expression in HeLa cells prevented TNF alpha-induced apoptosis, While the repression of v-Rel was accompanied by the rapid degradation of I kappa B alpha, changes in the steady-state levels of the apoptosis inhibitors Bcl-2 and Bcl-X-L were only observed following the onset of cell death in transformed lymphoid cells. This suggests that the anti-apoptotic activity of v-Rel may affect other apoptosis inhibitors or other factors in the death pathway, Together, these findings demonstrate that v-Rel blocks apoptosis and suggest that this activity may be an important component of its transforming function.	UNIV MED & DENT NEW JERSEY,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,GRAD PROGRAM BIOCHEM & MOL BIOL,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,GRAD PROGRAM MICROBIOL & MOL GENET,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CANC INST NEW JERSEY,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey					NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Houldsworth J, 1996, BLOOD, V87, P25; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LU D, 1991, ONCOGENE, V6, P1235; LUQUE I, 1997, IN PRESS SEMIN CANC, V8; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUBIN BY, 1988, CANCER RES, V48, P6006; SACHDEV S, 1997, IN PRESS ONCOGENE, V14; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	54	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					971	980		10.1038/sj.onc.1201266	http://dx.doi.org/10.1038/sj.onc.1201266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285692				2022-12-25	WOS:A1997XR76700010
J	Kim, E; Albrechtsen, N; Deppert, W				Kim, E; Albrechtsen, N; Deppert, W			DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53	ONCOGENE			English	Article						p53 DNA binding; DNA conformation; p53 conformation; p53 consensus sequence	WILD-TYPE; GENE-EXPRESSION; PROTEIN; TRANSCRIPTION; NUCLEI; IDENTIFICATION; ENHANCER; ELEMENT; DOMAIN; CELLS	Sequence-specific transactivation of target genes is one of the most important molecular properties of the tumor suppressor p53. Binding of p53 to its target DNAs is tightly regulated, with modifications in the carboxyterminal regulatory domain of the p53 protein playing an important role. In this study we examined the possible influence of DNA structure on sequence-specific DNA binding by p53, by analysing its binding to p53 consensus elements adopting different conformations. We found that p53 has the ability to bind to consensus elements which are present in a double-helical form, as well as to consensus elements which are located within alternative non-B-DNA structures. The ability of a consensus element to adopt either one of these conformations is dependent on its sequence symmetry, and is strongly influenced by its sequence environment. Our data suggest a model according to which the conformational status of the target DNA is an important determinant for sequence-specific DNA binding by p53. Modifications in the carboxy-terminal regulatory region of p53 possibly determine the preference of p53 for a given DNA conformation.	UNIV HAMBURG,HEINRICH PETTE INST EXPT VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg			Holst, Jens/AAA-8022-2022					Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DELIC J, 1991, BIOCHEM BIOPH RES CO, V181, P818, DOI 10.1016/0006-291X(91)91263-C; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P185; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Flaman JM, 1996, ONCOGENE, V12, P813; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HANKE JH, 1995, J MOL BIOL, V246, P63, DOI 10.1006/jmbi.1994.0066; Hecker D, 1996, ONCOGENE, V12, P953; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEITH IR, 1993, BIOCHEM BIOPH RES CO, V196, P601, DOI 10.1006/bbrc.1993.2292; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MAYFIELD C, 1994, NUCLEIC ACIDS RES, V22, P1909, DOI 10.1093/nar/22.10.1909; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MIYASHITA T, 1995, CELL, V80, P293; Muller BF, 1996, ONCOGENE, V12, P1941; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SOLARO P, 1995, EUR J BIOCHEM, V230, P926, DOI 10.1111/j.1432-1033.1995.tb20638.x; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WANG Y, 1995, ONCOGENE, V10, P779; WARD GK, 1991, EXP CELL RES, V195, P92, DOI 10.1016/0014-4827(91)90503-M; WARD GK, 1990, EXP CELL RES, V188, P235, DOI 10.1016/0014-4827(90)90165-7; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; WEISSKER S, 1992, ONCOGENE, V7, P155; WITTIG B, 1989, J CELL BIOL, V108, P755, DOI 10.1083/jcb.108.3.755; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao JQ, 1996, ONCOGENE, V13, P293	70	54	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					857	869		10.1038/sj.onc.1201412	http://dx.doi.org/10.1038/sj.onc.1201412			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266973				2022-12-25	WOS:A1997XQ11700013
J	Kai, M; Wada, I; Imai, S; Sakane, F; Kanoh, H				Kai, M; Wada, I; Imai, S; Sakane, F; Kanoh, H			Cloning and characterization of two human isozymes of Mg2+-independent phosphatidic acid phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-D; RAT-LIVER; PHOSPHOHYDROLASE ACTIVITY; DIACYLGLYCEROL KINASE; ENDOPLASMIC-RETICULUM; SPHINGOSINE 1-PHOSPHATE; MOLECULAR-CLONING; ESCHERICHIA-COLI; IDENTIFICATION	We obtained two human cDNA clones encoding phosphatidic acid phosphatase (PAP) isozymes named PAP-2a (M-r = 32,158) and -2b (M-r = 35, 119), both of which contained six putative transmembrane domains, Both enzymes were glycosylated and cleaved by N glycanase and endo-beta-galactosidase, thus suggesting their post-Golgi localization. PAP-Za and -2b shared 47% identical sequence and were judged to be the human counterparts of the previously sequenced mouse 35-kDa PAP(83% identity) and rat Dri42 protein (94% identity), respectively, Furthermore, the sequences of both PAPs were 34-39% identical to that of Drosophila Wunen protein. In view of the functions ascribed to Wunen and Dri42 in germ cell migration and epithelial differentiation, respectively, these findings unexpectedly suggest critical roles of PAP isoforms in cell growth and differentiation, Although the two PAPs hydrolyzed lysophosphatidate and ceramide-l-phosphate. in addition to phosphatidate, the hydrolysis of sphingosine-l-phosphate was detected only for PAP-2b, PAP-2b was expressed almost ubiquitously in all human tissues examined, whereas the expression of PAP-2a was relatively variable, being extremely low in the placenta and thymus, In HeLa cells, the transcription of PAP-2a was not affected by different stimuli, whereas PAP-2b was induced (up to 3-fold) by epidermal growth factor. These findings indicate that despite structural similarities, the two PAP isozymes may play distinct functions through their different patterns of substrate utilization and transcriptional regulation.	SAPPORO MED UNIV,SCH MED,DEPT BIOCHEM,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Sapporo Medical University			Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; Wada, Ikuo/0000-0001-5668-6994				ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Barila D, 1996, J BIOL CHEM, V271, P29928, DOI 10.1074/jbc.271.47.29928; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; EGAWA K, 1995, FEBS LETT, V372, P74, DOI 10.1016/0014-5793(95)00957-B; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HII CST, 1991, J BIOL CHEM, V266, P20238; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Jiang YW, 1996, J BIOL CHEM, V271, P29529, DOI 10.1074/jbc.271.47.29529; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1992, J BIOL CHEM, V267, P25309; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KANOH H, 1997, IN PRESS BIOCH BIOPH; KOLESNICK R, 1994, CELL, V77, P326; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PERRY DK, 1993, J BIOL CHEM, V268, P25302; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Siess EA, 1996, FEBS LETT, V381, P169, DOI 10.1016/0014-5793(96)00111-1; SMITH SW, 1957, J BIOL CHEM, V228, P915; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Stukey J, 1997, PROTEIN SCI, V6, P469; TRUETT AP, 1992, FASEB J, V6, P2720, DOI 10.1096/fasebj.6.9.1612297; WADA I, 1994, J BIOL CHEM, V269, P7464; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WALSH JP, 1986, J BIOL CHEM, V261, P6239; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	45	136	147	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24572	24578		10.1074/jbc.272.39.24572	http://dx.doi.org/10.1074/jbc.272.39.24572			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305923	hybrid			2022-12-25	WOS:A1997XY51500074
J	Nagendra, SN; Faiman, MD; Davis, K; Wu, JY; Newby, X; Schloss, JV				Nagendra, SN; Faiman, MD; Davis, K; Wu, JY; Newby, X; Schloss, JV			Carbamoylation of brain glutamate receptors by a disulfiram metabolite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATORY AMINO-ACIDS; TOXICITY; SUBUNITS	S-Methyl-N,N-diethylthiolcarbamate sulfoxide (DETC-MeSO), a metabolite of the drug disulfiram, is a selective carbamoylating agent for sulfhydryl groups, Treatment of glutamate receptors isolated from mouse brain with DETC-MeSO blocks glutamate binding, In vivo, carbamoylated glutathione, administered directly to mice or formed by reaction of DETC-MeSO with glutathione in the blood, also blocks brain glutamate receptors, Carbamoyl groups appear to be delivered to brain glutamate receptors or to liver aldehyde dehydrogenase in vivo by a novel glutathione-mediated mechanism. Seizures caused by the glutamate analogs N-methyl-D-aspartate and methionine sulfoximine, or by hyperbaric oxygen, are prevented by DETC-MeSO, indicating that carbamoylation of glutamate receptors gives an antagonist effect, These observations offer an explanation for some of the previously reported neurological effects of disulfiram, such as its ability to prevent O-2-induced seizures, Furthermore, some of the physiology of the disulfiram-ethanol reaction, that could not be accounted for based on the known inhibition of aldehyde dehydrogenase alone, may be explained by disulfiram's effect on glutamate receptors.	UNIV KANSAS,DEPT MED CHEM,LAWRENCE,KS 66045; UNIV KANSAS,DEPT PHARMACOL & TOXICOL,LAWRENCE,KS 66045; UNIV KANSAS,DEPT PHYSIOL & CELL BIOL,LAWRENCE,KS 66045	University of Kansas; University of Kansas; University of Kansas			WU, JANG-YEN/I-6424-2013	Schloss, John/0000-0002-6586-7508				BONHAUS DW, 1989, MOL PHARMACOL, V36, P273; BRANCHEY L, 1987, AM J PSYCHIAT, V144, P1310; BURNASHEV N, 1993, CELL PHYSIOL BIOCHEM, V3, P318, DOI 10.1159/000154696; CINCOTTA M, 1989, ANAL BIOCHEM, V177, P150, DOI 10.1016/0003-2697(89)90030-4; ENEANYA DI, 1981, ANNU REV PHARMACOL, V21, P575, DOI 10.1146/annurev.pa.21.040181.003043; FAIMAN MD, 1974, AEROSPACE MED, V45, P29; FAIMAN MD, 1971, BIOCHEM PHARMACOL, V20, P3059, DOI 10.1016/0006-2952(71)90110-9; FAIMAN MD, 1979, BIOCH PHARMACOLOGY E, V2, P325; FISHER CM, 1989, ARCH NEUROL-CHICAGO, V46, P798, DOI 10.1001/archneur.1989.00520430094024; Follesa P, 1996, J BIOL CHEM, V271, P13297, DOI 10.1074/jbc.271.23.13297; GOZLAN H, 1995, TRENDS PHARMACOL SCI, V16, P368, DOI 10.1016/S0165-6147(00)89077-X; HALD J, 1948, LANCET, V252, P1001, DOI 10.1016/S0140-6736(48)91514-1; HALEY TJ, 1979, DRUG METAB REV, V9, P319, DOI 10.3109/03602537908993897; HART BW, 1992, BIOCHEM PHARMACOL, V43, P403, DOI 10.1016/0006-2952(92)90555-W; HOTSON JR, 1976, ARCH NEUROL-CHICAGO, V33, P141, DOI 10.1001/archneur.1976.00500020069012; JIN LX, 1994, CHEM RES TOXICOL, V7, P526, DOI 10.1021/tx00040a008; LAMAR C, 1968, BIOCHEM PHARMACOL, V17, P636, DOI 10.1016/0006-2952(68)90280-3; LEE YH, 1995, J NEUROSCI RES, V40, P797, DOI 10.1002/jnr.490400611; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 1996, NEUROCHEM INT, V29, P111, DOI 10.1016/0197-0186(95)00150-6; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MADAN A, 1995, DRUG METAB DISPOS, V23, P1153; MOKRI B, 1981, NEUROLOGY, V31, P730, DOI 10.1212/WNL.31.6.730; NEVO I, 1995, NEUROCHEM INT, V26, P305, DOI 10.1016/0197-0186(94)00139-L; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POTTER DW, 1993, TOXICOL APPL PHARM, V120, P186, DOI 10.1006/taap.1993.1102; RAO SLN, 1972, BIOCHEMISTRY-US, V11, P1123, DOI 10.1021/bi00757a001; SCATTON B, 1994, LIFE SCI, V55, P2115, DOI 10.1016/0024-3205(94)00392-0; SCHOEPP DD, 1994, NEUROCHEM INT, V24, P439, DOI 10.1016/0197-0186(94)90092-2; THOMAS RJ, 1995, J AM GERIATR SOC, V43, P1279, DOI 10.1111/j.1532-5415.1995.tb07407.x	30	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24247	24251		10.1074/jbc.272.39.24247	http://dx.doi.org/10.1074/jbc.272.39.24247			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305877	hybrid			2022-12-25	WOS:A1997XY51500028
J	Cote, HCF; Pratt, KP; Davie, EW; Chung, DW				Cote, HCF; Pratt, KP; Davie, EW; Chung, DW			The polymerization pocket ''a'' within the carboxyl-terminal region of the gamma chain of human fibrinogen is adjacent to but independent from the calcium-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLY-HIS-ARG; SYNTHETIC PEPTIDES; ALPHA-CHAIN; FRAGMENTS-D; PRO-ARG; LOCALIZATION; COMPLEMENTARY; COAGULATION; AGGREGATION; DEGRADATION	The carboxy terminal region of the gamma chain of fibrinogen is involved in calcium binding, fibrin polymerization, factor XIIIa-mediated cross-linking, and binding to the platelet fibrin(ogen) receptor, Protein fragments encoding amino acids Val(143) to Val(411) (rFbg gamma C30) or Val(143) to Leu(427) (gamma'C30) from the carboxyl end of the gamma or gamma' chains, respectively, of human fibrinogen were expressed in yeast (Pichia pastoris) and characterized as to their cross-linking by factor XIIIa, polymerization pocket, and calcium-binding site, rFbg gamma C30 and gamma'C30 were both readily cross-linked by factor XIIIa, but only rFbg gamma C30 was capable of inhibiting thrombin-induced platelet aggregation. Two mutants, gamma C30-Q329R and gamma C30-D364A, which were based on the three-dimensional structure of the polymerization pocket within rFbg gamma C30 and on information derived from naturally occurring mutant fibrinogens, were also expressed and characterized, rFbg gamma C30 inhibited (desAA)fibrin polymerization in a dose-dependent manner, while the two mutant forms did not, Similarly, rFbg gamma C30 and gamma'C30 were protected from plasmin degradation by the presence of Ca2+ or the peptide Gly-Pro-Arg-Pro, indicating that a functional Ca2+-binding site and polymerization pocket are contained within each of these fragments. The mutant fragments, however, were protected from plasmin only by metal ions, while net protective effect was conferred by GPRP or by any other peptide tested. These results indicate that the polymerization pocket ''a'', which binds the peptide GPRP, functions independently from the nearby calcium-binding site and that amino acids Gln(329) and Asp(364) play a crucial role in fibrin polymerization.			Cote, HCF (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.		Sessum, Rachel/F-7312-2015; Cote, Helene/K-7896-2012; Pratt, Kathleen P/E-9489-2019	Sessum, Rachel/0000-0002-2444-7056; Pratt, Kathleen/0000-0001-6837-6133; Chung, Dominic/0000-0002-2645-5703	NHLBI NIH HHS [HL-16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; Bentolila S, 1995, ANN MED INTERNE, V146, P575; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BOYER MH, 1972, BLOOD-J HEMATOL, V39, P382, DOI 10.1182/blood.V39.3.382.382; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; CIERNIEWSKI CS, 1993, EUR J BIOCHEM, V218, P321, DOI 10.1111/j.1432-1033.1993.tb18380.x; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; Doolittle RF, 1996, FASEB J, V10, P1464, DOI 10.1096/fasebj.10.13.8940292; DOOLITTLE RF, 1980, PROTIDES BIOL FLUIDS, V28, P311; Ebert RF., 1994, INDEX VARIANT HUMAN; ENDRES GF, 1972, ARCH BIOCHEM BIOPHYS, V153, P266, DOI 10.1016/0003-9861(72)90445-6; EVERSE SJ, 1995, PROTEIN SCI, V4, P1013; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FORNACE AJ, 1984, J BIOL CHEM, V259, P2826; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FURLAN M, 1983, BIOCHIM BIOPHYS ACTA, V742, P25, DOI 10.1016/0167-4838(83)90354-0; Furlan M, 1996, THROMB HAEMOSTASIS, V76, P377; FURLAN M, 1992, THROMB HAEMOSTASIS, V47, P118; HASEGAWA N, 1990, THROMB RES, V57, P183, DOI 10.1016/0049-3848(90)90318-7; HAVERKATE F, 1977, THROMB RES, V10, P803, DOI 10.1016/0049-3848(77)90137-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARRIEU MJ, 1972, BRIT J HAEMATOL, V22, P719, DOI 10.1111/j.1365-2141.1972.tb05717.x; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LAUDANO AP, 1981, SCIENCE, V212, P457, DOI 10.1126/science.7209542; LAUDANO AP, 1983, ANN NY ACAD SCI, V408, P315, DOI 10.1111/j.1749-6632.1983.tb23254.x; LORAND L, 1993, METHOD ENZYMOL, V222, P22; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; MARGUERIE G, 1982, BIOCHIM BIOPHYS ACTA, V701, P410, DOI 10.1016/0167-4838(82)90246-1; MARGUERIE G, 1977, BIOCHIM BIOPHYS ACTA, V490, P94, DOI 10.1016/0005-2795(77)90109-X; Medved L, 1997, BIOCHEMISTRY-US, V36, P4685, DOI 10.1021/bi962795l; MEDVED LV, 1993, FEBS LETT, V320, P239, DOI 10.1016/0014-5793(93)80594-K; MIYATA T, 1989, J BIOCHEM, V105, P10, DOI 10.1093/oxfordjournals.jbchem.a122601; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; NIEUWENHUIZEN W, 1983, ANN NY ACAD SCI, V408, P92, DOI 10.1111/j.1749-6632.1983.tb23236.x; Okumura N, 1996, THROMB HAEMOSTASIS, V75, P887; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PRATT KP, 1997, P NATL ACAD SCI USA, V95, P7176; SCORER CA, 1994, BIO-TECHNOL, V12, P181, DOI 10.1038/nbt0294-181; SHAINOFF JR, 1979, SCIENCE, V204, P200, DOI 10.1126/science.155308; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; YAMAZUMI K, 1992, PROTEIN SCI, V1, P1719, DOI 10.1002/pro.5560011220; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	49	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23792	23798		10.1074/jbc.272.38.23792	http://dx.doi.org/10.1074/jbc.272.38.23792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295325	hybrid			2022-12-25	WOS:A1997XX38100050
J	Schwarz, M; Lund, EG; Lathe, R; Bjorkhem, I; Russell, DW				Schwarz, M; Lund, EG; Lathe, R; Bjorkhem, I; Russell, DW			Identification and characterization of a mouse oxysterol 7 alpha-hydroxylase cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID BIOSYNTHESIS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; MESSENGER-RNA; REGULATION INVIVO; ENZYME; LIVER; CLONING; GENE; MICE; DISRUPTION	The synthesis of essential 7 alpha-hydroxylated bile acids in the liver is mediated by two pathways that involve distinct 7 alpha-hydroxylases. One pathway is initiated in the endoplasmic reticulum by cholesterol 7 alpha-hydroxylase, a well studied cytochrome P450 enzyme. A second pathway is initiated by a less well defined oxysterol 7 alpha-hydroxylase. Here, we show that a mouse hepatic oxysterol 7 alpha-hydroxylase is encoded by Cyp7b1, a cytochrome P450 cDNA originally isolated from the hippocampus. Expression of a Cyp7b1 cDNA in cultured cells produces an enzyme with the same biochemical and, pharmacological properties as those of the hepatic oxysterol 7 alpha-hydroxylase. Cyp7b1 mRNA and protein are induced in the third week of life commensurate with an increase in hepatic oxysterol 7 alpha-hydroxylase activity. In the adult mouse, dietary cholesterol or colestipol induce cholesterol 7 alpha-hydroxylase mRNA levels but do not affect oxysterol 7 alpha-hydroxylase enzyme activity, mRNA, or protein levels. Cholesterol 7 alpha-hydroxylase mRNA is reduced to undetectable levels in response to bile acids, whereas expression of oxysterol 7 alpha-hydroxylase is modestly decreased, The liver thus maintains the capacity to synthesize 7 alpha-hydroxylated bile acids regardless of dietary composition, underscoring the central role of 7 alpha-hydroxylated bile acids in lipid metabolism.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; HUDDINGE HOSP,KAROLINSKA INST,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Edinburgh; Karolinska Institutet				Russell, David/0000-0002-0277-403X; Lathe, Richard/0000-0001-9698-9834; Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1992, J BIOL CHEM, V267, P1701; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; DUELAND S, 1993, J LIPID RES, V34, P923; DUMASWALA R, 1989, J LIPID RES, V30, P847; HASLEWOOD GA, 1967, J LIPID RES, V8, P535; Hylemon P B, 1994, Prog Liver Dis, V12, P99; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; LI YC, 1990, J BIOL CHEM, V265, P12012; MARTIN KO, 1993, J LIPID RES, V34, P581; Martin KO, 1997, J LIPID RES, V38, P1053; MATSCHINER JT, 1971, BILE ACIDS CHEM PHYS, V1, P11; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; PAYNE DW, 1995, J BIOL CHEM, V270, P1888; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; RUDLING M, 1992, J LIPID RES, V33, P493; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SHEFER S, 1991, J BIOL CHEM, V266, P2693; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; TOLL A, 1994, EUR J BIOCHEM, V224, P309, DOI 10.1111/j.1432-1033.1994.00309.x; TURLEY SD, 1994, J LIPID RES, V35, P328; WACHTEL N, 1968, J BIOL CHEM, V243, P5207	29	138	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23995	24001		10.1074/jbc.272.38.23995	http://dx.doi.org/10.1074/jbc.272.38.23995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295351	hybrid			2022-12-25	WOS:A1997XX38100076
J	Mezgrhani, H; Mziaut, H; Courageot, J; Oughideni, R; Bastiani, P; Miquelis, R				Mezgrhani, H; Mziaut, H; Courageot, J; Oughideni, R; Bastiani, P; Miquelis, R			Identification of the membrane receptor binding domain of thyroglobulin - Insights into quality control of thyroglobulin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE SYNTHESIS; AMINO-ACID-SEQUENCE; DEHYDROALANINE RESIDUES; HORMONOGENIC SITES; RECOGNITION; IODINATION; THYROCYTES; PROTEINS; BOVINE	The last stages of thyroglobulin maturation occur in the thyroid follicular lumen and include thyroid hormone formation and glycan completion, In this compartment, newly secreted thyroglobulins interact with a thyrocyte membrane receptor that prevents their premature lysosomal transfer and degradation. Both GlcNAc moieties and thyroglobulin peptide determinants are involved in receptor interaction, Here me used monoclonal antibodies (mAbs) directed against human thyroglobulin either to inhibit (mAb78) or to enhance (mAb240) the thyroglobulin binding and to identify the region of the thyroglobulin involved in the receptor recognition. Peptides containing the mAb epitopes were obtained by immunoscreening cyanogen bromide-derived native human thyroglobulin peptides and a cDNA thyroglobulin expression library. Three peptides, localized in the thyroglobulin N-terminal domain, were obtained. Peptides N1 (Ala(1148)-Gln(1295)) and N2 (Ser(789)-Met(1008)) were recognized by mAb240 and mAb78, respectively. None of them bound the receptor. The third peptide, N3 (Ser(789)-Met(1172)), (i) overlapped all or part of the N1 and N2 peptide sequences and was recognized by both mAbs, (ii) carried two complex glycans at Asn(797) and Asn(928), of which a subset presented accessible GlcNAc residues, and (iii) inhibited the thyroglobulin binding to FRTL5 cell membrane preparations. The N3 peptide includes tyrosine residues that have been reported to be involved in hormone formation. These results suggest that structural modifications closely associated with hormone formation within this domain act as sensors for the receptor interaction and thus for the intrafollicular retention or lysosomal homing of the prohormone.	FAC MED NORD,INST FED JEAN ROCHE,LAB BIOCHIM INGN PROT,UMR 6660,F-13916 MARSEILLE 20,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite								BASTIANI P, 1977, ACTA ENDOCRINOL-COP, V85, P357, DOI 10.1530/acta.0.0850357; BASTIANI P, 1995, ENDOCRINOLOGY, V136, P4204, DOI 10.1210/en.136.10.4204; BJORKMAN U, 1990, BIOCH THYROID HORMON, P83; DUNN JT, 1987, J BIOL CHEM, V262, P16948; EDELHOCH H, 1985, THYROGLOBULIN PROTHY, P1; EKHOLM R, 1975, ENDOCRINOLOGY, V97, P1432, DOI 10.1210/endo-97-6-1432; FASSLER CA, 1988, J BIOL CHEM, V263, P17366; GAVARET JM, 1981, J BIOL CHEM, V256, P9167; GAVARET JM, 1980, J BIOL CHEM, V255, P5281; GENTILE F, 1993, EUR J BIOCHEM, V218, P603, DOI 10.1111/j.1432-1033.1993.tb18414.x; HENRY M, 1990, J IMMUNOL, V145, P3692; IMBERTY A, 1995, PROTEIN ENG, V8, P699, DOI 10.1093/protein/8.7.699; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMAS L, 1989, J BIOL CHEM, V264, P13541; MALLET B, 1995, J BIOL CHEM, V270, P29881; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MARRIQ C, 1986, FEBS LETT, V207, P302, DOI 10.1016/0014-5793(86)81509-5; MERKEN L, 1985, EUR J BIOCHEM, V147, P59; MIQUELIS R, 1993, J CELL BIOL, V123, P1695, DOI 10.1083/jcb.123.6.1695; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; MIQUELIS R, 1980, ACTA ENDOCRINOL-COP, V95, P489, DOI 10.1530/acta.0.0950489; Molina F, 1996, EUR J BIOCHEM, V240, P125, DOI 10.1111/j.1432-1033.1996.0125h.x; Molina F, 1996, FEBS LETT, V391, P229, DOI 10.1016/0014-5793(96)00708-9; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; OHMIYA Y, 1990, J BIOL CHEM, V265, P9066; PARMA J, 1987, J MOL BIOL, V196, P769, DOI 10.1016/0022-2836(87)90403-7; RAWITCH AB, 1983, J BIOL CHEM, V258, P2079; ROE MT, 1989, ENDOCRINOLOGY, V124, P1327, DOI 10.1210/endo-124-3-1327; SHIFRIN S, 1981, J BIOL CHEM, V256, P600; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; WITHEHEART SW, 1989, METHOD ENZYMOL, V179, P82; XIO S, 1995, ARCH BIOCHEM BIOPHYS, V320, P96; Yamashita M, 1996, J BIOL CHEM, V271, P1282, DOI 10.1074/jbc.271.3.1282	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23340	23346		10.1074/jbc.272.37.23340	http://dx.doi.org/10.1074/jbc.272.37.23340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287346	hybrid			2022-12-25	WOS:A1997XV74400057
J	Tapping, RI; Tobias, PS				Tapping, RI; Tobias, PS			Cellular binding of soluble CD14 requires lipopolysaccharide (LPS) and LPS-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; MURINE SPLENOCYTES; ENDOTHELIAL-CELLS; CROSS-LINKING; 70Z/3 CELLS; ENDOTOXIN; RECOGNITION; MACROPHAGES; COMPLEXES; RESPONSES	The stimulation of nonmyeloid cells by lipopolysaccharide (LPS) is mediated by the serum protein, soluble CD14 (sCD14), We have examined the interaction of sCD14 with whole cells using a biologically active radio labeled sCD14 molecule as a ligand, Specific binding of sCD14 to nonmyeloid cells is detected only when it is first incubated with both LPS and the serum LPS-binding protein (LBP), Through the use of an anti-CD14 monoclonal antibody, we demonstrate that sCD14 must interact with LPS in order for cellular binding to occur. Although LBP is traditionally known to function as a catalyst in the transfer of LPS to sCD14, our results reveal that LBP is actually a physical part of sCD14-c ontaining, cell-associating complexes. The LPS- and LBP-dependent cell surface binding of sCD14 appears to be distinct from events leading to cell stimulation, since certain anti-CD14 and anti-LBP monoclonal antibodies have different effects on cellular binding versus cellular activation, Bound sCD14 is internalized, indicating that the LBP- and LPS dependent binding of sCD14 may represent a novel general mechanism by which nonmyeloid cells clear LPS.	Scripps Res Inst, DEPT IMMUNOL, IMM12, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL23584] Funding Source: Medline; NIAID NIH HHS [AI32021] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032021] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; FUNG HF, 1986, METHOD ENZYMOL, V119, P296; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GOLENBOCK DT, 1995, J LAB CLIN MED, V125, P662; GRUBE BJ, 1994, J BIOL CHEM, V269, P8477; Grunwald U, 1996, J IMMUNOL, V157, P4119; GRUNWALD U, 1992, J IMMUNOL METHODS, V155, P225, DOI 10.1016/0022-1759(92)90289-6; Hailman E, 1996, J IMMUNOL, V156, P4384; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAZIOT A, 1995, J IMMUNOL, V154, P6529; HAZIOT A, 1994, J IMMUNOL, V152, P5868; HAZIOT A, 1993, J IMMUNOL, V151, P1500; JACK RS, 1995, EUR J IMMUNOL, V25, P1436, DOI 10.1002/eji.1830250545; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; KIRKLAND TN, 1990, J BIOL CHEM, V265, P9520; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEI MG, 1988, J IMMUNOL, V141, P996; LEI MG, 1988, J IMMUNOL, V141, P1006; LETURCQ D, 1992, J CELL BIOCHEM, V16, P161; LUCHI M, 1993, J IMMUNOL, V151, P959; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SCHLETTER J, 1995, INFECT IMMUN, V63, P2576, DOI 10.1128/IAI.63.7.2576-2580.1995; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SCHUTT C, 1992, RES IMMUNOL, V143, P71, DOI 10.1016/0923-2494(92)80082-V; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P14; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Tobias PS, 1992, J CELL BIOCHEM, V16C, P151; Troelstra A, 1997, J LEUKOCYTE BIOL, V61, P173, DOI 10.1002/jlb.61.2.173; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vita N, 1997, J IMMUNOL, V158, P3457; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yu B, 1996, J BIOL CHEM, V271, P4100	45	88	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23157	23164		10.1074/jbc.272.37.23157	http://dx.doi.org/10.1074/jbc.272.37.23157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287319	hybrid			2022-12-25	WOS:A1997XV74400030
J	Laterza, OF; Hansen, WR; Taylor, L; Curthoys, NP				Laterza, OF; Hansen, WR; Taylor, L; Curthoys, NP			Identification of an mRNA-binding protein and the specific elements that may mediate the pH-responsive induction of renal glutaminase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; PHOSPHATE-DEPENDENT GLUTAMINASE; 3' UNTRANSLATED REGION; CYCLIC-AMP ELEVATION; ACID-BASE-BALANCE; AU-RICH ELEMENTS; GENE-EXPRESSION; C-FOS; 3'-UNTRANSLATED REGION; METABOLIC-ACIDOSIS	Various segments of the 3'-nontranslated region of the renal glutaminase (GA) mRNA were tested for their ability to enhance turnover and pH responsiveness. The combined effects were retained in the 340-base R-2 segment, However, the combined R-l and R-3 fragments also imparted a partial destabilization and pH responsiveness to a chimeric beta-globin mRNA, RNA electrophoretic mobility shift assays indicated that cytosolic extracts of rat renal cortex contain a protein that binds to the R-2 and R-3 RNAs. The binding observed with the R-2 RNA was mapped to a direct repeat of an 8-base AU sequence, This binding was effectively competed with an excess of the same RNA, but not by adjacent or unrelated RNAs. UV cross-linking experiments identified a 48-kDa protein that binds to the AU repeats of the R-2 RNA. The apparent binding of this protein was greatly reduced in renal cytosolic extracts prepared from acutely acidotic rats, Two related RNA sequences in the R-3 segment also exhibited specific binding, However, the latter binding was more effectively competed by R-2 RNA than by itself, indicating that the homologous sites may be weaker binding sites for the same 48-kDa protein, Thus, a single protein may bind specifically to multiple instability elements within the 3'-nontranslated region of the GA mRNA and mediate its pH-responsive stabilization.	COLORADO STATE UNIV,DEPT MOL BIOL & BIOCHEM,FT COLLINS,CO 80523	Colorado State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037124] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37124] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosnan JT, 1988, PH HOMEOSTASIS MECHA, P281; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; DAS AT, 1989, NUCLEIC ACIDS RES, V17, P2355, DOI 10.1093/nar/17.6.2355; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; GSTRAUNTHALER G, 1987, AM J PHYSIOL, V252, pC232, DOI 10.1152/ajpcell.1987.252.2.C232; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hansen WR, 1996, AM J PHYSIOL-RENAL, V271, pF126, DOI 10.1152/ajprenal.1996.271.1.F126; HARGROVE JL, 1993, FASEB J, V7, P1163, DOI 10.1096/fasebj.7.12.8375615; Holcomb T, 1996, AM J PHYSIOL-RENAL, V271, pF340, DOI 10.1152/ajprenal.1996.271.2.F340; HOLCOMB T, 1995, AM J PHYSIOL-CELL PH, V268, pC449, DOI 10.1152/ajpcell.1995.268.2.C449; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; HWANG JJ, 1991, BIOCHEMISTRY-US, V30, P7522, DOI 10.1021/bi00244a022; KAISER S, 1992, AM J PHYSIOL, V262, pF507, DOI 10.1152/ajprenal.1992.262.3.F507; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; PORTER D, 1995, AM J PHYSIOL-RENAL, V269, pF363, DOI 10.1152/ajprenal.1995.269.3.F363; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO RA, 1991, J BIOL CHEM, V266, P18792; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; TANNEN RL, 1993, HDB PHYSL RENAL PHYS, V1, P1017; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TONG J, 1987, BIOCHEMISTRY-US, V26, P2773, DOI 10.1021/bi00384a018; TONG J, 1986, BIOCHEM J, V233, P139, DOI 10.1042/bj2330139; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF961, DOI 10.1152/ajprenal.1990.259.6.F961; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF53, DOI 10.1152/ajprenal.1990.259.1.F53; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	38	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22481	22488		10.1074/jbc.272.36.22481	http://dx.doi.org/10.1074/jbc.272.36.22481			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278399	hybrid			2022-12-25	WOS:A1997XV49200019
J	Panozzo, C; Capuano, V; Fillinger, S; Felenbok, B				Panozzo, C; Capuano, V; Fillinger, S; Felenbok, B			The zinc binuclear cluster activator AlcR is able to bind to single sites but requires multiple repeated sites for synergistic activation of the alcA gene in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; ETHANOL UTILIZATION REGULON; POSITIVE REGULATORY GENE; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR ALCR; DNA RECOGNITION; CREA; GAL4; PROTEIN; SEQUENCE	The alcA gene which is part of the recently identified ethanol regulon, is one of the most strongly inducible genes in Aspergillus nidulans, Its transcriptional activation is mediated by the AlcR transactivator which contains a DNA-binding domain belonging to the C6 zinc binuclear cluster family, AlcR differs from the other members of this family by several features, the most striking characteristic being its binding to both. symmetric and asymmetric DNA sites with the same apparent affinity, However, AlcR is also able to bind to a single site with high affinity, suggesting that unlike the other C6 proteins, AlcR binds as a monomer. In this report, we show that AlcR targets, to be functional in vivo, have to be organized as inverted or direct repeats, In addition, we show a strong synergistic activation of alcA transcription in which the number and the position of the AlcR-binding sites are crucial, The fact that the AlcR unit for in vitro binding is a single site whereas the in vivo functional unit is a repeat ope:ns the question of the mechanism of the strong alcA transactivation, These results show that AlcR displays both in vitro and in vivo a new range of binding specificity and provides a novel example in the C6 zinc cluster protein family.	UNIV PARIS 11,URA CNRS D 2225,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE; CBAI,INA,PG,LAB GENET MICROORGANISMES,F-78850 THIVERVAL GRIGNON,FRANCE	UDICE-French Research Universities; Universite Paris Saclay				Capuano, Veronique/0000-0001-8738-0947				BAILEY C, 1975, EUR J BIOCHEM, V51, P573, DOI 10.1111/j.1432-1033.1975.tb03958.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHENG C, 1994, MOL CELL BIOL, V14, P3842, DOI 10.1128/MCB.14.6.3842; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; Creaser EH, 1984, BIOCHEM J, V225, P449; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FELENBOK B, 1991, J BIOTECHNOL, V17, P11, DOI 10.1016/0168-1656(91)90023-O; Felenbok B, 1994, Prog Ind Microbiol, V29, P141; FILLINGER S, 1995, FEBS LETT, V368, P547, DOI 10.1016/0014-5793(95)00736-S; Fillinger S, 1996, MOL MICROBIOL, V20, P475, DOI 10.1046/j.1365-2958.1996.5301061.x; FILLINGER S, 1996, THESIS U PARIS SUD O; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KULMBURG P, 1992, J BIOL CHEM, V267, P21146; KULMBURG P, 1991, FEBS LETT, V280, P11, DOI 10.1016/0014-5793(91)80193-7; KULMBURG P, 1992, MOL CELL BIOL, V12, P1932, DOI 10.1128/MCB.12.5.1932; KULMBURG P, 1993, MOL MICROBIOL, V7, P847, DOI 10.1111/j.1365-2958.1993.tb01175.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGDON T, 1995, MOL MICROBIOL, V17, P877, DOI 10.1111/j.1365-2958.1995.mmi_17050877.x; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LOCKINGTON R, 1987, MOL MICROBIOL, V1, P275, DOI 10.1111/j.1365-2958.1987.tb01933.x; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MATHIEU M, 1994, EMBO J, V13, P4022, DOI 10.1002/j.1460-2075.1994.tb06718.x; PATEMAN JA, 1983, PROC R SOC SER B-BIO, V217, P243, DOI 10.1098/rspb.1983.0009; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SCHERLING P, 1996, NUCLEIC ACIDS RES, V24, P4599; SEALYLEWIS HM, 1992, CURR GENET, V22, P293, DOI 10.1007/BF00317924; SEQUEVAL D, 1994, MOL GEN GENET, V242, P33, DOI 10.1007/BF00277345; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x	40	35	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22859	22865		10.1074/jbc.272.36.22859	http://dx.doi.org/10.1074/jbc.272.36.22859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278448	hybrid			2022-12-25	WOS:A1997XV49200069
J	Wright, SC; Schellenberger, U; Ji, L; Wang, H; Larrick, JW				Wright, SC; Schellenberger, U; Ji, L; Wang, H; Larrick, JW			Calmodulin-dependent protein kinase II mediates signal transduction in apoptosis	FASEB JOURNAL			English	Article						tumor necrosis factor; PMSF; CaM-KII; AP24 activity	DNA FRAGMENTATION; T-LYMPHOCYTES; U937 CELLS; ACTIVATION; TNF; DEATH; RESISTANT; INHIBITOR; MECHANISM; PROTEASES	The present studies describe a new function for calmodulin-dependent protein kinase II (CaM-KII) in signal transduction leading to apoptosis, Both tumor necrosis factor a (TNF) and UV light rapidly stimulated Ca2+-independent activity of CaM-KII in the monocytic leukemia, U937, Two mechanistically different inhibitors of CaM-KII blocked activation of CaM-KII and prevented DNA fragmentation and death, Activation of CaM-KII during apoptosis and inhibition of DNA fragmentation by the two CaM-KII. inhibitors were reproduced in several other lines including KG1a, HL-60, and YAC-1. However, K562, which is relatively resistant to apoptosis induced by either TNF or UV light, did not activate CaM-KII in response to these stimuli, A variant derived from U937 that is resistant to TNF-or UV light-induced apoptosis also lacked a CaM-KII response, Activation of Cam-KII was blocked by two protease inhibitors, VAD-fmk and TPCK, but not by other inhibitors of serine proteases, Both inhibitors of CaM-KII and the protease inhibitors blocked activation of AP24, a serine protease originally isolated from apoptotic cells that induces DNA fragmentation in nuclei, Our evidence supports a model in which proteolytic activity functions upstream of CaM-KII. This kinase then leads to activation of AP24, which transmits signals to the nucleus to initiate DNA fragmentation.			Wright, SC (corresponding author), PALO ALTO INST MOL MED,2462 WYANDOTTE ST,MT VIEW,CA 94043, USA.				NCI NIH HHS [CA68223] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HASEGAWA Y, 1989, J IMMUNOL, V14, P2670; HASHIMOTO Y, 1991, BIOCHEM BIOPH RES CO, V181, P423, DOI 10.1016/S0006-291X(05)81436-6; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; TOKUMITSU H, 1990, J BIOL CHEM, V26, P4314; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463	27	79	81	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					843	849		10.1096/fasebj.11.11.9285482	http://dx.doi.org/10.1096/fasebj.11.11.9285482			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285482				2022-12-25	WOS:A1997XT79000003
J	Li, QB; Cerione, RA				Li, QB; Cerione, RA			Communication between switch II and switch III of the transducin alpha subunit is essential for target activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; NUCLEOTIDE-BINDING-PROTEIN; HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; GAMMA-SUBUNIT; SITE; G(I-ALPHA-1); ANTIBODIES; MECHANISM	Comparisons of the tertiary structures of the GDP-bound and guanosine 5'-O-(thiotriphosphate) (GTP gamma S)- bound forms of the alpha subunit of transducin (alpha(T)) indicate that there are three regions that undergo changes in conformation upon alpha(T) activation, Two of these regions, Switch I and Switch II, were originally identified in Ras, while Switch III appears to be unique to trimeric GTP-binding proteins (G proteins), We find that replacement of the Switch III region (aspartic acid 227 through asparagine 237) with a single alanine residue yields an alpha(T) subunit that fully binds and hydrolyzes GTP but no longer stimulates the activity of the cyclic GMP phosphodiesterase (PDE), the physiological target for transducin, We also show that changing glutamic acid 232 of alpha(T) to a leucine (E232L) had no effect on rhodopsin-stimulated GTP-GDP exchange nor on the GTP hydrolytic activity of alpha(T). However, the GTP gamma S-bound form of the alpha(T)E232L mutant was unable to stimulate the activity of the cyclic GMP PDE. The lack of stimulation was not due to an inability of the alpha(T)E232L mutant to bind to the target, Taken together, these results indicate that glutamic acid 232 mediates a conformational coupling between Snitch II and Switch III, which is essential for converting GTP-dependent G protein-target interactions into a stimulation of target/effector activity.	CORNELL UNIV,DEPT PHARMACOL,CTR VET MED,ITHACA,NY 14853	Cornell University					NEI NIH HHS [EY06429] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CUNNICK J, 1994, BIOCHEM J, V297, P87, DOI 10.1042/bj2970087; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOSWAMI BB, 1991, BIOTECHNIQUES, V5, P626; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YEE R, 1978, J BIOL CHEM, V253, P8902	30	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21673	21676		10.1074/jbc.272.35.21673	http://dx.doi.org/10.1074/jbc.272.35.21673			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268292	hybrid			2022-12-25	WOS:A1997XT85000004
J	Xiao, CY; Hubner, S; Jans, DA				Xiao, CY; Hubner, S; Jans, DA			SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; TERMINAL TRANSACTIVATION DOMAIN; HUMAN KU-AUTOANTIGEN; II SITE; PHOSPHORYLATION SITES; V(D)J RECOMBINATION; KARYOPHERIN-ALPHA; PORE BINDING; BREAK REPAIR; MOUSE P53	Nuclear localization sequence (NLS)-dependent nuclear import of SV40 large tumor antigen (T-Ag) fusion proteins is regulated by phosphorylation sites for casein kinase II (CKII) and the cyclin dependent kinase Cdc2 amino-terminal to the NLS (amino acids 126-132), Between the T-Ag CKII and Cdc2 sites is a site (Ser(120)) for the double-stranded DNA-dependent protein kinase (dsDNA-PK), which we show here for the first time to play a role in regulating T-Ag nuclear import. We replaced Ser(120) by aspartic acid or alanine using site-directed mutagenesis and assessed the effects on nuclear transport kinetics both in vivo (microinjected cells) and in vitro (mechanically perforated cells) in HTC rat hepatoma cells, Maximal nuclear accumulation of the Asp(120) and Ala(120) protein derivatives was approximately 40% and 70% reduced in vivo, respectively, compared with that of the wild type protein, and similarly reduced in vitro, although to a lesser extent, This implies that the dsDNA-PK site regulates the maximal level of nuclear accumulation, normally functioning to enhance T-Ag nuclear transport; the higher accumulation of the Asp(120) protein compared with the Ala(120) protein indicates that negative charge at the dsDNA-PK site is mechanistically important in regulating nuclear import, The Asp(120) protein accumulated in the nucleus at a faster rate than the wild type protein, implying that phosphorylation at Ser(120) may also regulate the nuclear import rate, CKII phosphorylation of the Asp(120) protein in cytosol or by purified CKII was approximately 30% higher than that of the Ser(120) and Ala(120) proteins, while negative charge at the CKII site increased dsDNA-PK phosphorylation of Ser(120) by approximately 80% compared with wild type, implying physical and functional interactions between the two phosphorylation sites. Quantitation of NLS recognition by the importin 58/97 subunits using an enzyme-linked immunosorbent assay indicated that while the Ala(120) protein derivative had a binding affinity very similar to that of wild type, the Asp(120) derivative showed 40% higher affinity, In vitro CKII phosphorylation increased importin binding by about 30% in all cases, These results imply that negative charge at the dsDNA-PK site may enhance nuclear import through increasing both NLS recognition by importin subunits, and phosphorylation at the CKII site, which itself also facilitates NLS recognition by importin 58/97.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOL BIOL, NUCL SIGNALING LAB, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research								ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOTTERELL SH, 1987, EUR J BIOCHEM, V164, P39, DOI 10.1111/j.1432-1033.1987.tb10989.x; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; LIU SH, 1993, J BIOL CHEM, V268, P21147; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHEIDTMANN KH, 1984, J VIROL, V50, P636, DOI 10.1128/JVI.50.2.636-640.1984; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; Seydel U, 1996, BIOCHEM J, V315, P33, DOI 10.1042/bj3150033; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451	53	115	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22191	22198		10.1074/jbc.272.35.22191	http://dx.doi.org/10.1074/jbc.272.35.22191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268364	hybrid			2022-12-25	WOS:A1997XT85000076
J	Zhang, YL; Sun, VY; Spremulli, LL				Zhang, YL; Sun, VY; Spremulli, LL			Role of domains in Escherichia coli and mammalian mitochondrial elongation factor Ts in the interaction with elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; COMPLEX; PURIFICATION; EXPRESSION; CLONING; BOVINE	Bovine mitochondrial elongation factor Ts (EF-Ts-mt) stimulates the activity of Escherichia coli elongation factor Tu (EF-Tu), In contrast, E. coli EF-Ts is unable to stimulate mitochondrial EF-Tu. EF-Ts-mt forms a tight complex with E. coli EF-Tu governed by an association constant of 8.6 x 10(10), This value is 100-fold stronger than the binding constant for the formation of the E. coli EF-Tu . Ts complex. To test which domain of EF-Ts-mt is important for its strong binding with EF-Tu, chimeras were made between E. coli EF-Ts and EF-Ts-mt. Replacing the N-terminal domain of E, coli EF-Ts with that of EF-Ts-mt increases its binding to E. coli EF-Tu 2-3-fold, Replacing the N-terminal domain of EF-Ts-mt with the corresponding region of E. coli EF-Ts decreases its binding to E, coli EF Tu similar to 4-5-fold, A chimera consisting of the C-terminal half of E. cold EF-Ts and the N-terminal half of EF-Ts-mt binds to E. coli EF-Tu as strongly as EF-Ts-mt. A chimera in which Subdomain N of the core of EF-Ts is replaced by the corresponding region of EF-Ts-mt binds E, coli EF-Tu similar to 25-fold more tightly than E. coli EF-Ts, Thus, the higher strength of the interaction between EF-Ts-mt and EF-Tu can be localized primarily to a single subdomain.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI KI, 1978, EUR J BIOCHEM, V92, P509, DOI 10.1111/j.1432-1033.1978.tb12773.x; Blank J, 1996, EUR J BIOCHEM, V236, P222, DOI 10.1111/j.1432-1033.1996.00222.x; BOGESTRAND S, 1995, FEBS LETT, V368, P49, DOI 10.1016/0014-5793(95)00597-3; BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91; FOX L, 1980, J BIOL CHEM, V255, P6018; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DL, 1970, BIOCHEM BIOPH RES CO, V38, P1016, DOI 10.1016/0006-291X(70)90341-4; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1991, J BIOL CHEM, V266, P16324; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; Woriax VL, 1997, BBA-GENE STRUCT EXPR, V1352, P91, DOI 10.1016/S0167-4781(97)00002-X; XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243; Xin H, 1997, BBA-GENE STRUCT EXPR, V1352, P102, DOI 10.1016/S0167-4781(97)00003-1; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2	20	22	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21956	21963		10.1074/jbc.272.35.21956	http://dx.doi.org/10.1074/jbc.272.35.21956			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268331	hybrid			2022-12-25	WOS:A1997XT85000043
J	Whitaker, LL; Hansen, MF				Whitaker, LL; Hansen, MF			Induction of apoptosis in Mv1Lu cells by expression of competitive RB1 mutants	ONCOGENE			English	Article						dominant-negative; growth suppression domain; tumor suppressor	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN LYMPHOID NEOPLASMS; LARGE T-ANTIGEN; SUSCEPTIBILITY GENE; HUMAN CANCER; FUNCTIONAL INTERACTIONS; PROTEIN; BINDING; MUTATIONS	The Retinoblastoma tumor suppressor gene (RB1) plays a role in a variety of human cancers, Experimental analyses have indicated that the protein product of the RB1 gene (pRb) plays a role in cell cycle regulation. pRb function is dependent on its ability to bind to cellular factors, which is facilitated by multiple protein binding domains within pRb. Mutations within these domains which eliminate the ability of pRb to bind its targets result in loss of function. Although loss of pRb function may lead to uncontrolled cellular proliferation, tumorigenesis is not the only response to pRb inactivation. Examination of various tissues from RB1-nullizygous mouse embryos showed problems in differentiation and induction of apoptosis, suggesting that the ultimate response to the loss of pRb is influenced by cellular context. It has previously been demonstrated in RB1-negative Saos-2 cells that co-expression of the C-terminal domain of pRb with wildtype pRb resulted in escape from G1 arrest and continued cell cycling. In this paper we demonstrate that in RB1-positive Mv1Lu cells, expression of the A/B pocket region or the N-terminus (when combined with a nuclear localization signal), but not the C-terminal domain, is able to competitively disrupt the function of the endogenous pRb, and that the result of this disruption is apoptosis.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009299, R01CA050331] Funding Source: NIH RePORTER; NCI NIH HHS [CA09299, CA50331] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA HG, 1991, BLOOD, V78, P3259; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ANTELMAN D, 1995, ONCOGENE, V10, P697; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANERJEE A, 1992, CANCER RES, V52, P6297; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN YC, 1990, BLOOD, V76, P2060; CHITTENDEN T, 1991, COLD SPRING HARB SYM, V56, P187; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fung Y K, 1992, Cancer Treat Res, V61, P59; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GALLIE BL, 1994, NEW ENGL J MED, V330, P786, DOI 10.1056/NEJM199403173301112; GINSBERG AM, 1992, LEUKEMIA LYMPHOMA, V7, P359, DOI 10.3109/10428199209049791; GINSBERG AM, 1991, BLOOD, V77, P833; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; ISHIKAWA J, 1991, CANCER RES, V51, P5736; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO J, 1993, GENE DEV, V7, P331; KATO MV, 1994, HUM MUTAT, V3, P44, DOI 10.1002/humu.1380030108; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KLOSS K, 1991, AM J MED GENET, V39, P196, DOI 10.1002/ajmg.1320390215; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MELING GI, 1991, BRIT J CANCER, V64, P475, DOI 10.1038/bjc.1991.334; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NAKAMURA T, 1991, JPN J CLIN ONCOL, V21, P325; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; REISSMANN PT, 1989, ONCOGENE, V4, P839; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TANG A, 1989, ONCOGENE, V4, P401; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UZVOLGYI E, 1991, CELL GROWTH DIFFER, V2, P297; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEIDE R, 1991, BRIT J HAEMATOL, V78, P500, DOI 10.1111/j.1365-2141.1991.tb04479.x; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1992, Semin Immunol, V4, P389; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU HJ, 1991, CANCER RES, V51, P4481; Yamaguchi T, 1996, ANTICANCER RES, V16, P2009; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	79	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1069	1077		10.1038/sj.onc.1201277	http://dx.doi.org/10.1038/sj.onc.1201277			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285561				2022-12-25	WOS:A1997XT16100008
J	Garton, AJ; Burnham, MR; Bouton, AH; Tonks, NK				Garton, AJ; Burnham, MR; Bouton, AH; Tonks, NK			Association of PTP-PEST with the SH3 domain of p130(cas); a novel mechanism of protein tyrosine phosphatase substrate recognition	ONCOGENE			English	Article						p130(cas); SH3 domain; PTP-PEST; tyrosine phosphorylation; PTP	FOCAL ADHESION KINASE; SWISS 3T3 CELLS; V-CRK ONCOGENE; GROWTH-FACTOR; STRUCTURAL BASIS; RECEPTOR-BETA; CROSS-TALK; PHOSPHORYLATION; PHOSPHOTYROSINE; PAXILLIN	The protein tyrosine phosphatase PTP-PEST displays remarkable substrate specificity, in vitro and in vivo for p130(cas) a signalling intermediate implicated in mitogenic signalling, cell-adhesion induced signalling, and in transformation by a variety of oncogenes. We have identified a high affinity interaction between the SH3 domain of p130(cas) and a proline-rich sequence ((PPPKPPR)-P-335) within the C-terminal segment of PTP-PEST. Mutation of proline 337 within this sequence to alanine significantly impairs the ability of PTP-PEST to recognise tyrosine phosphorylated p130(cas) as a substrate, without qualitatively affecting the selectivity of the interaction. Thus the highly specific nature of the interaction between PTP-PEST and p130(cas) appears to result from a combination of two distinct substrate recognition mechanisms; the catalytic domain of PTP-PEST contributes specificity to the interaction with p130(cas), whereas the SH3 domain-mediated association of p130(cas) and PTP-PEST dramatically increases the efficiency of the interaction. Furthermore, our results indicate that one important function of the p130(cas) SH3 domain is to associate with PTP-PEST and thereby facilitate the dephosphorylation of p130(cas), resulting in the termination of tyrosine phosphorylation-dependent signalling events downstream of p130(cas).	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	Cold Spring Harbor Laboratory; University of Virginia; University of Virginia					NCI NIH HHS [CA 53840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Burnham MR, 1996, ONCOGENE, V12, P2467; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, J BIOL CHEM, V269, P704; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SCHNEIDER C, 1992, J BIOL CHEM, V267, P10766; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1993, J BIOL CHEM, V268, P17650; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	142	146	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	1997	15	8					877	885		10.1038/sj.onc.1201279	http://dx.doi.org/10.1038/sj.onc.1201279			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285683				2022-12-25	WOS:A1997XR76700001
J	Ann, K; Kowalchyk, JA; Loyet, KM; Martin, TFJ				Ann, K; Kowalchyk, JA; Loyet, KM; Martin, TFJ			Novel Ca2+-binding protein (CAPS) related to UNC-31 required for Ca2+-activated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROENDOCRINE CELLS; VESICLE FUSION; SECRETION; CA2+; SEQUENCES; RELEASE; SITE; STEP	Exocytotic secretion in neuroendocrine cells is activated by cytoplasmic Ca2+ increases. Late post-docking events in dense core vesicle exocytosis in permeable PC12 cells require cytosolic factors for sequential ATP-dependent priming and Ca2+-dependent triggering steps. The cytosolic proteins phosphatidylinositol transfer protein and phosphatidylinositol (4)-phosphate 5-kinase, as well as membrane-bound N-ethylmaleimide-sensitive factor, are required for the ATP dependent priming step. Following priming, the Ca2+-dependent triggering of vesicle fusion requires an additional cytosolic factor, CAPS, which was purified as a 145-kDa protein. To clarify late Ca2+-dependent events in vesicle fusion, the sequence of rat CAPS cDNA was determined and found to encode a novel protein that is the vertebrate homologue of the Caenorhabditis elegans UNC-31 protein shown genetically to be required for neurosecretion. Recombinant CAPS substituted for cytosol in the Ca2+ triggering step in permeable PC12 cells and exhibited moderate affinity (K-d = 270 mu M) Ca2+ binding (2 mol Ca2+/mol CAPS dimer), consistent with a role at a Ca2+-regulated step in exocytosis.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040428, R37DK025861, R01DK025861] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25861, DK40428] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Avery Leon, 1993, Genetics, V134, P455; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; Calakos N, 1996, PHYSIOL REV, V76, P1; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HARTMANN J, 1995, FEBS LETT, V363, P217, DOI 10.1016/0014-5793(95)00318-4; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; LIVINGSTONE D, 1991, STUDIES UNC 31 GENE; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	29	143	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19637	19640		10.1074/jbc.272.32.19637	http://dx.doi.org/10.1074/jbc.272.32.19637			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9289490	hybrid			2022-12-25	WOS:A1997XQ05900002
J	Scimeca, JC; Servant, MJ; Dyer, JO; Meloche, S				Scimeca, JC; Servant, MJ; Dyer, JO; Meloche, S			Essential role of calcium in the regulation of MAP kinase phosphatase-1 expression	ONCOGENE			English	Article						phosphatase; MAP kinase; gene expression; calcium	ACTIVATED PROTEIN-KINASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE CELLS; TYROSINE-PHOSPHATASE; HEAT-SHOCK; IN-VIVO; MITOGEN; PHOSPHORYLATION; TRANSCRIPTION	Mitogen-activated protein (MAP) kinase phosphatase-l (MKP-1) is a dual-specificity protein phosphatase encoded by an immediate-early gene responsive to growth factors and stress. The MKP-1 protein selectively inactivates MAP kinases in vitro by dephosphorylation of the regulatory Thr and Tyr residues. Little is known on the mechanisms that regulate MKP-1 gene expression. Here, we demonstrate that Ca2+ is both necessary and sufficient for the induction of MKP-1 gene expression. Treatment of Rat1 fibroblasts with the Ca2+ chelating agent BAPTA completely suppressed serum-induced MKP-1 expression in a dose- and time-dependent manner. The inhibitory effect of BAPTA was observed at the level of the protein and the mRNA. Importantly, Ca2+ chelation blocked the induction of MKP-1 expression in response to all stimuli tested and in different cell types. Increasing the intracellular concentration of Ca2+ with the ionophore A23187 was sufficient to induce MKP-1 mRNA and protein expression in rat fibroblasts. We also provide evidence that activation of MAP kinases is not an absolute requirement for induction of the MKP-1 gene. Exposure of rat fibroblasts to A23187 induced MKP-1 expression without activating the JNK and p38 MAP kinase pathways. Also, inhibition of the ERK pathway with the selective MEK inhibitor PD98059 did not interfere with serum-stimulated MKP-1 mRNA expression. These results will help define the regulatory mechanisms that govern MKP-1 gene transcription in target cells.	HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ H2W 1T8,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H2W 1T8,CANADA	Universite de Montreal; Universite de Montreal			; Scimeca, Jean-Claude/P-3830-2016	Dyer, Joseph-Omer/0000-0002-7570-9941; Scimeca, Jean-Claude/0000-0003-3773-6110				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEJONGE PC, 1983, BIOCHIM BIOPHYS ACTA, V722, P219, DOI 10.1016/0005-2728(83)90177-9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1993, J BIOL CHEM, V268, P26037; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FUKUDA M, 1995, ONCOGENE, V11, P239; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MILLAR JBA, 1995, GENE DEV, V9, P2217; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	76	52	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					717	725		10.1038/sj.onc.1201231	http://dx.doi.org/10.1038/sj.onc.1201231			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264412	Bronze			2022-12-25	WOS:A1997XP68300011
J	Weinberg, WC; Montano, NE; Deng, C				Weinberg, WC; Montano, NE; Deng, C			Loss of p21(CIP1/WAF1) does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis	ONCOGENE			English	Article						p53; p21(CIP1/WAF1); epidermal carcinogenesis	P53-MEDIATED G(1) ARREST; HARVEY SARCOMA-VIRUS; P53-INDEPENDENT PATHWAY; PRIMARY KERATINOCYTES; GENE DOSAGE; EXPRESSION; P21; PROGRESSION; INHIBITOR; WAF1/CIP1	The p21(CIP1/WAF1) protein is considered a downstream effector of tumor suppression by p53, We have previously demonstrated that p53 null keratinocytes have lower basal p21(CIP1/WAF1) mRNA levels and that tumors derived from these cells following transduction with the v-ras(Ha) oncogene grow faster than wildtype keratinocytes and rapidly progress to undifferentiated carcinomas (Cancer Res 54: 5584-5592, 1994), In this study, primary keratinocytes differing in p21(CIP1/WAF1) gene dose were transduced with v-ras(Ha) encoding retrovirus and grafted to nude mouse hosts to test whether the p53 null phenotype is mediated through p21(CIP1/WAF1). Resulting tumors from all genotypes were well differentiated papillomas; focal carcinomas were observed in 43, 30 and 44% of papillomas derived from +/+, +/- and -/- keratinocytes, respectively, p21(CIP1/WAF1) deficient keratinocytes expressing v-ras(Ha) do not display the degree of increased growth observed in p53 deficient tumors irt vivo or the decreased responsiveness to negative growth regulation by Ca2+ in vitro. These results suggest that p21(CIP1/WAF1) does not regulate the differentiated phenotype or malignant progression of v-ras(Ha) initiated keratinocytes and that additional functions of the p53 protein other than transcriptional regulation Of the p21(CIP1/WAF1) gene are required for p53 mediated tumor suppression.	NIDDKD,BIOCHEM & METAB LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Weinberg, WC (corresponding author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,NIH,BETHESDA,MD 20892, USA.		Weinberg, Wendy/A-8920-2009; deng, chuxia/N-6713-2016					Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAE IS, 1995, CANCER RES, V55, P2387; BRISSETTE JL, 1993, MOL CARCINOGEN, V7, P21, DOI 10.1002/mc.2940070105; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CONWAY K, 1992, CANCER RES, V52, P6487; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIU M, 1995, ONCOGENE, V10, P1955; Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D; MICHIELI P, 1994, CANCER RES, V54, P3391; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Reiners JJ, 1997, CARCINOGENESIS, V18, P593, DOI 10.1093/carcin/18.3.593; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; TENNENBAUM T, 1993, CANCER RES, V53, P4803; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1996, ONCOGENE, V12, P1557	33	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					685	690		10.1038/sj.onc.1201230	http://dx.doi.org/10.1038/sj.onc.1201230			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264409				2022-12-25	WOS:A1997XP68300008
J	Tailor, RH; Acland, DP; Attenborough, S; Cammue, BPA; Evans, IJ; Osborn, RW; Ray, JA; Rees, SB; Broekaert, WF				Tailor, RH; Acland, DP; Attenborough, S; Cammue, BPA; Evans, IJ; Osborn, RW; Ray, JA; Rees, SB; Broekaert, WF			A novel family of small cysteine-rich antimicrobial peptides from seed of Impatiens balsamina is derived from a single precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT ANTIFUNGAL PROTEINS; LIPID TRANSFER PROTEINS; CDNA SEQUENCE; RADISH; BARLEY; INHIBITORS; MAGAININS; MECHANISM; DEFENSE	Four closely related peptides were isolated from seed of lmpatiens balsamina and were shown to be inhibitory to the growth of a range of fungi and bacteria, while not being cytotoxic to cultured human cells, The peptides, designated Ib-AMP1, Ib-AMP2, Ib-AMP3, and Ib-AMP4, are 20 amino acids long and are the smallest plant-derived antimicrobial peptides isolated to date, The Ib-AMPs (I. balsaminn antimicrobial peptides) are highly basic and contain four cysteine residues which form two intramolecular disulfide bonds. Searches of protein data bases have failed to identify any proteins with significant homology to the peptides described here, Characterization of isolated cDNAs reveals that all four peptides are encoded within a single transcript, The predicted Ib-AMP precursor protein consists of a prepeptide followed by 6 mature peptide domains, each flanked by propeptide domains ranging from 16 to 35 amino acids in length, Such a primary structure with repeated alternating basic mature peptide domains and acidic propeptide domains has, to date, not been reported in plants.	ZENECA AGROCHEM, JEALOTTS HILL RES STN, BRACKNELL RG42 6EY, BERKS, ENGLAND; KATHOLIEKE UNIV LEUVEN, FA JANSSENS LAB GENET, B-3001 HEVERLEE, BELGIUM	KU Leuven			Cammue, Bruno/M-9575-2013					ATKINSON AH, 1993, PLANT CELL, V5, P203, DOI 10.1105/tpc.5.2.203; Belknap WR, 1996, TRENDS PLANT SCI, V1, P331; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; CAMMUE BRUNO PA, 1995, PLANT PHYSIOL, V109, P445, DOI 10.1104/pp.109.2.445; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; COLILLA FJ, 1990, FEBS LETT, V270, P191, DOI 10.1016/0014-5793(90)81265-P; DUVICK JP, 1992, J BIOL CHEM, V267, P18814; Garcia-Olmedo F., 1989, OXFORD SURV PLANT MO, V6, P31; GRAY WR, 1981, J BIOL CHEM, V256, P4734; Jepson I., 1991, PLANT MOL BIOL REP, V9, P131; KIYOMASU T, 1991, J VIROL, V65, P4539, DOI 10.1128/JVI.65.8.4539-4542.1991; KOVARIK A, 1987, FOLIA BIOL-PRAGUE, V33, P253; Marcus JP, 1997, EUR J BIOCHEM, V244, P743, DOI 10.1111/j.1432-1033.1997.00743.x; MENDEZ E, 1990, EUR J BIOCHEM, V194, P533, DOI 10.1111/j.1432-1033.1990.tb15649.x; MOLINA A, 1993, FEBS LETT, V316, P119, DOI 10.1016/0014-5793(93)81198-9; OHTANI S, 1977, J BIOCHEM-TOKYO, V82, P753; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; PARDI A, 1989, BIOCHEMISTRY-US, V28, P5494, DOI 10.1021/bi00439a026; TERRAS FRG, 1993, FEBS LETT, V316, P233, DOI 10.1016/0014-5793(93)81299-F; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TERRAS FRG, 1992, PLANT PHYSIOL, V100, P1055, DOI 10.1104/pp.100.2.1055; TERRAS FRG, 1995, PLANT CELL, V7, P573, DOI 10.1105/tpc.7.5.573; TERRY AS, 1988, J BIOL CHEM, V263, P5745; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	29	140	162	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24480	24487		10.1074/jbc.272.39.24480	http://dx.doi.org/10.1074/jbc.272.39.24480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305910	hybrid			2022-12-25	WOS:A1997XY51500061
J	Cappelli, E; Taylor, R; Cevasco, M; Abbondandolo, A; Caldecott, K; Frosina, G				Cappelli, E; Taylor, R; Cevasco, M; Abbondandolo, A; Caldecott, K; Frosina, G			Involvement of XRCC1 and DNA ligase III gene products in DNA base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELL EXTRACTS; POLYMERASE-BETA; IN-VITRO; PROTEIN	DNA ligase III and the essential protein XRCC1 are present at greatly reduced levels in the xrcc1 mutant CHO cell line EM-C11, Cell-free extracts prepared from these cells were used to examine the role of the XRCC1 gene product in DNA base excision repair is vitro. EM-C11 cell extract was partially defective in ligation of base excision repair patches, in comparison to wild type CHO-9 extracts, Of the two branches of the base excision repair pathway, only the single nucleotide insertion pathway was affected; no ligation defect was observed in the proliferating cell nuclear antigen-dependent pathway. Full complementation of the ligation defect in EM-C11 extracts was achieved by addition to the repair reaction of recombinant; human DNA ligase III but not by XRCC1. This is consistent with the notion that XRCC1 acts as an important stabilizing factor of DNA ligase III. These data demonstrate for the first time that xrcc1 mutant cells are partially defective in ligation of base excision repair patches and that the defect is specific to the polymerase beta-dependent single nucleotide insertion pathway.	IST NAZL RIC CANC, DNA REPAIR UNIT, CSTA LAB, I-16132 GENOA, ITALY; UNIV MANCHESTER, SCH BIOL SCI, ZENECCA LAB CELL & MOL BIOL, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV GENOA, CHAIR GENET, GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST; University of Manchester; University of Genoa			Caldecott, Keith/S-4245-2019; Frosina, Guido/Z-2382-2019; cappelli, enrico/K-7954-2016	Frosina, Guido/0000-0002-6717-5097; Caldecott, Keith/0000-0003-4255-9016; cappelli, enrico/0000-0001-5910-9260				Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CAPPELLI E, 1995, CARCINOGENESIS, V16, P2267, DOI 10.1093/carcin/16.9.2267; DEMURCIA G, 1996, WORKSH PROC DNA DAM; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; FRASAD R, 1996, J BIOL CHEM, V271, P16000; FRIGENT C, 1994, MOL CELL BIOL, V14, P310; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; SAPORITO SM, 1989, J BACTERIOL, V171, P2542, DOI 10.1128/jb.171.5.2542-2546.1989; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; THOMPSON LH, 1982, MUTAT RES, V95, P247; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; ZDZIENICKA MZ, 1992, MUTAGENESIS, V7, P265, DOI 10.1093/mutage/7.4.265	18	265	275	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23970	23975		10.1074/jbc.272.38.23970	http://dx.doi.org/10.1074/jbc.272.38.23970			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295348	hybrid			2022-12-25	WOS:A1997XX38100073
J	Herbert, JM; Lamarche, I; Carmeliet, P				Herbert, JM; Lamarche, I; Carmeliet, P			Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HUMAN-ENDOTHELIAL CELLS; RAT CAROTID-ARTERY; EXTRACELLULAR-MATRIX; THROMBIN RECEPTOR; EXPRESS UROKINASE; GENE-EXPRESSION; INHIBITOR; INDUCTION; MICE	The present study was undertaken to evaluate in vitro the relative importance of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) in the mitogenic and chemotactic potential of bovine fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF)-BB for smooth muscle cells (SMC), Aortic SMC were isolated from transgenic mice showing single inactivations of the t-PA, u-PA, plasminogen activator inhibitor-1, or urokinase-type plasminogen activator receptor (u-PAR) genes. With regard to serum-induced proliferation, all cell types showed similar responses, However, SMC isolated from t-PA-deficient mice did not proliferate or migrate in response to PDGF, whereas SMC isolated from u-PA-deficient animals appeared to be much less sensitive to bFGF than the cells isolated from the other animals, Supplementation of cells from deficient animals with exogenous murine t-PA or u-PA restored the normal response of the growth factors with regard to both migration and proliferation, The mitogenic and chemotactic responses of bFGF were specifically inhibited in u-PAR-deficient cells or in wild-type SMC, cultured in the presence of antibodies to u-PAR, The role of u-PA and t-PA in bFGF and PDGF-induced growth and migration of SMC was not dependent on plasmin generation and activity as demonstrated by the inactivity of epsilon-aminocaproic acid and aprotinin, A 4-5-fold increase in the steady-state levels of u-PA and t-PA mRNA and proteins were observed after 24 h of incubation of the cell cultures with bFGF and PDGF-BB, respectively, These results therefore indicate that, at least in vitro, t-PA is an important element of the activity of PDGF-BB with regard to the proliferation and migration of SMC whereas u-PA is a key factor in the effect of bFGF on SMC.	KATHOLIEKE UNIV LEUVEN,CTR TRANSGENE TECHNOL & GENE THERAPY,B-3000 LOUVAIN,BELGIUM	KU Leuven	Herbert, JM (corresponding author), SANOFI RECH,HAEMOBIOL RES DEPT,195 ROUTE ESPAGNE,F-31036 TOULOUSE,FRANCE.		Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821				AU YPT, 1992, J BIOL CHEM, V267, P3438; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; BJORKERUD S, 1988, CIRC RES, V62, P1011, DOI 10.1161/01.RES.62.5.1011; Carmeliet P, 1996, FIBRINOLYSIS, V10, P195, DOI 10.1016/S0268-9499(96)80017-8; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CARMELIET P, 1997, IN PRESS J CLIN INVE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1992, CIRC RES, V70, P1128, DOI 10.1161/01.RES.70.6.1128; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; DECLERCK PJ, 1995, J BIOL CHEM, V270, P8397, DOI 10.1074/jbc.270.15.8397; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GOLDSMITH GH, 1981, EXP MOL PATHOL, V35, P257, DOI 10.1016/0014-4800(81)90065-4; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; HERBERT JM, 1994, J BIOL CHEM, V269, P3076; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KORNER G, 1993, J CELL PHYSIOL, V154, P456, DOI 10.1002/jcp.1041540303; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; LEVIN EG, 1978, THROMB RES, V15, P869; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MIMURO J, 1987, BLOOD, V70, P721; MORE RS, 1995, CARDIOVASC RES, V29, P22, DOI 10.1016/0008-6363(96)88541-5; MORIOKA S, 1987, J INVEST DERMATOL, V88, P418, DOI 10.1111/1523-1747.ep12469754; NODAHEINY H, 1995, ARTERIOSCL THROM VAS, V15, P37, DOI 10.1161/01.ATV.15.1.37; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PAUL R, 1987, THROMB RES, V46, P793, DOI 10.1016/0049-3848(87)90071-5; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; REILLY CF, 1991, J BIOL CHEM, V266, P9419; REUNING U, 1994, BLOOD, V84, P3700, DOI 10.1182/blood.V84.11.3700.bloodjournal84113700; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SCHOLLMANN C, 1992, J BIOL CHEM, V267, P18032; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; STAHL A, 1994, CANCER RES, V54, P3066; TAIJI M, 1992, MOL CELL BIOL, V12, P2193, DOI 10.1128/MCB.12.5.2193; TODD RF, 1995, LEUKOCYTE TYPING, V5, P111; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WATANABE Y, 1994, ARTERIOSCLER THROMB, V14, P1000, DOI 10.1161/01.ATV.14.6.1000; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WEISS RH, 1993, J BIOL CHEM, V268, P5724	60	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23585	23591		10.1074/jbc.272.38.23585	http://dx.doi.org/10.1074/jbc.272.38.23585			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295297	hybrid			2022-12-25	WOS:A1997XX38100022
J	Perez, PJ; RamosFranco, J; Fill, M; Mignery, GA				Perez, PJ; RamosFranco, J; Fill, M; Mignery, GA			Identification and functional reconstitution of the type 2 inositol 1,4,5-trisphosphate receptor from ventricular cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNELS; RYANODINE RECEPTOR; INSP3 RECEPTOR; TRISPHOSPHATE; BINDING; HEART; EXPRESSION; MECHANISM; MITOCHONDRIAL; CEREBELLUM	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) is an intracellular Ca2+ release channel that mediates the rise in cytoplasmic calcium in response to receptor-activated production of InsP(3). The InsP(3)R-mediated signaling pathway appears to be ubiquitous and is involved in many cellular processes including cell division, smooth muscle contraction, and neuronal signaling. Different regions of the heart also express InsP(3) receptors, We report here that acutely dissociated ventricular myocytes from ferret and rat hearts express significant levels of InsP(3)R as indicated by immunoblotting with a receptor consensus antibody, InsP(3) binding experiments (K-D = 23.6 nM and B-max = 0.46 pmol/mg) suggest the myocytes contain the high affinity type 2 InsP(3) receptor. Exhaustive mRNA screening by polymerase chain reaction, RNase protection, and subsequent DNA sequencing positively identify the InsP(3)R as type 2, The type 2 receptor from ferret heart was then incorporated into planar lipid bilayers and formed Ca2+-selective, InsP(3)-activated, heparin-blocked ion channels. We conclude that the predominant InsP(3) receptor isoform expressed in cardiac myocytes is type 2 and that it forms a functional InsP(3)-gated Ca2+ channel when reconstituted in planar lipid bilayers.	LOYOLA UNIV,STRITCH SCH MED,DEPT PHYSIOL,MAYWOOD,IL 60153; LOYOLA UNIV,STRITCH SCH MED,CARDIOVASC INST,MAYWOOD,IL 60153; LOYOLA UNIV,STRITCH SCH MED,PROGRAM MOL BIOL,MAYWOOD,IL 60153; INST NACL CARDIOL IGNACIO CHAVEZ,DEPT PHYSIOL,MEXICO CITY 14080,DF,MEXICO	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; National Institute of Cardiology - Mexico				Ramos-Franco, Josefina/0000-0001-5404-9481	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053367] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29 AR41197] Funding Source: Medline; NIMH NIH HHS [R29 MH53367] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BASSANI RA, 1992, J PHYSIOL-LONDON, V453, P591, DOI 10.1113/jphysiol.1992.sp019246; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; BROWN J H, 1986, P245; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; GORZA L, 1993, J CELL BIOL, V121, P345, DOI 10.1083/jcb.121.2.345; GORZA L, 1995, ANN NY ACAD SCI, V752, P141, DOI 10.1111/j.1749-6632.1995.tb17417.x; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HIRATA M, 1984, BIOCHEM J, V223, P229, DOI 10.1042/bj2230229; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; KIJIMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P728, DOI 10.1016/0006-291X(92)92262-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIGNERY GA, 1993, METH NEUROSCI, V18, P247; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Sambrook J, 1989, MOL CLONING LAB MANU, P382; SCHOLZ H, 1986, J MOL CELL CARDIOL, V18, P79, DOI 10.1016/S0022-2828(86)80463-1; SMITH JS, 1989, J GEN PHYSIOL, V92, P1; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5	34	137	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23961	23969		10.1074/jbc.272.38.23961	http://dx.doi.org/10.1074/jbc.272.38.23961			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295347	hybrid			2022-12-25	WOS:A1997XX38100072
J	Schroder, I; Rech, S; Krafft, T; Macy, JM				Schroder, I; Rech, S; Krafft, T; Macy, JM			Purification and characterization of the selenate reductase from Thauera selenatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPLASMIC NITRATE REDUCTASE; JOAQUIN DRAINAGE WATER; ELEMENTAL SELENIUM; ANAEROBIC RESPIRATION; BIOREMEDIATION; CALIFORNIA; SEDIMENTS; SYSTEM	Thauera selenatis is one of two isolated bacterial species that can obtain energy by respiring anaerobically with selenate as the terminal electron acceptor. The reduction of selenate to selenite is catalyzed by a selenate reductase, previously shown to be located in the periplasmic space of the cell. This study describes the purification of the enzyme from T. selenatis grown anaerobically with selenate. The enzyme is a trimeric alpha beta gamma complex with an apparent M-r of 180,000. The alpha, beta, and gamma subunits are 96 kDa, 40 kDa, and 23 kDa, respectively, in size. The selenate reductase contains molybdenum, iron, and acid-labile sulfur as prosthetic group constituents. UV-visible absorption spectroscopy also revealed the presence of one cytochrome b per alpha beta gamma complex, The K-m for selenate was determined to be 16 mu M, and the V-max was 40 mu mol/min/mg of protein. The enzyme is specific for the reduction of selenate; nitrate, nitrite, chlorate, and sulfate were not reduced at detectable rates, These studies constitute the first description of a selenate reductase, which represents a new class of enzymes. The significance of this enzyme in relation to cell growth and energy generation is discussed.	LA TROBE UNIV,SCH MICROBIOL,BUNDOORA,VIC 3083,AUSTRALIA; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095	La Trobe University; University of California System; University of California Los Angeles								BERKS BC, 1994, EUR J BIOCHEM, V220, P117, DOI 10.1111/j.1432-1033.1994.tb18605.x; BODE C, 1969, Z KLIN CHEM KLIN BIO, V6, P419; Brumby P.E., 1967, METHOD ENZYMOL, V10, P463, DOI DOI 10.1016/0076-6879(67)10078-5; BYRNE MD, 1987, BIOCHIM BIOPHYS ACTA, V915, P120, DOI 10.1016/0167-4838(87)90131-2; Cantafio AW, 1996, APPL ENVIRON MICROB, V62, P3298, DOI 10.1128/AEM.62.9.3298-3303.1996; DEMOLLDECKER H, 1993, ARCH MICROBIOL, V160, P241; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Garbisu C, 1995, BIOFACTORS, V5, P29; Hanlon SP, 1996, EUR J BIOCHEM, V239, P391, DOI 10.1111/j.1432-1033.1996.0391u.x; KING TE, 1967, METHOD ENZYMOL, V10, P634; LAWSON S, 1995, APPL MICROBIOL BIOT, V43, P762, DOI 10.1007/BF00164785; LORTIE L, 1992, APPL ENVIRON MICROB, V58, P4042, DOI 10.1128/AEM.58.12.4042-4044.1992; MACY JM, 1993, APPL MICROBIOL BIOT, V40, P588; MACY JM, 1993, INT J SYST BACTERIOL, V43, P135, DOI 10.1099/00207713-43-1-135; MACY JM, 1989, FEMS MICROBIOL LETT, V61, P195, DOI 10.1111/j.1574-6968.1989.tb03577.x; MACY JM, 1993, ARCH MICROBIOL, V160, P295, DOI 10.1007/BF00292080; OREMLAND RS, 1991, APPL ENVIRON MICROB, V57, P615, DOI 10.1128/AEM.57.2.615-617.1991; OREMLAND RS, 1994, APPL ENVIRON MICROB, V60, P3011, DOI 10.1128/AEM.60.8.3011-3019.1994; OREMLAND RS, 1989, APPL ENVIRON MICROB, V55, P2333, DOI 10.1128/AEM.55.9.2333-2343.1989; OREMLAND RS, 1990, ENVIRON SCI TECHNOL, V24, P1157, DOI 10.1021/es00078a001; OREMLAND RS, 1993, SELENIUM ENV, P389; Osborn M J, 1974, Methods Enzymol, V31, P642; RECH SA, 1992, J BACTERIOL, V174, P7316, DOI 10.1128/jb.174.22.7316-7320.1992; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; SAIKI MK, 1987, ARCH ENVIRON CON TOX, V16, P657, DOI 10.1007/BF01055416; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; SIDDIQUI RA, 1993, J BACTERIOL, V175, P5867, DOI 10.1128/JB.175.18.5867-5876.1993; Smith L, 1978, Methods Enzymol, V53, P202; STEINBERG NA, 1990, APPL ENVIRON MICROB, V56, P3550, DOI 10.1128/AEM.56.11.3550-3557.1990; TOMEI FA, 1992, CAN J MICROBIOL, V38, P1328, DOI 10.1139/m92-219; WERES O, 1989, APPL GEOCHEM, V4, P543, DOI 10.1016/0883-2927(89)90066-8	31	170	177	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23765	23768		10.1074/jbc.272.38.23765	http://dx.doi.org/10.1074/jbc.272.38.23765			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295321	hybrid			2022-12-25	WOS:A1997XX38100046
J	Taylor, GS; Liu, Y; Baskerville, C; Charbonneau, H				Taylor, GS; Liu, Y; Baskerville, C; Charbonneau, H			The activity of Cdc14p, an oligomeric dual specificity protein phosphatase from Saccharomyces cerevisiae, is required for cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; DNA-REPLICATION; STRUCTURAL BASIS; YEAST; PURIFICATION; KINASE; RECOGNITION; MUTATIONS; SEQUENCE; CLONING	The essential CDC14 gene of the budding yeast, Saccharomyces cerevisiae, encodes a 62-kDa protein containing a sequence that conforms to the active site motif found in all enzymes of the protein tyrosine phosphatase superfamily. Genetic studies suggest that Cdc14p may be involved in the initiation of DNA replication, but its precise cell cycle function is unknown. Recombinant Cdc14p was produced in bacteria, characterized, and shown to be a dual specificity protein phosphatase. Polyanions such as polyglutamate and double-stranded and single-stranded DNA bind to Cdc14p and affect its activity, Native molecular weights of 131,000 and 169,000 determined by two independent methods indicate that recombinant Cdc14p self-associates in vitro to form active oligomers, The catalytically inactive Cdc14p C283S/ R289A mutant is not able to suppress the temperature sensitivity of a cdc14-1(ts) mutant nor replace the wild type gene in vivo, demonstrating that phosphatase activity is required for the cell cycle function of Cdc14p, A distinctive COOH-terminal segment (residues 375-551) is rich in Asn and Ser residues, carries a net positive charge, and contains two tandem 21-residue repeats. This COOH-terminal segment is not required for activity, for oligomerization, or for the critical cell cycle function of Cdc14p.	PURDUE UNIV, DEPT BIOCHEM 1153, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA59935, CA23168] Funding Source: Medline; NIDDK NIH HHS [DK20542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059935, P30CA023168, R01CA059935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beavo J A, 1974, Methods Enzymol, V38, P299; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CIGAN AM, 1987, GENE, V59, P1; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Eki T, 1996, YEAST, V12, P177; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Freifelder D, 1973, Methods Enzymol, V27, P140; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Harlow E., 1988, ANTIBODIES LAB MANUA; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kaiser C., 1994, METHODS YEAST GENETI; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Kroll ES, 1996, GENETICS, V143, P95; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHILD D, 1980, GENETICS, V96, P859; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shirayama M, 1996, MOL GEN GENET, V251, P176; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1994, MOL GENETICS YEAST P, P97; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WAN J, 1992, J BIOL CHEM, V267, P11274; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; WOOD JS, 1982, J CELL BIOL, V94, P718, DOI 10.1083/jcb.94.3.718; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	48	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24054	24063		10.1074/jbc.272.38.24054	http://dx.doi.org/10.1074/jbc.272.38.24054			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295359	hybrid			2022-12-25	WOS:A1997XX38100084
J	Tsuji, M; Ezumi, Y; Arai, M; Takayama, H				Tsuji, M; Ezumi, Y; Arai, M; Takayama, H			A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; TYROSINE PHOSPHORYLATION; HUMAN-MONOCYTES; EPSILON-RI; U937 CELLS; AGGREGATION; MEMBRANE; ACTIVATION; PATIENT; SUBUNIT	The mechanism by which occupancy of collagen receptors is coupled to platelet activation has been uncertain, Our group previously demonstrated that glycoprotein (GP) VI, an uncharacterized platelet membrane protein, is specifically required for collagen-platelet interaction leading to activation of protein-tyrosine kinase Syk. Since collagen stimulation of platelets has recently been found to induce tyrosine phosphorylation of Fc receptor (FcR) gamma-chain, a signal-generating subunit of FcR, we further investigated She relationships between FcR gamma-chain and GPVI in human platelets. Our present study revealed the following. FcR gamma-chain was physically and stably associated with GPVI in human platelets; both FcR gamma-chain and GPVI were proportionally absent in GPVI-deficient platelets; GPVI cross-linking or collagen stimulation of platelets resulted in tyrosine phosphorylation of GPVI-associated FcR gamma-chain accompanied by Syk association and activation. These findings strongly suggest that the associated complex of GPVI and FcR gamma-chain is a collagen receptor featuring the signaling through immune receptors.	KYOTO UNIV,DEPT HEMATOL & ONCOL,GRAD SCH MED,SAKYO KU,KYOTO 60601,JAPAN; TOKYO MED COLL,DEPT CLIN PATHOL,TOKYO 160,JAPAN	Kyoto University; Tokyo Medical University								ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; DECKMYN H, 1992, BLOOD, V79, P1466, DOI 10.1182/blood.V79.6.1466.bloodjournal7961466; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HYNES RO, 1992, CELL, V69, P1; Ichinohe T, 1997, J BIOL CHEM, V272, P63; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; LOONEY RJ, 1986, J IMMUNOL, V136, P1641; MASUDA M, 1993, J IMMUNOL, V151, P7188; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SANTOSO S, 1989, HUM IMMUNOL, V25, P237, DOI 10.1016/0198-8859(89)90086-4; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKAYAMA H, 1983, PROSTA LEUKOTR MED, V12, P261, DOI 10.1016/0262-1746(83)90004-5; TANDON NN, 1989, J BIOL CHEM, V264, P7576; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; Zipser Y, 1996, BIOCHEM J, V314, P881, DOI 10.1042/bj3140881	31	229	237	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23528	23531		10.1074/jbc.272.38.23528	http://dx.doi.org/10.1074/jbc.272.38.23528			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295288	hybrid			2022-12-25	WOS:A1997XX38100013
J	Ramamurthy, V; Oliver, D				Ramamurthy, V; Oliver, D			Topology of the integral membrane form of Escherichia coli SecA protein reveals multiple periplasmically exposed regions and modulation by ATP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN TRANSLOCASE; PLASMA-MEMBRANE; INNER MEMBRANE; ESSENTIAL COMPONENT; SECRETORY PROTEIN; TERMINAL REGION; PHOSPHOLIPIDS; SUBUNIT; INSERTION; DOMAINS	SecA insertion and integration into the Escherichia coli inner membrane is a critical step for the catalysis of protein translocation across this layer, To understand this step further, SecA topology was investigated, To determine which regions of SecA are periplasmically exposed, right-side out membrane vesicles were prepared from strains synthesizing monocysteine SecA variants produced by mutagenesis and probed with a membrane-impermeant sulfhydryl-labeling reagent, To determine which regions of SecA contain membrane-integration determinants, inverted inner membrane vesicles were subjected to proteolysis, and integral-membrane fragments of SecA were identified with region-specific antibodies, The membrane association properties of various truncated SecA species produced in vivo were also determined, Our analysis indicates that the membrane topology of SecA is complex with amino-terminal, central, and carboxyl-terminal regions of SecA integrated into the membrane where portions are periplasmically accessible, Furthermore, the insertion and penetration of the amino-terminal third of SecA, which includes the proposed preprotein binding domain, is subject to modulation by ATP binding, The importance of these studies to the cycle of membrane insertion and de-insertion of SecA that promotes protein translocation and SecA's proximity to the preprotein channel are discussed.	WESLEYAN UNIV, DEPT MOL BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA	Wesleyan University					NIGMS NIH HHS [GM42033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; COLE ST, 1982, EUR J BIOCHEM, V122, P479; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; HANADA M, 1994, J BIOL CHEM, V269, P23625; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KIM YJ, 1994, CELL, V78, P845; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; KIMURA E, 1991, J BIOL CHEM, V266, P6600; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Miller J. H., 1972, EXPT MOL GENETICS, P431; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RAJAPANDI T, 1991, J BACTERIOL, V173, P7092, DOI 10.1128/jb.173.22.7092-7097.1991; Randall LL, 1997, P NATL ACAD SCI USA, V94, P802, DOI 10.1073/pnas.94.3.802; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Snyders S, 1997, J BIOL CHEM, V272, P11302; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAMATSU H, 1994, J BIOCHEM-TOKYO, V116, P1287, DOI 10.1093/oxfordjournals.jbchem.a124677; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	54	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23239	23246		10.1074/jbc.272.37.23239	http://dx.doi.org/10.1074/jbc.272.37.23239			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287332	hybrid			2022-12-25	WOS:A1997XV74400043
J	Zhang, L; Kelley, J; Schmeisser, G; Kobayashi, YM; Jones, LR				Zhang, L; Kelley, J; Schmeisser, G; Kobayashi, YM; Jones, LR			Complex formation between junction, triadin, calsequestrin, and the ryanodine receptor - Proteins of the cardiac junctional sarcoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; BINDING 30-KDA PROTEIN; AMINO-ACID SEQUENCE; SKELETAL-MUSCLE; BIOCHEMICAL-CHARACTERIZATION; GLYCOPROTEIN TRIADIN; VESICLES; PURIFICATION; CDNA; PHOSPHOLAMBAN	Several key proteins have been localized to junctional sarcoplasmic reticulum which are important for Ca2+ release. These include the ryanodine receptor, triadin, and calsequestrin, which may associate into a stable complex at the junctional membrane. We recently purified and cloned a fourth component of this complex, junctin, which exhibits homology with triadin and is the major I-125-calsequestrin-binding protein detected in cardiac sarcoplasmic reticulum vesicles (Jones, L. R., Zhang, L., Sanborn, K., Jorgensen, A. O., and Kelley, J. (1995) J. Biol. Chem. 270, 30787-30796). In the present study, we have examined the binding interactions between the cardiac forms of these four proteins with emphasis placed on the role of junctin. By a combination of approaches including calsequestrin-affinity chromatography, filter overlay, immunoprecipitation assays, and fusion protein binding analyses, we find that junctin binds directly to calsequestrin, triadin, and the ryanodine receptor. This binding interaction is localized to the lumenal domain of junctin, which is highly enriched in charged amino acids organized into ''KEKE'' motifs. KEKE repeats are also found in the common lumenal domain of triadin, which likewise is capable of binding to calsequestrin and the ryanodine receptor (Guo, W., and Campbell, K. P. (1995) J. Biol. Chem. 270, 9027-9030). It appears that junctin and triadin interact directly in the junctional sarcoplasmic reticulum membrane and stabilize a complex that anchors calsequestrin to the ryanodine receptor. Taken together, these results suggest that junctin, calsequestrin, triadin, and the ryanodine receptor form a quaternary complex that may be required for normal operation of Ca2+ release.	INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AlSeikhan BA, 1997, BIOPHYS J, V72, pTU185; Cala S E, 1990, Semin Cell Biol, V1, P265; CALA SE, 1983, J BIOL CHEM, V258, P1932; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; Chen W, 1996, J BIOL CHEM, V271, P7398, DOI 10.1074/jbc.271.13.7398; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; DAMIANI E, 1990, BIOCHEM BIOPH RES CO, V172, P1253, DOI 10.1016/0006-291X(90)91584-F; Donoso P, 1996, BIOCHEMISTRY-US, V35, P13419, DOI 10.1021/bi9616209; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Harlow E, 1988, ANTIBODIES LABORATOR, P521; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; IKEMOTO N, 1971, BIOCHEM BIOPH RES CO, V44, P1510, DOI 10.1016/S0006-291X(71)80257-7; JOHNSON EA, 1967, J CELL BIOL, V33, P103, DOI 10.1083/jcb.33.1.103; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; Kagari T, 1996, BIOCHEM BIOPH RES CO, V227, P700, DOI 10.1006/bbrc.1996.1572; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1995, J BIOL CHEM, V270, P29664; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; YAMAGUCHI N, 1995, BIOCHEM BIOPH RES CO, V210, P648, DOI 10.1006/bbrc.1995.1709; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961	42	439	451	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23389	23397		10.1074/jbc.272.37.23389	http://dx.doi.org/10.1074/jbc.272.37.23389			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287354	hybrid			2022-12-25	WOS:A1997XV74400065
J	Fang, WH; Wu, JY; Su, MJ				Fang, WH; Wu, JY; Su, MJ			Methyl-directed repair of mismatched small heterologous sequences in cell extracts from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERODUPLEX DNA; SACCHAROMYCES-CEREVISIAE; GENE CONVERSION; BASE MISMATCHES; DUPLEX DNA; STRAND; EFFICIENCIES; SPECIFICITY; RESOLUTION; MOLECULES	The methyl-directed DNA repair efficiency of a set of M13mp18 heteroduplexes containing 1-8 or 22 unpaired bases was determined by using an in vitro DNA mismatch repair assay. The unpaired bases of each heteroduplex residing at overlapping recognition sites of two restriction endonucleases allow independent assay of repair on either DNA strand. Our results showed that the repair of small nucleotide heterologies in Escherichia coli extracts was very similar to base-base mismatch repair, being strand-specific and highly biased to the unmethylated strand. The in vitro activity was also dependent on products of mutH, mutL, mutS, and uvrD loci and was equally efficient on nucleotide insertions and deletions. The repair levels of small heterologies were affected by base composition of the heterologies. However, the extent of repair of heteroduplexes containing small heterologous sequences was found to decrease with an increase in the number of unpaired bases. Heteroduplexes containing an extra nucleotide of 22 bases provoked very low level of methyl-directed repair.			Fang, WH (corresponding author), NATL TAIWAN UNIV, COLL MED, SCH MED TECHNOL, TAIPEI 10016, TAIWAN.			FANG, WOEI-HORNG/0000-0003-4728-5931				AU KG, 1992, J BIOL CHEM, V267, P12142; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; COOPER DL, 1993, J BIOL CHEM, V268, P11823; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; FISHEL RA, 1986, J MOL BIOL, V188, P147, DOI 10.1016/0022-2836(86)90300-1; GASC AM, 1989, GENETICS, V121, P29; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; KENNARD O, 1985, J BIOMOL STRUCT DYN, V3, P205, DOI 10.1080/07391102.1985.10508412; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LEARN BA, 1989, J BACTERIOL, V171, P6473, DOI 10.1128/jb.171.12.6473-6481.1989; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MUSTERNASSAL C, 1986, P NATL ACAD SCI USA, V83, P7618, DOI 10.1073/pnas.83.20.7618; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PUKKILA PJ, 1983, GENETICS, V104, P571; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4004, DOI 10.1021/bi00131a016; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4015, DOI 10.1021/bi00131a017; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WANG YH, 1991, BIOCHEMISTRY-US, V30, P1358, DOI 10.1021/bi00219a028; WERNTGES H, 1986, NUCLEIC ACIDS RES, V14, P3773, DOI 10.1093/nar/14.9.3773; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22714	22720		10.1074/jbc.272.36.22714	http://dx.doi.org/10.1074/jbc.272.36.22714			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278429	hybrid			2022-12-25	WOS:A1997XV49200050
J	Gomes, CM; Silva, G; Oliveira, S; LeGall, J; Liu, MY; Xavier, AV; RodriguesPousada, C; Teixeira, M				Gomes, CM; Silva, G; Oliveira, S; LeGall, J; Liu, MY; Xavier, AV; RodriguesPousada, C; Teixeira, M			Studies on the redox centers of the terminal oxidase from Desulfovibrio gigas and evidence for its interaction with rubredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SPECTROSCOPIC CHARACTERIZATION; YEAST FLAVOCYTOCHROME-B2; BACILLUS-MEGATERIUM; REDUCING BACTERIA; IRON PROTEIN; OXYGEN; PURIFICATION; CYTOCHROME; BINDING	Rubredoxin-oxygen oxidoreductase (ROO) is the final component of a soluble electron transfer chain that couples NADH oxidation to oxygen consumption in the anaerobic sulfate reducer Desulfovibrio gigas. It is an 86-kDa homodimeric flavohemeprotein containing two FAD molecules, one mesoheme IX, and one Fe-uroporphyrin I per monomer, capable of fully reducing oxygen to water. EPR studies on the native enzyme reveal two components with g values at similar to 2.46, 2.29, and 1.89, which are assigned to low spin hemes and are similar to the EPR features of P-450 hemes, suggesting that ROO hemes have a cysteinyl axial ligation. At pH 7.6, the flavin redox transitions occur at 0 +/- 15 mV for the quinone/semiquinone couple and at -130 +/- 15 mV for the semiquinone/hydroquinone couple; the hemes reduction potential is -350 +/- 15 mV. Spectroscopic studies provided unequivocal evidence that the flavins are the electron acceptor centers from rubredoxin, and that their reduction proceed through an anionic semiquinone radical. The reaction with oxygen occurs in the flavin moiety. These data are strongly corroborated by the finding that rubredoxin and ROO are located in the same polycistronic unit of D. gigas genome. For the first time, a clear role for a rubredoxin in a sulfate-reducing bacterium is presented.	UNIV NOVA LISBOA,INST TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL; INST GULBENKIAN CIENCIAS,GENET MOL LAB,OEIRAS,PORTUGAL; UNIV GEORGIA,DEPT BIOCHEM & MOL BIOL,ATHENS,GA 30602	Universidade Nova de Lisboa; Instituto Gulbenkian de Ciencia; University System of Georgia; University of Georgia			Gomes, Cláudio M./A-8152-2008; Teixeira, Miguel/M-1509-2019; Teixeira, Miguel/A-9098-2011; Oliveira, Solange/M-4047-2013	Gomes, Cláudio M./0000-0003-4662-6933; Teixeira, Miguel/0000-0003-4124-6237; Teixeira, Miguel/0000-0003-4124-6237; Oliveira, Solange/0000-0003-4984-4805; Silva, Gabriela/0000-0002-4004-9904; Rodrigues-Pousada, Claudina/0000-0002-5075-3639				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ALBERTA JA, 1989, J BIOL CHEM, V264, P20467; BLACK MT, 1989, BIOCHEM J, V258, P255, DOI 10.1042/bj2580255; BOLARD J, 1972, BIOCHIM BIOPHYS ACTA, V263, P535, DOI 10.1016/0005-2795(72)90034-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSCHI M, 1972, BIOCHIM BIOPHYS ACTA, V263, P279, DOI 10.1016/0005-2795(72)90080-3; BRUSCHI M, 1977, J BACTERIOL, V129, P30, DOI 10.1128/JB.129.1.30-38.1977; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CALCATERRA NB, 1995, BIOCHEMISTRY-US, V34, P12842, DOI 10.1021/bi00039a045; CHEN L, 1993, BIOCHEM BIOPH RES CO, V193, P100, DOI 10.1006/bbrc.1993.1595; CHEN L, 1993, EUR J BIOCHEM, V216, P443, DOI 10.1111/j.1432-1033.1993.tb18162.x; COOPER CE, 1994, BIOCHEM SOC T, V22, P709, DOI 10.1042/bst0220709; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DILING W, 1990, FEMS MICROBIOL LETT, V71, P123; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KRONECK PMH, 1991, BIOL MET, V4, P119, DOI 10.1007/BF01135389; LEGALL J, 1965, BIOCHIM BIOPHYS ACTA, V99, P385; LEGALL J, 1968, ANN I PASTEUR PARIS, V114, P109; LEGALL J, 1966, BIOCHEM BIOPH RES CO, V23, P145, DOI 10.1016/0006-291X(66)90519-5; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; MARSCHALL C, 1993, ARCH MICROBIOL, V159, P168, DOI 10.1007/BF00250278; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MCKNIGHT J, 1993, EUR J BIOCHEM, V213, P683, DOI 10.1111/j.1432-1033.1993.tb17808.x; Moore DD, 1995, GLOB MOB SURV; MORRIS CJ, 1994, BIOCHEM J, V302, P587, DOI 10.1042/bj3020587; MOURA I, 1977, BIOCHEM BIOPH RES CO, V75, P1037, DOI 10.1016/0006-291X(77)91486-3; MOURA I, 1979, FEBS LETT, V107, P419, DOI 10.1016/0014-5793(79)80421-4; NARHI LO, 1986, J BIOL CHEM, V261, P7160; Nielsen AK, 1996, MICROBIOL-UK, V142, P1289, DOI 10.1099/13500872-142-5-1289; NOLLING J, 1995, EUR J BIOCHEM, V231, P628, DOI 10.1111/j.1432-1033.1995.0628d.x; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; RAGSDALE SW, 1983, J BACTERIOL, V155, P1224, DOI 10.1128/JB.155.3.1224-1237.1983; Romero A, 1996, EUR J BIOCHEM, V239, P190, DOI 10.1111/j.1432-1033.1996.0190u.x; RUETTINGER RT, 1977, ARCH BIOCHEM BIOPHYS, V183, P528, DOI 10.1016/0003-9861(77)90388-5; SAEKI K, 1993, PLANT CELL PHYSIOL, V34, P185; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOS H, 1993, BIOCHEM BIOPH RES CO, V195, P551, DOI 10.1006/bbrc.1993.2081; SIGAL N, 1963, J BACTERIOL, V85, P1315, DOI 10.1128/JB.85.6.1315-1318.1963; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TEGONI M, 1986, EUR J BIOCHEM, V155, P491, DOI 10.1111/j.1432-1033.1986.tb09516.x; TEIXEIRA M, 1995, EUR J BIOCHEM, V227, P322, DOI 10.1111/j.1432-1033.1995.tb20392.x; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; TIMKOVICH R, 1994, BIOORG CHEM, V22, P284, DOI 10.1006/bioo.1994.1022; VANBEEUMEN JJ, 1991, J BIOL CHEM, V266, P12921; Yamazaki M, 1996, J BACTERIOL, V178, P2676, DOI 10.1128/jb.178.9.2676-2687.1996	49	126	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22502	22508		10.1074/jbc.272.36.22502	http://dx.doi.org/10.1074/jbc.272.36.22502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278402	hybrid			2022-12-25	WOS:A1997XV49200022
J	Harth, G; Horwitz, MA				Harth, G; Horwitz, MA			Expression and efficient export of enzymatically active Mycobacterium tuberculosis glutamine synthetase in Mycobacterium smegmatis and evidence that the information for export is contained within the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GLNA; GENES; BACILLUS; REGION; LEPRAE	We have investigated the expression and extracellular release of active, recombinant Mycobacterium tuberculosis glutamine synthetase (EC 6.3.1.2), an enzyme that is a potentially important determinant of M. tuberculosis infection and whose extracellular release is correlated with pathogenicity, The M. tuberculosis glutamine synthetase gene encodes a polypeptide of 478 amino acids; 12 such subunits comprise the active enzyme, Northern blot, nuclease S1, and primer extension analyses revealed glutamine synthetase specific transcripts of similar to 1,550 and 1,650 nucleotides produced under low and high nitrogen conditions, respectively, Expression of recombinant M. tuberculosis glutamine synthetase in Escherichia coli YMC21E, a glutamine synthetase deletion mutant, led to transcomplementation of the mutant but not to release of active enzyme, Expression in Mycobacterium smegmatis 1-2c, from the gene's own promoter, resulted in the release of > 95% of all recombinant enzyme, No hybrid molecules containing M. tuberculosis and M. smegmatis glutamine synthetase subunits were detected, Native and recombinant exported and intracellular glutamine synthetase molecules were indistinguishable from one another by mass, N-terminal amino acid sequence, antibody reactivity, and enzymatic activity, Since M. tuberculosis glutamine synthetase is similar to other, strictly intracellular, bacterial glutamine synthetases and the DNA sequence upstream of the structural gene does not encode a leader peptide, the information to target the protein for export must be contained in its amino acid sequence and/or conformation.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV INFECT DIS,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCRR NIH HHS [1 S10RR05554] Funding Source: Medline; NIAID NIH HHS [AI 35275, AI 31338] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035275, R01AI031338] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; AUSUBEL FM, 1984, CELL, V37, P5, DOI 10.1016/0092-8674(84)90294-0; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; COLOMBO G, 1986, J BIOL CHEM, V261, P587; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANAU R, 1983, J BACTERIOL, V155, P82, DOI 10.1128/JB.155.1.82-89.1983; HARTH G, 1994, P NATL ACAD SCI USA, V91, P9342, DOI 10.1073/pnas.91.20.9342; HERRMANN JL, 1991, EMBIO J, V15, P3547; KEMPSELL KE, 1992, J GEN MICROBIOL, V138, P1717, DOI 10.1099/00221287-138-8-1717; KIMURA K, 1989, J BIOCHEM, V105, P648, DOI 10.1093/oxfordjournals.jbchem.a122719; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; NAKANO Y, 1989, FEMS MICROBIOL LETT, V57, P81, DOI 10.1016/0378-1097(89)90151-1; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; WEISBROD RE, 1973, J BIOL CHEM, V248, P3997	21	53	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22728	22735		10.1074/jbc.272.36.22728	http://dx.doi.org/10.1074/jbc.272.36.22728			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278431	hybrid			2022-12-25	WOS:A1997XV49200052
J	May, JM; Mendiratta, S; Hill, KE; Burk, RF				May, JM; Mendiratta, S; Hill, KE; Burk, RF			Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLUTATHIONE-PEROXIDASE; HUMAN NEUTROPHILS; PURIFICATION; ACID; IDENTIFICATION; DEHYDROGENASE; GLUTAREDOXIN; EXPRESSION; CLONING	Recycling of ascorbate from its oxidized forms is essential to maintain stores of the vitamin in human cells, Whereas reduction of dehydroascorbate to ascorbate is thought to be largely GSH-dependent, we reconsidered the possibility that the selenium-dependent thioredoxin system might contribute to ascorbate regeneration. We found that purified rat liver thioredoxin reductase fractions as an NADPH-dependent dehydroascorbate reductase, with an apparent K-m of 2.5 mM for dehydroascorbate, and a k(cat) of 90 min(-1), Addition of 2.8 mu M purified rat liver thioredoxin lowered the apparent K-m to 0.7 mM, without affecting the turnover (k(cat) of 71 min(-1)), Since thioredoxin reductase requires selenium, we tested the physiologic importance of this enzyme for dehydroascorbate reduction in livers from control and selenium-deficient rats, Selenium deficiency lowered liver thioredoxin reductase activity by 88%, glutathione peroxidase activity by 99%, and ascorbate content by 33%, but did not affect GSH content, NADPH-dependent dehydroascorbate reductase activity due to thioredoxin reductase, on the basis of inhibition by aurothioglucose, was decreased 88% in dialyzed liver cytosolic fractions from selenium-deficient rats, GSH-dependent dehydroascorbate reductase activity in liver cytosol was variable, but typically 2-3-fold that of NADPH-dependent activity. These results show that the thioredoxin system can reduce dehydroascorbate, and that this function is required for maintenance of liver ascorbate content.			May, JM (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MED,715 MED RES BLDG 2,NASHVILLE,TN 37232, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050435, P30DK026657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002497, R01ES002497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26657, DK50435] Funding Source: Medline; NIEHS NIH HHS [ES02497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; BOX GEP, 1960, ANN NY ACAD SCI, V86, P792, DOI 10.1111/j.1749-6632.1960.tb42843.x; BURK RF, 1987, METHOD ENZYMOL, V143, P307; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; DELBELLO B, 1994, BIOCHEM J, V304, P385, DOI 10.1042/bj3040385; DUE AD, 1995, BIOCHEMISTRY-US, V34, P5462, DOI 10.1021/bi00016a017; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HUGHES RE, 1964, NATURE, V203, P1068, DOI 10.1038/2031068a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; May JM, 1996, J BIOL CHEM, V271, P10577, DOI 10.1074/jbc.271.18.10577; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; Rikans LE, 1996, MECH AGEING DEV, V91, P165, DOI 10.1016/S0047-6374(96)01784-8; ROSE RC, 1992, ENZYME, V46, P196, DOI 10.1159/000468788; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WELLS WW, 1995, METHOD ENZYMOL, V252, P30; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; Xu DP, 1996, BIOCHEM BIOPH RES CO, V221, P117, DOI 10.1006/bbrc.1996.0555	29	257	267	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22607	22610		10.1074/jbc.272.36.22607	http://dx.doi.org/10.1074/jbc.272.36.22607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278416	hybrid			2022-12-25	WOS:A1997XV49200036
J	Michelotti, EF; Sanford, S; Freije, JMP; MacDonald, NJ; Steeg, PS; Levens, D				Michelotti, EF; Sanford, S; Freije, JMP; MacDonald, NJ; Steeg, PS; Levens, D			Nm23/PuF does not directly stimulate transcription through the CT element in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; NUCLEAR RIBONUCLEOPROTEIN-K; BREAST-CARCINOMA CELLS; TUMOR-METASTASIS; MYC PROMOTER; DROSOPHILA DEVELOPMENT; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; MELANOMA-CELLS; DNA-BINDING	Decreased levels of the nm23 gene product have been correlated with increased tumor metastatic potential in a variety of malignancies. At least a subset of the regulatory properties of Nm23 has been proposed to be due to transactivation of the human c-myc oncogene through binding to a homopyrimidine tract 140 base pairs upstream of the transcription start site (termed the CT element or the PuF site). Conventional transcription factors possess DNA binding and transactivation domains; Nm23 fusion proteins were used to address two questions. First, if provided with a well characterized DNA binding domain, does Nm23 possess a transactivation domain capable of stimulating transcription of an appropriate reporter? Second, if provided with a potent transactivation domain, is the DNA binding of Nm23 of sufficient specificity and affinity to direct the fusion protein to a CT-dependent reporter? Since reporter gene expression was not stimulated in either case, we conclude that Nm23 does not directly stimulate transcription through binding to the CT element and that its antimetastatic and other reported functions are likely due to other biochemical activities.	NCI,WOMENS CANC SECT,PATHOL LAB,DIV CLIN SCI,NIH,BETHESDA,MD 20892; NCI,GENE REGULAT SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009; Freije, José M.P./A-6535-2008	Levens, David/0000-0002-7616-922X; Freije, José M.P./0000-0002-4688-8266				ARCINAS M, 1994, ONCOGENE, V9, P2699; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BABA H, 1995, CANCER RES, V55, P1977; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; PARHAR RS, 1995, INT J CANCER, V60, P204; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; Zhang XL, 1996, J BACTERIOL, V178, P4115, DOI 10.1128/jb.178.14.4115-4121.1996	41	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22526	22530		10.1074/jbc.272.36.22526	http://dx.doi.org/10.1074/jbc.272.36.22526			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278405	hybrid			2022-12-25	WOS:A1997XV49200025
J	Skinner, J; Sinclair, C; Romeo, C; Armstrong, D; Charbonneau, H; Rossie, S				Skinner, J; Sinclair, C; Romeo, C; Armstrong, D; Charbonneau, H; Rossie, S			Purification of a fatty acid-stimulated protein-serine/threonine phosphatase from bovine brain and its identification as a homolog of protein phosphatase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; SERINE THREONINE PHOSPHATASES; LIGHT-CHAIN-PHOSPHATASE; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID; ACTIVATING PROTEIN; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; RAT-BRAIN; CALCIUM	An arachidonic acid-stimulated Ser/Thr phosphatase activity was detected in soluble extracts prepared from rat pituitary clonal GH(4)C(1) cells, rat or bovine brain, and bovine heart. The enzyme activity was purified to homogeneity from bovine brain as a monomer with a M-r of 63,000 and a specific activity of 32 nmol of P-i released per min/mg of protein when assayed in the presence of 10 mu M phosphocasein in the absence of lipid. Arachidonic acid stimulated activity 4-14-fold, with half-maximal stimulation at 50-100 mu M, when assayed in the presence of a variety of phosphosubstrates including casein, reduced carboxamidomethylated and maleylated lysozyme, myelin basic protein, and histone. Oleic acid, linoleic acid, and palmitoleic acid also stimulated activity; however, saturated fatty acids and alcohol or methyl ester derivatives of fatty acids did not significantly affect activity. The lipid-stimulated phosphatase was identified as the bovine equivalent of protein phosphatase 5 or a closely related homolog by sequence analysis of proteolytic fragments generated from the purified enzyme, When recombinant rat protein phosphatase 5 was expressed as a cleavable glutathione S-transferase fusion protein, the affinity-purified thrombin-cleaved enzyme exhibited a specific activity and sensitivity to arachidonic acid similar to those of the purified bovine brain enzyme. These results suggest that protein phosphatase 5 may be regulated in vivo by a lipid second messenger or another endogenous activator.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; NIEHS,LAB SIGNAL TRANSDUCT,RES TRIANGLE PK,NC 27709	Purdue University System; Purdue University; Purdue University West Lafayette Campus; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NCI NIH HHS [CA59935] Funding Source: Medline; NIDDK NIH HHS [DK20542] Funding Source: Medline; NINDS NIH HHS [NS31221] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059935, R29CA059935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031221, R29NS031221] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; ARMSTRONG DL, 1992, TRENDS NEUROSCI, V15, P403, DOI 10.1016/0166-2236(92)90192-B; AUSUBEL F, 1995, SHORT PROTOCOLS MOL, P1621; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BECKER W, 1994, J BIOL CHEM, V269, P22586; Becker W, 1996, MOL BRAIN RES, V36, P23, DOI 10.1016/0169-328X(95)00233-I; BLOBE GC, 1995, PROSTAG LEUKOTR ESS, V52, P129, DOI 10.1016/0952-3278(95)90011-X; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Duerson K, 1996, NEUROPHARMACOLOGY, V35, P949, DOI 10.1016/0028-3908(96)00131-1; Fukuda H, 1996, BIOCHEM BIOPH RES CO, V220, P160, DOI 10.1006/bbrc.1996.0374; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; GONG MC, 1992, J BIOL CHEM, V267, P21492; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lammers CH, 1996, J NEUROCHEM, V66, P147; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Maizel JV, 1971, METHOD VIROL, V5, P179; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PetitJacques J, 1996, J PHYSIOL-LONDON, V493, P67, DOI 10.1113/jphysiol.1996.sp021365; PETROU S, 1995, PROSTAG LEUKOTR ESS, V52, P173, DOI 10.1016/0952-3278(95)90018-7; RAO GN, 1994, J BIOL CHEM, V269, P32586; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STONE KL, 1993, PRACTICAL GUIDE PROT, P45; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Xu XL, 1996, BIOCHEM BIOPH RES CO, V218, P514, DOI 10.1006/bbrc.1996.0092; YONG WH, 1995, GENOMICS, V29, P533, DOI 10.1006/geno.1995.9972; YU SP, 1995, J PHYSIOL-LONDON, V487, P797, DOI 10.1113/jphysiol.1995.sp020919	51	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22464	22471		10.1074/jbc.272.36.22464	http://dx.doi.org/10.1074/jbc.272.36.22464			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278397	hybrid			2022-12-25	WOS:A1997XV49200017
J	VuDac, N; Gervois, P; Grotzinger, T; DeVos, P; Schoonjans, K; Fruchart, JC; Auwerx, J; Mariani, J; Tedgui, A; Staels, B				VuDac, N; Gervois, P; Grotzinger, T; DeVos, P; Schoonjans, K; Fruchart, JC; Auwerx, J; Mariani, J; Tedgui, A; Staels, B			Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor ROR alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; GLAND HORMONE MELATONIN; TRANSGENIC MICE; RETINOIC ACID; ORPHAN RECEPTORS; MESSENGER-RNA; PLASMA-LEVELS; DNA-BINDING; RAT-LIVER; ATHEROSCLEROSIS	Since elevated concentrations of plasma high density lipoprotein (HDL) and its major apolipoprotein (ape), apoA-I, confer protection against atherosclerosis, considerable research efforts have focussed on the identification of factors regulating apoA-I gene expression in an attempt to increase its production. Nuclear receptors are interesting candidates because they are transcription factors whose activity is ligand-dependent. In the present study we identified the orphan receptor ROR alpha 1 as an activator of apoA-I gene transcription. In apoA-I-expressing intestinal Caco-2 cells, overexpression of the ROR alpha 1, but not the ROR alpha 2 or ROR alpha 3 isoforms, increased rat apoA-I gene transcription. Deletion and site-directed mutagenesis experiments identified a functional ROR-responsive element (RORE) in the rat; and mouse apoA-I gene promoters, which overlaps with the TATA box. Gel shift experiments indicated that this RORE binds the ROR alpha 1 isoform, but not the ROR alpha 2 or ROR alpha 3 isoforms, Furthermore, compared with wild type mice, apoA-I mRNA levels were significantly lower in small intestines of staggerer mice homozygous for a deletion in the ROR alpha gene. In addition, reverse transcriptase-polymerase chain reaction analysis revealed the expression of ROR alpha in small intestinal epithelium and in Caco-2 cells. These data indicate a novel, physiological role for ROR alpha 1 in the regulation of genes involved in lipid and lipoprotein metabolism and possibly in the development of metabolic diseases, such as atherosclerosis.	INST PASTEUR, DEPT ATHEROSCLEROSE, U325 INSERM, F-59019 LILLE, FRANCE; UNIV LILLE 2, F-59019 LILLE, FRANCE; U141 INSERM, F-75745 PARIS 10, FRANCE; INST FEDERAT RECH CIRCULAT LARIBOISIERE, F-75745 PARIS 10, FRANCE; INST NEUROSCI, DEV NEUROBIOL LAB, CNRS URA 1488, F-75005 PARIS, FRANCE; UNIV PARIS 06, F-75005 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393; Mariani, Jean/0000-0002-2701-1581; Schoonjans, Kristina/0000-0003-1247-4265				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BERTHOU L, 1994, ARTERIOSCLER THROMB, V14, P1657, DOI 10.1161/01.ATV.14.10.1657; BOSSU JP, 1994, BIOCHEM BIOPH RES CO, V202, P822, DOI 10.1006/bbrc.1994.2004; BRESLOW JL, 1989, METABOLIC BASIS INHE, V1, P1251; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; FRUCHART JC, 1993, CIRCULATION, V87, P22; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Saladin R, 1996, EUR J BIOCHEM, V239, P451, DOI 10.1111/j.1432-1033.1996.0451u.x; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; STAELS B, 1990, ENDOCRINOLOGY, V126, P2153; STAELS B, 1991, ARTERIOSCLER THROMB, V11, P760, DOI 10.1161/01.ATV.11.3.760; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1989, J LIPID RES, V30, P1137; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WALSH A, 1989, J BIOL CHEM, V264, P6488; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327	40	109	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22401	22404		10.1074/jbc.272.36.22401	http://dx.doi.org/10.1074/jbc.272.36.22401			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278389	hybrid			2022-12-25	WOS:A1997XV49200008
J	Chalk, JG; Barr, FG; Mitchell, CD				Chalk, JG; Barr, FG; Mitchell, CD			Translin recognition site sequences flank chromosome translocation breakpoints in alveolar rhabdomyosarcoma cell lines	ONCOGENE			English	Article							PAX3-FKHR FUSION PROTEIN; GENE; PAX3; HYBRID; DIFFERENTIATION; REARRANGEMENT; CLUSTER; REGION	Alveolar rhabdomyosarcoma is characterized by a t(2;13)(q35;q14) chromosome translocation, which leads to the fusion of the PAX3 and the FKHR genes, The resulting fusion gene encodes a chimeric protein which has aberrant transcriptional activity, We report the molecular definition of the genomic breakpoints on both derivative chromosomes in one case and the derivative chromosome 13 breakpoints in two other cases, The DNA sequences adjacent to the breakpoints on the derivative chromosome 13 are remarkable for their resemblance to recognition sequences for the protein translin. Gel shift analyses confirm that these sequences bind translin, These findings suggest that translin may not only be important in the genesis of chromosomal translocations in lymphoid malignancy, but also in translocations found in solid tumours.	UNIV OXFORD, JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND; UNIV PENN, DIV PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DIV LAB MED, PHILADELPHIA, PA 19104 USA	University of Oxford; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R29CA061935] Funding Source: NIH RePORTER; NCI NIH HHS [CA61935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CHEN SJ, 1989, ONCOGENE, V4, P195; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; MACINA RA, 1995, GENOMICS, V26, P1, DOI 10.1016/0888-7543(95)80076-X; MITCHELL CD, 1991, ONCOGENE, V6, P89; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAN Z, 1992, HUM GENET, V90, P435; SORENSEN PHB, 1995, CANCER RES, V55, P1385	18	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1199	1205		10.1038/sj.onc.1201285	http://dx.doi.org/10.1038/sj.onc.1201285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294613				2022-12-25	WOS:A1997XU99100009
J	SchmidtUllrich, RK; Mikkelsen, RB; Dent, P; Todd, DG; Valerie, K; Kavanagh, BD; Contessa, JN; Rorrer, WK; Chen, PB				SchmidtUllrich, RK; Mikkelsen, RB; Dent, P; Todd, DG; Valerie, K; Kavanagh, BD; Contessa, JN; Rorrer, WK; Chen, PB			Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation	ONCOGENE			English	Article						ionizing radiation; epidermal growth factor receptor; calcium; phospholipase C; mitogen-activated protein kinase; cell proliferation	EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASES; FACTOR RECEPTOR; IONIZING-RADIATION; BREAST-CANCER; MCF-7 CELLS; IN-VITRO; INHIBITION; APOPTOSIS; STRESS	Accelerated cellular repopulation has been described as a response of tumors to fractionated irradiation in both normal tissue and tumor systems, To identify the mechanisms by which cells enhance their proliferative rate in response to clinically used doses of ionizing radiation (IR) we have studied human mammary and squamous carcinoma cells which are autocrine growth regulated by the epidermal growth factor receptor (EGFR) and its ligands, transforming growth factor-alpha and EGF, Both EGF and IR induced EGFR autophosphorylation, comparable levels of phospholipase C gamma activation as measured by inositol-1,4,5-triphosphate production, and as a consequence oscillations in cytosolic [Ca2+]. Activities of Raf-l and mitogen-activated protein kinase (MAPK) were also stimulated by EGF and IR by Ca2+-dependent mechanisms. All these responses to EGF and IR were dependent upon activation of EGFR as judged by the use of the specific inhibitor of EGFR autophosphorylation, tyrphostin AG1478. Importantly, IR-induced proliferation of A431 cells was also inhibited by AG1478. This is the first report which demonstrates a link between IR-induced activation of proliferative signal transduction pathways and enhanced proliferation, We propose that accelerated repopulation of tumors whose growth is regulated by EGFR is initiated by an IR-induced EGFR activation mechanism that mimics the effects of growth factors.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University	SchmidtUllrich, RK (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT RADIAT ONCOL,POB 980058,RICHMOND,VA 23298, USA.		Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [R01CA065896] Funding Source: NIH RePORTER; NCI NIH HHS [CA65896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHAJRY N, 1994, BIOCHEM BIOPH RES CO, V203, P984, DOI 10.1006/bbrc.1994.2279; DENEKAMP J, 1973, BRIT J RADIOL, V46, P381, DOI 10.1259/0007-1285-46-545-381; DENT P, 1995, MOL CELL BIOL, V15, P4125; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FAN Z, 1994, J BIOL CHEM, V269, P27595; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HERNANDEZSOTOMAYOR SMT, 1993, BIOCHEM J, V293, P507, DOI 10.1042/bj2930507; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIANG M, 1992, MOL PHARMACOL, V42, P743; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; SCHMIDTULLRICH RK, 1994, INT J RADIAT ONCOL, V29, P813, DOI 10.1016/0360-3016(94)90570-3; SCHMIDTULLRICH RK, 1996, RADIAT RES, V145, P79; SCHMIDTULLRICH RK, 1992, INT J RADIAT BIOL, V61, P141; STEVENSON MA, 1994, CANCER RES, V54, P12; TODD DG, 1994, CANCER RES, V54, P5224; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WITHERS HR, 1995, INT J RADIAT ONCOL, V33, P549, DOI 10.1016/0360-3016(95)00228-Q; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	36	375	388	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1191	1197		10.1038/sj.onc.1201275	http://dx.doi.org/10.1038/sj.onc.1201275			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294612				2022-12-25	WOS:A1997XU99100008
J	VonKnethen, A; Brune, B				VonKnethen, A; Brune, B			Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis	FASEB JOURNAL			English	Article						macrophage; interferon; nitric oxide; LDH; transfection	NF-KAPPA-B; OXIDE-INDUCED APOPTOSIS; RAT MESANGIAL CELLS; NITRIC-OXIDE; PERITONEAL-MACROPHAGES; MESSENGER-RNA; PROSTAGLANDIN SYNTHASE; IFN-GAMMA; IN-VITRO; DEATH	Lipopolysaccharide/interferon gamma upregulated inducible nitric oxide synthase and caused nitric oxide generation and concomitant apoptotic cell death in RAW 264.7 macrophages. Exogenously supplied nitric oxide donors such as S-nitrosoglutathione produced equivalent alterations, Preactivation of macrophages with a combination of lipopolysaccharide/interferon gamma under conditions of blocked NO synthase-N-G-monomethyl-L-arginine addition-or stimulation with a low, nondestructive dose of S-nitrosoglutathione conferred protection against high and thus apoptotic NO concentrations, Here we report that induction of cyclooxygenase-2 during the preactivation period is a critical regulator of macrophage apoptosis, Under resting conditions, macrophages do not express cyclooxygenase-2, whereas lipopolysaccharide/interferon gamma/N-G-monomethyl-L-arginine prestimulation for 12-15 h caused protein expression, In parallel, preactivation of RAW cells with a low, nontoxic dose of S-nitrosoglutathione promoted protection and cyclooxygenase-2 up-regulation, To prove cyclooxygenase-2 involvement during protection, we stably transfected RAW 264.7 macrophages with a rat cyclooxygenase-2 expression vector, Cyclooxygenase-2 overexpressing macrophages, preactivated with the calcium liberating and thus phopholipase A(2)-activating agent A23187, revealed protection against exogenously supplied NO, Protection afforded by lipopolysaccharide/interferon gamma/N-G-monomethyl-L-arginine prestimulation was completely reversed by the addition of the cyclooxygenase-2 selective inhibitor NS-398 or in macrophages stably transfected with an antisense cyclooxygegase-2 expression vector, Our results point to cyclooxygenase-2 induction by lipopolysaccharide/interferon gamma/N-G-monomethyl-L-arginine or low-dose nitric oxide pretreatment conferring macrophage protection to the apoptotic action of nitric oxide.	UNIV ERLANGEN NURNBERG,FAC MED,DEPT MED 4,DIV EXPT,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg								Albina JE, 1996, J IMMUNOL, V157, P279; ALBINA JE, 1993, J IMMUNOL, V150, P5080; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Brune B, 1995, TOXICOL LETT, V82-3, P233, DOI 10.1016/0378-4274(95)03481-1; BRUNE B, 1996, BIOCHEM BIOPH RES CO, V299, P396; BUCHMULLERROUILLER Y, 1992, J IMMUNOL, V148, P1171; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Corbett JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1581, DOI 10.1152/ajpcell.1996.270.6.C1581; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DEAKIN AM, 1995, CYTOKINE, V7, P408, DOI 10.1006/cyto.1995.0056; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GENG Y, 1995, J IMMUNOL, V155, P796; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IKEDA M, 1994, CYTOKINE, V6, P602, DOI 10.1016/1043-4666(94)90047-7; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KIM YM, 1995, FEBS LETT, V374, P228, DOI 10.1016/0014-5793(95)01115-U; Kitade H, 1996, HEPATOLOGY, V23, P797, DOI 10.1002/hep.510230421; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MAGNELLI L, 1995, BIOCHEM BIOPH RES CO, V215, P641, DOI 10.1006/bbrc.1995.2512; MARNETT LJ, 1992, CANCER RES, V52, P5575; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, FEBS LETT, V384, P162; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Packham G, 1996, J IMMUNOL, V156, P2792; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RIDGWAY WM, 1994, CURR OPIN IMMUNOL, V6, P946, DOI 10.1016/0952-7915(94)90018-3; Salvemini D, 1996, J CLIN INVEST, V97, P2562, DOI 10.1172/JCI118704; Sandau K, 1996, CELL SIGNAL, V8, P173, DOI 10.1016/0898-6568(95)02051-9; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TESUKA T, 1996, BIOCHEM BIOPH RES CO, V218, P808; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; TORDJMAN C, 1995, BBA-LIPID LIPID MET, V1256, P249, DOI 10.1016/0005-2760(95)00026-9; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weisz A, 1996, BIOCHEM J, V316, P209, DOI 10.1042/bj3160209; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	69	118	121	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					887	895						9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285487				2022-12-25	WOS:A1997XT79000008
J	Acs, P; Bogi, K; Lorenzo, PS; Marquez, AM; Biro, T; Szallasi, Z; Blumberg, PM				Acs, P; Bogi, K; Lorenzo, PS; Marquez, AM; Biro, T; Szallasi, Z; Blumberg, PM			The catalytic domain of protein kinase C chimeras modulates the affinity and targeting of phorbol ester-induced translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-ISOFORM; BINDING-PROTEIN; CELLS; ISOZYMES; ACTIVATION; BETA; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION; FIBROBLASTS	Emerging evidence suggests important differences among protein kinase C (PKC) isozymes in terms of their regulation and biological functions, PKC is regulated by multiple interdependent mechanisms, including enzymatic activation, translocation of the enzyme in response to activation, phosphorylation, and proteolysis. As part of our ongoing studies to define the factors contributing to the specificity of PKC isozymes, we prepared chimeras between the catalytic and regulatory domains of PKC alpha, -delta, and -epsilon. These chimeras, which preserve the overall structure of the native PKC enzymes, were stably expressed in NIH 3T3 fibroblasts. Their intracellular distribution was similar to that of the endogenous enzymes, and they responded with translocation upon treatment with phorbol 12-myristate 13-acetate (PMA). We found that the potency of PMA for translocation of the PKC alpha/x chimeras from the soluble fraction was influenced by the catalytic domain. The ED50 for translocation of PKC alpha/alpha was 26 nM, in marked contrast to the ED50 of 0.9 nM in the case of the PKC alpha/epsilon chimera. In addition to this increase in potency, the site of translocation was also changed; the PKC alpha/epsilon chimera translocated mainly into the cytoskeletal fraction. PKCx/epsilon chimeras displayed twin isoforms with different mobilities on Western blots. PMA treatment increased the proportion of the higher mobility isoform. The two PKCx/epsilon isoforms differed in their localization; moreover, their localization pattern depended on the regulatory domain, Our results emphasize the complex contributions of the regulatory and catalytic domains to the overall behavior of PKC.	NCI,MOL MECH TUMOR PROMOT SECT,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,NIH,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA				Szallasi, Zoltan/0000-0001-5395-7509				BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CACACE AM, 1993, ONCOGENE, V8, P2095; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; DISATNIK MH, 1994, CELL GROWTH DIFFER, V5, P873; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KILEY SC, 1995, J CELL SCI, V108, P1003; KILEY SC, 1995, BIOCHEM SOC T, V23, P601, DOI 10.1042/bst0230601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; ORR JW, 1994, J BIOL CHEM, V269, P27715; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	35	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22148	22153		10.1074/jbc.272.35.22148	http://dx.doi.org/10.1074/jbc.272.35.22148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268359	hybrid			2022-12-25	WOS:A1997XT85000071
J	Chan, A; Berry, L; OBrodovich, H; Klement, P; Mitchell, L; Baranowski, B; Monagle, P; Andrew, M				Chan, A; Berry, L; OBrodovich, H; Klement, P; Mitchell, L; Baranowski, B; Monagle, P; Andrew, M			Covalent antithrombin-heparin complexes with high anticoagulant activity - Intravenous, subcutaneous, and intratracheal administration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SEQUENCE; ANTI-THROMBIN; CHAIN	Although heparin has been used clinically for prophylaxis and treatment of thrombosis, it has suffered from problems such as short duration within compartments in vivo that require long term anticoagulation. A covalent antithrombin-heparin complex has been produced with high anticoagulant activity and a long half-life relative to heparin. The product had high anti-factor Xa and antithrombin activities compared with noncovalent mixtures of antithrombin and heparin (861 and 753 units/mg versus 209 and 198 units/mg, respectively). Reaction with thrombin was rapid with bimolecular and second order rate constants of 1.3 x 10(9) M-1 s(-1) and 3.1 x 10(9) M-1 s(-1), respectively. The intravenous half-life of the complex in rabbits was 2.6 h as compared with 0.32 h for similar loads of heparin. Subcutaneous injection of antithrombin-heparin resulted in plasma levels (peaking at 24-30 h) that were still detectable 96 h post-injection. Given the increased lifetime in these vascular and intravascular spaces, use of the covalent complex in the lung was investigated. Activity of antithrombin-heparin instilled into rabbit lungs remained for 48 h with no detection of any complex systemically. Thus, this highly active agent has features required for pulmonary sequestration as a possible treatment for thrombotic diseases such as respiratory distress syndrome.	HAMILTON CIV HOSP,RES CTR,HENDERSON GEN DIV,HAMILTON,ON L8V 1C3,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT,MRC,GRP DEV LUNG BIOL,RESP RES DIV,RES INST,TORONTO,ON M5G 1X8,CANADA	McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Chan, Anthony K. C./AAR-8892-2021	Chan, Anthony K. C./0000-0003-1551-3995; Monagle, Paul/0000-0002-3970-8984				BACHOFEN M, 1982, CLIN CHEST MED, V3, P35; Bergqvist D, 1996, J INTERN MED, V240, P63, DOI 10.1046/j.1365-2796.1996.494834000.x; BERGSTEIN JM, 1992, NEW ENGL J MED, V327, P755, DOI 10.1056/NEJM199209103271102; BJORK I, 1982, FEBS LETT, V143, P96, DOI 10.1016/0014-5793(82)80281-0; BREGMAN MD, 1977, BIOCHEM BIOPH RES CO, V78, P584, DOI 10.1016/0006-291X(77)90219-4; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CEUSTERMANS R, 1982, J BIOL CHEM, V257, P3401; COALSON JJ, 1992, AM REV RESPIR DIS, V145, P872, DOI 10.1164/ajrccm/145.4_Pt_1.872; CONOVER P T, 1990, Pediatric Pathology, V10, P707; DAWES J, 1994, BIOCHEMISTRY-US, V33, P4375, DOI 10.1021/bi00180a035; EVANS DL, 1991, J BIOL CHEM, V266, P22307; FUKUDA Y, 1987, AM J PATHOL, V126, P171; GITLIN D, 1956, PEDIATRICS, V17, P64; HATTON MWC, 1980, ANAL BIOCHEM, V106, P417, DOI 10.1016/0003-2697(80)90542-4; HIXON SH, 1975, BIOCHEMISTRY-US, V14, P4251; HORNER AA, 1971, J BIOL CHEM, V246, P231; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLE B, 1994, J BIOL CHEM, V269, P29435; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PETERSEN LC, 1983, BIOCHEM J, V211, P91, DOI 10.1042/bj2110091; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; ROSENBERG RD, 1979, BIOCHEM BIOPH RES CO, V86, P1319, DOI 10.1016/0006-291X(79)90260-2; SALDEEN T, 1982, ANN NY ACAD SCI, V384, P319, DOI 10.1111/j.1749-6632.1982.tb21381.x; SEEGER W, 1985, J APPL PHYSIOL, V58, P326, DOI 10.1152/jappl.1985.58.2.326; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; WRIGHT CJ, 1981, CAN J SURG, V24, P130	30	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22111	22117		10.1074/jbc.272.35.22111	http://dx.doi.org/10.1074/jbc.272.35.22111			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268354	hybrid			2022-12-25	WOS:A1997XT85000066
J	Garrett, TA; Kadrmas, JL; Raetz, CRH				Garrett, TA; Kadrmas, JL; Raetz, CRH			Identification of the gene encoding the Escherichia coli lipid a 4'-kinase - Facile phosphorylation of endotoxin analogs with recombinant LpxK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE ENDOTOXIN; UDP-N-ACETYLGLUCOSAMINE; A DISACCHARIDE SYNTHASE; EUKARYOTIC SIGNAL-TRANSDUCTION; ACID-DEFICIENT MUTANT; HTRB GENE; SALMONELLA-TYPHIMURIUM; BACTERIAL-ENDOTOXINS; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; MUTATIONAL ANALYSIS	The genes for seven of nine enzymes needed for the biosynthesis of Kdo(2)-lipid A (Re endotoxin) in Escherichia coli have been reported, We have now identified a novel gene encoding the lipid A 4'-kinase (the sixth step of the pathway). The 4'-kinase transfers the (gamma) over dot-phosphate of ATP to the 4'-position of a tetraacyldisaccharide 1-phosphate intermediate (termed DS-1-P) to form tetraacyldisaccharide 1,4'-bis-phosphate (lipid IVA). The 4'-phosphate is required for the action of distal enzymes, such as Kdo transferase and also renders lipid A substructures active as endotoxin antagonists or mimetics, Lysates of E. coli generated using individual A clones from the ordered Kohara library were assayed for over-production of 4'-kinase. Only one clone, [218]E1D1, which directed 2-2.5-fold overproduction, was identified. This construct contains 20 kilobase pairs of E. coli DNA from the vicinity of minute 21. Two genes related to the lipid A system map in this region: msbA, encoding a putative translocator, and kdsB, the structural gene for CMP-Kdo synthase, msbA forms an operon with a downstream, essential open reading frame of unknown function, designated orfE. orfE was cloned into a T7 expression system. Washed membranes from cells overexpressing orfE display similar to 2000-fold higher specific activity of 4'-kinase than membranes from cells with vector alone. Membranes containing recombinant, overexpressed 4'-kinase (but not membranes with wild-type kinase levels) efficiently phosphorylate three DS-1-P analogs: 3-aza-DS-1-P, base-treated DS-1-P, and base-treated 3-aza-DS-1-P. A synthetic hexaacylated DS-1-P analog, compound 505, can also be phosphorylated by membranes from the overproducer, yielding [4'-P-32] lipid A (endotoxin). The overexpressed lipid A 4'-kinase is very useful for making new 4'-phosphorylated lipid A analogs with potential utility as endotoxin mimetics or antagonists, We suggest that orfE is the structural gene for the 4'-kinase and that it be redesignated IpxK.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, V2, P1715; BORODOVSKY M, 1994, TRENDS BIOCHEM SCI, V19, P309, DOI 10.1016/0968-0004(94)90067-1; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BUNNELL E, 1995, CRIT CARE MED S, V23, pA151; BUNNELL E, 1995, CRIT CARE MED S, V23, pA147; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1995, FASEB J, V9, pA1311; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; CROWELL DN, 1987, J BACTERIOL, V169, P5727, DOI 10.1128/jb.169.12.5727-5734.1987; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HAMPTON RY, 1991, J BIOL CHEM, V266, P19499; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HASELBERGER A, 1987, TRIANGLE, V26, P33; IMOTO M, 1987, B CHEM SOC JPN, V60, P2205, DOI 10.1246/bcsj.60.2205; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUSUMOTO S, 1992, BACTERIAL ENDOTOXIC, V1, P81; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; MDLULI KE, 1994, MICROBIOL-SGM, V140, P3309, DOI 10.1099/13500872-140-12-3309; Miller J. H., 1972, EXPT MOL GENETICS, P433; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; RADIKA K, 1988, J BIOL CHEM, V263, P14859; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; REEVES PR, 1994, BACTERIAL CELL WALL, V27, P281; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHOLZ D, 1992, J MED CHEM, V35, P2070, DOI 10.1021/jm00089a019; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; VYPLEL H, 1991, J MED CHEM, V34, P2759, DOI 10.1021/jm00113a013; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	69	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21855	21864		10.1074/jbc.272.35.21855	http://dx.doi.org/10.1074/jbc.272.35.21855			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268317	hybrid			2022-12-25	WOS:A1997XT85000029
J	Graff, JR; Herman, JG; Myohanen, S; Baylin, SB; Vertino, PM				Graff, JR; Herman, JG; Myohanen, S; Baylin, SB; Vertino, PM			Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; DNA METHYLATION; DENOVO METHYLATION; HUMAN CANCERS; HUMAN BREAST; HYPERMETHYLATION; INACTIVATION; PROMOTER; RETINOBLASTOMA; CARCINOMAS	Promoter region CpG island methylation is associated with tumor suppressor gene silencing in neoplasia, Gen-Bank sequence analyses revealed that a number of CpG islands are juxtaposed to multiple Alu repeats, which have been proposed as ''de novo methylation centers.'' These islands also contain multiple Sp1 elements located upstream and downstream of transcription start, which have been shown to protect CpG islands from methylation. We mapped the methylation patterns of the E-cadherin (E-cad) and von Hippel-Lindau (VHL) tumor suppressor gene CpG island regions in normal and neoplastic cells, Although unmethylated in normal tissue, these islands were embedded between densely methylated flanking regions containing multiple Alu repeats, These methylated flanks were segregated from the unmethylated, island CpG sites by Sp1-rich boundary regions. Finally, in human fibroblasts overexpressing DNA methyltransferase, de novo methylation of the Ecad CpG island initially involved sequences at both ends of the island and the adjacent, flanking regions and progressed with time to encompass the entire CpG island region, Together, these data suggest that boundaries exist at both ends of a CpG island to maintain the unmethylated state in normal tissue and that these boundaries may be progressively overridden, eliciting the de novo methylation associated with tumor suppressor gene silencing in neoplasia.	JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21231	Johns Hopkins University	Graff, JR (corresponding author), JOHNS HOPKINS UNIV,CTR ONCOL,424 N BOND ST,RM 132,BALTIMORE,MD 21231, USA.				NCI NIH HHS [CA43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BAYLIN SB, 1997, IN PRESS ADV CANC RE; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRAFF JR, 1995, CANCER RES, V55, P5195; GREGER V, 1994, HUM GENET, V94, P491; HASSE A, 1994, J BIOL CHEM, V269, P1821; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1996, CANCER RES, V56, P2463; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; KUZMIN I, 1995, ONCOGENE, V10, P2185; LAIRD PW, 1997, ANNU REV GENET, V30, P4441; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; MYOHANEN S, 1994, DNA SEQUENCE, V5, P1, DOI 10.3109/10425179409039698; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUENTIN Y, 1994, NUCLEIC ACIDS RES, V25, P2222; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	34	280	292	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22322	22329		10.1074/jbc.272.35.22322	http://dx.doi.org/10.1074/jbc.272.35.22322			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268383	hybrid			2022-12-25	WOS:A1997XT85000095
J	Haruki, M; Noguchi, E; Kanaya, S; Crouch, RJ				Haruki, M; Noguchi, E; Kanaya, S; Crouch, RJ			Kinetic and stoichiometric analysis for the binding of Escherichia coli ribonuclease HI to RNA-DNA hybrids using surface plasmon resonances	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 REVERSE-TRANSCRIPTASE; SITE-DIRECTED MUTAGENESIS; DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; DOMAIN; SUBSTRATE; SEQUENCE; RECOGNITION; RESOLUTION	To understand how ribonucleases H recognize RNA-DNA hybrid substrates, we analyzed kinetic parameters of binding of Escherichia coli RNase HI to RNA-DNA hybrids ranging in length from 18 to 36 base pairs (bp) using surface plasmon resonance (BIAcore((TM))). The k(on) and k(off) values for the binding of the enzyme to the 36 bp substrate were 1.5 x 10(6) M-1 s(-1) and 3.2 x 10(-2) s(-1), respectively, Similar values were obtained with the shorter substrates, Using uncleavable 2'-O-methylated RNA-DNA substrates, values for h(on) and h(off) were 2.1 x 10(5) M-1 s(-1) and 1.3 x 10(-1) s(-1) in the absence of Mg2+ that were further reduced in the presence of Mg2+ to 7.4 x 10(3) M-1 s(-1) and 2.6 x 10(-2) s(-1). Kinetic parameters similar to the wild-type enzyme were obtained using an active-site mutant enzyme, Asp(134) replaced by Ala, whereas a greatly reduced on-rate was observed for another inactive mutant enzyme, in which the basic protrusion is eliminated, thereby distinguishing between poor catalysis and inability to bind to the substrate. Stoichiometric analyses of RNase HI binding to substrates of 18, 24, 30, and 36 bp are consistent with previous reports suggesting that RNase HI binds to 9-10 bp of RNA DNA hybrid.	NICHHD,MOL GENET LAB,NIH,BETHESDA,MD 20892; OSAKA UNIV,GRAD SCH ENGN,DEPT MAT & LIFE SCI,SUITA,OSAKA 565,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Osaka University								BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BLOMMERS MJJ, 1994, NUCLEIC ACIDS RES, V22, P4187, DOI 10.1093/nar/22.20.4187; CERRITELLI SM, 1995, RNA, V1, P246; Crouch R. J., 1982, NUCLEASES, P211; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FISHER RJ, 1994, PROTEIN SCI, V3, P257; GERSHON PD, 1995, J IMMUNOL METHODS, V183, P65, DOI 10.1016/0022-1759(95)00032-6; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HALL SH, 1977, J BIOL CHEM, V252, P4092; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; IWAI S, 1995, FEBS LETT, V368, P315, DOI 10.1016/0014-5793(95)00683-Z; Iwai S, 1996, J MOL BIOL, V263, P699, DOI 10.1006/jmbi.1996.0609; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; KANAYA E, 1995, EUR J BIOCHEM, V231, P557, DOI 10.1111/j.1432-1033.1995.0557d.x; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Keck JL, 1996, J BIOL CHEM, V271, P19883, DOI 10.1074/jbc.271.33.19883; KECK JL, 1995, P NATL ACAD SCI USA, V92, P2740, DOI 10.1073/pnas.92.7.2740; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma W P, 1994, Bioorg Med Chem, V2, P169, DOI 10.1016/S0968-0896(00)82012-X; Miller J. H., 1972, EXPT MOL GENETICS, P433; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; ODA Y, 1993, NUCLEIC ACIDS RES, V21, P4690, DOI 10.1093/nar/21.20.4690; ODA Y, 1993, J BIOL CHEM, V268, P88; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; UCHIYAMA Y, 1994, J MOL BIOL, V243, P782, DOI 10.1016/0022-2836(94)90047-7; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; Zhan XY, 1997, J BIOL CHEM, V272, P22023, DOI 10.1074/jbc.272.35.22023	40	55	56	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22015	22022		10.1074/jbc.272.35.22015	http://dx.doi.org/10.1074/jbc.272.35.22015			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268340	hybrid			2022-12-25	WOS:A1997XT85000052
J	Huang, CH; Lin, HN; Li, SS; Wang, GQ				Huang, CH; Lin, HN; Li, SS; Wang, GQ			Influence of the positions of cis double bonds in the sn-2-acyl chain of phosphatidylethanolamine on the bilayer's melting behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-TRANSITION TEMPERATURES; HETEROACID PHOSPHATIDYLCHOLINES; MOLECULAR MECHANICS; UNSATURATION; SERIES	In an attempt to examine the effects of different numbers and positions of cis double bonds in the sn-2-acyl chain of phosphatidylethanolamine (PE) on the bilayer's melting behavior, 21 molecular species of PE were first semisynthesized, and their T-m and Delta H values were subsequently determined by high resolution differential scanning calorimetry, In the plot of T-m versus the number of the cis double bond, some characteristic profiles were observed for the various series of PEs, For instance, if the cis double bond was first introduced into the sn-2-acyl chain of C(20):C(20)PE at the Delta(5)-position, the T-m was observed to reduce drastically. Subsequent stepwise additions of up to five cis double bonds at the methylene-interrupted positions toward the methyl end resulted in a progressive yet smaller decrease in T-m. If, on the other hand, the cis double bonds were introduced sequentially at the Delta(11)-, Delta(11,14)-, and Delta(11,14,17)-positions along the sn-2-acyl chain of C(20):C(20)PE, the T-m profile in the T-m versus the number of the cis double bond showed a down-and-up trend. Most interestingly, for positional isomers of C(20):C(20:3 Delta(5,8,11))PE,C(20):C(20:3 Delta(8,11,14))PE, and C(20):C(20:3 Delta(11,14,17))PE) an inverted bell-shaped T-m profile was detected in the plot of T-m against the position of the omega-carbon for these isomers. Similar T-m profiles were also observed for C(18):C(20)PE, C(20):C(18)PE, and their unsaturated derivatives. This work thus demonstrated that both the positions and the numbers of cis double bonds in the sn-2 acyl chain could exert noticeable influence on the gel-to-liquid crystalline phase transition behavior of the lipid bilayer. Finally, a molecular model was presented, with which the behavior of the gel-to-liquid crystalline phase transition observed for lipid bilayers composed of various sn-1-saturated/sn-2-unsaturated lipids can be rationalized.			Huang, CH (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,BOX 440,CHARLOTTESVILLE,VA 22908, USA.				NIGMS NIH HHS [GM-17452] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017452] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CHANG H, 1983, BIOCHIM BIOPHYS ACTA, V728, P319, DOI 10.1016/0005-2736(83)90501-1; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; COOLBEAR KP, 1983, BIOCHEMISTRY-US, V22, P1466, DOI 10.1021/bi00275a022; HERNANDEZBORRELL J, 1993, BIOCHIM BIOPHYS ACTA, V1153, P277, DOI 10.1016/0005-2736(93)90416-W; HUANG C, 1994, BBA-BIOMEMBRANES, V1189, P7, DOI 10.1016/0005-2736(94)90273-9; Huang CH, 1996, ARCH BIOCHEM BIOPHYS, V334, P135, DOI 10.1006/abbi.1996.0438; KEOUGH KMW, 1987, BIOCHIM BIOPHYS ACTA, V902, P1, DOI 10.1016/0005-2736(87)90129-5; KEOUGH KMW, 1990, BIOCHEM SOC T, V18, P835, DOI 10.1042/bst0180835; LI SS, 1994, BIOPHYS J, V66, P2005, DOI 10.1016/S0006-3495(94)80993-2; LIN HN, 1990, BIOCHEMISTRY-US, V29, P7063, DOI 10.1021/bi00482a017; LIU S, 1994, BIOCHEM J, V299, P831, DOI 10.1042/bj2990831; MANTSCH HH, 1983, BIOCHIM BIOPHYS ACTA, V728, P325, DOI 10.1016/0005-2736(83)90502-3; MCCABE MA, 1994, BIOCHEMISTRY-US, V33, P8203; NIEBYLSKI CD, 1994, BIOPHYS J, V67, P2387, DOI 10.1016/S0006-3495(94)80725-8; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; SanchezMigallon M, 1996, BBA-BIOMEMBRANES, V1279, P251; SEDDON JM, 1984, BIOCHEMISTRY-US, V23, P2634, DOI 10.1021/bi00307a015; WANG GQ, 1995, J BIOL CHEM, V270, P22738, DOI 10.1074/jbc.270.39.22738; Wang GQ, 1997, BIOPHYS J, V73, P283, DOI 10.1016/S0006-3495(97)78069-X; WANG ZQ, 1994, J BIOL CHEM, V269, P23491; WANG ZQ, 1995, J BIOL CHEM, V270, P2014, DOI 10.1074/jbc.270.5.2014; XU H, 1988, BIOCHIM BIOPHYS ACTA, V940, P63	23	20	20	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21917	21926		10.1074/jbc.272.35.21917	http://dx.doi.org/10.1074/jbc.272.35.21917			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268325	hybrid			2022-12-25	WOS:A1997XT85000037
J	Huang, W; Meng, Q; Suzuki, K; Nagase, H; Brew, K				Huang, W; Meng, Q; Suzuki, K; Nagase, H; Brew, K			Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases I (TIMP-1) locates an inhibitory region for matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; GROWTH-PROMOTING ACTIVITY; PROGELATINASE-A; ACTIVATION; CLONING; MEMBER; FAMILY; STROMELYSIN; SEQUENCE; COMPLEX	A bacterial expression system for the inhibitory N-terminal domain of human tissue inhibitor of metalloproteinases 1(N-TTMP-1) (Huang, W., Suzuki, K., Nagase, H., Arumugam, S., Van Doren, S. R., and Brew, K. (1996) FEBS Lett. 384, 155-161) has been used to produce 20 single-and double site mutants that probe the roles of different residues in its inhibitory action on metalloproteinases. Mutations that produce the largest increases in the K-i for a C-terminally truncated form of stromelysin 1, MMP-3(Delta C), but do not disturb the conformation involve substitutions of residues that are located in a ridge that is centered around the disulfide bond between Cys(1) and Cys(70). Specific residues that have a large influence on activity include Cys(1), Thr(2), Met(66), Val(69), and Cys(70) Of the mutations introduced, the greatest functional disturbances, reflected in K-i increases of 2-4 orders of magnitude, are generated by changes that disrupt the Cys(1)-Cys(70) disulfide bond and by substitution of Ala for Thr(2). Most mutations that perturb the interaction with MMP-3 have parallel effects on the affinity of N-TIMP-1 for MMP-1 (interstitial collagenase) and MMP-2 (gelatinase A). However, the Thr(2) to Ala mutation produces an inhibitor that is 17-fold more effective against MMP-3 than MMP-1, suggesting that it is feasible to engineer TIMP-1 variants that are more specifically targeted to selected matrix metalloproteinases, The reactive site identified by these studies is a structurally constrained but elongated region of TIMP that can fit the matrix metalloproteinase substrate-binding site.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOL BIOL, R629, MIAMI, FL 33101 USA; UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOL BIOL, KANSAS CITY, KS 66160 USA	University of Miami; University of Kansas; University of Kansas Medical Center			Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032	NIAMS NIH HHS [AR40994] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; BODDEN MK, 1994, ANN NY ACAD SCI, V732, P84, DOI 10.1111/j.1749-6632.1994.tb24727.x; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Edwards DR, 1996, INT J OBESITY, V20, pS9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nagase H, 1996, ADV EXP MED BIOL, V389, P23; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, ZINC METALLOPROTEASE, P153; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1993, BIOCHIM BIOPHYS ACTA, V1203, P147, DOI 10.1016/0167-4838(93)90049-W; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOODY RW, 1995, METHOD ENZYMOL, V246, P34	32	86	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22086	22091		10.1074/jbc.272.35.22086	http://dx.doi.org/10.1074/jbc.272.35.22086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268350	hybrid			2022-12-25	WOS:A1997XT85000062
J	Liu, CE; Liu, PQ; Ames, GFL				Liu, CE; Liu, PQ; Ames, GFL			Characterization of the adenosine triphosphatase activity of the periplasmic histidine permease, a traffic ATPase (ABC transporter)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-PROTEIN; MALTOSE TRANSPORT; SALMONELLA-TYPHIMURIUM; MULTIDRUG-RESISTANCE; MEMBRANE-COMPONENTS; CYSTIC-FIBROSIS; DEPENDENT TRANSPORT; STRUCTURAL MODEL; P-GLYCOPROTEIN	The superfamily of traffic ATPases (ABC transporters) includes bacterial periplasmic transport systems (permeases) and eukaryotic transporters. The histidine permease of Salmonella typhimurium is composed of a membrane-bound complex (HisQMP(2)) containing four subunits, and of a soluble receptor, the histidine-binding protein (HisJ). Transport is energized by ATP, In this article the ATPase activity of HisQMP(2) has been characterized, using a novel assay that is independent of transport. The assay uses Mg2+ ions to permeabilize membrane vesicles or proteoliposomes, thus allowing access of ATP to both sides of the bilayer, HisQMP(2) displays a low level of intrinsic ATPase activity in the absence of HisJ; unliganded HisJ stimulates the activity and liganded HisJ stimulates to an even higher level, All three levels of activity display positive cooperativity for ATP with a Hill coefficient of 2 and a K-0.5 value of 0.6 mM. The activity has been characterized with respect to pH, salt, phospholipids, substrate, and inhibitor specificity, Free histidine has no effect. The activity is inhibited by orthovanadate, but not by N-ethylmaleimide, bafilomycin A(1), or ouabain. Several nucleotide analogs, ADP, 5'-adenylyl-beta,gamma-imidodiphosphate, adenosine 5'-(beta,gamma-imino)triphosphate, and adenosine 5'-O-(3-thio)triphosphate, inhibit the activity. Unliganded HisJ does not compete with liganded HisJ for the stimulation of the ATPase activity of HisQMP(2).	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R37DK012121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK12121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN TM, 1990, BIOCHEMISTRY-US, V29, P2976, DOI 10.1021/bi00464a013; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMES BN, 1960, J BIOL CHEM, V235, P769; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; AMES GFL, 1990, BACTERIAL ENERGETICS, P225; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; GUNTER KK, 1982, ANAL BIOCHEM, V120, P113, DOI 10.1016/0003-2697(82)90326-8; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; RICHARME G, 1993, J BIOL CHEM, V268, P9473; ROSIER RN, 1979, ANAL BIOCHEM, V96, P384, DOI 10.1016/0003-2697(79)90596-7; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; SPEISER DM, 1989, THESIS U CALIFORNIA; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WALTER C, 1992, J BIOL CHEM, V267, P8863	47	108	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21883	21891		10.1074/jbc.272.35.21883	http://dx.doi.org/10.1074/jbc.272.35.21883			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268321	hybrid			2022-12-25	WOS:A1997XT85000033
J	Zhan, XY; Crouch, RJ				Zhan, XY; Crouch, RJ			The isolated RNase H domain of murine leukemia virus reverse transcriptase - Retention of activity with concomitant loss of specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RIBONUCLEASE-H; ESCHERICHIA-COLI; DNA-POLYMERASE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; PRIMER-TEMPLATE; STRAND TRANSFER; TYPE-1; MUTATIONS	Retroviral RNases H are similar in sequence and structure to Escherichia coli RNase HI and yet have differences in substrate specificities, metal ion requirements, and specific activities. Separation of reverse transcriptase (RT) into polymerase and RNase H domains yields an active RNase H from murine leukemia virus (MuLV) but an inactive human immunodeficiency virus (HN) RNase H. The ''handle region'' present in E. coli RNase HI but absent in HIV RNase H contributes to the binding to its substrate and when inserted into HIV RNase H results in an active enzyme retaining some degree of specificity. Here, we show MuLV protein containing the C-terminal 175 amino acids with its own handle region or that of E. coli RNase HI has the same specific activity as the RNase H of RT, retains a preference for Mn2+ as the cation required for activity, and has association rate (K-A) 10% that of E. coli RNase HI. However, with model substrates, specificities for removal of the tRNA(Pro) primer and polypurine tract stability are lost, indicating specificity of RNase H of MuLV requires the remainder of the RT. Differences in K-A, while significant, appear insufficient to account for the differences in specific activities of the bacterial and viral RNases H.	NICHHD, MOL GENET LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BLAIN SW, 1995, J VIROL, V69, P4440, DOI 10.1128/JVI.69.7.4440-4452.1995; CARL PL, 1980, J BACTERIOL, V144, P28, DOI 10.1128/JB.144.1.28-35.1980; CERRITELLI SM, 1993, BIOCHIMIE, V75, P107, DOI 10.1016/0300-9084(93)90031-M; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DIRKSEN ML, 1981, J BIOL CHEM, V256, P1569; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; Haruki M, 1997, J BIOL CHEM, V272, P22015, DOI 10.1074/jbc.272.35.22015; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Keck JL, 1996, J BIOL CHEM, V271, P19883, DOI 10.1074/jbc.271.33.19883; KECK JL, 1995, P NATL ACAD SCI USA, V92, P2740, DOI 10.1073/pnas.92.7.2740; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MIZRAHI V, 1994, J BIOL CHEM, V269, P19245; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; POST K, 1993, BIOCHEMISTRY-US, V32, P5508, DOI 10.1021/bi00072a004; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHULTZ SJ, 1995, J BIOL CHEM, V270, P24135, DOI 10.1074/jbc.270.41.24135; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JK, 1984, J VIROL, V49, P200, DOI 10.1128/JVI.49.1.200-204.1984; SMITH JS, 1994, J VIROL, V68, P5721, DOI 10.1128/JVI.68.9.5721-5729.1994; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WONDRAK EM, 1986, J GEN VIROL, V67, P2791, DOI 10.1099/0022-1317-67-12-2791; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZHAN XY, 1994, BIOCHEMISTRY-US, V33, P1366, DOI 10.1021/bi00172a012	50	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22023	22029		10.1074/jbc.272.35.22023	http://dx.doi.org/10.1074/jbc.272.35.22023			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268341	hybrid			2022-12-25	WOS:A1997XT85000053
J	Zhang, BL; Wang, ZX; Zheng, Y				Zhang, BL; Wang, ZX; Zheng, Y			Characterization of the interactions between the small GTPase Cdc42 and its GTPase-activating proteins and putative effectors - Comparison of kinetic properties of Cdc42 binding to the Cdc42-interactive domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; ALDRICH SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; INORGANIC-PHOSPHATE; N-CHIMAERIN; RAS; KINASE; RAC1; FILOPODIA; ASSAY	The small GTPase Cdc42 interacts with multiple factors to transduce diverse intracellular signals, The factors that preferentially recognize the GTP bound, active state of Cdc42 include a panel of GTPase-activating proteins (GAPs), the Cdc42/Rac interactive binding (CRIB) motif-containing molecules, and the RasGAP domain containing IQGAP1 and IQGAP2. In the present study, we have determined the kinetic parameters underlying the functional interactions between the Cdc42-binding domains of some of these factors and Cdc42 by monitoring the continuous release of gamma P-i and have compared the ability of the domains to bind to Cdc42, The catalytic efficiencies (K-cat/K-m) of the GAP domains of Bcr, 3BP-1, and p190 on Cdc42 are found to be 60-, 160-, and over 500-fold less than that of Cdc42GAP, respectively, and the differences are due, to a large part, to differences in K-m. The K-m values of the GAP domains compare well to the binding affinity to the guanylyl imidodiphosphate-bound Cdc42, suggesting a rapid equilibrium reaction mechanism, The affinity of the Cdc42-binding domains of the CRIB motif of Wiskott Aldrich Syndrome protein and p21(cdc42/rac)-activated kinase 1, and the RasGAP-related domain of IQGAP1, which all inhibit the intrinsic rate of GTP hydrolysis of Cdc42, are found to be 4, 0.7, and 0.08 mu M, respectively, These quantitative analysis provide insight that Cdc42GAP functions as an effective negative regulator of Cdc42 by fast, relatively tight binding to the GTP-bound Cdc42, whereas IQGAP1 interacts with Cdc42 as a putative effector with over 10-fold higher affinity than the CRIB domains and GAPs, and suggest that various GAPs and effecters employ distinct mechanism to play roles in Cdc42-mediated signaling pathways.	UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163; ACAD SINICA,INST BIOPHYS,BEIJING 100080,PEOPLES R CHINA	University of Tennessee System; University of Tennessee Health Science Center; Chinese Academy of Sciences; Institute of Biophysics, CAS			Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM53943] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1993, J BIOL CHEM, V268, P10709; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Brill S, 1996, MOL CELL BIOL, V16, P4869; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; Bryant SS, 1996, J BIOL CHEM, V271, P5195; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dutartre H, 1996, J CELL SCI, V109, P367; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEOANRD DA, 1997, BIOCHEMISTRY-US, V36, P1173; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WEBB MR, 1992, BIOCHEM J, V287, P555, DOI 10.1042/bj2870555; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	59	81	84	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21999	22007		10.1074/jbc.272.35.21999	http://dx.doi.org/10.1074/jbc.272.35.21999			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268338	hybrid			2022-12-25	WOS:A1997XT85000050
J	Madden, SL; Galella, EA; Zhu, JS; Bertelsen, AH; Beaudry, GA				Madden, SL; Galella, EA; Zhu, JS; Bertelsen, AH; Beaudry, GA			SAGE transcript profiles for p53-dependent growth regulation	ONCOGENE			English	Article						SAGE; p53; transcription	MESSENGER-RNA; DIFFERENTIAL DISPLAY; GENE-EXPRESSION; P53 MUTANTS; CELL-CYCLE; APOPTOSIS; IDENTIFICATION; PROTEIN; OSTEOPONTIN; ACTIVATION	Serial analysis of gene expression (SAGE) allows for a quantitative, representative, and comprehensive profile of gene expression, We have utilized SAGE technology to contrast the differential gene expression profile in rat embryo fibroblast cells producing temperature-sensitive p53 tumor suppressor protein at permissive or nonpermissive temperatures, Analysis of similar to 15 000 genes revealed that the expression of 14 genes (P<0.001, greater than or equal to 0.03% abundance) was dependent on functional p53 protein, whereas the expression of three genes was significantly higher in cells producing non-functional p53 protein, Those genes whose expression was increased by functional p53 include RAS, U6 snRNA, cyclin G, EGR-1, and several novel genes, The expression of actin, tubulin, and HSP70 genes was elevated at the nonpermissive temperature for p53 function, Interestingly, the expression of several genes was dependent on a non-temperature-sensitive mutant p53 suggesting altered transcription profiles dependent on specific p53 mutant proteins. These results demonstrate the utility of SAGE for rapidly and reproducibly evaluating global transcriptional responses within different cell populations.			Madden, SL (corresponding author), PHARMAGEN INC,DEPT CELLULAR & MOL BIOL,4 PEARL COURT,ALLENDALE,NJ 07401, USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AMBARTSUMIAN N, 1995, GENE, V159, P125, DOI 10.1016/0378-1119(94)00778-Q; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Arai T, 1996, INT J RADIAT BIOL, V69, P547, DOI 10.1080/095530096145553; Bains W, 1996, NAT BIOTECHNOL, V14, P711, DOI 10.1038/nbt0696-711; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BERTIOLI DJ, 1995, NUCLEIC ACIDS RES, V23, P4520, DOI 10.1093/nar/23.21.4520; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAMBERS AF, 1995, ANN NY ACAD SCI, V760, P101, DOI 10.1111/j.1749-6632.1995.tb44623.x; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HARPER JW, 1993, CELL, V75, P805; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Madden SL, 1996, CANCER RES, V56, P5384; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Oates AJ, 1996, ONCOGENE, V13, P97; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wright PS, 1996, EXP CELL RES, V222, P54, DOI 10.1006/excr.1996.0007; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	37	148	162	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1079	1085		10.1038/sj.onc.1201091	http://dx.doi.org/10.1038/sj.onc.1201091			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285562				2022-12-25	WOS:A1997XT16100009
J	Ueno, NT; Yu, DH; Hung, MC				Ueno, NT; Yu, DH; Hung, MC			Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A	ONCOGENE			English	Article						HER-2/neu; E1A; paclitaxel; breast neoplasms; gene therapy	GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-PRODUCTS; EGF RECEPTOR; PROGNOSTIC-SIGNIFICANCE; EXPRESSION; METASTASIS; P53; TRANSFORMATION; C-ERBB-2	Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu. In previous work, we showed that the adenovirus type 5 E1A can repress HER-2/neu expression at the transcriptional level, Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. To further test whether E1A can sensitize HER-2/neu-overexpressing human breast cancer cells to paclitaxel through E1A-mediated HER-2/neu repression, an adenoviral vector was used to transfer the E1A gene into two human breast cancer cell lines, MDA-MB-453 and MDA-MB-361, that overexpress HER-2/neu. After E1A delivery, we observed that HER-2/neu expression level was reduced, and cells mere treated with paclitaxel. Cell proliferation assays showed a synergistic growth inhibition effect of E1A and paclitaxel, The synergistic effect was also confirmed by soft agar colony-formation assay, Breast cancer cell lines that express low levels of HER-2/neu, MDA-MB-435 and MDA-MB-231 cells showed no synergistic growth inhibition effect when treated on the same protocols, Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression. This in turn may have important implications for the development of a novel therapy that combines chemotherapy and gene therapy.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,SECT BLOOD & MARROW TRANSPLANTAT,DEPT HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BAS RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [CA58880, CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, R01CA060856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Chang JY, 1996, ONCOGENE, V13, P1405; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; FRISCH SM, 1995, CANCER RES, V55, P5551; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HATA Y, 1994, ONCOL RES, V6, P19; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MATIN A, 1990, ONCOGENE, V5, P111; MCCANN AH, 1991, CANCER RES, V51, P3296; MILLER SJ, 1995, ONCOL REP, V2, P497; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1994, J NATL CANCER I, V86, P1018, DOI 10.1093/jnci/86.13.1018; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Ullrich Axel, 1989, SCIENCE, V244, P707, DOI DOI 10.1126/SCIENCE.2470152; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEBB JL, 1963, ENZYMES METABOL INH, V1, P507; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1994, CELL GROWTH DIFFER, V5, P431; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang LS, 1996, ONCOGENE, V12, P571; ZHANG YJ, 1995, ONCOGENE, V10, P1947	52	92	102	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					953	960		10.1038/sj.onc.1201250	http://dx.doi.org/10.1038/sj.onc.1201250			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285690				2022-12-25	WOS:A1997XR76700008
J	Huang, CC; Papas, TS; Bhat, NK				Huang, CC; Papas, TS; Bhat, NK			A variant form of ETS1 induces apoptosis in human colon cancer cells	ONCOGENE			English	Article						oncogene; tumor suppressor gene; colon cancer; ETS1 protein; epithelial cancer	TRANSCRIPTION FACTORS; EXPRESSION; GENES; ISOFORMS; PROTEINS; BINDING; FAMILY	We have previously shown that the human ETS1 protein (pS1-ETS1), when ectopically expressed in colon cancer cell lines, is able to reduce its tumorigenicity without affecting its growth properties, To understand the mechanism of tumor reduction, we have expressed two different forms of ETS1 in colon cancer cell lines, Data presented in this paper indicate that the naturally occurring spliced variant protein, p42-ETS1, lacking the region encoded by ETS1 exon VII, represses the tumorigenicity, while p51-ETS1 reduces the tumorigenicity, Repression of tumorigenicity mediated by p42-ETS1 appears to be caused by its ability to induce apoptosis in epithelial cancer cells, This work can have profound medical significance in that it may open up new insights into the potential role of the p42-ETS1 in the induction of apoptosis in epithelial cell cancers and may provide a rationale for its use for potential gene therapy experiments to initiate cell death in cancer cells.	NCI,FREDERICK CANC RES & DEV CTR,SAIC,RECOMBINANT DNA LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Huang, CC (corresponding author), MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOL & STRUCT BIOL,CHARLESTON,SC 29425, USA.							BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; Bhat NK, 1996, INT J ONCOL, V8, P841; BHAT NK, 1994, CHALLENGES MODERN ME, V5, P63; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; JORCYK CL, 1991, ONCOGENE, V6, P523; KOIZUMI S, 1990, ONCOGENE, V5, P675; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2726; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; SUZUKI H, 1993, INT J ONCOL, V3, P56; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	20	39	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					851	856		10.1038/sj.onc.1201408	http://dx.doi.org/10.1038/sj.onc.1201408			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266972				2022-12-25	WOS:A1997XQ11700012
J	vandenBerghe, N; Cool, RH; Horn, G; Wittinghofer, A				vandenBerghe, N; Cool, RH; Horn, G; Wittinghofer, A			Biochemical characterization of C3G: an exchange factor that discriminates between Rap1 and Rap2 and is not inhibited by Rap1A(S17N)	ONCOGENE			English	Article						Rap; C3G; small G proteins; nucleotide exchange factor; Rap1A(S17N)	GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR ACTIVITY; RAS-RELATED GENE; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; BINDING; MUTANTS; SITE; IDENTIFICATION	A catalytically active fragment of the Rap-specific guanine-nucleotide exchange factor C3G was expressed in E coli. It was purified and its interaction with GTP-binding proteins was investigated using fluorescence spectroscopy, C3G stimulates GDP dissociation from Rap1, but not from Rap2, neither from Bud1, which is believed to be the yeast homologue of Rap1 nor from all other proteins of the human Ras-subfamily, Like the corresponding fragment from CDC25(Mm), the increase in the GDP dissociation rate is linear with increasing concentration of Rap1A.GDP up to 100 mu M, indicating an apparent K-M higher than 100 mu M. Unlike the Ras-CDC25(Mm) system, the Rap1A(S17N) mutant does not inhibit the C3G-activated guanine nucleotide dissociation from wild-type Rap1A in vitro. These data suggest that Rap1A(S17N) is unlikely to titrate away C3G in vivo, the proposed mechanism by which S17N-mutants exert their dominant negative effects.	MAX PLANCK INST MOL PHYSIOL,D-44139 DORTMUND,GERMANY	Max Planck Society				Cool, Robbert/0000-0002-9845-2202				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNERO A, 1995, BIOCHEM BIOPH RES CO, V216, P748, DOI 10.1006/bbrc.1995.2685; ECCLESTON JF, 1988, NATO ASI A, V165, P87; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HANEY SA, 1994, J BIOL CHEM, V269, P16541; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; JOHN J, 1993, J BIOL CHEM, V268, P923; JOHN J, 1988, NATO ASI A, V165, P209; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LEROSEY I, 1991, J BIOL CHEM, V466, P4315; MALY FE, 1994, J BIOL CHEM, V269, P18743; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PIZON V, 1988, ONCOGENE, V3, P210; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATO KY, 1994, CANCER RES, V54, P552; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TANAKA X, 1994, P NATL ACAD SCI USA, V91, P3442; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	44	89	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					845	850		10.1038/sj.onc.1201407	http://dx.doi.org/10.1038/sj.onc.1201407			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266971				2022-12-25	WOS:A1997XQ11700011
J	NegreSalvayre, A; Hirtz, C; Carrera, G; Cazenave, R; Troly, M; Salvayre, R; Penicaud, L; Casteilla, L				NegreSalvayre, A; Hirtz, C; Carrera, G; Cazenave, R; Troly, M; Salvayre, R; Penicaud, L; Casteilla, L			Role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation	FASEB JOURNAL			English	Article						mitochondria; inflammation; monocyte/macrophage; adipose tissue; rhodamine 123; UCP	BROWN ADIPOSE-TISSUE; LIVER-MITOCHONDRIA; H2O2; NUCLEOTIDES; EVOLUTION; CELLS	According to the state of mitochondrial respiration, the respiratory chain generates superoxide anions converted into hydrogen peroxide. Two uncoupling proteins (UCP) able to modulate the coupling between the respiratory chain and ATP synthesis are now identified and could be involved in mitochondrial H2O2 generation. UCP1 is specific to brown adipose tissue (BAT) whereas UCP2 is expressed in numerous tissues, particularly in monocytes/macrophages. Preincubation of BAT mitochondrial fractions with GDP, an inhibitor of UCP1, induced a rise in mitochondrial membrane potential (assessed by rhodamine 123 uptake) and H2O2 production. An uncoupling agent reversed this effect. Liver mitochondria exhibited a similar phenotype. CDP was also able to raise membrane potential and H2O2 production of the mitochondria from nonparenchymal cells expressing UCP2, but was completely ineffective on mitochondria from hepatocytes deprived of UCP2. The GDP effect was also observed with mitochondrial fractions of the spleen or thymus, which highly expressed UCP2. Altogether, these results strongly suggest that UCP2 is sensitive to GDP and that the UCPs, particularly UCP2, are able to modulate H2O2 mitochondrial generation. This supports a role for UCP2 in cellular (patho-) physiological processes involving free radicals generated by mitochondria, such as oxidative damage, inflammation, or apoptosis.	CHU RANGUEIL, CNRS, UPRESA 5018, IFR L BUGNARD, F-31054 TOULOUSE, FRANCE; CHU RANGUEIL, EA 824, F-31054 TOULOUSE, FRANCE; CHU RANGUEIL, INSERM U466, IFR L BUGNARD, F-31054 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Hirtz, Christophe/AAD-1662-2022; Hirtz, Christophe/R-9255-2017	Hirtz, Christophe/0000-0002-7313-0629; Hirtz, Christophe/0000-0002-7313-0629; Casteilla, Louis/0000-0001-9647-3248; Negre-Salvayre, Anne/0000-0003-2136-5706				APRILLE JR, 1980, ARCH BIOCHEM BIOPHYS, V201, P564, DOI 10.1016/0003-9861(80)90546-9; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BRAND MD, 1991, BIOCHEM J, V275, P81, DOI 10.1042/bj2750081; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LARROUY D, IN PRESS BIOCH BIOPH; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; LOSCHEN G, 1973, FEBS LETT, V33, P84, DOI 10.1016/0014-5793(73)80165-6; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MABILE L, 1997, IN PRESS ARTERIOSCLE; MUKHERJEE SP, 1980, BIOCHEM PHARMACOL, V29, P1239; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; PORTER RK, 1995, AM J PHYSIOL-REG I, V269, pR1213, DOI 10.1152/ajpregu.1995.269.5.R1213; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; ViguerieBascands N, 1996, J CLIN ENDOCR METAB, V81, P368, DOI 10.1210/jc.81.1.368; Wharton DC., 1967, METHOD ENZYMOL, P245	32	648	661	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1997	11	10					809	815		10.1096/fasebj.11.10.9271366	http://dx.doi.org/10.1096/fasebj.11.10.9271366			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271366				2022-12-25	WOS:A1997XR10500011
J	Gudz, TI; Tserng, KY; Hoppel, CL				Gudz, TI; Tserng, KY; Hoppel, CL			Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; LIVER-MITOCHONDRIA; ELECTRON-TRANSFER; CYTOTOXICITY; INVOLVEMENT; REPERFUSION; GENERATION; METABOLISM; MUSCLE	Ceramide is a lipid second messenger that mediates the effects of tumor necrosis factor a! and other agents on cell growth and differentiation, Ceramide is believed to act via activation of protein phosphatase, proline-directed protein kinase, or protein kinase C, Tumor necrosis factor alpha-induced common pathway of apoptosis is associated with am early impairment of mitochondria. Herein, we demonstrate that ceramide earn directly inhibit mitochondrial respiratory chain function, In isolated mitochondria, a rapid decline of mitochondrial oxidative phosphorylation occurs in the presence of N-acetylsphingosine (C-2-ceramide), a synthetic cell-permeable ceramide analog. An investigation of the Bite of ceramide action revealed that tbe activity of respiratory chain complex III is reduced by C-2-ceramide with half-maximum effect al 5-7 PM. in contrast, N-acetylsphinganine (C-2-dihydroceramide), which lacks a functionally critical double bond and is ineffective in cells, did not alter mitochondrial respiration or complex III activity. We suggest that these in vitro observations may set the stage for identifying a novel mechanism of regulation of mitochondrial function in vivo.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT NUTR,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Gudz, TI (corresponding author), VET AFFAIRS MED CTR,MED RES SERV,10701 EAST BLVD,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK036069, R01DK036069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012447] Funding Source: NIH RePORTER; NIA NIH HHS [AG12447] Funding Source: Medline; NIDDK NIH HHS [DK36069] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gudz T, 1997, ARCH BIOCHEM BIOPHYS, V342, P143, DOI 10.1006/abbi.1997.0113; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Gurevitch J, 1996, J AM COLL CARDIOL, V28, P247, DOI 10.1016/0735-1097(96)00105-2; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOPPEL C, 1979, J BIOL CHEM, V254, P4164; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; KRAHENBUHL S, 1994, CLIN CHIM ACTA, V230, P177, DOI 10.1016/0009-8981(94)90270-4; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LUI J, 1994, J BIOL CHEM, V269, P3047; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PALMER JW, 1977, J BIOL CHEM, V252, P8731; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROMANI A, 1991, J BIOL CHEM, V266, P24376; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; TAYLOR RW, 1994, J BIOL CHEM, V269, P3523; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211	33	349	353	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24154	24158		10.1074/jbc.272.39.24154	http://dx.doi.org/10.1074/jbc.272.39.24154			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305864	hybrid			2022-12-25	WOS:A1997XY51500015
J	Seyfang, A; Kavanaugh, MP; Landfear, SM				Seyfang, A; Kavanaugh, MP; Landfear, SM			Aspartate 19 and glutamate 121 are critical for transport function of the myo-inositol/H+ symporter from Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENTS; GLUCOSE-TRANSPORTER; ESCHERICHIA-COLI; MELIBIOSE PERMEASE; ACIDIC RESIDUES; EXPRESSION; BINDING; PROMASTIGOTES; MUTAGENESIS; FAMILY	The protozoan flagellate Leishmania donovani has an active myo-inositol/proton symporter (MIT), which is driven by a proton gradient across the parasite membrane. We have used site-directed mutagenesis in combination with functional expression of transporter mutants in Xenopus oocytes and overexpression in Leishmania transfectants to investigate the significance of acidic transmembrane residues for proton relay and inositol transport, MIT has only three charged amino acids within predicted transmembrane domains. Two of these residues, Asp(19) (TM1) and Glu(121) (TM4), appeared to be critical for transport function of MIT, with a reduction of inositol transport to about 2% of wild-type activity when mutated to the uncharged amides D19N or E121Q and 20% (D19E) or 4% (E121D) of wild-type activity for the conservative mutations that retained tare charge. Immunofluorescence microscopy oocyte cryosections showed that MIT mutants were expressed on the oocyte surface at a similar level as MIT wild type, confirming that these mutations that transport function and do not prevent trafficking of the transporter to the plasma membrane, The proton uncouplers carbonylcyanide-4-(trifluor omethoxy)phenylhydrazone and dinitrophenol inhibited inositol transport by 50-70% in the wild-type as well as in E121Q, despite its reduced transport activity. The mutant D19N, however, was stimulated about 4-fold by either protonophore and 2-fold bg cyanide or increase of pH 7.5 to 8.5 but inhibited at pH 6.5. The conservative mutant D19E, ire contrast, showed an inhibition profile similar to MIT wild type. We conclude that Asp(19) and Glu(121) are critical for myo-inositol transport, while the negatively charged carboxylate at Asp(19) may be important for proton coupling of MIT.	OREGON HLTH SCI UNIV, DEPT MOL MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			Seyfang, Andreas/H-2445-2012	Landfear, Scott/0000-0002-1643-6664; Seyfang, Andreas/0000-0001-6231-9955	NIAID NIH HHS [AI01162, AI25920] Funding Source: Medline; NIGMS NIH HHS [GM48709] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALVAR J, 1994, PARASITOL TODAY, V10, P160, DOI 10.1016/0169-4758(94)90270-4; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; DEGORGOLAS M, 1994, NATURE, V372, P734, DOI 10.1038/372734b0; DREW ME, 1995, MOL CELL BIOL, V15, P5508; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FERGUSON MAJ, 1994, PARASITOLOGY, V108, pS45, DOI 10.1017/S0031182000075715; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Henderson PJF, 1991, CURR OPIN STRUC BIOL, V1, P590, DOI 10.1016/S0959-440X(05)80082-X; HUTCHISON CA, 1991, METHOD ENZYMOL, V202, P356; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; KABACK R, 1992, MOL BIOL RECEPTORS T, P97; KEITHLY JS, 1976, J PROTOZOOL, V23, P244, DOI 10.1111/j.1550-7408.1976.tb03763.x; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; Lachaal M, 1996, J BIOL CHEM, V271, P5225; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; LANGFORD CK, 1992, MOL BIOCHEM PARASIT, V55, P51, DOI 10.1016/0166-6851(92)90126-5; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; POURCHER T, 1993, J BIOL CHEM, V268, P3209; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TITUS DE, 1991, PROMEGA PROTOCOLS AP, P98; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wu JH, 1996, BIOCHEMISTRY-US, V35, P5213, DOI 10.1021/bi960064f; ZANI ML, 1993, J BIOL CHEM, V268, P3216; Zar JH, 1984, BIOSTAT ANAL, P150; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013	42	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24210	24215		10.1074/jbc.272.39.24210	http://dx.doi.org/10.1074/jbc.272.39.24210			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305873	hybrid			2022-12-25	WOS:A1997XY51500024
J	DeCesare, D; Palazzolo, M; Berthelsen, J; Blasi, F				DeCesare, D; Palazzolo, M; Berthelsen, J; Blasi, F			Characterization of UEF-4, a DNA-binding protein required for transcriptional synergism between two AP-1 sites in the human urokinase enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR GENE; COLONY-STIMULATING FACTOR; PHORBOL ESTER INDUCTION; REGULATORY ELEMENT; RNA-POLYMERASE; C-JUN; EXPRESSION; MOUSE; INTERLEUKIN-3; PROMOTERS	The enhancer of the inducible urokinase gene depends on three essential but not sufficient transactivating elements, an upstream PEA3/AP-1A and a downstream AP-1B site. Enhancer activity also requires the interposed 74-base pair-long cooperation mediator (COM) region that allows transcriptional synergism between the transactivating sites. The 5'-half of COM (uCOM) forms four retarded complexes with HeLa or Hep-G2 nuclear proteins (UEF-1-4). We have identified the binding sequence for UEF-4 and generated uCOM elements uniquely mutated in the UEF-4-binding site or uniquely binding UEF-4. Introduction of these and other mutations in the context of the urokinase enhancer showed that all uCOM sites are important for enhancer activity but that UEF-4 and UEF-1 plus UEF-2/3 can substitute for each other, suggesting functional redundancy of urokinase enhancer factors. UEF-4 was purified from HeLa nuclear extract by affinity chromatography and shown to contain two polypeptides of 105 and 65 kDa, respectively, of which at least the former was endowed with DNA binding activity.	HS RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICROORGANISMI,MILAN,ITALY	University of Milan				Blasi, Francesco/0000-0001-9406-1784				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; BLASI F, 1994, FIBRINOLYSIS, V8, P182, DOI 10.1016/0268-9499(94)90716-1; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DECESARE D, 1995, ONCOGENE, V11, P365; DeCesare D, 1996, ONCOGENE, V13, P2551; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LU QA, 1995, MOL CELL BIOL, V15, P3786; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Sambrook J., 2002, MOL CLONING LAB MANU; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Teesalu T, 1996, MECH DEVELOP, V56, P103, DOI 10.1016/0925-4773(96)00515-1; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WIGLER M, 1976, NATURE, V259, P232, DOI 10.1038/259232a0	33	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23921	23929		10.1074/jbc.272.38.23921	http://dx.doi.org/10.1074/jbc.272.38.23921			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295342	hybrid			2022-12-25	WOS:A1997XX38100067
J	Mitsuda, N; Roses, AD; Vitek, MP				Mitsuda, N; Roses, AD; Vitek, MP			Transcriptional regulation of the mouse presenilin-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; SYNAPSIN-II GENE; APOLIPOPROTEIN-E; DISTINCT PROMOTERS; TYPE-4 ALLELE; MUTATIONS; PROTEIN; EXPRESSION; DIFFERENTIATION; BINDING	The presenilin-1 (PS-1) gene encodes at least three separate mRNA transcripts from its 12 exons, which are spread over 50 kilobase pairs of mouse DNA. The first transcript begins with exon 1A, whereas the other transcripts begin with exon 1B. Different portions of exon 1B are spliced to give long and short mRNAs. The expression of all of these transcripts depends on a single promoter located just upstream of exon 1A. Although this region lacks a TATA box and a number of common initiator sequences, it does contain a CAAT box, a heat-shock responsive element, a polyomavirus enhancer activator-3 site, an Ets 1-3 site, and multiple-Sp1 and multiple-Ap2 binding sites, which are typically found in eukaryotic promoters. We have combined a reporter gene with various portions of this putative PS-1 promoter and measured firefly luciferase activity relative to an internal renilla luciferase standard. We identified a 25-base pair fragment spanning the 5'-transcription start site of exon 1A as containing the core of the promoter activity. The sequences downstream of this region had undetectable promoter activity, suggesting that this core element is the gene's only promoter, and it controls expression of all three transcripts. Although human PS-1 mRNA expression is clearly different from the mouse PS-1 mRNA pattern, the human and mouse core promoters do share limited homology.	DUKE UNIV,MED CTR,DIV NEUROL,DURHAM,NC 27710; GLAXO WELLCOME INC,DEPT MOL PHARMACOL,RES TRIANGLE PK,NC 27709	Duke University; GlaxoSmithKline				Vitek, Michael/0000-0001-8140-8048	NATIONAL INSTITUTE ON AGING [R01AG013839] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG-13839] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERT VR, 1992, P NATL ACAD SCI USA, V89, P12053, DOI 10.1073/pnas.89.24.12053; *ALZH DIS COLL GRO, 1995, NAT GENET, V11, P219; Boteva K, 1996, LANCET, V347, P130, DOI 10.1016/S0140-6736(96)90261-5; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FISHER RJ, 1991, ONCOGENE, V6, P2249; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; Kamino K, 1996, NEUROSCI LETT, V208, P195, DOI 10.1016/0304-3940(96)12587-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 1997, J NEUROSCI, V17, P1971; LEINGARTNER A, 1994, EUR J NEUROSCI, V6, P1149, DOI 10.1111/j.1460-9568.1994.tb00613.x; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; PerezTur J, 1995, NEUROREPORT, V7, P297; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; Rossor MN, 1996, LANCET, V347, P1560, DOI 10.1016/S0140-6736(96)90715-1; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P775, DOI 10.1001/jama.277.10.775; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TENHUNEN J, 1994, EUR J BIOCHEM, V223, P1049, DOI 10.1111/j.1432-1033.1994.tb19083.x; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a	30	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23489	23497		10.1074/jbc.272.38.23489	http://dx.doi.org/10.1074/jbc.272.38.23489			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295283	hybrid			2022-12-25	WOS:A1997XX38100008
J	Poluha, W; Schonhoff, CM; Harrington, KS; Lachyankar, MB; Crosbie, NE; Bulseco, DA; Ross, AH				Poluha, W; Schonhoff, CM; Harrington, KS; Lachyankar, MB; Crosbie, NE; Bulseco, DA; Ross, AH			A novel, nerve growth factor-activated pathway involving nitric oxide, p53, and p21(WAF1) regulates neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; INDUCED APOPTOSIS; NADPH DIAPHORASE; HUMAN NEUROBLASTOMA; FACTOR INCREASES; GENE-EXPRESSION; CANCER-CELLS; WILD-TYPE; INDUCTION	During development, neuronal differentiation is closely coupled with cessation of proliferation. We use nerve growth factor (NGF)-induced differentiation of PC12 pheochromocytoma cells as a model and find a novel signal transduction pathway that blocks cell proliferation, Treatment of PC12 cells with. NGF leads to induction of nitric oxide synthase (NOS) (Peunova, N., and Enikolopov, G. (1995) Nature 375, 68-73). The result ing nitric oxide (NO) acts as a second messenger, activating the p21(WAF1) promoter and inducing expression of p21(WAF1) cyclin-dependent kinase inhibitor. NO activates the p21(WAF1) promoter by p53-dependent and p53-independent mechanisms. Blocking production of NO with an inhibitor of NOS reduces accumulation of p53, activation of the p21(WAF1) promoter, expression of neuronal markers, and neurite extension. To determine whether p21(WAF1) is required for neurite extension, we prepared a PC12 line with an inducible p21(WAF1) expression vector. Blocking NOS with an inhibitor decreases neurite extension, but induction of p21(WAF1) with isopropyl-1-thio-beta-D-galactopyranoside restored this response, Levels of p21(WAF1) induced by isopropyl-1-thio-beta-D-galactopyranoside were similar to those induced by NGF. Therefore, we have identified a signal transduction pathway that is activated by NGF; proceeds through NOS, p53, and p21(WAF1) to block cell proliferation; and is required for neuronal differentiation by PC12 cells.	WORCESTER FDN EXPT BIOL INC, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028760, R01NS021716] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-07366, NS-28760, NS-21716] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bevington PR, 1992, DATA REDUCTION ERROR; Billon N, 1996, ONCOGENE, V13, P2047; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Flodstrom M, 1996, FEBS LETT, V385, P4, DOI 10.1016/0014-5793(96)00337-7; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; Gotz C, 1996, ONCOGENE, V13, P391; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAINAUT P, 1993, CANCER RES, V53, P4469; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HENDERSON LP, 1994, J NEUROSCI, V14, P1153, DOI 10.1523/JNEUROSCI.14-03-01153.1994; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Holtzman DM, 1996, NEUROCHEM RES, V21, P861, DOI 10.1007/BF02532310; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; Ientile R, 1996, FEBS LETT, V379, P82, DOI 10.1016/0014-5793(95)01490-X; JIANG HP, 1994, ONCOGENE, V9, P3397; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOGNER P, 1993, CANCER RES, V53, P2044; KOMURO H, 1993, CANCER RES, V53, P5284; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LAASBERG T, 1988, FEBS LETT, V239, P367, DOI 10.1016/0014-5793(88)80953-0; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; LUCA FC, 1986, P NATL ACAD SCI USA, V83, P1006, DOI 10.1073/pnas.83.4.1006; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, FEBS LETT, V384, P162; Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MESSMER UK, 1994, FEBS LETT, V355, P23; MICHIELI P, 1994, CANCER RES, V54, P3391; MIZUKAWA K, 1989, J COMP NEUROL, V279, P281, DOI 10.1002/cne.902790210; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Ockel M, 1996, DEVELOPMENT, V122, P301; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TOHYAMA T, 1991, J COMP NEUROL, V310, P285, DOI 10.1002/cne.903100302; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; VOGAN K, 1993, CANCER RES, V53, P5269; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE QW, 1994, J BIOL CHEM, V269, P4705; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	79	136	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24002	24007		10.1074/jbc.272.38.24002	http://dx.doi.org/10.1074/jbc.272.38.24002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295352	hybrid			2022-12-25	WOS:A1997XX38100077
J	Wilkinson, JR; Towle, HC				Wilkinson, JR; Towle, HC			Identification and characterization of the AF-1 transactivation domain of thyroid hormone receptor beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION FUNCTIONS; RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; V-ERBA; CO-REPRESSOR; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR	Physiological responses to thyroid hormones are regulated by a set of nuclear receptors (TRs) related to the steroid receptor superfamily of ligand-dependent transcription factors. Although TR isoforms are highly conserved in their DNA binding, ligand binding, and carboxyl-terminal transactivation domains, their aminoterminal regions are completely divergent. We examined the contribution of these amino-terminal sequences to TR beta 1 function. An amino-terminally truncated version of rat TR beta 1 lacking amino acids 4-89 was impaired in hormone-dependent activation in both yeast and mammalian cells. This defect was not due to impairment of DNA binding, because the truncated receptor displayed enhanced homodimer binding on several different TREs, indicating that residues in the amino-terminal domain of TR beta 1 interfere with homodimerization of the receptor. The presence of an autonomous transactivation domain in the amino-terminal region was demonstrated by its ability to activate transcription in a constitutive manner when fused to the GAL4 DNA binding domain, Deletional analyses localized the residues comprising the amino-terminal transactivation region of TR beta 1 to 19 amino acids residing between residues 69 and 89. Thus, the amino-terminal region of TR beta 1 contains an activation domain (AF-1) that call modulate the function of the receptor and may allow for the fine-tuning of receptor activity in various target tissues.	UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007323] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39997] Funding Source: Medline; NIGMS NIH HHS [5T32-GM07323] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1986, MOL CELL BIOL, V6, P3685, DOI 10.1128/MCB.6.11.3685; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; LEE Y, 1993, J BIOL CHEM, V268, P2021; LIN KH, 1990, J BIOL CHEM, V265, P5161; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OHASHI H, 1991, BIOCHEM BIOPH RES CO, V178, P1167, DOI 10.1016/0006-291X(91)91015-5; ONATE SA, 1995, SCIENCE, V270, P1354; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; QI JS, 1995, MOL CELL BIOL, V15, P1817; Rahman A, 1995, J BIOL CHEM, V270, P31059, DOI 10.1074/jbc.270.52.31059; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; TOMURA H, 1995, P NATL ACAD SCI USA, V92, P5600, DOI 10.1073/pnas.92.12.5600; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	66	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23824	23832		10.1074/jbc.272.38.23824	http://dx.doi.org/10.1074/jbc.272.38.23824			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295330	hybrid			2022-12-25	WOS:A1997XX38100055
J	Nigou, J; Gilleron, M; Cahuzac, B; Bounery, JD; Herold, M; Thurnher, M; Puzo, G				Nigou, J; Gilleron, M; Cahuzac, B; Bounery, JD; Herold, M; Thurnher, M; Puzo, G			The phosphatidyl-myo-inositol anchor of the lipoarabinomannans from Mycobacterium bovis bacillus Calmette Guerin - Heterogeneity, structure, and role in the regulation of cytokine secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MACROPHAGES; TUBERCULOSIS; STRAINS; SPECTROSCOPY; VIRULENT; PROTEINS; BCG; PERSISTENCE	Lipoarabinomannans are major mycobacterial antigens capable of modulating the host immune response; however, the molecular basis underlying the diversity of their immunological properties remain an open question. In this study a new extraction and purification approach was successfully applied to isolate ManLAMs (lipoarabinomannans with mannosyl extensions) from bacillus Calmette Guerin leading to the obtention of two types of ManLAMs namely parietal and cellular, Structurally, they were found to differ by the percentage of mannooligosaccharide caps, 76 and 48%, respectively, and also, thanks to a new analytical method, by the structure of the phasphatidyl-myo-inositol anchor lipid moiety, A novel fatty acid in the mycobacterium genus assigned to a 12-O-(methoxypropanoyl)-12-hydroxystearic acid was the only fatty acid esterifying C-1 of the glycerol residue of the parietal ManLAMs, while the phosphatidyl unit of the cellular ManLAMs showed a large heterogeneity due to a combination of palmitic and tuberculostearic acid. Finally, parietal and cellular ManLAMs were found to differentially affect interleukin-8 and tumor necrosis factor-alpha secretion from human dendritic cells. We show that parietal but not cellular ManLAMs were able to stimulate tumor necrosis factor-alpha secretion from dendritic cells, From these studies we propose that the 1-[12-O-(methoxypropanoyl)-12-hydroxystearoyl]-sn-glycerol part is the major cytokine-regulating component of the ManLAMs, It seems likely that modification of the ManLAM Lipid part, which may occur in hostile environments, could regulate macrophagic mycobacterial survival by altering cytokine stimulation.	CNRS, INST PHARMACOL & BIOL STRUCT, F-31062 TOULOUSE, FRANCE; UNIV INNSBRUCK, DEPT UROL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Innsbruck; University of Innsbruck			Nigou, Jérôme/D-6802-2019; Thurnher, Martin/AAD-5922-2020	Nigou, Jérôme/0000-0002-6233-2487; Thurnher, Martin/0000-0001-9940-7326; GILLERON, Martine/0000-0002-2581-3302				ADAM O, 1995, ANAL BIOCHEM, V225, P321, DOI 10.1006/abio.1995.1161; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Britton Warwick J., 1994, Trends in Microbiology, V2, P284, DOI 10.1016/0966-842X(94)90005-1; BUDZIKIE.H, 1973, Z NATURFORSCH C, VC 28, P499; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DELMAS C, 1997, IN PRESS GLYCOBIOLOG, V7; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; FINE PEM, 1989, REV INFECT DIS, V11, pS353; Gilleron M, 1997, J BIOL CHEM, V272, P117; GLUSHKA J, 1992, BIOCHEMISTRY-US, V31, P10741, DOI 10.1021/bi00159a014; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Guttman A, 1996, ANAL BIOCHEM, V233, P234, DOI 10.1006/abio.1996.0034; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MUHLRADT PF, 1977, EUR J BIOCHEM, V81, P193, DOI 10.1111/j.1432-1033.1977.tb11941.x; ROACH TIA, 1993, J IMMUNOL, V150, P1886; ROCHE PW, 1995, TRENDS MICROBIOL, V3, P397, DOI 10.1016/S0966-842X(00)88986-6; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SCHNITGER H, 1959, BIOCHEM Z, V332, P167; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SWEET DP, 1975, CARBOHYD RES, V40, P967; Thurnher M, 1997, INT J CANCER, V70, P128; VENISSE A, 1993, J BIOL CHEM, V268, P12401; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012; WANG Y, 1995, ANAL BIOCHEM, V225, P242, DOI 10.1006/abio.1995.1149; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702	38	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23094	23103		10.1074/jbc.272.37.23094	http://dx.doi.org/10.1074/jbc.272.37.23094			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287310	hybrid			2022-12-25	WOS:A1997XV74400021
J	Alvarez, L; SanchezGongora, E; Mingorance, J; Pajares, MA; Mato, JM				Alvarez, L; SanchezGongora, E; Mingorance, J; Pajares, MA; Mato, JM			Characterization of rat liver-specific methionine adenosyltransferase gene promoter - Role of distal upstream cis-acting elements in the regulation of the transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; ADENOSYL-L-METHIONINE; NUCLEAR FACTOR-III; HEPATOMA-CELLS; BINDING-PROTEIN; MESSENGER-RNA; DNA METHYLATION; EXPRESSION; ENHANCER; ACTIVATION	Methionine adenosyltransferase is a ubiquitous enzyme that catalyzes the only known route of biosynthesis of S-adenosylmethionine, the major methyl group donor in cell metabolism, In mammals, two different methionine adenosyltransferases exist: one is confined to the liver, and the other one is distributed in extrahepatic tissues, In the present study, we report the cloning of the 5'-flanking region of liver-specific methionine adenosyltransferase gene from rat. Two closely spaced sites for transcriptional initiation were identified by primer extension analysis, The major transcription start site was determined to be 29 nucleotides downstream from the putative TATA box, Transient transfection assays of constructs containing sequentially deleted 5'-flanking sequences fused to the luciferase gene showed that rat hepatic methionine adenosyltransferase promoter was able to efficiently drive reporter expression not only in liver-type cells (rat hepatoma H35 cells and human hepatoblastoma HepG2 cells) but also in Chinese hamster ovary cells, Two regions spanning nucleotides -1251 to -958 and -197 to +65 were found to be crucial for the promoter efficiency, The distal upstream region contains elements that positively regulate promoter activity in H35 and HepG2 cells but are ineffective in Chinese hamster ovary cells, Eight protein binding sites were characterized in both regions by DNase I footprinting analysis, Two of these elements, sites A and B, located in the distal region, were found to be essential for the regulation of promoter activity, Electrophoretic mobility shift assays and competition experiments showed that site A is recognized by an NF1 protein. Site B was able to interact with a member of HNF-3 family when nuclear extracts from rat liver and H35 cells were used in the in vitro assay, but an additional binding activity to an NHF1-like protein was obtained with the hepatoma cell extracts, It is suggested that this differential binding can contribute to the cell specificity of promoter function.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Mingorance, Jesus/B-7562-2009; MATO, JOSE/A-5187-2011; Pajares, Maria Angeles/I-5952-2012	Mingorance, Jesus/0000-0001-6173-5711; MATO, JOSE/0000-0003-1264-3153; Pajares, Maria Angeles/0000-0002-4714-9051				ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ALVAREZ L, 1994, BIOCHEM J, V301, P557, DOI 10.1042/bj3010557; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Arenzana N, 1996, J IMMUNOL, V156, P168; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Avila MA, 1997, HEPATOLOGY, V25, P391; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; Cai JX, 1996, HEPATOLOGY, V24, P1090; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHAWLA RK, 1994, BBA-GEN SUBJECTS, V1199, P45, DOI 10.1016/0304-4165(94)90094-9; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; Gil B, 1997, ENDOCRINOLOGY, V138, P1251, DOI 10.1210/en.138.3.1251; Gil B, 1996, HEPATOLOGY, V24, P876; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Kotb M, 1997, TRENDS GENET, V13, P51; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato Jose M., 1994, P461; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; Sambrook J., 2002, MOL CLONING LAB MANU; SanchezGongora E, 1996, BIOCHEM J, V319, P767, DOI 10.1042/bj3190767; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VALLET V, 1995, MOL CELL BIOL, V15, P5453; WU GD, 1994, J BIOL CHEM, V269, P17080; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; Zaret Kenneth S., 1994, P53	60	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22875	22883		10.1074/jbc.272.36.22875	http://dx.doi.org/10.1074/jbc.272.36.22875			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278450	Green Published, hybrid			2022-12-25	WOS:A1997XV49200071
J	Bonday, ZQ; Taketani, S; Gupta, PD; Padmanaban, G				Bonday, ZQ; Taketani, S; Gupta, PD; Padmanaban, G			Heme biosynthesis by the malarial parasite - Import of delta-aminolevulinate dehydrase from the host red cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; ERYTHROLEUKEMIA-CELLS; ACID DEHYDRATASE; IDENTIFICATION; ERYTHROCYTES; TRANSPORT	The mouse and human malarial parasites, Plasmodium berghei and Plasmodium falciparum, respectively, synthesize heme de novo following the standard pathway observed in animals despite the availability of large amounts of heme, derived from red cell hemoglobin, which is stored as hemozoin pigment, The enzymes, delta-aminolevulinate dehydrase (ALAD), coproporphyrinogen oxidase, and ferrochelatase are present at strikingly high levels in the P, berghei infected mouse red cell in vivo, The isolated parasite has low levels of ALAD and the data clearly indicate it to be of red cell origin. The purified enzyme preparations from the uninfected red cell and the parasite are identical in kinetic properties, subunit molecular weight, cross-reaction with antibodies to the human enzyme, and N-terminal amino acid sequence. Immunogold electron microscopy of the infected culture indicates that the enzyme is present inside the parasite and, therefore, is not a contaminant, The parasite derives functional ALAD from the host and the enzyme binds specifically to isolated parasite membrane in vitro, suggestive of the involvement of a receptor in its translocation into the parasite, While, ALAD, coproporphyrinogen oxidase, and ferrochelatase from the parasite and the uninfected red cell supernatant have identical subunit molecular weights on SDS-polyacrylamide gel electrophoresis and show immunological cross-reaction with antibodies to the human enzymes, as revealed by Western analysis, the first enzyme of the pathway, namely, delta-aminolevulinate synthase (ALAS) in the parasite, unlike that of the red cell host, does not cross-react with antibodies to the human enzyme, However, ALAS enzyme activity in the parasite is higher than that of the infected red cell supernatant. We therefore conclude that the parasite, while making its own ALAS, imports ALAD and perhaps most of the other enzymes of the pathway from the host to synthesize heme de novo, and this would enable it to segregate this heme from the heme derived from red cell hemoglobin degradation, ALAS of the parasite and the receptor(s) involved in the translocation of the host enzymes into the parasite would be unique drug targets.	KANSAI MED UNIV,OSAKA 570,JAPAN; CTR CELLULAR & MOL BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA; JAWAHARLAL NEHRU CTR ADV SCI RES,BANGALORE 560064,KARNATAKA,INDIA	Kansai Medical University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Bonday, ZQ (corresponding author), INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA.							ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; BECUWE P, 1996, MOL BIOCHEM PARASIT, V76, P124; BHAT GJ, 1988, ARCH BIOCHEM BIOPHYS, V264, P584, DOI 10.1016/0003-9861(88)90324-4; BOESE QF, 1991, J BIOL CHEM, V266, P17060; Burnham B.F., 1970, METHOD ENZYMOL, V17, P195, DOI DOI 10.1016/0076-6879(71)17179-0; DAILEY HA, 1977, J BACTERIOL, V129, P815, DOI 10.1128/JB.129.2.815-820.1977; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; ELFORD BC, 1995, BIOCHEM J, V308, P361, DOI 10.1042/bj3080361; FAIRFIELD AS, 1983, SCIENCE, V221, P764, DOI 10.1126/science.6348944; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FRY M, 1991, PARASITOLOGY, V102, P17, DOI 10.1017/S0031182000060297; GARDNER LC, 1991, J BIOL CHEM, V266, P22010; GAUGHAN PLZ, 1971, COMP BIOCHEM PHYSIOL, V39, P5, DOI 10.1016/0305-0491(71)90247-1; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; LEVIN W, 1983, DRUG METAB DISPOS, V1, P267; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; LWOFF M, 1951, BIOCH PHYSL PROTOZOA, P131; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; SALGANIK RI, 1987, B WORLD HEALTH ORGAN, V65, P381; SALZMAN TA, 1982, COMP BIOCHEM PHYS B, V72, P663, DOI 10.1016/0305-0491(82)90523-5; Scheibel L. W., 1988, Malaria: principles and practice of malariology. Volume 1., P219; SHAHABUDDIN M, 1992, EXP PARASITOL, V74, P11, DOI 10.1016/0014-4894(92)90134-V; Sullivan AD, 1996, PARASITOL TODAY, V12, P161, DOI 10.1016/0169-4758(96)40001-1; SUROLIA N, 1992, BIOCHEM BIOPH RES CO, V187, P744, DOI 10.1016/0006-291X(92)91258-R; SUROLIA N, 1991, P NATL ACAD SCI USA, V88, P4786, DOI 10.1073/pnas.88.11.4786; TAKETANI S, 1994, J BIOL CHEM, V269, P7527; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; Wilson CM, 1996, MOL BIOCHEM PARASIT, V79, P135, DOI 10.1016/0166-6851(96)02690-4	29	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21839	21846		10.1074/jbc.272.35.21839	http://dx.doi.org/10.1074/jbc.272.35.21839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268315	hybrid			2022-12-25	WOS:A1997XT85000027
J	Hamer, I; Haft, CR; Paccaud, JP; Maeder, C; Taylor, S; Carpentier, JL				Hamer, I; Haft, CR; Paccaud, JP; Maeder, C; Taylor, S; Carpentier, JL			Dual role of a dileucine motif in insulin receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DI-LEUCINE MOTIF; DENSITY-LIPOPROTEIN RECEPTOR; TYROSINE KINASE-ACTIVITY; INTERNALIZATION SIGNALS; TRANSMEMBRANE DOMAIN; MEDIATED INTERNALIZATION; JUXTAMEMBRANE REGION; DOWN-REGULATION; BETA-SUBUNIT	Two leucines (Leu(986) and Leu(987)) have recently been shown to take part in the control of human insulin receptor (HIR) internalization (Renfrew-Haft, C,, Klausner, R, D,, and Taylor, S, I, (1994) J, Biol, Chem, 269, 26286-26294), The aim of the present study was to further investigate the exact mechanism of this control process, Constitutive and insulin-induced HIR internalizations were studied biochemically and morphologically in NIH 3T3 cells overexpressing either a double alanine (amino acid residues 986-987) mutant NIR (HIR AA1) or HIR truncated at either amino acid residue 981 (HIR Delta 981) or 1000 (HIR Delta 1000). Data collected indicate that: (a) the three mutant HIR show a reduced association with microvilli as compared with HIR wild-type; (b) the two receptors containing the dileucine motif (HIR WT and HIR Delta 1000) show the highest propensity to associate with clathrin-coated pits, independently of kinase activation; (c) the two receptors lacking the dileucine motif but containing two tyrosine-based motifs, previously described as participating in clathrin-coated pit segregation, associate with these surface domains with a lower affinity than the two others, (d) in the presence of the kinase domain, an unmasking of the tyrosine-based motifs mediated by kinase activation is required. These results indicate that the dileucine motif is not sufficient by itself, but participates in anchoring HIR on microvilli and that another sequence, located downstream from position 1000 is crucial for this event, This dileucine motif also plays a role in HIR segregation in clathrin-coated pits, This latter function is additive with that of the tyrosine-based motifs but the role of the dileucine motif predominates, Eventually, the clathrin-coated pit anchoring function of the dileucine motif is independent of receptor kinase activation in contrast to the tyrosine-based motifs.	CMU,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND; NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892	University of Geneva; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1985, J CELL BIOL, V101, P887, DOI 10.1083/jcb.101.3.887; CARPENTIER JL, 1994, DIABETOLOGIA, V37, pS117, DOI 10.1007/BF00400835; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CARPENTIER JL, 1993, J CELL BIOL, V118, P831; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FAN JY, 1982, P NATL ACAD SCI-BIOL, V79, P7788, DOI 10.1073/pnas.79.24.7788; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HAFT CR, 1994, BIOCHEMISTRY-US, V33, P9143, DOI 10.1021/bi00197a017; HAFT CR, 1995, BIOCHEMISTRY-US, V34, P15880; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; MORI S, 1994, J BIOL CHEM, V269, P4917; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PACCAUD JP, 1993, J BIOL CHEM, V268, P23191; PACCAUD JP, 1992, J BIOL CHEM, V267, P13101; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; THIES RS, 1990, J BIOL CHEM, V265, P10132; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; YAMADA K, 1995, BIOCHEMISTRY-US, V34, P946, DOI 10.1021/bi00003a029; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115	48	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21685	21691		10.1074/jbc.272.35.21685	http://dx.doi.org/10.1074/jbc.272.35.21685			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268295	hybrid			2022-12-25	WOS:A1997XT85000007
J	Payne, MA; Igo, JD; Cao, ZH; Foster, SB; Newton, SMC; Klebba, PE				Payne, MA; Igo, JD; Cao, ZH; Foster, SB; Newton, SMC; Klebba, PE			Biphasic binding kinetics between FepA and its ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC ENTEROBACTIN RECEPTOR; ESCHERICHIA-COLI K-12; OUTER-MEMBRANE RECEPTOR; TRITON X-100; GROUP-B; ENTEROCHELIN; TRANSPORT; PROTEIN; SYSTEM; SPECIFICITY	The Escherichia coli FepA protein is an energy-and TonB dependent, ligand-binding porin that functions as a receptor for the siderophore ferric enterobactin and colicins B and D, We characterized the kinetic and thermodynamic parameters associated with the initial, energy-independent steps in ligand binding to FepA. In vivo experiments produced K-d values of 24, 185, and 560 nM for ferric enterobactin, colicin B, and colicin D, respectively, The siderophore and colicin B bound to FepA with a 1:1 stoichiometry, but colicin D bound to a maximum level that was 3-fold lower, Preincubation with ferric enterobactin prevented colicin B binding, and preincubation with colicin B prevented ferric enterobactin binding, Colicin B release from FepA was unexpectedly slow in vivo, about 10-fold slower than ferric enterobactin release, This slow dissociation of the coli cin B . FepA complex facilitated the affinity purification of FepA and FepA mutants with colicin B-Sepharose. Analysis of a fluorescent FepA derivative showed that ferric enterobactin and colicin B adsorbed with biphasic kinetics, suggesting that both ligands bind in at least two distinct steps, an initial rapid stage and a subsequent slower step, that presumably establishes a transport-competent complex.	UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019; UNIV SAO PAULO,DEPT MICROBIOL,BR-08805900 SAO PAULO,BRAZIL	University of Oklahoma System; University of Oklahoma - Norman; Universidade de Sao Paulo					NCRR NIH HHS [RR1182] Funding Source: Medline; NIGMS NIH HHS [GM53836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053836] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; BENEDETTI H, 1991, J MOL BIOL, V217, P429, DOI 10.1016/0022-2836(91)90747-T; CARBONETTI NH, 1984, INFECT IMMUN, V46, P7, DOI 10.1128/IAI.46.1.7-12.1984; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; DIMASI DR, 1973, J BACTERIOL, V115, P514; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FISS EH, 1982, BIOCHEMISTRY-US, V21, P4517, DOI 10.1021/bi00261a050; GUTERMAN SK, 1973, J BACTERIOL, V114, P1217, DOI 10.1128/JB.114.3.1217-1224.1973; GUTERMAN SK, 1971, BIOCHEM BIOPH RES CO, V44, P1149, DOI 10.1016/S0006-291X(71)80206-1; GUTERMAN SK, 1973, J BACTERIOL, V114, P1225, DOI 10.1128/JB.114.3.1225-1230.1973; HOLLIFIELD WC, 1978, BIOCHEMISTRY-US, V17, P1922, DOI 10.1021/bi00603a019; JEANTEUR D, 1994, P NATL ACAD SCI USA, V91, P10675, DOI 10.1073/pnas.91.22.10675; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; KLUG CS, 1995, BIOCHEMISTRY-US, V34, P14230, DOI 10.1021/bi00043a030; LAZDUNSKI CJ, 1995, MOL MICROBIOL, V16, P1059, DOI 10.1111/j.1365-2958.1995.tb02331.x; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; LIU J, 1994, BIOCHEMISTRY-US, V33, P13274, DOI 10.1021/bi00249a014; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDE J, 1990, MOL MICROBIOL, V4, P1523, DOI 10.1111/j.1365-2958.1990.tb02063.x; Mishell B.B., 1980, SELECTED METHODS CEL; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; Newton SMC, 1997, P NATL ACAD SCI USA, V94, P4560, DOI 10.1073/pnas.94.9.4560; OUDEGA B, 1979, J BACTERIOL, V138, P7, DOI 10.1128/JB.138.1.7-16.1979; PUGSLEY AP, 1977, ANTIMICROB AGENTS CH, V11, P345, DOI 10.1128/AAC.11.2.345; PUGSLEY AP, 1976, J BACTERIOL, V127, P218, DOI 10.1128/JB.127.1.218-228.1976; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; RUTZ JM, 1991, J BACTERIOL, V173, P5964, DOI 10.1128/jb.173.19.5964-5974.1991; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHNAITMAN CA, 1971, J BACTERIOL, V108, P553, DOI 10.1128/JB.108.1.553-563.1971; TIMMIS K, 1972, J BACTERIOL, V109, P12, DOI 10.1128/JB.109.1.12-20.1972; WANG CC, 1971, J BIOL CHEM, V246, P2147; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WAYNE R, 1975, J BACTERIOL, V121, P497, DOI 10.1128/JB.121.2.497-503.1975; WAYNE R, 1976, J BACTERIOL, V126, P7, DOI 10.1128/JB.126.1.7-12.1976; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WIENER M, 1997, NATURE, V385, P390	39	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21950	21955		10.1074/jbc.272.35.21950	http://dx.doi.org/10.1074/jbc.272.35.21950			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268330	hybrid			2022-12-25	WOS:A1997XT85000042
J	Sheikh, MS; Carrier, F; Johnson, AC; Ogdon, SE; Fornace, AJ				Sheikh, MS; Carrier, F; Johnson, AC; Ogdon, SE; Fornace, AJ			Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor	ONCOGENE			English	Article						p53; EGF-R promotor; transactivation	TUMOR-SUPPRESSOR PROTEIN; HUMAN BREAST-CARCINOMA; DNA-BINDING FUNCTION; WILD-TYPE P53; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; CELLS; EXPRESSION; RADIATION; ACTIVATION	Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-deficient Saos2 osteosarcoma cells. A p53 binding site residing at position -265/-239 in the EGF-R proximal promoter has also been identified. We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status. Wild-type and mutant p53(Ala143) enhanced the EGF-R core promotor activity in cells that were either p53-deficient or contained wild-type or mutant endogenous p53. Upon further characterization of the various deletion fragments of the EGF-R promoter, we identified a wild-type p53 responsive 62 bp region residing at position -167/-105. The -167/-105 segment was responsive only to wild-type p53 but not to mutant p53(Ala143) Or p53(His273). The -167/-105 segment of the EGF-R promotor contains one perfect and several imperfect consensus p53-binding half sites; indeed in gel shift experiments the 62 bp -167/-105 segment as well as the oligonucleotides corresponding to two p53 consensus half-sites within the 62 bp fragment, exhibited binding to p53-containing protein complexes. Thus, we have identified an additional wild-type p53 responsive site in the human EGF-R promoter. This site containing consensus p53-binding sequences resides at position -167/-105 and is proximal to recently identified p53 binding element located at position -265/-239 in the EGF-R promotor.	NCI, MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sheikh, MS (corresponding author), NCI, MOL PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA.		Carrier, France/C-3063-2008; Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Carrier, France/0000-0002-5517-5284				ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY C, 1993, NAT GENET, V4, P42; FISCELLA M, 1994, ONCOGENE, V9, P3249; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hollander M. C., 1995, DNA REPAIR MECH IMPA, P221; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JOHNSON GL, 1994, SCIENCE, V266, P1719; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANTON JB, 1986, CANCER RES, V46, P4701; SCHMIDTULLRICH RK, 1994, INT J RADIAT ONCOL, V29, P813, DOI 10.1016/0360-3016(94)90570-3; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; STOSCHECK CM, 1986, CANCER RES, V46, P1030; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WARMUTH I, 1994, CANCER RES, V54, P374; WEINMANN R, 1992, P NATL ACAD SCI USA, V89, P12028; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1994, ONCOGENE, V9, P3743	56	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1095	1101		10.1038/sj.onc.1201264	http://dx.doi.org/10.1038/sj.onc.1201264			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285564				2022-12-25	WOS:A1997XT16100011
J	Magae, J; Illenye, S; Tejima, T; Chang, YC; Mitsui, Y; Tanaka, K; Omura, S; Heintz, NH				Magae, J; Illenye, S; Tejima, T; Chang, YC; Mitsui, Y; Tanaka, K; Omura, S; Heintz, NH			Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystin	ONCOGENE			English	Article						E2F/DP; transcription; p53	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; TATA-BINDING PROTEIN; S-PHASE ENTRY; IN-VIVO; CELL-CYCLE; ACTIVATING MUTATIONS; APOPTOSIS; FAMILY; REPRESSION	The transcription factors p53 and E2F-1 play important roles in the control of cell cycle progression. In transient transfection experiments, expression of E2F-1, other E2F family members, or p53 squelched transcription from cotransfected plasmids in a dose-dependent manner, Although the proteasome inhibitors MG-132 and lactacystin markedly increased the level of expression of E2F-1 and p53, these inhibitors completely alleviated squelching by both proteins, Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1 MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107, The protease inhibitors ALLN and ALLM did not influence expression of E2F-1 or p53, nor did they alleviate squelching by either transcription factor, Because MG-132 and lactacycstin are highly specific inhibitors of the proteasome protease, our results suggest that the proteasome influences post-translational processes involved in proper folding and cytoplasmic clearing of E2F-1 and p53.	UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405; NATL INST BIOSCI & HUMAN TECHNOL,TSUKUBA,IBARAKI 305,JAPAN; TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,TOKYO 113,JAPAN; KITASATO INST,MINATO KU,TOKYO 108,JAPAN	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Metropolitan Institute of Medical Science								ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATAOKA T, 1992, J ANTIBIOT, V45, P1618, DOI 10.7164/antibiotics.45.1618; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Magae J, 1996, J CELL SCI, V109, P1717; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MILBRANDT JD, 1981, P NATL ACAD SCI-BIOL, V78, P6043, DOI 10.1073/pnas.78.10.6043; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHULL S, 1991, J BIOL CHEM, V266, P24398; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOO JT, 1992, J ANTIBIOT, V45, P1108, DOI 10.7164/antibiotics.45.1108; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	70	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					759	769		10.1038/sj.onc.1201251	http://dx.doi.org/10.1038/sj.onc.1201251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266962				2022-12-25	WOS:A1997XQ11700002
J	Node, K; Kitakaze, M; Kosaka, H; Minamino, T; Sato, H; Kuzuya, T; Hori, M				Node, K; Kitakaze, M; Kosaka, H; Minamino, T; Sato, H; Kuzuya, T; Hori, M			Roles of NO and Ca2+-activated K+ channels in coronary vasodilation induced by 17 beta-estradiol in ischemic heart failure	FASEB JOURNAL			English	Article						nitric oxide; myocardial ischemia; coronary blood flow	NITRIC-OXIDE; POSTMENOPAUSAL WOMEN; MYOCARDIAL-ISCHEMIA; SMOOTH-MUSCLE; ESTROGEN; ARTERY; RELEASE; CONDUCTANCE; ENDOTHELIUM; RELAXATION	Estrogen induces the generation of nitric oxide (NO) and produces coronary vasodilation by opening the Ca2+-activated K+ (K-Ca) channels, The hypothesis that 17 beta-estradiol produces NO and activates K-Ca channels during coronary hypoperfusion was investigated, In open-chest dogs, the left anterior descending coronary artery was perfused through an extracorporeal bypass tube from the left carotid artery, 17 beta-Estradiol was infused into the bypass tube for 20 min after coronary blood flow was reduced by partial occlusion of the bypass tube, 17 beta-Estradiol increased the difference in NO concentrations between the coronary venous and arterial blood as well as coronary blood flow, The lactate extraction ratio and pH of coronary venous blood were both also increased by 17 beta-estradiol, indicating a reduction in myocardial anaerobic metabolism, Whereas the increase in the coronary arteriovenous difference in NO concentration was completely attenuated by N-G-nitro-L-arginine methyl ester (L-NAME, an inhibitor of NO synthase), the increase in coronary blood flow induced by 17 beta-estradiol was only partially attenuated by L-NAME. The combination of L-NAME and iberiotoxin (a blocker of high-conductance K-Ca channels) completely abolished the coronary vasodilatory effect of 17 beta-estradiol, The data indicate that during coronary hypoperfusion in canine hearts, 17 beta-estradiol increases coronary blood flow and improves metabolic dysfunction by increasing NO release and opening K-Ca channels.	OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL 1,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Kuzuya, Teiji/ABG-8786-2021					ABRAHAM GE, 1972, J CLIN ENDOCR METAB, V34, P312, DOI 10.1210/jcem-34-2-312; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; COLLINS P, 1994, CIRCULATION, V90, P1964, DOI 10.1161/01.CIR.90.4.1964; COWAN CL, 1991, AM J PHYSIOL, V261, pH830, DOI 10.1152/ajpheart.1991.261.3.H830; GILLIGAN DM, 1994, CIRCULATION, V89, P2545, DOI 10.1161/01.CIR.89.6.2545; HAN SZ, 1995, CIRCULATION, V91, P2619, DOI 10.1161/01.CIR.91.10.2619; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; HAYASHI T, 1995, BIOCHEM BIOPH RES CO, V214, P847, DOI 10.1006/bbrc.1995.2364; HUTCHESON IR, 1994, AM J PHYSIOL, V266, pH590, DOI 10.1152/ajpheart.1994.266.2.H590; IVERSEN LL, 1973, BRIT MED BULL, V29, P130, DOI 10.1093/oxfordjournals.bmb.a070982; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; KOHNO Y, 1993, HYPERTENSION, V22, P34; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MORI H, 1992, AM J PHYSIOL, V263, pH1946, DOI 10.1152/ajpheart.1992.263.6.H1946; NAGAO T, 1992, J PHYSIOL-LONDON, V445, P355, DOI 10.1113/jphysiol.1992.sp018928; Node K, 1997, CIRCULATION, V95, P1560; Node K, 1996, CIRCULATION, V93, P356, DOI 10.1161/01.CIR.93.2.356; NODE K, 1995, BIOCHEM BIOPH RES CO, V211, P370, DOI 10.1006/bbrc.1995.1823; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; RUSKO J, 1995, BIOCHEM BIOPH RES CO, V214, P367, DOI 10.1006/bbrc.1995.2297; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SAKUMA I, 1992, CIRC RES, V70, P607, DOI 10.1161/01.RES.70.3.607; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SUDHIR K, 1995, J AM COLL CARDIOL, V26, P807, DOI 10.1016/0735-1097(95)00248-3; VARGAS R, 1993, BRIT J PHARMACOL, V109, P612, DOI 10.1111/j.1476-5381.1993.tb13616.x; WADA A, 1995, N-S ARCH PHARMACOL, V352, P545; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; YAO SK, 1995, CIRCULATION, V92, P1005, DOI 10.1161/01.CIR.92.4.1005	28	59	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					793	799		10.1096/fasebj.11.10.9271364	http://dx.doi.org/10.1096/fasebj.11.10.9271364			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271364				2022-12-25	WOS:A1997XR10500009
J	Badola, P; Sanders, CR				Badola, P; Sanders, CR			Escherichia coli diacylglycerol kinase is an evolutionarily optimized membrane enzyme and catalyzes direct phosphoryl transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-1,2-DIACYLGLYCEROL KINASE; ADENYLATE KINASES; PROTEIN-KINASES; INHIBITORS; DEPENDENCE; MOVEMENTS; DIFFUSION	Pn this contribution the kinetic mechanism and substrate specificity of Escherichia coli diacylglycerol kinase were examined. Steady state kinetic studies were carried out under mixed micellar conditions using a novel continuous coupled assay system. The kinetic data were consistent with a random equilibrium mechanism, implying that diacylglycerol kinase catalyzes direct phosphoryl transfer from MgATP to diacylglycerol, This was supported by failure to detect an enzyme-phosphate covalent intermediate and by the observation that the bisubstrate analog adenosine 5'-tetraphosphoryl-3-O-(1,2-dihexanoyl)-sn-glycerol inhibits the enzyme (K-i much less than K-m,K-DAG). While diacylglycerol kinase's k(cat)/K-m is modest compared with the efficiency of many water-soluble enzymes, the enzyme nevertheless appears to be all evolutionarily optimized biocatalyst in the sense that its chemical reaction rate approaches the substrate diffusion-controlled limit, The fit vitro rate-limiting step of DAGK's reaction appears to be, in part, the transbilayer diffusion of diacylglycerol from the outer leaflet to the inner leaflet of the cytoplasmic membrane where DAGK's active site is located, DAGK was observed to maintain a high nucleotide substrate specificity, with most of this specificity being expressed in the form of reductions in K-cat for ATP analogs.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University					NIGMS NIH HHS [GM47485] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047485, R01GM047485] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERY WJ, 1977, ANGEW CHEM INT EDIT, V16, P285, DOI 10.1002/anie.197702851; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; ANDERSSON CM, 1979, SCIENCE, V235, P569; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BOHNENBERGER E, 1988, EUR J BIOCHEM, V132, P645; BROOM AD, 1989, J MED CHEM, V32, P2, DOI 10.1021/jm00121a001; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CRONAN JE, 1996, ESCHERICHIA COLI SAL, V1, P612; FELDHAUS P, 1975, EUR J BIOCHEM, V57, P197, DOI 10.1111/j.1432-1033.1975.tb02291.x; Fersht A., 1985, ENZYME STRUCTURE MEC; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P182; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GOLDFINE H, 1982, CURR TOP MEMBR TRANS, V17, P1; HAMILTON JA, 1991, J BIOL CHEM, V266, P1177; Hammes G.G., 1970, ENZYMES, V2, P67; IKEDA S, 1986, J BIOL CHEM, V261, P5836; KENNEDY EP, 1996, ESCHERICHIA COLI SAL, V1, P1064; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P88, DOI 10.1083/jcb.102.1.88; MEDZIHRADSZKY D, 1994, J AM CHEM SOC, V116, P9413, DOI 10.1021/ja00100a001; MERCHANTE R, 1995, J BACTERIOL, V177, P6176, DOI 10.1128/jb.177.21.6176-6183.1995; PREISS J, 1986, J BIOL CHEM, V261, P8597; PURICH DL, 1972, BIOCHIM BIOPHYS ACTA, V276, P563, DOI 10.1016/0005-2744(72)91021-2; RAETZ CRH, 1979, J BACTERIOL, V137, P860, DOI 10.1128/JB.137.2.860-868.1979; RHOADS DG, 1968, J BIOL CHEM, V243, P3963; RUSS E, 1988, EUR J BIOCHEM, V171, P335, DOI 10.1111/j.1432-1033.1988.tb13795.x; SANDERS CR, 1993, BIOPHYS J, V65, P1207, DOI 10.1016/S0006-3495(93)81158-5; Sanders CR, 1996, BIOCHEMISTRY-US, V35, P8610, DOI 10.1021/bi9604892; SANDERS CR, 1994, CHEM PHYS LIPIDS, V72, P41, DOI 10.1016/0009-3084(94)90016-7; SCHAAP D, 1994, BIOCHEM J, V304, P661, DOI 10.1042/bj3040661; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Segel I. H., 1975, ENZYME KINETICS, P273; SHIBUYA I, 1992, PROG LIPID RES, V31, P245, DOI 10.1016/0163-7827(92)90010-G; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; SMITH RL, 1994, J BACTERIOL, V176, P5459, DOI 10.1128/JB.176.17.5459-5465.1994; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VINOGRADOVA O, 1996, BIOPHYS J, V72, P2688; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1990, J BIOL CHEM, V265, P4374; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WALSH JP, 1986, J BIOL CHEM, V261, P1021; Wen JA, 1996, NAT STRUCT BIOL, V3, P141, DOI 10.1038/nsb0296-141; YAMASHITA Y, 1993, J BACTERIOL, V175, P6220, DOI 10.1128/JB.175.19.6220-6228.1993; YAN H, 1991, BIOCHEMISTRY-US, V31, P6806	47	71	72	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24176	24182		10.1074/jbc.272.39.24176	http://dx.doi.org/10.1074/jbc.272.39.24176			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305868	hybrid			2022-12-25	WOS:A1997XY51500019
J	Hinderlich, S; Stasche, R; Zeitler, R; Reutter, W				Hinderlich, S; Stasche, R; Zeitler, R; Reutter, W			A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver - Purification and characterization of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; TRIPHOSPHATE; MECHANISM; SIALURIA; BINDING	Biosynthesis of N-acetylneuraminic acid (Neu5Ac), a prominent component of glycoconjugates, is initiated by the action of UDP-N-acetylglucosamine a-epimerase (UDP-GlcNAc a-epimerase, EC 5.1.3.14) and N-acetylmannosamine kinase (ManNAc kinase, EC 2.7.1.60), We demonstrate for the first time that the two activities are parts of one bifunctional enzyme in rat liver, The enzyme was purified to homogeneity from rat liver cytosol using salmine sulfate precipitation and chromatography on phenyl-Sepharose, ATP-agarose, and Mono Q. The purification resulted in one polypeptide with an apparent molecular mass of 75 kDa, Immunoprecipitation with a polyclonal antibody against the polypeptide reduced both enzyme activities in equal amounts, Gel filtration analysis of purified UDP-GlcNAc 2-epimerase/ManNAc kinase showed that the polypeptide self-associates as a dimer and as a hexamer with apparent molecular masses of 150 and 450 kDa, respectively, The hexamer was fully active for both enzyme activities, whereas the dimer catalyzed only the phosphorylation of N-acetylmannosamine (ManNAc), Incubation of the dimer with UDP-N-acetylglucosamine led to reassembly of the fully active hexamer; maximal quantities of the hexamer were produced after incubation for 3 h. Kinetic analysis of purified hexameric and dimeric enzyme revealed significantly lower Michaelis constants (93 +/- 3 to 121 +/- 15 mu M for ManNAc and 1.18 +/- 0.13 to 1.67 +/- 0.20 mm for ATP) and higher cooperativity (Hill coefficients of 1.42 +/- 0.16 to 1.17 +/- 0.06 for ManNAc and 1.30 +/- 0.09 to 1.05 +/- 0.14 for ATP) for the hexamer for both substrates of ManNAc kinase, The Michaelis constant of UDP-GlcNAc a-epimerase for its substrate was 11 +/- 2 mu M. The Hill coefficient of 0.45 +/- 0,07 represents strongly negative cooperativity in substrate binding, UDP-GlcNAc a-epimerase was feedback inhibited by CMP-Neu5Ac. Complete inhibition was achieved with 60 mu M CMP-Neu5Ac, and highly positive cooperativity (Hill coefficient of 4.1) was found for inhibitor binding.	FREE UNIV BERLIN,INST MOL BIOL & BIOCHEM,D-14195 BERLIN,GERMANY	Free University of Berlin								BOULARD C, 1982, J IMMUNOL METHODS, V50, P221, DOI 10.1016/0022-1759(82)90228-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brockhausen I., 1997, GLYCOSCIENCES STATUS, P79; COMB DG, 1958, BIOCHIM BIOPHYS ACTA, V29, P653, DOI 10.1016/0006-3002(58)90031-3; DATTA A, 1970, BIOCHEMISTRY-US, V9, P3363, DOI 10.1021/bi00819a011; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Fritsch M, 1996, J CHROMATOGR A, V727, P223, DOI 10.1016/0021-9673(95)01157-9; GOSH S, 1961, P NATL ACAD SCI USA, V47, P955; HARMS E, 1973, EUR J BIOCHEM, V32, P254, DOI 10.1111/j.1432-1033.1973.tb02605.x; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; KIKUCHI K, 1973, BIOCHIM BIOPHYS ACTA, V327, P193, DOI 10.1016/0005-2744(73)90117-4; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; KUNDIG W, 1966, J BIOL CHEM, V241, P5619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1969, P NATL ACAD SCI USA, V62, P1121, DOI 10.1073/pnas.62.4.1121; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; SEPPALA R, 1991, J BIOL CHEM, V266, P7456; SOMMAR KM, 1972, BIOCHIM BIOPHYS ACTA, V269, P581; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; VANRINSUM J, 1983, BIOCHEM J, V210, P21, DOI 10.1042/bj2100021; WARREN L, 1972, GLYCOPROTEINS, P1097; WEISS P, 1989, J BIOL CHEM, V264, P17635; YABLONSKI MJ, 1996, J BIOL CHEM, V270, P10704; ZEITLER R, 1992, BIOMETALS, V5, P103, DOI 10.1007/BF01062221	27	228	237	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24313	24318		10.1074/jbc.272.39.24313	http://dx.doi.org/10.1074/jbc.272.39.24313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305887	hybrid			2022-12-25	WOS:A1997XY51500038
J	Jagath, JR; Sharma, B; Rao, NA; Savithri, HS				Jagath, JR; Sharma, B; Rao, NA; Savithri, HS			The role of His-134, -147, and -150 residues in subunit assembly, cofactor binding, and catalysis of sheep liver cytosolic serine hydroxymethyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; ASPARTATE-AMINOTRANSFERASE; EVOLUTIONARY RELATIONSHIPS; TRYPTOPHAN SYNTHASE; NUCLEOTIDE-SEQUENCE; CDNA CLONING; GLYA GENE; IDENTIFICATION; MITOCHONDRIAL	In an attempt to unravel the role of conserved histidine residues in the structure-function of sheep liver cytosolic serine hydroxymethyltransferase (SHMT), three site-specific mutants (H134N, H147N, and H150N) were constructed and expressed, H134N and H147N SHMTs had K-m values for L-serine, L-allo-threonine and beta-phenylserine similar to that of wild type enzyme, although the k(cat) values were markedly decreased, H134N SHMT was obtained in a dimeric form with only 6% of bound pyridoxal 5'-phosphate (PLP) compared with the wild type enzyme, Increasing concentrations of PLP (up to 500 mu M) enhanced the enzyme activity without changing its oligomeric structure, indicating that His-134 may be involved in dimer-dimer interactions, H147N SHMT was obtained in a tetrameric form but with very little PLP (3%) bound to it, suggesting that this residue was probably involved in cofactor binding, Unlike the wild type enzyme, the cofactor could be easily removed by dialysis from H147N SHMT, and the apoenzyme thus formed was present predominantly in the dimeric form, indicating that PLP binding is at the dimer-dimer interface, H150N SHMT was obtained in a tetrameric form with bound PLP, However, the mutant had very little enzyme activity (<2%). The k(cat)/K-m values for L-serine, L-allo-threonine and beta-phenylserine were 80-, 56-, and SS-fold less compared with wild type enzyme, Unlike the wild type enzyme, it failed to form the characteristic quinonoid intermediate and was unable to carry out the exchange of 2-S proton from glycine in the presence of H-4-folate. However, it could form an external aldimine with serine and glycine, The wild type and the mutant enzyme had similar K-d values for serine and glycine, These results suggest that His-150 may be the base that abstracts the alpha-proton of the substrate, leading to formation of the quinonoid intermediate in the reaction catalyzed by SHMT.	INDIAN INST SCI, DEPT BIOCHEM, BANGALORE 560012, KARNATAKA, INDIA	Indian Institute of Science (IISC) - Bangalore			Junutula, Jagath Reddy/ABD-4753-2020; Sharma, Balasubramanya/ABA-9152-2021	Junutula, Jagath Reddy/0000-0002-5942-4428; Sharma, Balasubramanya/0000-0002-9923-5699				ALEXANDER DC, 1987, METHOD ENZYMOL, V154, P41; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ATSURO M, 1993, EUR J BIOCHEM, V212, P745; BHATIA MB, 1993, J BIOL CHEM, V268, P6932; BLAKLEY RL, 1955, BIOCHEM J, V61, P315, DOI 10.1042/bj0610315; Brahatheeswaran B, 1996, ARCH BIOCHEM BIOPHYS, V330, P363, DOI 10.1006/abbi.1996.0263; BYRNE PC, 1992, BIOCHEM J, V286, P117, DOI 10.1042/bj2860117; CHAN VL, 1991, GENE, V101, P51, DOI 10.1016/0378-1119(91)90223-X; CHEN MS, 1973, J BIOL CHEM, V248, P3631; CIOTTI MM, 1957, METHOD ENZYMOL, V3, P890, DOI 10.1016/S0076-6879(57)03472-2; GARROW TA, 1993, J BIOL CHEM, V268, P11910; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HATEFI Y, 1960, BIOCHEM PREP, V7, P89; HAYASHI H, 1990, BIOCHEM BIOPH RES CO, V167, P407, DOI 10.1016/0006-291X(90)92037-Z; Jagath JR, 1997, EUR J BIOCHEM, V247, P372, DOI 10.1111/j.1432-1033.1997.00372.x; JAGATHREDDY J, 1995, EUR J BIOCHEM, V230, P533, DOI 10.1111/j.1432-1033.1995.0533h.x; JagathReddy J, 1996, CURR SCI INDIA, V71, P710; KURAMITSU S, 1990, P 8 INT S VIT B6 CAR, P179; LU ZC, 1993, J BIOL CHEM, V268, P8727; MALKIN LI, 1964, BIOCHIM BIOPHYS ACTA, V85, P117, DOI 10.1016/0926-6569(64)90172-5; MALTHOUSE JPG, 1991, BIOCHEM J, V274, P807, DOI 10.1042/bj2740807; MANOHAR R, 1982, J BIOSCIENCES, V4, P31, DOI 10.1007/BF02702579; MANOHAR R, 1984, BIOCHEM J, V224, P703, DOI 10.1042/bj2240703; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MCCLUNG CR, 1992, MOL CELL BIOL, V12, P1412, DOI 10.1128/MCB.12.4.1412; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; MIYAZAKI SS, 1987, EUR J BIOCHEM, V162, P533, DOI 10.1111/j.1432-1033.1987.tb10672.x; PASCARELLA S, 1993, FEBS LETT, V331, P145, DOI 10.1016/0014-5793(93)80314-K; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; RAO NA, 1987, J SCI IND RES INDIA, V46, P248; ROSSBACH S, 1991, MOL MICROBIOL, V5, P39, DOI 10.1111/j.1365-2958.1991.tb01824.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRCH D, 1993, J BIOL CHEM, V268, P23132; SCHIRCH L, 1964, J BIOL CHEM, V239, P3801; SCHIRCH L, 1964, J BIOL CHEM, V239, P3797; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH LV, 1971, J BIOL CHEM, V246, P3961; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; SNELL K, 1989, FALK SYMP, V51, P375; SNELL K, 1988, BRIT J CANCER, V57, P87, DOI 10.1038/bjc.1988.15; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR RT, 1965, ANAL BIOCHEM, V13, P80, DOI 10.1016/0003-2697(65)90120-X; TONEY MD, 1992, PROTEIN SCI, V1, P109; TURNER SR, 1992, J BIOL CHEM, V267, P13528; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5355, DOI 10.1021/bi00643a029; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; URBANOWSKI ML, 1984, GENE, V27, P47, DOI 10.1016/0378-1119(84)90237-3; USHA R, 1994, BBA-PROTEIN STRUCT M, V1204, P75, DOI 10.1016/0167-4838(94)90035-3; USHA R, 1992, THESIS INDIAN I SCI; WEBB HK, 1995, J BIOL CHEM, V270, P17204, DOI 10.1074/jbc.270.29.17204; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	55	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24355	24362		10.1074/jbc.272.39.24355	http://dx.doi.org/10.1074/jbc.272.39.24355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305893	hybrid			2022-12-25	WOS:A1997XY51500044
J	Alevizopoulos, A; Dusserre, Y; Ruegg, U; Mermod, N				Alevizopoulos, A; Dusserre, Y; Ruegg, U; Mermod, N			Regulation of the transforming growth factor beta-responsive transcription factor CTF-1 by calcineurin and calcium/calmodulin-dependent protein kinase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NUCLEAR FACTOR-I; TGF-BETA; CYCLOSPORINE-A; MAD PROTEINS; HISTONE H3; CTF/NF-I; CALCIUM; ACTIVATION; RECEPTOR	Transforming growth factor beta (TGF-beta) is a pluripotent peptide hormone that regulates various cellular activities, including growth, differentiation, and extracellular matrix protein gene expression, We previously showed that TGF-beta induces the transcriptional activation domain (TAD) of CTF-1, the prototypic member of the CTF/NF-I family of transcription factors. This induction correlates with the proposed role of CTF/NF-I binding sites in collagen gene induction by TGF-beta. However, the mechanisms of TGF-beta signal transduction remain poorly understood. Here, we analyzed the role of free calcium signaling in the induction of CTF-1 transcriptional activity by TGF-beta, We found that TGF-beta stimulates calcium influx and mediates an increase of the cytoplasmic calcium concentration in NIH3T3 cells. TGF-beta induction of CTF-1 is inhibited in cells pretreated with thapsigargin, which depletes the endoplasmic reticulum calcium stores, thus further arguing for the potential relevance of calcium mobilization in TGF-beta action. Consistent with this possibility, expression of a constitutively active form of the calcium/calmodulin-dependent phosphatase calcineurin or of the calcium/calmodulin-dependent kinase IV (Delta CaMKIV) specifically induces the CTF-1 TAD and the endogenous mouse CTF/NF-I proteins, Both calcineurin- and Delta CaMKIV-mediated induction require the previously identified TGF-beta responsive domain of CTF-1. The immunosuppressants cyclosporin A and FK506 abolish calcineurin-mediated induction of CTF-1 activity, However, TGF-beta still induces the CTF-1 TAD in cells treated with these compounds or in cells overexpressing both calcineurin and Delta CaMKIV, suggesting that other calcium-sensitive enzymes might mediate TGF-beta action. These results identify CTF/NF-I as a novel calcium signaling pathway-responsive transcription factor and further suggest multiple molecular mechanisms for the induction of CTF/NF-I transcriptional activity by growth factors.	ECOLE POLYTECH FED LAUSANNE,INST GENIE CHIM,DC,LAB MOL BIOTECHNOL,CTR BIOTECHNOL,UNIL,CH-1015 LAUSANNE,SWITZERLAND; UNIV LAUSANNE,SCH PHARM,PHARMACOL GRP,CH-1015 LAUSANNE,SWITZERLAND	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne				RUEGG, Urs/0000-0001-6078-8280				Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; Ishiyama N, 1996, MOL CELL ENDOCRINOL, V117, P1, DOI 10.1016/0303-7207(95)03726-8; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LoRusso A, 1996, BRIT J PHARMACOL, V118, P885; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MULDOON LL, 1988, J BIOL CHEM, V263, P18834; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	38	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23597	23605		10.1074/jbc.272.38.23597	http://dx.doi.org/10.1074/jbc.272.38.23597			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295299	hybrid			2022-12-25	WOS:A1997XX38100024
J	FloresDiaz, M; AlapeGiron, A; Persson, B; Pollesello, P; Moos, M; vonEichelStreiber, C; Thelestam, M; Florin, I				FloresDiaz, M; AlapeGiron, A; Persson, B; Pollesello, P; Moos, M; vonEichelStreiber, C; Thelestam, M; Florin, I			Cellular UDP-glucose deficiency caused by a single point mutation in the UDP-glucose pyrophosphorylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLC-GLYCOPROTEIN GLUCOSYLTRANSFERASE; GLYCOGEN PHOSPHORYLASE-B; GTP-BINDING PROTEINS; DIFFICILE TOXIN-B; CLOSTRIDIUM-DIFFICILE; ETHYL METHANESULFONATE; TRANSGENIC MICE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE	We previously isolated a mutant cell that is the only mammalian cell reported to have a persistently low level of UDP-glucose. In this work we obtained a spontaneous revertant whose UDP-glucose level lies between those found in the wild type and the mutant cell, The activity of UDP-glucose pyrophosphorylase (UDPG:PP), the enzyme that catalyzes the formation of UDP-glucose, was in the mutant 4% and in the revertant 56% of the activity found in the wild type cell. Sequence analysis of UDPG:PP cDNAs from the mutant cell showed one missense mutation, which changes amino acid residue 115 hom glycine to aspartic acid. The substituted glycine is located within the largest stretch of strictly conserved residues among eukaryotic UDPG:PPs. The analysis of the cDNAs from the revertant cell indicated the presence of an equimolar mixture of the wild type and the mutated mRNAs, suggesting that the mutation has reverted in only one of the alleles. In summary, we demonstrate that the G115D substitution in the Chinese hamster UDPG:PP dramatically impairs its enzymatic activity, thereby causing cellular UDP-glucose deficiency.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; UNIV COSTA RICA,FAC MED,DEPT BIOQUIM,SAN JOSE,COSTA RICA; UNIV COSTA RICA,FAC MICROBIOL,INST CLODOMIRO PICADO,SAN JOSE,COSTA RICA; ORION PHAMACEUT CO,R&D,DRUG DESIGN UNIT,NMR LAB,FIN-02101 ESPOO,FINLAND; UNIV MAINZ,INST MED MICROBIOL & HYG,VERFUGUNGSGEBAUDE FORSCH & ENTWICKLUNG,D-55101 MAINZ,GERMANY	Karolinska Institutet; Karolinska Institutet; Universidad Costa Rica; Universidad Costa Rica; Orion Corporation; Johannes Gutenberg University of Mainz			Pollesello, Piero/I-6884-2019	Pollesello, Piero/0000-0001-6994-768X; Alape-Giron, Alberto/0000-0003-3934-8496				ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; ASHMAN CR, 1987, SOMAT CELL MOLEC GEN, V13, P563, DOI 10.1007/BF01534497; AW TY, 1984, BIOCHEM J, V219, P707, DOI 10.1042/bj2190707; AW TY, 1982, ANAL BIOCHEM, V127, P32, DOI 10.1016/0003-2697(82)90140-3; BETTE P, 1989, INFECT IMMUN, V57, P2507, DOI 10.1128/IAI.57.8.2507-2513.1989; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COROMINAS J, 1992, FEBS LETT, V310, P182, DOI 10.1016/0014-5793(92)81325-G; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; DESMOND GH, 1996, METHOD ENZYMOL, V266, P383; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; Eimert K, 1996, GENE, V170, P227, DOI 10.1016/0378-1119(95)00873-X; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; Franks SE, 1996, ANTICANCER RES, V16, P1365; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HAJDU J, 1987, EMBO J, V6, P539, DOI 10.1002/j.1460-2075.1987.tb04786.x; HAMES BD, 1976, ANAL BIOCHEM, V73, P215, DOI 10.1016/0003-2697(76)90157-3; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hellerstein MK, 1997, AM J PHYSIOL-ENDOC M, V272, pE155, DOI 10.1152/ajpendo.1997.272.1.E155; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; INGLE CA, 1989, MUTAT RES, V220, P133, DOI 10.1016/0165-1110(89)90019-5; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KATSUBE T, 1991, BIOCHEMISTRY-US, V30, P8546, DOI 10.1021/bi00099a008; KONISHI Y, 1993, J BIOCHEM-TOKYO, V114, P61, DOI 10.1093/oxfordjournals.jbchem.a124141; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABRIOLA C, 1995, J CELL BIOL, V130, P771, DOI 10.1083/jcb.130.4.771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBKOWSKI JS, 1986, MOL CELL BIOL, V6, P1838, DOI 10.1128/MCB.6.5.1838; LOWIK CWGM, 1993, ANAL BIOCHEM, V213, P426, DOI 10.1006/abio.1993.1442; LUNN JE, 1990, BIOCHEM J, V267, P739, DOI 10.1042/bj2670739; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; MOLLBY R, 1974, J MEMBRANE BIOL, V16, P313, DOI 10.1007/BF01872421; MPOLLESELLO P, 1995, NMR BIOMED, V8, P190; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P528, DOI 10.1093/oxfordjournals.jbchem.a122886; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; RAGHEB JA, 1987, NUCLEIC ACIDS RES, V15, P3891, DOI 10.1093/nar/15.9.3891; REN JM, 1993, J BIOL CHEM, V268, P16113; ROACH PJ, 1975, BIOCHEMISTRY-US, V14, P5445, DOI 10.1021/bi00696a010; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROTH J, 1995, GLYCOPROTEINS, P287; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANDHOFF K, 1992, BIOCHEM SOC T, V20, P695, DOI 10.1042/bst0200695; SASSON S, 1986, J BIOL CHEM, V261, P6827; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHEED SF, 1993, NMR BIOMED, V6, P254; SHOSHAN MC, 1990, EUR J CELL BIOL, V53, P357; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SOCHOR M, 1991, DIABETES, V40, P1467, DOI 10.2337/diabetes.40.11.1467; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SPIRO MJ, 1984, DIABETOLOGIA, V26, P70; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Tyagi RK, 1996, MAGN RESON MED, V35, P194, DOI 10.1002/mrm.1910350210; ULLREY DB, 1979, ANAL BIOCHEM, V95, P245, DOI 10.1016/0003-2697(79)90212-4; VANZEELAND AA, 1995, TOXICOL LETT, V77, P49, DOI 10.1016/0378-4274(95)03271-1; VERBERT A, 1995, GLYCOPROTEINS, P145; VIHINEN M, 1994, PROTEINS, V19, P141, DOI 10.1002/prot.340190207; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Watson KA, 1997, EMBO J, V16, P1, DOI 10.1093/emboj/16.1.1; WICE BM, 1985, J BIOL CHEM, V260, P139; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	73	71	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23784	23791		10.1074/jbc.272.38.23784	http://dx.doi.org/10.1074/jbc.272.38.23784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295324	hybrid			2022-12-25	WOS:A1997XX38100049
J	Shin, JH; Ji, CH; Casinghino, S; McCarthy, TL; Centrella, M				Shin, JH; Ji, CH; Casinghino, S; McCarthy, TL; Centrella, M			Parathyroid hormone-related protein enhances insulin-like growth factor-I expression by fetal rat dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-ENRICHED CULTURES; SQUAMOUS-CELL CARCINOMA; RECEPTOR MESSENGER-RNA; PROSTAGLANDIN E(2); HUMAN-SKIN; HUMAN KERATINOCYTES; RESPONSE ELEMENT; GENE-EXPRESSION; FACTOR-BETA; BONE-CELLS	Interactions between cells of differing embryonic origins comprise a common theme during tissue development and repair. Often, communication between them can be mediated by soluble growth mediators and in some cases is restricted in focus. That is, some cells respond to, but do not produce, mediators expressed by other cells within the tissue. Because keratinocytes respond to but do not express insulin-like growth factor I (IGF-I), another skin cell population, the dermal fibroblast, may supply this factor. However, keratinocytes express, but do not respond to parathyroid hormone related protein (PTHrp), which increases cAMP production by dermal fibroblasts. Based on earlier results where inducers of cAMP increase local IGF-I expression in skeletal tissue, we postulated that PTHrp might induce local IGF-I by dermal fibroblasts and provide a source of this factor for keratinocyte activity. Our studies reveal that IGF-I mRNA and protein levels increase in response to PTHrp in vitro, and that this effect is replicated by inducers of cAMP, but not be activators of protein kinase C. Consequently, these factors appear to comprise a paracrine loop within the skin, permitting focused but restricted IGF-I expression to support skin growth, remodeling, or repair.			Shin, JH (corresponding author), YALE UNIV,SCH MED,DEPT SURG,SECT PLAST SURG,333 CEDAR ST,POB 208401,NEW HAVEN,CT 06520, USA.				NIAMS NIH HHS [AR41942] Funding Source: Medline; NIDDK NIH HHS [DK47421] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1991, INSULIN LIKE GROWTH; BARRECA A, 1992, J CELL PHYSIOL, V151, P262, DOI 10.1002/jcp.1041510207; BHORA FY, 1995, J SURG RES, V59, P236, DOI 10.1006/jsre.1995.1160; BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENTRELLA M, 1993, ANN PLAS SURG, V31, P434, DOI 10.1097/00000637-199311000-00008; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; Dunbar ME, 1996, AM J MED SCI, V312, P287, DOI 10.1097/00000441-199612000-00007; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOLDRING SR, 1979, J CLIN ENDOCR METAB, V48, P655, DOI 10.1210/jcem-48-4-655; HANAFIN NM, 1995, J INVEST DERMATOL, V105, P133, DOI 10.1111/1523-1747.ep12313466; HOEKMAN K, 1990, CANCER RES, V50, P3589; INSOGNA KL, 1989, J CLIN INVEST, V83, P1057, DOI 10.1172/JCI113947; INSOGNA KL, 1989, ANN NY ACAD SCI, V548, P146; JYUNG RW, 1994, SURGERY, V115, P233; KAMALATI T, 1989, DEVELOPMENT, V106, P283; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; McCarthy TL, 1996, J BIOL CHEM, V271, P6666, DOI 10.1074/jbc.271.12.6666; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; NEELY EK, 1991, J INVEST DERMATOL, V96, P104, DOI 10.1111/1523-1747.ep12515914; ORLOFF JJ, 1995, ENDOCRINOLOGY, V136, P3016, DOI 10.1210/en.136.7.3016; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; Reiser K, 1996, AM J PHYSIOL-REG I, V271, pR696, DOI 10.1152/ajpregu.1996.271.3.R696; RIZZOLI R, 1994, J ENDOCRINOL, V143, P333, DOI 10.1677/joe.0.1430333; SILVE C, 1985, J CLIN ENDOCR METAB, V60, P1144, DOI 10.1210/jcem-60-6-1144; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; WU TL, 1987, J CLIN ENDOCR METAB, V65, P105, DOI 10.1210/jcem-65-1-105; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133	40	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23498	23502		10.1074/jbc.272.38.23498	http://dx.doi.org/10.1074/jbc.272.38.23498			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295284	hybrid			2022-12-25	WOS:A1997XX38100009
J	Sun, ZY; Jiang, YP; Ma, Z; Wu, H; Liu, BF; Xu, YM; Tang, W; Chen, YH; Li, CZ; Zhu, DX; Gurewich, V; Liu, JN				Sun, ZY; Jiang, YP; Ma, Z; Wu, H; Liu, BF; Xu, YM; Tang, W; Chen, YH; Li, CZ; Zhu, DX; Gurewich, V; Liu, JN			Identification of a flexible loop region (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PRO-UROKINASE; INTRINSIC ACTIVITY; CRYSTAL-STRUCTURE; GLU-PLASMINOGEN; PROUROKINASE; FIBRIN; LOCALIZATION; FRAGMENT-E-2; PROMOTION	Pro-urokinase has a much higher intrinsic catalytic activity than other zymogens of the serine protease family. Lys(300(c143)) in an apparent ''flexible loop'' region (297-313) was previously shown to be an important determinant of this intrinsic catalytic activity. This was related to the loop allowing the positive charge of Lys(300(c143)) to transiently interact with Asp(355(c194)), thereby inducing an active conformation of the protease domain (Liu, J. N., Tang, W., Sun, Z., Kung, W., Pannell, R., Sarmientos, P., and Gurewich, V. (1996) Biochemistry 35, 14070-14076). To further test this hypothesis, the charge at position 300(c143) and the flexibility of the loop were altered using site-directed mutagenesis designed according to a computer model to affect the interaction between Lys(300(c143)) and Asp(355(c194)). When the charge at Lys(300(c143)) but not Lys(313(c156)) was reduced, a significant reduction in the intrinsic catalytic activity occurred. Similarly, when the flexibility (wobbliness) of the loop was enhanced reducing the size of side chain, the intrinsic catalytic activity was also reduced. By contrast, when the loop was made less flexible, the intrinsic catalytic activity was increased, These findings were consistent with the hypothesis. The effects of these mutations on two-chain activity were less and often discordant with the intrinsic catalytic activity, indicating that they can be modulated independently. This structure-function disparity can he exploited to create a more zymogenic pro-urokinase (lower intrinsic catalytic activity) with a high catalytic activity, as exemplified by two of the mutants. The changes in intrinsic catalytic activity and tyro-chain activity induced by the mutations were due to changes in k(cat) rather than K-m. Some significant structure-function differences between prourokinase and its highly homologous counterpart, tissue plasminogen activator, were also found.	HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,INST PREVENT CARDIOVASC DIS,VASC RES LAB,BOSTON,MA 02215; NANJING UNIV,DEPT BIOCHEM,STATE KEY LAB PHARMACEUT BIOTECHNOL,NANJING 210008,PEOPLES R CHINA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Nanjing University				Jiang, Yongping/0000-0001-6024-4187				Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; GUREWICH V, 1989, J CLIN INVEST, V82, P1956; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; Liu JN, 1996, BIOCHEMISTRY-US, V35, P14070, DOI 10.1021/bi9605393; LIU JN, 1993, BLOOD, V81, P980; LIU JN, 1995, J BIOL CHEM, V270, P8408, DOI 10.1074/jbc.270.15.8408; LIU JN, 1992, J BIOL CHEM, V267, P15289; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; ORINI G, 1991, EUR J BIOCHEM, V195, P691; PANNELL R, 1986, BLOOD, V67, P1215; PANNELL R, 1987, BLOOD, V69, P22; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PETERSEN LC, 1990, BIOCHEMISTRY-US, V29, P3451, DOI 10.1021/bi00466a005; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; Tachias K, 1997, J BIOL CHEM, V272, P28; Tachias K, 1996, J BIOL CHEM, V271, P28749, DOI 10.1074/jbc.271.46.28749; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; VALINSKY JE, 1981, CELL, V25, P471, DOI 10.1016/0092-8674(81)90065-9; VOSKUILEN M, 1987, J BIOL CHEM, V262, P5944; WINKLER ME, 1986, BIOCHEMISTRY-US, V25, P4041, DOI 10.1021/bi00362a008	30	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23818	23823		10.1074/jbc.272.38.23818	http://dx.doi.org/10.1074/jbc.272.38.23818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295329	hybrid			2022-12-25	WOS:A1997XX38100054
J	Whitman, SP; Civoli, F; Daniel, LW				Whitman, SP; Civoli, F; Daniel, LW			Protein kinase C beta II activation by 1-beta-D-arabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl-2 alpha down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; JUN GENE-EXPRESSION; ETHER LIPID ANALOGS; HL-60 CELLS; BCL-2; INHIBITION; DEATH; CERAMIDE; DIFFERENTIATION; PATHWAY	1-beta-D-Arabinofuranosylcytosine (ara-C) stimulates the formation of both diglyceride and ceramide in the acute myelogenous leukemia cell line HL-60 (Strum, J. C., Small, G. W., Pauig, S. B., and Daniel, L. W. (1994) J. Biol. Chem 269, 15493-15497). ara-C also causes apoptosis in HL-60 cells which can be mimicked by exogenous ceramide. However, the signaling role for ara-C-induced diacylglycerol (DAG) is not defined. We found that Bcl-2 levels were increased by treatment of HL-60 cells with exogenous DAG or 12-O-tetradecanoylphorbol-13-acetate (TPA). In contrast, exogenous ceramide treatment caused a decrease in cellular Bcl-2 levels. Thus, ara-C stimulates the synthesis of two second messengers with opposing effects on Bcl-2. Since the effects of ara-C-induced DAG could be due to protein kinase C (PKC) activation, we determined the effects of ara-C on PKC isozymes. ara-C caused an increase in membrane-bound PKC beta II (but not PKC alpha or PKC delta). ara-C or TPA-induced translocation of PKC beta II was inhibited by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3), and ara-C-induced apoptosis was stimulated by pretreatment of the cells with ET-18-OCH3. ET-18-OCH3 also inhibited stimulation of Bcl-2 by TPA and enhanced the decrease in Bcl-2 observed in ara-C-treated cells. These data indicate that ara-C-induced apoptosis is limited by ara-C-stimulated PKC beta II through effects on Bcl-2. To further determine the role of PKC, we used antisense oligonucleotides directed toward PKC beta II. The antisense, but not the sense, oligonucleotide inhibited PKC beta II activation and enhanced ara-C-induced apoptosis. These data demonstrate that the stimulation of apoptosis by ara-C is self-limiting and can be enhanced by inhibition of PKC.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NCI NIH HHS [CA43297, CA48995, CA67717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA067717, R01CA048995, R01CA043297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BERGGREN MI, 1993, CANCER RES, V53, P4297; BLUMBERG PM, 1994, CANC METASTASIS REV, V13, P411; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BURNS D, 1992, ADV EXP MED BIOL, V318, P275; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CHEN M, 1995, CANCER RES, V55, P991; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DANIEL LW, 1987, LIPIDS, V22, P851, DOI 10.1007/BF02535543; DANIEL LW, 1991, CANC CHEMOTHERAPY, P2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DIOMEDE L, 1997, J CANC, V53, P124; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; HASHIMOTO K, 1990, FEBS LETT, V263, P31, DOI 10.1016/0014-5793(90)80698-I; HELFMAN DM, 1983, CANCER RES, V43, P2955; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOFFMAN DR, 1992, BIOCHIM BIOPHYS ACTA, V1127, P74, DOI 10.1016/0005-2760(92)90203-8; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KEITH FJ, 1995, LEUKEMIA, V9, P131; KHARBANDA S, 1991, BIOCHEMISTRY-US, V30, P7947, DOI 10.1021/bi00246a011; KHARBANDA S, 1994, MOL PHARMACOL, V46, P67; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUCERA GL, 1992, CANCER RES, V52, P3886; Lohmeyer Matthias, 1994, Drugs of the Future, V19, P1021; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MOLINEDO F, 1997, CANCER RES, V57, P1320; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; PRINCIPE P, 1992, CANCER RES, V52, P2509; RAY S, 1994, CANCER CHEMOTH PHARM, V34, P365, DOI 10.1007/s002800050156; SEEWALD MJ, 1990, CANCER RES, V50, P4458; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; WHITMAN SP, 1996, THESIS WAKE FOREST U; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4	44	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23481	23484		10.1074/jbc.272.38.23481	http://dx.doi.org/10.1074/jbc.272.38.23481			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295281	hybrid			2022-12-25	WOS:A1997XX38100006
J	Sutton, MD; Kaguni, JM				Sutton, MD; Kaguni, JM			Threonine 435 of Escherichia coli DnaA protein confers sequence-specific DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ORIGIN; REPLICATION ORIGIN; INITIATOR PROTEIN; AUTO-REGULATION; GENE-PRODUCT; TRANSCRIPTION; COMPLEX; REGION; PURIFICATION; TERMINATION	The Escherichia coli DnaA protein, as a sequence-specific DNA binding protein, promotes the initiation of chromosomal replication by binding to four asymmetric 9-mer sequences termed DnaA boxes in oriC. Characterization of N terminal, C-terminal, and internal in-frame deletion mutants identified residues near the C terminus of DnaA protein required for DNA binding. Furthermore, genetic and biochemical characterization of 11 missense mutations mapping within the C-terminal 89 residues indicated that they were defective in DNA binding. Detailed biochemical characterization of one mutant protein bearing a threonine to methionine substitution at position 435 (T435M) revealed that it retained only nonspecific DNA binding activity, suggesting that threonine 435 imparts specificity in binding. Finally, T435M was inactive on its own for in vitro replication of an oriC plasmid but was able to augment limiting levels of wild type DnaA protein, consistent with the proposal that not all of the DnaA monomers in the initial complex are bound specifically to oriC and that direct interaction occurs among monomers.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University				Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; AUGUSTIN LB, 1994, J BACTERIOL, V176, P378, DOI 10.1128/JB.176.2.378-387.1994; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BEYERSMANN D, 1974, J BACTERIOL, V118, P783, DOI 10.1128/JB.118.3.783-789.1974; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FLOWER AM, 1991, J MOL BIOL, V220, P649, DOI 10.1016/0022-2836(91)90107-H; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GIELOW A, 1988, MOL GEN GENET, V214, P474, DOI 10.1007/BF00330483; GINESCANDELARIA E, 1995, J BACTERIOL, V177, P705, DOI 10.1128/jb.177.3.705-715.1995; HANSEN EB, 1982, NUCLEIC ACIDS RES, V10, P7373, DOI 10.1093/nar/10.22.7373; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; HWANG DS, 1988, J BIOL CHEM, V263, P10625; KUCHERER C, 1986, MOL GEN GENET, V205, P115, DOI 10.1007/BF02428040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YS, 1997, J BIOL CHEM, V272, P83; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; OGAWA T, 1994, J BACTERIOL, V176, P1609, DOI 10.1128/jb.176.6.1609-1615.1994; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SCHAEFER C, 1988, GENE, V73, P347, DOI 10.1016/0378-1119(88)90499-4; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SUTTON MD, 1995, J BACTERIOL, V177, P6657, DOI 10.1128/jb.177.22.6657-6665.1995; TESFASELASE F, 1992, MOL GEN GENET, V231, P256, DOI 10.1007/BF00279799; TUCKER WT, 1984, CELL, V38, P191, DOI 10.1016/0092-8674(84)90540-3; WANG QP, 1989, J BIOL CHEM, V264, P7338; WANG QP, 1987, MOL GEN GENET, V209, P518, DOI 10.1007/BF00331158; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	41	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23017	23024		10.1074/jbc.272.37.23017	http://dx.doi.org/10.1074/jbc.272.37.23017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287298	hybrid			2022-12-25	WOS:A1997XV74400009
J	Tirode, F; Malaguti, C; Romero, F; Attar, R; Camonis, J; Egly, JM				Tirode, F; Malaguti, C; Romero, F; Attar, R; Camonis, J; Egly, JM			A conditionally expressed third partner stabilizes or prevents the formation of a transcriptional activator in a three-hybrid system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE MET25 GENE; RING FINGER PROTEIN; 2-HYBRID SYSTEM; YEAST; COMPLEX; RAS; MAT1; ASSOCIATION; KINASES; REPAIR	We describe a three-hybrid system that involves three polypeptides that allow or prevent the formation of the transcriptional activator. Beside the two-hybrid fusion proteins, the third partner is under the control of the Met25 promoter, which is positively regulated in medium lacking methionine. We document a situation where such a third partner promotes interaction between two proteins, one fused to a DNA-binding domain and the other fused to an activator domain. This is demonstrated for cdk7-MAT1 interaction stabilized by the presence of cyclin H; these three polypeptides are found either free or associated with the transcription/DNA repair factor TFIIH. We also document the capacity of our system to conditionally inhibit the interaction between two polypeptides that otherwise elicit a positive two-hybrid response. This is demonstrated for Ras-Raf interaction precluded by an excess of Raf. The presence of a methionine-regulated promoter provides an ''on'' or ''off'' switch for the formation of the transcriptional activator, thus also providing an excellent control to evaluate the activation or inhibition properties of the third partner.	CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,COMMUNAUTE URBA,FRANCE; INST COCHIN GENET MOL,F-75014 PARIS,FRANCE; INST CURIE,INSERM,U248,F-75231 PARIS 05,FRANCE; BRISTOL MEYER SQUIBB,PRINCETON,NJ	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			TIRODE, Franck/HHS-7070-2022; Romero, Francisco/K-2101-2014; Tirode, Franck/B-4586-2009	Romero, Francisco/0000-0002-9588-6881; Tirode, Franck/0000-0003-4731-7817				Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; Bartel P. L., 1993, CELLULAR INTERACTION, P153; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARPER JW, 1993, CELL, V75, P805; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KERJAN P, 1986, NUCLEIC ACIDS RES, V14, P7861, DOI 10.1093/nar/14.20.7861; LEGRAIN P, 1994, NUCLEIC ACIDS RES, V22, P3241, DOI 10.1093/nar/22.15.3241; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Rose MD., 1990, METHODS YEAST GENETI; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Zhang J, 1996, ANAL BIOCHEM, V242, P68, DOI 10.1006/abio.1996.0429	29	89	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					22995	22999		10.1074/jbc.272.37.22995	http://dx.doi.org/10.1074/jbc.272.37.22995			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287295	hybrid			2022-12-25	WOS:A1997XV74400006
J	Hayashi, Y; Hirose, F; Nishimoto, Y; Shiraki, M; Yamagishi, M; Matsukage, A; Yamaguchi, M				Hayashi, Y; Hirose, F; Nishimoto, Y; Shiraki, M; Yamagishi, M; Matsukage, A; Yamaguchi, M			Identification of CFDD (common regulatory factor for DNA replication and DREF genes) and role of its binding site in regulation of the proliferating cell nuclear antigen gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE BETA-GENE; DROSOPHILA-MELANOGASTER; TRANSCRIPTION FACTOR; ELEMENT; PROTEIN; EXPRESSION; CYCLIN; E2F; PURIFICATION; CULTURE	The Drosophila proliferating cell nuclear antigen (PCNA) gene promoter contains at least three transcriptional regulatory elements, the URE (upstream regulatory element), DRE (DNA replication-related element), and E2F recognition sites, In nuclear extracts of Drosophila Kc cells, we detected a novel protein factor(s), CFDD (common regulatory factor for DNA replication and DREF genes) that appeared to recognize two unique nucleotide sequences (5'-CGATA and 5'-CAATCA) and bind to three sites in the PCNA gene promoter, These sites were located at positions -84 to -77 (site 1), -100 to -93 (site 2) and -134 to -127 (site 3) with respect to the transcription initiation sites, Sites 2 and 3 overlapped with DRE and URE, respectively, and the 5'-CGATA matched with the reported recognition sequence of BEAF-32 (boundary element-associated factor of 32 kDa), Detailed analyses of CFDD recognition sequences and experiments with specific antibodies to DREF (DRE-binding factor) and BEAF-32 suggest that CFDD is different from DREF, UREF (URE-binding factor) and BEAF-32, A UV cross-linking experiment revealed that polypeptides of similar to 76 kDa in the nuclear extract interact directly with the CFDD site 1 sequence, Transient expression assays of chloramphenicol acetyltransferase (CAT) in Ke cells transfected with PCNA promoter-CAT fusion genes carrying mutations in CFDD site 1 and examination of lacZ expression from PCNA promoter-lacZ fusion genes carrying mutations in site 1, introduced into flies by germ line transformation, revealed that CFDD site 1 plays an important role for the promoter activity both in cultured cells and in living flies, In addition to the PCNA gene, multiple CFDD sites were found in promoters of the DNA polymerase alpha and DREF genes, and CFDD binding to the DREF promoter was confirmed, Therefore, CFDD may play important roles in regulation of Drosophila DNA replication-related genes.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center				Yamaguchi, Masamitsu/0000-0002-6321-9750; Hirose, Fumiko/0000-0003-4586-4892				CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; HAO XF, 1995, J CELL SCI, V108, P2945; Hart CM, 1997, MOL CELL BIOL, V17, P999, DOI 10.1128/MCB.17.2.999; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KASAI Y, 1992, P NATL ACAD SCI USA, V89, P3414, DOI 10.1073/pnas.89.8.3414; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; Matsukage A, 1995, GENE, V166, P233, DOI 10.1016/0378-1119(95)00586-2; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MORIUCHI T, 1990, Medical Science Research, V18, P911; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ROBERTSON HM, 1988, GENETICS, V118, P461; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	40	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22848	22858		10.1074/jbc.272.36.22848	http://dx.doi.org/10.1074/jbc.272.36.22848			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278447	hybrid			2022-12-25	WOS:A1997XV49200068
J	Misaka, T; Kusakabe, Y; Emori, Y; Gonoi, T; Arai, S; Abe, K				Misaka, T; Kusakabe, Y; Emori, Y; Gonoi, T; Arai, S; Abe, K			Taste buds have a cyclic nucleotide-activated channel, CNGgust	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CATION CHANNEL; PROTEIN-COUPLED RECEPTORS; FUNCTIONAL EXPRESSION; ROD PHOTORECEPTOR; MOLECULAR-CLONING; ALPHA-SUBUNIT; CELLS; IDENTIFICATION; TRANSDUCTION; LOCALIZATION	Cyclic nucleotide-gated (CNG) channels have been characterized as important factors involved in physiological processes including sensory reception for vision and olfaction. The possibility thus exists that a certain CNG channel functions in gustation as well. In the present study, we carried out reverse transcription-polymerase chain reaction and genomic DNA cloning and characterized a CNG channel (CNGgust) as a cyclic nucleotide-activated species expressed in rat tongue epithelial tissues where taste reception takes place. Several types of 5'-rapid amplification of cDNA ends clones of CNGgust cDNA were obtained with various 5'-terminal sequences. As the CNGgust gene was a single copy, the formation of such CNGgust variants should result from alternative splicing. The encoded protein was homologous to known vertebrate CNG channels with 50-80% similarities in amino acid sequence, and particularly homologous to bovine testis CNG channel and human cone CNG channel with 82% similarities, CNGgust was functional when expressed in human embryonic kidney cells, where it opened upon the addition of cGMP or cAMP. Immunohistochemical analysis using an antibody raised against a CNGgust peptide demonstrated the channel to be localized on the pore side of each taste bud in the circumvallate papillae, with no signal observed for degenerated taste buds after denervation of the glossopharyngeal nerve. All these results, together with the indication that cyclic nucleotides play a role gustatory signaling pathway(s), strongly suggest the involvement of CNGgust in taste signal transduction.	UNIV TOKYO,GRAD SCH AGR & LIFE SCI,DEPT APPL BIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT BIOCHEM & BIOPHYS,FAC SCI,BUNKYO KU,TOKYO 113,JAPAN; CHIBA UNIV,RES CTR PATHOGEN FUNGI & MICROBIAL TOXICOSES,CHUO KU,CHIBA 260,JAPAN	University of Tokyo; University of Tokyo; Chiba University			gonoi, tohru/AAC-5181-2021; , gonoi/GRS-0648-2022	gonoi, tohru/0000-0003-3655-7911; , gonoi/0000-0003-3655-7911; Misaka, Takumi/0000-0002-9547-5767				ABE K, 1993, FEBS LETT, V316, P253, DOI 10.1016/0014-5793(93)81302-G; ABE K, 1993, J BIOL CHEM, V268, P12033; ASANUMA N, 1995, CHEM SENSES, V20, P231, DOI 10.1093/chemse/20.2.231; Barnstable CJ, 1995, J MOL NEUROSCI, V6, P289, DOI 10.1007/BF02736787; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; GUTH L, 1957, ANAT REC, V128, P715, DOI 10.1002/ar.1091280406; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; KURIHARA K, 1972, BIOCHEM BIOPH RES CO, V48, P30, DOI 10.1016/0006-291X(72)90339-7; Kusakabe Y, 1996, CHEM SENSES, V21, P335, DOI 10.1093/chemse/21.3.335; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; MATSUOKA I, 1993, BIOCHEM BIOPH RES CO, V194, P504, DOI 10.1006/bbrc.1993.1848; MCLAUGHLIN SK, 1994, PHYSIOL BEHAV, V56, P1157, DOI 10.1016/0031-9384(94)90360-3; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; NINOMIYA Y, 1994, PHYSIOL BEHAV, V56, P1179, DOI 10.1016/0031-9384(94)90363-8; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; TAL M, 1995, BIOCHEM BIOPH RES CO, V209, P752, DOI 10.1006/bbrc.1995.1563; Thomas MB, 1996, GENE, V178, P1, DOI 10.1016/0378-1119(96)00311-3; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; WONG GT, 1996, NATURE, V17, P681; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; Yu WP, 1996, FEBS LETT, V393, P211, DOI 10.1016/0014-5793(96)00889-7	35	76	86	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22623	22629		10.1074/jbc.272.36.22623	http://dx.doi.org/10.1074/jbc.272.36.22623			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278419	hybrid			2022-12-25	WOS:A1997XV49200039
J	Koera, K; Nakamura, K; Nakao, K; Miyoshi, J; Toyoshima, K; Hatta, T; Otani, H; Aiba, A; Katsuki, M				Koera, K; Nakamura, K; Nakao, K; Miyoshi, J; Toyoshima, K; Hatta, T; Otani, H; Aiba, A; Katsuki, M			K-ras is essential for the development of the mouse embryo	ONCOGENE			English	Article						K-ras; ras genes; gene targeting	N-MYC GENE; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; MICE LACKING; RXR-ALPHA; PROTEIN; DEFECTS; CELLS; HEART	ras genes encode members of the small GTP-binding proteins, Ras protein is highly conserved in various species from yeast to humans and plays a key role in signal transduction, Ras is related to cell proliferation and differentiation, While, in addition, mutations in the ras genes are implicated in a variety of tumors, However, the physiological functions and specific roles of each ras gene, H-ras, K-ras and N-ras, are still not fully understood, To clarify the role of the K-Ras in vivo, we generated K-ras mutant mice by gene targeting, In contrast to the findings that H-Ras-deficient mice and N-Ras-deficient mice are born and grow normally, the K-Ras-deficient embryos die progressively between embryonic day 12.5 and term, At embryonic day 15.5, their ventricular walls are extremely thin, Besides, at embryonic day 11.5, they demonstrate increased cell death of motoneurons in the medulla and the cervical spinal cord, Our results thus indicate K-Ras to be essential for normal development in mice and residual Ras composed of H-Ras and N-Ras cannot compensate for the loss of K-Ras function in the mutant mice.	UNIV TOKYO,INST MED SCI,DEPT DNA BIOL & EMBRYO ENGN,TOKYO 108,JAPAN; OSAKA MED CTR CANC & CARDIOVASC DIS,OSAKA 537,JAPAN; SHIMANE MED UNIV,DEPT ANAT,IZUMO,SHIMANE 693,JAPAN	University of Tokyo; Osaka Medical Center for Cancer & Cardiovascular Diseases; Shimane University				Aiba, Atsu/0000-0002-8192-0778; zhong wei, he gui/0000-0002-3066-3564				BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOENS CB, 1993, DEVELOPMENT, V119, P485; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; SATOH T, 1992, J BIOL CHEM, V267, P24149; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; Shorey ML, 1909, J EXP ZOOL, V7, P25, DOI 10.1002/jez.1400070103; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	56	278	282	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1151	1159		10.1038/sj.onc.1201284	http://dx.doi.org/10.1038/sj.onc.1201284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294608				2022-12-25	WOS:A1997XU99100004
J	Drab, M; Haller, H; Bychkov, R; Erdmann, B; Lindschau, C; Haase, H; Morano, I; Luft, FC; Wobus, AM				Drab, M; Haller, H; Bychkov, R; Erdmann, B; Lindschau, C; Haase, H; Morano, I; Luft, FC; Wobus, AM			From totipotent embryonic stem cells to spontaneously contracting smooth muscle cells: a retinoic acid and db-cAMP in vitro differentiation model	FASEB JOURNAL			English	Article						vascular smooth muscle cells; myosin heavy chain; retinoic acid receptors; oligonucleotide; intracellular calcium; immunocytochemistry; embryoid body	CARDIAC-SPECIFIC GENES; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; CARCINOMA-CELLS; PHENOTYPIC CHANGES; XENOPUS EMBRYOS; IONIC CURRENTS; F9 CELLS; EXPRESSION; MYOSIN	Vascular smooth muscle cell (VSMC) differentiation is important in understanding vascular disease; however, no in vitro model is available. Totipotent mouse embryonic stem (ES) cells were used to establish such a model. To test whether the ES cell-derived smooth muscle cells expressed VSMC-specific properties, the differentiated cells were characterized by 1) morphological analysis, 2) gene expression, 3) immunostaining for VSMC-specific proteins, 4) expression of characteristic VSMC ion channels, and 5) formation of [Ca2+](i) transients in response to VSMC-specific agonists. Treatment of embryonic stem cell-derived embryoid bodies with retinoic acid and dibutyryl-cyclic adenosine monophosphate (db-cAMP) induced differentiation of spontaneously contracting cell clusters in 67% of embryoid bodies compared with 10% of untreated controls. The highest differentiation rate was observed when retinoic acid and db-cAMP were applied to the embryoid bodies between days 7 and 11 in combination with frequent changes of culture medium. Other protocols with retinoic acid and db-cAMP, as well as single or combined treatment with VEGF, ECGF, bFGF, aFGF, fibronectin, matrigel, or hypoxia did not influence the differentiation rate. Single-cell RTPCR and sequencing of the PCR products identified myosin heavy chain (MHC) splice variants distinguishing: between gut and VSMC isoforms. RT-PCR with VSMC-specific MHC primers and immunostaining confirmed the presence of VSMC transcripts and MHC protein. Furthermore, VSMC expressing MHC had typical ion channels and responded to specific agonists with an increased [Ca2+](i). Here we present a retinoic acid + dbcAMP-inducible embryonic stem cell model of in vitro vasculogenesis. ES cell-derived cells expressing VSMC-specific MHC and functional VSMC properties may be a suitable system to study mechanisms of VSMC differentiation.	HUMBOLDT UNIV BERLIN,FRANZ VOLHARD CLIN,MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; INST PLANT GENET & CROP PLANT RES,GATERSLEBEN,GERMANY; MAX DELBRUCK CTR MOL MED,BERLIN,GERMANY	Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Drab, Marek/J-5196-2013; Drab, Marek/AAQ-1892-2020; Lindschau, Carsten/G-1798-2011; Lindschau, Carsten/AAE-6721-2020	Drab, Marek/0000-0002-2771-1692; Lindschau, Carsten/0000-0003-1960-099X; Luft, Friedrich/0000-0002-8635-1199				AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Bagutti C, 1996, DEV BIOL, V179, P184, DOI 10.1006/dbio.1996.0250; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BLANK RS, 1995, CIRC RES, V76, P742, DOI 10.1161/01.RES.76.5.742; CALOVINI T, 1995, J CELL BIOCHEM, V59, P69, DOI 10.1002/jcb.240590109; CARNEGIE JA, 1994, BIOL REPROD, V50, P413, DOI 10.1095/biolreprod50.2.413; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; Colbert MC, 1996, CIRC RES, V78, P790, DOI 10.1161/01.RES.78.5.790; CURIEL OA, 1993, DIFFERENTIATION, V52, P201; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FRAICHARD A, 1995, J CELL SCI, V108, P3181; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GLUKHOVA MA, 1991, AM J PHYSIOL, V261, P78, DOI 10.1152/ajpheart.1991.261.4.78; Gollasch M, 1996, CIRC RES, V78, P676, DOI 10.1161/01.RES.78.4.676; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GROSCHELSTEWART U, 1989, CELL TISSUE RES, V257, P137; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Haase H, 1996, J CELL BIOCHEM, V60, P521, DOI 10.1002/(SICI)1097-4644(19960315)60:4<521::AID-JCB8>3.0.CO;2-U; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; HALLER H, 1994, KIDNEY INT, V46, P1653, DOI 10.1038/ki.1994.465; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; JOHANSEN FF, 1995, NEUROCHEM INT, V26, P239, DOI 10.1016/0197-0186(94)00129-I; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIKAWA T, 1992, P NATL ACAD SCI USA, V89, P9504, DOI 10.1073/pnas.89.20.9504; Morano I, 1997, J CELL BIOCHEM, V64, P171, DOI 10.1002/(SICI)1097-4644(199702)64:2<171::AID-JCB1>3.0.CO;2-U; MUMMERY CL, 1990, CELL DIFFER DEV, V30, P195, DOI 10.1016/0922-3371(90)90139-N; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; OWENS GK, 1995, PHYSIOL REV, V75, P487; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; PAULETTO P, 1994, CIRC RES, V74, P774, DOI 10.1161/01.RES.74.5.774; PRICE RJ, 1994, CIRC RES, V75, P520, DOI 10.1161/01.RES.75.3.520; RISAU W, 1988, DEVELOPMENT, V102, P471; ROHWEDEL J, 1995, EXP CELL RES, V220, P92, DOI 10.1006/excr.1995.1295; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SIMEONE A, 1995, MECH DEVELOP, V51, P83, DOI 10.1016/0925-4773(95)96241-M; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Suzuki T, 1996, CIRC RES, V78, P395, DOI 10.1161/01.RES.78.3.395; WANG R, 1992, DEVELOPMENT, V114, P303; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P563, DOI 10.1071/RD9940563; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; WOBUS AM, 1995, ANN NY ACAD SCI, V752, P460, DOI 10.1111/j.1749-6632.1995.tb17456.x; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; WOBUS AM, 1994, ROUX ARCH DEV BIOL, V204, P36, DOI 10.1007/BF00189066; Wright G, 1996, AM J PHYSIOL-HEART C, V270, pH1363, DOI 10.1152/ajpheart.1996.270.4.H1363; XIAO YH, 1995, J CELL BIOL, V129, P1345, DOI 10.1083/jcb.129.5.1345	61	179	207	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					905	915		10.1096/fasebj.11.11.9285489	http://dx.doi.org/10.1096/fasebj.11.11.9285489			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285489				2022-12-25	WOS:A1997XT79000010
J	Boese, M; Keese, MA; Becker, K; Busse, R; Mulsch, A				Boese, M; Keese, MA; Becker, K; Busse, R; Mulsch, A			Inhibition of glutathione reductase by dinitrosyl-iron-dithiolate complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SERUM-ALBUMIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; GUANYLYL CYCLASE; S-NITROSOTHIOLS; DRUGS; NITROSYLATION; TRANSPORT; MECHANISM; NITROGEN	The biological signal molecule nitric oxide (NO) exists in a free and carrier-bound form. Since the structure of the carrier is likely to influence the interaction of NO with macromolecular targets, we assessed the interaction of a dinitrosyl-iron-dithiolate complex carrying different thiol ligands with glutathione reductase. The enzyme was irreversibly inhibited by dinitrosyl-iron-di-L-cysteine and dinitrosyl-iron-di-glutathione in a concentration-and time-dependent manner (IC50 30 and 3 mu m, respectively), Evaluation of the inhibition kinetics according to Kitz-Wilson yielded a K-i of 14 mu M, and a k(3) of 1.3 x 10(-3) s(-1), A participation of catalytic site thiols in the inhibitory mechanism was indicated by the findings that only the NADPH-reduced enzyme was inhibited by dinitrosyl-iron complex and that blockade of these thiols by Hg2+ afforded protection against irreversible inhibition, This inhibition was not accompanied by formation of a protein-bound dinitrosyl-iron complex and/or S-nitrosation of active site thiols (Cys-58 and Cys-63), However, one NO moiety exhibiting an acid lability similar to a secondary N-nitrosamine was present per mol of inhibited monomeric enzyme, These findings suggest specifically N-nitrosation of glutathione reductase as a likely mechanism of inhibition elicited by dinitrosyl-iron complex and demonstrate in general that structural resemblance of an NO carrier with a natural ligand enhances NO+ transfer to the ligand-binding protein.	UNIV FRANKFURT KLINIKUM, ZENTRUM PHYSIOL, D-60590 FRANKFURT, GERMANY; UNIV HEIDELBERG, INST BIOCHEM 2, D-69120 HEIDELBERG, GERMANY	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Ruprecht Karls University Heidelberg								BECKER K, 1995, EUR J BIOCHEM, V234, P472, DOI 10.1111/j.1432-1033.1995.472_b.x; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CHAMULITRAT W, 1995, ARCH BIOCHEM BIOPHYS, V316, P30, DOI 10.1006/abbi.1995.1006; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; FREEDMAN JE, 1995, J CLIN INVEST, V96, P394, DOI 10.1172/JCI118047; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; JOCHERSSCHERUBL MC, 1989, EUR J BIOCHEM, V180, P267; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KITZ R, 1962, J BIOL CHEM, V237, P3245; LEE MH, 1994, BIOCHEMISTRY-US, V33, P3679, DOI 10.1021/bi00178a026; MCDONALD B, 1993, P NATL ACAD SCI USA, V90, P11122, DOI 10.1073/pnas.90.23.11122; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Mohr S, 1996, J BIOL CHEM, V271, P4209; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MULSCH A, 1991, METHOD ENZYMOL, V195, P377; OAE S, 1977, CHEM LETT, V893, P65; PAI EF, 1983, J BIOL CHEM, V258, P1752; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHALLREUTER KU, 1990, BIOCHIM BIOPHYS ACTA, V1054, P14, DOI 10.1016/0167-4889(90)90199-N; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TRAVIS MD, 1997, IN PRESS AM J PHYSL; VANIN AF, 1975, BIOFIZIKA+, V20, P1068; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WORTHINGTON DJ, 1976, EUR J BIOCHEM, V67, P231, DOI 10.1111/j.1432-1033.1976.tb10654.x	35	67	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21767	21773		10.1074/jbc.272.35.21767	http://dx.doi.org/10.1074/jbc.272.35.21767			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268306	hybrid			2022-12-25	WOS:A1997XT85000018
J	Bohlmann, J; Steele, CL; Croteau, R				Bohlmann, J; Steele, CL; Croteau, R			Monoterpene synthases from Grand fir (Abies grandis) - cDNA isolation, characterization, and functional expression of myrcene synthase, (-)(4S)-limonene synthase, and (-)-(1S,5S)-pinene synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-DIPHOSPHATE SYNTHASE; SITE-DIRECTED MUTAGENESIS; SAGE SALVIA-OFFICINALIS; RESIN ACID BIOSYNTHESIS; SCOLYTUS-VENTRALIS COLEOPTERA; HIGH-LEVEL EXPRESSION; BACTERIAL EXPRESSION; SESQUITERPENE CYCLASE; PARTIAL-PURIFICATION; (+)-DELTA-CADINENE SYNTHASE	Grand fir (Abies grandis) has been developed as a model system for studying defensive oleoresin formation in conifers in response to insect attack or other injury, The turpentine fraction of the oleoresin is a complex mixture of monoterpene (C-10) olefins in which (-)-limonene and (-)-alpha- and (-)-beta-pinene are prominent components; (-)-limonene and (-)-pinene synthase activities are also induced upon stem wounding, A similarity based cloning strategy yielded three new cDNA species from a mounded stem cDNA library that appeared to encode three distinct monoterpene synthases, After expression in Escherichia coli and enzyme assay with geranyl diphosphate as substrate, subsequent analysis of the terpene products by chiral phase gas chromatography and mass spectrometry showed that these sequences encoded a (-)-limonene synthase, a myrcene synthase, and a (-)-pinene synthase that produces both alpha-pinene and beta-pinene. In properties and reaction stereochemistry, the recombinant enzymes resemble the corresponding native monoterpene synthases of wound-induced grand fir stem. The deduced amino acid sequences indicated the limonene synthase to be 637 residues in length (73.5 kDa), the myrcene synthase to be 627 residues in length (72.5 kDa), and the pinene synthase to be 628 residues in length (71.5 kDa); all of these monoterpene synthases appear to be translated as preproteins bearing an amino-terminal plastid targeting sequence. Sequence comparison revealed that these monoterpene synthases from grand fir resemble sesquiterpene (C-15) synthases and diterpene (C-20) synthases from conifers more closely than other monoterpene synthases from angiosperm species. This similarity between extant monoterpene, sesquiterpene, and diterpene synthases of gymnosperms is surprising since functional diversification of this enzyme class is assumed to have occurred over 300 million years ago. Wound-induced accumulation of transcripts for monoterpene synthases was demonstrated by RNA blot hybridization using probes derived from the three monoterpene synthase cDNAs. The availability of cDNA species encoding these monoterpene synthases mill allow an understanding of the regulation of oleoresin formation in conifers and will ultimately permit the transgenic manipulation of this defensive secretion to enhance resistance to insects. These cDNAs also furnish tools for defining structure-function relationships in this group of catalysts that generate acyclic, monocyclic, and bicyclic olefin products.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University; Washington State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031354, R01GM031354] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31354] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam KP, 1996, ARCH BIOCHEM BIOPHYS, V332, P352, DOI 10.1006/abbi.1996.0352; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; Bohlmann J, 1996, PLANT PHYSIOL, V111, P507, DOI 10.1104/pp.111.2.507; BOHLMANN J, 1995, PLANT J, V7, P491, DOI 10.1046/j.1365-313X.1995.7030491.x; Byers John A., 1995, P154; CANE DE, 1992, CIBA F SYMP, V171, P163; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chen XY, 1996, J NAT PROD, V59, P944, DOI 10.1021/np960344w; Chen XY, 1995, ARCH BIOCHEM BIOPHYS, V324, P255, DOI 10.1006/abbi.1995.0038; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CROTEAU R, 1989, J BIOL CHEM, V264, P15309; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1994, ARCH BIOCHEM BIOPHYS, V309, P184, DOI 10.1006/abbi.1994.1101; CROTEAU R, 1989, J BIOL CHEM, V264, P2075; CROTEAU R, 1988, J BIOL CHEM, V263, P10063; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; CROTEAU RB, 1990, J CHROMATOGR, V500, P349, DOI 10.1016/S0021-9673(00)96076-X; CROTEAU RB, 1987, BIOCHEMISTRY-US, V26, P5383, DOI 10.1021/bi00391a025; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; Dudareva N, 1996, PLANT CELL, V8, P1137, DOI 10.1105/tpc.8.7.1137; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUNK C, 1994, PLANT PHYSIOL, V106, P999, DOI 10.1104/pp.106.3.999; FUNK C, 1994, ARCH BIOCHEM BIOPHYS, V308, P258, DOI 10.1006/abbi.1994.1036; GAMBLIEL H, 1984, J BIOL CHEM, V259, P740; Gershenzon Jonathan, 1993, P339; GIJZEN M, 1991, ARCH BIOCHEM BIOPHYS, V289, P267, DOI 10.1016/0003-9861(91)90471-T; GIJZEN M, 1993, ACS SYM SER, V525, P8; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; HOHN TM, 1992, MOL PLANT MICROBE IN, V5, P249, DOI 10.1094/MPMI-5-249; JOHNSON MA, 1987, ACS SYM SER, V325, P76; JOLY A, 1993, J BIOL CHEM, V268, P26983; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; LAFEVER RE, 1994, ARCH BIOCHEM BIOPHYS, V313, P139, DOI 10.1006/abbi.1994.1370; LAFEVER RE, 1993, ARCH BIOCHEM BIOPHYS, V301, P361, DOI 10.1006/abbi.1993.1156; LANGENHEIM JH, 1990, AM SCI, V78, P16; LANGENHEIM JH, 1969, SCIENCE, V163, P1157, DOI 10.1126/science.163.3872.1157; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P38, DOI 10.1104/pp.96.1.38; LEWINSOHN E, 1992, ACS SYM SER, V497, P8; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P44, DOI 10.1104/pp.96.1.44; Lewinsohn E., 1994, Plant Molecular Biology Reporter, V12, P20, DOI 10.1007/BF02668660; LEWINSOHN E, 1993, PHYTOCHEM ANALYSIS, V4, P220, DOI 10.1002/pca.2800040506; LEWINSOHN E, 1992, ARCH BIOCHEM BIOPHYS, V293, P167, DOI 10.1016/0003-9861(92)90380-F; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; MCCASKILL D, 1997, ADV BIOCHEM ENG BIOT, V55, P108; MCGARVEY DJ, 1995, PLANT CELL, V7, P1015, DOI 10.1105/tpc.7.7.1015; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; RAFFA KF, 1982, CAN ENTOMOL, V114, P797, DOI 10.4039/Ent114797-9; RAFFA KF, 1985, ENVIRON ENTOMOL, V14, P552, DOI 10.1093/ee/14.5.552; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V296, P49, DOI 10.1016/0003-9861(92)90543-6; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; Sambrock J, 1989, MOL CLONING LAB MANU; SAVAGE TJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P257, DOI 10.1016/0003-9861(95)90008-X; SAVAGE TJ, 1994, J BIOL CHEM, V269, P4012; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; STEELE CL, 1995, P NATL ACAD SCI USA, V92, P4164, DOI 10.1073/pnas.92.10.4164; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Vogel BS, 1996, J BIOL CHEM, V271, P23262, DOI 10.1074/jbc.271.38.23262; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAGSCHAL K, 1991, TETRAHEDRON, V47, P5933, DOI 10.1016/S0040-4020(01)86486-3; WAGSCHAL KC, 1994, ARCH BIOCHEM BIOPHYS, V308, P477, DOI 10.1006/abbi.1994.1068; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201; Yamaguchi S, 1996, PLANT J, V10, P203, DOI 10.1046/j.1365-313X.1996.10020203.x; Yuba A, 1996, ARCH BIOCHEM BIOPHYS, V332, P280, DOI 10.1006/abbi.1996.0343	75	190	229	2	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21784	21792		10.1074/jbc.272.35.21784	http://dx.doi.org/10.1074/jbc.272.35.21784			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268308	hybrid			2022-12-25	WOS:A1997XT85000020
J	Lee, H; Suh, BC; Kim, KT				Lee, H; Suh, BC; Kim, KT			Feedback regulation of ATP-induced Ca2+ signaling in HL-60 cells is mediated by protein kinase A- and C-mediated changes in capacitative Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ENTRY; EXTRACELLULAR ATP; PLASMA-MEMBRANE; P2-PURINERGIC RECEPTORS; HUMAN-NEUTROPHILS; CA-2+ RELEASE; PC12 CELLS; INFLUX; ACTIVATION; INHIBITION	Extracellular ATP increases intracellular Ca2+ ([Ca2+](i)) in HL-60 cells. When cells are stimulated with supramaximal concentrations of ATP, although the initial [Ca2+](i) increase is similar over a range of 30, 100, and 300 mu M ATP, the rate of the return to basal [Ca2+](i) level is faster in cells treated with higher concentrations of ATP, This probably results from differences in Ca2+ influx rather than Ca2+ release, since the influx of the unidirectional Ca2+ surrogates Ba2+ and Mn2+ also exhibit similar responses, Furthermore, while 300 mu M ATP had an inhibitory effect on the thapsigargin-induced capacitative Ca2+ entry, 30 mu M ATP potentiated the response, However, the inhibitory action of 300 mu M ATP was blocked by protein kinase C (PKC) inhibitors, such as GF 109203X and chelerythrine, and the potentiating action of 30 mu M ATP was blocked by protein kinase A (PKA) inhibitors H89 and Rp-cAMPS, The PKC inhibitors also slowed the decay rate of the Ca2+ response induced by 300 mu M ATP, and the PKA inhibitors increased it when induced by 30 mu M ATP. In the measurements of PKA and PKC activity, 30 mu M ATP activates only PKA, while 300 mu M ATP activates both kinases, Taken together, these data suggest that the changes in the ATP-induced Ca2+ response result from differential modulation of ATP-induced capacitative Ca2+ entry by PKC and PKA in HL-60 cells.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POSTECH,POHANG 790784,SOUTH KOREA	Pohang University of Science & Technology (POSTECH)				KIM, KYONG-TAI/0000-0001-7292-2627				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; Buell G, 1996, BLOOD, V87, P2659, DOI 10.1182/blood.V87.7.2659.bloodjournal8772659; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; Choi SY, 1997, BIOCHEM PHARMACOL, V53, P429, DOI 10.1016/S0006-2952(96)00719-8; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; DAVIES WA, 1993, ENDOCRINOLOGY, V132, P2491, DOI 10.1210/en.132.6.2491; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; KRAUTWURST D, 1992, BIOCHEM J, V288, P1025, DOI 10.1042/bj2881025; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; LEE KM, 1993, J BIOL CHEM, V268, P9945; MCCARTHY SA, 1989, BIOCHEM J, V264, P357, DOI 10.1042/bj2640357; MONTERO M, 1993, J BIOL CHEM, V268, P13055; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; NOLAND TA, 1986, BIOL REPROD, V35, P863, DOI 10.1095/biolreprod35.4.863; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SUH BC, 1995, J NEUROCHEM, V64, P2500; Suh BC, 1996, J BIOL CHEM, V271, P32753, DOI 10.1074/jbc.271.51.32753; SUH BC, 1995, J NEUROCHEM, V64, P1071; SUH BC, 1994, BIOCHEM PHARMACOL, V47, P1262, DOI 10.1016/0006-2952(94)90399-9; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPEL M, 1994, J BIOL CHEM, V269, P26239; TORNQUIST K, 1993, BIOCHEM J, V290, P443; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21831	21838		10.1074/jbc.272.35.21831	http://dx.doi.org/10.1074/jbc.272.35.21831			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268314	hybrid			2022-12-25	WOS:A1997XT85000026
J	Yoshizumi, M; Wang, H; Hsieh, CM; Sibinga, NES; Perrella, MA; Lee, ME				Yoshizumi, M; Wang, H; Hsieh, CM; Sibinga, NES; Perrella, MA; Lee, ME			Down-regulation of the cyclin a promoter by transforming growth factor-beta 1 is associated with a reduction in phosphorylated activating transcription factor-1 and cyclic AMP-responsive element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NUCLEAR FACTOR CREB; FACTOR-BETA; TGF-BETA; GENE-EXPRESSION; A EXPRESSION; ENDOTHELIAL-CELLS; CDK INHIBITORS; KINASE-A; C-MYC	Transforming growth factor (TGF)-beta 1 prevents cell cycle progression by inhibiting several regulators, including cyclin A. To study the mechanisms by which TGF-beta 1 down-regulates cyclin A gene expression, we transfected reporter plasmids driven by the cyclin A prometer into mink lung epithelial cells in the absence and presence of TGF-beta 1, The TGF-beta 1-induced down-regulation of cyclin A promoter activity appeared to be mediated via the activating transcription factor (ATF) site, because mutation of this site abolished down-regulation, Surprisingly, although TGF-beta 1 treatment for 24 h markedly decreased cyclin A promoter activity, it did not decrease the abundance of the ATF-binding proteins ATF-1 and cyclic AMP-responsive binding protein (CREB), However, we detected 90 and 78% reductions (by Western analysis) in phosphorylated CREB and ATF-1, respectively, in mink lung epithelial cells treated with TGF-beta 1, TGF-beta 1-induced down-regulation of cyclin A promoter activity was reversed by okadaic acid (a phosphatase inhibitor) and by cotransfection with plasmids expressing the cAMP dependent protein kinase catalytic subunit or the simian virus small tumor antigen (Sm-t, an inhibitor of PP2A), These data indicate that TGF-beta 1 may down-regulate cyclin A promoter activity by decreasing phosphorylation of CREB and ATF-1.	HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital			Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03194, HL03274] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE ME, 1991, J BIOL CHEM, V266, P16188; LIU F, 1993, J BIOL CHEM, V268, P6714; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SCHNEIDER MD, 1986, MOL CELL BIOL, V6, P4140, DOI 10.1128/MCB.6.11.4140; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	51	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22259	22264		10.1074/jbc.272.35.22259	http://dx.doi.org/10.1074/jbc.272.35.22259			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268374	hybrid			2022-12-25	WOS:A1997XT85000086
J	Chi, KD; McPhee, RA; Wagner, AS; Dietz, JJ; Pantazis, P; Goustin, AS				Chi, KD; McPhee, RA; Wagner, AS; Dietz, JJ; Pantazis, P; Goustin, AS			Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I-infected T-cells results in a novel tyrosine kinase product with transforming activity	ONCOGENE			English	Article						receptor tyrosine kinase; PDGF; insertional mutagenesis; HTLV-I; long terminal repeat; T-lymphocyte	VIRUS TYPE-I; DIFFERENT SIGNALING PATHWAYS; BOVINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL TRANSLOCATION; NUCLEOTIDE-SEQUENCE; HUMAN RETROVIRUS; RNA EXPRESSION	We have previously shown that noninfected human T-cell lines express the canonical 5.7 kb mRNA coding for the type beta platelet-derived growth factor-receptor (PDGF beta-receptor), whereas HTLV-I-infected T-cell lines express a novel PDGF beta-receptor mRNA of 3.8 kb, In this report, we have extended those studies to molecularly characterize the 3.8 kb PDGF beta-receptor mRNA and show that it has resulted from integration of an apparently undeleted HTLV-I provirus into the PDGF beta-receptor gene in an orientation enabling expression of a truncated PDGF beta-receptor mRNA using the 3' HTLV-I long terminal repeat as a promoter, Further, NIH3T3 cells transfected with a plasmid containing the truncated PDGF beta-receptor ORF plasmid generate colonies in soft agar with more cells per colony than untransfected cells, or cells transfected with the Tax 1 or PDGF-B (c-sis) plasmids, These results indicate that the truncated PDGF beta-receptor protein acquires transforming capability and that HTLV-I-induced truncation of PDGF beta-receptor may correlate with HTLV-I-associated neoplasia of human T-cells.	WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,DETROIT,MI 48201; STEHLIN FDN CANC RES,HOUSTON,TX 77003	Wayne State University; Wayne State University			Goustin, Anton Scott/A-2136-2011	Goustin, Anton Scott/0000-0002-4483-5101	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027444] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD27444] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEPPER JM, 1984, J IMMUNOL, V133, P1691; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Goustin AS, 1990, GROWTH FACTORS, V2, P189, DOI 10.3109/08977199009071505; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3425; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KETTMANN R, 1982, P NATL ACAD SCI-BIOL, V79, P2465, DOI 10.1073/pnas.79.8.2465; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; Kubota S, 1996, ONCOGENE, V12, P1441; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARRIOTT SJ, 1992, ONCOGENE, V7, P1749; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; OHSHIMA K, 1991, CANCER RES, V51, P4639; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; PANTAZIS P, 1987, ONCOGENE, V1, P285; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; RAO VN, 1993, ONCOGENE, V8, P2167; RATNER L, 1985, J VIROL, V54, P781, DOI 10.1128/JVI.54.3.781-790.1985; REITZ MS, 1981, P NATL ACAD SCI-BIOL, V78, P1887, DOI 10.1073/pnas.78.3.1887; SAGGIORO D, 1990, CANCER RES, V50, P4968; SAKURAI H, 1992, LEUKEMIA RES, V16, P941, DOI 10.1016/0145-2126(92)90040-E; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SEIGEL LJ, 1986, VIROLOGY, V154, P67, DOI 10.1016/0042-6822(86)90430-7; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P6657, DOI 10.1073/pnas.81.21.6657; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; UMADOME H, 1988, J CLIN INVEST, V81, P52, DOI 10.1172/JCI113309; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDENBROEKE A, 1988, P NATL ACAD SCI USA, V85, P9263, DOI 10.1073/pnas.85.23.9263; WATANABE T, 1984, VIROLOGY, V133, P238, DOI 10.1016/0042-6822(84)90446-X	48	10	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1051	1057		10.1038/sj.onc.1201267	http://dx.doi.org/10.1038/sj.onc.1201267			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285559				2022-12-25	WOS:A1997XT16100006
J	Gaffet, P; Jones, AT; Clague, MJ				Gaffet, P; Jones, AT; Clague, MJ			Inhibition of calcium-independent mannose 6-phosphate receptor incorporation into trans-Golgi network-derived clathrin-coated vesicles by Wortmannin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; ENDOCYTIC VESICLES; LYSOSOMAL-ENZYMES; KINASE-ACTIVITY; PROTEIN-KINASE; YEAST; CELLS; INTERNALIZATION; TRAFFICKING; COMPLEX	The transport of pro-catepsin D from the trans-Golgi network (TGN) to the endosomal pathway is dependent on binding to the calcium-independent mannose 6-phosphate receptor (ci-M6PR), which is incorporated into TGN-derived clathrin-coated transport vesicles (CCVs). Inhibition of this transport step by wortmannin has led to the proposal that it is dependent upon a phosphoinositide 3-kinase activity necessary for ci-M6PR recruitment into TGM-derived CCVs or in the formation of those vesicles (Brown, W., J,, DeWald, D, B,, Emr, S. D,, Plutner, H., and Balch, W, E, (1995) J. Cell Biol. 130, 781-796; Davidson, H, W. (1995) J. Cell Biol. 130, 781-796), In this study we have addressed the effect of wortmannin on the TGN step of the ci-M6PR, cycle, CCVs from H562 cells, pretreated or not with 250 nM wortmannin, were purified on equilibrium density gradients. Quantification of TGN-derived CCVs, assessed by gamma-adaptin content in purified vesicle fractions, showed that the formation of the vesicles was only marginally decreased after 20 min of treatment with the drug, while for the same wortmannin treatment, the drug of ci-M6PR recruited into those vesicles was decreased by 70% compared with control, At a later time point (2 h), a reduction in the amount of gamma-adaptin in CCV fractions was also observed, These findings demonstrate that inhibition of ci-M6PR recruitment into CCVs but not of vesicle formation is the primary reason for the observed defect in cathepsin D transport following wortmannin treatment.	UNIV LIVERPOOL,PHYSIOL LAB,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Clague, Michael J/A-7199-2008; Jones, Arwyn/ABE-8709-2020; Jones, Arwyn T/E-4787-2010	Clague, Michael J/0000-0003-3355-9479; Jones, Arwyn/0000-0003-2781-8905; Jones, Arwyn T/0000-0003-2781-8905	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CLAGUE MJ, 1995, FEBS LETT, V367, P272, DOI 10.1016/0014-5793(95)00576-U; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JIN M, 1989, J BIOL CHEM, V264, P7675; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; Nakajima Y, 1997, MOL BIOL CELL, V8, P577, DOI 10.1091/mbc.8.4.577; Panaretou C, 1997, J BIOL CHEM, V272, P2477; PEARSE BMF, 1983, METHOD ENZYMOL, V98, P320; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Sato SB, 1996, J BIOCHEM, V119, P887; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEPHENS L, 1995, BIOCHEM SOC T, V23, P207, DOI 10.1042/bst0230207; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; WOODMAN PG, 1992, METHOD ENZYMOL, V219, P251; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	39	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24170	24175		10.1074/jbc.272.39.24170	http://dx.doi.org/10.1074/jbc.272.39.24170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305867	hybrid			2022-12-25	WOS:A1997XY51500018
J	Gordon, DF; Lewis, SR; Haugen, BR; James, RA; McDermott, MT; Wood, WM; Ridgway, EC				Gordon, DF; Lewis, SR; Haugen, BR; James, RA; McDermott, MT; Wood, WM; Ridgway, EC			Pit-1 and GATA-2 interact and functionally cooperate to activate the thyrotropin beta-subunit promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-2; COMPOSITE RESPONSE ELEMENT; GENE-EXPRESSION; PITUITARY-GLAND; GROWTH-HORMONE; POU-DOMAIN; MURINE THYROTROPIN; ANTERIOR-PITUITARY; FACTOR PIT-1/GHF-1; HOMEODOMAIN FACTOR	The molecular determinants governing cell-specific expression of the thyrotropin (TSH) beta-subunit gene in pituitary thyrotropes are not well understood, The P1 region of the mouse TSH beta promoter (-133 to -88) region interacts with Pit-1 and an additional 50-kDa factor at an adjacent site that resembles a consensus GATA binding site. Northern and Western blot assays demonstrated the presence of GATA-2 transcripts and protein in TtT-97 thyrotropic tumors, In electrophoretic mobility shift assays, a comigrating complex was observed with both TtT-97 nuclear extracts and GATA-2 expressed in COS cells, The complex demonstrated binding specificity to the P1 region DNA probe and could be disrupted by a GATA-2 antibody, When both Pit-1 and GATA-2 were combined, a slower migrating complex, indicative of a ternary protein-DNA interaction was observed. Cotransfection of both Pit-1 and GATA-2 into CV-1 cells synergistically stimulated mouse TSH beta promoter activity 8.5-fold, while each factor alone had a minimal effect, Mutations that abrogated this functional stimulatory effect mapped to the P1 region. Finally, we show that GATA-2 directly interacts with Pit-1 in solution, In summary, these data demonstrate functional synergy and physical interaction between homeobox and zinc finger factors and provide insights into the transcriptional mechanisms of thyrotrope-specific gene expression.	UNIV COLORADO,HLTH SCI CTR,DIV ENDOCRINOL DIABET & METAB,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036843, K08DK002331] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NIDDK NIH HHS [DK36843, DK02331] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERBLOM IE, 1990, MOL ENDOCRINOL, V4, P589, DOI 10.1210/mend-4-4-589; ALEXANDER LM, 1989, MOL ENDOCRINOL, V3, P1037, DOI 10.1210/mend-3-7-1037; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GORDON DF, 1990, MOL CELL ENDOCRINOL, V71, P93, DOI 10.1016/0303-7207(90)90246-5; GORDON DF, 1993, MOL CELL ENDOCRINOL, V96, P75, DOI 10.1016/0303-7207(93)90097-4; GORDON DF, 1988, DNA-J MOLEC CELL BIO, V7, P17, DOI 10.1089/dna.1988.7.17; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAUGEN BR, 1994, MOL ENDOCRINOL, V8, P1574, DOI 10.1210/me.8.11.1574; Haugen BR, 1996, J BIOL CHEM, V271, P385, DOI 10.1074/jbc.271.1.385; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; KENDALL SK, 1994, MOL ENDOCRINOL, V8, P1420, DOI 10.1210/me.8.10.1420; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; LIN SC, 1994, DEVELOPMENT, V120, P515; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Mink S, 1996, MOL CELL BIOL, V16, P1316; NAGAI T, 1994, BLOOD, V84, P1074, DOI 10.1182/blood.V84.4.1074.bloodjournal8441074; OCRAN KW, 1990, MOL ENDOCRINOL, V4, P766, DOI 10.1210/mend-4-5-766; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSS DS, 1983, ENDOCRINOLOGY, V112, P2050, DOI 10.1210/endo-112-6-2050; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; SHUPNIK MA, 1992, MOL ENDOCRINOL, V6, P43, DOI 10.1210/me.6.1.43; SHUPNIK MA, 1989, ENDOCR REV, V10, P459, DOI 10.1210/edrv-10-4-459; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WOOD WM, 1990, MOL ENDOCRINOL, V4, P1897, DOI 10.1210/mend-4-12-1897; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	77	110	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24339	24347		10.1074/jbc.272.39.24339	http://dx.doi.org/10.1074/jbc.272.39.24339			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305891	hybrid			2022-12-25	WOS:A1997XY51500042
J	Liu, XL; DeMoss, JA				Liu, XL; DeMoss, JA			Characterization of NarJ, a system-specific chaperone required for nitrate reductase biogenesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-B; GENE-PRODUCT; OPERON; SEQUENCE; PROTEINS; SUBUNIT; IDENTIFICATION; ASSOCIATION; INVOLVEMENT; EXPRESSION	The narGHJI operon encodes the three subunits, alpha, beta, and gamma, of the respiratory nitrate reductase complex in Escherichia coli, A fourth open reading frame of the operon encodes a putative protein, NarJ, which is not present in purified nitrate reductase, bat is required for biogenesis of the membrane-bound complex. NarJ was identified with a T7 expression system and was produced at significantly less than stoichiometric levels relative to the three enzyme subunits. A functional His-tagged NarJ fusion protein was overexpressed di om a multicopy plasmid, purified by Ni2+ affinity chromatography, and characterized. Western blot analysis with antibodies raised against the fusion protein demonstrated that NarJ remained in the cytosol after assembly of the active membrane complex, The cytosolic alpha beta complex accumulated in a nard insertion mutant was rapidly degraded after induction, but was stabilized by NarJ expressed from a multicopy plasmid. Overproduction of the His-tagged NarJ fusion protein in the same mutant led to the formation of an alpha beta NarJ complex, which was resolved by Ni2+ affinity chromatography, The NarJ protein therefore has the properties of a system-specific (private) chaperone that reacts directly with and modifies the properties of the cytosolic alpha beta subunit complex, but remains in the cytoplasm after the assembly of the active alpha beta gamma complex in the membrane.	UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA	University of Texas System								ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; BERKS BC, 1995, MOL MICROBIOL, V15, P319, DOI 10.1111/j.1365-2958.1995.tb02246.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BLASCO F, 1992, MOL MICROBIOL, V6, P221, DOI 10.1111/j.1365-2958.1992.tb02003.x; CHAUDHRY GR, 1983, J BIOL CHEM, V258, P5819; DUBOURDIEU M, 1992, J BACTERIOL, V174, P867, DOI 10.1128/jb.174.3.867-872.1992; EDWARDS ES, 1983, J BACTERIOL, V153, P1513, DOI 10.1128/JB.153.3.1513-1520.1983; Edwards RA, 1996, J BACTERIOL, V178, P3426, DOI 10.1128/jb.178.12.3426-3433.1996; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ENOCH HG, 1974, BIOCHEM BIOPH RES CO, V61, P1234, DOI 10.1016/S0006-291X(74)80416-X; GLASER JH, 1972, MOL GEN GENET, V116, P1, DOI 10.1007/BF00334254; HOBSON AH, 1993, P NATL ACAD SCI USA, V90, P5682, DOI 10.1073/pnas.90.12.5682; HOFFMANN T, 1995, FEMS MICROBIOL LETT, V131, P219, DOI 10.1111/j.1574-6968.1995.tb07780.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND K, 1976, J BIOL CHEM, V251, P2207; MACGREGOR CH, 1974, J BIOL CHEM, V249, P5321; MORPETH FF, 1985, BIOCHEMISTRY-US, V24, P40, DOI 10.1021/bi00322a007; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; SCHUMPERLI D, 1982, CELL, V30, P865, DOI 10.1016/0092-8674(82)90291-4; SODERGREN EJ, 1988, J BACTERIOL, V170, P1721, DOI 10.1128/jb.170.4.1721-1729.1988; SODERGREN EJ, 1988, J BIOL CHEM, V263, P16156; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; STEWART V, 1988, MICROBIOL REV, V52, P190, DOI 10.1128/MMBR.52.2.190-232.1988; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	29	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24266	24271		10.1074/jbc.272.39.24266	http://dx.doi.org/10.1074/jbc.272.39.24266			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305880	hybrid			2022-12-25	WOS:A1997XY51500031
J	Stasche, R; Hinderlich, S; Weise, C; Effertz, K; Lucka, L; Moormann, P; Reutter, W				Stasche, R; Hinderlich, S; Weise, C; Effertz, K; Lucka, L; Moormann, P; Reutter, W			A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver - Molecular cloning and functional expression of UDP-N-acetyl-glucosamine 2-epimerase/N-acetylmannosamine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID; PROTEINS; TUMOR; OLIGOSACCHARIDES; RECOGNITION; 2-EPIMERASE; MUTANTS; BINDING; KIDNEY	N-Acetylneuraminic acid (Neu5Ac) is the precursor of sialic acids, a group of important molecules in biological recognition systems, Biosynthesis of Neu5Ac is initiated and regulated by its key enzyme, UDP-N-acetylglucosamine a-epimerase (UDP-GlcNAc a-epimerase, EC 5.1.3.14)/N-acetylmannosamine kinase (ManNAc kinase, EC 2.7.1.60) in rat liver (Hinderlich, S., Stasche, R., Zeitler, R., and Reutter, W. (1997) J. Biol. Chen. 272, 24313-24318), In the present paper we report the isolation and characterization of a cDNA clone encoding this bifunctional enzyme. An open reading frame of 2166 base pairs encodes 722 amino acids with a predicted molecular mass of 79 kDa. The deduced amino acid sequence contains exact matches of the sequences of five peptides derived from tryptic cleavage of the enzyme, The recombinant bifunctional enzyme was expressed in COS7 cells, where it displayed both epimerase and kinase activity. Distribution of UDP-GlcNAc 2-epimerase/ManNAc kinase in the cytosol of several rat tissues was investigated by determining both specific enzyme activities. Secreting organs (liver, salivary glands, and intestinal mucosa) showed high specific activities of UDP-GlcNAc 2-epimerase/ManNAc kinase, whereas significant levels of these activities were absent from other organs (lung, kidney, spleen, brain, heart, skeletal muscle, and testis). Northern blot analysis revealed no UDP-GlcNAc 2-epimerase/ManNAc kinase mRNA in the non-secreting tissues.	FREE UNIV BERLIN, INST MOL BIOL & BIOCHEM, D-14195 BERLIN, GERMANY; FREE UNIV BERLIN, INST BIOCHEM, D-14195 BERLIN, GERMANY	Free University of Berlin; Free University of Berlin								ALLEN MB, 1980, BIOCHEM J, V185, P577, DOI 10.1042/bj1850577; BASU S, 1995, BIOL SIALIC ACIDS, P7; BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BOULARD C, 1982, J IMMUNOL METHODS, V50, P221, DOI 10.1016/0022-1759(82)90228-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTA A, 1970, BIOCHEMISTRY-US, V9, P3363, DOI 10.1021/bi00819a011; DENNIS JW, 1986, EUR J BIOCHEM, V161, P359, DOI 10.1111/j.1432-1033.1986.tb10455.x; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Maru I, 1996, J BIOL CHEM, V271, P16294, DOI 10.1074/jbc.271.27.16294; NUCK R, 1990, GLYCOCONJUGATE J, V7, P279, DOI 10.1007/BF01073372; PESSINO A, 1991, J BIOL CHEM, V266, P20213; PIRIESHEPHERD SR, 1995, J BIOL CHEM, V270, P5877, DOI 10.1074/jbc.270.11.5877; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; Reuter G, 1996, BIOL CHEM H-S, V377, P325; Reutter, 1997, GLYCOSCIENCES STATUS, P245; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; SAITO M, 1995, BIOL SIALIC ACIDS, P7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; VANRINSUM J, 1983, BIOCHEM J, V210, P21, DOI 10.1042/bj2100021; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WARREN L, 1972, GLYCOPROTEINS, P1097; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YANG PF, 1994, J BIOL CHEM, V269, P23039	39	150	158	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24319	24324		10.1074/jbc.272.39.24319	http://dx.doi.org/10.1074/jbc.272.39.24319			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305888	hybrid			2022-12-25	WOS:A1997XY51500039
J	Zha, JP; Harada, H; Osipov, K; Jockel, J; Waksman, G; Korsmeyer, SJ				Zha, JP; Harada, H; Osipov, K; Jockel, J; Waksman, G; Korsmeyer, SJ			BH3 domain of BAD is required for heterodimerization with BCL-X-L and pro-apoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-X(L); PROTEIN; INHIBITION; INTERACTS; DISTINCT; SEQUENCE; SURVIVAL	BAD interacts with anti-apoptotic molecules BCL-2 and BCL-X-L and promotes apoptosis. BAD is phosphorylated on serine residues in response to a survival factor, interleukin-3. Phosphorylated BAD cannot bind to BCL-X-L or BCL-2 at membrane sites and is found in the cytosol bound to 14-3-3. We report here that deletion mapping and site-directed mutagenesis identified a BH3 domain within BAD that proved necessary for both its heterodimerization with BCL-X-L and its death agonist activity. Substitution of the conserved Leu(151) with Ala in the BH3 amphipathic alpha-helix abrogated both functions. The BAD Leu(151) mutant was predominantly in the cytosol bound to 14-3-3. The BH3 domain of BCL-2 also proved important for BCL-2/BAD interaction. These results establish a critical role for a BH3 domain within BAD and provide evidence that BAD may function as a death ligand whose pro-apoptotic activity requires heterodimerization with BCL-X-L.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	Zha, JP (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED & PATHOL,ST LOUIS,MO 63110, USA.							BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Han J, 1996, MOL CELL BIOL, V16, P5857; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	18	257	284	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24101	24104		10.1074/jbc.272.39.24101	http://dx.doi.org/10.1074/jbc.272.39.24101			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305851	hybrid			2022-12-25	WOS:A1997XY51500002
J	Chen, Y; Sharp, ZD; Lee, WH				Chen, Y; Sharp, ZD; Lee, WH			HEC binds to the seventh regulatory subunit of the 26 S proteasome and modulates the proteolysis of mitotic cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-MEDIATED TRANSACTIVATION; ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE; RETINOBLASTOMA PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; ATPASE ACTIVITY; GENE; IDENTIFICATION; YEAST	A newly identified nuclear protein rich in leucine heptad repeats called HEC is important for mitosis. To elucidate its mechanism of action, the region containing leucine heptad repeats was used to identify cellular proteins that potentially interact with HEC. Complementary DNAs encoding several proteins including MSS1, p45, Nek2, and Smc1/Smc2, known to be important for G(2)/M progression, were identified. The interaction be tween HEC and MSS1, the seventh regulatory subunit of the 26 S proteasome, was further demonstrated by in vitro GST pull-down assays. HEC is not a part of the 26 S proteasome and interacts with MSS1 only when it is dissociated from the complex during M phase. Purified MSS1 specifically hydrolyzes ATP, an activity inhibited by HEC. In addition, HEC inhibits the proteolysis of mitotic cyclin B in vitro. Consistent with this biochemical activity, ectopic expression of HEC inhibits the degradation of mitotic cyclins after telophase, resulting eventually in cell death. These results show that HEC is a negative regulator of MSS1 and suggest that it may modulate M phase progression, in part, through the regulation of proteasome mediated degradation of cell cycle regulatory proteins.	UNIV TEXAS,HLTH SCI CTR,DEPT MOL MED,SAN ANTONIO,TX 78245; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio					NATIONAL CANCER INSTITUTE [R01CA058318] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [CA58318] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN Y, 1997, IN PRESS MOL CELL BI, V17; Chen YM, 1996, CANCER RES, V56, P3168; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; He D, 1995, INT REV CYTOL, V162B, P1; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; LU KP, 1994, J BIOL CHEM, V269, P6603; LUCERO HA, 1995, J BIOL CHEM, V270, P9178, DOI 10.1074/jbc.270.16.9178; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; ROCQUES PJ, 1995, HUM MOL GENET, V4, P243, DOI 10.1093/hmg/4.2.243; ROY R, 1994, J BIOL CHEM, V269, P9826; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	40	40	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24081	24087		10.1074/jbc.272.38.24081	http://dx.doi.org/10.1074/jbc.272.38.24081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295362	hybrid			2022-12-25	WOS:A1997XX38100087
J	ZernikKobak, M; Vasunia, K; Connelly, M; Anderson, CW; Dixon, K				ZernikKobak, M; Vasunia, K; Connelly, M; Anderson, CW; Dixon, K			Sites of UV-induced phosphorylation of the p34 subunit of replication protein A from HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; NUCLEOTIDE EXCISION-REPAIR; BINDING-PROTEIN; A PHOSPHORYLATION; PURIFIED PROTEINS; POLYMERASE-ALPHA; SV40 ORIGIN; T-ANTIGEN; IN-VITRO; CYCLIN-A	Exposure of mammalian cells to UV radiation alters gene expression and cell cycle progression; some of these responses may ensure survival or serve as mutation-avoidance mechanisms, lessening the consequences of UV-induced DNA damage, We showed previously that UV irradiation increases phosphorylation of the p34 subunit of human replication protein A (RPA) and that this hyperphosphorylation correlated with loss of activity of the DNA replication complex. To characterize further the role of RPA hyperphosphorylation in the cellular response to UV irradiation and to determine which protein kinases might be involved, we identified by phosphopeptide analysis the sites phosphorylated in the p34 subunit of RPA (RPA-p34) from HeLa cells before and after exposure to 30 J/m(2) UV light. In unirradiated HeLa cells, RPA-p34 is phosphorylated primarily at Ser-23 and Ser-29. At least four of the eight serines and one threonine in the N-terminal 33 residues of RPA-p34 can become phosphorylated after UV irradiation, Two of these sites (Ser-23 and Ser-29) ape known to be sites phosphorylated by Cdc2 kinase; two others (Thr-21 and Ser-33) are consensus sites for the DNA-dependent protein kinase (DNA-PK); the fifth site (Ser-11, -12, or -13) does not correspond to the (Ser/Thr)-Gln DNA-PK consensus, All five can be phosphorylated in vitro by incubating purified RPA with purified DNA-PK. Two additional sites, probably Ser-4 and Ser-8, are phosphorylated in vivo after UV irradiation and in vitro by purified DNA-PK. The capacity of purified DNA-PK to phosphorylate many of these same sites on RPA-p34 in vitro implicates DNA-PK or a kinase with similar specificity in the UV-induced hyperphosphorylation of RPA in vivo.	BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	ZernikKobak, M (corresponding author), UNIV CINCINNATI, MED CTR, SCH MED, DEPT ENVIRONM HLTH, CINCINNATI, OH 45267 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05400, P30 ES06096] Funding Source: Medline; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BENOREPARSONS M, 1989, ARCH BIOCHEM BIOPHYS, V272, P274, DOI 10.1016/0003-9861(89)90220-8; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI L, 1995, MOL CELL BIOL, V15, P5396; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	51	110	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23896	23904		10.1074/jbc.272.38.23896	http://dx.doi.org/10.1074/jbc.272.38.23896			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295339	hybrid			2022-12-25	WOS:A1997XX38100064
J	Maucuer, A; Ozon, S; Manceau, V; Gavet, O; Lawler, S; Curmi, P; Sobel, A				Maucuer, A; Ozon, S; Manceau, V; Gavet, O; Lawler, S; Curmi, P; Sobel, A			KIS is a protein kinase with an RNA recognition motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNAL-TRANSDUCTION; TRANSLATION INITIATION; DISTINCT PATTERNS; ESCHERICHIA-COLI; PHOSPHORYLATION; STATHMIN; CELLS; IDENTIFICATION; ONCOPROTEIN-18; GENE	Protein phosphorylation is involved at multiple steps of RNA processing and in the regulation of protein expression, We present here the first identification of a serine/threonine kinase that possesses an RNP-type RNA recognition motif: KIS. We originally isolated KIS in a two-hybrid screen through its interaction with stathmin, a small phosphoprotein proposed to play a general role in the relay and integration of diverse intracellular signaling pathways. Determination of the primary sequence of KIS shows that it is formed by the juxtaposition of a kinase core with little homology to known kinases and a C-terminal domain that contains a characteristic RNA recognition motif with an intriguing homology to the C-terminal motif of the splicing factor U2AF, KIS produced in bacteria has an autophosphorylating activity and phosphorylates stathmin on serine residues. It also phosphorylates in vitro other classical substrates such as myelin basic protein and synapsin but not histones that inhibit its autophosphorylating activity, Immunofluorescence and biochemical analyses indicate that KIS overexpressed in HEK293 fibroblastic cells is partly targetted to the nucleus. Altogether, these results suggest the implication of KIS in the control of trafficking and/or splicing of RNAs probably through phosphorylation of associated factors.			Maucuer, A (corresponding author), INSERM, U440, 17 RUE FER A MOULIN, F-75005 PARIS, FRANCE.		CURMI, Patrick/G-4036-2013; Maucuer, Alexandre/B-1069-2019	Maucuer, Alexandre/0000-0003-2947-6654; CURMI, Patrick A./0000-0001-5045-8501				Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BERETTA L, 1989, ENDOCRINOLOGY, V125, P1358, DOI 10.1210/endo-125-3-1358; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOYE V, 1990, J BIOL CHEM, V265, P11650; FRITSCH EF, 1989, MOL CHANGE LAB MANUA; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILBERG MS, 1994, FASEB J, V8, P13, DOI 10.1096/fasebj.8.1.8299885; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; OZON S, 1997, IN PRESS EUR J BIOCH; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POTASHKIN J, 1993, SCIENCE, V262, P573, DOI 10.1126/science.8211184; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; SAWADA S, 1991, MOL CELL BIOL, V11, P5506, DOI 10.1128/MCB.11.11.5506; SCHUBART UK, 1982, J BIOL CHEM, V257, P2231; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK SA, 1995, MOL CELL BIOL, V15, P4497; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	45	43	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23151	23156		10.1074/jbc.272.37.23151	http://dx.doi.org/10.1074/jbc.272.37.23151			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287318	hybrid			2022-12-25	WOS:A1997XV74400029
J	Lopez, S; Reeves, R; Island, ML; Bandu, MT; Christeff, N; Doly, J; Navarro, S				Lopez, S; Reeves, R; Island, ML; Bandu, MT; Christeff, N; Doly, J; Navarro, S			Silencer activity in the interferon-A gene promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA-GENE; MOBILITY-GROUP PROTEIN; STIMULATED RESPONSE ELEMENT; INDUCIBLE ENHANCER ELEMENT; REGULATORY FACTOR FAMILY; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; VIRUS INDUCTION; ALPHA PROMOTER; INDUCED EXPRESSION	Interferon-A (IFN-A) differential gene expression is modulated by a complex interplay between cis-acting DNA elements and the corresponding specific trans-regulating factors, Substitutions in the proximal virus-responsive element of the interferon-A (IFN-A) promoters contribute to their differential gene expression, The 5' distal silencing region in the weakly virus-inducible murine IFN-A11 gene has been previously delimited. DNase I footprinting experiments and transient gene expression assays demonstrate identical silencing activity in equivalent regions of the genes for IFN-A11 and IFN-A4 promoters. A minimal 20-mer distal negative regulatory element (DNRE) in both promoters is necessary and sufficient for the silencing and a region in the highly inducible IFN-A4 promoter located between the silencer and the virus-responsive element overrides the silencer activity. Mutations in the central region of the DNRE, causing derepression, also altered the formation of one of the two major DNA-protein complexes, One of these contains a protein related to or identical to the high mobility group I(Y) proteins, while the other complex contains a major protein present in uninduced and virus-induced cells with a molecular mass of 38 kDa, which may be related to the silencer activity. Similar DNREs are present in other virus-uninducible IFN-A promoters, and these data suggest that a common silencer may mediate the transcriptional repression in different genes of this family.	UNIV PARIS 05,CNRS,UFR BIOMED ST PERES,UPR 37,LAB REGULAT EXPRESS GENES EUCARYOTES,F-75270 PARIS 06,FRANCE; WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Washington State University								AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BISAT F, 1988, NUCLEIC ACIDS RES, V16, P6067, DOI 10.1093/nar/16.13.6067; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CIVAS A, 1991, NUCLEIC ACIDS RES, V19, P4497, DOI 10.1093/nar/19.16.4497; COULOMBEL C, 1991, GENE, V104, P187, DOI 10.1016/0378-1119(91)90249-B; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DION M, 1986, BIOCHEM BIOPH RES CO, V138, P826, DOI 10.1016/S0006-291X(86)80571-X; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; French SW, 1996, MOL CELL BIOL, V16, P5393; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GRANT CE, 1995, NUCLEIC ACIDS RES, V23, P2137, DOI 10.1093/nar/23.12.2137; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIN RT, 1994, J BIOL CHEM, V269, P17542; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; REEVES R, 1990, J BIOL CHEM, V265, P8573; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Roffet P, 1996, BIOCHEM J, V317, P697, DOI 10.1042/bj3170697; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Yoneyama M, 1996, J BIOCHEM-TOKYO, V120, P160	61	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22788	22799		10.1074/jbc.272.36.22788	http://dx.doi.org/10.1074/jbc.272.36.22788			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278440	hybrid			2022-12-25	WOS:A1997XV49200061
J	Midgley, CA; Lane, DP				Midgley, CA; Lane, DP			p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding	ONCOGENE			English	Article						p53 tumour suppressor protein; Mdm2 tumour suppressor protein; protein stability; DNA damage	WILD-TYPE P53; LI-FRAUMENI SYNDROME; C-TERMINAL DOMAIN; TRANSFORMED-CELLS; SUPPRESSOR PROTEIN; BREAST-CANCER; DNA-BINDING; SV40-TRANSFORMED CELLS; IONIZING-RADIATION; IN-VITRO	The tumour suppressor protein p53 is expressed at very low levels in normal cells but accumulates in response to DNA damaging agents such as u.v. irradiation. This increase is accompanied by transcriptional upregulation of the expression of a number of proteins including Mdm2 which can in turn inhibit p53 dependent transcriptional activation, creating a feedback loop resulting in down-regulation of p53 activity. Mutant p53 proteins are however frequently detected at constitutively high levels in many tumours and tumour cell lines, indeed this phenomenon has been used in several studies to diagnose p53 mutation in patient tumours. We show here that expression of mouse mutant p53 in tumour cell lines of this type results in high levels of both the endogenous p53 protein and the exogenously expressed mutant mouse protein, whereas the human tumour line MCF7 does not exhibit high levels of either endogenous human or exogenously expressed mouse mutant p53 unless stabilisation is induced by DNA damage, This suggests that the stability of mutant p53 is not intrinsic to mutant p53 protein structure but may vary in different cell backgrounds. We present evidence that p53 protein stability in tumour cell lines is determined by association with the Mdm2 tumour suppressor protein, and that p53 mutants which are unable to bind Mdm2 are stable in MCF7 cells, We propose that tumour lines which express high levels of transcriptionally inactive mutant p53 are unable to induce the expression of the Mdm2 protein which would normally provide a feedback mechanism down-regulating p53 protein levels in the absence of DNA damage signals, MCF7 cells however express a transcriptionally active p53 and retain the feedback regulation of p53 protein levels by Mdm2.	UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CANC RES CAMPAIGN,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1991, ONCOGENE, V6, P1699; BENNETT WP, 1993, CANCER RES, V53, P4817; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall AR, 1997, ONCOGENE, V14, P1371, DOI 10.1038/sj.onc.1200962; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOMAX ME, 1997, ONCOGENE, V14, P1868; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; REIHSAUS E, 1990, ONCOGENE, V5, P137; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J., MOL CLONING LAB MANU; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOMINAGA O, 1993, ONCOGENE, V8, P2653; Varley JM, 1996, ONCOGENE, V12, P2437; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	66	267	271	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1179	1189		10.1038/sj.onc.1201459	http://dx.doi.org/10.1038/sj.onc.1201459			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294611				2022-12-25	WOS:A1997XU99100007
J	Renatus, M; Bode, W; Huber, R; Sturzebecher, J; Prasa, D; Fischer, S; Kohnert, U; Stubbs, MT				Renatus, M; Bode, W; Huber, R; Sturzebecher, J; Prasa, D; Fischer, S; Kohnert, U; Stubbs, MT			Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator - Implications for the design of low molecular weight substrates and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ARG CHLOROMETHYLKETONE; RAY CRYSTAL-STRUCTURE; HUMAN ALPHA-THROMBIN; T-PA; FACTOR-XA; SYNTHETIC INHIBITORS; TRYPSIN-INHIBITOR; CATALYTIC DOMAIN; FIBRIN; ERYTHRINA	The recent structure determination of the catalytic domain of tissue-type plasminogen activator (tPA) suggested residue Arg(174) could play a role in P3/P4 substrate specificity, Six synthetic chromogenic tPA substrates of the type R-Xaa-Gly-Arg-p-nitroanilide, in which R is an N-terminal protection group, were synthesized to test this property, Although changing the residue Xaa (in its L or D form) at position P3 from the hydrophobic Phe to an acidic residue, Asp or Glu, gave no improvement in catalytic efficiency, comparative analysis of the substrates indicated a preference for an acidic substituent occupying the S3 site when the S4 site contains a hydrophobic or basic moiety, The 2.9 Angstrom structure determination of the catalytic domain of human tPA in complex with the bis-benzamidine inhibitor 2,7-bis (4-amidinobenzylidene)-cycloheptan-1-one reveals a three-site interaction, salt bridge formation of the proximal amidino group of the inhibitor with Asp(189) in the primary specificity pocket, extensive hydrophobic surface burial, and a weak electrostatic interaction between the distal amidino group of the inhibitor and two carbonyl oxygens of the protein, The latter position was previously occupied by the guanidino group of Arg(174), which swings out to form the western edge of the S3 pocket, These data suggest that the side chain of Arg(174) is flexible, and does not play a major role in the S4 specificity of tPA, On the other hand, this residue would modulate S3 specificity, and may be exploited to fine tune the specificity and selectivity of tPA substrates and inhibitors.	UNIV JENA,CTR VASC BIOL & MED,D-99089 ERFURT,GERMANY; BOEHRINGER MANNHEIM GMBH,BIOCHEM RES CTR,D-82372 PENZBERG,GERMANY	Friedrich Schiller University of Jena	Renatus, M (corresponding author), MAX PLANCK INST BIOCHEM,DEPT STRUCT RES,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Stubbs, Milton/ABC-7585-2020	Stubbs, Milton/0000-0003-1278-9013				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACHMANN F, 1994, HAEMOSTASIS THROMBOS, V1, P575; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; *BIOS TECHN SAN DI, 1993, INS VERS 2 2 0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1994, FIBRINOLYSIS, V8, P161, DOI 10.1016/0268-9499(94)90714-5; BODE W, 1992, PROTEIN SCI, V1, P426; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CAMANI C, 1994, J BIOL CHEM, V269, P5770; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; JOUBERT FJ, 1987, THROMB HAEMOSTASIS, V57, P356; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOHNERT U, 1992, PROTEIN ENG, V5, P93, DOI 10.1093/protein/5.1.93; Kohnert U, 1996, FIBRINOLYSIS, V10, P93, DOI 10.1016/S0268-9499(96)80084-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MACARTNEY HW, 1989, Patent No. 502503; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MARKWARDT F, 1989, DESIGN ENZYME INHIBI, P619; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PANNEKOEK H, 1990, THROMB HAEMOSTASIS, V64, P600; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RENATUS M, 1997, IN PRESS BIOCHEMISTR; RENATUS M, 1997, IN PRESS EMBO J; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; RUDOLPH R, 1987, Patent No. 219874; Rudolph R, 1990, U.S. Patent, Patent No. [4,933,434, 4933434]; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; Stern A., 1990, European Patent Application, Patent No. [0382174 B1, 0382174]; STUBBS MT, 1995, FEBS LETT, V375, P103, DOI 10.1016/0014-5793(95)01190-P; STURZEBECHER J, 1982, PHARMAZIE, V37, P281; STURZEBECHER J, 1992, PROTEIN SCI, V1, P1007; STURZEBECHER J, 1978, ACTA BIOL MED GER, V35, P1665; SVENDSEN LG, 1983, Patent No. 34122; TEIXEIRA AV, 1994, BBA-GENE STRUCT EXPR, V1217, P23, DOI 10.1016/0167-4781(94)90120-1; TURK D, 1992, THESIS TU MUNCHEN; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; WALSMANN P, 1976, ACTA BIOL MED GER, V35, pK1	52	62	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21713	21719		10.1074/jbc.272.35.21713	http://dx.doi.org/10.1074/jbc.272.35.21713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268299	hybrid			2022-12-25	WOS:A1997XT85000011
J	Chen, XG; Brining, SK; Nguyen, VQ; Yergey, AL				Chen, XG; Brining, SK; Nguyen, VQ; Yergey, AL			Simultaneous assessment of conformation and aggregation of beta-amyloid peptide using electrospray ionization mass spectrometry	FASEB JOURNAL			English	Article						protein conformation; protein aggregation; Alzheimer disease	AMINO-TERMINAL FRAGMENT; ALZHEIMERS-DISEASE; SECONDARY STRUCTURE; SENILE PLAQUES; CORE PROTEIN; IN-VITRO; DEPOSITION; DETERMINANTS; TRANSITION; PATHOLOGY	Electrospray ionization mass spectrometry was used to study conformation and aggregation of the synthetic beta-amyloid peptide, residues 140 (beta A4), as a function of concentration and sample aging, All mass spectra showed a major envelope of peaks corresponding to charge states of 7-3 of the monomeric form of beta A4, In addition, weaker envelopes of peaks corresponding to charge states of dimeric, trimeric, and tetrameric beta A4 species were seen under gentle ionization conditions, The average charge state of the envelope associated with the monomeric form decreased by ca. 0.5 z as samples were aged, indicating that the relatively open form (likely random coil) of the peptide was modified into the more compact form (likely beta-sheet) as a function of sample aging, The aggregate forms became weaker and ultimately were absent both in the more dilute solutions and in aged aliquots of the concentrated sample, These aggregates were interpreted as assemblies of the random coil form, We interpret our inability to see an ion envelope that can be associated with aggregates of the beta-sheet form to be a consequence of the presumed very compact nature of this form, A model for the formation of beta A4 fibrils is proposed and discussed.	NICHHD,BETHESDA,MD 20892; NIA,NEUROSCI LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; DOWNARD KM, 1995, INT J MASS SPECTROM, V148, P191, DOI 10.1016/0168-1176(95)04295-V; ELHADDAOUI A, 1995, J MOL STRUCT, V347, P363, DOI 10.1016/0022-2860(95)08558-D; FENN JB, 1993, J AM SOC MASS SPECTR, V4, P524, DOI 10.1016/1044-0305(93)85014-O; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GLENNER GG, 1974, J HISTOCHEM CYTOCHEM, V22, P1141, DOI 10.1177/22.12.1141; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARRETT JT, 1994, J AM CHEM SOC, V116, P9741, DOI 10.1021/ja00100a046; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; LACZKOHOLLOSI I, 1992, EUR BIOPHYS J BIOPHY, V21, P345, DOI 10.1007/BF00188347; LANSBURY PT, 1995, EUR J MED CHEM, V30, pS621; LANSBURY PT, 1992, BIOCHEMISTRY-US, V31, P6865, DOI 10.1021/bi00145a001; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LIGHTWAHL KJ, 1994, J AM CHEM SOC, V116, P5271, DOI 10.1021/ja00091a035; Maggio JE, 1996, BRAIN PATHOL, V6, P147, DOI 10.1111/j.1750-3639.1996.tb00797.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Naslund J, 1996, J NEUROCHEM, V67, P294; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; ROGERS J, 1985, J NEUROSCI, V5, P2801; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; Schnier PD, 1996, J AM SOC MASS SPECTR, V7, P972, DOI 10.1016/1044-0305(96)00071-2; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SIUZDAK G, 1996, MASS SPECTROMETRY BI, P89; SMITH DL, 1994, MASS SPECTROM REV, V13, P411, DOI 10.1002/mas.1280130503; SMITH RD, 1993, BIOL MASS SPECTROM, V22, P493, DOI 10.1002/bms.1200220902; SOTO C, 1994, J NEUROCHEM, V63, P1191; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SPENCER RGS, 1991, BIOCHEMISTRY-US, V30, P10382, DOI 10.1021/bi00107a004; TALAFOUS J, 1994, BIOCHEMISTRY-US, V33, P7788, DOI 10.1021/bi00191a006; TERRY RD, 1964, AM J PATHOL, V44, P269; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; Xu YD, 1996, J AM SOC MASS SPECTR, V7, P25, DOI 10.1016/1044-0305(95)00625-7; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028	51	20	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					817	823		10.1096/fasebj.11.10.9271367	http://dx.doi.org/10.1096/fasebj.11.10.9271367			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271367				2022-12-25	WOS:A1997XR10500012
J	Gary, R; Ludwig, DL; Cornelius, HL; MacInnes, MA; Park, MS				Gary, R; Ludwig, DL; Cornelius, HL; MacInnes, MA; Park, MS			The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL REGION; POLYMERASE-DELTA; RAD PROTEINS; REPLICATION; BACTERIOPHAGE-T4; DOMAINS; GENE; CDK; COMPLEMENTATION	Proliferating cell nuclear antigen (PCNA) is a DNA polymerase accessory factor that is required for DNA replication during S phase of the cell cycle and for resynthesis during nucleotide excision repair of damaged DNA, PCNA binds to flap endonuclease 1 (FEN-1), a structure-specific endonuclease involved in DNA replication. Here we report the direct physical interaction of PCNA with xeroderma pigmentosum (XP) G, a structure-specific repair endonuclease that is homologous to FEN-1, We have identified a 28-amino acid region of human FEN-1 (residues 328-355) and a 29-amino acid region of human XPG (residues 981-1009) that contains the PCNA binding activity, These regions share key hydrophobic residues with the PCNA-binding domain of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1), and all three competed with one another for binding to PCNA. A conserved arginine in FEN-1 (Arg(339)) and XPG (Arg(992)) was found to be crucial for PCNA binding activity, R992A and R992E mutant forms of XPG failed to fully reconstitute nucleotide excision repair in an in vivo complementation assay, These results raise the possibility of a mechanistic linkage between excision and repair synthesis that is mediated by PCNA.	LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory			Park, Min Sung/HCH-2207-2022; Gary, Ronald K/A-8650-2008	Gary, Ronald K/0000-0001-5079-1953	NATIONAL CANCER INSTITUTE [R29CA071630] Funding Source: NIH RePORTER; NCI NIH HHS [CA71630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Ball KL, 1996, EUR J BIOCHEM, V237, P854, DOI 10.1111/j.1432-1033.1996.0854p.x; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEIN K, 1992, MOL CELL BIOL, V12, P155; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Knauf JA, 1996, MUTAT RES-DNA REPAIR, V363, P67, DOI 10.1016/0921-8777(95)00062-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LIU M, 1995, ONCOGENE, V10, P1955; Ludwig DL, 1996, MAMM GENOME, V7, P644, DOI 10.1007/s003359900198; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; McDonald E, 1996, CANCER RES, V56, P2250; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; Petrocelli T, 1996, ONCOGENE, V12, P1387; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	43	196	206	12	99	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24522	24529		10.1074/jbc.272.39.24522	http://dx.doi.org/10.1074/jbc.272.39.24522			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305916	hybrid			2022-12-25	WOS:A1997XY51500067
J	Raman, B; Rao, CM				Raman, B; Rao, CM			Chaperone-like activity and temperature structural changes of alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; B-CRYSTALLIN; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; THERMAL-STABILITY; MOLTEN-GLOBULE; POSTTRANSLATIONAL MODIFICATIONS; NONLENTICULAR TISSUES; CARBONIC-ANHYDRASE; GAMMA-CRYSTALLIN	alpha-Crystallin is known to exhibit chaperone-like activity, We have studied its chaperone-like activity toward the aggregation of beta(L)-crystallin upon refolding of this protein from its unfolded state in guanidinium chloride, The chaperone-like activity of alpha-crystallin is less pronounced below 30 degrees C and is enhanced above this temperature, The plot of percentage protection as a function of temperature shows two transitions; one at 30 degrees C and another at around 55 degrees C. We have performed steady state fluorescence, fluorescence polarization, fluorescence quenching, circular dichroism, sedimentation analysis, and gel filtration chromatography to probe the temperature-induced structural changes of alpha-crystallin. Our results show that at above 50 degrees C, alpha-crystallin undergoes a transition to a multimeric molten globule-like state. Above 30 degrees C, a minor but detectable perturbation in its tertiary structure occurs that might lead to the observed exposure of its hydrophobic surfaces, These results support our earlier hypothesis that alpha-crystallin prevents the aggregation of other proteins by providing appropriately placed hydrophobic surfaces; a structural transition above 30 degrees C involving enhanced or reorganized hydrophobic surfaces of alpha-crystallin is important for its chaperone like activity, It is possible that a structural alteration induced by temperature forms a part of the general mechanism of chaperone function, because they are required to function more effectively at non-permissible temperatures.	CTR CELLULAR & MOL BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GANEA E, 1995, EUR J BIOCHEM, V231, P181, DOI 10.1111/j.1432-1033.1995.0181f.x; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HARTL MKH, 1996, EMBO J, V15, P6111; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Ptitsyn Oleg B., 1992, P243; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; RAO CM, 1994, INVEST OPHTH VIS SCI, V35, P1905; RAO CM, 1993, INVEST OPHTH VIS SCI, V34, P988; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SHIH P, 1995, PROTEIN SCI, V4, P2050, DOI 10.1002/pro.5560041010; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; Singh N, 1996, BIOPHYS CHEM, V63, P27, DOI 10.1016/S0301-4622(96)02192-8; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; vanBoekel MAM, 1996, OPHTHALMIC RES, V28, P32, DOI 10.1159/000267940; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	48	124	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23559	23564		10.1074/jbc.272.38.23559	http://dx.doi.org/10.1074/jbc.272.38.23559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295293	hybrid			2022-12-25	WOS:A1997XX38100018
J	Zhu, XY; Volz, K; Matsumura, P				Zhu, XY; Volz, K; Matsumura, P			The CheZ-binding surface of CheY overlaps the CheA- and FliM-binding surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC RESPONSE REGULATOR; PHOSPHORYLATION-DEPENDENT BINDING; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; FLAGELLAR SWITCH; PROTEIN CHEY; PHOSPHATASE-ACTIVITY; GENE-PRODUCTS; MUTANTS	CheY, the response regulator of bacterial chemotaxis, plays a pivotal role in signal transduction in bacterial chemotaxis and interacts with at least three proteins: CheA, FliM, and CheZ, CheA receives signals from chemoreceptors and then transfers the signal to CheY by a phosphotransfer reaction. Phosphorylated CheY binds to FliM, one of the switch proteins, resulting in a change in flagellar rotation from counterclockwise to clockwise, Phosphorylated CheY is dephosphorylated by its intrinsic autophosphatase activity and by CheZ. The CheA- and FliM-binding surfaces of CheY have been well studied, but characterization of She CheZ-binding surface of CheY is incomplete, We have analyzed the effect of CheZ on the dephosphorylation rates of 14 mutants of CheY, Nine mutant CheY proteins showed more resistance to CheZ phosphatase activity than did wild-type CheY, These nine mutant CheY proteins could be divided into two groups: one with altered CheZ binding and the other with normal CheZ binding The mutations causing reduced CheZ binding altered residues an the same surface of CheY, a region consisting of the beta(5)-alpha(5) loop, the alpha(1)-helix, and part of the alpha(5)-helix. Mutations rendering CheY resistant to CheZ, isolated by Sanna et al, (Sanna, M. G., Swanson, R. V., Bourret, R. B., and Simon, M. I, (1995) Mol. Microbiol; 15, 1069-1079), were also found to affect this surface, The mutations ill the CheY protein that affect CheZ activity but not CheZ binding-are located in the beta(4)-alpha(4) loop, which appears to be involved in the; catalytic activity of CheZ, Finally, our results indicate that the CheY surfaces that bind CheA, FliM, and CheZ overlap, but are not completely identical.	UNIV ILLINOIS,DEPT IMMUNOL & MICROBIOL,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047522] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18985] Funding Source: Medline; NIGMS NIH HHS [GM47522] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSLER CD, 1993, J BACTERIOL, V175, P6238, DOI 10.1128/JB.175.19.6238-6244.1993; Amsler CD., 1995, 2 COMPONENT SIGNAL T, P89; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; Blat Y, 1996, J BIOL CHEM, V271, P1232, DOI 10.1074/jbc.271.2.1232; Blat Y, 1996, J BIOL CHEM, V271, P1226, DOI 10.1074/jbc.271.2.1226; Blat Y, 1996, BIOCHEMISTRY-US, V35, P5679, DOI 10.1021/bi9530447; BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; Eisenbach M, 1996, MOL MICROBIOL, V20, P903, DOI 10.1111/j.1365-2958.1996.tb02531.x; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; HUANG CX, 1993, BIOCHIM BIOPHYS ACTA, V1202, P297, DOI 10.1016/0167-4838(93)90019-N; KUO SC, 1989, J BACTERIOL, V171, P6279, DOI 10.1128/jb.171.11.6279-6287.1989; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MORRISON TB, 1994, BIOTECHNIQUES, V17, P922; MORRISON TB, 1994, P NATL ACAD SCI USA, V91, P5495; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PARKINSON JS, 1976, J BACTERIOL, V126, P758, DOI 10.1128/JB.126.2.758-770.1976; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PARKINSON JS, 1979, P NATL ACAD SCI USA, V76, P2390, DOI 10.1073/pnas.76.5.2390; RAVID S, 1986, P NATL ACAD SCI USA, V83, P7157, DOI 10.1073/pnas.83.19.7157; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; Sanna MG, 1996, J BIOL CHEM, V271, P7357, DOI 10.1074/jbc.271.13.7357; SANNA MG, 1995, MOL MICROBIOL, V15, P1069, DOI 10.1111/j.1365-2958.1995.tb02282.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHUKLA D, 1995, J BIOL CHEM, V270, P24414, DOI 10.1074/jbc.270.41.24414; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SWANSON RV, 1995, NAT STRUCT BIOL, V2, P906, DOI 10.1038/nsb1095-906; VOLZ K, 1991, J BIOL CHEM, V266, P15511; Wang H, 1996, MOL MICROBIOL, V19, P695, DOI 10.1046/j.1365-2958.1996.393934.x; WARRICK HM, 1977, J BACTERIOL, V130, P223, DOI 10.1128/JB.130.1.223-231.1977; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	49	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23758	23764		10.1074/jbc.272.38.23758	http://dx.doi.org/10.1074/jbc.272.38.23758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295320	hybrid			2022-12-25	WOS:A1997XX38100045
J	Zhang, LL; Tschantz, WR; Casey, PJ				Zhang, LL; Tschantz, WR; Casey, PJ			Isolation and characterization of a prenylcysteine lyase from bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN-CONTAINING MONOOXYGENASE; NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; P-GLYCOPROTEIN; S-OXYGENATION; FARNESYLCYSTEINE; TRANSPORTER; MEMBRANES; CLEAVAGE; CELLS	Prenylated proteins contain one of two isoprenoid lipids, either the 15-carbon farnesyl or the 20-carbon geranylgeranyl, covalently attached to cysteine residues at or near their C terminus. The cellular abundance of prenylated proteins, which can comprise up to 2% of total cellular protein, raises the question of how cells dispose of prenylcysteines produced during the normal turnover of prenylated proteins. We have identified and characterized a novel enzyme, which we term prenylcysteine lyase, that is capable of cleaving the thioether bond of prenylcysteines. The enzyme was isolated from bovine brain membranes and exhibits an apparent molecular mass of 63 kDa. The enzyme did not require NADPH as cofactor for prenylcysteine degradation, thus distinguishing it from cytochrome P450- and flavin-containing monooxygenases that catalyze S-oxidation of thioethers. Purified prenylcysteine lyase shows similar kinetics in utilization of both farnesylcysteine and geranylgeranylcysteine as substrates, although V-max is 2-fold higher with the former compound. Interaction of prenylcysteine substrates with the enzyme requires that they possess a free amino group; N-acetylated prenylcysteines and prenyl peptides are not substrates. These findings suggest that prenylcysteine lyase is a specific enzyme involved in prenylcysteine metabolism in mammalian cells, most likely comprising the final step ill the degradation of prenylated proteins.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM46372, F32 GM18069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372, F32GM018069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CASHMAN JR, 1990, CHEM RES TOXICOL, V3, P344, DOI 10.1021/tx00016a012; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MA YT, 1994, BIOCHEMISTRY-US, V33, P5414, DOI 10.1021/bi00184a009; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; PARK SB, 1994, CHEM RES TOXICOL, V7, P191, DOI 10.1021/tx00038a012; PARK SB, 1992, CHEM RES TOXICOL, V5, P193, DOI 10.1021/tx00026a008; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; ROWELL CA, 1997, J BIOL CHEM, V272, P14903; SAUSEN PJ, 1990, J BIOL CHEM, V265, P6139; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHANG L, 1994, J BIOL CHEM, V269, P15973; ZHANG LL, 1995, J BIOL CHEM, V270, P22859, DOI 10.1074/jbc.270.39.22859	26	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23354	23359		10.1074/jbc.272.37.23354	http://dx.doi.org/10.1074/jbc.272.37.23354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287348	hybrid			2022-12-25	WOS:A1997XV74400059
J	Falkenberg, M; Bushnell, DA; Elias, P; Lehman, IR				Falkenberg, M; Bushnell, DA; Elias, P; Lehman, IR			The UL8 subunit of the heterotrimeric herpes simplex virus type 1 helicase-primase is required for the unwinding of single strand DNA-binding protein (ICP8)-coated DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 GENE-41; PRIMER SYNTHESIS; POLYMERASE; ORIGIN; IDENTIFICATION; REPLICATION; COMPLEX; COMPONENT; PRODUCTS; ICP8	The Herpes simplex virus type 1 primosome consists of three subunits that are the products of the UL5, UL8, and UL52 genes. The heterotrimeric enzyme has DNA-dependent ATPase, helicase, and primase activities. Earlier studies show that a subassembly consisting of the UL5 and UL52 gene products was indistinguishable from the heterotrimeric enzyme in its helicase and primase activities. We demonstrate here that the UL8 protein is required for the helicase activity of the UL5/52 subassembly on long duplex DNA substrates (>30 nucleotides) with a single-stranded DNA loading site fully coated with the virus-encoded single strand DNA binding protein, ICP8. The Escherichia coli single strand PNA binding protein cannot substitute for ICP8, suggesting a specific physical interaction between ICPS and the UL8 protein. Surface plasmon resonance measurements demonstrated an interaction between ICP8 and the UL5/52/8 heterotrimer but not with the UL5/52 subassembly or the UL8 protein alone. At a subsaturating level of ICP8, the UL5/52 subassembly does show helicase activity, suggesting that the subassembly can bind to single-stranded DNA but not to ICP8-coated DNA.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT STRUCT BIOL,STANFORD,CA 94305; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN	Stanford University; Stanford University; University of Gothenburg					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538, R01AI121144] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26538, AI-121144] Funding Source: Medline; NIGMS NIH HHS [GM070276-20] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; ODONNELL ME, 1987, J BIOL CHEM, V262, P4242; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; PARRY ME, 1993, J GEN VIR, V607; POWELL KL, 1981, J VIROL, V39, P894, DOI 10.1128/JVI.39.3.894-902.1981; PURIFOY DJM, 1977, NATURE, V269, P621, DOI 10.1038/269621a0; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; VAUGHAN PJ, 1985, J VIROL, V53, P501, DOI 10.1128/JVI.53.2.501-508.1985; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	31	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22766	22770		10.1074/jbc.272.36.22766	http://dx.doi.org/10.1074/jbc.272.36.22766			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278436	hybrid			2022-12-25	WOS:A1997XV49200057
J	Finnis, ML; Gibson, MA				Finnis, ML; Gibson, MA			Microfibril-associated glycoprotein-1 (MAGP-1) binds to the pepsin-resistant domain of the alpha 3(VI) chain of type VI collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; SULFATE PROTEOGLYCANS; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; CL GLYCOPROTEIN; TERMINAL DOMAIN; FIBRILLIN	The interactions of type VI collagen have been investigated, using solid phase binding assays, with two components of the fibrillin-containing microfibrils, the elastin-binding protein, MAGP-1 and its structural relative MAGP-2. Both native and pepsin-treated forms of type VI collagen specifically bound to MAGP-1 but not to MAGP-2, Pepsin type VI collagen was shown to block the binding of MAGP-1 to native type VI collagen indicating that the major MAGP-1-binding site was in the triple-helical region of the molecule. MAGP-1 was found not to bind to collagens I, III, and V. Affinity blotting of pepsin-treated type VI collagen showed that MAGP-1 binding was specific for the collagenous domain of the alpha 3(VI) chain. Decorin and biglycan were found not to inhibit the interaction of pepsin-treated type VI collagen with MAGP-1, indicating that its binding site on the collagen is not close to that for the proteoglycans. Reduction and alkylation of disulfide bonds in MAGP-1 did not destroy its type VI collagen-binding properties, indicating. that the binding site was likely to be in the cysteine-free, N-terminal domain of MAGP-1. Interestingly, the interaction of MAGP-1 with type VI collagen was inhibit ed by tropoelastin, suggesting that the binding sites for tropoelastin and type VI collagen may be in the same domain of MAGP-1. A peptide, corresponding to amino acids 29-38 of MAGP-1, was found to inhibit the interactions of MAGP-1 with type VI collagen and tropoelastin. The results suggest that the peptide may contain the binding sequences for both type VI collagen and tropoelastin, and thus that these two proteins may share the same binding site on MAGP-1. The interactions of MAGP-1 with type VI collagen and tropoelastin were both determined to be of moderately high affinity, with K-d values of 5.6 x 10(-7) M and 2.6 x 10(-7) M, respectively. The findings indicate that MAGP-1 may mediate a molecular interaction between type M collagen microfibrils and fibrillin-containing microfibrils, structures which are often found in close proximity to each other in a wide range of extracellular matrices.	UNIV ADELAIDE,DEPT PATHOL,ADELAIDE,SA 5006,AUSTRALIA	University of Adelaide								ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; BROWN PL, 1992, BIOCHEM BIOPH RES CO, V186, P549, DOI 10.1016/S0006-291X(05)80843-5; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; CHU ML, 1990, EMBO J, V9, P285; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; CLEARY EG, 1996, STRUCTURE FUNCTION E, V2, P95; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GIBSON MA, 1985, J BIOL CHEM, V260, P1149; GIBSON MA, 1983, COLLAGEN REL RES, V3, P469; GIBSON MA, 1987, IMMUNOL CELL BIOL, V65, P349; GIBSON MA, 1997, IN PRESS J HISTOCHEM, V45; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; Kielty CM, 1996, FEBS LETT, V386, P169, DOI 10.1016/0014-5793(96)00423-1; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; MAIER A, 1987, AM J ANAT, V180, P226, DOI 10.1002/aja.1001800303; MCDEVITT CA, 1991, FEBS LETT, V294, P167, DOI 10.1016/0014-5793(91)80660-U; OKADA Y, 1990, LAB INVEST, V63, P647; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PROSSER IW, 1984, AUST J EXP BIOL MED, V62, P485, DOI 10.1038/icb.1984.46; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; RITTIG M, 1990, CELL TISSUE RES, V259, P305, DOI 10.1007/BF00318453; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; TOMASINIJOHANSSON BR, 1993, MATRIX, V13, P203, DOI 10.1016/S0934-8832(11)80004-1; TRUEB B, 1984, J BIOL CHEM, V259, P8597; WALLACE RN, 1991, CURR EYE RES, V10, P99, DOI 10.3109/02713689109007614; Wu XX, 1996, AM J PATHOL, V149, P283; YEH H, 1994, GENOMICS, V23, P443, DOI 10.1006/geno.1994.1521; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589; ZHU D, 1994, J HISTOCHEM CYTOCHEM, V42, P577, DOI 10.1177/42.5.8157929	54	78	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22817	22823		10.1074/jbc.272.36.22817	http://dx.doi.org/10.1074/jbc.272.36.22817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278443	hybrid			2022-12-25	WOS:A1997XV49200064
J	Kirkwood, KL; Homick, K; Dragon, MB; Bradford, PG				Kirkwood, KL; Homick, K; Dragon, MB; Bradford, PG			Cloning and characterization of the type I inositol 1,4,5-trisphosphate receptor gene promoter - Regulation by 17 beta-estradiol in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE RECEPTOR; TRANSCRIPTIONAL REGULATION; FUNCTIONAL EXPRESSION; NUCLEOTIDE-SEQUENCE; ESTROGEN-RECEPTOR; HL-60 CELLS; LOCALIZATION; ACTIVATION; INTERLEUKIN-6; TISSUES	The inositol 1,4,5-trisphosphate (InsP(3)) receptor is essential for signal Ca2+ release from intracellular stores and for capacitative Ca2+ entry, We have isolated the promoter and proximal DNA segments of the human type I InsP(3) receptor gene, Transcription initiation in human 6-292 osteosarcoma and HL-60 promyelocytic leukemia cells was shown to occur predominantly from an adenine residue located 39 base pairs downstream of a consensus TATA box element, Upstream DNA including the TATA box promoted directional transcription of a chloramphenicol acetyltransferase reporter gene when transfected into 6-292 cells, A negative regulatory element in the distal promoter and a positive element in the proximal region were identified by deletion mapping and transcription assays, The proximal region enhanced transcription in response to 12-O-tetradecanoylphorbol-13-acetate or serum, but conferred transcriptional repression in response to 1,25-dihydroxyvitamin D-3 or 17 beta-estradiol. The repressive effect of 17 beta-estradiol was mediated by the nuclear estrogen receptor, as estrogen-dependent transcriptional repression was inhibited by the antiestrogen tamoxifen and the estrogen receptor antagonist ICI 182,780. This is the first study of the type I InsP(3) receptor gene promoter, and the results suggest a mechanism by which chronic estrogen treatment of osteoblasts affects type I InsP(3) receptor gene expression, signal transduction, and secretion.	SUNY BUFFALO, DEPT PHARMACOL & TOXICOL, SCH MED & BIOMED SCI, BUFFALO, NY 14214 USA; SUNY BUFFALO, SCH DENT MED, DEPT ORAL BIOL, BUFFALO, NY 14214 USA; SUNY BUFFALO, CTR MOL MECHANISMS DIS & AGING, BUFFALO, NY 14214 USA; SUNY BUFFALO, HOWARD HUGHES MED INST, UNDERGRAD BIOL SCI EDUC PROGRAM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Kirkwood, Keith L/L-4728-2018	Kirkwood, Keith/0000-0003-4519-8973	NIDCR NIH HHS [F32 DE005697-01, F32 DE005697, F32 DE005697-02] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005697] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; BRADFORD PG, 1993, MOL PHARMACOL, V44, P292; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; JONES TH, 1994, CLIN ENDOCRINOL, V40, P703, DOI 10.1111/j.1365-2265.1994.tb02502.x; Kirkwood K, 1997, J DENT RES, V76, P2625; Kirkwood KL, 1996, J BONE MINER RES, V11, P1889; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARTIN TJ, 1993, OSTEOPOROSIS INT, V3, pS121, DOI 10.1007/BF01621884; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STROBL JS, 1990, CANCER RES, V50, P5399; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9	38	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22425	22431		10.1074/jbc.272.36.22425	http://dx.doi.org/10.1074/jbc.272.36.22425			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278393	Green Accepted, hybrid			2022-12-25	WOS:A1997XV49200012
J	Whiteley, EM; Hsu, TA; Betenbaugh, MJ				Whiteley, EM; Hsu, TA; Betenbaugh, MJ			Thioredoxin domain non-equivalence and anti-chaperone activity of protein disulfide isomerase mutants in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; ESCHERICHIA-COLI; SITE CYSTEINE; BONDS; PDI; IMMUNOGLOBULINS; YIELD; CELL	Coexpression of the enzyme, protein disulfide isomerase (PDI), has been shown to increase soluble and secreted IgG levels from baculovirus-infected insect cells (Hsu, T.-A., Watson, S., Eiden, J. J., and Betenbaugh, M. J. (1996) Protein Expression Purif. 7, 281-288), PDI is known to include catalytic active sites in two separate thioredoxin-like domains, one near the amino terminus and another near the carboxyl terminus, To examine the role of these catalytic active sites in enhancing immunoglobulin solubility, baculovirus constructs were utilized with cysteine to serine mutations at the first cysteine of one or both of the CGHC active site sequences, Trichoplusia ni insect cells were coinfected with a baculovirus vector coding for IgG in concert with either the wild-type human PDI virus, amino-terminal mutant (PDI-N), carboxyl-terminal mutant (PDI-C), or mutant with both active sites altered (PDI-NC), Western blot analysis revealed that both immunoglobulins and PDI protein were expressed in the coinfected cells, To evaluate the effect of the PDI variants on immunoglobulin solubility and secretion, the infected cells were labeled with S-35-amino-acids for different periods, and the soluble immunoglobulins were immunoprecipitated from clarified cell lysates and culture medium using anti-IgG antibodies, Only coinfections with the wild-type PDI and PDI-N mutant led to increased immunoglobulin solubility and higher IgG secretion, In contrast, infection with the PDI-C and PDI-NC variants actually lowered immunoglobulin solubility levels below those achieved with a negative control virus, Immunoprecipitation with anti-PDI antibody revealed that heterologous PDI-C and PDI-NC were insoluble, even though PDI-N and wild-type PDI protein were detected in soluble form, The capacity for PDI-N to increase immunoglobulin solubility whereas the PDI-C mutant lowered solubility indicates that the amino-and carboxyl-terminal thioredoxin domains of PDI are functionally distinct in vivo following mutations to the active site, Furthermore, mutations at the active site of the carboxyl-terminal thioredoxin domain result in PDI variants that can act as anti-chaperones of immunoglobulin solubility in vivo as has been observed in vitro for lysozyme aggregation by wild-type PDI and PDI mutants (Puig, A., and Gilbert, H. F. (1994) J. Biol. Chem. 269, 7764-7771).	JOHNS HOPKINS UNIV, DEPT CHEM ENGN, BIOTECHNOL LAB, BALTIMORE, MD 21218 USA	Johns Hopkins University			Hsu, John Tsu-An/C-1199-2010; Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659				BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CAI H, 1994, J BIOL CHEM, V269, P24550; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; DAVIS TR, 1993, IN VITRO CELL DEV-AN, V29A, P842, DOI 10.1007/BF02631361; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; Hsu TA, 1997, BIOTECHNOL PROGR, V13, P96, DOI 10.1021/bp960088d; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; Hsu TA, 1996, PROTEIN EXPRES PURIF, V7, P281, DOI 10.1006/prep.1996.0040; HSU TA, 1994, ANN NY ACAD SCI, V721, P208, DOI 10.1111/j.1749-6632.1994.tb47393.x; Humphreys DP, 1996, FEBS LETT, V380, P194, DOI 10.1016/0014-5793(96)00028-2; JARVIS DL, 1993, J BIOL CHEM, V268, P16754; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILIE H, 1994, J BIOL CHEM, V269, P14290; LINDSAY DA, 1993, VIROLOGY, V193, P367, DOI 10.1006/viro.1993.1133; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Luckow Verne A., 1995, P51; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1991, J BIOL CHEM, V266, P19645; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SCHULTZ LD, 1994, ANN NY ACAD SCI, V721, P148, DOI 10.1111/j.1749-6632.1994.tb47387.x; Shuler Michael L., 1995, P1; SUMMERS MD, 1987, B TEXAS A M U COLLEG, V1555; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WALKER KW, 1995, BIOCHEMISTRY-US, V34, P13642, DOI 10.1021/bi00041a045; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; Wittrup K. Dane, 1995, Current Opinion in Biotechnology, V6, P203, DOI 10.1016/0958-1669(95)80033-6	50	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22556	22563		10.1074/jbc.272.36.22556	http://dx.doi.org/10.1074/jbc.272.36.22556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278409	hybrid			2022-12-25	WOS:A1997XV49200029
J	Scheibel, T; Bell, S; Walke, S				Scheibel, T; Bell, S; Walke, S			S-cerevisiae and sulfur: a unique way to deal with the environment	FASEB JOURNAL			English	Article						cysteine; methionine; toxicity; SOD; heat shock protein	CU,ZN SUPEROXIDE-DISMUTASE; SACCHAROMYCES-CEREVISIAE; TRIOSEPHOSPHATE ISOMERASE; CRYSTAL-STRUCTURE; AMINO-ACIDS; YEAST; METABOLISM; RESOLUTION; CYSTEINE	Saccharomyces cerevisiae is by far the best-studied unicellular eukaryote, Although yeast cells are very similar to higher eukaryotes in many respects, there is striking evidence that S, cerevisiae is not a perfect model for a eukaryotic cell (cf, 1), Here we report that yeast proteins contain a significantly lower amount of cysteine residues compared to other eukaryotes. Explanations for this phenomenon could not be found in the sulfur metabolism of yeast, which showed no major differences from other organisms (2-4), However, previous examinations could link a defect in sulfate uptake of S, cerevisiae to an increased resistance against toxic substances like selenate and chromate in the environment, which share the same permeases (5-7), This environmental problem might have caused S, cerevisiae to down-regulate its sulfate uptake and therefore lead to a lower amount of available sulfur in the cell, making it necessary to replace all dispensable sulfur amino acids in proteins, We show in two examples that S, cerevisiae proteins contain only such cysteine residues that are structurally or functionally needed, Therefore, we conclude that S. cerevisiae has solved a widespread environmental problem in a specific way which might be unique among eukaryotes.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	Scheibel, T (corresponding author), UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,D-93040 REGENSBURG,GERMANY.		Scheibel, Thomas/I-1170-2014	Scheibel, Thomas/0000-0002-0457-2423				ANDERSON ME, 1987, METHOD ENZYMOL, V143, P313; BRETON A, 1977, J BACTERIOL, V132, P224, DOI 10.1128/JB.132.1.224-232.1977; CHEREST H, 1992, GENETICS, V130, P51; Creighton T.E., 1993, PROTEINS STRUCTURES, P2; CREIGHTON TE, 1993, PROTEINS, P316; DJINOVIC K, 1992, J MOL BIOL, V225, P791, DOI 10.1016/0022-2836(92)90401-5; Glick BS, 1996, CURR BIOL, V6, P1570, DOI 10.1016/S0960-9822(02)70774-4; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366; HARRIS JI, 1976, ENZYMES, V13, P1; Lachance MA, 1997, YEAST, V13, P225, DOI 10.1002/(SICI)1097-0061(19970315)13:3<225::AID-YEA87>3.0.CO;2-I; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MANDE SC, 1994, PROTEIN SCI, V3, P810, DOI 10.1002/pro.5560030510; MUDD SH, 1983, METABOLIC BASIS INHE, P522; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PASZEWSKI A, 1992, CURR GENET, V22, P273, DOI 10.1007/BF00317920; ROSE AH, 1976, CHEM MICROBIOLOGY IN, P93; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCARINCI HE, 1990, ARCH LATINOAM NUTR, V40, P594; SMITH FW, 1995, MOL GEN GENET, V247, P709, DOI 10.1007/BF00290402; SODA K, 1987, METHOD ENZYMOL, V143, P453; STARMER WT, 1987, CAN J MICROBIOL, V33, P783, DOI 10.1139/m87-134; VanMantgem PJ, 1996, ECOTOX ENVIRON SAFE, V34, P228, DOI 10.1006/eesa.1996.0068	23	8	9	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					917	921		10.1096/fasebj.11.11.9285490	http://dx.doi.org/10.1096/fasebj.11.11.9285490			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285490				2022-12-25	WOS:A1997XT79000011
J	Bundgaard, JR; Vuust, J; Rehfeld, JF				Bundgaard, JR; Vuust, J; Rehfeld, JF			New consensus features for tyrosine O-sulfation determined by mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYLPROTEIN SULFOTRANSFERASE; HUMAN PROGASTRIN; BALANCE-SHEET; P-SELECTIN; GASTRIN; PEPTIDES; CHOLECYSTOKININ; SEQUENCE; EXPRESSION; PROTEINS	Tyrosine sulfation is an ubiquitous modification of proteins synthesized along the secretory pathway, It enhances protein-protein interactions and may be necessary for the bioactivity of secreted proteins and peptides. To predict tyrosine sulfation, a consensus has been proposed based on sequence comparisons of known substrates and on in vitro studies using synthetic peptides, This consensus predicts the presence of acidic residues on the amino-terminal side of the target tyrosine as the key feature, Using site-directed mutagenesis, we have examined the role of residues neighboring the sulfation site of an intact protein, human progastrin, in vivo. The results show that the charge of the residue in the amino-terminal position (-1) of the tyrosine is critical and can be neutral or acidic, whereas a basic residue abolishes sulfation, In addition, the degree of sulfation is influenced by the residues in positions -2 and -3, Hence, surprisingly a basic residue in position -2 enhances sulfation, Our data suggest a considerably broader range of substrates for the tyrosylprotein sulfotransferase than hitherto assumed and that the tyrosylprotein sulfotransferase is cell-specifically expressed.	STATENS SERUM INST,MOL BIOL LAB,DK-2300 COPENHAGEN,DENMARK	Statens Serum Institut	Bundgaard, JR (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN BIOCHEM,KB3014,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ANDERSEN BN, 1985, REGUL PEPTIDES, V10, P329, DOI 10.1016/0167-0115(85)90045-X; ANDERSEN BN, 1983, CLIN CHIM ACTA, V127, P29, DOI 10.1016/0009-8981(83)90072-4; ANDERSEN BN, 1985, GEN COMP ENDOCR, V58, P44, DOI 10.1016/0016-6480(85)90134-0; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAEUERLE PA, 1985, J BIOL CHEM, V260, P6434; BALDWIN GS, 1983, NATURE, V301, P435, DOI 10.1038/301435a0; BARDRAM L, 1989, SCAND J CLIN LAB INV, V49, P173, DOI 10.3109/00365518909105418; BARDRAM L, 1990, P NATL ACAD SCI USA, V87, P298, DOI 10.1073/pnas.87.1.298; BUNDGAARD JR, 1995, EMBO J, V14, P3073, DOI 10.1002/j.1460-2075.1995.tb07310.x; Bundgaard JR, 1996, DNA CELL BIOL, V15, P147, DOI 10.1089/dna.1996.15.147; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FRIISHANSEN L, 1994, FEBS LETT, V343, P115, DOI 10.1016/0014-5793(94)80301-3; GREGORY RA, 1966, NATURE, V209, P583, DOI 10.1038/209583a0; HILLE A, 1990, EUR J BIOCHEM, V188, P577, DOI 10.1111/j.1432-1033.1990.tb15438.x; HILLE A, 1990, EUR J BIOCHEM, V188, P587, DOI 10.1111/j.1432-1033.1990.tb15439.x; HILSTED L, 1986, ANAL BIOCHEM, V152, P119, DOI 10.1016/0003-2697(86)90129-6; HOFSTEENGE J, 1990, EUR J BIOCHEM, V188, P55, DOI 10.1111/j.1432-1033.1990.tb15370.x; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JOHNSEN AH, 1990, J BIOL CHEM, V265, P3054; JOHNSEN AH, 1992, EUR J BIOCHEM, V207, P419, DOI 10.1111/j.1432-1033.1992.tb17065.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIN WH, 1992, J BIOL CHEM, V267, P2876; MONSTEIN HJ, 1993, FEBS LETT, V331, P60, DOI 10.1016/0014-5793(93)80297-8; MUTT V, 1980, GASTROINTESTINAL HOR, P169; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NIEHRS C, 1994, CHEM-BIOL INTERACT, V92, P257, DOI 10.1016/0009-2797(94)90068-X; PAUWELS S, 1989, BIOCHIM BIOPHYS ACTA, V996, P82, DOI 10.1016/0167-4838(89)90098-8; PAUWELS S, 1987, GASTROENTEROLOGY, V92, P1220, DOI 10.1016/S0016-5085(87)91081-X; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; REHFELD JF, 1981, J BIOL CHEM, V256, P426; REHFELD JF, 1978, NATURE, V271, P771, DOI 10.1038/271771a0; REHFELD JF, 1995, EMBO J, V14, P389, DOI 10.1002/j.1460-2075.1995.tb07013.x; REHFELD JF, 1978, J BIOL CHEM, V253, P4016; RENSDOMIANO S, 1989, MOL PHARMACOL, V36, P647; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; UNSWORTH CD, 1982, NATURE, V295, P519, DOI 10.1038/295519a0; VANSOLINGE WW, 1990, CLIN CHIM ACTA, V192, P35, DOI 10.1016/0009-8981(90)90269-X; WALSH JH, 1987, PHYSL GASTROINTESTIN, P181; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	45	95	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21700	21705		10.1074/jbc.272.35.21700	http://dx.doi.org/10.1074/jbc.272.35.21700			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268297	hybrid			2022-12-25	WOS:A1997XT85000009
J	Jagiello, I; Beullens, M; Vulsteke, V; Wera, S; Sohlberg, B; Stalmans, W; vonGabain, A; Bollen, M				Jagiello, I; Beullens, M; Vulsteke, V; Wera, S; Sohlberg, B; Stalmans, W; vonGabain, A; Bollen, M			NIPP-1, a nuclear inhibitory subunit of protein phosphatase-1, has RNA-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-A; PHOSPHORYLATION; POLYPEPTIDES; MECHANISM	NIPP-1 is a nuclear inhibitory subunit of protein phosphatase-1 with structural similarities to some proteins involved in RNA processing, We report here that baculovirus-expressed recombinant NIPP-1 displays RNA-binding properties, as revealed by North-Western analysis, by UV-mediated cross-linking, by RNA mobility-shift assays, and by chromatography on poly(U)- Sepharose, NIPP-1 preferentially bound to U-rich sequences, including RNA-destabilizing AUUUA motifs. NIPP-1 also associated with single-stranded DNA, but had no affinity for double-stranded DNA. The binding of NIPP-1 to RNA was blocked by antibodies directed against the COOH terminus of NIPP-1, but was not affected by prior phosphorylation of NIPP-1 with protein kinase A or casein kinase-2, which decreases the affinity of NIPP-1 for protein phosphatase-1. The catalytic sub unit of protein phosphatase-1 did not bind to poly(U)Sepharose, but it bound very tightly after complexation with NIPP-1. These data are in agreement with a function of NIPP-1 in targeting protein phosphatase-1 to RNA.	CATHOLIC UNIV LEUVEN,AFDELING BIOCHEM,FAC GENEESKUNDE,B-3000 LOUVAIN,BELGIUM; UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,A-1030 VIENNA,AUSTRIA	KU Leuven; University of Vienna; Vienna Biocenter (VBC)								ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; FAN XC, 1996, RNA 96 1 ANN M RNA S, P208; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; SHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; WANG M, 1994, P NATL ACAD SCI USA, V91, P10591, DOI 10.1073/pnas.91.22.10591; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WILL CL, 1995, NUCLEIC ACIDS MOL BI, V9, P342	22	35	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22067	22071		10.1074/jbc.272.35.22067	http://dx.doi.org/10.1074/jbc.272.35.22067			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268347	hybrid			2022-12-25	WOS:A1997XT85000059
J	Li, W; Dennis, CA; Moore, GR; James, R; Kleanthous, C				Li, W; Dennis, CA; Moore, GR; James, R; Kleanthous, C			Protein-protein interaction specificity of Im9 for the endonuclease toxin colicin E9 defined by homologue-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNITY PROTEIN; ESCHERICHIA-COLI; RECEPTOR; DNASE; BINDING; SITE; IDENTIFICATION; ASSIGNMENTS; COMPLEXES; COGNATE	The colicin DNase-specific immunity proteins interact with the endonuclease domain of the bacterial toxin colicin E9 with dissociation constants that span the millimolar to femtomolar affinity range, Among the noncognate interactions Im2 shows the strongest binding toward the E9 DNase domain with a K-d of 10(-8) M, 6 orders of magnitude weaker than that of the cognate immunity protein Im9, Based on a NMR structure of Im9 that shows it to be a 4-helix protein, we have conducted a mutagenic scan in which elements of Im9 secondary structure were substituted into Im2 to precisely delineate regions that define specificity, Eleven chimeras were constructed, and their biological cross-reactivity toward colicins E2 and E9 was evaluated, From this set of mutants seven proteins were purified, and the K-d for their interaction with the E9 DNase domain was measured by a combination of stopped-flow fluorescence and subunit exchange kinetics. Our results show that immunity specificity is dominated by residues on helix II, accounting for 5 orders of magnitude binding specificity relative to Im2, and that packing interactions of helix II with its neighbor helix I and the loop connecting helix III with helix IV play minor roles, The conformational stability of these chimeric proteins was also determined, Proteins displaying an Im9 phenotype were all more stable than the parent Im2 protein, and surprisingly some chimeras were significantly more stable than either Im2 or Im9.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; ZENECA PHARMACEUT, PROT STRUCT GRP, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND; UNIV E ANGLIA, SCH CHEM SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND	University of East Anglia; University of East Anglia			James, Richard/B-2252-2009	James, Richard/0000-0002-5086-788X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BETTLER B, 1992, J BIOL CHEM, V267, P185; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; Chak KF, 1996, P NATL ACAD SCI USA, V93, P6437, DOI 10.1073/pnas.93.13.6437; CHAK KF, 1991, J GEN MICROBIOL, V137, P91, DOI 10.1099/00221287-137-1-91; COOPER PC, 1984, J GEN MICROBIOL, V130, P209; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIMASI DR, 1973, J BACTERIOL, V115, P506, DOI 10.1128/JB.115.2.506-513.1973; EATON T, 1989, NUCLEIC ACIDS RES, V17, P1761, DOI 10.1093/nar/17.4.1761; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; GarinotSchneider C, 1996, J MOL BIOL, V260, P731, DOI 10.1006/jmbi.1996.0433; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; JANIN J, 1990, J BIOL CHEM, V265, P16027; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LAU CK, 1992, NATO ASI SERIES H, P353; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; Luisi B., 1995, DNA PROTEIN STRUCTUR, P1; OSBORNE MJ, 1994, BIOCHEMISTRY-US, V33, P12347, DOI 10.1021/bi00207a001; Osborne MJ, 1997, BIOCHEM J, V323, P823, DOI 10.1042/bj3230823; Osborne MJ, 1996, BIOCHEMISTRY-US, V35, P9505, DOI 10.1021/bi960401k; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHALLER K, 1976, P NATL ACAD SCI USA, V73, P3989, DOI 10.1073/pnas.73.11.3989; SENIOR BW, 1971, P NATL ACAD SCI USA, V68, P959, DOI 10.1073/pnas.68.5.959; TOBA M, 1988, J BACTERIOL, V170, P3237, DOI 10.1128/jb.170.7.3237-3242.1988; WALLIS R, 1992, EUR J BIOCHEM, V210, P923, DOI 10.1111/j.1432-1033.1992.tb17496.x; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13751, DOI 10.1021/bi00042a005; WALLIS R, 1992, EUR J BIOCHEM, V207, P687, DOI 10.1111/j.1432-1033.1992.tb17096.x; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13743, DOI 10.1021/bi00042a004; WATSON RJ, 1985, PLASMID, V13, P205, DOI 10.1016/0147-619X(85)90044-7	29	38	38	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22253	22258		10.1074/jbc.272.35.22253	http://dx.doi.org/10.1074/jbc.272.35.22253			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268373	hybrid			2022-12-25	WOS:A1997XT85000085
J	Pena, TL; Rane, SG				Pena, TL; Rane, SG			The small conductance calcium-activated potassium channel regulates ion channel expression in C3H10T1/2 cells ectopically expressing the muscle regulatory factor MRF4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CURRENT; ACETYLCHOLINE-RECEPTORS; MOUSE FIBROBLASTS; DIFFERENTIATION; TRANSFORMATION; LYMPHOCYTES; INDUCTION; LINE	We investigated small conductance (SK) potassium channel-mediated regulation of muscle-specific, ion channel functional expression in the C3H10T1/2-MRF4 cell model system, a stable fibroblast line ectopically overexpressing the myogenic regulatory transcription factor, MRF4. Mitogenic stimulation of C3H10T1/2-MRF4 cells with basic fibroblast growth factor negatively regulates MRF4 transcriptional activity, inhibiting myogenesis. Using patch clamp techniques we found that mitogenic stimulation of C3H10T1/2-MRF4 cells also up-regulated SK. SK is a charybdotoxin-sensitive, apamin-insensitive channel that exerts positive proliferative control in fibroblasts. Mitogen withdrawal, which removes negative regulation of MRF4 thus initiating myogenesis, also eliminated SK channel currents, coincident both with induction of acetylcholine receptor channels, and up-regulation of muscle inward rectifier potassium channels. Addition of the SK channel blocker charybdotoxin to growth factor-containing culture medium overcame basic fibroblast growth factor-induced negative regulation of MRF4, as evidenced by induction of inward rectifier potassium and acetylcholine receptor channel expression identical to that observed in mitogen-withdrawn cells. Thus, the SK channel can govern electrophysiological phenotype in C3H10T1/2-MRF4 cells, consistent with an ability of SK to affect MRF4-dependent transcriptional activity. SK appears to be a pivotal signaling component for growth factor regulation of both cell proliferation and differentiation.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [R01GM43462] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043462] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAMACHO P, 1993, J NEUROSCI, V13, P605; DAY ML, 1993, NATURE, V365, P560, DOI 10.1038/365560a0; DRAHEIM HJ, 1995, BBA-MOL CELL RES, V1269, P57, DOI 10.1016/0167-4889(95)00106-3; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; GONOI T, 1991, PFLUG ARCH EUR J PHY, V419, P657, DOI 10.1007/BF00370311; HAMANN M, 1994, J PHYSIOL-LONDON, V475, P305, DOI 10.1113/jphysiol.1994.sp020071; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; HUANG Y, 1993, J PHYSIOL-LONDON, V461, P601, DOI 10.1113/jphysiol.1993.sp019531; HUANG Y, 1994, J BIOL CHEM, V269, P31183; KOPTA C, 1994, J NEUROSCI, V14, P3922; Krause RM, 1995, J PHYSIOL-LONDON, V489, P779, DOI 10.1113/jphysiol.1995.sp021091; KUBO Y, 1991, J PHYSIOL-LONDON, V442, P711, DOI 10.1113/jphysiol.1991.sp018816; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; RANE SG, 1991, AM J PHYSIOL, V260, pC104, DOI 10.1152/ajpcell.1991.260.1.C104; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; TRAUTMANN A, 1986, PFLUG ARCH EUR J PHY, V406, P163, DOI 10.1007/BF00586678; WANG Z, 1993, AM J PHYSIOL, V265, pC1239, DOI 10.1152/ajpcell.1993.265.5.C1239; WIELAND SJ, 1995, AM J PHYSIOL-CELL PH, V268, pC490, DOI 10.1152/ajpcell.1995.268.2.C490; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	26	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21909	21916		10.1074/jbc.272.35.21909	http://dx.doi.org/10.1074/jbc.272.35.21909			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268324	hybrid			2022-12-25	WOS:A1997XT85000036
J	Raibekas, AA; Massey, V				Raibekas, AA; Massey, V			Glycerol-assisted restorative adjustment of flavoenzyme conformation perturbed by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; FLAVIN BINDING-SITES; PIG-KIDNEY; ESCHERICHIA-COLI; PROTEIN STABILIZATION; GEL-ELECTROPHORESIS; FLAVOPROTEINS; PURIFICATION; 8-MERCAPTOFLAVINS; TYROSINE-224	The replacement of histidine 307 with leucine in pig kidney D amino acid oxidase perturbs its active site conformation accompanied by dramatic losses in protein-flavin interactions and enzymatic activity. However, the negative effect of this mutation on the holoenzyme structure is essentially eliminated in the presence of glycerol, resulting in up to 50% activity recovery and greater than 16-fold increase in the flavin affinity. Further analysis revealed that glycerol assists in the rearrangement of the protein toward its holoenzyme-like conformation together with reduction in the solvent-accessible protein hydrophobic area as demonstrated by limited proteolysis and use of affinity and hydrophobic probes. A substantial decrease in the protein-flavin interactions was demonstrated at a low temperature, but this reversible process was completely blocked in the presence of 40% glycerol. We suggest that the perturbation of the D-amino acid oxidase active site is due to the nonpolar nature of the mutation whose negative impact on the holoenzyme structure can be overcome by glycerol-induced strengthening of protein internal hydrophobic interactions.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CURTI B, 1973, BIOCHIM BIOPHYS ACTA, V327, P266, DOI 10.1016/0005-2744(73)90409-9; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; FAOTTO L, 1995, BIOTECHNOL LETT, V17, P193, DOI 10.1007/BF00127987; FARRIS FJ, 1978, J AM CHEM SOC, V100, P4469, DOI 10.1021/ja00482a026; FITZPATRICK PF, 1983, J BIOL CHEM, V258, P9700; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1986, BIOCHEM J, V239, P1; HORIIKE K, 1975, J BIOCHEM-TOKYO, V78, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; MARCOTTE P, 1976, BIOCHEMISTRY-US, V15, P3070, DOI 10.1021/bi00659a021; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1979, J BIOL CHEM, V254, P9640; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; MIYANO M, 1991, J BIOCHEM-TOKYO, V109, P171, DOI 10.1093/oxfordjournals.jbchem.a123340; Mizutani H, 1996, J BIOCHEM-TOKYO, V120, P14; Murthy YVSN, 1996, J BIOL CHEM, V271, P19915, DOI 10.1074/jbc.271.33.19915; MURTHY YVSN, 1995, J BIOL CHEM, V270, P28586, DOI 10.1074/jbc.270.48.28586; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P2034, DOI 10.1021/bi00329a035; NAOI M, 1973, J BIOCHEM-TOKYO, V74, P1097, DOI 10.1093/oxfordjournals.jbchem.a130337; NICHOLSON BH, 1988, BIOCHEM J, V255, P907, DOI 10.1042/bj2550907; Palfey B. A., 1995, ACTIVE OXYGEN BIOCH, P37, DOI DOI 10.1007/978-94-011-0609-2_2; POLLEGIONI L, 1994, J BIOL CHEM, V269, P31666; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; Raibekas AA, 1996, P NATL ACAD SCI USA, V93, P7546, DOI 10.1073/pnas.93.15.7546; RAIBEKAS AA, 1994, BIOCHEMISTRY-US, V33, P12656, DOI 10.1021/bi00208a017; RAIBEKAS AA, 1994, BIOCHEMISTRY-US, V33, P12649, DOI 10.1021/bi00208a016; RAIBEKAS AA, 1997, FLAVINS FLAVOPROTEIN; RONCHI S, 1982, J BIOL CHEM, V257, P8824; RONCHI S, 1980, FLAVINS FLAVOPROTEIN, P511; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TARELLI GT, 1990, J BIOL CHEM, V265, P21242; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; WATANABE F, 1989, BIOCHEM BIOPH RES CO, V165, P1422, DOI 10.1016/0006-291X(89)92762-9; WATANABE F, 1989, J BIOCHEM-TOKYO, V105, P1024, DOI 10.1093/oxfordjournals.jbchem.a122760	40	23	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22248	22252		10.1074/jbc.272.35.22248	http://dx.doi.org/10.1074/jbc.272.35.22248			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268372	hybrid			2022-12-25	WOS:A1997XT85000084
J	Chattopadhyay, P; Rathore, A; Mathur, M; Sarkar, C; Mahapatra, AK; Sinha, S				Chattopadhyay, P; Rathore, A; Mathur, M; Sarkar, C; Mahapatra, AK; Sinha, S			Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours	ONCOGENE			English	Article						glioma, genetics; chromosomes, human, pair 17; gene, suppressor, tumour	POLYMERASE CHAIN-REACTION; SUPPRESSOR GENE; MUTATIONS; CHROMOSOME-17; PATHWAYS; GLIOMAS; TUMORS	Amongst the human astrocytic tumours, the commonest of primary brain tumours, the clinical outcome of astrocytoma (AS) is significantly better than anaplastic astrocytoma (AA) and glioblastoma multiforme (GEM), Often, low grade tumours can progress to or recur with a more malignant phenotype, Recent loss of heterozygosity (LOH) reports suspect the involvement of a suppressor gene, different from p53, in the region of the human chromosome, However, the effect of LOH of 17p13.3 region on tumour histology at presentation and prognosis is as yet undefined, As a first step to define the role of this putative oncogene in astrocytic tumour progression, we correlated the LOH of a locus, D17S379, in 17p13.3 region and the p53 locus in 17p13.1 region with the histopathology of astrocytic tumours by PCR based microsatellite and restriction fragment length polymorphism of DNA extracted from microdissected paraffin sections of 45 astrocytic tumours of different histopathological grades, LOH of D17S379 was significantly associated (P=0.02) with AA and GBM (high grade malignancy), while no such preferential association was found with LOH of p53. There were no mutations in the exons 5 to 9 of p53 gene in the five tumours with LOH of D17S379 but not of p53 region, In a case of AA with a heterogenous microscopic appearance, heterozygosity of D17S379 was lost only in the area with a more malignant histology while both areas had no LOH or mutation of p53, A locus at the 17p13.3 region, independent of the p53 locus, is involved in a large subset of astrocytic tumours during transformation into a more malignant phenotype, and thus may be a link in the chain of genetic events occurring in astrocytic tumour progression.	ALL INDIA INST MED SCI,DEPT BIOCHEM,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT PATHOL,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT NEUROSURG,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi								CARROZZO R, 1993, HUM MOL GENET, V2, P615, DOI 10.1093/hmg/2.5.615; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAHN M, 1993, CLIN CHEM, V39, P549; Hermanson M, 1996, CANCER RES, V56, P164; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LARGEY JS, 1993, CANCER, V71, P1933, DOI 10.1002/1097-0142(19930315)71:6<1933::AID-CNCR2820710602>3.0.CO;2-D; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; SHAPIRO WR, 1986, SEMIN ONCOL, V13, P38; SHAW EG, 1989, INT J RADIAT ONCOL, V16, P663, DOI 10.1016/0360-3016(89)90482-3; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	16	45	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					871	874		10.1038/sj.onc.1201238	http://dx.doi.org/10.1038/sj.onc.1201238			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266974				2022-12-25	WOS:A1997XQ11700014
J	Bauer, A; Ulrich, E; Andersson, M; Beug, H; vonLindern, M				Bauer, A; Ulrich, E; Andersson, M; Beug, H; vonLindern, M			Mechanism of transformation by v-ErbA: Substitution for steroid hormone receptor function in self renewal induction	ONCOGENE			English	Article						leukemogenesis; receptor tyrosine kinases; steroid hormone receptors; thyroid hormone receptor; v-ErbA	AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTORS; GROWTH-FACTOR RECEPTOR; DNA-SEQUENCE SPECIFICITY; THYROID-HORMONE; ESTROGEN-RECEPTOR; C-ERBA; ERYTHROID-DIFFERENTIATION; RESPONSE ELEMENT; BINDING DOMAIN	V-ErbA, a mutated thyroid hormone receptor (TR) alpha cooperates with tyrosine kinase oncoproteins to induce fatal erythroleukemia in chicks, In vitro, v-ErbA employs a similar cooperation to induce sustained proliferation and arrest differentiation of committed erythroid progenitors, V-ErbA has been proposed to function as a dominant-negative c-ErbA/TR alpha, since it lacks an AF-2 transactivation domain and cannot be activated by hormone but retains the capacity to bind corepressors, v-ErbA fails to heterodimerize with the RXR, exhibits an altered DNA binding specificity and fails to suppress the action of coexpressed TR alpha/c-ErbA in erythroblasts, In this paper, we identify a novel mechanism by which v-ErbA contributes to leukemogenesis, Recently, the glucocorticoid receptor (GR) was identified as a key regulator of proliferation and differentiation in normal erythroid progenitors, For this, the GR required to cooperate with endogenous receptor tyrosine kinases (c-Kit) and with the estrogen receptor (ER). Here, we demonstrate that v-ErbA can substitute for the ligand-activated GR and ER, inducing proliferation and arresting differentiation in the presence of specific GR and ER antagonists, Like the GR, v-ErbA required to cooperate with c-Kit for both proliferation induction and differentiation arrest, being devoid of biological activity in the absence of an active c-Kit, In self-renewing erythroblasts, v-ErbA not only repressed known v-ErbA target genes but also maintained high expression of c-myb, These biological activities of v-ErbA depended on distinct mutations in the DNA-binding domain, Additionally, v-ErbA acted as a partial, weak repressor of c-ErbA/TR alpha function in normal erythroblasts, It could be converted into a truly dominant-negative receptor by restoring its ability to heterodimerize with RXR.	VIENNA BIOCTR,INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; KAROLINSKA INST,MED NOBEL INST,DEPT MOL & CELL BIOL,DEV BIOL LAB,S-17177 STOCKHOLM,SWEDEN	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Karolinska Institutet			Andersson Lendahl, Monika/ABE-5981-2021; von Lindern, Marieke/AAH-2350-2020	Andersson Lendahl, Monika/0000-0002-5690-8515				AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1995, METHOD ENZYMOL, V254, P41; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P284; BIGLER J, 1994, MOL CELL BIOL, V14, P7621, DOI 10.1128/MCB.14.11.7621; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CASINI T, 1995, ONCOGENE, V11, P1019; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWE AJ, 1991, J VIROL, V65, P6173; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1992, CANCER SURV, V15, P53; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MADER S, 1993, J BIOL CHEM, V268, P591; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAGL SB, 1995, MOL ENDOCRINOL, V9, P1522, DOI 10.1210/me.9.11.1522; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANDE S, 1994, MOL ENDOCRINOL, V8, P1455, DOI 10.1210/me.8.11.1455; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SELMI S, 1991, J BIOL CHEM, V266, P11589; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; Wahlstrom GM, 1996, ONCOGENE, V13, P843; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; WINBERGER C, 1986, NATURE, V324, P641; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZILLIACUS J, 1992, J BIOL CHEM, V267, P24941; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	82	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					701	715		10.1038/sj.onc.1201208	http://dx.doi.org/10.1038/sj.onc.1201208			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264411	Bronze			2022-12-25	WOS:A1997XP68300010
J	Suske, WA; Held, M; Schmid, A; Fleischmann, T; Wubbolts, MG; Kohler, HPE				Suske, WA; Held, M; Schmid, A; Fleischmann, T; Wubbolts, MG; Kohler, HPE			Purification and characterization of 2-hydroxybiphenyl 3-monooxygenase, a novel NADH-dependent, FAD-containing aromatic hydroxylase from Pseudomonas azelaica HBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYBENZOATE HYDROXYLASE; SP STRAIN HBP1; 2,4-DICHLOROPHENOL HYDROXYLASE; ORTHO-PHENYLPHENOL; FLUORESCENS; DIBENZOTHIOPHENE; METABOLISM; CLEAVAGE; SEQUENCE; DESULFURIZATION	2-Hydroxybiphenyl 3-monooxygenase (HbpA), the first enzyme of a-hydroxybiphenyl degradation in Pseudomonas azelaica HBP1, was purified 26-fold with a yield of 8% from strain HBP1 grown on a-hydroxybiphenyl, The enzyme was also purified from a recombinant of Escherichia coli JM109, which efficiently expressed the hbpA gene, Computer densitometry of scanned slab gels revealed a purity of over 99% for both enzyme preparations, Gel filtration, subunit cross-linking, and SDS-polyacrylamide gel electrophoresis showed that the enzyme was a homotetramer with a molecular mass of 256 kDa, Each subunit had a molecular mass of 60 kDa containing one molecule of noncovalently bound FAD, The monooxygenase had a pi of 6.3, It catalyzed the NADH-dependent ortho-hydroxylation of 2-hydroxybiphenyl to 2,3-dihydroxybiphenyl. Molecular oxygen was the source of the additional oxygen of the product, The enzyme hydroxylated various phenols with a hydrophobic side chain adjacent to the hydroxy group, All substrates effected partial uncoupling of NADH oxidation from hydroxylation with the concomitant formation of hydrogen peroxide, 2,3-Dihydroxybiphenyl, the product of the reaction with a-hydroxybiphenyl, was a non-substrate effector that strongly facilitated NADH oxidation and hydrogen peroxide formation without being hydroxylated and also was an inhibitor, The apparent K-m, values (30 degrees C, pH 7.5) were 2.8 mu m for 2-hydroxybiphenyl, 26.8 mu m for NADH, and 29.2 mu m for oxygen, The enzyme was inactivated by p-hydroxymercuribenzoate, a cysteine-blocking reagent, In the presence of a-hydroxybiphenyl, the enzyme was partly protected against the inactivation, which was reversed by the addition of an excess of dithiothreitol, The NH2-terminal amino acid sequence of the enzyme contained the consensus sequence GXGXXG, indicative of the beta alpha beta-fold of the flavin binding site and shared homologies with that of phenol a-hydroxylase from Pseudomonas strain EST1001 as well as with that of 2,4-dichlorophenol 6-hydroxylase from Ralstonia eutropha.	EAWAG,DEPT MICROBIOL,CH-8600 DUBENDORF,SWITZERLAND; ETH ZURICH,INST BIOTECHNOL,CH-8093 ZURICH,SWITZERLAND; UNIV STUTTGART,DEPT BIOL WASTE AIR PURIFICAT,D-70569 STUTTGART,GERMANY	Swiss Federal Institute of Aquatic Science & Technology (EAWAG); ETH Zurich; University of Stuttgart			Kohler, Hans-Peter/C-1456-2015	Kohler, Hans-Peter/0000-0001-7667-0762				BEADLE CA, 1982, EUR J BIOCHEM, V123, P323, DOI 10.1111/j.1432-1033.1982.tb19771.x; BEINERT H, 1960, ENZYMES, V2, P339; CATELANI D, 1974, BIOCHEM J, V143, P431, DOI 10.1042/bj1430431; Copeland R. A., 1994, METHODS PROTEIN ANAL, P59; DENOME SA, 1993, APPL ENVIRON MICROB, V59, P2837, DOI 10.1128/AEM.59.9.2837-2843.1993; DETMER F, 1984, CHEM BIOCH FLAVOENZY, V259, P12125; Eckert J.W., 1977, ANTIFUNGAL COMPOUNDS, VFirst, P269; ENGESSER KH, 1989, FEMS MICROBIOL LETT, V65, P205; FORTNAGEL P, 1990, APPL ENVIRON MICROB, V56, P1148, DOI 10.1128/AEM.56.4.1148-1156.1990; GALLAGHER JR, 1993, FEMS MICROBIOL LETT, V107, P31, DOI 10.1111/j.1574-6968.1993.tb05999.x; GIBSON DT, 1973, BIOCHEM BIOPH RES CO, V50, P211, DOI 10.1016/0006-291X(73)90828-0; GRIFFITH IP, 1972, BIOCHEM J, V126, P553, DOI 10.1042/bj1260553; HOFSTEENGE J, 1983, EUR J BIOCHEM, V133, P91, DOI 10.1111/j.1432-1033.1983.tb07433.x; KOHLER HPE, 1988, APPL ENVIRON MICROB, V54, P2683, DOI 10.1128/AEM.54.11.2683-2688.1988; KOHLER HPE, 1993, APPL ENVIRON MICROB, V59, P860, DOI 10.1128/AEM.59.3.860-866.1993; KOHLER HPE, 1993, J BACTERIOL, V175, P1621, DOI 10.1128/JB.175.6.1621-1628.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU T, 1984, FEBS LETT, V173, P314, DOI 10.1016/0014-5793(84)80797-8; Maarel M. J. E. C. van der, 1993, Biodegradation, V4, P81, DOI 10.1007/BF00702324; MASSEY V, 1975, ENZYMES, V12, P191; Mullis K B, 1991, PCR Methods Appl, V1, P1; NAKAGAWA Y, 1989, XENOBIOTICA, V19, P499, DOI 10.3109/00498258909042289; NAKAGAWA Y, 1995, LIFE SCI, V57, P1433, DOI 10.1016/0024-3205(95)02106-S; NEUJAHR HY, 1978, J BIOL CHEM, V253, P8835; NEUJAHR HY, 1991, CHEM BIOCH FLAVOENZY, V2, P65; NURK A, 1991, GENE, V102, P13, DOI 10.1016/0378-1119(91)90531-F; Ohshiro T, 1996, J FERMENT BIOENG, V81, P121, DOI 10.1016/0922-338X(96)87588-X; OMORI T, 1992, APPL ENVIRON MICROB, V58, P911, DOI 10.1128/AEM.58.3.911-915.1992; PERKINS EJ, 1990, J BACTERIOL, V172, P2351, DOI 10.1128/jb.172.5.2351-2359.1990; Ratkowsky D., 1983, NONLINEAR REGRESSION; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID A, 1997, THESIS U STUTTGART; SCHREUDER HA, 1991, CHEM BIOCH FLAVOENZY, V2, P31; SPECTOR T, 1972, J BIOL CHEM, V247, P4679; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; STRUBEL V, 1991, J BACTERIOL, V173, P1932, DOI 10.1128/jb.173.6.1932-1937.1991; TAYAMA S, 1994, MUTAT RES, V324, P121, DOI 10.1016/0165-7992(94)90056-6; van Berkel W.J.H., 1991, CHEM BIOCH FLAVOENZY, P1; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1991, EUR J BIOCHEM, V201, P585; VANBERKEL WJH, 1984, EUR J BIOCHEM, V145, P245; VANDERBOLT FJT, 1994, PROTEIN ENG, V7, P801, DOI 10.1093/protein/7.6.801; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	44	64	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24257	24265		10.1074/jbc.272.39.24257	http://dx.doi.org/10.1074/jbc.272.39.24257			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305879	hybrid, Green Published			2022-12-25	WOS:A1997XY51500030
J	McCormick, SPA; Ng, JK; Cham, CM; Taylor, S; Marcovina, SM; Segrest, JP; Hammer, RE; Young, SG				McCormick, SPA; Ng, JK; Cham, CM; Taylor, S; Marcovina, SM; Segrest, JP; Hammer, RE; Young, SG			Transgenic mice expressing human apoB95 and apoB97	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-B; MONOCLONAL-ANTIBODY; YEAST; DNA; PLASMINOGEN; PLASMA; MUTAGENESIS; REPLACEMENT; EVOLUTION	The structural features of apolipoprotein (apo) B that are important for its covalent linkage to apo(a) to form lipoprotein(a) (Lp(a)) are incompletely understood. Although apoB100 cysteine 4326 is required for the disulfide linkage with apo(a), other structural features, aside from a single free cysteine residue, must be important for apoB's initial interaction with apo(a) and far facilitating the formation of the disulfide bond, To determine if sequences carboxyl-terminal to cysteine 4326 affect the efficiency of Lp(a) formation, we used ''pop-in, pop out'' gene targeting in a human apoB yeast artificial chromosome to introduce nonsense mutations into exon 29 of the apoB gene, The mutant yeast artificial chromosomes, which coded for the truncated versions of human apoB, apoB95, and apoB97, were then used to express these mutant forms of apoB in transgenic mice, As judged by in vitro assays of Ly(a) formation, apoB95 (4330 amino acids) formed a small amount of Lp(a) but did so slowly. In contrast, apoB97 (4397 amino acids) formed Ep(a) rapidly, although not quite as rapidly as the full-length apoB100 (4536 amino acids). These results were supported by an analysis of double-transgenic mice expressing both human apo(a) and either-apoB95 or apoB97. Iu mice expressing bath apoB95 and apo(a), there was only a trace amount of Lp(a) in the plasma, and most of the apo(a) was free, whereas in mice expressing both apoB97 and apo(a), virtually all of the apo(a) was bound to apoB97 in the farm of Lp(a), These results show that sequences carboxyl-terminal to apoB95 (amino acids 4331-4536) are not absolutely required for Lp(a) formation, but this segment of the apoB molecule, particularly residues 4331-4397, is necessary for the efficient assembly of LP(a).	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV WASHINGTON, DEPT MED, NW LIPID RES LABS, SEATTLE, WA 98103 USA; UNIV ALABAMA, MED CTR, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Hammer, Robert E./0000-0001-5487-7551; McCormick, Sally/0000-0001-9857-0703; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; CHIESA G, 1992, J BIOL CHEM, V267, P24369; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; KARADI I, 1988, BIOCHIM BIOPHYS ACTA, V960, P91, DOI 10.1016/0005-2760(88)90013-6; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KRUL ES, 1988, J LIPID RES, V29, P937; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LAWN RM, 1995, J BIOL CHEM, V270, P24004, DOI 10.1074/jbc.270.41.24004; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MAKINO K, 1989, ATHEROSCLEROSIS, V78, P81, DOI 10.1016/0021-9150(89)90161-5; MANCINI FP, 1995, ARTERIOSCL THROM VAS, V15, P1911, DOI 10.1161/01.ATV.15.11.1911; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; MCCORMICK SPA, 1995, P NATL ACAD SCI USA, V92, P10147, DOI 10.1073/pnas.92.22.10147; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; McCormick SPA, 1996, TRENDS CARDIOVAS MED, V6, P16, DOI 10.1016/1050-1738(95)00125-5; MCCORMICK SPA, 1994, GENET ANAL-BIOMOL E, V11, P158, DOI 10.1016/1050-3862(94)90036-1; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, CURR OPIN LIPIDOL, V2, P253; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1994, J LIPID RES, V35, P399	33	19	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23616	23622		10.1074/jbc.272.38.23616	http://dx.doi.org/10.1074/jbc.272.38.23616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295301	hybrid			2022-12-25	WOS:A1997XX38100026
J	Noti, JD				Noti, JD			Sp3 mediates transcriptional activation of the leukocyte integrin genes CD11C and CD11B and cooperates with c-Jun to activate CD11C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; MYELOID CELLS; ZINC-FINGER; SP1-MEDIATED TRANSCRIPTION; NEGATIVE REGULATION; MOLECULAR-CLONING; PROMOTER ACTIVITY; RB PROTEIN; EXPRESSION; PRODUCT	The leukocyte integrin genes CD11c and CD11b are expressed predominately in myelomonocytic cells. In previous experiments, the -70 to -65 and -121 to -103 regions of the CD11c promoter and the -66 to -59 region of the CD11b promoter were shown to be essential for Sp1-mediated activation of these genes. In vivo genomic footprinting had also revealed cell-specific binding of protein, presumably Sp1, to these regions. In this study, electrophoretic mobility shift analysis showed that the Sp1-related factor, Sp3, also binds at or near these same regions, Cotransfection of Sp3 along with CD11c promoter-luciferase constructs into Sp-deficient Drosophila Schneider 2 cells showed that Sp3 could activate the CD11c promoter, Deletion of both the -70 to -65 and -121 to -103 regions of the CD11c promoter resulted in the loss of activation by Sp3. Both sites showed activation by Sp3; however, the -70 to -65 region was more responsive to Sp3 than to Sp1. Similar transfection analysis of the -66 to -59 region of the CD11b promoter showed Sp3-dependent expression. Further, cotransfection analysis in Drosophila cells showed that Sp3, as was previously shown for Sp1, also synergizes with c-Jun to activate CD11c. Antisense experiments that knocked out endogenous Sp3 expression in the myelomocytic cell line, HL60, revealed that Sp3 participates in activation of the CD11c and CD11b promoters in vivo.			Noti, JD (corresponding author), GUTHRIE RES INST,SAYRE,PA 18840, USA.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN XR, 1994, ONCOGENE, V9, P3179; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HROMAS R, 1991, J BIOL CHEM, V266, P14183; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; NOTI JD, 1992, DNA CELL BIOL, V11, P123, DOI 10.1089/dna.1992.11.123; NOTI JD, 1995, MOL IMMUNOL, V32, P361, DOI 10.1016/0161-5890(94)00164-V; Noti JD, 1996, MOL CELL BIOL, V16, P2940; OHYASHIKI JH, 1995, BLOOD, V85, P3713, DOI 10.1182/blood.V85.12.3713.bloodjournal85123713; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSMARIN AG, 1989, BLOOD, V73, P131; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1986, J IMMUNOL, V136, P230; Sturrock A, 1996, J BIOL CHEM, V271, P32392, DOI 10.1074/jbc.271.50.32392; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; Williams CL, 1996, BIOCHEM PHARMACOL, V51, P707, DOI 10.1016/S0006-2952(95)02393-3; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282; YU DH, 1992, J BIOL CHEM, V267, P10203; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	54	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24038	24045		10.1074/jbc.272.38.24038	http://dx.doi.org/10.1074/jbc.272.38.24038			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295357	hybrid			2022-12-25	WOS:A1997XX38100082
J	Ollinger, K; Roberg, K				Ollinger, K; Roberg, K			Nutrient deprivation of cultured rat hepatocytes increases the desferrioxamine-available iron pool and augments the sensitivity to hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT IRON; OXIDATIVE STRESS; FERRIC IRON; LIQUID-CHROMATOGRAPHY; RADICAL FORMATION; INSULINOMA CELLS; ASCORBIC-ACID; MODEL SYSTEM; SUPEROXIDE; INJURY	Primary cultures of rat hepatocytes were subjected to amino acid and serum deprivation for 4 h, This treatment augmented the sensitivity to ensuing hydrogen peroxide exposure for 30 min, The by nutrient deprivation-increased autophagocytosis was confirmed by transmission electron microscopy and uptake of the lysosomotropic weak base acridine orange within the intracellular acidic vacuolar apparatus, The desferrioxamine-available pool of iron increased 2.5-fold during deprivation, compared with control cells, Furthermore, amino acid deprivation increased the cellular protein turnover, measured by radioactive labeling with [H-3]Leu, Exposure to 40 mu M ascorbic acid specifically decreased the turnover of ferritin, as estimated by enzyme-linked immunosorbent assay, and prevented an increase of the desferrioxamine available iron pool, resulting in protection against hydrogen peroxide-induced cell killing. Thus, hepatocytes with nutrient deprivation-enhanced autophagocytosis contain a larger pool of catalytically active iron than control cells, This iron pool is mainly derived from the turnover (autophagocytosis) of cytosolic ferritin and is probably situated in the lysosomes. Furthermore, nutrient deprived cells show augmented sensitivity to hydrogen peroxide-induced oxidative stress, since the enhanced availability of iron in low molecular weight form results in an increased potential of intralysosomal Fenton chemistry, that may cause lysosomal rupture with release of potent hydrolytic enzymes.			Ollinger, K (corresponding author), LINKOPING UNIV, FAC HLTH SCI, DEPT PATHOL 2, S-58185 LINKOPING, SWEDEN.							ABOK K, 1988, APMIS, V96, P589, DOI 10.1111/j.1699-0463.1988.tb00915.x; AUST SD, 1993, TOXICOL APPL PHARM, V120, P168, DOI 10.1006/taap.1993.1100; BALLA G, 1992, J BIOL CHEM, V267, P18148; BANDO Y, 1990, BIOCHEM BIOPH RES CO, V168, P389, DOI 10.1016/0006-291X(90)92333-U; BOLANN BJ, 1990, EUR J BIOCHEM, V193, P899, DOI 10.1111/j.1432-1033.1990.tb19415.x; BRIDGES KR, 1986, J BIOL CHEM, V261, P14273; BRIDGES KR, 1987, J BIOL CHEM, V262, P14773; BRUN A, 1970, J HISTOCHEM CYTOCHEM, V18, P820, DOI 10.1177/18.11.820; BRUNK UT, 1995, REDOX REP, V1, P267, DOI 10.1080/13510002.1995.11746997; CRAMER SM, 1984, J CHROMATOGR, V295, P405, DOI 10.1016/S0021-9673(01)87642-1; FLOYD RA, 1983, BIOCHEMISTRY-US, V22, P2645, DOI 10.1021/bi00280a008; GOWER JD, 1989, ANAL BIOCHEM, V180, P126, DOI 10.1016/0003-2697(89)90099-7; GRAF E, 1984, J BIOL CHEM, V259, P3620; GREEN CJ, 1989, FREE RADICAL RES COM, V7, P255, DOI 10.3109/10715768909087950; HONEGGER CG, 1989, J CHROMATOGR-BIOMED, V487, P463, DOI 10.1016/S0378-4347(00)83056-X; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KREBERLE H, 1964, ANN NY ACAD SCI, V119, P758; LATOUR I, 1992, ARCH TOXICOL, V66, P743, DOI 10.1007/BF01972625; LINDER CM, 1983, STRUCTURE FUNCTIONS, P465; LLOYD JB, 1991, BIOCHEM PHARMACOL, V41, P1361, DOI 10.1016/0006-2952(91)90109-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARZABADI MR, 1988, MECH AGEING DEV, V46, P145, DOI 10.1016/0047-6374(88)90122-4; MYERS BM, 1991, J CLIN INVEST, V88, P1207, DOI 10.1172/JCI115423; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; OZAKI M, 1994, TRANSPLANT P, V26, P918; PERTOFT H, 1987, CELL SEPARATION METH, V4, P1; REDEGELD FAM, 1992, EUR J PHARM-ENVIRON, V228, P229, DOI 10.1016/0926-6917(92)90034-A; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; RUBIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P450, DOI 10.1016/0003-9861(84)90010-9; RUNDQUIST I, 1984, ACTA PATH MICRO IM A, V92, P303; SAKAIDA I, 1990, MOL PHARMACOL, V37, P435; SCHELLENS JPM, 1991, HISTOCHEM J, V23, P460, DOI 10.1007/BF01041376; SCHRAUFSTATTER IU, 1987, B EUR PHYSIOPATH RES, V23, P297; STARKE PE, 1985, BIOCHEM BIOPH RES CO, V133, P371, DOI 10.1016/0006-291X(85)90916-7; STARKE PE, 1985, J BIOL CHEM, V260, P99; VOOGD A, 1992, J CLIN INVEST, V90, P2050, DOI 10.1172/JCI116086; ZHANG H, 1993, DIABETOLOGIA, V36, P707, DOI 10.1007/BF00401140; Zhang H, 1996, REDOX REP, V2, P235, DOI 10.1080/13510002.1996.11747056; ZHANG H, 1995, DIABETOLOGIA, V38, P635, DOI 10.1007/BF00401832	41	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23707	23711		10.1074/jbc.272.38.23707	http://dx.doi.org/10.1074/jbc.272.38.23707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295314	hybrid			2022-12-25	WOS:A1997XX38100039
J	Zhang, QM; Berggren, PO; Tally, M				Zhang, QM; Berggren, PO; Tally, M			Glucose increases both the plasma membrane number and phosphorylation of insulin-like growth factor II mannose 6-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-LINE; BINDING; EXPRESSION	We have investigated the effect of glucose on insulinlike growth factor II (IGF-II) binding to, and intracellular phosphorylation of, the IGF-II/mannose B-phosphate (M6P) receptor in the insulin-secreting cell line RINm5F. Glucose, at a concentration of 3 mM, significantly increased binding of IGF-II to the cells. A further increase of the binding was observed at a glucose concentration of 10 mM. Scatchard analysis showed that the increased binding was caused by an increased number of the receptors rather than changes in affinity. This effect of glucose was also demonstrated in another insulin-secreting cell line HIT as well as in the human erythroleukemia cell line K562. Affinity cross-linking of the RLNm5F cells, using I-125-IGF-II, revealed increased binding to the IGF-II/M6P receptor induced by glucose. The effect of glucose on IGF-II binding was mimicked by fructose (10 mm), but not by 3-O-methylglucose (10 mM), and was abolished by the protein kinase C (PKC) inhibitor calphostin C, or down-regulation of PKC, but not by the protein phosphatase inhibitor, okadaic acid, Glucose dose dependently stimulated phosphorylation of the IGF-II/M6P receptor, an effect that was inhibited by down-regulation of PKC activity. This study suggests that the distribution of the IGF-II/M6P receptor in insulin-secreting cells can be regulated by glucose-induced phosphorylation, a mechanism mediated by PKC.			Zhang, QM (corresponding author), KAROLINSKA INST,ROLF LUFT CTR DIABET RES,DEPT MOL MED,ENDOCRINE & DIABET UNIT,S-17176 STOCKHOLM,SWEDEN.			Berggren, Per-Olof/0000-0001-8991-413X				ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRAULKE T, 1992, J BIOL CHEM, V267, P17347; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; CORVERA S, 1988, BIOCHEM J, V250, P47, DOI 10.1042/bj2500047; CORVERA S, 1988, J BIOL CHEM, V263, P3116; HU KQ, 1990, J BIOL CHEM, V265, P13864; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAURENZI MA, 1995, NEUROSCI RES COMMUN, V16, P37; OH Y, 1993, GROWTH REGULAT, V3, P113; OKA Y, 1985, J BIOL CHEM, V260, P9435; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PILCH PF, 1979, J BIOL CHEM, V254, P3375; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; Roth R A, 1994, Growth Regul, V4 Suppl 1, P31; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; Zhang QM, 1997, P NATL ACAD SCI USA, V94, P6232, DOI 10.1073/pnas.94.12.6232; Zhang QM, 1996, MOL CELL BIOCHEM, V154, P47	21	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23703	23706		10.1074/jbc.272.38.23703	http://dx.doi.org/10.1074/jbc.272.38.23703			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295313	hybrid			2022-12-25	WOS:A1997XX38100038
J	Muller, JN; Krauss, B; Kaltschmidt, C; Baeuerle, PA; Rupec, RA				Muller, JN; Krauss, B; Kaltschmidt, C; Baeuerle, PA; Rupec, RA			Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SERUM RESPONSE ELEMENT; DNA-BINDING ACTIVITY; TERNARY COMPLEX; GENE-EXPRESSION; OXIDATIVE STRESS; HUMAN-BREAST; TUMOR-CELLS; AP-1; ELK-1	Hypoxia is a pathophysiological condition that occurs during injury, ischemia, and stroke. It is characterized by a decrease of reactive oxygen intermediates and a change of the intracellular redox level. In tumors hypoxia is regarded as a trigger for enhanced growth and metastasis. Here we report that in HeLa cells, hypoxic conditions induce the transcriptional activation of c-fos transcription via the serum response element. Mutations in the binding site for the ternary complex factor Elk-1 and the serum response factor abolished this induction, indicating that a ternary complex at the serum response element is necessary for the induction of the c-fos gene under hypoxia, The transcription factor Elk-1 was covalently modified by phosphorylation in response to hypoxia. Furthermore this hyperphosphorylation of Elk-1, the activation of mitogen-activated protein kinase (MAPK), and the induction of c-fos transcripts were blocked by PD98059, a specific inhibitor of mitogen activated protein kinase kinase/extracellular signal-regulated protein kinase kinase 1. An in vitro kinase assay with Elk-1 as substrate showed that MAPK is activated under hypoxia, The activation of MAPK corresponds temporally with the phosphorylation and activation of Elk-1, Thus, a decrease of the intracellular reactive oxygen intermediate level by hypoxia induces c-fos via the MAPK pathway. These results suggest that the intracellular redox levels may be directly coupled to tumor growth, invasion, and metastasis via Elk-1-dependent induction of c-Fos controlled genes.	UNIV FREIBURG, INST BIOCHEM & MOL BIOL, D-79104 FREIBURG, GERMANY	University of Freiburg								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANSEL PK, 1994, FOS JUN FAMILIES TRA; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BERGELSON S, 1994, ONCOGENE, V9, P565; BIUNNO I, 1988, BRIT J CANCER, V57, P464, DOI 10.1038/bjc.1988.108; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN CN, 1988, J CLIN ONCOL, V6, P709, DOI 10.1200/JCO.1988.6.4.709; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HONOKI K, 1992, MOL CARCINOGEN, V6, P122, DOI 10.1002/mc.2940060207; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KENNEDY KA, 1980, BIOCHEM PHARMACOL, V29, P1, DOI 10.1016/0006-2952(80)90235-X; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; RUTHER U, 1989, ONCOGENE, V4, P861; SAKATA K, 1991, BRIT J CANCER, V64, P809, DOI 10.1038/bjc.1991.405; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; SILVA CM, 1989, J BIOL CHEM, V264, P6638; TANNOCK I, 1981, BRIT J CANCER, V43, P245, DOI 10.1038/bjc.1981.37; TEICHER BA, 1990, CANCER RES, V52, P4372; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; URABE A, 1992, J PATHOL, V168, P281, DOI 10.1002/path.1711680307; WALKER RA, 1991, J PATHOL, V163, P323, DOI 10.1002/path.1711630409; Wang GL, 1996, REDOX REP, V2, P89, DOI 10.1080/13510002.1996.11747034; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	57	131	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23435	23439		10.1074/jbc.272.37.23435	http://dx.doi.org/10.1074/jbc.272.37.23435			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287359	hybrid			2022-12-25	WOS:A1997XV74400070
J	Bobkova, EV; Hall, BD				Bobkova, EV; Hall, BD			Substrate specificity of the RNase activity of yeast RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATED TRANSCRIPT CLEAVAGE; ELONGATION-FACTOR; TERNARY COMPLEXES; ESCHERICHIA-COLI; NASCENT RNA; DEPENDENT TRANSCRIPTION; TERMINATION; BINDING; GENE; IDENTIFICATION	Using yeast RNA polymerase III ternary complexes stalled at various positions on the template, we have analyzed the cleavage products that are retained and released by the transcription complexes. The retained 5' products result from cleavage at uridine residues during retraction, whereas the yield of mononucleotides and dinucleotides released indicates that multiple cuts occur near the 3' end, Comparison of the cleavage patterns of uridine-containing and 5-bromouridine-containing transcripts suggests that RNA within an RNA-DNA hybrid duplex is the substrate for the 3'-5' exonuclease. During transcription of the SUP4 tRNA(Tyr) gene, RNA polymerase III produces not only full-length pre-tRNA(Tyr) but also short oligonucleotides, indicating that exonuclease digestion and transcription are concurrent processes. To explore the possibility that these oligonucleotides are released by the action of the RNA polymerase III nuclease at previously observed uridine-rich pause sites, we tested modified templates lacking the arrest sites present in the SUP4 tRNA(Tyr) gene, Comparative studies of cleavage during transcription for these templates show a direct correlation between the number of natural pause sites and the yield of 3' products made, At the natural arrest sites and the terminator, RNA polymerase III carries out multiple cleavage resynthesis steps, producing short Oligoribonucleotides with uridine residues at the 3' terminus.	UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM11895] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011895] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HAGLER J, 1993, J BIOL CHEM, V268, P2166; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JACOBS BL, 1988, J INTERFERON RES, V8, P617, DOI 10.1089/jir.1988.8.617; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KORNBERG A, 1980, DNA REPLICATION, P127; KORNBERG A, 1980, DNA REPLICATION, P232; KURJAN J, 1982, MOL CELL BIOL, V2, P1501, DOI 10.1128/MCB.2.12.1501; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SONENBERG N, 1981, CELL, V27, P563, DOI 10.1016/0092-8674(81)90398-6; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; UCHIDA T, 1970, J BIOCHEM-TOKYO, V67, P91, DOI 10.1093/oxfordjournals.jbchem.a129239; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299	31	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22832	22839		10.1074/jbc.272.36.22832	http://dx.doi.org/10.1074/jbc.272.36.22832			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278445	hybrid			2022-12-25	WOS:A1997XV49200066
J	Jenkins, CM; Genzor, CG; Fillat, MF; Waterman, MR; GomezMoreno, C				Jenkins, CM; Genzor, CG; Fillat, MF; Waterman, MR; GomezMoreno, C			Negatively charged Anabaena flavodoxin residues (Asp(144) and Glu(145)) are important for reconstitution of cytochrome P450 17 alpha-hydroxylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERREDOXIN-NADP+ REDUCTASE; LASER FLASH-PHOTOLYSIS; AMINO-ACID-RESIDUES; ELECTRON-TRANSFER; FLAVIN MONONUCLEOTIDE; CODING NUCLEOTIDE; P-450 REDUCTASE; OXIDOREDUCTASE; PURIFICATION; BINDING	Catalysis by microsomal cytochromes P450 requires the membrane-bound enzyme NADPH-cytochrome P450 reductase (P450 reductase), which transfers electrons to the P450 heme via a flavodoxin-like domain, Previously, we reported that Escherichia coli flavodoxin (Fld), a soluble electron transfer protein, directly interacts with bovine cytochrome P450 17 alpha-hydroxylase/17,20-lyase (P450c17) and donates electrons to this enzyme when reconstituted with NADPH-ferredoxin (flavodoxin) reductase (FNR) (Jenkins, C. M., and Waterman, M. R. (1994) J. Biol. Chem. 269, 27401-27408). To investigate whether flavodoxins can serve as useful models of the analogous domain in P450 reductase, we have examined the FNR-Fld system from the cyanobacterium Anabaena, Mutagenesis of two acidic Anabaena Fld residues (D144A and E145A) significantly decreased flavodoxin-supported P450c17 progesterone 17 alpha-hydroxylase activity, Specifically, D144A exhibited only 15% of the activity of wild-type Fld, whereas the adjacent mutation, E145A, caused a 40% loss in activity. P450-dependent hydrogen peroxide/superoxide production by wild-type FNR-Fld was measurably higher than that generated by FNR-D144A or FNR E145A, indicating that the mutations do not lead to P450 heme-mediated electron uncoupling, Interestingly, the D144A and E145A mutants bind with equal or even greater affinity to P450c17 than wild-type Fld, Furthermore, these mutations (D144A and E145A) actually increased cytochrome c reductase activity (35 and 100% higher than wild type), Anabaena Fld residues Asp(144) and Glu(145) align closely with rat P450 reductase residue Asp(208), which has been shown by mutagenesis to be important in electron transfer to P4502B1 but not to cytochrome c (Shen, A. L., and Rasper, C. B. (1995) J. Biol. Chem. 270, 27475-27480). Thus, these residues in flavodoxins and P450 reductase appear to have similar functions in P450 recognition and/or electron transfer, supporting the hypothesis that flavodoxins represent valid models for the FMN-binding domain of P450 reductase.	UNIV ZARAGOZA,FAC CIENCIAS,DEPT BIOQUIM & BIOL MOL & CELULAR,E-50009 ZARAGOZA,SPAIN	University of Zaragoza	Jenkins, CM (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.		Fillat, María F/G-2609-2015	Fillat Castejon, Maria Francisca/0000-0001-8644-4574	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R37GM037942] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES07208, P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM37942] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURKHART BM, 1995, ACTA CRYSTALLOGR D, V51, P318, DOI 10.1107/S0907444994011716; DEISTUNG J, 1985, BIOCHEM J, V231, P743, DOI 10.1042/bj2310743; Dong MS, 1996, ARCH BIOCHEM BIOPHYS, V327, P11, DOI 10.1006/abbi.1996.0086; Estabrook RW, 1996, ARCH BIOCHEM BIOPHYS, V333, P308, DOI 10.1006/abbi.1996.0395; FILLAT MF, 1988, ARCH MICROBIOL, V150, P160, DOI 10.1007/BF00425156; FUJII K, 1974, J BIOL CHEM, V249, P6745; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; GOMEZMORENO C, 1994, BIOCHEM SOC T, V22, P796, DOI 10.1042/bst0220796; GRANDORI R, 1994, PROTEIN SCI, V3, P2185, DOI 10.1002/pro.5560031204; GROSS EL, 1993, PHOTOSYNTH RES, V37, P103, DOI 10.1007/BF02187469; HAZZARD JT, 1988, BIOCHEMISTRY-US, V27, P4445, DOI 10.1021/bi00412a035; HAZZARD JT, 1991, BIOCHEMISTRY-US, V30, P213, DOI 10.1021/bi00215a031; HILDEBRANDT AG, 1978, METHOD ENZYMOL, V52, P346; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; KIM JJ, 1996, 11 INT S MICR DRUG O, pL120; KLUGKIST J, 1986, EUR J BIOCHEM, V155, P33, DOI 10.1111/j.1432-1033.1986.tb09455.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; MEDINA M, 1992, EUR J BIOCHEM, V203, P373, DOI 10.1111/j.1432-1033.1992.tb16560.x; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P622, DOI 10.1021/bi00053a030; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NAVARRO JA, 1995, ARCH BIOCHEM BIOPHYS, V321, P229, DOI 10.1006/abbi.1995.1390; NISIMOTO Y, 1988, BIOCHEMISTRY-US, V27, P5869, DOI 10.1021/bi00416a008; OSTER T, 1991, J BIOL CHEM, V266, P22718; PALMA PN, 1994, BIOCHEMISTRY-US, V33, P6394, DOI 10.1021/bi00187a003; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PUEYO JJ, 1991, EUR J BIOCHEM, V202, P1065, DOI 10.1111/j.1432-1033.1991.tb16471.x; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SANCHO J, 1988, ARCH BIOCHEM BIOPHYS, V260, P200, DOI 10.1016/0003-9861(88)90441-9; SCHMITZ S, 1995, BBA-BIOENERGETICS, V1231, P335, DOI 10.1016/0005-2728(95)00097-3; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020	39	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22509	22513		10.1074/jbc.272.36.22509	http://dx.doi.org/10.1074/jbc.272.36.22509			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278403	hybrid			2022-12-25	WOS:A1997XV49200023
J	Kaartinen, MT; Pirhonen, A; LinnalaKankkunen, A; Maenpaa, PH				Kaartinen, MT; Pirhonen, A; LinnalaKankkunen, A; Maenpaa, PH			Transglutaminase-catalyzed cross-linking of osteopontin is inhibited by osteocalcin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CRYSTAL-GROWTH; FACTOR-XIII; BONE; PROTEIN; TISSUES; PHOSPHOPROTEIN; LOCALIZATION; SUBSTRATE; MATRIX	Osteocalcin, the most abundant noncollagenous protein of bone matrix, has been demonstrated to inhibit bone growth by gene knockout experiments (Ducy, P., Desbois, C., Boyce, B., Pinero, G., Story, B., Dunstan, C., Smith, E., Bonadio, J., Goldstein, S., Gundberg, C., Bradley, A., and Karsenty, G. (1996) Nature 382, 448-452). Its specific functional mechanism in bone metabolism is, however, largely unknown. In this study, we provide evidence that osteocalcin has an inhibitory effect on tissue transglutaminase activity, as measured by cross-linking of osteopontin, another bone matrix protein. Using a set of synthetic peptides, we found that the inhibitory activity resided within the first 13 N-terminal amino acid residues of osteocalcin. An N-terminal peptide also inhibited cross-linking of another tissue transglutaminase substrate, beta-casein. The inhibitory peptide was shown to have affinity for the substrates of transglutaminase rather than for the enzyme. Since the N terminus of osteocalcin exhibits homology to the substrate recognition site sequences of two transglutaminases, we conclude that the inhibitory effect is most likely due to competition with the enzyme for the transglutaminase-binding region of the substrates, osteopontin and beta-casein, which prevents access of the enzyme to them to perform its function. The interference of osteocalcin with osteopontin cross-linking gives osteocalcin a new potential function as the first protein inhibitor of tissue transglutaminase. This suggests a specific role and a plausible mechanism for it as a modulator of maturation, stabilization, and calcification of bone matrix.			Kaartinen, MT (corresponding author), UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,POB 1627,FIN-70211 KUOPIO,FINLAND.			Kaartinen, Mari/0000-0003-2999-6502				ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BENINATI S, 1994, J BIOCHEM-TOKYO, V115, P675, DOI 10.1093/oxfordjournals.jbchem.a124395; BOSKEY AL, 1992, CLIN ORTHOP RELAT R, V281, P244; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; Christensen BM, 1996, J AGR FOOD CHEM, V44, P1943, DOI 10.1021/jf9602131; COLOMBO G, 1993, J BONE MINER RES, V8, P733; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HAUSCHKA PV, 1982, BIOCHEMISTRY-US, V21, P2538, DOI 10.1021/bi00539a038; HOHENADL C, 1995, J BIOL CHEM, V270, P23415, DOI 10.1074/jbc.270.40.23415; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IKURA K, 1980, AGR BIOL CHEM TOKYO, V44, P1567, DOI 10.1080/00021369.1980.10864171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAN JB, 1984, J CLIN INVEST, V73, P1223, DOI 10.1172/JCI111308; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MARK MP, 1987, J HISTOCHEM CYTOCHEM, V35, P707, DOI 10.1177/35.7.3295029; MARK MP, 1988, DIFFERENTIATION, V37, P123, DOI 10.1111/j.1432-0436.1988.tb00804.x; McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W; McKee MD, 1996, ANAT RECORD, V245, P394, DOI 10.1002/(SICI)1097-0185(199606)245:2<394::AID-AR19>3.0.CO;2-K; PRICE PA, 1982, P NATL ACAD SCI-BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; RITTER NM, 1992, J BONE MINER RES, V7, P877; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SORENSEN ES, 1994, BIOCHEM J, V304, P13, DOI 10.1042/bj3040013; SORENSEN ES, 1993, J DAIRY RES, V60, P189, DOI 10.1017/S0022029900027503; WIEBE RI, 1991, BIOCHEM CELL BIOL, V69, P821, DOI 10.1139/o91-122	38	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22736	22741		10.1074/jbc.272.36.22736	http://dx.doi.org/10.1074/jbc.272.36.22736			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278432	hybrid			2022-12-25	WOS:A1997XV49200053
J	Klein, BK; Feng, YQ; McWherter, CA; Hood, WF; Paik, K; McKearn, JP				Klein, BK; Feng, YQ; McWherter, CA; Hood, WF; Paik, K; McKearn, JP			The receptor binding site of human interleukin-3 defined by mutagenesis and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING-FACTOR; HIGH-AFFINITY BINDING; HUMAN GROWTH-HORMONE; COMMON BETA-CHAIN; GM-CSF; ALPHA-CHAIN; BIOLOGICAL-ACTIVITY; HEMATOPOIETIC ACTIVITY; INTERSPECIES CHIMERA; SECONDARY STRUCTURE	Interleukin-3 (IL-3) is a member of the cytokine superfamily that promotes multi-potential hematopoietic cell growth by interacting with a cell surface receptor composed of alpha and beta chains, The newly available three-dimensional structure of a variant of human (h) IL-3 allowed us to evaluate new and existing mutagenesis data and to rationally interpret the structure-function relationship of hIL-3 on a structural basis, The amino acid residues that were identified to be important for hIL-3 activity are grouped into two classes, The first class consists of largely hydrophobic residues required for the structural integrity of the protein, including the residues in IL-3 that are largely conserved among 10 mammalian species, These residues form the core of a scaffold for the second class of more rapidly diverging solvent-exposed residues, likely to be required for interaction with the receptor, Ten important and solvent-exposed residues, Asp(21), Gly(42), Glu(43), Gln(45), Asp(46), Met(49), Arg(94), Pro(96), Phe(113), and Lys(116), map to one side of the protein and form a putative binding site for the alpha subunit of the receptor, A model of the IL-3.IL-3 receptor complex based on the human growth hormone (hGH).hGH soluble receptor complex structure suggests that the interface between IL-3 and the IL-3 receptor alpha subunit consists of a cluster of hydrophobic residues flanked by electrostatic interactions, Although the IL-3/IL-3 receptor beta subunit interface cannot be uniquely located due to the lack of sufficient experimental data, several residues of the beta subunit that may interact with Glu(22) of IL-3 are proposed, The role of these residues can be tested in future mutagenesis studies to define the interaction between IL-3 and IL-3 receptor beta subunit.			Klein, BK (corresponding author), GD SEARLE & CO,700 CHESTERFIELD PKY N,ST LOUIS,MO 63198, USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; Bagley CJ, 1996, J BIOL CHEM, V271, P31922, DOI 10.1074/jbc.271.50.31922; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROWN CB, 1994, EUR J BIOCHEM, V225, P873, DOI 10.1111/j.1432-1033.1994.0873b.x; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURGER H, 1994, BIOCHIM BIOPHYS ACTA, V217, P195; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARKLEWIS I, 1988, P NATL ACAD SCI USA, V85, P7897, DOI 10.1073/pnas.85.21.7897; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DORSSERS LCJ, 1994, GROWTH FACTORS, V11, P93, DOI 10.3109/08977199409001051; DORSSERS LCJ, 1991, J BIOL CHEM, V266, P21310; Feng YP, 1996, J MOL BIOL, V259, P524, DOI 10.1006/jmbi.1996.0337; FENG YQ, 1995, BIOCHEMISTRY-US, V34, P6540, DOI 10.1021/bi00019a036; *GEN COMP GROUP, 1991, UWGCG SOFTW PACK; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; HERCUS TR, 1994, BLOOD, V83, P3500; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUSHANSKY K, 1992, J CLIN INVEST, V90, P1879, DOI 10.1172/JCI116065; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J IMMUNOL, V146, P893; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11872; LYNE PD, 1995, PROTEIN SCI, V4, P2223, DOI 10.1002/pro.5560041027; MCINNES CJ, 1994, GENE, V139, P289, DOI 10.1016/0378-1119(94)90772-2; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLINS PO, 1995, J BIOL CHEM, V270, P23754, DOI 10.1074/jbc.270.40.23754; ROZARSKI DA, 1994, STRUCTURE, V2, P159; SANTOLI D, 1987, J IMMUNOL, V139, P3348; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SEELIG GF, 1994, J BIOL CHEM, V269, P5548; SHANAFELT AB, 1991, J BIOL CHEM, V266, P1804; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THOMAS JW, 1995, P NATL ACAD SCI USA, V92, P3779, DOI 10.1073/pnas.92.9.3779; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999	50	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22630	22641		10.1074/jbc.272.36.22630	http://dx.doi.org/10.1074/jbc.272.36.22630			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278420	Green Published, hybrid			2022-12-25	WOS:A1997XV49200040
J	Oguri, S; Minowa, MT; Ihara, Y; Taniguchi, N; Ikenaga, H; Takeuchi, M				Oguri, S; Minowa, MT; Ihara, Y; Taniguchi, N; Ikenaga, H; Takeuchi, M			Purification and characterization of UDP-N-acetylglucosamine: alpha 1,3-D-mannoside beta 1,4-N-acetylglucosaminyltransferase (N-acetylglucosaminyltransferase-IV) from bovine small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SUGAR CHAINS; HAMSTER-KIDNEY CELLS; GLYCOPROTEIN-SYNTHESIS; UDP-N-ACETYLGLUCOSAMINE-ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFE; MOLECULAR-CLONING; CDNA CLONING; OVARY CELLS; HEN OVIDUCT; RAT-KIDNEY; EXPRESSION	A new beta 1,4-N-acetylglucosaminyltransferase (GnT) which involves in branch formation of Asn-linked complex-type sugar chains has been purified 224,000-fold from bovine small intestine. This enzyme requires divalent cations, such as Mn2+, and catalyzes the transfer of GlcNAc from UDP-GlcNAc to biantennary oligosaccharide and produces triantennary oligosaccharide with the beta 1-4-linked GlcNAc residue on the Man alpha 1-3 arm. The purified enzyme shows a single band of M-r 58,000 and behaves as a monomer. The substrate specificity demonstrated that the beta 1-2-linked GlcNAc residue on the Man alpha 1-3 arm (GnT-I product) is essential for the enzyme activity, beta 1-4-Galactosylaion to this essential beta 1-2-linked GlcNAc residue or N-acetylglucosaminylation to the beta-linked Man residue (bisecting GlcNAc, GnT-III product) blocks the enzyme action, while beta 1-6-N-acetylglucosaminylation to the Man alpha 1-6 arm (GnT-V product) increases the transfer. Based on these findings, we conclude that the purified enzyme is UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1,4-N-acetylglucosaminyltransferase IV (GnT-IV), that has been a missing link on biosynthesis of complex-type sugar chains.	KIRIN BREWERY CO LTD, CENT LABS KEY TECHNOL, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN; OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN	Kirin Brewery Company Limited; Osaka University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; DAGOSTARO GAF, 1995, J BIOL CHEM, V270, P15211, DOI 10.1074/jbc.270.25.15211; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DO KY, 1994, J BIOL CHEM, V269, P23456; GLEESON PA, 1983, J BIOL CHEM, V258, P6162; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOBATA A, 1988, J CELL BIOCHEM, V37, P79, DOI 10.1002/jcb.240370108; KOBATA A, 1993, GLYCOBIOLOGY PRACTIC, P165; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZUOCHI T, 1983, J BIOL CHEM, V258, P4126; NILSSON B, 1979, J BIOL CHEM, V254, P4545; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1989, METHOD ENZYMOL, V179, P351; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; TAKEUCHI M, 1989, P NATL ACAD SCI USA, V86, P7819, DOI 10.1073/pnas.86.20.7819; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; TAKEUCHI M, 1991, Glycobiology, V1, P337, DOI 10.1093/glycob/1.4.337; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; TOKUGAWA K, 1995, GLYCOCOJUGATE J, V13, P95; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1989, J BIOCHEM-TOKYO, V105, P728, DOI 10.1093/oxfordjournals.jbchem.a122736; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	35	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22721	22727		10.1074/jbc.272.36.22721	http://dx.doi.org/10.1074/jbc.272.36.22721			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278430	hybrid			2022-12-25	WOS:A1997XV49200051
J	Allen, JD; Verhoeven, E; Domen, J; vanderValk, M; Berns, A				Allen, JD; Verhoeven, E; Domen, J; vanderValk, M; Berns, A			Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc	ONCOGENE			English	Article						lymphomagenesis; leukemogenesis; transgenic mice; X-inactivation; oncogene; pim-2	E-MU-MYC; MURINE LEUKEMIA-VIRUS; PUTATIVE ONCOGENE PIM-1; T-CELL LYMPHOMAS; MESSENGER-RNA; BONE-MARROW; B-CELLS; N-MYC; MICE; ACTIVATION	Evidence from proviral tagging experiments has suggested that pim-2 is similar in oncogenic behavior to its well characterized relative pim-1. While expression in tissues differs, both genes expressed in mitogenically stimulated hematopoietic cells and their transcription is induced in response to the same cytokines, Expression of a pim-2 transgene in lymphoid cells predisposed mice to T-cell lymphomas like those promoted by pim-1 transgenes, Moreover, strong collaboration with an E mu-myc transgene was manifested as pre-B cell leukemia in neonate bi-transgenic animals, Remarkably, this collaboration was attenuated but not prevented by X-inactivation of one of the transgenes. The addition of pim-2 to the fold increases the prominence of the pim proto-oncogene family in tumorigenesis.	NETHERLANDS CANC INST,DIV MOL GENET,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; ALLEN JD, 1995, J IMMUNOL, V154, P1531; ANSON R, 1989, P NATL ACAD SCI USA, V86, P8857; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; DOMEN J, 1993, LEUKEMIA, pS108; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HARRISON PTC, 1984, LAB ANIM, V18, P325, DOI 10.1258/002367784780865324; Hogan B, 1994, MANIPULATING MOUSE E; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LILLY M, 1992, ONCOGENE, V7, P727; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; RENAULD JC, 1994, ONCOGENE, V9, P1327; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WINGETT D, 1991, J IMMUNOL, V147, P3653; YIP SM, 1995, BLOOD, V85, P3494	33	135	146	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1133	1141		10.1038/sj.onc.1201288	http://dx.doi.org/10.1038/sj.onc.1201288			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294606				2022-12-25	WOS:A1997XU99100002
J	Komatsu, M; Li, HO; Tsutsui, H; Itakura, K; Matsumura, M; Yokoyama, KK				Komatsu, M; Li, HO; Tsutsui, H; Itakura, K; Matsumura, M; Yokoyama, KK			MAZ, a Myc-associated zinc finger protein, is essential for the ME1a1-mediated expression of the c-myc gene during neuroectodermal differentiation of P19 cells	ONCOGENE			English	Article						MAZ; c-myc; ME1a1 site; gene expression	ERYTHROLEUKEMIA-CELLS; PROMOTER ACTIVITY; RETINOIC ACID; TRANSCRIPTION; LINE; COMMITMENT; SITE; E1A; PROLIFERATION; SEQUENCES	To investigate whether MAZ (Myc-associated zinc finger protein) affects the expression of the c-myc gene during the retinoic acid-induced (RA-induced) neuroectodermal differentiation of P19 embryonal carcinoma (EC) cells, we introduced a CAT reporter construct, human c-myc promoter/CAT (pMyc2CAT), and a mutant CAT derivative that lacked an ME1a1 site (pMyc1CAT) into P19EC cells tp monitor the promoter activity of the c-myc gene, The expression of CAT in pMyc2CAT-transformed cells declined fivefold after 24 h in the presence of RA, returned to the normal level within 48 h, and decreased again to below 20% of the normal level after 96 h. By contrast, the expression of CAT in pMyc1CAT-transformed cells did not return to the normal level after 48 h in the presence of RA, In addition, an electrophoretic mobility shift assay (EMSA) with ME1a1 DNA as probe demonstrated that the kinetics of the DNA-binding activity of MAZ were closely correlated with the changes in the expression of CAT from the c-myc promoter/CAT gene during the differentiation of P19EC cells, Taken together, these results suggest that MAZ plays a key role in the transient increase in the expression of the c-myc gene after 48 h of exposure to RA during the neuroectodermal differentiation of P19EC cells.	RIKEN, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI 305, JAPAN; CITY HOPE NATL MED CTR, BECKMAN RES INST, DEPT MOL GENET, DUARTE, CA 91010 USA; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN	RIKEN; City of Hope; Beckman Research Institute of City of Hope; University of Tsukuba			Komatsu, Masaaki/B-8321-2011	Komatsu, Masaaki/0000-0001-7672-7722				ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASSELIN C, 1989, ONCOGENE, V4, P549; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSSONE SA, 1992, P NATL SCI US, V89, P11498; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HALL DJ, 1990, ONCOGENE, V5, P47; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; Kawasaki H, 1996, NUCLEIC ACIDS RES, V24, P3010, DOI 10.1093/nar/24.15.3010; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MOBERG KH, 1992, ONCOGENE, V7, P411; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; Parks CL, 1996, J BIOL CHEM, V271, P4417; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PYRC J, 1994, INT J ONCOL, V5, P1085; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Sambrook D.J., 1989, MOL CLONING LAB MANU; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STARNAUD R, 1988, ONCOGENE, V3, P553; Tsutsui H, 1996, BIOCHEM BIOPH RES CO, V226, P801, DOI 10.1006/bbrc.1996.1432; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Ye JP, 1996, MOL CELL BIOL, V16, P157; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	41	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1123	1131		10.1038/sj.onc.1201283	http://dx.doi.org/10.1038/sj.onc.1201283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294605				2022-12-25	WOS:A1997XU99100001
J	Gurvitz, A; Rottensteiner, H; Kilpelainen, SH; Hartig, A; Hiltunen, JK; Binder, M; Dawes, IW; Hamilton, B				Gurvitz, A; Rottensteiner, H; Kilpelainen, SH; Hartig, A; Hiltunen, JK; Binder, M; Dawes, IW; Hamilton, B			The Saccharomyces cerevisiae peroxisomal 2,4-dienoyl-CoA reductase is encoded by the oleate-inducible gene SPS19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; BETA-OXIDATION; ESCHERICHIA-COLI; COENZYME-A; RAT-LIVER; TRANSCRIPTIONAL CONTROL; CANDIDA-TROPICALIS; GOLD PARTICLES; BOVINE LIVER; PURIFICATION	beta-Oxidation is compartmentalized in mammals into both mitochondria and peroxisomes. Fatty acids with double bonds at even-numbered positions require for their degradation the auxiliary enzyme 2,4-dienoyl-CoA reductase, and at least three isoforms, two mitochondrial and one peroxisomal, exist in the rat. The Saccharomyces cerevisiae Sps19p is 34% similar to the human and rat mitochondrial reductases, and an SPS19 deleted strain was unable to utilize petroselineate (cis-C-18:1(6)) as the sole carbon source, but remained viable on oleate (cis-C-18:1(9)). Sps19p was purified to homogeneity from oleate-induced cells and the homodimeric enzyme (native molecular weight 69,000) converted 2,4-hexadienoyl-CoA into 3-hexenoyl-CoA in an NADPH-dependent manner and therefore contained 2,4-dienoyl-CoA reductase activity, Antibodies raised against Sps19p decorated the peroxisomal matrix of oleate-induced cells. SPS19 shares with the sporulation-specific SPS18 a common promoter region that contains an oleate response element, This element unidirectionally regulates transcription of the reductase and is sufficient for oleate induction of a promoterless CYC1-lacZ reporter gene. SPS19 is dispensable for growth and sporulation on solid acetate and oleate media, but is essential for these processes to occur on petroselineate.	UNIV NEW S WALES,SCH BIOCHEM & MOL GENET,SYDNEY,NSW 2052,AUSTRALIA; UNIV VIENNA,INST BIOCHEM & MOL ZELLBIOL,A-1030 VIENNA,AUSTRIA; VIENNA BIOCTR,LUDWIG BOLTZMANN FORSCHUNGSSTELLE BIOCHEM,A-1030 VIENNA,AUSTRIA; UNIV OULU,DEPT BIOCHEM,BIOCTR OULU,FIN-90570 OULU,FINLAND; UNIV VIENNA,INST TUMORBIOL KREBSFORSCH,A-1090 VIENNA,AUSTRIA	University of New South Wales Sydney; University of Vienna; Ludwig Boltzmann Institute; Vienna Biocenter (VBC); Finland National Institute for Health & Welfare; University of Oulu; University of Vienna				Hartig, Andreas/0000-0003-3334-2763; Hiltunen, Kalervo/0000-0002-3073-9602				BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; COE JGS, 1994, MOL GEN GENET, V244, P661, DOI 10.1007/BF00282757; COE JGS, 1992, MOL MICROBIOL, V6, P75, DOI 10.1111/j.1365-2958.1992.tb00839.x; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; DOMMES P, 1983, J BIOL CHEM, V258, P846; DOMMES V, 1984, J BIOL CHEM, V259, P1781; DOMMES V, 1981, J BIOL CHEM, V256, P8259; DOMMES V, 1982, EUR J BIOCHEM, V125, P335, DOI 10.1111/j.1432-1033.1982.tb06688.x; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GOLDMAN P, 1961, J BIOL CHEM, V236, P2620; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; HAKKOLA EH, 1993, EUR J BIOCHEM, V215, P199, DOI 10.1111/j.1432-1033.1993.tb18023.x; HARTIG A, 1990, CURR GENET, V18, P23, DOI 10.1007/BF00321111; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HILTUNEN JK, 1993, BIOCHIMIE, V75, P175, DOI 10.1016/0300-9084(93)90075-4; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; HIROSE A, 1990, BIOCHIM BIOPHYS ACTA, V1049, P346, DOI 10.1016/0167-4781(90)90109-F; JONES EW, 1977, GENETICS, V85, P23; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KIMURA C, 1984, J BIOCHEM, V96, P1463, DOI 10.1093/oxfordjournals.jbchem.a134975; KOIVURANTA KT, 1994, BIOCHEM J, V304, P787, DOI 10.1042/bj3040787; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; Miller JH., 1972, EXPT MOL GENETICS; MIZUGAKI M, 1982, J BIOCHEM-TOKYO, V92, P1671, DOI 10.1093/oxfordjournals.jbchem.a134095; MIZUGAKI M, 1983, J BIOCHEM, V94, P409, DOI 10.1093/oxfordjournals.jbchem.a134370; MIZUGAKI M, 1985, J BIOCHEM-TOKYO, V97, P837, DOI 10.1093/oxfordjournals.jbchem.a135124; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; RICHTER K, 1980, J BIOL CHEM, V255, P8019; ROE CR, 1990, J CLIN INVEST, V85, P1703, DOI 10.1172/JCI114624; ROTH J, 1982, HISTOCHEM J, V14, P791, DOI 10.1007/BF01033628; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANG TW, 1994, J BIOL CHEM, V269, P24480; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; YOKOTA S, 1988, HISTOCHEM J, V20, P679, DOI 10.1007/BF01002748; YOU SY, 1989, J BIOL CHEM, V264, P16489; ZEELEN JP, 1992, J MOL BIOL, V244, P273	61	77	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22140	22147		10.1074/jbc.272.35.22140	http://dx.doi.org/10.1074/jbc.272.35.22140			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268358	hybrid			2022-12-25	WOS:A1997XT85000070
J	Holliday, LS; Welgus, HG; Fliszar, CJ; Veith, GM; Jeffrey, JJ; Gluck, SL				Holliday, LS; Welgus, HG; Fliszar, CJ; Veith, GM; Jeffrey, JJ; Gluck, SL			Initiation of osteoclast bone resorption by interstitial collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; MATRIX METALLOPROTEINASES; CATHEPSIN-K; CYSTEINE-PROTEINASES; GELATINOLYTIC ACTIVITY; RESORBING COMPARTMENT; OSTEOBLASTIC CELLS; MOLECULAR-CLONING; MARROW CULTURES; SMOOTH-MUSCLE	Osteoclasts form an acidic compartment at their attachment site in which bone demineralization and matrix degradation occur, Although both the cysteine proteinases and neutral collagenases participate in bone resorption, their roles have remained unclear, Here we show that interstitial collagenase has an essential role in initiating bone resorption, distinct from that of the cysteine proteinases. Treatment of osteoclasts with cysteine proteinase inhibitors did not affect the number of resorption lacunae (''pits'') formed on the surface of dentine slices, but it generated abnormal pits that were demineralized but filled with undegraded matrix. Treatment with metalloproteinase inhibitors did not alter the qualitative features of lacunae, but it greatly reduced the number of pits and surface area resorbed, Treatment of bone cells with an inhibitory anti-rat interstitial collagenase antiserum reduced bone resorption markedly, In the presence of collagenase inhibitors, resorption was restored by pretreatment of dentine slices with rat interstitial collagenase or by precoating the dentine slices with collagenase-derived gelatin peptides or heat-gelatinized collagen. Immunostaining revealed that interstitial collagenase is produced at high levels by stromal cells and osteoblasts adjacent to osteoclasts, These results indicate that interstitial collagenase can function as a ''coupling factor,'' allowing osteoblasts to initiate bone resorption by generating collagen fragments that activate osteoclasts.	WASHINGTON UNIV,SCH MED,DIV RENAL,GEORGE M OBRIEN CTR KIDNEY & UROL DIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOL,ST LOUIS,MO 63110; ALBANY MED COLL,DEPT BIOCHEM,ALBANY,NY 12208	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Albany Medical College			Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965	NIAMS NIH HHS [AR32087] Funding Source: Medline; NICHD NIH HHS [HD05291] Funding Source: Medline; NIDDK NIH HHS [DK38848] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD005291, R01HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BUTLER TA, 1991, BIOL REPROD, V44, P1183, DOI 10.1095/biolreprod44.6.1183; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; CHAMBERS TJ, 1985, J CELL SCI, V76, P155; CRUWYS SC, 1990, BRIT J PHARMACOL, V100, P631, DOI 10.1111/j.1476-5381.1990.tb15858.x; DELAISSE JM, 1985, BIOCHEM BIOPH RES CO, V133, P483, DOI 10.1016/0006-291X(85)90932-5; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; DELAISSE JM, 1993, J CELL SCI, V106, P1071; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FULLER K, 1995, J CELL SCI, V108, P2221; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GILLET C, 1977, FEBS LETT, V74, P126, DOI 10.1016/0014-5793(77)80768-0; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; Helfrich MH, 1996, BONE, V19, P317, DOI 10.1016/S8756-3282(96)00223-2; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIGHBERGER JH, 1978, BIOCHEM BIOPH RES CO, V83, P43, DOI 10.1016/0006-291X(78)90395-9; HILL PA, 1994, J CELL SCI, V107, P3055; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; KAHN AJ, 1987, AM J OTOLARYNG, V8, P258, DOI 10.1016/S0196-0709(87)80044-3; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAGE AE, 1993, INT J BIOCHEM, V25, P545, DOI 10.1016/0020-711X(93)90662-X; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Schnebli H P, 1985, Prog Clin Biol Res, V180, P287; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; VAANANEN HK, 1993, ANN MED, V25, P353, DOI 10.3109/07853899309147297; Vaes G, 1992, Matrix Suppl, V1, P383; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1985, J BIOL CHEM, V260, P3601; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	45	198	204	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22053	22058		10.1074/jbc.272.35.22053	http://dx.doi.org/10.1074/jbc.272.35.22053			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268345	hybrid			2022-12-25	WOS:A1997XT85000057
J	Jacobi, A; HuberWunderlich, M; Hennecke, J; Glockshuber, R				Jacobi, A; HuberWunderlich, M; Hennecke, J; Glockshuber, R			Elimination of all charged residues in the vicinity of the active-site helix of the disulfide oxidoreductase DsbA - Influence of electrostatic interactions on stability and redox properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; BOND FORMATION INVIVO; FORMATION IN-VIVO; CYSTEINE RESIDUES; EFFICIENT CATALYSIS; ASPARTIC-ACID; CRYSTAL-STRUCTURE; FOLDING PATHWAY; ISOMERASE DSBA; PROTEIN	Disulfide oxidoreductases are structurally related proteins that share the thioredoxin fold and a catalytic disulfide bond that is located at the N terminus of an alpha-helix, The different redox potentials of these enzymes varying from -270 mV for thioredoxin to -125 mV for DsbA have been attributed to the lowered pK(a) values of their nucleophilic, active-site cysteines and the difference in thermodynamic stability between their oxidized and reduced forms (Delta Delta G(ox/red)). The lowered pK(a) of the nucleophilic cysteine thiols was proposed to result from favorable interactions with the helix dipole and charged residues in their vicinity, In this study, we have eliminated all charged residues in the neighborhood of the active-site disulfide of DsbA from Escherichia coli to analyze their contribution to the physicochemical properties of the protein, We show that the conserved charge network among residues Glu(24), Glu(37), and Lys(58) stabilizes the oxidized form of DsbA and thus does not cause the high redox potential of the enzyme, The pK(a) values of the nucleophilic cysteine (Cys(30)) and the redox potentials of the DsbA variants E24Q, E37Q, K58M, E24Q/K58M, E37Q/K58M, E24Q/E37Q, E24Q/E37Q/K58M, and E24Q/E37Q/E38Q/K58M are similar to those of DsbA wild type, The redox potentials of the variants neither correlate with the Cys(30) pK(a) values nor with the Delta Delta G(ox/red) values, demonstrating that the relationship between these parameters is far more complex than previously thought.			Jacobi, A (corresponding author), ETH HONGGERBERG,INST MOL BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND.							BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; Creighton T. E., 1993, PROTEINS STRUCTURES, P6; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; CREIGHTON TE, 1988, SCIENCE, V240, P344; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORMANKAY JD, 1992, BIOCHEMISTRY-US, V31, P3442, DOI 10.1021/bi00128a019; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; Hennecke J, 1997, J BIOL CHEM, V272, P189; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOROVITZ A, 1996, FOLDING DESIGN, V1, P121, DOI DOI 10.1016/S1359-0278(96)00056-9; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jeng MF, 1996, BIOCHEMISTRY-US, V35, P1, DOI 10.1021/bi952404n; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; JENG MF, 1995, BIOCHEMISTRY-US, V34, P611, DOI 10.1021/bi00002a028; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELLEY RF, 1987, BIOCHEMISTRY-US, V26, P1406, DOI 10.1021/bi00379a029; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LADBURY JE, 1993, BIOCHEMISTRY-US, V32, P7526, DOI 10.1021/bi00080a026; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7603, DOI 10.1021/bi00244a032; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7609, DOI 10.1021/bi00244a033; LI HM, 1993, BIOCHEMISTRY-US, V32, P5800, DOI 10.1021/bi00073a012; MARKWARDT F, 1967, H-S Z PHYSIOL CHEM, V348, P1381, DOI 10.1515/bchm2.1967.348.1.1381; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nozaki Y, 1972, Methods Enzymol, V26, P43; Oliveberg M, 1996, BIOCHEMISTRY-US, V35, P6795, DOI 10.1021/bi9529317; Pace C N, 1986, Methods Enzymol, V131, P266; POLGAR L, 1974, FEBS LETT, V38, P187, DOI 10.1016/0014-5793(74)80110-9; Qin J, 1996, BIOCHEMISTRY-US, V35, P7, DOI 10.1021/bi952299h; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; ROST N, 1964, NATURE, V201, P185; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Takahashi N, 1996, BIOCHEMISTRY-US, V35, P8342, DOI 10.1021/bi960465v; TANFORD C, 1956, J AM CHEM SOC, V78, P5287, DOI 10.1021/ja01601a036; Tissot AC, 1996, BIOCHEMISTRY-US, V35, P6786, DOI 10.1021/bi952930e; Warwicker J, 1996, FEBS LETT, V385, P105, DOI 10.1016/0014-5793(96)00358-4; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; Williams S, 1996, BIOCHEMISTRY-US, V35, P691, DOI 10.1021/bi952217p; WILSON NA, 1995, BIOCHEMISTRY-US, V34, P8931, DOI 10.1021/bi00028a001; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038	66	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21692	21699		10.1074/jbc.272.35.21692	http://dx.doi.org/10.1074/jbc.272.35.21692			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268296	hybrid			2022-12-25	WOS:A1997XT85000008
J	Lorenzi, MV; Castagnino, P; Chen, Q; Chedid, M; Miki, T				Lorenzi, MV; Castagnino, P; Chen, Q; Chedid, M; Miki, T			Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations	ONCOGENE			English	Article						FGFs; cell transformation; phosphotyrosine; receptor tyrosine kinases; MAP kinases	FMS PROTO-ONCOGENE; TRANSFORMED PHENOTYPE; KINASE-ACTIVITY; POINT MUTATION; K-SAM; EXPRESSION; FGF; DOMAIN; CELLS; CLONING	To assess the effect(s) of the C-terminal domain on FGFR2 function, we engineered a series of mutant FGFR2 cDNAs encoding deletions in the C-terminus of the receptor and compared their growth properties in NIH3T3 fibroblasts, In contrast to FGFR2-WT, receptors with C-terminal truncations induced ligand-independent transformation of NIH3T3 cells and transfectants expressing these mutant receptors efficiently formed colonies in semisolid medium. Introduction of point mutations (Y to F) into the C-terminus of FGFR2 at positions 813, 784 or 780 revealed that these mutant receptors also displayed activities similar to that of C-terminally truncated receptors. C-terminally altered FGF receptors did not show an increase in the basal level of receptor phosphorylation compared to that of FGFR2-WT suggesting that elevated receptor phosphorylation does not underlie the transforming activity of these receptors. Interestingly, expression of transforming FGFR2 derivatives, unlike H-Ras transformed cells, did not result in the activation of the mitogen-activated protein kinases (MAPKs), p42/ERK2 and p44/ERK1, indicating that this pathway is not constitutively active in FGFR2-transformed cells, Finally, we report the overexpression of FGFR2 mRNA and protein in several human tumor cell lines suggesting activation of the receptor in these tumors.			Lorenzi, MV (corresponding author), NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892, USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1993, PROTEIN SCI, V2, P86; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; ITOH H, 1994, CANCER RES, V54, P3237; KALIMAN P, 1993, BIOCHEMISTRY-US, V32, P9539, DOI 10.1021/bi00088a004; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; LORENZI MV, 1995, ONCOGENE, V10, P2051; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOR O, 1993, CANCER GENET CYTOGEN, V65, P111, DOI 10.1016/0165-4608(93)90217-A; PANG L, 1994, J BIOL CHEM, V269, P10604; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RON D, 1993, J BIOL CHEM, V268, P5388; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHAOUL E, 1995, ONCOGENE, V10, P1554; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILKIE AOM, 1995, CURR BIOL, V5, P500; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, BIOCHEM BIOPH RES CO, V194, P512, DOI 10.1006/bbrc.1993.1849; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	45	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					817	826		10.1038/sj.onc.1201242	http://dx.doi.org/10.1038/sj.onc.1201242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266968				2022-12-25	WOS:A1997XQ11700008
J	Horsten, U; MullerNewen, G; Gerhartz, C; Wollmer, A; Wijdenes, J; Heinrich, PC; Grotzinger, J				Horsten, U; MullerNewen, G; Gerhartz, C; Wollmer, A; Wijdenes, J; Heinrich, PC; Grotzinger, J			Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6)center dot IL-6 receptor center dot gp130 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; ACUTE-PHASE RESPONSE; TRANSCRIPTION FACTOR APRF; HUMAN IL-6 RECEPTOR; ESCHERICHIA-COLI; GROWTH-HORMONE; EXPRESSION; ACTIVATION; BINDING; PURIFICATION	The transmembrane protein gp130 is involved in many cytokine-mediated cellular responses and acts therein as the signal-transducing subunit, In the case of interleukin-6 (IL-6), the signal-transducing complex is composed of the ligand IL-6, the IL-6 receptor (IL-6R, gp80, CD126), and at least two gp130 (CD130) molecules, The extracellular part of the signal transducer gp130 consists of sis fibronectin type III-like domains, It has recently been shown that the three membrane distal domains bind to the IL-6.IL-6R complex. A structural model of the IL-6.IL-6R gp130 complex enabled us to propose amino acid residues in these domains of gp130 interacting with IL-6 bound to its receptor. The proposed amino acid residues located in the B'C' loop (Val(252)) and in the F'G' loop (Gly(306), Lys(307)) of domain 3 and in the hinge region (Tyr(21S)) connecting domains 2 and 3 of gp130 were mutated to disturb ternary complex formation, Binding of wild type and mutants of the extracellular region of gp130 was studied by use of a co-precipitation assay and Scatchard analysis, All mutants showed decreased binding to the IL-6.IL-6R complex, Biological function of the membrane bound gp130 mutants was studied by STAT (signal transducer and activator of transcription) activation in COS-7 cells and by proliferation of stably transfected Ba/F3 cells. Reduced binding of the mutants was accompanied by decreased biological activity, The combined approach of molecular modeling and site-directed mutagenesis has led to the identification of amino acid residues in gp130 required for complex formation with IL-6 and its receptor.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; DIACLONE,F-25020 BESANCON,FRANCE	RWTH Aachen University								ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P946; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EHLERS M, 1994, J IMMUNOL, V153, P1744; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GRAEVE L, 1989, J CELL BIOL, V265, P1216; Grotzinger J, 1997, PROTEINS, V27, P96; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Kalai M, 1996, EUR J BIOCHEM, V238, P714, DOI 10.1111/j.1432-1033.1996.0714w.x; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Sambrook J., 2002, MOL CLONING LAB MANU; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; WELLS JA, 1995, BIO-TECHNOL, V13, P647, DOI 10.1038/nbt0795-647; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	37	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23748	23757		10.1074/jbc.272.38.23748	http://dx.doi.org/10.1074/jbc.272.38.23748			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295319	hybrid			2022-12-25	WOS:A1997XX38100044
J	Maeda, M; Firtel, RA				Maeda, M; Firtel, RA			Activation of the mitogen-activated protein kinase ERK2 by the chemoattractant folic acid in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE CHEMOTACTIC RECEPTORS; MAP KINASE; MULTICELLULAR DEVELOPMENT; CAENORHABDITIS-ELEGANS; CELL-DIFFERENTIATION; SIGNALING PATHWAYS; ADENYLYL-CYCLASE; VULVAR INDUCTION; BETA-SUBUNIT; DISCOIDEUM	The Dictyostelium MAP kinase ERK2 is activated by extracellular cAMP in aggregation-competent cells and is required far receptor activation of adenylyl cyclase (Maeda, M., Aubry, L., Insall, R., Gaskins, C., Devreotes, P. N., and Firtel, R.A. (1996) J. Biol. Chem, 271, 3351-3354; Segall, J., Kuspa, A., Shaulsky, G., Ecke, M., Maeda, M., Gaskins, C., Firtel, R., and Loomis, W. (1995) J. Cell Biol. 128, 405-413). This cAMP-dependent activation of ERK2 is mediated by the serpentine, G protein-coupled cAMP receptors. However, ERK2 activation by cAMP is at least partially heterotrimeric G protein-independent, with a level of activation in cells lacking the sole G beta subunit or the G protein-coupled cAMP receptors-coupled G alpha 2, subunit that is similar to 50% that of wild-type cells (Maeda, M., Aubry, L., Insall, R., Gaskins, C., Devreotes, P. N., and Firtel, R. A. (1996) J. Biol. Chem, 271, 3351-3354; Segall, J., Kuspa, A., Shaulsky, G., Ecke, M., Maeda, M., Gaskins, C., Firtel, R., and Loomis, W. (1995) J. Cell Biol. 128, 405-413). Folic acid, a chemoattractant in the vegetative cells that enables amoebae to find bacteria in the wild, also triggers the activation of adenylyl cyclase, which is impaired in the vegetative cells lacking the G alpha protein subunit G alpha 4 (Hadwiger, J., Lee, S,, and Firtel, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10566-10570). In this study, we show that folic acid activates ERK2 in developmentally regulated manner and is required far ERK2 stimulation of adenylyl cyclase activity. Maximum levels of folate-stimulated ERK2 activity occur in cells from very early in development, prior to aggregation, and again at the tipped aggregate stages, corresponding to the stages in which folate receptors and the coupled G alpha subunit G alpha 4 are maximally expressed. During the activation by folic acid, ERK2 is phosphorylated on tyrosine residue(s) and contemporaneously shows a mobility shift on SDS-PAGE. Interestingly, this activation is not elicited in the absence of GP subunits, in contrast to the response to cAMP. This response also requires the G alpha 4 subunit known to be required for other folic acid-mediated responses (Hadwiger, J., Lee, S., and Firtel, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10566-10570). Furthermore, we show that the activation of ERK2 by cAMP is independent of the G alpha 4 subunit, while the activation of ERK2 by folate is independent of G alpha 2. Taken together, these data indicate that there are at least two pathways of ERK2 activation, heteroaromatic G protein-dependent and -independent pathways.	UNIV CALIF SAN DIEGO,CTR MOL GENET,DEPT BIOL,SAN DIEGO,CA 92093; OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	University of California System; University of California San Diego; Osaka University								Aubry L, 1997, J BIOL CHEM, V272, P3883, DOI 10.1074/jbc.272.7.3883; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; DEWIT RJW, 1986, BIOCHIM BIOPHYS ACTA, V886, P88, DOI 10.1016/0167-4889(86)90214-4; DEWIT RJW, 1985, FEBS LETT, V179, P257, DOI 10.1016/0014-5793(85)80530-5; DEWIT RJW, 1986, DIFFERENTIATION, V32, P192, DOI 10.1111/j.1432-0436.1986.tb00573.x; DEWIT RJW, 1983, CELL DIFFER DEV, V12, P205, DOI 10.1016/0045-6039(83)90029-5; DEWIT RJW, 1985, BIOCHIM BIOPHYS ACTA, V814, P214, DOI 10.1016/0005-2736(85)90439-0; DEWIT RJW, 1986, BIOCHIM BIOPHYS ACTA, V886, P76, DOI 10.1016/0167-4889(86)90213-2; DHARMAWARDHANE S, 1994, DEVELOPMENT, V120, P3549; Gaskins C, 1996, GENE DEV, V10, P118, DOI 10.1101/gad.10.1.118; GASKINS C, 1994, MOL CELL BIOL, V14, P996; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; Hadwiger JA, 1996, DEVELOPMENT, V122, P1215; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; HOPPER NA, 1993, DEVELOPMENT, V119, P147; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; Knetsch MLW, 1996, EMBO J, V15, P3361, DOI 10.1002/j.1460-2075.1996.tb00701.x; KORNFELD K, 1995, GENE DEV, V9, P756, DOI 10.1101/gad.9.6.756; KUBOHARA Y, 1993, EXP CELL RES, V207, P107, DOI 10.1006/excr.1993.1168; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MA H, 1997, IN PRESS EMBO J, V16; Maeda M, 1996, J BIOL CHEM, V271, P3351; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MANN SKO, 1991, MECH DEVELOP, V35, P89, DOI 10.1016/0925-4773(91)90060-J; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; PAN P, 1972, NATURE-NEW BIOL, V237, P181, DOI 10.1038/newbio237181a0; SEGALL JE, 1988, J CELL SCI, V91, P479; SEGALL JE, 1995, J CELL BIOL, V128, P405, DOI 10.1083/jcb.128.3.405; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; TILLINGHAST HS, 1987, J CELL SCI, V87, P45; WU L, 1994, HDB EXPT PHARM, V108, P335; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742; WURSTER B, 1979, CELL DIFFER DEV, V8, P235, DOI 10.1016/0045-6039(79)90050-2	51	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23690	23695		10.1074/jbc.272.38.23690	http://dx.doi.org/10.1074/jbc.272.38.23690			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295311	hybrid			2022-12-25	WOS:A1997XX38100036
J	Qi, XM; He, HL; Zhong, HY; Distelhorst, CW				Qi, XM; He, HL; Zhong, HY; Distelhorst, CW			Baculovirus p35 and Z-VAD-fmk inhibit thapsigargin-induced apoptosis of breast cancer cells	ONCOGENE			English	Article						thapsigargin; apoptosis; Bcl-1; ICE-like protease	ICE FAMILY PROTEASES; ENDOPLASMIC-RETICULUM; CAENORHABDITIS-ELEGANS; LYMPHOMA-CELLS; DEATH; PROTEIN; CALCIUM; EXPRESSION; BCL-2; ACTIVATION	Programmed cell death, or apoptosis, is inhibited by the antiapoptotic oncogene, Bcl-2, and is mediated by a cascade of aspartate-specific cysteine proteases, or caspases, related to interleukin 1-beta converting enzyme, Depending on cell type, apoptosis can be induced by treatment with thapsigargin (TG); a selective inhibitor of the endoplasmic reticulum-associated calcium-ATPase. The role of caspases in mediating TG-induced apoptosis was investigated in the Bcl-2-negative human breast cancer cell line, MDA-MB-468. Apoptosis developed in MDA-MB-468 cells over a period of 24-72 h following treatment with 100 nM TG, and was prevented by Bcl-2 overexpression, TG-induced apoptosis was associated with activation of caspase-3 and was inhibited by stable expression of the baculovirus p35 protein, an inhibitor of caspase activity, Also, TG-induced apoptosis was inhibited by treating cells with Z-VAD-fmk, a cell-permeable fluoromethylketone inhibitor of caspases, These findings indicate that TG-induced apoptosis of MDA-MB-468 breast cancer cells is subject to inhibition by Bcl-2 and is mediated by caspase activity, This model system should be useful for further investigation directed toward understanding the role of calcium in signaling apoptosis, and its relationship to Bcl-2 and the caspase proteolytic cascade.	CASE WESTERN RESERVE UNIV,IRELAND CANC CTR,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL CANCER INSTITUTE [R21CA066221, T32CA059366] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA59366, R21 CA/AG66221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG DK, 1994, CANCER RES, V54, P5280; ARMSTRONG DK, 1992, CANCER RES, V52, P3418; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FURUYA Y, 1994, CANCER RES, V54, P6167; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HAY BA, 1994, DEVELOPMENT, V120, P2121; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LI WWF, 1993, J BIOL CHEM, V268, P12003; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McCloskey DE, 1996, RECENT PROG HORM RES, V51, P493; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; Shimizu S, 1996, ONCOGENE, V12, P2251; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	40	42	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1207	1212		10.1038/sj.onc.1201290	http://dx.doi.org/10.1038/sj.onc.1201290			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294614				2022-12-25	WOS:A1997XU99100010
J	Ervasti, JM; Burwell, AL; Geissler, AL				Ervasti, JM; Burwell, AL; Geissler, AL			Tissue-specific heterogeneity in alpha-dystroglycan sialoglycosylation - Skeletal muscle alpha-dystroglycan is a latent receptor for Vicia villosa agglutinin B-4 masked by sialic acid modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; SYNAPSE-SPECIFIC CARBOHYDRATE; SULFATIDE-BINDING DOMAIN; AGRIN RECEPTOR; ACETYLCHOLINE-RECEPTOR; MDX MOUSE; NEUROMUSCULAR-JUNCTION; MUSCULAR-DYSTROPHIES; EXTRACELLULAR-MATRIX; PERIPHERAL-NERVE	Because the polypeptide core of alpha-dystroglycan is encoded by a single gene, the difference in apparent molecular mass between alpha-dystroglycans expressed in various tissues is presumably due to differential glycosylation, However, little is presently known about the tissue-specific differences in alpha-dystroglycan glycosylation and whether these modifications may confer functional variability to alpha-dystroglycan. We recently observed that laminin-1 binding to skeletal muscle alpha-dystroglycan was dramatically inhibited by heparin, whereas the binding of commercial merosin to skeletal muscle alpha-dystroglycan was only marginally inhibited (Pall, E. A., Bolton, K. M., and Ervasti, J. M. (1996) J. Biol. Chem. 3817-3821). In contrast to 156-kDa skeletal muscle alpha-dystroglycan, both laminin-1 and merosin binding to 120-kDa brain alpha-dystroglycan were sensitive to heparin, We have now examined the laminin binding properties of 140-kDa alpha-dystroglycan purified from cardiac muscle and observed that like skeletal muscle alpha-dystroglycan, heparin inhibited cardiac alpha-dystroglycan binding to laminin-1, but not to merosin. On the other hand, cardiac and brain alpha-dystroglycans could be distinguished from skeletal muscle alpha-dystroglycan by their reactivity with the terminal GalNAc-specific lectin Vicia villosa agglutinin, Interestingly, skeletal muscle alpha-dystroglycan became reactive with V. villosa agglutinin upon digestion with sialidase from Clostridium perfringens, Arthrobacter neurofaciens, or Streptococcus, but not Vibrio cholerae or Newcastle disease virus sialidase, While none of the sialidase treatments affected the laminin binding properties of alpha-dystroglycan, the sum of our results suggests that skeletal muscle alpha-dystroglycan contains a novel sialic acid residue linked alpha 2-6 to GalNAc, These properties are also consistent with the cellular characteristics of a GalNAc-terminated glycoconjugate recently implicated in neuromuscular synaptogenesis, Thus, variations in alpha-dystroglycan sialoglycosylation may prove as useful markers to further elucidate the role of alpha-dystroglycan glycoforms in different tissues and perhaps within a single cell type.			Ervasti, JM (corresponding author), UNIV WISCONSIN,DEPT PHYSIOL,SERV MEM INST 120,SCH MED,1300 UNIV AVE,MADISON,WI 53706, USA.		Ervasti, James/AAZ-4786-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985, R01AR042423] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42423, AR01985] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chiba A, 1997, J BIOL CHEM, V272, P2156; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HIRSH EF, 1970, INNVERVATION VERTEBR; Hopf C, 1996, J BIOL CHEM, V271, P5231; Horackova M, 1996, TISSUE CELL, V28, P411, DOI 10.1016/S0040-8166(96)80027-9; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KATZ AM, 1977, PHYSL HEART, P1; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; MA JY, 1993, J BIOL CHEM, V268, P25108; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Meier T, 1996, EMBO J, V15, P2625, DOI 10.1002/j.1460-2075.1996.tb00622.x; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Pall EA, 1996, J BIOL CHEM, V271, P3817; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; Rosenberg A, 1976, BIOL ROLES SIALIC AC, P295; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; SANES JR, 1982, NATURE, V300, P646, DOI 10.1038/300646a0; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SHIBUYA N, 1987, ARCH BIOCHEM BIOPHYS, V254, P1, DOI 10.1016/0003-9861(87)90074-9; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; SMALHEISER NR, 1993, J NEUROSCI RES, V36, P528, DOI 10.1002/jnr.490360505; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUNADA Y, 1995, NEUROLOGY, V45, P2084, DOI 10.1212/WNL.45.11.2084; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; Yotsumoto S, 1996, HUM MOL GENET, V5, P1259, DOI 10.1093/hmg/5.9.1259	61	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22315	22321		10.1074/jbc.272.35.22315	http://dx.doi.org/10.1074/jbc.272.35.22315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268382	hybrid			2022-12-25	WOS:A1997XT85000094
J	Liu, H; Bowes, RC; vandeWater, B; Sillence, C; Nagelkerke, JF; Stevens, JL				Liu, H; Bowes, RC; vandeWater, B; Sillence, C; Nagelkerke, JF; Stevens, JL			Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULAR CELLS; HEAT-SHOCK PROTEINS; INTRACELLULAR CALCIUM; LLC-PK1 CELLS; LIPID-PEROXIDATION; COVALENT BINDING; REDUCING AGENTS; GROWTH ARREST; DNA-DAMAGE; C-FOS	Activation of stress response genes can impart cellular tolerance to environmental stress, Iodoacetamide (IDAM) is an alkylating toxicant that up-regulates expression of hsp70 (Liu, H,, Lightfoot, D, L., and Stevens, J. L. (1996) J. Blot. Chem. 271, 4805-4812) and grp78 in LLC-PK1 renal epithelial cells, Therefore, we used IDAM to determine the role of these genes in tolerance to toxic chemicals, Prior heat shock did not protect cells from IDAM but pretreatment with trans-4,5-dihydroxy-1,2-dithiane (DTTox), thapsigargin, or tunicamycin enhanced expression of the endoplasmic reticulum (ER) chaperones GRP78 and GRP94 and rendered cells tolerant to IDAM. Cells expressing a 524-base pair antisense grp78 fragment (pkASgrp78) had a diminished capacity to upregulate grp78 and grp94 expression after ER stress, Protection against IDAM due to prior ER stress was also attenuated in pkASgrp78 cells suggesting that ER chaperones of the GRP family are critical for tolerance, Covalent binding of IDAM to cellular macromolecules and depletion of cellular thiols was similar in tolerant and naive cells, However, DTTox pretreatment blocked the increases in cellular Ca2+ and lipid peroxidation observed after IDAM treatment, Overexpressing the ER Ca2+-binding protein calreticulin prevented IDAM-induced cell death, the rise in cytosolic Ca2+, and oxidative stress, Although activation of the ER stress response did not prevent toxicity due to Ca2+ influx, EGTA-ARI and ruthenium red both blocked cell death suggesting that redistribution of intracellular Ca2+ to the mitochondria may be important in toxicity, The data support a model in which induction of ER stress proteins prevents disturbances of intracellular Ca2+ homeostasis, thus uncoupling toxicant exposure from oxidative stress and cell death, Multiple ER stress proteins are likely to be involved in this tolerance response.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946; CLARKSON UNIV,DEPT CHEM,POTSDAM,NY 13676; LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV TOXICOL,LEIDEN,NETHERLANDS	Clarkson University; Leiden University; Leiden University - Excl LUMC					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267, F32DK009253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46267, DK09253] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Black A R, 1991, Methods Achiev Exp Pathol, V15, P126; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CHATTERJEE S, 1994, CANCER RES, V54, P4405; CHEN Q, 1992, J BIOL CHEM, V267, P24322; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHEN Q, 1991, ARCH BIOCHEM BIOPHYS, V284, P422, DOI 10.1016/0003-9861(91)90318-D; CHEN Q, 1994, J CELL PHYSIOL, V161, P293, DOI 10.1002/jcp.1041610214; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; Distelhorst CW, 1996, ONCOGENE, V12, P2051; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GOLDSTEIN RS, 1996, TOXICOLOGY, P417; GOMER CJ, 1991, CANCER RES, V51, P6574; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Halleck MM, 1997, J BIOL CHEM, V272, P21760, DOI 10.1074/jbc.272.35.21760; HARMAN AW, 1995, ANNU REV PHARMACOL, V35, P129, DOI 10.1146/annurev.pa.35.040195.001021; HENSCHKE PN, 1995, BIOCHEM J, V312, P485, DOI 10.1042/bj3120485; Hoyal CR, 1996, J BIOL CHEM, V271, P29205, DOI 10.1074/jbc.271.46.29205; HUGHES CS, 1989, CANCER RES, V49, P4452; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jeong JMK, 1996, MOL PHARMACOL, V50, P592; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1996, J BIOL CHEM, V271, P4805; LIU NG, 1994, J BIOL CHEM, V269, P28635; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MACER DRJ, 1988, J CELL SCI, V91, P61; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MAYEUX PR, 1993, J PHARMACOL EXP THER, V266, P47; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Mitchell J. R., 1984, DRUG METABOLISM DRUG, P301; MOORE L, 1976, J BIOL CHEM, V251, P1197; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROY B, 1995, MOL CELL BIOL, V15, P2263; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHACHAR I, 1994, J BIOL CHEM, V269, P27344; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; STEVENS J, 1986, J BIOL CHEM, V261, P3325; SUGAWARA S, 1993, CANCER RES, V53, P6001; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; UEDA N, 1992, AM J PHYSIOL, V263, pF214, DOI 10.1152/ajprenal.1992.263.2.F214; VAMVAKAS S, 1993, TOXICOL LETT, V67, P161, DOI 10.1016/0378-4274(93)90053-Z; VAMVAKAS S, 1990, MOL PHARMACOL, V38, P455; vandeWater B, 1996, ARCH BIOCHEM BIOPHYS, V327, P71, DOI 10.1006/abbi.1996.0094; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VANDEWATER B, 1993, BIOCHEM PHARMACOL, V45, P2259, DOI 10.1016/0006-2952(93)90197-5; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YU KF, 1994, J CELL PHYSIOL, V161, P303, DOI 10.1002/jcp.1041610215	79	328	349	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21751	21759		10.1074/jbc.272.35.21751	http://dx.doi.org/10.1074/jbc.272.35.21751			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268304	hybrid			2022-12-25	WOS:A1997XT85000016
J	Myllyharju, J; Lamberg, A; Notbohm, H; Fietzek, PP; Pihlajaniemi, T; Kivirikko, KI				Myllyharju, J; Lamberg, A; Notbohm, H; Fietzek, PP; Pihlajaniemi, T; Kivirikko, KI			Expression of wild-type and modified pro alpha chains of human type I procollagen in insect cells leads to the formation of stable [alpha 1(I)](2)alpha 2(I) collagen heterotrimers and [alpha 1(I)](3) homotrimers but not [alpha 2(I)](3) homotrimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE ISOMERASE; MOLECULAR-CLONING; 4-HYDROXYLASE; SUBUNIT; SECRETION; SYSTEM; HSP47; GENE; GLYCOSYLATION; DOMAIN	Insect cells coinfected with a baculovirus coding for the pro alpha 1(I) chain of human type I procollagen and a double promoter virus coding for the alpha and beta subunits of human prolyl 4-hydroxylase produced homotrimeric [pro alpha 1(I)](3) procollagen molecules, The use of an additional virus coding for the pro alpha 2(I) chain led to the formation of a heterotrimeric molecule with the correct 2:1 ratio of pro alpha 1 to pro alpha 2 chains of type I procollagen (pro alpha 1(I) and pro alpha 2(I) chains, respectively), unless the pro alpha 1(I) chain was expressed in a relatively large excess, Replacement of the sequences coding for the signal peptide and the N propeptide of the pro alpha 1(I) chain with those of the pro alpha 1(III) chain increased level of expression of the pro alpha 1(I) chain, whereas no similar effect was found when the corresponding modification was made to the virus coding for the pro alpha 2(I) chain, Molecules containing such modified N propeptides were found to be processed at their N terminus more rapidly than those containing the wild-type propeptides, The T-m of the type I collagen homotrimer was similar to that of the heterotrimer, both values being about 42-43 degrees C when determined by circular dichroism. The wild-type pro alpha 2(I) chain formed no homotrimers. Replacement of the C propeptide of the pro alpha 2(I) chain with that of the pro alpha 1(I) chain or pro alpha 1 chain of type III procollagen (pro alpha 1(III) chain) led to the formation of homotrimers, but the alpha 2(I) chains in such molecules were completely digested by pepsin in 1 h at 22 degrees C, The data thus suggest that, in addition to control at the level of the C propeptide, other restrictions may exist at the level of the collagen domain that prevent the formation of stable homotrimeric [pro alpha 2(I)](3) molecules in insect cells.	UNIV OULU, DEPT MED BIOCHEM, FIN-90220 OULU, FINLAND; UNIV OULU, COLLAGEN RES UNIT, BIOCTR, FIN-90220 OULU, FINLAND; UNIV LUBECK, INST MED MOL BIOL, D-23538 LUBECK, GERMANY	University of Oulu; University of Oulu; University of Lubeck				Pihlajaniemi, Taina/0000-0002-1664-9045				BREWTON RG, 1994, EXTRACELLULAR MATRIX, P129; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; COOPERMAN L, 1984, J AM ACAD DERMATOL, V10, P638, DOI 10.1016/S0190-9622(84)80271-6; FUJIOKA K, 1995, J CONTROL RELEASE, V33, P307, DOI 10.1016/0168-3659(94)00107-6; GEDDIS AE, 1993, MATRIX, V13, P399, DOI 10.1016/S0934-8832(11)80045-4; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HU G, 1995, J CELL BIOCHEM, V59, P350, DOI 10.1002/jcb.240590307; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; Kadler KE, 1996, BIOCHEM J, V316, P1; Kielty Cay M., 1993, P103; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MILLER EJ, 1982, METHOD ENZYMOL, V82, P3; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Pachence JM, 1996, J BIOMED MATER RES, V33, P35, DOI 10.1002/(SICI)1097-4636(199621)33:1<35::AID-JBM6>3.0.CO;2-N; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ramshaw JAM, 1996, BIOTECHNOL GENET ENG, V13, P335, DOI 10.1080/02648725.1996.10647934; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; TKOCZ C, 1969, EUR J BIOCHEM, V7, P454; TRAUB W, 1976, FEBS LETT, V68, P245, DOI 10.1016/0014-5793(76)80446-2; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VERNET T, 1990, J BIOL CHEM, V265, P16661; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x	34	68	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21824	21830		10.1074/jbc.272.35.21824	http://dx.doi.org/10.1074/jbc.272.35.21824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268313	hybrid			2022-12-25	WOS:A1997XT85000025
J	Ocaktan, A; Yoneyama, H; Nakae, T				Ocaktan, A; Yoneyama, H; Nakae, T			Use of fluorescence probes to monitor function of the subunit proteins of the MexA-MexB-OprM drug extrusion machinery in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; OUTER-MEMBRANE; ANTIBIOTIC-RESISTANCE; MULTIDRUG-RESISTANCE; EFFLUX SYSTEMS; P-GLYCOPROTEIN; 2-(4-DIMETHYLAMINOSTYRYL)-1-ETHYLPYRIDINIUM; INVOLVEMENT; NORFLOXACIN	The MexA-MexB-OprM efflux pump of Pseudomonas aeruginosa consists of two inner membrane proteins, MexA and MexB, and one outer membrane protein, OprM, We investigated the role of the components of this drug extrusion system by evaluating the repercussions of deleting these subunit components on the accumulation of several fluorescent probes, Fluorescence intensities of positively charged 2-(4-dimethylaminostyryl)-1-ethylpyridinium and uncharged N-phenyl-1-naphtylamine were 7 and 4 times higher, respectively, in the mutant lacking OprM and 4 and 1.7 times higher, respectively, in the mutants lacking MexA or MexB than in the wild type strain, This order of fluorescence intensity was fully consistent with a previously reported minimum inhibitory concentration of antibiotics such as tetracycline, chloramphenicol, and fluoroquinolones, Ethidium bromide accumulation in all the Mex mutants proceeded at about 5 times faster than the rate in the wild type cells, This result is in accord with the minimum inhibitory concentration of beta-lactam antibiotics. These results suggest that the fluorescence probes could be successfully used in real time monitoring of the function of the drug extrusion machinery in Gram-negative bacteria, The downhill extrusion kinetics of 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene, which orients perpendicular to the inner leaflet of the cytoplasmic membrane, from preloaded cells lacking the extrusion pump was preceded by a slow increase in fluorescence intensity, whereas the wild type cell immediately released the dye, This observation was explained by a slow trans-cytoplasmic membrane crossing of intracellular dye in the mutants, These results reflected higher accumulation of the probe in the cytoplasmic membrane in the mutants and strengthened the hypothesis that extrusion of hydrophobic substrate mediated by MexA-MexB-OprM mainly takes place from the interior of the cytoplasmic membrane.	TOKAI UNIV,SCH MED,DEPT MOL LIFE SCI,ISEHARA,KANAGAWA 25911,JAPAN	Tokai University								Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; COHEN SP, 1988, ANTIMICROB AGENTS CH, V32, P1187, DOI 10.1128/AAC.32.8.1187; CRAMER WA, 1976, BIOCHIM BIOPHYS ACTA, V449, P401, DOI 10.1016/0005-2728(76)90151-1; Fralick JA, 1996, J BACTERIOL, V178, P5803, DOI 10.1128/jb.178.19.5803-5805.1996; FUKUDA H, 1990, ANTIMICROB AGENTS CH, V34, P15757; George AM, 1996, FEMS MICROBIOL LETT, V139, P1, DOI 10.1016/0378-1097(96)00127-9; HIRAI K, 1987, ANTIMICROB AGENTS CH, V31, P582, DOI 10.1128/AAC.31.4.582; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; LEI Y, 1991, BIOCHEM BIOPH RES CO, V178, P1043, DOI 10.1016/0006-291X(91)90997-L; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MIDGLEY M, 1986, J GEN MICROBIOL, V132, P3187; MORSHED SRM, 1991, BIOCHEM BIOPH RES CO, V210, P356; MORTIMER PGS, 1991, J ANTIMICROB CHEMOTH, V28, P639, DOI 10.1093/jac/28.5.639; MULDER HS, 1993, EUR J BIOCHEM, V218, P871, DOI 10.1111/j.1432-1033.1993.tb18443.x; NAKAE T, 1995, MICROBIOL IMMUNOL, V39, P221, DOI 10.1111/j.1348-0421.1995.tb02193.x; NAKAMURA H, 1968, J BACTERIOL, V96, P987, DOI 10.1128/JB.96.4.987-996.1968; NIEVAGOMEZ D, 1977, P NATL ACAD SCI USA, V74, P1811, DOI 10.1073/pnas.74.5.1811; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; Poole K, 1996, MOL MICROBIOL, V21, P713, DOI 10.1046/j.1365-2958.1996.281397.x; Ringe D, 1995, CURR OPIN STRUC BIOL, V5, P825, DOI 10.1016/0959-440X(95)80017-4; SEDGWICK EG, 1993, BIOCHIM BIOPHYS ACTA, V1146, P113, DOI 10.1016/0005-2736(93)90345-Z; Sedgwick EG, 1996, BBA-BIOMEMBRANES, V1278, P205, DOI 10.1016/0005-2736(95)00228-6; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; STEIN WD, 1994, MOL PHARMACOL, V45, P763; YONEYAMA H, 1986, BIOCHEM BIOPH RES CO, V134, P106; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; YONEYAMA H, 1986, EUR J BIOCHEM, V157, P33, DOI 10.1111/j.1432-1033.1986.tb09634.x	33	85	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21964	21969		10.1074/jbc.272.35.21964	http://dx.doi.org/10.1074/jbc.272.35.21964			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268332	hybrid			2022-12-25	WOS:A1997XT85000044
J	Sabharwal, AK; Padmanabhan, K; Tulinsky, A; Mathur, A; Gorka, J; Bajaj, SP				Sabharwal, AK; Padmanabhan, K; Tulinsky, A; Mathur, A; Gorka, J; Bajaj, SP			Interaction of calcium with native and decarboxylated human factor X. Effect of proteolysis in the autolysis loop on catalytic efficiency and factor Va binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BLOOD-COAGULATION FACTOR; AFFINITY CA2+-BINDING SITE; CA-PROTHROMBIN FRAGMENT-1; SERINE-PROTEASE DOMAIN; HUMAN FACTOR-VIIA; HUMAN FACTOR-IX; TISSUE FACTOR; BOVINE PROTHROMBIN; MEMBRANE-BINDING	Human factor X is a two-chain, 58-kDa, vitamin K-dependent blood coagulation zymogen, The light chain of factor X consists of an NH2-terminal gamma-carboxyglutamic acid (Cia) domain, followed by a few helical hydrophobic residues and the two epidermal growth factor-like domains, whereas the heavy chain contains the serine protease domain, In this study, native factor X was found to contain three classes of Ca2+-binding sites: two high affinity (K-d 100 +/- 30 mu M), four intermediate affinity (K-d 450 +/- 70 mu M), and five to six low affinity (K-d 2 +/- 0.2 mm). Decarboxylated factor X in which the Gla residues were converted to Glu retained the two high affinity sites (K-d 140 +/- 20 mu M). In contrast, factor X lacking the Gla domain as well as a part of the helical hydrophobic residues (des-44-X) retained only one high affinity Ca2+-binding site (K-d 130 +/- 20 mu M). Moreover, a synthetic peptide composed of residues 238-277 (58-97 in chymotrypsinogen numbering) from the protease domain of factor X bound one Ca2+ with high affinity (K-d 150 +/- 20 mu M). From competitive inhibition assays for binding of active site-blocked factor Xa to factor Va in the prothrombinase complex, the K-d for peptide-Va interaction was calculated to be similar to 10 mu M as compared with 30 phn for factor Xa and similar to 1.5 mu M for decarboxylated factor Xa, A peptide containing residues 238-262 (58-82) bound Ca2+ with reduced affinity (K-d similar to 600 mu M) and did not inhibit Xa:Va interaction, In contrast, a peptide containing residues 253-277(73-97) inhibited Xa:Va interaction (K-d similar to 10 mu M) but did not bind Ca2+. In additional studies, Ca2+ increased the amidolytic activity of native and des-44-Xa toward a tetrapeptide substrate (benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide) by approximately 1.6-fold. The half-maximal increase was observed at similar to 150 mu M Ca2+ and the effect was primarily on the k(cat). Ca2+ also significantly protected cleavage at Arg-332-Gln-333(150-151) in the protease domain autolysis loop, Des-44-Xa in which the autolysis loop was cleaved possessed less than or equal to 5% of the amidolytic activity of the noncleaved form; however, the S1 binding site was not affected, as determined by the p-aminobenzamidine binding, Additionally, autolysis loop-cleaved, active site-blocked native factor Xa was calculated to have similar to 10-fold reduced affinity for factor Va as compared with that of the noncleaved form.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63104; MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	Washington University (WUSTL); Saint Louis University; Saint Louis University; Saint Louis University; Michigan State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL036365, R55HL036365, R01HL025942, R01HL036365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25942, HL36365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1994, CHEM PHYS LIPIDS, V67-8, P59, DOI 10.1016/0009-3084(94)90124-4; Bajaj MS, 1994, ANTICOAGULANTS PHYSL, P41; BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1975, J BIOL CHEM, V250, P98; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHRISTIANSEN WT, 1994, BIOCHEMISTRY-US, V33, P14993, DOI 10.1021/bi00254a007; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEERFIELD DW, 1987, J BIOL CHEM, V262, P4017; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GORKA J, 1989, Peptide Research, V2, P376; GRAHAM JB, 1957, J CLIN INVEST, V36, P497, DOI 10.1172/JCI103447; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HUH NW, 1991, ANAL BIOCHEM, V198, P391, DOI 10.1016/0003-2697(91)90445-Y; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LINDHOUT MJ, 1978, BIOCHIM BIOPHYS ACTA, V553, P318; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1990, BLOOD, V76, P1; MATHUR A, 1997, IN PRESS J BIOL CHEM, V272; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; Monroe D M, 1990, Blood Coagul Fibrinolysis, V1, P633; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; MORITA T, 1986, J BIOL CHEM, V261, P4015; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; PRICE PA, 1981, J BIOL CHEM, V256, P1172; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16614, DOI 10.1074/jbc.271.28.16614; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rosenberg I.M., 1996, PROTEIN ANAL PURIFIC, V1996, P153; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SABHARWAL AK, 1993, BLOOD, V82, pA64; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SESHADRI TP, 1994, BIOCHEMISTRY-US, V33, P1087, DOI 10.1021/bi00171a006; SHERRILL GB, 1988, THROMB RES, V52, P53; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; YE J, 1995, BIOCHEMISTRY-US, V34, P6448, DOI 10.1021/bi00019a026	65	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22037	22045		10.1074/jbc.272.35.22037	http://dx.doi.org/10.1074/jbc.272.35.22037			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268343	hybrid			2022-12-25	WOS:A1997XT85000055
J	Jonca, F; Ortega, N; Gleizes, PE; Bertrand, N; Plouet, J				Jonca, F; Ortega, N; Gleizes, PE; Bertrand, N; Plouet, J			Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; TYROSINE KINASE; BINDING-SITES; TUMOR-CELLS; RECEPTOR; IDENTIFICATION; VASCULOTROPIN; HEPARIN; MITOGEN; KDR	Vascular endothelial growth factor (VEGF) is a potent angiogenic factor which is synthesized and secreted by many differentiated cells in response to various stimuli including hypoxia and growth factor exposure, Alternative splicing of vascular endothelial growth factor mRNA results in three distinct molecular forms: V189 and V165 or V121 which lack the exons 6 or 6 and 7, respectively, To clarify the functions of the 24-amino acid insertion, the biological activity of V165 was com pared with that exerted by purified recombinant V189 and a synthetic peptide designed on the sequence encoded by exon 6 (Ex6P), V189 and Ex6P, but not V165, induced cell proliferation on corneal endothelial cells cultured in vitro. These effects were due to the release of fibroblast growth factor 2 (FGF2) stored in the extracellular matrix but not to direct interactions with FGF receptors since V189 was inefficient on heparan sulfate-deficient cells expressing constitutively FGF-R1. Moreover corneas incubated ex vivo with Ex6P solubilized 10-fold more FGF2 than a isocationic peptide containing a scrambled sequence. Ex6P elicited an angiogenic response in a corneal pocket assay which was totally inhibited by addition of anti-FGF2 IgG. Moreover the angiogenic response to V189, but not to V165, was inhibited by FGF2 immunoneutralization. These findings demonstrate that the presence of the exon g-encoded sequence confers VEGF with the ability to exert its biological effects through FGF2 signaling pathways.	CNRS UPR 9006,LAB BIOL MOL EUCARYOTE,F-31062 TOULOUSE,FRANCE; HOP PURPAN,DEPT UROL,F-31052 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse			Gleizes, Pierre-Emmanuel/H-3821-2014; Ortega, Nathalie/C-3382-2019; Gleizes, Pierre-Emmanuel/ABB-9653-2021	Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Gleizes, Pierre-Emmanuel/0000-0003-0830-7341				BEDNARZ J, 1995, CORNEA, V14, P372, DOI 10.1097/00003226-199507000-00005; Berard M, 1997, AM J PATHOL, V150, P1315; BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BOENSCH C, 1995, J BIOL CHEM, V270, P1807, DOI 10.1074/jbc.270.4.1807; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FAVARD C, 1991, BIOL CELL, V73, P1, DOI 10.1016/0248-4900(91)90002-5; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; GOTO F, 1993, LAB INVEST, V69, P508; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P7478; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; PLOUET J, 1990, BIOCHIMIE, V72, P51, DOI 10.1016/0300-9084(90)90172-D; PLOUET J, 1990, EXP EYE RES, V51, P519, DOI 10.1016/0014-4835(90)90082-6; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; PRALORAN V, 1991, CR ACAD SCI III-VIE, V313, P21; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	40	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24203	24209		10.1074/jbc.272.39.24203	http://dx.doi.org/10.1074/jbc.272.39.24203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305872	hybrid			2022-12-25	WOS:A1997XY51500023
J	Algenstaedt, PM; Antonetti, DA; Yaffe, MB; Kahn, CR				Algenstaedt, PM; Antonetti, DA; Yaffe, MB; Kahn, CR			Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CA-2+ TRANSPORT; PHOSPHATASE; IRS-1; SH2; DOMAIN; ATPASE; STIMULATION	Following phosphorylation by the insulin receptor kinase, the insulin receptor substrates (IRS)-1 and IRS-2 bind to and activate several Src homology 2 (SH2) domain proteins. To identify novel proteins that interact with IRS proteins in muscle, a human skeletal muscle cDNA expression library was created in the lambda EXLox system and probed with baculovirus-produced and tyrosine-phosphorylated human IRS-I. One clone of the 10 clones which was positive through three rounds of screening represented the C terminus of the human homologue of the adult fast twitch skeletal muscle Ca2+ ATPase (SERCA1) including the cytoplasmic tail and part of transmembrane region 10. Western blot analysis of extracts of rat muscle demonstrated co-immunoprecipitation of both IRS-1 and IRS-2 with the skeletal muscle Ca2+-ATPase (SERCA1) and the cardiac muscle isoform (SERCA2). In both cases, injection of insulin stimulated a 2- to 6-fold increase in association of which was maximal within 5 min. In primary cultures of aortic smooth muscle cells and C2C12 cells, the insulin-stimulated interaction between IRS proteins and SERCA1 and -2 was dose-dependent with a maximum induction at 100 nM insulin. This interaction was confirmed in a ''pull down'' experiment using a glutathione S-transferase fusion protein containing the C terminus of the human SERCA. isoform and phosphorylated IRS-I in vitro and could be blocked by a FLVRES-like domain peptide present in the human SERCA sequence. Affinity chromatography of phosphopeptide libraries using the glutathione S-transferase fusion protein of the C terminus of SERCA1 indicated a consensus sequence for binding of XpYGSS; this is identical to potential tyrosine phosphorylation sites at position 431 of human IRS-1 and at position 500 of human IRS-2. In streptozotocin diabetic rats the interaction between IRS proteins and SERCA1 in skeletal muscle and SERCA2 in cardiac muscle was significantly reduced. Taken together, these results indicate that the IRS proteins bind to the Ca2+-ATPase of the sarcoplasmic reticulin in an insulin-regulated fashion, thus creating a potential link between the tyrosine phosphorylation cascade and effects of insulin on calcium.	JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DEPT CELL BIOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; antonetti, david/0000-0003-1130-6577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201, P30 DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BORDA E, 1988, CAN J CARDIOL, V4, P97; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; EIBSCHUTZ B, 1984, RES COMMUN CHEM PATH, V45, P301; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; FOLLI F, 1992, J BIOL CHEM, V267, P22171; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KAELIN, 1993, CELL, V64, P521; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAHN CR, 1995, NEW HORIZONS DIABETE, P46; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAKINO N, 1987, AM J PHYSIOL, V253, pE202, DOI 10.1152/ajpendo.1987.253.2.E202; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAIRA Y, 1991, AM J PHYSIOL, V260, pE626, DOI 10.1152/ajpendo.1991.260.4.E626; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	73	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23696	23702		10.1074/jbc.272.38.23696	http://dx.doi.org/10.1074/jbc.272.38.23696			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295312	hybrid			2022-12-25	WOS:A1997XX38100037
J	Kostenis, E; Gomeza, J; Lerche, C; Wess, J				Kostenis, E; Gomeza, J; Lerche, C; Wess, J			Genetic analysis of receptor-G alpha(q) coupling selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; G-PROTEIN; MOLECULAR-CLONING; ADRENERGIC-RECEPTORS; TERMINAL MUTATIONS; SYNTHETIC PEPTIDES; LIGAND-BINDING; ALPHA-SUBUNIT; AMINO-ACID; ACTIVATION	Many different G protein-linked receptors are preferentially coupled to G proteins of the G(q/11) family, To elucidate the molecular basis underlying this selectivity, different G(q/11)-coupled receptors (m3 muscarinic, V1a vasopressin, and gastrin-releasing peptide receptor) were coexpressed (in COS-7 cells) with mutant alpha(s) subunits in which residues present at the C terminus of alpha(s) were replaced with the corresponding alpha(q/11), residues, Remarkably, whereas none of the receptors was able to interact with wild type alpha(s) to a significant extent, all three receptors gained the ability to productively couple to a mutant alpha(s) subunit containing a single Glu --> Asn point mutation at position -3, Moreover, the m3 muscarinic and the Via vasopressin receptors but not the GRP receptor also gained the ability to interact with a mutant alpha(s) subunit containing a single Gln --> Glu point mutation at position -5, indicating that the alpha(q/11) residues present in these mutant G protein constructs play key roles in determining the selectivity of receptor recognition. To identify the site(s) on G(q/11)-coupled receptors that can functionally interact with the C terminus of alpha(q/11) subunits, we next analyzed the ability of a series of hybrid m2/m3 muscarinic receptors to interact with a mutant alpha(s) subunit (sq5) in which the last five amino acids of alpha(s) were replaced with the corresponding alpha(q/11) sequence, Similar to the wild type m2 and m3 muscarinic receptors, none of the investigated hybrid receptors was able to efficiently interact with wild type alpha(s). Interestingly, however, three mutant m2 receptors in which different segments of the second and third intracellular loops were replaced with the corresponding m3 receptor sequences were identified, which, in contrast to the G(i/o)-coupled wild type m2 receptor, gained the ability to efficiently activate the sq5 subunit, This observation suggests that multiple intracellular receptor domains form a binding pocket for the C terminus of G protein alpha(q/11) subunits.	NIDDK,BIOORGAN CHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, J BIOL CHEM, V269, P11537; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WESS J, 1990, MOL PHARMACOL, V38, P872; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	46	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23675	23681		10.1074/jbc.272.38.23675	http://dx.doi.org/10.1074/jbc.272.38.23675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295309	hybrid			2022-12-25	WOS:A1997XX38100034
J	Oppert, B; Kramer, KJ; Beeman, RW; Johnson, D; McGaughey, WH				Oppert, B; Kramer, KJ; Beeman, RW; Johnson, D; McGaughey, WH			Proteinase-mediated insect resistance to Bacillus thuringiensis toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIOTHIS-VIRESCENS; PLUTELLA-XYLOSTELLA; PLODIA-INTERPUNCTELLA; CRYSTAL PROTEINS; BINDING; LEPIDOPTERA; ENDOTOXINS; RECEPTOR; PROTOXIN; STRAINS	Two Bacillus thuringiensis (Bt)-resistant strains of the Indianmeal moth, Plodia interpunctella, lack a major gut proteinase that activates Bt protoxins. The absence of this enzyme is genetically linked to larval survival on Bt-treated diets. When considered with previous data supporting the existence of receptor-mediated insect resistance to Bt, these results provide evidence that insect adaptation to these toxins occurs through multiple physiological mechanisms, which complicate efforts to prevent or manage resistance to Bt toxins in insect control programs.			Oppert, B (corresponding author), USDA ARS, N CENT REG, US GRAIN MKT RES LAB, 1515 COLL AVE, MANHATTAN, KS 66502 USA.							Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P247, DOI 10.1016/0022-2011(92)90005-O; ESCRICHE B, 1995, BIOCHEM BIOPH RES CO, V212, P388, DOI 10.1006/bbrc.1995.1982; Estruch JJ, 1997, NAT BIOTECHNOL, V15, P137, DOI 10.1038/nbt0297-137; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; Forcada C, 1996, ARCH INSECT BIOCHEM, V31, P257, DOI 10.1002/(SICI)1520-6327(1996)31:3&lt;257::AID-ARCH2&gt;3.0.CO;2-V; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; GOULD F, 1992, P NATL ACAD SCI USA, V89, P7986, DOI 10.1073/pnas.89.17.7986; HOFTE H, 1989, MICROBIOL REV, V53, P242; Keller M, 1996, INSECT BIOCHEM MOLEC, V26, P365, DOI 10.1016/0965-1748(95)00102-6; LEE MK, 1995, APPL ENVIRON MICROB, V61, P3836, DOI 10.1128/AEM.61.11.3836-3842.1995; Luo K, 1997, APPL ENVIRON MICROB, V63, P1024, DOI 10.1128/AEM.63.3.1024-1027.1997; MACINTOSH SC, 1991, P NATL ACAD SCI USA, V88, P8930, DOI 10.1073/pnas.88.20.8930; MASSON L, 1995, J BIOL CHEM, V270, P1; MCGAUGHEY WH, 1992, J ECON ENTOMOL, V85, P1594, DOI 10.1093/jee/85.5.1594; MCGAUGHEY WH, 1992, SCIENCE, V258, P1451, DOI 10.1126/science.258.5087.1451; MOAR WJ, 1995, APPL ENVIRON MICROB, V61, P2086, DOI 10.1128/AEM.61.6.2086-2092.1995; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; NICKERSON KW, 1974, APPL MICROBIOL, V28, P129, DOI 10.1128/AEM.28.1.129-132.1974; OPPERT B, 1994, BIOCHEM BIOPH RES CO, V198, P940, DOI 10.1006/bbrc.1994.1134; Oppert B, 1996, INSECT BIOCHEM MOLEC, V26, P571, DOI 10.1016/S0965-1748(96)00013-6; PASTEUR N, 1988, PRACTICAL ISOZYME GE, P42; TABASHNIK BE, 1994, P NATL ACAD SCI USA, V91, P4120, DOI 10.1073/pnas.91.10.4120; Tang JD, 1996, APPL ENVIRON MICROB, V62, P564, DOI 10.1128/AEM.62.2.564-569.1996; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593	26	214	239	2	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23473	23476		10.1074/jbc.272.38.23473	http://dx.doi.org/10.1074/jbc.272.38.23473			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295279	hybrid			2022-12-25	WOS:A1997XX38100004
J	Wang, XS; Diener, K; Manthey, CL; Wang, SW; Rosenzweig, B; Bray, J; Delaney, J; Cole, CN; ChanHui, PY; Mantlo, N; Lichenstein, HS; Zukowski, M; Yao, ZB				Wang, XS; Diener, K; Manthey, CL; Wang, SW; Rosenzweig, B; Bray, J; Delaney, J; Cole, CN; ChanHui, PY; Mantlo, N; Lichenstein, HS; Zukowski, M; Yao, ZB			Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; C-JUN; GENE-EXPRESSION; MAMMALIAN-CELLS; PHOSPHORYLATION; STRESS; IDENTIFICATION; CASCADE; DOMAIN	The p38 mitogen-activated protein kinases (MAPK) are activated by cellular stresses and play an important role in regulating gene expression. We have isolated a cDNA encoding a novel protein kinase that has significant homology (57% amino acid identity) to human p38 alpha/CSBP. The novel kinase, p38 delta, has a nucleotide sequence encoding a protein of 365 amino acids with a putative TGY dual phosphorylation motif. Dot-blot analysis of p38 delta mRNA in 50 human tissues revealed a distribution profile of p38 delta that differs from p38 alpha. p38 delta is highly expressed in salivary gland, pituitary gland, and adrenal gland, whereas p38 alpha is highly expressed in placenta, cerebellum, bone marrow, thyroid gland, peripheral leukocytes, liver, and spleen. Like p38 alpha, p38 delta is activated by cellular stress and proinflammatory cytokines. p38 delta phosphorylates AFT-2 and PHAS-I, but not MAPK-activated protein kinase-2 and -3, known in vivo and in vitro substrates of p38 alpha. We also observed that p38 delta was strongly activated by MKK3 and MKK6, while p38 alpha was preferentially activated by MKK6. Other experiments showed that a potent p38 alpha kinase inhibitor AMG 2372 minimally inhibited the kinase activity of p38 delta. Taken together, these data indicate that p38 delta is a new member of the p38 MAPK family and that p38 delta likely has functions distinct from that of p38 alpha.	AMGEN INC,BOULDER,CO 80801; AMGEN INC,THOUSAND OAKS,CA 91320	Amgen; Amgen			Cole, Charles/GRR-1551-2022					BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	46	289	325	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23668	23674		10.1074/jbc.272.38.23668	http://dx.doi.org/10.1074/jbc.272.38.23668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295308	hybrid			2022-12-25	WOS:A1997XX38100033
J	Shang, F; Gong, X; Taylor, A				Shang, F; Gong, X; Taylor, A			Activity of ubiquitin-dependent pathway in response to oxidative stress - Ubiquitin-activating enzyme is transiently up-regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS EPITHELIAL-CELLS; KAPPA-B-ALPHA; SITE-SPECIFIC PHOSPHORYLATION; PROTEIN LIGASE SYSTEM; HYDROGEN-PEROXIDE; PROTEASOME PATHWAY; CONJUGATING ENZYME; RADIOISOTOPIC DETERMINATION; AFFINITY PURIFICATION; CATARACT FORMATION	Relations between the ubiquitin pathway and cellular stress have been noted, but data regarding responses of the ubiquitin pathway to oxidative stress are scanty. This paper documents the response of this pathway to oxidative stress in lens cells. A brief exposure of lens epithelial cells to physiologically relevant levels of H2O2 induces a transient increase in activity of the ubiquitin-dependent pathway. Ubiquitin conjugation activity was maximal and increased 3.5-9.2-fold over the activity noted in untreated cells by 4 h after removal of H2O2. By 24 h after removal of H2O2, ubiquitin conjugation activity returned to the level noted in untreated cells. In parallel to the changes in ubiquitin conjugation activity, the activity of ubiquitin-activating enzyme (E1), as determined by thiol ester formation, increased 2-6.7-fold during recovery from oxidation, Addition of exogenous E1 resulted in an increase in ubiquitin conjugation activity and in the levels of ubiquitin carrier protein (E2)-ubiquitin thiol esters in both the untreated cells and the H2O2-treated cells, These data suggest that E1 is the rate-limiting enzyme in the ubiquitin conjugation process and. that the increases in ubiquitin conjugation activity which are induced upon recovery from oxidation are primarily due to increased E1. activity. The oxidation-and recovery-induced up-regulation of E1 activity is primarily due to post-synthetic events, Substrate availability and up-regulation of E2 activities also appear to be related to the enhancement in ubiquitinylation upon recovery from oxidative stress, The oxidation-induced increases in ubiquitin conjugation activity were associated with an increase in intracellular proteolysis, suggesting that the transient increase in ubiquitinylation noted upon recovery from oxidative stress may play a role in removal of damaged proteins from the cells.	TUFTS UNIV, USDA, JEAN MAYER HUMAN NUTR RES CTR AGING, LAB NUTR & VIS RES, BOSTON, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA)								ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; BARCHOWSKY A, 1994, FREE RADICAL BIO MED, V16, P771, DOI 10.1016/0891-5849(94)90192-9; BLONDIN J, 1987, MECH AGEING DEV, V41, P39, DOI 10.1016/0047-6374(87)90052-2; BLONDIN J, 1986, Journal of Free Radicals in Biology and Medicine, V2, P275; BRAWN MK, 1995, FREE RADICAL RES, V22, P23, DOI 10.3109/10715769509147525; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BRUNK UT, 1995, FREE RADICAL BIO MED, V19, P813, DOI 10.1016/0891-5849(95)02001-Q; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; COOK JC, 1995, P NATL ACAD SCI USA, V92, P3454, DOI 10.1073/pnas.92.8.3454; DEVAMANOHARAN PS, 1991, CURR EYE RES, V10, P831, DOI 10.3109/02713689109013879; DEVAMANOHARAN PS, 1995, OPHTHALMIC RES, V27, P39, DOI 10.1159/000267837; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GIBLIN FJ, 1984, EXP EYE RES, V38, P87, DOI 10.1016/0014-4835(84)90142-8; GIBLIN FJ, 1990, EXP EYE RES, V50, P795, DOI 10.1016/0014-4835(90)90130-M; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1979, P NATL ACAD SCI USA, V76, P3107, DOI 10.1073/pnas.76.7.3107; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280, DOI 10.1016/0006-291X(92)91555-5; HUANG LL, 1993, BIOCHIM BIOPHYS ACTA, V1175, P181, DOI 10.1016/0167-4889(93)90021-G; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K; Jahngen-Hodge J., 1996, Investigative Ophthalmology and Visual Science, V37, pS799; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KONG SK, 1992, J BIOL CHEM, V267, P14189; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Maki CG, 1996, CANCER RES, V56, P2649; MULLER S, 1995, BIOESSAYS, V17, P677, DOI 10.1002/bies.950170804; NAGAI Y, 1995, J CELL SCI, V108, P2145; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REDDAN JR, 1993, EXP EYE RES, V56, P543, DOI 10.1006/exer.1993.1068; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; SPECTOR A, 1989, EXP EYE RES, V49, P685, DOI 10.1016/S0014-4835(89)80063-6; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Stephen AG, 1996, J BIOL CHEM, V271, P15608, DOI 10.1074/jbc.271.26.15608; TAYLOR A, 1993, TOXICOL IND HEALTH, V9, P349, DOI 10.1177/0748233793009001-226; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; VARMA SD, 1984, CURR EYE RES, V3, P35, DOI 10.3109/02713688408997186; WHISLER RL, 1994, LYMPHOKINE CYTOK RES, V13, P399	73	200	202	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23086	23093		10.1074/jbc.272.37.23086	http://dx.doi.org/10.1074/jbc.272.37.23086			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287309	hybrid			2022-12-25	WOS:A1997XV74400020
J	Tsubaki, M; Nakayama, M; Okuyama, E; Ichikawa, Y; Hori, H				Tsubaki, M; Nakayama, M; Okuyama, E; Ichikawa, Y; Hori, H			Existence of two heme B centers in cytochrome b(561) from bovine adrenal chromaffin vesicles as revealed by a new purification procedure and EPR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANES; PROTEIN; COMPLEX; POLYPEPTIDE; SYSTEM; B561	We have established a new purification procedure of cytochrome b(561) from bovine adrenomedullary chromaffin vesicles, The heme content analysis of the purified sample indicated the presence of 1.7 molecules of heme B/cytochrome b(561), molecule. EPR spectroscopy of the purified enzyme in oxidized state showed that there were three types of law spill heme species. Two of them showed usual EPR signals at g(z) = 3.14 and g(z) = 2.84 arising from the same heme and were interconvertible depending on pH. The other species showed a highly anisotropic low spin signal at g(z) = 3.70, with a lower redox potential than the others, and a temperature-sensitive character, These properties are very similar to low potential cytochrome b (b(L) or b(566)) of the mitochondrial complex III, indicating that the g(z) = 3.70 species is derived from a heme component different from the one that shows the usual low spin EPR signals. Based on our new structural model, these two heme B prosthetic groups are likely to be located on both sides of the membranes in close contact with the ascorbic acid- and semi-dehydroascorbic acid-binding sites, respectively, to facilitate the electron transfer across the membranes, This molecular architecture may provide a structural basis for the transmembrane electron transfer catalyzed by this hemoprotein.	KAGAWA MED UNIV,DEPT BIOCHEM,MIKI,KAGAWA 76107,JAPAN; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	Kagawa University; Osaka University	Tsubaki, M (corresponding author), HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN.							APPS DK, 1984, BIOCHIM BIOPHYS ACTA, V764, P8, DOI 10.1016/0005-2728(84)90134-8; APPS DK, 1980, NEUROSCIENCE, V5, P2279, DOI 10.1016/0306-4522(80)90143-8; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; Bartlett S F, 1974, Methods Enzymol, V31, P379; BERGSTROM J, 1983, FEBS LETT, V164, P71, DOI 10.1016/0014-5793(83)80021-0; BURBAEV DS, 1991, FEBS LETT, V283, P97, DOI 10.1016/0014-5793(91)80562-H; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DUONG LT, 1982, J BIOL CHEM, V257, P8561; FLATMARK T, 1971, BIOCHIM BIOPHYS ACTA, V253, P487, DOI 10.1016/0005-2728(71)90052-1; Fuhrhop J.-H., 1975, PORPHYRINS METLLOPOR, P755; IKEDA M, 1974, BIOCHIM BIOPHYS ACTA, V336, P15, DOI 10.1016/0005-2795(74)90378-X; Markwell M A, 1981, Methods Enzymol, V72, P296; NJUS D, 1993, BIOCHIM BIOPHYS ACTA, V1144, P235, DOI 10.1016/0005-2728(93)90108-R; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; ORMEJOHN.NR, 1971, BIOCHEM BIOPH RES CO, V45, P871, DOI 10.1016/0006-291X(71)90419-0; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; QUINN R, 1982, J AM CHEM SOC, V104, P2588, DOI 10.1021/ja00373a042; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SILSAND T, 1974, BIOCHIM BIOPHYS ACTA, V359, P257, DOI 10.1016/0005-2795(74)90223-2; SRIVASTAVA M, 1994, BIOCHEM J, V303, P915, DOI 10.1042/bj3030915; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; WAKEFIELD LM, 1984, J BIOCHEM BIOPH METH, V9, P331, DOI 10.1016/0165-022X(84)90017-4; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7	23	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23206	23210		10.1074/jbc.272.37.23206	http://dx.doi.org/10.1074/jbc.272.37.23206			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287327	hybrid			2022-12-25	WOS:A1997XV74400038
J	Lyman, S; Gilmore, A; Burridge, K; Gidwitz, S; White, GC				Lyman, S; Gilmore, A; Burridge, K; Gidwitz, S; White, GC			Integrin-mediated activation of focal adhesion kinase is independent of focal adhesion formation or integrin activation - Studies with activated and inhibitory beta(3) cytoplasmic domain mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; TYROSINE PHOSPHORYLATION; LIGAND-BINDING; CELL-ADHESION; MONOCLONAL-ANTIBODIES; FIBRONECTIN RECEPTOR; PLATELET ACTIVATION; SIGNAL-TRANSDUCTION; FIBRINOGEN BINDING; MOLECULAR-CLONING	Integrin alpha(IIb)beta(3) functions as the fibrinogen receptor on platelets and mediates platelet aggregation and clot retraction. Among the events that occur during either ''inside-out'' or ''outside-in'' signaling through alpha(IIb)beta(3) is the phosphorylation of focal adhesion kinase (pp125(FAK)) and the association of pp125(FAK) with cytoskeletal components. To examine the role of pp125(FAK) in these integrin-mediated events, pp125(FAK) phosphorylation and association with the cytoskeleton was determined in cells expressing two mutant forms of alpha(IIb)beta(3): alpha(IIb)beta(3)(D723A/E726A), a constitutively active integrin in which the putative binding site for pp125(FAK) in altered, and alpha(IIb)beta(3)(F727A/K729E/F730A), in which the putative binding site for a-actinin is altered. Both mutants were expressed on the cell surface and were able to bind ligand, either spontaneously or upon activation. Whereas cells expressing alpha(IIb)beta(3)(D723A/E726A) were able to form focal adhesions and stress fibers upon adherence to fibrinogen, cells expressing alpha(IIb)beta(3)(F727A/K729E/F730A) adhere to fibrinogen, but had reduced focal adhesions and stress fibers. pp125(FAK) is recruited to focal adhesions in adherent cells expressing alpha(IIb)beta(3)(D723A/E726A) and is phosphorylated in adherent cells or in cells in suspension in the presence of fibrinogen. In adherent cells expressing alpha(IIb)beta(3)(F727A/K729E/F730A), pp125(FAK) was phosphorylated despite reduced formation of focal adhesions and stress fibers. We conclude that activation of pp125(FAK) can be dissociated from two important events in integrin signaling, the assembly of focal adhesions in adherent cells and integrin activation following ligand occupation.	UNIV N CAROLINA,DIV HEMATOL ONCOL,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BELIN AM, 1996, J CELL BIOL, V132, P211; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BRIESEWITZ R, 1995, MOL BIOL CELL, V6, P997, DOI 10.1091/mbc.6.8.997; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GINSBERG MH, 1992, COLD SPRING HARB SYM, V57, P221, DOI 10.1101/SQB.1992.057.01.027; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOUNS WC, 1994, BLOOD, V84, P1108; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMON KO, 1994, THESIS U N CAROLINA; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAPLEY P, 1989, ONCOGENE, V4, P325; TURNER CE, 1994, J CELL SCI, V107, P1583; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	70	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22538	22547		10.1074/jbc.272.36.22538	http://dx.doi.org/10.1074/jbc.272.36.22538			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278407	hybrid			2022-12-25	WOS:A1997XV49200027
J	Ren, DJ; Hall, LM				Ren, DJ; Hall, LM			Functional expression and characterization of skeletal muscle dihydropyridine receptors in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; BETA-SUBUNIT; CA2+ CHANNEL; ALLOSTERIC REGULATION; RYANODINE RECEPTOR; ALPHA(1) SUBUNIT; CHARGE MOVEMENT; GAMMA-SUBUNITS; CA-2+ CHANNEL; FAST-TWITCH	Dihydropyridine receptors in vertebrate skeletal muscle serve a dual role: as voltage sensors for excitation-contraction coupling and as voltage-activated calcium channels. Although they were the first of six classes of calcium channels to be cloned, skeletal muscle dihydropyridine receptors remain the only ones not functionally expressed as calcium channels in Xenopus oocytes, leading to the hypothesis that an interacting component is missing. Using beta(1b), an isoform previously found in brain, we have for the first time reconstituted skeletal muscle calcium channel function in Xenopus oocytes. We show that this beta subunit is necessary for functional expression and that the alpha(2) delta subunit significantly enhances the expressed current. The majority of the alpha(1) subunit in skeletal muscle is a truncated form. Here we show that both the full-length and truncated forms produce functional calcium channels in Xenopus oocytes, but the truncated form gives significantly larger currents. In addition, we show that the beta(1b) transcript is expressed in rat skeletal muscle, although at a much lower level than the abundant beta(1a) isoform.	SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260; SUNY BUFFALO,DEPT BIOPHYS,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Tuluc, Petronel/C-2527-2011		NHLBI NIH HHS [HL39369] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039369, R37HL039369] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; CASTELLANO A, 1994, BIOCHEM SOC T, V22, P483, DOI 10.1042/bst0220483; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DASCAL N, 1992, J PHYSIOL-LONDON, V450, P469, DOI 10.1113/jphysiol.1992.sp019137; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DONALDSON PL, 1983, J GEN PHYSIOL, V82, P449, DOI 10.1085/jgp.82.4.449; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; Johnson BD, 1997, J NEUROSCI, V17, P1243; KIM HS, 1990, J BIOL CHEM, V265, P11858; KRIZANOVA O, 1995, BIOCHEM BIOPH RES CO, V211, P921, DOI 10.1006/bbrc.1995.1900; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LAMB GD, 1987, J PHYSIOL-LONDON, V393, P595, DOI 10.1113/jphysiol.1987.sp016843; LORY P, 1992, BIOPHYS J, V63, P1421, DOI 10.1016/S0006-3495(92)81705-8; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; NARGEOT J, 1992, J MEMBRANE BIOL, V126, P97; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Strube C, 1996, BIOPHYS J, V71, P2531, DOI 10.1016/S0006-3495(96)79446-8; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WANG ZY, 1995, J PHYSIOL-LONDON, V486, P131, DOI 10.1113/jphysiol.1995.sp020797; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106; WEI XY, 1991, J BIOL CHEM, V266, P21943; ZHENG W, 1995, J NEUROSCI, V15, P1132	43	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22393	22396		10.1074/jbc.272.36.22393	http://dx.doi.org/10.1074/jbc.272.36.22393			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278387	hybrid			2022-12-25	WOS:A1997XV49200006
J	Shiba, K; Stello, T; Motegi, H; Noda, T; MusierForsyth, K; Schimmel, P				Shiba, K; Stello, T; Motegi, H; Noda, T; MusierForsyth, K; Schimmel, P			Human lysyl-tRNA synthetase accepts nucleotide 73 variants and rescues Escherichia coli double-defective mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SPECIES-SPECIFIC AMINOACYLATION; DISCRIMINATOR BASE; SINGLE NUCLEOTIDE; CRYSTAL-STRUCTURE; BINDING DOMAIN; AMINO-ACIDS; IN-VITRO; SEQUENCE; RECOGNITION	The nucleotide 73 (N-73) ''discriminator'' base in the acceptor stem is a key element for efficient and specific aminoacylation of tRNAs and of microhelix substrates derived from tRNA acceptor stems, This nucleotide was possibly one of the first to be used for differentiating among groups of early RNA substrates by tRNA synthetases, In contrast to many other synthetases, we report here that the class II human lysyl-tRNA synthetase is relatively insensitive to the nature of N-73. We cloned, sequenced, and expressed the enzyme, which is a close homologue of the class II yeast aspartyl-tRNA synthetase whose co-crystal structure (with tRNA(Asp)) is known. The latter enzyme has a strong requirement for G(73), which interacts with 4 of the 14 residues within the ''motif 2'' loop of the enzyme. Even though eukaryotic lysine tRNAs also encode G(73), the motif 2 loop sequence of lysyl-tRNA synthetase differs at multiple positions from that of the aspartate enzyme, Indeed, the recombinant human lysine enzyme shows little preference fair G, and even charges human tRNA transcripts encoding the A(73) found in E. coli lysine tRNAs, Moreover, while the lysine enzyme is the only one in E. coli to be encoded by two separate genes, a double mutant that disables both genes is complemented by a cDNA expressing the human protein. Thus, the sequence of the loop of motif 2 of human lysyl-tRNA synthetase specifies a structural variation that accommodates nucleotide degeneracy at position 73, This sequence might be used as a starting point for obtaining highly specific interactions with any given N-73 by Simple amino acid replacements.	UNIV MINNESOTA, JAPAN SCI & TECHNOL CORP, PRESTO, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Massachusetts Institute of Technology (MIT)	Shiba, K (corresponding author), JAPANESE FDN CANC RES, INST CANC, DEPT CELL BIOL, TOSHIMA KU, TOKYO 170, JAPAN.		Shiba, Kiyotaka/I-9588-2014; Noda, Tetsuo/B-1667-2016	Shiba, Kiyotaka/0000-0001-6459-0204; 				ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; Agou F, 1996, BIOCHEMISTRY-US, V35, P15322, DOI 10.1021/bi9617926; AULD DS, 1995, SCIENCE, V267, P1994, DOI 10.1126/science.7701322; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHAN VL, 1992, J BACTERIOL, V174, P695, DOI 10.1128/jb.174.3.695-701.1992; CHEN JS, 1994, J BACTERIOL, V176, P2699, DOI 10.1128/JB.176.9.2699-2705.1994; CLARK RL, 1990, J BACTERIOL, V172, P3237, DOI 10.1128/jb.172.6.3237-3243.1990; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRUGIER M, 1994, EMBO J, V13, P2218, DOI 10.1002/j.1460-2075.1994.tb06499.x; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HEDGCOTH C, 1984, NUCLEIC ACIDS RES, V12, P2535, DOI 10.1093/nar/12.5.2535; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; KAWAKAMI K, 1989, MOL GEN GENET, V219, P333, DOI 10.1007/BF00259604; KAWAKAMI K, 1992, MOL MICROBIOL, V6, P1739, DOI 10.1111/j.1365-2958.1992.tb01346.x; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE CP, 1993, P NATL ACAD SCI USA, V90, P7149, DOI 10.1073/pnas.90.15.7149; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; LI SH, 1993, J BIOL CHEM, V268, P18335; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; LIU HJ, 1994, BIOCHEMISTRY-US, V33, P12708, DOI 10.1021/bi00208a023; LIU MS, 1993, BIOTECHNIQUES, V15, P264; MARTINEZ R, 1992, EUR J BIOCHEM, V207, P1, DOI 10.1111/j.1432-1033.1992.tb17012.x; Martinis Susan A., 1995, P349; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MCCLAIN WH, 1994, NUCLEIC ACIDS RES, V22, P522, DOI 10.1093/nar/22.3.522; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; NADA S, 1993, J BIOL CHEM, V268, P7660; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; SALUTA MV, 1995, J BACTERIOL, V177, P1872, DOI 10.1128/jb.177.7.1872-1878.1995; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIMMEL P, 1995, J MOL EVOL, V40, P531; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SHIBA K, 1994, J BIOL CHEM, V269, P30049; SHIBA K, 1992, J BIOL CHEM, V267, P22703; SHIBA K, 1995, BIOCHEMISTRY-US, V34, P10340, DOI 10.1021/bi00033a004; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; YAN W, 1994, J BIOL CHEM, V269, P10022	59	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22809	22816		10.1074/jbc.272.36.22809	http://dx.doi.org/10.1074/jbc.272.36.22809			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278442	hybrid			2022-12-25	WOS:A1997XV49200063
J	Takahashi, T; Guron, C; Shetty, S; Matsui, H; Raghow, R				Takahashi, T; Guron, C; Shetty, S; Matsui, H; Raghow, R			A minimal murine Msx-1 gene promoter - Organization of its cis-regulatory motifs and their role in transcriptional activation in cells in culture and in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; APICAL ECTODERMAL RIDGE; DEVELOPING VERTEBRATE LIMBS; HOMEOBOX-CONTAINING GENE; IN-SITU HYBRIDIZATION; RNA-POLYMERASE-II; HOMEOTIC GENES; COLLAGEN GENE; CHROMOSOMAL LOCATION; NUCLEOTIDE-SEQUENCE	To dissect the cis-regulatory elements of the murine Msx-1 promoter, which lacks a conventional TATA element, a putative Msx-1 promoter DNA fragment (from -1282 to +106 base pairs (bp)) or its congeners containing site-specific alterations were fused to luciferase reporter and introduced into NIH3T3 and C2C12 cells, and the expression of luciferase was assessed in transient expression assays, The functional consequences of the sequential 5' deletions of the promotor revealed that multiple positive and negative regulatory elements participate in regulating transcription of the Msx-1 gene, Surprisingly, however, the optimal expression of Msx-1 promoter in either NIH3T3 or C2C12 cells required only 165 bp of the upstream sequence to warrant detailed examination of its structure, Therefore, the functional consequences of site-specific deletions and point mutations of the cis-acting elements of the minimal Msx-1 promoter were systematically examined, Concomitantly, potential transcriptional factor(s) interacting with the cis-acting elements of the minimal promoter were also studied by gel electrophoretic mobility shift assays and DNase I footprinting. Combined analyses of the minimal promoter by DNase I footprinting, electrophoretic mobility shift assays, and super shift assays with specific antibodies revealed that 5'-flanking regions from -161 to -154 and from -26 to -13 of the Msx-1 promoter contains an authentic E box (proximal E box), capable of binding a protein immunologically related to the upstream stimulating factor 1 (USF-1) and a CC-rich sequence motif which can bind to Sp1 (proximal Sp1), respectively, Additionally, we observed that the promoter activation was seriously hampered if the proximal. E box was removed or mutated, and the promoter activity was eliminated completely if the proximal sp1 site was similarly altered, Absolute dependence of the Msx-1 minimal promoter on Sp1 could be demonstrated by transient expression assays in the Sp1-deficient Drosophila cell line cotransfected with Msx-1-luciferase and an Sp1 expression vector pPacSp1, The transgenic mice embryos containing -165/106-bp Msx-1 promoter-LacZ DNA in their genomes abundantly expressed beta-galactosidase in maxillae and mandibles and in the cellular primordia involved in the formation of the meninges and the bones of the skull, Thus, the truncated murine Msx-1 promoter can target expression of a heterologous gene in the craniofacial tissues of transgenic embryos known for high level of expression of the endogenous Msx-1 gene and found to be severely defective in the Msx-1 knock-out mice.	DEPT VET AFFAIRS MED CTR,RES SERV 151,MEMPHIS,TN 38104; UNIV TENNESSEE,COLL MED,DEPT PHARMACOL,MEMPHIS,TN 38163; UNIV TENNESSEE,COLL MED,DEPT MED,MEMPHIS,TN 38163	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center					NIAMS NIH HHS [AR-39166] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039166] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; ARMENDARIZBORUNDA J, 1994, BIOCHEM J, V304, P817, DOI 10.1042/bj3040817; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELL JR, 1993, GENOMICS, V16, P123, DOI 10.1006/geno.1993.1149; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COELHO CND, 1991, DEVELOPMENT, V113, P1487; COELHO CND, 1993, DEV BIOL, V156, P303, DOI 10.1006/dbio.1993.1078; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GEHRING WJ, 1992, TRENDS BIOCHEM SCI, V17, P277, DOI 10.1016/0968-0004(92)90434-B; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HOGAN B, 1994, MANIPULATING MOUSE E, P1; HOLLAND PWH, 1991, GENE, V98, P253, DOI 10.1016/0378-1119(91)90182-B; HOLLAND PWH, 1994, DEVELOPMENT, P125; IGNATIUSOU SH, 1994, J VIROL, V68, P7188; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KESSEL M, 1990, SCIENCE, V249, P4374; KRABBENHOFT KM, 1992, DEV DYNAM, V194, P52, DOI 10.1002/aja.1001940107; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUZUOKA M, 1994, GENOMICS, V21, P85, DOI 10.1006/geno.1994.1228; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEVINE EM, 1993, P NATL ACAD SCI USA, V90, P2729, DOI 10.1073/pnas.90.7.2729; MacKenzie A, 1997, MECH DEVELOP, V62, P29, DOI 10.1016/S0925-4773(96)00646-6; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MACKENZIE A, 1991, DEVELOPMENT, V113, P601; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MANAK JR, 1994, DEVELOPMENT, P61; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MUNEOKA K, 1992, DEV BIOL, V152, P37, DOI 10.1016/0012-1606(92)90154-9; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SATOKATA I, 1994, NAT GENET, V6, P3248; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SIMON HG, 1995, DEV DYNAM, V202, P1, DOI 10.1002/aja.1002020102; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SU MW, 1991, DEVELOPMENT, V111, P1179; TAKAHASHI Y, 1990, P NATL ACAD SCI USA, V87, P7482, DOI 10.1073/pnas.87.19.7482; Wang QJ, 1996, MOL CELL BIOCHEM, V158, P33; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	75	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22667	22678		10.1074/jbc.272.36.22667	http://dx.doi.org/10.1074/jbc.272.36.22667			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278425	hybrid			2022-12-25	WOS:A1997XV49200045
J	Breyton, C; Tribet, C; Olive, J; Dubacq, JP; Popot, JL				Breyton, C; Tribet, C; Olive, J; Dubacq, JP; Popot, JL			Dimer to monomer conversion of the cytochrome b(6)f complex - Causes and consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; PHOTOSYNTHETIC REACTION-CENTER; CHLAMYDOMONAS-REINHARDTII; C REDUCTASE; 3-DIMENSIONAL STRUCTURE; PHOTOSYSTEM-II; B6-F COMPLEX; BOVINE HEART; BF COMPLEX; RHODOPSEUDOMONAS-VIRIDIS	The molecular weight of the cytochrome b(6)f complex purified from Chlamydomonas reinhardtii thylakoid membranes has been determined by combining velocity sedimentation measurements, molecular sieving analyses, and determination of its lipid and detergent content. The complex in its enzymatically active form is a dimer. Upon incubation in detergent solution, it converts irreversibly into an inactive, monomeric form that has lost the Rieske iron-sulfur protein, the b(6)f-associated chlorophyll, and, under certain conditions, the small 32-residue subunit PetL. The results are consistent with the view that the dimer is the predominant form of the b(6)f in situ while the monomer observed in detergent solution is a breakdown product. Indirect observations suggest that subunit PetL plays a role in stabilizing the dimeric state. Delipidation is shown to be a critical factor in detergent-induced monomerization.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; UNIV PARIS 07,CNRS UPR 9052,F-75005 PARIS,FRANCE; ECOLE SUPER PHYS & CHIM IND VILLE PARIS,F-75231 PARIS 05,FRANCE; UNIV PARIS 06,CNRS URA 278,F-75231 PARIS 05,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,CNRS UMR 9922,F-75251 PARIS 05,FRANCE; ECOLE NORMALE SUPER,CNRS URA 1810,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)			TRIBET, Christophe/N-3390-2019; TRIBET, christophe/C-2868-2008	TRIBET, Christophe/0000-0002-5953-0968; TRIBET, christophe/0000-0002-5953-0968				ADAM Z, 1987, FEBS LETT, V225, P67, DOI 10.1016/0014-5793(87)81132-8; Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; ATTEIA A, 1994, CR ACAD SCI III-VIE, V317, P11; ATTEIA A, 1992, J BIOL CHEM, V267, P226; Bald D., 1992, RES PHOTOSYNTHESIS, VI, P629; BECHMANN G, 1992, EUR J BIOCHEM, V208, P315, DOI 10.1111/j.1432-1033.1992.tb17189.x; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BREYTON C, 1995, PHOTOSYNTHESIS LIGHT, V2, P591; CHAIN RK, 1985, FEBS LETT, V180, P321, DOI 10.1016/0014-5793(85)81095-4; Chain RK, 1995, PHOTOSYNTH RES, V46, P419, DOI 10.1007/BF00032296; CHAIN RK, 1991, PHOTOSYNTH RES, V28, P59, DOI 10.1007/BF00033715; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; CRAMER WA, 1987, LIGHT REACTIONS, P447; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P263; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DEMANDRE C, 1986, BIOCHIM BIOPHYS ACTA, V877, P380, DOI 10.1016/0005-2760(86)90203-1; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; DEVRIES S, 1986, J BIOENERG BIOMEMBR, V18, P195, DOI 10.1007/BF00743464; ENGEL WD, 1983, EUR J BIOCHEM, V132, P395, DOI 10.1111/j.1432-1033.1983.tb07376.x; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; GRAAN T, 1986, ARCH BIOCHEM BIOPHYS, V248, P445, DOI 10.1016/0003-9861(86)90497-2; GUTIERREZCIRLOS EB, 1994, J BIOL CHEM, V269, P9147; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HOVMOLLER S, 1981, FEBS LETT, V123, P118, DOI 10.1016/0014-5793(81)80033-6; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, FEBS LETT, V134, P1, DOI 10.1016/0014-5793(81)80537-6; HURT E, 1981, EUR J BIOCHEM, V117, P591; Ketchner SL, 1996, BBA-BIOENERGETICS, V1273, P195, DOI 10.1016/0005-2728(95)00157-3; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; LINKE P, 1986, EUR J BIOCHEM, V158, P615, DOI 10.1111/j.1432-1033.1986.tb09799.x; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MATAGNE RF, 1989, J CELL BIOL, V108, P1221, DOI 10.1083/jcb.108.4.1221; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; METCALFE LD, 1966, ANAL CHEM, V38, P514, DOI 10.1021/ac60235a044; Moller J. V., 1986, PROGR PROTEIN LIPID, P147; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; MORSCHEL E, 1983, J CELL BIOL, V97, P301, DOI 10.1083/jcb.97.2.301; MOSSER G, 1997, IN PRESS J BIOL CHEM, V272; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P13005, DOI 10.1021/bi00248a009; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V240, P921; NIEBOER P, 1992, BIOCHIM BIOPHYS ACTA, V1011, P90; NUGENT JHA, 1987, BIOCHIM BIOPHYS ACTA, V893, P177, DOI 10.1016/0005-2728(87)90037-5; ORTIZ W, 1985, BIOCHIM BIOPHYS ACTA, V808, P164, DOI 10.1016/0005-2728(85)90039-8; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; POPOT JL, 1981, EUR J BIOCHEM, V118, P203; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; POPOT JL, 1995, PHOTOSYNTHESIS LIGHT, V2, P507; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; RIVAS E, 1980, BIOCHEMISTRY-US, V19, P2943, DOI 10.1021/bi00554a020; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHMIDT CL, 1993, PHOTOSYNTH RES, V38, P73, DOI 10.1007/BF00015063; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SHIMOMURA Y, 1984, J BIOL CHEM, V259, P4059; SHIMOMURA Y, 1984, BIOCHEM INT, V8, P187; SONE N, 1990, BIOCHIM BIOPHYS ACTA, V1020, P207, DOI 10.1016/0005-2728(90)90052-6; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; TSIOTIS G, 1992, RES PHOTOSYNTHESIS, V2, P511; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VALPUESTA JM, 1985, BIOCHIM BIOPHYS ACTA, V807, P96, DOI 10.1016/0005-2728(85)90056-8; WEISS H, 1979, EUR J BIOCHEM, V99, P139, DOI 10.1111/j.1432-1033.1979.tb13240.x; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WOLLMAN FA, 1980, J CELL BIOL, V87, P728, DOI 10.1083/jcb.87.3.728; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; ZHANG H, 1986, J BIOL CHEM, V271, P31360	78	125	126	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21892	21900		10.1074/jbc.272.35.21892	http://dx.doi.org/10.1074/jbc.272.35.21892			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268322	hybrid			2022-12-25	WOS:A1997XT85000034
J	Ichiba, T; Kuraishi, Y; Sakai, O; Nagata, S; Groffen, J; Kurata, T; Hattori, S; Matsuda, M				Ichiba, T; Kuraishi, Y; Sakai, O; Nagata, S; Groffen, J; Kurata, T; Hattori, S; Matsuda, M			Enhancement of guanine-nucleotide exchange activity of C3G for Rap1 by the expression of Crk, CrkL, and Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT MANNER; GTP-BINDING PROTEIN; COMPLEXES IN-VIVO; SH3 DOMAINS; TYROSINE PHOSPHORYLATION; PC12 CELLS; KINETIC-PROPERTIES; MOLECULAR-CLONING; ADAPTER PROTEIN; ENCODE PROTEINS	Crk is an adaptor protein that consists almost entirely of SH2 and SH3 domains, We have previously demonstrated, by using in vivo and in vitro systems, that C3G, which was identified as a Crk SH3 domain-binding guanine nucleotide exchange factor, specifically activates Rap1, C3G also binds to other adaptor proteins, including CrkL and Grb2. In the present study, we analyzed the effect of Crk, CrkL, and Grb2 on the C3G-Rap1 pathway, Expression of Crk, CrkL, and Grb2 with C3G in Cos1 cells significantly increased the ratio of GTP/GDP bound to Rap1, Both the SH2 and SH3 domains of Crk were required for this activity, However, Crk did not stimulate the guanine nucleotide exchange activity of C3G for Rap1 in vitro, suggesting that Crk does not activate C3G by an allosteric mechanism. The requirement of the SH2 domain of Crk for the enhancement of guanine nucleotide exchange activity for Rap1 could be compensated for by the addition of a farnesylation signal to Crk, indicating that Crk enhanced the guanine nucleotide exchange activity of C3G by membrane recruitment of C3G, These results demonstrate that Crk, CrkL, and Grb2 positively modulate the C3G-Rap1 pathway primarily by recruiting C3G to the cell membrane.	NATL INST HLTH,DEPT PATHOL,SHINJUKU KU,TOKYO 162,JAPAN; JIKEI UNIV,SCH MED,DEPT INTERNAL MED 3,MINATO KU,TOKYO 105,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; INT MED CTR JAPAN,DEPT PATHOL,RES INST,SHINJUKU KU,TOKYO 162,JAPAN; CHILDRENS HOSP,DEPT PATHOL,SECT MOL CARCINOGENESIS,LOS ANGELES,CA 90027	Jikei University; National Center for Neurology & Psychiatry - Japan; National Center for Global Health & Medicine - Japan; Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012; Nagata, Satoshi/B-5781-2008	Heisterkamp, Nora/0000-0003-2769-2273; Nagata, Satoshi/0000-0001-9156-5215; Matsuda, Michiyuki/0000-0002-5876-9969				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HATA Y, 1991, J BIOL CHEM, V266, P6571; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; NAKANISHI H, 1994, BIOCHEM BIOPH RES CO, V198, P1255, DOI 10.1006/bbrc.1994.1177; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ORITA S, 1993, J BIOL CHEM, V268, P25542; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIZON V, 1988, ONCOGENE, V3, P201; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAKODA T, 1992, ONCOGENE, V7, P1705; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; WEINECKE R, 1995, J BIOL CHEM, V270, P16409; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	46	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22215	22220		10.1074/jbc.272.35.22215	http://dx.doi.org/10.1074/jbc.272.35.22215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268367	hybrid			2022-12-25	WOS:A1997XT85000079
J	Wissink, S; vanHeerde, EC; Schmitz, ML; Kalkhoven, E; vanderBurg, H; Baeuerle, PA; vanderSaag, PT				Wissink, S; vanHeerde, EC; Schmitz, ML; Kalkhoven, E; vanderBurg, H; Baeuerle, PA; vanderSaag, PT			Distinct domains of the RelA NF-kappa B subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL ACTIVATION; P65 SUBUNIT; TRANSACTIVATION DOMAIN; DNA; PROTEIN; P50; IMMUNOSUPPRESSION; COACTIVATORS; REPRESSION	The RelA subunit of NF-kappa B and the glucocorticoid receptor mutually repress each others transcriptional activity, thus providing a mechanism for immunosuppression, Deletion analysis of the glucocorticoid receptor has shown that the DNA binding domain and the ligand binding domain are essential components for repression, Here, we show by deletions and point mutations that both the Rel homology domain and the transactivation domains of RelA are required for repression of the transcriptional activity of the glucocorticoid receptor in intact cells, However, only the Rel homology domain of RelA was found to associate with the glucocorticoid receptor in vitro. RelA mutants, not able to repress glucocorticoid receptor activity, but still able to dimerize, behaved as transdominant inhibitors of the repressive activity of wild type RelA. Furthermore, we show that the 13 S E1A protein is able to interfere with the transrepressive activity of RelA. We propose that negative cross-talk between the glucocorticoid receptor and RelA is due to direct interaction via the Rel homology domain of RelA and the DNA binding domain of the glucocorticoid receptor in combination with interference by the transactivation domains of RelA with the transcriptional activity of the glucocorticoid receptor.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; UNIV FREIBURG,INST BIOCHEM & MOL BIOL,FREIBURG,GERMANY	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of Freiburg			Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHMITZ ML, 1996, MOL CELL BIOL, V15, P4052; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185	35	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22278	22284		10.1074/jbc.272.35.22278	http://dx.doi.org/10.1074/jbc.272.35.22278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268377	hybrid			2022-12-25	WOS:A1997XT85000089
J	Ziebold, U; Klempnauer, KH				Ziebold, U; Klempnauer, KH			Linking Myb to the cell cycle: cyclin-dependent phosphorylation and regulation of A-Myb activity	ONCOGENE			English	Article						A-myb; cell cycle; cyclins A and E; phosphorylation; transactivation	DNA-POLYMERASE-ALPHA; PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; S-PHASE; C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATOR; MAMMALIAN FIBROBLASTS; GENE-EXPRESSION; G(1) CYCLINS	A-myb, a conserved member of the Myb proto-oncogene family, encodes a sequence-specific DNA binding protein (A-Myb) that binds to and transactivates promoters containing myb-binding sites, Previous work has suggested that the C-terminus of A-Myb functions as a regulatory domain, however, the physiological signals that control the activity of A-Myb have not yet been identified, The presence of potential phosphorylation sites for cyclin-dependent kinases in the C-terminus of A-Myb has prompted us to examine the possibility that the function of A-Myb is controlled by the cell cycle. We here show that the transactivation potential of A-Myb is repressed by the C-terminal domain and that phosphorylation of A-Myb, induced by cyclins A and E, relieves this inhibitory effect, Our work provides the first evidence that the function of A-Myb is regulated by the cell cycle machinery and that the carboxy-terminal domain of A-Myb acts as a cell cycle sensor, In addition, we show that A-myb mRNA expression is also cell cycle regulated and attains maximal levels during the late G(1)- and early S-phase, Thus, A-Myb appears to be controlled by two different mechanisms maximal A-Myb activity during the G(1)/S-transition and the S-phase of the cell cycle.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; UNIV FREIBURG,KINDERKLIN,D-79106 FREIBURG,GERMANY	Max Planck Society; University of Freiburg			Ziebold, Ulrike/N-4487-2013					AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FOOS G, 1994, ONCOGENE, V9, P2481; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Golay J, 1996, BLOOD, V87, P1900; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Latham KE, 1996, ONCOGENE, V13, P1161; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MASSAGUE J, 1995, CURR OPIN CELL BIOL, V7, P769, DOI 10.1016/0955-0674(95)80059-X; METTUS RV, 1994, ONCOGENE, V9, P3077; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Sitzmann J, 1996, ONCOGENE, V12, P1889; Sitzmann J, 1995, ONCOGENE, V11, P2273; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5894; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	56	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1011	1019		10.1038/sj.onc.1201282	http://dx.doi.org/10.1038/sj.onc.1201282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285555				2022-12-25	WOS:A1997XT16100002
J	Maier, D; Comparone, D; Taylor, E; Zhang, ZW; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A				Maier, D; Comparone, D; Taylor, E; Zhang, ZW; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A			New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26	ONCOGENE			English	Article						oligodendroglioma; glioblastoma suppressor gene; deletion mapping; chromosome 10q25-26	HUMAN-BRAIN-TUMORS; HUMAN GLIOMAS; GENE; HETEROZYGOSITY; RETINOBLASTOMA; MUTATIONS; ORIGIN	Loss of heterozygosity on chromosome 10 is considered to be associated with the progression of glioblastomas. Two closely related regions have recently been proposed to contain the glioblastoma suppressor locus on chromosome 10q25-26; a 1 cM region between the polymorphic (CA)(n)-repeat markers D10S587 and D10S216, and an area of 5 cM between the markers D10S221 and D10S209, To confirm and further delineate this region, we analyzed 51 glioblastomas and 11 intermediate and low-grade gliomas for loss of heterozygosity on chromosome 10, 47/62 mostly malignant gliomas displayed complete loss of chromosome 10 and nine tumors were unaltered, whereas four glioblastomas and two low-grade oligodendrogliomas had partial loss on distal 10q, With these six tumors, we constructed a deletion map with increased marker density at 10q25-26 which shows two centromeric breakpoints at the markers D10S587 and D10S216, thus only confirming the distal, but not the proximal candidate glioblastoma suppressor locus, Two out of four low-grade oligodendrogliomas displayed partial deletions on 10q25-26, This suggests that deletion on chromosome 10 is not merely a late event in the progression of glioblastomas, but could play a role earlier in the development of gliomas.	UNIV BASEL HOSP, DEPT RES, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT NEUROSURG, CH-4031 BASEL, SWITZERLAND; CHU VAUDOIS, LAB TUMOR BIOL & GENET, DEPT NEUROSURG, UNIV HOSP, CH-1011 LAUSANNE, SWITZERLAND	University of Basel; University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Scott, Rodney J/B-2827-2013	Scott, Rodney J/0000-0001-7724-3404; Van Meir, Erwin G./0000-0003-2444-7707				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GYAPAY G, 1994, NAT GENET, V7, P294; JAMES CD, 1988, CANCER RES, V48, P5546; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; Kleihues P, 1993, HISTOLOGICAL TYPING; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MERLO A, 1994, CANCER RES, V54, P640; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; VENTER DJ, 1991, BRIT J CANCER, V63, P753, DOI 10.1038/bjc.1991.168; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WU JK, 1993, J NEURO-ONCOL, V15, P29, DOI 10.1007/BF01050260	23	44	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					997	1000		10.1038/sj.onc.1201209	http://dx.doi.org/10.1038/sj.onc.1201209			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285695				2022-12-25	WOS:A1997XR76700013
J	Larsson, LG; Bahram, F; Burkhardt, H; Luscher, B				Larsson, LG; Bahram, F; Burkhardt, H; Luscher, B			Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells	ONCOGENE			English	Article						cell growth control; c-Myc; Mad1; oncoprotein	CASEIN KINASE-II; C-MYC PROTEIN; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; OPPOSITE REGULATION; ONCOGENIC ACTIVITY; REPRESSOR SIN3; MAX; MXI1; TRANSFORMATION	The bHLHZip protein Max interacts with both the Myc and Mad family proteins forming heterodimers which specifically bind certain E-box DIVA recognition sequences, thereby regulating transcription, Whereas Myc proteins actively promote cell proliferation, Mad complexes have the opposite function, Although the main regulation of this network seems to be the control of myc- and mad family gene expression, regulation at the level of DNA-binding and transactivation may also be in operation, Few studies on the DNA-binding activity of native Myc:Max or Max:Mad complexes have been reported mainly due to technical difficulties, To overcome these problems we have developed a specific and sensitive solid phase DNA-binding assay based on partial purification of native Myc, Max and Mad1 complexes by immunological methods, Using this technique we report that the DNA-binding activity of c-Myc-containing complexes is reduced during induced differentiation of U-937 monoblasts and F9 embryonic teratocarcinoma cells. In contrast, the DNA-binding of Mad1-containing complexes increases during monocytic differentiation, In general, the DNA-binding activity of c-Myc and Mad1 correlate with their expression, However, our studies of early kinetics of TPA-induced differentiation of U-937 cells as well as of late events during F9 differentiation suggest that post-translational regulation of Myc and Max DNA-binding may also occur. The solid phase DNA-binding assay may thus provide a tool to study the regulation of DNA-binding in more detail.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School	Larsson, LG (corresponding author), UNIV UPPSALA,DEPT PATHOL,LAB TUMOR BIOL,S-75185 UPPSALA,SWEDEN.		Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; CERNI C, 1995, ONCOGENE, V11, P587; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DELGADO MD, 1995, ONCOGENE, V10, P1659; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAN T, 1980, J CLIN LAB IMMUNOL, V4, P169; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIHARA H, 1974, NATL I ANIM HEALTH Q, V14, P163; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1994, ONCOGENE, V9, P1247; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nilsson K., 1980, INT S NEW TRENDS HUM, P271; NISHIKORI M, 1984, CANCER GENET CYTOGEN, V12, P39, DOI 10.1016/0165-4608(84)90006-2; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	52	34	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					737	748		10.1038/sj.onc.1201390	http://dx.doi.org/10.1038/sj.onc.1201390			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264414				2022-12-25	WOS:A1997XP68300013
J	Miller, RA; Chrisp, C; Galecki, A				Miller, RA; Chrisp, C; Galecki, A			CD4 memory T cell levels predict life span in genetically heterogeneous mice	FASEB JOURNAL			English	Article						T lymphocytes; memory T cells; aging; mice; longevity	PERIPHERAL-BLOOD; P-GLYCOPROTEIN; SUBSETS; AGE; LYMPHOCYTES; EXPRESSION; NUMBERS	Aging leads to changes in the relative proportions of several functionally distinct T cell subsets, including increases in the proportions of memory cells in the CD4 and CD8 subsets and in the proportion of T cells expressing the multiple-drug resistance pump P-glycoprotein. To see whether individual differences in T cell subset levels predict Life span, we measured the levels of five age-sensitive T cell subsets, at 8 and again at 18 months of age, in the peripheral blood of genetically heterogeneous mice bred as the progeny of CBGF1 females and C3D2F1 males. The strongest immunological predictor of Life span in univariate regression analyses was the proportion of CD4 memory cells measured at 18 months of age (P=0.003). CD4 memory cell levels remained strongly correlated with life span (P<0.0003) in a multiple regression analysis after adjustment for sex. The proportion of CD4 cells expressing P-glycoprotein was also correlated with life span (P<0.01), but only in male mice. Weaker relationships were observed between life span and 8-month tests of CD8 memory and CD8 P-glycoprotein levels, for CD4 naive cells at 18 months, and for the change in CD4 naive cells between 8 and 18 months of age; these were, however, near the margin of statistical significance and could reflect chance relationships. The relationship between CD4 memory cell levels and life span was similarly strong regardless of the cause of death in mice whose death was attributable to lymphoma, fibrosarcoma, mammary carcinoma, and other forms of terminal pathology. Additional work is needed to discriminate between two hypotheses: 1) that high levels of CD4 memory cell themselves predispose to disease and early death, particularly from neoplasia; or 2) that accumulation of CD4 memory cells is a biomarker of some underlying process process-perhaps accelerated aging-that itself leads to early mortality.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,UNIT LAB ANIM MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,ANN ARBOR DVA MED CTR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE ON AGING [R01AG011687, P60AG008808, R01AG011067, P30AG008808] Funding Source: NIH RePORTER; NIA NIH HHS [AG08808, AG11067, AG11687] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER GT, 1988, EXP GERONTOL, V23, P223, DOI 10.1016/0531-5565(88)90025-3; Bining N, 1997, J GERONTOL A-BIOL, V52, pB137, DOI 10.1093/gerona/52A.3.B137; BOERSMA WJA, 1985, CELL IMMUNOL, V93, P417, DOI 10.1016/0008-8749(85)90146-7; Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; Chrisp CE, 1996, VET PATHOL, V33, P735, DOI 10.1177/030098589603300620; COSTA PT, 1988, ARCH GERONTOL GERIAT, V7, P211, DOI 10.1016/0167-4943(88)90003-9; COSTA PT, 1995, HDB PHYSL 11; COVELLI V, 1989, J IMMUNOL, V142, P1224; ERNST DN, 1990, J IMMUNOL, V145, P1295; ERSHLER WB, 1993, J GERONTOL, V48, pB3, DOI 10.1093/geronj/48.1.B3; EVERITT JI, 1988, LAB ANIM SCI, V38, P609; FERGUSON FG, 1995, J GERONTOL A-BIOL, V50, pB378, DOI 10.1093/gerona/50A.6.B378; FLURKEY K, 1992, EUR J IMMUNOL, V22, P931, DOI 10.1002/eji.1830220408; GROSSMANN A, 1991, CELL IMMUNOL, V135, P118, DOI 10.1016/0008-8749(91)90259-E; HIROKAWA K, 1989, MECH AGEING DEV, V49, P49, DOI 10.1016/0047-6374(89)90067-5; LERNER A, 1989, EUR J IMMUNOL, V19, P977, DOI 10.1002/eji.1830190604; MASORO EJ, 1995, HDB PHYSL 11; MILLER RA, 1994, J GERONTOL, V49, pB255, DOI 10.1093/geronj/49.6.B255; MILLER RA, 1997, IN PRESS MECH AGEING; MILLER RA, 1996, J GERONTOL A-BIOL, V52, pB39; Miller Richard A., 1995, P555; MURASKO D M, 1988, Aging Immunology and Infectious Disease, V1, P1; NAKAMURA E, 1994, EXP GERONTOL, V29, P151, DOI 10.1016/0531-5565(94)90048-5; PILARSKI LM, 1991, J IMMUNOL, V147, P830; RAO CR, 1973, LINEAR STATISTICAL I; ROBERTST.IC, 1974, LANCET, V2, P368; SERRA HM, 1988, J IMMUNOL, V140, P1435; Short R, 1997, J GERONTOL A-BIOL, V52, pB26, DOI 10.1093/gerona/52A.1.B26; TUFFERY AA, 1966, J PATHOL BACTERIOL, V91, P301, DOI 10.1002/path.1700910203; UTSUYAMA M, 1992, MECH AGEING DEV, V63, P57, DOI 10.1016/0047-6374(92)90016-7; WAYNE SJ, 1990, J GERONTOL, V45, pM45, DOI 10.1093/geronj/45.2.M45; WITKOWSKI JM, 1994, J IMMUNOL, V153, P658; WITKOWSKI JM, 1993, J IMMUNOL, V150, P1296	33	53	53	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					775	783		10.1096/fasebj.11.10.9271362	http://dx.doi.org/10.1096/fasebj.11.10.9271362			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271362	Green Submitted			2022-12-25	WOS:A1997XR10500007
J	Jezek, P; Costa, ADT; Vercesi, AE				Jezek, P; Costa, ADT; Vercesi, AE			Reconstituted plant uncoupling mitochondrial protein allows for proton translocation via fatty acid cycling mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE OXIDASE; 5-DOXYL-STEARIC ACID; EPR SPECTROSCOPY; ADP/ATP CARRIER; ANION CHANNEL; TRANSPORT; CONDUCTANCE; SENESCENCE; MEMBRANES; LIPOSOMES	Potato and tomato plant uncoupling mitochondrial protein (PUMP) was reconstituted into liposomes, and K+ or H+ fluxes associated with fatty acid (FA)-induced ion movement were measured using fluorescent ion indicators potassium binding benzofuraneisophthalate and 6-methoxy-N-(3-sulfopropyl)-quinolinium. We suggest that PUMP, like its mammalian counterpart, the uncoupling protein of brown adipose tissue mitochondria (Garlid, K. D., Orosz, D. E., Modriansky, M., Vassanelli, S,, and Jezek, P, (1996), J, Biol, Chem, 271, 2615-2702), allows for H+ translocation via a FA cycling mechanism. Reconstituted PUMP translocated anionic linoleic: and heptylbenzoic acids, undecanesulfonate, and hexanesulfonate, but not phenylvaleric and abscisic acids or Cl-. Transport was inhibited by ATP and GDP. Internal acidification of protein-free liposomes by linoleic or heptylbenzoic acid indicated that H+ translocation occurs by FA flip-flopping across the lipid bilayer. However, addition of valinomycin after FA-initiated GDP-sensitive H+ efflux solely in proteoliposomes, indicating that influx of anionic: FA via PUMP precedes a return of protonated FA carrying, H+, Phenylvaleric acid, unable to flip-flop, was without effect, Kinetics of FA and undecanesulfonate uniport; suggested the existence of an internal anion binding site. Exponential flux-voltage characteristics were also studied, We suggest that regulated uncoupling in plant mitochondria may be important during-fruit ripening senescence, and seed dormancy.	UNIV ESTADUAL CAMPINAS,FAC CIENCIAS MED,DEPT PATOL CLIN,SAO PAULO,BRAZIL	Universidade Estadual de Campinas	Jezek, P (corresponding author), ACAD SCI CZECH REPUBL,INST PHYSIOL,DEPT MEMBRANE TRANSPORT BIOPHYS,VIDENSKA 1083,DEPT 375,CR-14220 PRAGUE 4,CZECH REPUBLIC.		Costa, Alexandre Augusto da/HCJ-0140-2022; Jezek, Petr/B-9264-2012; Vercesi, Aníbal E/C-8767-2012	Costa, Alexandre Augusto da/0000-0001-7558-5435; Jezek, Petr/0000-0002-2720-9395; Dias Tavares Costa, Alexandre/0000-0001-8434-2152; Vercesi, Anibal Eugenio/0000-0001-6671-7125				ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; CRUZHERNANDEZ A, 1995, PLANTA, V197, P569, DOI 10.1007/BF00191562; DAY DA, 1995, J BIOENERG BIOMEMBR, V27, P379, DOI 10.1007/BF02110000; Eyring H., 1963, MODERN CHEM KINETICS; Freisleben HJ, 1995, CHEM PHYS LIPIDS, V78, P137, DOI 10.1016/0009-3084(95)02491-Z; GARDESTROM P, 1995, J BIOENERG BIOMEMBR, V27, P415, DOI 10.1007/BF02110004; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P141; HULME AC, BIOCH FRUITS THEIR P; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; JEZEK P, 1990, J BIOL CHEM, V265, P19303; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; JEZEK P, 1990, J BIOL CHEM, V265, P10522; JEZEK P, 1995, FEBS LETT, V361, P303, DOI 10.1016/0014-5793(95)00201-J; JEZEK P, 1994, FEBS LETT, V343, P22, DOI 10.1016/0014-5793(94)80599-7; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KIDD F, 1925, 27 GREAT BRIT DEP SC; KRAB K, 1995, J BIOENERG BIOMEMBR, V27, P387, DOI 10.1007/BF02110001; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LAUGER P, 1970, BIOCHIM BIOPHYS ACTA, V211, P458, DOI 10.1016/0005-2736(70)90251-8; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; OROSZ DE, 1993, ANAL BIOCHEM, V150, P97; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; Ruzicka M, 1996, FEBS LETT, V382, P239, DOI 10.1016/0014-5793(96)00161-5; Schonfeld P, 1996, EUR J BIOCHEM, V240, P387, DOI 10.1111/j.1432-1033.1996.0387h.x; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SMART CM, 1994, NEW PHYTOL, V126, P419, DOI 10.1111/j.1469-8137.1994.tb04243.x; SOOLE KL, 1995, J BIOENERG BIOMEMBR, V27, P397, DOI 10.1007/BF02110002; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0	36	68	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24272	24278		10.1074/jbc.272.39.24272	http://dx.doi.org/10.1074/jbc.272.39.24272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305881	hybrid			2022-12-25	WOS:A1997XY51500032
J	Ji, ZS; Hadac, EM; Henne, RM; Patel, SA; Lybrand, TP; Miller, LJ				Ji, ZS; Hadac, EM; Henne, RM; Patel, SA; Lybrand, TP; Miller, LJ			Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTAGONIST BINDING DOMAINS; PROTEIN-COUPLED RECEPTORS; P NK-1 RECEPTOR; ADRENERGIC-RECEPTOR; AMINO-ACID; TRANSMEMBRANE DOMAIN; CCK RECEPTORS; SHORT PROBES; SUBSTANCE-P; B RECEPTOR	Mechanisms of ligand binding and activation of G protein-coupled receptors are particularly important, due to their ubiquitous expression and potential as drug targets, Molecular interactions between ligands and these receptors are best defined for small molecule ligands that bind within the transmembrane helices, Extracellular domains seem to be more important for peptide ligands, based largely on effects of receptor mutagenesis, where interference with binding or activity can reflect allosteric as well as direct effects, We now take the more direct approach of photoaffinity labeling the active site of the cholecystokinin (CCK) receptor, using a photolabile analogue of CCK having a blocked amino terminus, This probe, I-125-desaminotyrosyl-Gly-[Nle(28,31),pNO(2)-Phe(33)]CCK-(26-33), binds specifically, saturably, and with high affinity (K-i = 3.3 nM) and has full agonist activity, This makes likely its being sited in a natural position within the receptor, As substrate, we used CHO-CCK receptor cells overexpressing functional recombinant rat type A CCK receptor, Covalent labeling of the appropriate M-r = 85,000-95,000 plasma membrane glycoprotein with core of M-r = 42,000 was established by SDS-polyacrylamide gel electrophoresis and autoradiography, A single domain adjacent to transmembrane 1 was labeled, as established by cyanogen bromide cleavage and separation by gel and/or high pressure liquid chromatography, The site of interaction was further defined by additional proteolysis with trypsin, with purification of the labeled fragment, followed by manual Edman degradation and radiochemical sequencing, This demonstrated that Trp(39) was specifically labeled and likely resides proximate to the carboxyl-terminal pNO(2)-Phe(33) residue of the probe. A model of this ligand-bound receptor has been constructed and will be used to plan future experiments to refine our understanding of this interaction.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905; UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195	Mayo Clinic; University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK32878] Funding Source: Medline; NINDS NIH HHS [NS33290] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033290] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BLUML K, 1994, J BIOL CHEM, V269, P18870; BODANSZKY M, 1980, INT J PEPT PROT RES, V16, P402; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; FONG TM, 1992, J BIOL CHEM, V267, P25664; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG SC, 1989, PEPTIDES, V10, P785, DOI 10.1016/0196-9781(89)90114-9; JAGERSCHMIDT A, 1995, MOL PHARMACOL, V48, P783; JI H, 1994, J BIOL CHEM, V269, P16533; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KLUEPPELBERG UG, 1989, BIOCHEMISTRY-US, V28, P3463, DOI 10.1021/bi00434a047; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; Kontoyianni M, 1996, J MED CHEM, V39, P4406, DOI 10.1021/jm960241a; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABBEJULLIE C, 1995, MOL PHARMACOL, V47, P1050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MAMMI S, 1986, INT J PEPT PROT RES, V27, P145; MANTAMADIOTIS T, 1994, BIOCHEM BIOPH RES CO, V201, P1382, DOI 10.1006/bbrc.1994.1856; MORLEY JS, 1968, PROC R SOC SER B-BIO, V170, P97, DOI 10.1098/rspb.1968.0028; MUTT V, 1980, GASTROINTESTINAL HOR, P169; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; PEARLMAN DA, 1991, AMBER VERSION 4 1; PEARSON RK, 1987, BIOCHEM BIOPH RES CO, V147, P346, DOI 10.1016/S0006-291X(87)80128-6; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEARSON RK, 1987, J BIOL CHEM, V262, P869; POWERS SP, 1991, BIOCHEMISTRY-US, V30, P676, DOI 10.1021/bi00217a013; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; POWERS SP, 1988, J BIOL CHEM, V263, P5295; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; SWANSON E, 1995, PSSHOW SILICON GRAPH; TAKASUKA T, 1994, J BIOL CHEM, V269, P7509; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VINAYEK R, 1987, AM J PHYSIOL, V252, pG178, DOI 10.1152/ajpgi.1987.252.2.G178; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1988, J BIOL CHEM, V263, P7925	50	103	105	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24393	24401		10.1074/jbc.272.39.24393	http://dx.doi.org/10.1074/jbc.272.39.24393			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305898	hybrid			2022-12-25	WOS:A1997XY51500049
J	Arystarkhova, E; Sweadner, KJ				Arystarkhova, E; Sweadner, KJ			Tissue-specific expression of the Na,K-ATPase beta 3 subunit - The presence of beta 3 in lung and liver addresses the problem of the missing subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE COMPLEXES; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS; ALPHA-SUBUNIT; K+-ATPASE; HEPATIC (NA+,K+)-ATPASE; MONOCLONAL-ANTIBODIES; ENZYMATIC-PROPERTIES; KINETIC-PROPERTIES; ADHESION MOLECULE	The Na,R-ATPase belongs to a family of P-type ion-translocating ATPases sharing homologous catalytic subunits (alpha) that traverse the membrane several times and contain the binding sites for ATP and cations, In this family, only Na,K- and H,K-ATPases have been shown to have a second subunit, a single-span glycoprotein called beta. Recently a new isoform (beta 3) has been identified in mammals. Here we describe structural features and tissue distribution of the beta 3 protein, utilizing an antiserum specific for its N terminus, beta 3 was the only beta detected in Na,K-ATPase purified from C6 glioma, Treatment with N-glycosidase F confirmed that beta 3 is a glycoprotein containing N-linked carbohydrate chains, Molecular masses of the glycosylated protein and core protein were estimated to be 42 and 35 kDa, respectively, which are different from those of the beta 1 and beta 2 subunits. Detection of beta subunits has historically been difficult in certain tissues, Sensitivity was improved by deglycosylating, and expression was evaluated by obtaining estimates of beta 3/alpha ratio. The proportion of beta 3 protein in the rat was highest in lung and testis, It was also present in liver and skeletal muscle, whereas kidney, heart, and brain contained it only as a minor component of the Na,K-ATPase. In P7 rat, we found skeletal muscle and lung Na,K-ATPase to be the most enriched in beta 3 subunit, whereas expression in liver was very low, illustrating developmentally regulated changes in expression. The substantial expression in lung and adult liver very likely explains long-standing puzzles about an apparent paucity of beta subunit in membranes or in discrete cellular or subcellular structures.	MASSACHUSETTS GEN HOSP,CTR NEUROSCI,LAB MEMBRANE BIOL,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital					NINDS NIH HHS [NS27653] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Besirli CG, 1997, BBA-GENE STRUCT EXPR, V1350, P21, DOI 10.1016/S0167-4781(96)00192-3; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CHOW DC, 1995, J EXP BIOL, V198, P1; CRUMP RG, 1995, AM J PHYSIOL-LUNG C, V269, pL299, DOI 10.1152/ajplung.1995.269.3.L299; DESAIYAJNIK V, 1995, ENDOCRINOLOGY, V136, P629, DOI 10.1210/en.136.2.629; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; EMANUEL JR, 1987, P NATL ACAD SCI USA, V84, P9030, DOI 10.1073/pnas.84.24.9030; FAHRIG T, 1990, EUR J NEUROSCI, V2, P153, DOI 10.1111/j.1460-9568.1990.tb00407.x; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GICK GG, 1993, J MEMBRANE BIOL, V131, P229, DOI 10.1007/BF02260111; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HUBERT JJ, 1986, BIOCHEMISTRY-US, V25, P4156, DOI 10.1021/bi00362a025; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; LEFFERT HL, 1985, HEPATOLOGY, V5, P501, DOI 10.1002/hep.1840050327; LEMAS MV, 1993, BIOCHIM BIOPHYS ACTA, V1149, P339; LEVENSON R, 1994, REV PHYSIOL BIOCH P, V123, P1, DOI 10.1007/BFb0030902; LU XP, 1991, J BIOL CHEM, V266, P9276; Malik N, 1996, J BIOL CHEM, V271, P22754, DOI 10.1074/jbc.271.37.22754; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; OBRODOVICH H, 1993, AM J PHYSIOL, V264, pC1137, DOI 10.1152/ajpcell.1993.264.5.C1137; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; PINTER E, 1991, J CLIN INVEST, V87, P821, DOI 10.1172/JCI115085; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SCHNEEBERGER EE, 1986, J APPL PHYSIOL, V60, P1584, DOI 10.1152/jappl.1986.60.5.1584; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SIMON FR, 1995, AM J PHYSIOL-CELL PH, V269, pC69, DOI 10.1152/ajpcell.1995.269.1.C69; Simon FR, 1996, J BIOL CHEM, V271, P24967, DOI 10.1074/jbc.271.40.24967; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SUTHERLAND E, 1988, P NATL ACAD SCI USA, V85, P8673, DOI 10.1073/pnas.85.22.8673; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; TREUHEIT MJ, 1993, J BIOL CHEM, V268, P13914	37	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22405	22408		10.1074/jbc.272.36.22405	http://dx.doi.org/10.1074/jbc.272.36.22405			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278390	hybrid			2022-12-25	WOS:A1997XV49200009
J	Skrincosky, D; Kain, R; ElBattari, A; Exner, M; Kerjaschki, D; Fukuda, M				Skrincosky, D; Kain, R; ElBattari, A; Exner, M; Kerjaschki, D; Fukuda, M			Altered golgi localization of core 2 beta-1,6-N-acetylglucosaminyltransferase leads to decreased synthesis of branched O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; WISKOTT-ALDRICH SYNDROME; HAMSTER OVARY CELLS; MAJOR SIALOGLYCOPROTEIN; LINKED OLIGOSACCHARIDES; LYMPHOBLASTOID-CELLS; MOLECULAR-CLONING; EPITHELIAL-CELLS; CYTOPLASMIC TAIL; MEMBRANE-PROTEIN	Mucin type O-glycans with core 2 branches are distinct from nonbranched O-glycans, and the amount of core 2 branched O-glycans changes dramatically during T cell differentiation. This oligosaccharide is synthesized only when core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT) is present, and the expression of this glycosyltransferase is highly regulated. To understand how O-glycan synthesis is regulated by the orderly appearance of glycosyltransferases that form core 2 branched O-glycans, the subcellular localization of C2GnT was determined by using antibodies generated that are specific to C2GnT. The studies using confocal light microscopy demonstrated that C2GnT was localized mainly in cis to medial-cisternae of the Golgi. We then converted C2GnT to a trans-Golgi enzyme by replacing its Golgi retention signal with that of alpha-2,6-sialyltransferase, which resides in trans-Golgi. Chinese hamster ovary cells expressing wild type C2GnT and the chimeric C2GnT were then subjected to oligosaccharide analysis. The results obtained clearly indicate that the conversion of C2GnT into a trans-Golgi enzyme resulted in a substantial decrease of core 2 branched oligosaccharides. These results, taken together, strongly suggest that the predominance of core 2 branched oligosaccharides in those cells expressing C2GnT is due to the fact; that C2GnT is located earlier in the Golgi than alpha-2,3-sialyltransferase that competes with C2GnT far the common substrate. Furthermore, alteration of Golgi localization renders the chimeric C2GnT much less efficient in synthesizing core 2 branched oligosaccharides, indicating the critical role of orderly subcellular localization of glycosyltransferases.	BURNHAM INST, GLYCOBIOL PROGRAM, LA JOLLA, CA 92037 USA; UNIV MEDITERRANEAN, FAC MED, MARSEILLE 5, FRANCE; UNIV VIENNA, INST CLIN PATHOL, VIENNA, AUSTRIA	Sanford Burnham Prebys Medical Discovery Institute; UDICE-French Research Universities; Aix-Marseille Universite; University of Vienna			Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X	NATIONAL CANCER INSTITUTE [R37CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON LC, 1978, BLOOD, V52, P57; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; BURKE J, 1992, J BIOL CHEM, V267, P24433; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; Fukuda M, 1996, CANCER RES, V56, P2237; FUKUDA MN, 1995, GENE DEV, V9, P1199, DOI 10.1101/gad.9.10.1199; HAKOMORI S, 1985, CANCER RES, V45, P2405; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; KAIN R, 1995, J EXP MED, V181, P585, DOI 10.1084/jem.181.2.585; KERJASCHKI D, 1989, J IMMUNOL, V143, P546; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OGATA S, 1994, J BIOL CHEM, V269, P5210; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1990, J BIOL CHEM, V265, P9264; REMOLD-O'DONNELL E, 1990, Immunodeficiency Reviews, V2, P151; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SAITOH O, 1991, BLOOD, V77, P1491; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; UEMURA M, 1992, CANCER RES, V52, P6153; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	46	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22695	22702		10.1074/jbc.272.36.22695	http://dx.doi.org/10.1074/jbc.272.36.22695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278427	hybrid			2022-12-25	WOS:A1997XV49200048
J	Packham, G; Cleveland, JL				Packham, G; Cleveland, JL			Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways	ONCOGENE			English	Article						c-Myc; ODC; IL-3	CELL-CYCLE ARREST; INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SIGNALING PATHWAYS; PROTEIN COMPLEX; REPRESSOR SIN3; DNA-BINDING; IN-VIVO; MAX	Enforced c-Myc expression promotes continuous, growth factor-independent, cell cycle progression and activates expression of the ornithine decarboxylase (ODC) gene and its promoter. c-Myc-responsiveness of murine ODC is mediated by two conserved c-Myc:Max E-boxes in ODC intron 1. c-Myc and ODC are both required for cell growth and their expression is sequentially induced in G(0)/G(1) cells stimulated with mitogens, yet their expression is not modulated by the cell cycle in proliferating cells. Here we demonstrate that regulation of ODC and its promoter by Interleukin-3 (IL-3) in murine myeloid cells is mediated in part by c-Myc. c-Myc induced ODC through the same transcription start site as IL-3 and, in asynchronously growing cells, maximal activity of the ODC promoter required the intronic c-Myc binding sites. However, induction of ODC following IL-3 stimulation of quiescent cells is mediated by at least two pathways. The first phase of this response was independent of the intronic c-Myc:Max E-boxes and de novo protein synthesis. Sustained induction of the ODC promoter however required the c-Myc:Max binding sites and protein synthesis. Accumulation of c-Myc following stimulation of quiescent cells with IL-3 correlated with the delayed phase of the response. Consistent with a two pathway model of ODC regulation, inducible overexpression of dominant negative form of c-Myc (In373-Myc), which specifically inhibits the c-Myc-Max network, inhibited the delayed, but not immediate, induction of ODC promoter activity in response to IL-3. Dominant negative c-Myc protein also effectively suppressed induction of the endogenous ODC gene by IL-3. Therefore, c-Myc functions as a direct and required regulator of ODC. These results also suggest a model whereby c-Myc's role in regulating its targets may be to convert a transient, immediate-early, activation event into the persistent induction of gene expression.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST MARYS HOSP, SCH MED, IMPERIAL COLL, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, IMPERIAL COLL, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA 21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ARMATI B, 1993, CELL, V72, P233; ARMATI B, 1994, CURR OPIN GENET DEV, V4, P102; ARMATI B, 1992, NATURE, V359, P423; ARMATI B, 1993, EMBO J, V12, P5083; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COLMAN MS, 1996, NUCLEIC ACIDS RES, V21, P5372; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATZ A, 1988, J BIOL CHEM, V263, P7604; KATZAV S, 1995, ONCOGENE, V11, P1079; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANZELLA L, 1994, FEBS LETT, V348, P177, DOI 10.1016/0014-5793(94)00592-3; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOSHIER JA, 1992, NUCLEIC ACIDS RES, V20, P2581, DOI 10.1093/nar/20.10.2581; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Packham G, 1996, ONCOGENE, V13, P461; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PACKHAM G, 1995, CELL MOL BIOL RES, V40, P699; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6387; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHUETZ JD, 1995, CELL GROWTH DIFFER, V6, P1321; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHOR J, 1995, ONCOGENE, V10, P587; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; TOBIAS KE, 1995, ONCOGENE, V11, P1721; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WATERS CM, 1991, ONCOGENE, V6, P797; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Wu SJ, 1996, ONCOGENE, V12, P621; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	73	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1219	1232		10.1038/sj.onc.1201273	http://dx.doi.org/10.1038/sj.onc.1201273			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294616				2022-12-25	WOS:A1997XU99100012
J	Bouaboula, M; Perrachon, S; Milligan, L; Canat, X; RinaldiCarmona, M; Portier, M; Barth, F; Calandra, B; Pecceu, F; Lupker, J; Maffrand, JP; LeFur, G; Casellas, P				Bouaboula, M; Perrachon, S; Milligan, L; Canat, X; RinaldiCarmona, M; Portier, M; Barth, F; Calandra, B; Pecceu, F; Lupker, J; Maffrand, JP; LeFur, G; Casellas, P			A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED ADP-RIBOSYLATION; BLASTOMA CELL-MEMBRANES; SENSITIVE G-PROTEINS; SIGNAL-TRANSDUCTION; ADENYLATE-CYCLASE; GTP-BINDING; RAT-BRAIN; PHOSPHATIDYLINOSITOL 3-KINASE; BETA(2)-ADRENERGIC RECEPTOR; TRANSCRIPTION FACTOR	In the present study, we showed that Chinese hamster ovary (CHO) cells transfected with human central cannabinoid receptor (CB1) exhibit high constitutive activity at both levels of mitogen-activated protein kinase (MAPK) and adenylyl cyclase, These activities could be blocked by the CB1-selective ligand, SR 141716A, that functions as an inverse agonist. Moreover, binding studies showed that guanine nucleotides decreased the binding of the agonist CP-55,940, an effect usually observed with agonists, whereas it enhanced the binding of SR 141716A, a property of inverse agonists, Unexpectedly, me found that CB1-mediated effects of SR 141716A included inhibition of MAPK activation by pertussis toxin-sensitive receptor-tyrosine kinase such as insulin or insulin-like growth factor 1 receptors but not by pertussis toxin-insensitive receptor-tyrosine kinase such as the fibroblast growth factor receptor, We also observed similar results when cells were stimulated with Mas-7, a mastoparan analog, that directly activates the G(i) protein. Furthermore, SR 141716A inhibited guanosine 5'-0-(thiotriphosphate) uptake induced by CP-55,940 or Mas-7 in CHO-CB1 cell membranes, This indicates that, in addition to the inhibition of autoactivated CB1, SR 141716A can deliver a biological signal that blocks the G(i) protein and consequently abrogates most of the G(i)-mediated responses, By contrast, SR 141716A had no effect on MAPK activation by insulin or IGF1 in CHO cells lacking CB1 receptors, ruling out the possibility of a direct interaction of SR 141716A with the G(i) protein, This supports the notion that the G(i) protein may act as a negative intracellular signaling cross-talk molecule, From these original results, which considerably enlarge the biological properties of the inverse agonist, we propose a novel model for receptor/ligand interactions.	SANOFI RECH,F-34184 MONTPELLIER 04,FRANCE; SANOFI RECH,F-31676 LABEGE,FRANCE; SANOFI RECH,F-31036 TOULOUSE,FRANCE; SANOFI RECH,F-75374 PARIS 08,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France				Milligan, Laura/0000-0001-6985-3034				BARKER EL, 1994, J BIOL CHEM, V269, P11687; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CHIDIAC P, 1995, TRENDS PHARMACOL SCI, V16, P83, DOI 10.1016/S0165-6147(00)88986-5; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GLASS M, 1995, NEUROREPORT, V6, P241, DOI 10.1097/00001756-199501000-00004; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; JAHANGEER S, 1993, P NATL ACAD SCI USA, V90, P8782, DOI 10.1073/pnas.90.19.8782; JO H, 1992, ENDOCRINOLOGY, V131, P2855, DOI 10.1210/en.131.6.2855; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KELLERER M, 1991, BIOCHEM J, V276, P103, DOI 10.1042/bj2760103; Kenakin T, 1996, PHARMACOL REV, V48, P413; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LABRECQUE J, 1995, MOL PHARMACOL, V48, P150; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MAILLEUX P, 1994, NEUROREPORT, V5, P1265, DOI 10.1097/00001756-199406020-00028; MATESIC DF, 1989, J BIOL CHEM, V264, P21638; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; Mullaney L, 1996, BIOCHEM J, V315, P227, DOI 10.1042/bj3150227; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PYNE NJ, 1989, BIOCHEM BIOPH RES CO, V165, P251, DOI 10.1016/0006-291X(89)91062-0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; RinaldiCarmona M, 1996, LIFE SCI, V58, P1239, DOI 10.1016/0024-3205(96)00085-9; RinaldiCarmona M, 1996, J PHARMACOL EXP THER, V278, P871; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SA G, 1994, J BIOL CHEM, V269, P3219; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; Selley DE, 1996, LIFE SCI, V59, P659, DOI 10.1016/0024-3205(96)00347-5; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Siebler T, 1996, REGUL PEPTIDES, V62, P65, DOI 10.1016/0167-0115(95)00159-X; TIBERI M, 1994, J BIOL CHEM, V269, P27925; UEKI K, 1994, J BIOL CHEM, V269, P15756; VALIQUETTE M, 1995, EMBO J, V14, P5542, DOI 10.1002/j.1460-2075.1995.tb00241.x; Weiss JM, 1996, J THEOR BIOL, V178, P169, DOI 10.1006/jtbi.1996.0015; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937	66	396	413	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22330	22339		10.1074/jbc.272.35.22330	http://dx.doi.org/10.1074/jbc.272.35.22330			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268384	hybrid			2022-12-25	WOS:A1997XT85000096
J	Elmgren, A; Mollicone, R; Costache, M; Borjeson, C; Oriol, R; Harrington, J; Larson, G				Elmgren, A; Mollicone, R; Costache, M; Borjeson, C; Oriol, R; Harrington, J; Larson, G			Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human alpha(1,3/1,4)-fucosyltransferase, Fuc-TIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; BLOOD-GROUP SYSTEM; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; SIALYL-LEWIS; DETERMINES EXPRESSION; NEGATIVE INDIVIDUALS; HUMAN-MILK; RECOGNITION; SEQUENCE	The Lewis alpha(1,3/1,4)-fucosyltransferase, Fuc-TIII, encoded by the FUT3 gene is responsible for the final synthesis of Le(a) and Le(b) antigens, Various point mutations have been described explaining the Lewis negative phenotype, Le(a-b-), on erythrocytes and secretions, Two of these, T202C and C314T originally described in a Swedish population, have not been found as single isolated point mutations so far, To define the relative contribution of each of these two mutations to the Lewis negative phenotype, we cloned and made chimeric FUT3 constructs separating the T202C mutation responsible for the amino acid change Trp(68) --> Arg, from the C314T mutation leading to the Thr(l05) --> Met shift, COS-7 cells were transfected and the expression of Fuc-TIII enzyme activity and the presence of Lewis antigens were determined, There was no decrease in enzyme activity nor of immunofluorescence staining on cells transfected with the construct containing the isolated C314T mutation compared with cells transfected with a wild type FUT3 allele control, No enzyme activity nor immunoreactivity for Lewis antigens was detected in FUT3 constructs containing both mutations in combination, The T202C mutation alone decreased the enzyme activity to less than 1% of the activity of the wild type FUT3 allele, These results demonstrate, that the Trp(68) --> Arg substitution in human Fuc-TIII is the capital amino acid change responsible for the appearance of the Le(a-b-) phenotype on human erythrocytes in individuals homozygous for both the T202C and C314T mutations.	SAHLGRENS UNIV HOSP, DEPT CLIN CHEM & TRANSFUS MED, INST LAB MED, S-41345 GOTHENBURG, SWEDEN; INSERM, U178, F-94807 VILLEJUIF, FRANCE; NEW S WALES RED CROSS BLOOD TRANSFUS SERV, SYDNEY, NSW 2000, AUSTRALIA	Sahlgrenska University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Australian Red Cross Blood Service			Costache, Marieta D/F-2806-2016; Larson, Göran/AAF-3404-2019	Costache, Marieta D/0000-0002-8103-3693; 				ANDRESEN PH, 1948, ACTA PATHOL MIC SC, V24, P616; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Battey, 1986, BASIC METHODS MOL BI; BERGER SL, 1987, METHODS ENZYMOLOGY G; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; CANDELIER JJ, 1993, LAB INVEST, V69, P449; CEPPELLINI R., 1955, RIV 1ST SIEROTEROP ITAL, V30, P431; CHESTER MA, 1990, P 2 INT WORKSH MON A; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; Elmgren A, 1996, VOX SANG, V70, P97, DOI 10.1111/j.1423-0410.1996.tb01300.x; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOD AH, 1992, VOX SANG, V62, P180, DOI 10.1111/j.1423-0410.1992.tb01195.x; GRUBB R, 1951, ACTA PATHOL MIC SC, V28, P61; Henry S, 1997, GLYCOCONJUGATE J, V14, P209, DOI 10.1023/A:1018541821819; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P241, DOI 10.1007/BF00731136; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MARCUS DM, 1969, SCIENCE, V164, P553, DOI 10.1126/science.164.3879.553; Mollicone R, 1996, GLYCOCONJUGATE J, V13, P263, DOI 10.1007/BF00731501; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MOURANT AE, 1946, NATURE, V158, P237, DOI 10.1038/158237c0; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Schenkel-Brunner H, 1995, HUMAN BLOOD GROUPS; WESTON BW, 1993, J BIOL CHEM, V268, P18398; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	43	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21994	21998		10.1074/jbc.272.35.21994	http://dx.doi.org/10.1074/jbc.272.35.21994			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268337	hybrid			2022-12-25	WOS:A1997XT85000049
J	Sudbeck, BD; Pilcher, BK; Welgus, HG; Parks, WC				Sudbeck, BD; Pilcher, BK; Welgus, HG; Parks, WC			Induction and repression of collagenase-1 by keratinocytes is controlled by distinct components of different extracellular matrix compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; INTERSTITIAL COLLAGENASE; INTEGRIN EXPRESSION; TISSUE INHIBITOR; DOWN-REGULATION; CELL CARCINOMA; MESSENGER-RNA; METALLOPROTEINASES; ADHESION; INVITRO	In all forms of cutaneous wounds, collagenase-1 (matrix metalloproteinase-1 (MMP-1)) is invariably expressed by basal keratinocytes migrating over the dermal matrix, We report that native type I collagen mediates induction of MMP-1 by primary human keratinocytes, Collagen-mediated induction of MMP-1 was rapid, being detected 2 h after plating, and was transcriptionally regulated, As demonstrated by in situ hybridization, only migrating keratinocytes expressed MMP-1, suggesting that contact with collagen is not sufficient to induce MMP-1 expression in keratinocytes; the cells must also be migrating, Upon denaturation, type I collagen lost its ability to induce MMP-1 expression but still supported cell adhesion, Other dermal or wound matrix proteins, such as type III collagen, fibrin, and fibronectin, and a mixture of basement membrane proteins did not induce MMP-1 production. In the presence of collagen, laminin-1 inhibited induction of MMP-1 but laminin-5 did not, Taken together, these observations suggest that as basal keratinocytes migrate from the basal lamina onto the dermal matrix contact with native type I collagen induces MMP-1 expression, In addition, our findings suggest that re-establishment of the basement membrane and, in particular, contact with laminin-1 provides a potent signal to down-regulate MMP-1 production as the epithelium is repaired.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED DERMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594] Funding Source: Medline; NIADDK NIH HHS [AM35805] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; Fini ME, 1996, AM J PATHOL, V149, P1287; Garlick JA, 1996, J DENT RES, V75, P912, DOI 10.1177/00220345960750030801; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GUO M, 1991, EXP CELL RES, V195, P315, DOI 10.1016/0014-4827(91)90379-9; HERTLE MD, 1991, DEVELOPMENT, V112, P193; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; JUHASZ I, 1993, AM J PATHOL, V143, P1458; LANGE TS, 1994, EXP CELL RES, V214, P381, DOI 10.1006/excr.1994.1271; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; PARKS WC, 1992, BIOCHEMISTRY-US, V31, P6639, DOI 10.1021/bi00144a003; PARKS WC, 1995, WOUNDS, V7, pA23; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; PETERSEN MJ, 1989, J INVEST DERMATOL, V92, P156, DOI 10.1111/1523-1747.ep12276678; PETERSEN MJ, 1990, J INVEST DERMATOL, V94, P341, DOI 10.1111/1523-1747.ep12874471; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; PROSSER IW, 1989, AM J PATHOL, V135, P1073; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V104, P982, DOI 10.1111/1523-1747.ep12606231; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; STAHLEBACKDAHL M, 1992, J INVEST DERMATOL, V99, P497, DOI 10.1111/1523-1747.ep12616171; STAHLEBACKDAHL M, 1993, AM J PATHOL, V142, P995; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Sudbeck BD, 1997, MOL BIOL CELL, V8, P811, DOI 10.1091/mbc.8.5.811; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; UITTO J, 1989, J INVEST DERMATOL, V92, pS61; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689; Yamada K.M., 1996, MOL CELLULAR BIOL WO, P51; YAMADA KM, 1996, MOL CELLULAR BIOL WO, P311; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	42	93	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22103	22110		10.1074/jbc.272.35.22103	http://dx.doi.org/10.1074/jbc.272.35.22103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268353	hybrid			2022-12-25	WOS:A1997XT85000065
J	Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Treon, S; Urashima, M; Kharbanda, S; Anderson, KC				Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Treon, S; Urashima, M; Kharbanda, S; Anderson, KC			Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism	ONCOGENE			English	Article						multiple myeloma; irradiation; dexamethasone; apoptosis	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH FACTOR; JUN; DNA; EXPRESSION; PHOSPHORYLATION; INTERLEUKIN-6	The stress-activated protein kinases (SAPKs), also known as c-Jun amino-terminal kinases (JNKs), are activated in response to diverse stimuli including DNA damage, heat shock, interleukin-1, tumor necrosis factor-alpha and Fas, Although all these inducers cause apoptosis, whether SAPK/JNK activation is required for apoptosis is controversial, In this study, we demonstrate that ionizing radiation (IR) and dexamethasone (Dex) induce apoptosis in multiple myeloma (MM) derived cell lines, as well as in patient cells, IR-induced apoptosis is associated with activation of SAPK/JNK and p38 kinase, in contrast to Dex-induced apoptosis, which is not associated with activation of stress kinases, Moreover, Dex-induced apoptosis is associated with a significant decrease in the activities of mitogen activated protein kinase (MAPK) and p70(S6K), whereas IR-treatment does not alter the activity of these kinases. Both IR and Dex induce poly (ADP ribose) polymerase (PARP) cleavage, a signature event of apoptosis. Finally, interleukin-6 (IL-6) inhibits Dex-induced apoptosis, downregulation of MAP and p70(S6K) growth kinases and PARP cleavage; in contrast, IL-6 does not inhibit IR-induced apoptosis, activation of SAPK/JNK, and PARP cleavage, Taken together, our findings suggest that SAPK/JNK activation is not required for apoptosis in MM cells, and that there are at least two distinct apoptotic signaling pathways: (i) SAPK/JNK-associated, which is induced by IR and unaffected by IL-6; and (ii) SAPK/JNK-independent, which is induced by Dex, associated with downregulation of MAPK and p70(S6K) and inhibited by IL-6.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Ogata, Atsushi/0000-0003-3944-3442				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; DUKE RC, 1992, CURRENT PROTOCOLS IM, V1; FRANK R, 1992, NUCLEIC ACIDS RES, V20, P5243; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P128; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATA H, 1995, BLOOD, V86, P1939, DOI 10.1182/blood.V86.5.1939.bloodjournal8651939; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTENDORF JJ, 1995, BLOOD, V85, P3566, DOI 10.1182/blood.V85.12.3566.bloodjournal85123566; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZIA Z, 1995, SCIENCE, V270, P1326	45	148	155	3	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					837	843		10.1038/sj.onc.1201253	http://dx.doi.org/10.1038/sj.onc.1201253			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266970				2022-12-25	WOS:A1997XQ11700010
J	Hipp, ML; Bauer, G				Hipp, ML; Bauer, G			Intercellular induction of apoptosis in transformed cells does not depend on p53	ONCOGENE			English	Article						apoptosis; p53; TGF-beta	WILD-TYPE P53; BETA-INDUCED ELIMINATION; DNA STRAND BREAKS; TUMOR-SUPPRESSOR; TGF-BETA; P53-DEPENDENT APOPTOSIS; INDEPENDENT PATHWAYS; BCL-2 PROTEINS; CYCLE CONTROL; IN-VIVO	Transformed fibroblast from p53 null/null mice were tested for their sensitivity to intercellular induction of apoptosis by TGF-beta-treated nontransformed cells. They were found to be as sensitive as p53-positive transformed cells. Based on morphological criteria, detection of chromatin condensation and DNA strand breaks, death of p53-negative transformed cells was due to apoptosis. p53-negative nontransformed cells were as efficient in the induction of apoptosis in transformed cells as p53-positive nontransformed cells. These data show that intercellular induction of apoptosis in transformed cells does not depend on functional p53. Therefore it may be assumed that mutations of p53 or modulation of its concentration are without relevance for this particular aspect of control of oncogenesis.	UNIV FREIBURG,ABT VIROL,INST MED MIKROBIOL & HYG,D-79104 FREIBURG,GERMANY	University of Freiburg								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BASSLER D, 1997, IN PRESS EXP CELL RE; BAUER G, 1982, J BIOL CHEM, V257, P1405; BAUER G, 1995, INT J ONCOL, V6, P1227; Bauer G, 1996, HISTOL HISTOPATHOL, V11, P237; BECK E, 1997, IN PRESS EXP CELL RE; BRONNER MP, 1995, AM J PATHOL, V146, P20; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Descalzo AM, 1997, INT J ONCOL, V10, P765; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELEIRY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAUKROGER JM, 1993, J GEN VIROL, V74, P2275, DOI 10.1099/0022-1317-74-10-2275; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GOTZ C, 1995, INT J ONCOL, V6, P1129; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU ZM, 1994, ONCOGENE, V9, P629; Hackenjos K, 1996, ONCOL REP, V3, P27; HAVRE PA, 1995, CANCER RES, V55, P4420; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JURGENSMEIER JM, 1994, CANCER RES, V54, P393; JURGENSMEIER JM, 1997, IN PRESS INT J CANC; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Langer C, 1996, EXP CELL RES, V222, P117, DOI 10.1006/excr.1996.0015; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Melchinger W, 1996, INT J ONCOL, V9, P927; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Panse J, 1997, CARCINOGENESIS, V18, P259, DOI 10.1093/carcin/18.2.259; PICHT G, 1995, EXP CELL RES, V218, P71, DOI 10.1006/excr.1995.1132; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHAEFER D, 1995, INT J CANCER, V60, P520, DOI 10.1002/ijc.2910600416; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WEHRLE I, 1994, INT J ONCOL, V5, P1341; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	60	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					791	797		10.1038/sj.onc.1201247	http://dx.doi.org/10.1038/sj.onc.1201247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266965				2022-12-25	WOS:A1997XQ11700005
J	Tolkacheva, T; Feuer, B; Lorenzi, MV; Saez, R; Chan, AML				Tolkacheva, T; Feuer, B; Lorenzi, MV; Saez, R; Chan, AML			Cooperative transformation of NIH3T3 cells by G alpha 12 and Rac1	ONCOGENE			English	Article						Rac1; RhoA; Cdc42Hs; G alpha 12; oncogene; transformation	ACTIN STRESS FIBERS; GENE-PRODUCT; G-PROTEINS; RAS TRANSFORMATION; ALPHA-SUBUNITS; CDC42 GTPASES; RHO; BINDING; KINASE; FAMILY	The heterotrimeric G-protein, G alpha 12, together with the closely-related G alpha 13, are members of the G12 class of alpha-subunits important in mediating the signaling from seven transmembrane domain-spanning receptors, Recent evidence implicating both G alpha 12 and G alpha 13 in the activation of signaling pathways involving members of the RHO gene family led us to examine the role of Rad, RhoA and Cdc42Hs in the transforming properties of G alpha 12. Asparagine 17 (Asn 17) dominant inhibitory mutants of Rad, and to a lesser extent RhoA, block focus forming ability of the GTPase-deficient mutant of G alpha 12 (G alpha 12 Leu 229) in NIH3T3 cells, In turn, wild-type G alpha 12 cooperates well with Rad Val 12 but not with RhoA Leu 63 mutant in transforming NIH3T3 cells, Interestingly, the morphology of foci induced by G alpha 12 and RhoA mutants are strikingly similar and is distinct from those displayed by Rad Val 12 mutant, The fact that G alpha 12's ability to induce mitogenesis in NIH3T3 cells is not significantly perturbed by C3 ribosyltransferase suggested that RhoA does not play a major role in G alpha 12-induced mitogenic events, Activated mutant of Rad has previously been demonstrated to stimulate the activity of the stress-induced c-Jun IV-terminal kinase/stress-activated protein kinases (JNK/SAPKs), Transient co-transfection of Rad Val 12 mutant with the wild-type G alpha 12 in COS7 cells leads to the further activation of an exogenously expressed hemagglutinin(HA)-tagged JNK. Furthermore, the cooperation between G alpha 12 and Rad in cellular transformation is correlated with their ability to stimulate transcription from c-fos serum response element (SRE).	CUNY MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li WQ, 1996, ONCOGENE, V13, P731; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zhang YH, 1996, ONCOGENE, V12, P2377	36	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					727	735		10.1038/sj.onc.1201229	http://dx.doi.org/10.1038/sj.onc.1201229			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264413				2022-12-25	WOS:A1997XP68300012
J	Althoefer, H; EversoleCire, P; Simon, MI				Althoefer, H; EversoleCire, P; Simon, MI			Constitutively active G alpha q and G alpha 13 trigger apoptosis through different pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; CELL-DEATH; GENE FAMILY; ACTIVATION; SUBUNITS; RECEPTOR; RAS; OVEREXPRESSION; INVOLVEMENT	We investigated the effect of expression of constitutively active G alpha mutants on cell survival, Transfection of constitutively active G alpha q and G alpha 13 in two different cell lines caused condensation of genomic DNA and nuclear fragmentation. Endonuclease cleavage of genomic DNA was followed by labeling the DNA fragments and subsequent flow cytometric analysis. The observed cellular phenotype was identical to the phenotype displayed by cells undergoing apoptosis. To distinguish between the apoptosis-inducing ability of the two G alpha-subunits, the signaling pathways involved in this cellular function were investigated Whereas G alpha q induced apoptosis via a protein kinaseC-dependent pathway, G alpha 13 caused programmed cell death through a pathway involving the activation of the small G-protein Rho, Both of the pathways leading to apoptosis were blocked by overexpression of bcl-2, In contrast to other apoptosis-inducing systems, expression of constitutively active G alpha q and G alpha 13 triggered apoptosis in high serum as well as in defined medium.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology					NIGMS NIH HHS [GM 34236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; FOIXGOMEZ AM, 1992, P NATL ACAD SCI USA, V267, P25129; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JIMENEZ B, 1995, ONCOGENE, V10, P811; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Krieger C, 1996, TRENDS PHARMACOL SCI, V17, P114, DOI 10.1016/0165-6147(96)10004-3; LEE CH, 1992, J BIOL CHEM, V267, P16044; MCKENNA JP, 1993, BIOCHEM PHARMACOL, V46, P583, DOI 10.1016/0006-2952(93)90541-4; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; OHKUSU K, 1995, EUR J IMMUNOL, V25, P3180, DOI 10.1002/eji.1830251129; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, P1; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOJYO Y, 1990, BIOCHEM PHARMACOL, V39, P1775; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watson S., 1994, G PROTEIN LINKED REC; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349	41	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24380	24386		10.1074/jbc.272.39.24380	http://dx.doi.org/10.1074/jbc.272.39.24380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305896	hybrid, Green Submitted			2022-12-25	WOS:A1997XY51500047
J	Chen, SRW; Li, XL; Ebisawa, K; Zhang, L				Chen, SRW; Li, XL; Ebisawa, K; Zhang, L			Functional characterization of the recombinant type 3 Ca2+ release channel (ryanodine receptor) expressed in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; MUSCLE SARCOPLASMIC-RETICULUM; MAMMALIAN SKELETAL-MUSCLES; MYOMETRIAL SMOOTH-MUSCLE; CALCIUM-RELEASE; PROTEIN ISOFORMS; MICE LACKING; MALIGNANT HYPERTHERMIA; ADENINE-NUCLEOTIDE; CARDIAC-MUSCLE	To investigate the channel properties of the mammalian type 3 ryanodine receptor (RyR3), we have cloned the RyR3 cDNA from rabbit uterus by reverse transcriptase-polymerase chain reaction and expressed! the cDNA inn HEK293 cells, Immunoblotting studies showed that the cloned RyR3 was indistinguishable from the native mammalian RyR3 in molecular size and immunoreactivity. Ca2+ release measurements using the fluorescence Ca2+ indicator fluo 3 revealed that the cloned RyR3 functioned as a caffeine-and ryanodine-sensitive Ca2+ release channel in HEK293 cells, Functional properties of the cloned RyR3 were further characterized by using single channel recordings in lipid bilayers. The cloned RyR3 channel exhibited a K+ conductance of 777 picosiemens in 250 mM KCl and a Ca2+ conductance of 137 picosiemens inn 250 mM CaCl2 and displayed a pCa(2+)/pK(+) ratio of 6.3 and an open time constant of about 1.16 ms, The response of the cloned RyR3 to cytoplasmic Ca2+ concentrations was biphasic. The channel was activated by Ca2+ at about 100 nM and inactivated at about 10 mM. Ca2+ alone was able to activate the cloned RyR3 fully, Calmodulin activated the cloned RyR3 at low Ca2(+) concentrations but inhibited the channel at low Ca2+ concentrations. The cloned RyR3 was activated by ATP, caffeine, and perchlorate, inhibited by Mg2+ and ruthenium red, and modified by ryanodine, cyclic ADP-ribose did not seem to affect single channel activity of the cloned RyR3. The most prominent differences of the cloned RyR3 from the rabbit skeletal muscle ryanodine receptor were in the gating kinetics, extent of maximal activation by Ca2+, and sensitivity to Ca2+ inactivation. Results of the present study provide initial insights into the single channel properties of the mammalian RyR3.			Chen, SRW (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,CARDIOVASC RES GRP,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.							AIREY JA, 1990, J BIOL CHEM, V265, P14187; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1996, BIOPHYS J, V70, P390; CHEN SRW, 1997, IN PRESS BIOPHYS J, V73; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU A, 1993, J MEMBRANE BIOL, V135, P49; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; FRUEN BR, 1994, AM J PHYSIOL, V266, pC1729, DOI 10.1152/ajpcell.1994.266.6.C1729; FUTATSUGI A, 1995, BIOCHEM J, V305, P373, DOI 10.1042/bj3050373; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALLANT EM, 1993, AM J PHYSIOL, V264, pC559, DOI 10.1152/ajpcell.1993.264.3.C559; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GONZALEZ A, 1993, J GEN PHYSIOL, V102, P373, DOI 10.1085/jgp.102.3.373; GYORKE S, 1992, J PHYSIOL-LONDON, V456, P443; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LYNN S, 1993, FEBS LETT, V330, P227, DOI 10.1016/0014-5793(93)80279-4; LYNN S, 1995, FEBS LETT, V372, P6, DOI 10.1016/0014-5793(95)00924-X; MA J, 1993, J GEN PHYSIOL, V102, P423, DOI 10.1085/jgp.102.3.423; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MINTA A, 1989, J BIOL CHEM, V264, P8171; Miyatake R, 1996, FEBS LETT, V395, P123, DOI 10.1016/0014-5793(96)01022-8; Moore DD, 1995, GLOB MOB SURV; MORRISSETTE J, 1993, FEBS LETT, V330, P270, DOI 10.1016/0014-5793(93)80886-Y; MURAYAMA R, 1997, BIOPHYS J, V72, P169; Murayama T, 1996, J BIOL CHEM, V271, P5079; OBRIEN J, 1995, BIOPHYS J, V68, P471, DOI 10.1016/S0006-3495(95)80208-0; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OTSU K, 1994, J BIOL CHEM, V269, P9413; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; PHILLIPS M, 1996, GENOMICS, V33, P24; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; TANAKA Y, 1995, P NATL ACAD SCI USA, V92, P3244, DOI 10.1073/pnas.92.8.3244; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; XU L, 1994, P NATL ACAD SCI USA, V91, P3294, DOI 10.1073/pnas.91.8.3294; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; ZORZATO F, 1994, BIOCHEM BIOPH RES CO, V203, P1725, DOI 10.1006/bbrc.1994.2385	67	146	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24234	24246		10.1074/jbc.272.39.24234	http://dx.doi.org/10.1074/jbc.272.39.24234			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305876	hybrid			2022-12-25	WOS:A1997XY51500027
J	Muta, T; Kang, D; Kitajima, S; Fujiwara, T; Hamasaki, N				Muta, T; Kang, D; Kitajima, S; Fujiwara, T; Hamasaki, N			p32 protein, a splicing factor 2-associated protein, is localized in mitochondrial matrix and is functionally important in maintaining oxidative phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 TAT TRANSACTIVATOR; IN-VITRO INTERACTION; LAMIN-B RECEPTOR; SACCHAROMYCES-CEREVISIAE; CELLULAR PROTEIN; BINDING-PROTEIN; HEAT-SHOCK; YEAST MITOCHONDRIA; MOLECULAR-CLONING; ACTIVATION DOMAIN	Human p32, originally cloned as a splicing factor 2-associated protein, has been reported to interact with a variety of molecules including human immunodeficiency virus Tat and complement Iq (Clq). p32 protein is supposed to be in the nucleus and on the plasma membrane for the association with human immunodeficiency virus Tat and Clq, respectively. None of the interactions, however, is proven to have a physiological role. To investigate the physiological function of p32, we determined the intracellular localization of p32. The fractionation of cells, fluorescent immunocytochemistry, and electron microscopic immunostaining show that p32 is exclusively localized in the mitochondrial matrix. We cloned a Saccharomyces cerevisiae homologue of human p32 gene, referred to yeast p30 gene. The yeast p30 protein is also localized in the mitochondrial matrix. The disruption of the p30 gene caused the growth retardation of yeast cells in a glycerol medium but not in a glucose medium, i.e. the impairment of the mitochondrial ATP synthesis. The growth impairment was restored by the introduction of the human p32 cDNA, indicating that p30 is a functional yeast counterpart of human p32. Taken together, both p32 and p30 reside in mitochondrial matrix and play an important role in maintaining mitochondrial oxidative phosphorylation.	KYUSHU UNIV, FAC MED, DEPT CLIN CHEM & LAB MED, HIGASHI KU, FUKUOKA 81282, JAPAN; TOKYO MED & DENT UNIV, INST MED RES, DEPT BIOCHEM GENET, TOKYO 113, JAPAN; FUKUOKA UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 81401, JAPAN	Kyushu University; Tokyo Medical & Dental University (TMDU); Fukuoka University			Muta, Tsuyoshi/AAR-2162-2021					BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Becker A, 1996, ANAL BIOCHEM, V237, P204, DOI 10.1006/abio.1996.0230; Bergmeyer H.U., 1965, METHODS ENZYMATIC AN, P736, DOI [10.1016/b978-0-12-395630-9.50134-1, DOI 10.1016/B978-0-12-395630-9.50134-1]; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; GELLERA C, 1990, NEUROLOGY, V40, P495, DOI 10.1212/WNL.40.3_Part_1.495; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HONORE B, 1993, GENE, V134, P283, DOI 10.1016/0378-1119(93)90108-F; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; Kamura T, 1997, J BIOL CHEM, V272, P11361; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KONDO K, 1991, J BIOL CHEM, V266, P17537; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MACHO A, 1995, BLOOD, V86, P2481; MASTERS BSS, 1965, J BIOL CHEM, V240, P921; MCKEE EE, 1984, J BIOL CHEM, V259, P9320; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Seebacher T, 1996, ELECTROPHORESIS, V17, P1573, DOI 10.1002/elps.1150171013; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; SINGH B, 1990, BIOCHEM BIOPH RES CO, V169, P391, DOI 10.1016/0006-291X(90)90344-M; SMILEY JK, 1992, NUCLEIC ACIDS RES, V20, P4913, DOI 10.1093/nar/20.18.4913; TANAKA K, 1988, EMBO J, V7, P495, DOI 10.1002/j.1460-2075.1988.tb02837.x; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; Yamazaki S, 1997, J BIOCHEM, V121, P8; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	43	183	189	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24363	24370		10.1074/jbc.272.39.24363	http://dx.doi.org/10.1074/jbc.272.39.24363			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305894	hybrid			2022-12-25	WOS:A1997XY51500045
J	Rao, MN; Ghosh, P; Lakshman, MR				Rao, MN; Ghosh, P; Lakshman, MR			Purification and partial characterization of a cellular carotenoid-binding protein from ferret liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	FASEB Meeting	APR 14-17, 1996	WASHINGTON, DC	FASEB			TRANS-BETA-CAROTENE; CAROTENOPROTEIN; CRUSTACYANIN; ASTAXANTHIN; COMPLEX; RETINOL; TISSUES; MODEL	A cellular carotenoid-binding protein was purified to homogeneity from beta-carotene-fed ferret liver utilizing the following steps: ammonium sulfate precipitation, ion exchange, gel filtration, and affinity chromatography. The final purification was 607-fold. [C-14]beta-Carotene co-purified with the binding protein throughout the purification procedures. SDS-PAGE of the purified protein showed a single band with an apparent molecular mass of 67 kDa. Scatchard analysis of the specific binding of the purified protein to beta-carotene showed two classes of binding sites, a high affinity site with an apparent Kd Of 56 x 10(-9) M and a low affinity site with a K-d of 32 x 10(-6) M. The B-max for beta-carotene binding to the high affinity site was 1 mol/mol, while that for the low affinity site was 145 mol/mol. The absorption spectrum of the complex showed a 32-nm bathochromic shift in lambda(max) with minor peaks at 460 and 516 nm. Except for alpha-carotene and cryptoxanthin, none of the model carotenoids or retinol competed with beta-carotene binding to the protein. Thus, a specific carotenoid-binding protein of 67 kDa has been characterized in mammalian liver with a high degree of specificity for binding only carotenoids with at least one unsubstituted beta-ionone ring.	VET ADM MED CTR,LIPID RES LAB,WASHINGTON,DC 20422; GEORGE WASHINGTON UNIV,DEPT MED,WASHINGTON,DC 20037	US Department of Veterans Affairs; Veterans Health Administration (VHA); George Washington University					NCI NIH HHS [CA39999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ALPH TOC BET CART, 1994, NEW ENGL J MED, V330, pS1029; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLERJAHN GS, 1986, J BACTERIOL, V167, P396, DOI 10.1128/jb.167.1.396-399.1986; CHEN CH, 1982, J LIPID RES, V23, P680; CHYTIL F, 1984, RETINOIDS, P90; FOX JG, 1988, BIOL DIS FERRET; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; Jouni ZE, 1996, J BIOL CHEM, V271, P14722, DOI 10.1074/jbc.271.25.14722; KEEN JN, 1991, EUR J BIOCHEM, V202, P31, DOI 10.1111/j.1432-1033.1991.tb16340.x; KRINSKY NI, 1958, ARCH BIOCHEM BIOPHYS, V73, P233, DOI 10.1016/0003-9861(58)90259-5; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAKSHMAN MR, 1989, P NATL ACAD SCI USA, V86, P9124, DOI 10.1073/pnas.86.23.9124; MATHEWSROTH MM, 1993, ANN NY ACAD SCI, V691, P127, DOI 10.1111/j.1749-6632.1993.tb26164.x; Nielsen T B, 1978, Methods Enzymol, V48, P3; OKOH C, 1993, J NUTR BIOCHEM, V4, P569, DOI 10.1016/0955-2863(93)90025-R; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; ONG DE, 1982, J BIOL CHEM, V257, P13385; RIBAYAMERCADO JD, 1992, J NUTR, V122, P1898, DOI 10.1093/jn/122.9.1898; RIBAYAMERCADO JD, 1989, J NUTR, V119, P665, DOI 10.1093/jn/119.4.665; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; SUBBARAYAN C, 1966, INDIAN J BIOCHEM, V3, P225; TRABER MG, 1994, LIPIDS, V29, P665, DOI 10.1007/BF02538909; WHITE WS, 1993, J NUTR, V123, P1129; ZAGALSKY PF, 1991, BIOCHEM J, V274, P79, DOI 10.1042/bj2740079; ZHOU JR, 1994, J AGR FOOD CHEM, V42, P2386, DOI 10.1021/jf00047a005; ZIEGLER RG, 1992, CANCER RES, V52, pS2060	27	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24455	24460		10.1074/jbc.272.39.24455	http://dx.doi.org/10.1074/jbc.272.39.24455			6	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305906	hybrid			2022-12-25	WOS:A1997XY51500057
J	Asano, K; Merrick, WC; Hershey, JWB				Asano, K; Merrick, WC; Hershey, JWB			The translation initiation factor eIF3-p48 subunit is encoded by int-6, a site of frequent integration by the mouse mammary tumor virus genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA 5' CAP; MALIGNANT TRANSFORMATION; HELA-CELLS; PROTEIN; BINDING	Translation initiation factor eIF3 is a large, multisubunit protein complex that plays a central role in the pathway of initiation by promoting the binding of both methionyl-tRNA(i) and mRNA to the 40S ribosomal subunit. As part of a broad effort to elucidate the structure of eIF3, we have cloned and sequenced the human cDNA encoding the 48-kDa subunit, eIF3-p48. The recombinant protein comigrates with the authentic p48 subunit in purified eIF3 and coprecipitates with affinity-purified antibodies to the p170 subunit of eIF3. A search of the data base indicates that the mouse gene encoding eIF3 p48 had previously been identified and characterized by others as int-6. The int-6 gene is the site of frequent integration of mouse mammary tumor virus DNA into chromosomes, implicating the gene in the regulation of cell proliferation. In addition, it was shown elsewhere that the homologous human int-6 gene product binds to the human T-cell leukemia virus type I Tax protein, leading to the translocation of Int-6 to the cytoplasm. We discuss how the cytosolic function of eIF3-p48 (Int-6) in protein synthesis may account for oncogenesis caused by these two viruses.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	University of California System; University of California Davis; Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, R01GM026796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26796, GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; HERSHEY JWB, 1997, BIOCHIMIE, V78, P903; JOHNSON KR, 1997, J BIOL CHEM, V272, P7016; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; Sambrook J., 2002, MOL CLONING LAB MANU; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; VARMUS HE, 1982, CANCER SURV, V1, P309	20	129	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23477	23480		10.1074/jbc.272.38.23477	http://dx.doi.org/10.1074/jbc.272.38.23477			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295280	hybrid			2022-12-25	WOS:A1997XX38100005
J	James, PF; Zoeller, RA				James, PF; Zoeller, RA			Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase - Sensitivity to fatty aldehydes and Schiff's base modification of phospholipids: Implications for Sjogren-Larsson syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; ALCOHOL OXIDATION; METABOLISM; DEFICIENT; OXIDOREDUCTASE; CYCLE	Using tritium suicide, we have isolated a variant of the Chinese hamster ovary cell line, CHO-K1, that is deficient in long-chain fatty alcohol:NAD(+) oxidoreductase (FAO; FC 1.1.1.192), Specifically, it was the fatty aldehyde dehydrogenase component that was affected, The enzymatic deficiency found in this mutant strain, designated FAA.K1A, was similar to that displayed by fibroblasts from patients with Sjogren-Larsson syndrome (SLS), an inheritable neurocutaneaus disorder. Complementation analyses suggested that the deficiency in fatty alcohol oxidation in the FAA.K1A cells and the SLS fibroblasts is a result of lesions in homologous genes, The FAA.K1A cells were usable to convert long chain fatty aldehydes to the corresponding fatty acids, This resulted in a hypersensitivity of the FAA.K1A cells to the cytotoxic effects of long chain fatty aldehydes. The difference between the mutant and wild-type cans was most obvious when using fatty aldehydes between 14 and 20 carbons, with the greatest difference between wild-type and mutant cells found when using octadecanal, Fibroblasts from a patient with SLS also displayed the hypersensitivity phenotype when compared with FA1dDH(+) human fibroblasts. In both CHO and human FA1dDH(-) cell lines, addition of long chain fatty aldehydes to the medium caused a dramatic increase in aldehyde-modified phosphatidylethanolamine, presumably through Schiffs base addition to the primary amine of the ethanolamine head group, When 25 mu M hexadecanal was added to the growth medium, approximately 10% of the phosphatidylethanolamine was found in the fatty aldehyde-modified form in FAA.K1A, although this was not observed in wild-type cells, Modified phosphatidylethanolamine could be detected in FA1dDH(-) cells even when exogenous fatty aldehydes were not added to the medium, We propose a possible role for fatty aldehydes, or other aldehydic species, in mediating some of the symptoms associated with Sjogren-Larsson syndrome.	BOSTON UNIV,SCH MED,DEPT BIOPHYS,CTR ADV BIOMED RES,BOSTON,MA 02118	Boston University				Zoeller, Raphael/0000-0002-6560-0993	NIGMS NIH HHS [GM 50571] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050571] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; BORG J, 1987, FEBS LETT, V213, P406, DOI 10.1016/0014-5793(87)81531-4; CHIARPOTTO E, 1995, BIOCHEM BIOPH RES CO, V207, P477, DOI 10.1006/bbrc.1995.1213; COREY EJ, 1975, TETRAHEDRON LETT, V31, P2647; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; DeLaurenzi V, 1996, NAT GENET, V12, P52; DOWNING DT, 1968, J CHROMATOGR, V38, P91, DOI 10.1016/0021-9673(68)85011-3; FERRELL WJ, 1969, LIPIDS, V4, P278, DOI 10.1007/BF02533186; HEIJER A, 1965, ARCH DERMATOL, V92, P545, DOI 10.1001/archderm.92.5.545; HOGAN M, 1992, J CLIN INVEST, V90, P1110, DOI 10.1172/JCI115928; ICHIHARA K, 1986, BIOCHIM BIOPHYS ACTA, V878, P412, DOI 10.1016/0005-2760(86)90250-X; JAGELL S, 1981, CLIN GENET, V19, P233; JAGELL S, 1980, ACTA OPHTHALMOL, V58, P321; James PF, 1997, J BIOL CHEM, V272, P23540, DOI 10.1074/jbc.272.38.23540; JAMES PF, 1989, P NATL ACAD SCI USA, V87, P6102; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Kennett R H, 1979, Methods Enzymol, V58, P345; KUCHERLAPATI RS, 1975, CYTOGENET CELL GENET, V14, P362, DOI 10.1159/000130384; LIN RC, 1995, ALCOHOL CLIN EXP RES, V19, P314, DOI 10.1111/j.1530-0277.1995.tb01508.x; LINDAHL R, 1984, J BIOL CHEM, V259, P1986; LITTLEFIELD JW, 1964, SCIENCE, V129, P838; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MECHANIC GL, 1974, BIOCHEM BIOPH RES CO, V56, P923, DOI 10.1016/S0006-291X(74)80276-7; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; PAGE RC, 1968, BIOCHEM BIOPH RES CO, V33, P752, DOI 10.1016/0006-291X(68)90223-4; Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054; PRINGLE MJ, 1981, MOL PHARMACOL, V19, P49; RIZZO WB, 1989, J PEDIATR-US, V115, P228, DOI 10.1016/S0022-3476(89)80070-8; RIZZO WB, 1993, SEMIN DERMATOL, V12, P210; RIZZO WB, 1993, BIOCHEM MED METAB B, V50, P93, DOI 10.1006/bmmb.1993.1050; RIZZO WB, 1988, J CLIN INVEST, V81, P738, DOI 10.1172/JCI113379; RIZZO WB, 1991, J CLIN INVEST, V88, P1643, DOI 10.1172/JCI115478; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; SELMANOWITZ VJ, 1967, AM J MED, V42, P412, DOI 10.1016/0002-9343(67)90269-0; Sjogren T, 1957, ACTA PSYCHIAT NEUROL, V32, P1; THEILE U, 1974, HUMANGENETIK, V22, P91; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170	39	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23532	23539		10.1074/jbc.272.38.23532	http://dx.doi.org/10.1074/jbc.272.38.23532			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295289	hybrid			2022-12-25	WOS:A1997XX38100014
J	Kakizawa, T; Miyamoto, T; Kaneko, A; Yajima, H; Ichikawa, K; Hashizume, K				Kakizawa, T; Miyamoto, T; Kaneko, A; Yajima, H; Ichikawa, K; Hashizume, K			Ligand-dependent heterodimerization of thyroid hormone receptor and retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; ESCHERICHIA-COLI; ACID RECEPTORS; LEUCINE-ZIPPER; HUMAN TESTIS; C-ERB; BINDING; DNA	The thyroid hormone receptors (TR) bind to cis-acting DNA elements as heterodimers with the retinoid X receptors (RXR), These heterodimers display distinct specificities in mediating the hormonal response to target gene transcription, We characterized the interaction between TR alpha 1 and RXR alpha via their ligand binding domains (LBDs) and the effect of ligands on the interaction using a yeast two-hybrid system, The DNA binding domain (ED) of yeast Gal4 fusion to the LED of TR alpha 1 had no transcriptional activity on its own, but when it was coexpressed with the activation domain (AD) of yeast Gal4 fusion to LED of RXR alpha conferred activation to a reporter gene harboring a Gal4 binding site, indicating that LBDs of TR alpha 1 and RXR alpha interact with each other in solution, Furthermore, T-3 and 9-cis-RA increased the reporter activity, and an additive effect was observed when both ligands were added, indicating that the TR alpha 1.RXR alpha heterodimerization is augmented by their respective ligands in vivo, Using an in vitro pull down experiment, we confirmed the ligand dependent interaction observed in the yeast system, Matrix-bound glutathione S-transferase-RXR alpha specifically coprecipitated the S-35-labeled TR alpha 1 above the control, and associated S-35-labeled TR alpha 1 was increased by the addition of T-3 and 9-cis-RA. These results imply a complex, sensitive crosstalk in vivo among nuclear receptors and their respective ligands through distinct hormonal signaling pathways.	SHINSHU UNIV,SCH MED,DEPT GERIATR ENDOCRINOL & METAB,MATSUMOTO,NAGANO 390,JAPAN	Shinshu University								BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; ICHIKAWA K, 1988, J ENDOCRINOL, V119, P431, DOI 10.1677/joe.0.1190431; ICHIKAWA K, 1990, MOL CELL ENDOCRINOL, V70, P175; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Miller J.H., 1972, EXPT MOL GENETICS; MIYAMOTO T, 1991, ENDOCRINOLOGY, V129, P3027, DOI 10.1210/endo-129-6-3027; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; OPPENHEIMER JH, 1985, ANN INTERN MED, V102, P374, DOI 10.7326/0003-4819-102-3-374; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	36	26	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23799	23804		10.1074/jbc.272.38.23799	http://dx.doi.org/10.1074/jbc.272.38.23799			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295326	hybrid			2022-12-25	WOS:A1997XX38100051
J	LewisCarl, S; Kirley, TL				LewisCarl, S; Kirley, TL			Immunolocalization of the ecto-ATPase and ecto-apyrase in chicken gizzard and stomach - Purification and N-terminal sequence of the stomach ecto-apyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE HYDROLASE; SMOOTH-MUSCLE; TOXOPLASMA-GONDII; CELL ACTIVATION; PROTEIN ASSAY; MG-ATPASE; DIPHOSPHOHYDROLASE; IDENTIFICATION; CD39	We have examined the in vivo localization of extracellular ecto-ATPase and ecto-apyrase (ATPDase) in adult chicken gizzard and stomach by immunofluorescence and laser scanning confocal microscopy. In chicken gizzard, the ecto-ATPase was distributed in discrete clusters restricted to the sarcolemma of the smooth muscle cells, Anti-ecto-apyrase antibody detected a single 80-kDa band (putative apyrase) in Western blots of both chicken gizzard membrane extracts and partially purified anion exchange fractions, but the antibody did not detect ecto-apyrase in immunolabeled gizzard cryosections. In adult chicken stomach, the ecto-apyrase was observed at the apical membrane of the glandular oxyntico-peptic cells as described in previous immunoperoxidase studies (Stout, J. G., R. S. Strobel, and T. L. Kirley (1995) Biochem, Mol. Biol, Int. 36, 529-535). However, ecto-ATPase was clustered in the sarcolemma of the organized layer of circular smooth muscle and in smooth muscle cells of the septa surrounding the glandular tissue, but not in the glandular cells containing the ecto-apyrase, The findings indicate compartmentalization of the two related extracellular nucleotide hydrolyzing enzymes and suggest differential functions that are specialized for different regions of the chicken stomach, We also partially purified the ecto apyrase of chicken stomach, an 80 kDa membrane glycoprotein. Chicken stomach membranes were solubilized in digitonin, glycoproteins were separated from solubilized proteins by lectin chromatography, and nucleotide-binding glycoproteins were selected by immobilized Cibacron blue chromatography, Further purification by size exclusion and anion exchange chromatography yielded purification of 94-fold, The ATPase specific activity of the purified stomach ecto-apyrase was 75,000 mu mol of P-i/mg of protein/h, and the purified preparation consisted of a major band (55% of total protein) at 80 kDa, The purified enzyme could be deglycosylated with peptide N-glycosidase-F to a core molecular mass of 54 kDa. The N-terminal sequence of the 80-kDa stomach ecto-apyrase band (which reacted with anti-ecto-ATPDase antibodies) was determined to be: MEYKGKVVAGLLTATWV. Immunological cross-reactivity data indicate that the stomach 80-kDa protein isolated is an ecto apyrase and is related to both the chicken liver and oviduct ecto-ATPDase enzymes characterized earlier, as well as to the human lymphoid cell activation antigen, CD39.	UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati				Kirley, Terence/0000-0002-6211-1414				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BURNSTOCK G, 1988, TRENDS PHARMACOL SCI, V9, P116, DOI 10.1016/0165-6147(88)90185-X; Burnstock G, 1996, LANCET, V347, P1604, DOI 10.1016/S0140-6736(96)91082-X; Candinas D, 1996, THROMB HAEMOSTASIS, V76, P807; CORR L, 1991, BRIT J PHARMACOL, V104, P337, DOI 10.1111/j.1476-5381.1991.tb12432.x; CUNNINGHAM HB, 1993, ARCH BIOCHEM BIOPHYS, V303, P32, DOI 10.1006/abbi.1993.1252; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P1; EDWARDS FA, 1993, FEBS LETT, V325, P86, DOI 10.1016/0014-5793(93)81419-Z; Fiske CH, 1925, J BIOL CHEM, V66, P375; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kirley TL, 1997, ECTO-ATPASES, P111; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KIRLEY TL, 1988, J BIOL CHEM, V263, P12682; KITTEL A, 1994, CELL BIOL INT, V18, P875, DOI 10.1006/cbir.1994.1124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PLESNER L, 1995, INT REV CYTOL, V158, P141; PLESNER L, 1997, ECTOATPASES RECENT P; Robson SC, 1996, TRANSPLANT P, V28, P536; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; STOSCHECK CM, 1990, ANAL BIOCHEM, V184, P111, DOI 10.1016/0003-2697(90)90021-Z; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; STOUT JG, 1995, J BIOL CHEM, V270, P11845, DOI 10.1074/jbc.270.20.11845; Stout JG, 1995, BIOCHEM MOL BIOL INT, V36, P529; STROBEL R, 1993, ANN NY ACAD SCI, V671, P487; Strobel RS, 1996, J BIOL CHEM, V271, P16323, DOI 10.1074/jbc.271.27.16323; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; TREUHEIT MJ, 1992, J BIOL CHEM, V267, P11777; Vasconcelos EG, 1996, J BIOL CHEM, V271, P22139, DOI 10.1074/jbc.271.36.22139; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	37	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23645	23652		10.1074/jbc.272.38.23645	http://dx.doi.org/10.1074/jbc.272.38.23645			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295305	hybrid			2022-12-25	WOS:A1997XX38100030
J	Sine, SM				Sine, SM			Identification of equivalent residues in the gamma, delta, and epsilon subunits of the nicotinic receptor that contribute to alpha-bungarotoxin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ACETYLCHOLINE-RECEPTOR; MOLECULAR DISSECTION; TORPEDO-CALIFORNICA; LIGAND-BINDING; SELECTIVITY; INTERFACES; MARMORATA; AFFINITY; PEPTIDE; SITES	Cysteine was introduced from residues 116 to 121 of the gamma subunit of the fetal mouse acetylcholine receptor, and the mutant receptors were treated with methanethiosulfonate reagents and examined for changes in ligand binding properties, Of the 18 combinations of mutant and reagent, only receptors harboring gamma L119C treated with the quaternary ammonium reagent MTSET (trimethylammonium-ethyl methanethiosulfonate) show a decreased number of alpha-bungarotoxin (alpha-btx) sites, The decrease of 50% suggests that alpha-btx binding to the site harboring gamma L119C is blocked, Analysis of binding of the site-selective ligands dimethyl-d-tubocurarine (DMT) and alpha-conotoxin M1 (CTX) confirm specificity of modification for the site harboring gamma L119C, Cysteines placed at equivalent positions of the delta and epsilon subunits also lead to selective loss of alpha-btx binding following MTSET treatment, gamma L119C receptors treated with the primary amine reagent MTSEA (aminoethyl methanethiosulfonate) retain alpha-btx binding to both sites but show reduced affinity for DMT and CTX at the modified site, Lysine mutagenesis of Leu(gamma 119), Leu(delta 121), and Leu(epsilon 119) mimics MTSEA treatment, whereas mutagenesis of Thr(alpha 119) and Gln(beta 119) is without effect, demonstrating subunit and residue specificity of MTSEA modification, MTSET modification of nearby gamma Y117C does not block alpha-btx binding but markedly diminishes affinity for DMT and CTX, The overall findings indicate a localized point of interaction between alpha-btx and the modified gamma L119C, delta L121C, and epsilon L119C.			Sine, SM (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,RECEPTOR BIOL LAB,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031744, R01NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BLOUNT P, 1991, J BIOL CHEM, V266, P14692; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; FU DX, 1994, J BIOL CHEM, V269, P26152; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LENTZ TL, 1988, INT REV NEUROBIOL, V29, P117, DOI 10.1016/S0074-7742(08)60085-9; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; MAELICKE A, 1977, J BIOL CHEM, V252, P4811; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P3008, DOI 10.1073/pnas.83.9.3008; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; TZARTOS SJ, 1983, EMBO J, V2, P381, DOI 10.1002/j.1460-2075.1983.tb01434.x	21	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23521	23527		10.1074/jbc.272.38.23521	http://dx.doi.org/10.1074/jbc.272.38.23521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295287	hybrid			2022-12-25	WOS:A1997XX38100012
J	Tian, H; Yu, L; Mather, MW; Yu, CA				Tian, H; Yu, L; Mather, MW; Yu, CA			The involvement of serine 175 and alanine 185 of cytochrome b of Rhodobacter sphaeroides cytochrome bc(1) complex in interaction with iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONMOTIVE Q-CYCLE; SUBUNIT-IV; UBIQUINONE; SITE; MUTAGENESIS; BINDING; CHAIN; IDENTIFICATION; PURIFICATION; INHIBITORS	An approach involving cysteine replacement of potentially noncritical amino acid residues, followed by chemical modification studies, was used to investigate structure-function of the ''cd helix'' of cytochrome b from Rhodobacter sphaeroides. Three amino acid residues, Ser-155, Ser-175, and Ala-185, which span this region of cytochrome b, were selected for this study, The S155C substitution yields cells unable to support photosynthetic growth, indicating that Ser-155 is a critical amino acid residue, Further mutational studies of Ser-155 indicate that the size of the amino acid side chain at this position is critical for photosynthetical growth of R. sphaeroides. On the other hand, the S175C and A185C substitutions yield cells with photosynthetic growth rates and enzyme kinetics of the bc(1) complexes very similar to those of the unmutated complex, indicating that Ser-175 and Ala-185 are noncritical residues, Thus, engineered cysteines at these two positions of cytochrome b are suitable far membrane topology and domain/subunit interaction studies. Cys-185 does not react with a sulfhydryl-modifying reagent, N-ethylmaleimide (NEM), either in sealed, inside-out chromatophores or in detergent-disrupted chromatophores, indicating that position 175 of cytochrome b if inaccessible from both sides of the membrane and is probably buried within the protein complex. Cys-185 reacts with NEM only after detergent disruption of the sealed, inside-out chromatophores, indicating that this position of cytochrome b is accessible on the outer (periplasmic) surface of the membrane. These results place the cd helix of cytochrome b on the periplasmic side of the chromatophore membrane, When purified A185C-substituted bc(1) complex was treated with NEM, about 87% of the activity was abolished due to NEM modification of Cys-185. The signature of the Rieske iron-sulfur center is broadened upon NEM modification of A185C, with the g(x) signal shifting from g = 1.80 to g = 1.75, suggesting that Ala-185 of cytochrome b interacts with the iron-sulfur protein. When purified S175C-substituted bc(1) complex is treated with NEM, no change in the activity is observed, since Cys-175 is inaccessible to NEM. However, when the iron-sulfur protein is removed from the S175C-substituted bc(1) complex. Cys-175 becomes accessible to NEM, indicating that Ser-175 of cytochrome b is shielded by the iron-sulfur protein in the bc(1) complex.	OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOL BIOL,STILLWATER,OK 74078	Oklahoma State University System; Oklahoma State University - Stillwater				Mather, Michael/0000-0002-1062-0137	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; CANNON WR, 1995, PROTEIN SCI, V4, P387; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; Ding H, 1995, BIOCHEMISTRY-US, V34, P15997, DOI 10.1021/bi00049a013; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; DU ZJ, 1993, METHOD ENZYMOL, V218, P104; GABELLINI N, 1982, EUR J BIOCHEM, V126, P105, DOI 10.1111/j.1432-1033.1982.tb06753.x; GRAY KA, 1992, BIOCHEMISTRY-US, V31, P11864, DOI 10.1021/bi00162a027; HE DY, 1994, J BIOL CHEM, V269, P2292; HUNTER CN, 1988, BIOCHEMISTRY-US, V27, P3459, DOI 10.1021/bi00409a050; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWENDON A, 1990, BIOCHEMISTRY-US, V29, P2075, DOI 10.1021/bi00460a016; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; PADDOCK ML, 1995, BIOCHEMISTRY-US, V34, P15742, DOI 10.1021/bi00048a019; *PROM CORP, 1996, ALT SIT IN VITR MUT; PURVIS DJ, 1990, J BIOL CHEM, V265, P1208; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; SUWANTO A, 1992, J BACTERIOL, V174, P1124, DOI 10.1128/jb.174.4.1124-1134.1992; SZCZEPANIAK A, 1991, EMBO J, V10, P2757, DOI 10.1002/j.1460-2075.1991.tb07824.x; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU L, 1984, J BIOL CHEM, V259, P5752; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1987, BIOCHEMISTRY-US, V26, P3658, DOI 10.1021/bi00386a060; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23722	23728		10.1074/jbc.272.38.23722	http://dx.doi.org/10.1074/jbc.272.38.23722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295316	hybrid			2022-12-25	WOS:A1997XX38100041
J	Chang, CH; Luse, DS				Chang, CH; Luse, DS			The H3/H4 tetramer blocks transcript elongation by RNA polymerase II in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE OCTAMER; NUCLEOSOMAL TEMPLATES; HUMAN RAP74; MAJOR LATE; IN-VITRO; INVITRO; DNA; INITIATION; CHROMATIN; BINDING	We have investigated transcript elongation efficiency by RNA polymerase II on chromatin templates in vitro. Circular plasmid DNAs bearing purified RNA polymerase II transcription complexes were assembled into nucleosomes using purified histones and transient exposure to high salt, followed by dilution and dialysis. This approach resulted in nucleosome assembly beginning immediately downstream of the transcription complexes, RNA polymerases on these nucleosomal templates could extend their 15- or 35-nucleotide nascent RNAs by only about 10 nucleotides in 15 min, even in the presence of elongation factors TFIIF and SII, Efficient transcript elongation did occur upon dissociation of nucleosomes with 1% sarkosyl, indicating that the RNA polymerases were not damaged by the high salt reconstitution procedure. Since the elongation complexes were released by sarkosyl but not by SII, these complexes apparently did not enter the arrested conformation when they encountered nucleosomes. Surprisingly, elongation was no more efficient on nucleosomal templates reconstituted only with H3/H4 tetramers, even in the presence of elongation factors and/or competitor DNA at high concentration, Thus, in a purified system lacking nucleosome remodeling factors, not only the core histone octamer but also the H3/H4 tetramer provide an nearly absolute block to transcript elongation by RNA polymerase II, even in the presence of elongation factors.	CLEVELAND CLIN FDN, DEPT MOL BIOL, LERNER RES INST, NC20, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NIGMS NIH HHS [GM 29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; CAI H, 1987, J BIOL CHEM, V262, P298; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KIROV N, 1992, EMBO J, V11, P1941, DOI 10.1002/j.1460-2075.1992.tb05247.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LUSE DS, 1987, J BIOL CHEM, V262, P289; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; PATTERTON HG, 1993, J MOL BIOL, V229, P623, DOI 10.1006/jmbi.1993.1068; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; Protacio RU, 1996, J MOL BIOL, V256, P458, DOI 10.1006/jmbi.1996.0101; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RHODES D, 1989, METHOD ENZYMOL, V170, P575; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SHIMAMURA A, 1989, J BIOL CHEM, V264, P14524; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; STEIN A, 1989, METHOD ENZYMOL, V170, P585; Sternglanz R, 1996, TRENDS BIOCHEM SCI, V21, P357, DOI 10.1016/S0968-0004(96)90120-6; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Studitsky VM, 1996, METHOD ENZYMOL, V274, P246; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; Yankulov KY, 1996, MOL CELL BIOL, V16, P3291; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	57	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23427	23434		10.1074/jbc.272.37.23427	http://dx.doi.org/10.1074/jbc.272.37.23427			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287358	hybrid			2022-12-25	WOS:A1997XV74400069
J	Zheng, LM; Eckerdal, J; Dimitrijevic, I; Andersson, T				Zheng, LM; Eckerdal, J; Dimitrijevic, I; Andersson, T			Chemotactic peptide-induced activation of Ras in human neutrophils is associated with inhibition of p120-GAP activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; PLECKSTRIN HOMOLOGY DOMAINS; VAV PROTOONCOGENE PRODUCT; SHC ADAPTER PROTEIN; T-CELL ACTIVATION; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; CHEMOATTRACTANT RECEPTORS	The monomeric G-protein Ras is now considered to function as an initial regulator of multiple signaling pathways in both normal and transformed cell types, Adhesion and chemoattractant receptors are known to trigger activation of Ras in human neutrophils, but the signaling mechanism that, activates Ras has only been partially elucidated, The present results show that in neutrophils, a time-and dose-dependent f-Met-Leu-Phe (FMLP)-induced activation of Ras is mediated by G(i2)-proteins, because such activation is inhibited by pertussis toxin and because direct stimulation of heterotrimeric G-proteins with AlF4- is sufficient to activate Ras. Pretreatment of neutrophils with tyrosine kinase inhibitors, i.e. genistein or erbstatin that completely block FMLP-stimulated protein tyrosine phosphorylations, did not affect; the FMLP-induced activation of Ras. Moreover, FMLP did not induce any detectable translocation of Grb2 and Sos to the plasma membrane of neutrophils. Other signaling molecules, such as protein kinase C, phosphatidylinositol 3-kinase and Ca2+, do not appear to be involved in the FMLP-induced Pas activation. Instead, stimulation of neutrophils with FMLP or C5a, the latter of which also activates G(i2)-proteins, resulted ill transient inhibition of the activity of Ras GTPase-activating proteins (GAP) with kinetics that correlated well with the kinetics of Ras activation. Moreover, decreased Ras-GAP activity was found in p120-GAP but not in neurofibromin immunoprecipitates of FMLP-stimulated cells. These results suggest that tyrosine kinase-dependent Ras exchange factors do not contribute to the FMLP-induced activation of Ras but that such activation is mediated via inhibition of p120-GAP in neutrophils.			Zheng, LM (corresponding author), LUND UNIV,WALLENBERG LAB,DEPT LAB MED,DIV EXPT PATHOL,FLOOR 4,U-MAS,S-20502 MALMO,SWEDEN.		zheng, limin/HGB-2510-2022	Andersson, Tommy/0000-0003-4032-5769; Zheng, Limin/0000-0002-8281-1450				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BOGUSKI MS, 1993, NATURE, V366, P648; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CRAMER EB, 1992, INFLAMMATION BASIC P, P341; Downey GP, 1996, J BIOL CHEM, V271, P21005, DOI 10.1074/jbc.271.35.21005; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Dusi S, 1996, FEBS LETT, V383, P181, DOI 10.1016/0014-5793(96)00248-7; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GRAVES JD, 1991, J IMMUNOL, V146, P3709; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; Gulbins E, 1995, BIOCHEM BIOPH RES CO, V217, P876, DOI 10.1006/bbrc.1995.2853; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULHINS E, 1994, MOL CELL BIOL, V14, P4749; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hellberg C, 1996, BIOCHEM J, V317, P403, DOI 10.1042/bj3170403; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Katagiri K, 1996, BLOOD, V87, P4276, DOI 10.1182/blood.V87.10.4276.bloodjournal87104276; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RIDELY AJ, 1992, CELL, V40, P401; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sarndahl E, 1996, J BIOL CHEM, V271, P15267; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TORRES M, 1993, J IMMUNOL, V150, P1563; Torres M, 1996, J BIOL CHEM, V271, P13244, DOI 10.1074/jbc.271.22.13244; TORTI M, 1992, J BIOL CHEM, V267, P8293; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; ZHENG L, 1995, J IMMUNOL, V155, P776; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	58	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23448	23454		10.1074/jbc.272.37.23448	http://dx.doi.org/10.1074/jbc.272.37.23448			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287361	hybrid			2022-12-25	WOS:A1997XV74400072
J	Niswender, KD; Postic, C; Jetton, TL; Bennett, BD; Piston, DW; Efrat, S; Magnuson, MA				Niswender, KD; Postic, C; Jetton, TL; Bennett, BD; Piston, DW; Efrat, S; Magnuson, MA			Cell-specific expression and regulation of a glucokinase gene locus transgene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELL; DEPENDENT DIABETES-MELLITUS; INSULIN-SECRETION; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; RAT HEPATOCYTES; GLUCOSE SENSOR; X-INACTIVATION; GLOBIN GENE; HIGH-LEVEL	Transgenic mice containing one or more extra copies of the entire glucokinase (GK) gene locus were generated and characterized. The GK transgene, an 83-kilobase pair mouse genomic DNA fragment containing both promoter regions, was expressed and regulated in a cell-specific manner, and rescued GK null lethality when crossed into mice bearing a targeted mutation of the endogenous GK gene. Livers from the transgenic mice had elevated GK mRNA, protein, and activity levels, compared with controls, and the transgene was regulated in liver by dietary manipulations. The amount of GK immunoreactivity in hepatocyte nuclei, where GK binds to the GK regulatory protein, was also increased. Pancreatic islets displayed increased GK immunoreactivity and NAD(P)H responses to glucose, but only when isolated and cultured in 20 mM glucose, as a result of the hypoglycemic phenotype of these mice (Niswender, K. D., Shiota, M., Postic, C., Cherrington, A. D., and Magnuson, M. A. (1997) J. Biol. Chem. 272, 22604-22609). Together, these results indicate that the region of the gene from -55 to +28 kilobase pairs (relative to the liver GK transcription start site) contains all the regulatory sequences necessary for expression of both GK isoforms, thereby placing an upper limit on the size of the GK gene locus.	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA	Vanderbilt University; Yeshiva University; Albert Einstein College of Medicine			Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Postic, Catherine/P-2271-2017	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Postic, Catherine/0000-0002-1875-6960; Efrat, Shimon/0000-0001-5987-232X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42612, DK 42502] Funding Source: Medline; PHS HHS [5T3Z C-M07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Bennett BD, 1996, J BIOL CHEM, V271, P3647; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DISTECHE CM, 1995, TRENDS GENET, V11, P17, DOI 10.1016/S0168-9525(00)88981-7; EXTON JH, 1972, METABOLISM, V21, P945, DOI 10.1016/0026-0495(72)90028-5; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; HOGAN B, 1994, MANIPULATING MOUSE E, P217; Iynedjian PB, 1996, J BIOL CHEM, V271, P29113, DOI 10.1074/jbc.271.46.29113; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; JETTON TL, 1994, DIABETES, P193; KRAUSFRIEDMANN N, 1984, PHYSIOL REV, V64, P170, DOI 10.1152/physrev.1984.64.1.170; KRUMLAUF R, 1986, NATURE, V319, P224, DOI 10.1038/319224a0; LEIBIGER IB, 1994, FEBS LETT, V337, P161, DOI 10.1016/0014-5793(94)80265-3; LI QL, 1994, MOL CELL BIOL, V14, P6087, DOI 10.1128/MCB.14.9.6087; LIANG Y, 1994, DIABETES, V43, P1138, DOI 10.2337/diabetes.43.9.1138; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MIWA I, 1990, BIOCHEM INT, V22, P759; Moates JM, 1996, MOL ENDOCRINOL, V10, P723, DOI 10.1210/me.10.6.723; MOORMAN AFM, 1991, FEBS LETT, V287, P47, DOI 10.1016/0014-5793(91)80013-S; NAGAI K, 1978, BRAIN RES, V142, P384, DOI 10.1016/0006-8993(78)90648-0; NARKEWICZ MR, 1990, BIOCHEM J, V271, P585, DOI 10.1042/bj2710585; NISWENDER KD, 1997, J BIOL CHEM, V272, P22604; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; POSTIC C, 1995, GENOMICS, V29, P740, DOI 10.1006/geno.1995.9943; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHARP DW, 1973, TRANSPLANTATION, V16, P686, DOI 10.1097/00007890-197312000-00028; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; TOYODA Y, 1995, BIOCHEM BIOPH RES CO, V215, P467, DOI 10.1006/bbrc.1995.2488; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WU H, 1992, DEVELOPMENT, V116, P687; YIN L, 1992, DIABETES, V41, P792	53	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22564	22569		10.1074/jbc.272.36.22564	http://dx.doi.org/10.1074/jbc.272.36.22564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278410	hybrid			2022-12-25	WOS:A1997XV49200030
J	Braganca, J; Genin, P; Bandu, MT; Darracq, N; Vignal, R; Casse, C; Doly, J; Civas, A				Braganca, J; Genin, P; Bandu, MT; Darracq, N; Vignal, R; Casse, C; Doly, J; Civas, A			Synergism between multiple virus-induced factor-binding elements involved in the differential expression of interferon A genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; IFN-BETA GENE; REGULATORY FACTOR FAMILY; ALPHA PROMOTER REGION; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; RESPONSE ELEMENT; IRF FAMILY; INDUCTION	Comparative transfection analysis of murine interferon A4 and interferon All promoter constructs transiently transfected in mouse L929 and human HeLa S3 cells infected with Newcastle disease virus showed that the second positive regulatory domain I-like domain (D motif), located between nucleotides -57 and -46 upstream of the transcription start site, contributes to the activation of virus-induced transcription of the interferon (IFN)-A4 gene promoter by cooperating with the positive regulatory domain I-like and TG-like domains previously described. Electrophoretic mobility shift assay performed with the virus-inducible fragments containing these motifs indicated that the binding activity that we have denoted as virus-induced factor (Genin, P., Braganca, J., Darracq, N., Doly, J., and Civas, A. (1995) Nucleic Acids Res. 23, 5055-5063) is different from inter feron-stimulated gene factor 3, It binds to the D motif but not to the virus-unresponsive form of the D motif disrupted by a G(-57) --> C substitution. We show that the low levels of IFN-A11 gene expression are caused essentially by the lack of two inducible enhancer domains disrupted by the A(-78) --> G and the G(-57) --> C substitutions, These data suggest a model taking account of the differential regulation of IFN-A gene family members, They also suggest that virus-induced factor may correspond to the primary transcription factor directly activated by virus that is involved in the initiation of IFN-A gene transcription.	UNIV PARIS 05,LAB REGULAT EXPRESS GENES EUCARYOTES,CNRS,UPR 37,UFR BIOMED ST PERES,F-75270 PARIS 06,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			Braganca, Jose/F-4410-2012	Braganca, Jose/0000-0001-9566-400X; Genin, Pierre/0000-0002-7502-3851				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; CIVAS A, 1991, NUCLEIC ACIDS RES, V19, P4497, DOI 10.1093/nar/19.16.4497; COULOMBEL C, 1991, GENE, V104, P187, DOI 10.1016/0378-1119(91)90249-B; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DALY C, 1995, J BIOL CHEM, V270, P23739, DOI 10.1074/jbc.270.40.23739; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Maeyer E., 1994, CYTOKINE HDB, P265; Dent CL, 1996, EUR J BIOCHEM, V236, P895, DOI 10.1111/j.1432-1033.1996.t01-1-00895.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRANT CE, 1995, NUCLEIC ACIDS RES, V23, P2137, DOI 10.1093/nar/23.12.2137; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, NATURE, V337, P270; HISCOTT J, 1988, MOL CELL BIOL, V8, P3397, DOI 10.1128/MCB.8.8.3397; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P368; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; KELLER AD, 1992, MOL CELL BIOL, V12, P1940, DOI 10.1128/MCB.12.5.1940; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; KELLEY KA, 1985, VIROLOGY, V147, P382, DOI 10.1016/0042-6822(85)90140-0; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, V2, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PITHA PM, 1995, SEMIN VIROL, V6, P151, DOI 10.1006/smvy.1995.0020; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAJ NBK, 1989, J BIOL CHEM, V264, P16658; Roffet P, 1996, BIOCHEM J, V317, P697, DOI 10.1042/bj3170697; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUTTLEWORTH J, 1983, EUR J BIOCHEM, V133, P399, DOI 10.1111/j.1432-1033.1983.tb07476.x; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yoneyama M, 1996, J BIOCHEM-TOKYO, V120, P160	65	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22154	22162		10.1074/jbc.272.35.22154	http://dx.doi.org/10.1074/jbc.272.35.22154			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268360	hybrid			2022-12-25	WOS:A1997XT85000072
J	Efthymiadis, A; Shao, HM; Hubner, S; Jans, DA				Efthymiadis, A; Shao, HM; Hubner, S; Jans, DA			Kinetic characterization of the human retinoblastoma protein bipartite nuclear localization sequence (NLS) in vivo and in vitro - A comparison with the SV40 large T-antigen NLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II SITE FLANKING; NUCLEOCYTOPLASMIC TRANSPORT; BETA-GALACTOSIDASE; ESCHERICHIA-COLI; PORE COMPLEX; GENE-PRODUCT; GRANZYME-B; IN-VIVO; IMPORT; PHOSPHORYLATION	The retinoblastoma (RE) tumor suppressor is a nuclear phosphoprotein important for cell growth control and able to bind specifically to viral oncoproteins such as the SV40 large tumor antigen (T-ag), Human RE possesses a bipartite nuclear localization sequence (NLS) consisting of two clusters of basic amino acids within amino acids 860-877, also present in mouse and Xenopus homologs, which resembles that of nucleoplasmin, The T-ag NLS represents a different type of NLS, consisting of only one stretch of basic amino acids, To compare the nuclear import kinetics conferred by the bipartite NLS of RE to those conferred by the T-ag NLS, we used beta-galactosidase fusion proteins containing the NLSs of either RE or T-ag, The RE NLS was able to target beta-galactosidase to the nucleus both in vivo (in microinjected cells of the HTC rat hepatoma line) and in vitro (in mechanically perforated HTC cells), Mutational substitution of the proximal basic residues of the NLS abolished nuclear targeting activity, confirming its bipartite character, Nuclear accumulation of the RE fusion protein was half-maximal within about 8 min in vivo maximal levels being between 3-4-fold those in the cytoplasm, which was less than 50% of the maximal levels attained by the T-ag fusion protein, while the initial rate of nuclear import of the RE protein was also less than half that of T-ag, Nuclear import conferred by both NLSs in vitro was dependent on cytosol and ATP and inhibited by the nonhydrolyzable GTP analog GTP gamma S. Using an ELISA-based binding assay, we determined that the RE bipartite NLS had severely reduced affinity, compared with the T-ag NLS, for the high affinity heterodimeric NLS-binding protein complex importin 58/97, this difference presumably representing the basis of the reduced maximal nuclear accumulation and import rate in vivo, The results support the hypothesis that the affinity of NLS recognition by NLS-binding proteins is critical in determining the kinetics of nuclear protein import.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOL BIOL, NUCL SIGNALING LAB, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research								ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AGUTTER PS, 1994, BIOCHEM J, V300, P609, DOI 10.1042/bj3000609; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; STOCHAJ U, 1992, EUR J CELL BIOL, V59, P1; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	44	108	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22134	22139		10.1074/jbc.272.35.22134	http://dx.doi.org/10.1074/jbc.272.35.22134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268357	hybrid			2022-12-25	WOS:A1997XT85000069
J	Finlin, BS; Andres, DA				Finlin, BS; Andres, DA			Rem is a new member of the Rad- and Gem/Kir ras-related GTP-binding protein family repressed by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GENE; EXPRESSION; SEQUENCE; SUPERFAMILY; FIBROBLASTS; ACTIVATION; MEMBRANE; MUSCLE; P21RAS	We report the cDNA cloning and characterization of a novel GTP-binding protein, termed Rem (for Rad and Gem-related), that was identified as a product of polymerase chain reaction amplification using oligonucleotide primers derived from conserved regions of the Rad, Gem, and Kir Ras subfamily, Alignment of the full-length open reading frame of mouse Rem revealed the encoded protein to be 47% identical to the Rad, Gem, and Kir proteins, The distinct structural features of the Rad, Gem, and Kir subfamily are maintained including a series of nonconservative amino acid substitutions at positions important for GTPase activity and a unique sequence motif thought to direct membrane association. Recombinant Rem binds GTP in a specific and saturable manner, Ribonuclease protection analysis found Rem to be expressed at comparatively high levels in cardiac muscle and at moderate levels in lung, skeletal muscle, and kidney, The administration of lipopolysaccharide to mice, a potent activator of the inflammatory and immune systems, results in the general repression of Rem mRNA levels in a dose-and time-dependent manner, Thus, Rem is the first Ras-related gene whose mRNA levels have been shown to be regulated by repression.	UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky					NEI NIH HHS [EY 11231] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY011231] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Dorin D, 1995, ONCOGENE, V11, P2267; FARRELL FX, 1990, NUCLEIC ACIDS RES, V18, P4281, DOI 10.1093/nar/18.14.4281; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOBBS MV, 1993, J IMMUNOL, V150, P3602; HOD Y, 1992, BIOTECHNIQUES, V13, P852; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KAHN CR, 1993, SCIENCE, V262, P1441; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; Lowry D. R., 1993, ANNU REV BIOCHEM, V62, P4637; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; PIZON V, 1988, ONCOGENE, V3, P201; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; SAMBROOK J, 1989, MOL CLONING LAB CLIN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WANG K, 1994, BIOTECHNIQUES, V17, P236; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA; Zhu JH, 1996, J BIOL CHEM, V271, P768, DOI 10.1074/jbc.271.2.768; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	38	86	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21982	21988		10.1074/jbc.272.35.21982	http://dx.doi.org/10.1074/jbc.272.35.21982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268335	hybrid			2022-12-25	WOS:A1997XT85000047
J	Nakano, K; Mizuno, T; Sowa, Y; Orita, T; Yoshino, T; Okuyama, Y; Fujita, T; OhtaniFujita, N; Matsukawa, Y; Tokino, T; Yamagishi, H; Oka, T; Nomura, H; Sakai, T				Nakano, K; Mizuno, T; Sowa, Y; Orita, T; Yoshino, T; Okuyama, Y; Fujita, T; OhtaniFujita, N; Matsukawa, Y; Tokino, T; Yamagishi, H; Oka, T; Nomura, H; Sakai, T			Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; RNA POLYMERASE-II; SODIUM-BUTYRATE; POTENTIAL MEDIATOR; CARCINOMA CELLS; PROTEIN-KINASE; HT-29 CELLS; P21; DIFFERENTIATION; GROWTH	Butyrate is a well known colonic luminal short chain fatty acid, which arrests cell growth and induces differentiation in various cell types. We examined the effect of butyrate on the expression of WAF1/Cip1, a potent inhibitor of cyclin-dependent kinases, and its relation to growth arrest in a p53-mutated human colon cancer cell line WiDr, Five millimolar butyrate completely inhibited the growth of WiDr and caused G(1)-phase arrest. WAF1/Cip1 mRNA was rapidly induced within 3 h by treatment with 5.0 mM butyrate, and drastic WAF1/Cip1 protein induction was detected. Using several mutant WAF1/Cip1 promoter fragments, we found that the butyrate responsive elements are two Spl sites at -82 and -69 relative to the transcription start site. We also found that a TATA element at -46 and two overlapping consensus Spl sites at -60 and -55 are essential for the basal promoter activity of WAF1/Cip1. These findings suggest that butyrate arrests the growth of WiDr by activating the WAF1/Cip1 promoter through specific Sp1 sites in a p53-independent fashion.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT SURG 2,KAMIKYO KU,KYOTO 602,JAPAN; CHUGAI RES INST MOL MED,NIIHARI,IBARAKI 30041,JAPAN; UNIV TOKYO,INST MED SCI,TOKYO 108,JAPAN	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; University of Tokyo			Tokino, Takashi/AAI-9887-2021					BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BuquetFagot C, 1996, J CELL PHYSIOL, V166, P631, DOI 10.1002/(SICI)1097-4652(199603)166:3<631::AID-JCP18>3.0.CO;2-9; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG QG, 1993, ANTI-CANCER DRUG, V4, P617, DOI 10.1097/00001813-199312000-00003; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAHAM KA, 1988, J CELL PHYSIOL, V136, P63, DOI 10.1002/jcp.1041360108; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HEROLD KM, 1988, ONCOGENE, V3, P423; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JIANG HP, 1994, ONCOGENE, V9, P3397; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI YJ, 1995, ONCOGENE, V10, P599; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MICHIELI P, 1994, CANCER RES, V54, P3391; MORITA A, 1982, CANCER RES, V42, P4540; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; SAKAI T, 1996, JPN J HYG, V50, P1036; Sambrook J., 2002, MOL CLONING LAB MANU; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAMURA T, 1995, ONCOGENE, V11, P1939; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAO D, 1982, CANCER RES, V42, P1052; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	44	354	367	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22199	22206		10.1074/jbc.272.35.22199	http://dx.doi.org/10.1074/jbc.272.35.22199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268365	hybrid			2022-12-25	WOS:A1997XT85000077
J	Williams, EJ; Dunican, DJ; Green, PJ; Howell, FV; Derossi, D; Walsh, FS; Doherty, P				Williams, EJ; Dunican, DJ; Green, PJ; Howell, FV; Derossi, D; Walsh, FS; Doherty, P			Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; FACTOR RECEPTOR; INTACT-CELLS; EGF-RECEPTOR; SH2 DOMAIN; ACTIVATION; GRB2; RAS; IDENTIFICATION	The activation of the mitogen-activated protein kinase (MAPK) cascade by a variety of growth factors and other agents is central to a mitogenic response, In the case of polypeptide growth factors such as the epidermal growth factor (EGF) and platelet derived growth factor (PDGF), the steps leading to activation of MAPK require the function of the adaptor protein Grb2 (growth factor receptor binding protein 2), which can bind either directly or indirectly via its Src homology 2 domain to activated receptor tyrosine kinases, A cell-permeable mimetic of the EGF receptor Grb2 binding site has been investigated for its ability to inhibit biological responses stimulated by a variety of growth factors, Pretreatment of cells with this peptide results in the accumulation of the peptide in cells and its association with Grb2. This is associated with a complete inhibition of the mitogenic response stimulated by EGF and PDGF, In contrast, the peptide has no effect on the mitogenic response stimulated by fibroblast growth factor, The peptide could also inhibit the phosphorylation of MAPK stimulated with EGF and PDGF in the absence of an effect on the fibroblast growth factor response, These data demonstrate that cell-permeable mimetics of Src homology 2 binding sites can selectively inhibit growth factor stimulated mitogenesis, and also directly demonstrate specificity in the coupling of activated receptor tyrosine kinases to the MAPK cascade.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, DEPT EXPT PATHOL, LONDON SE1 9RT, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Dunican, Dara/A-1208-2010; Doherty, Patrick/A-8752-2008	Dunican, Dara/0000-0001-6563-8089; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRETTI P, 1988, J EXP ZOOL, V247, P77, DOI 10.1002/jez.1402470111; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI NX, 1994, ONCOGENE, V9, P3457; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Wang JK, 1996, ONCOGENE, V13, P721; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	79	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22349	22354		10.1074/jbc.272.35.22349	http://dx.doi.org/10.1074/jbc.272.35.22349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268386	hybrid			2022-12-25	WOS:A1997XT85000098
J	Martin, M; Vozenin, MC; Gault, N; Crechet, F; Pfarr, CM; Lefaix, JL				Martin, M; Vozenin, MC; Gault, N; Crechet, F; Pfarr, CM; Lefaix, JL			Coactivation of AP-1 activity and TGF-beta 1 gene expression in the stress response of normal skin cells to ionizing radiation	ONCOGENE			English	Article						AP-1; fos; jun; TGF-beta 1; skin; gamma-irradiation	TRANSFORMING GROWTH FACTOR-BETA-1; IMMEDIATE-EARLY GENES; C-FOS; FACTOR-BETA; PIG SKIN; FIBROBLAST GROWTH; MUSCULAR FIBROSIS; BINDING-PROTEINS; GAMMA-RAYS; JUN	Activation of the AP-1 transcription factor and TGF-beta 1 growth factor by ionizing radiation was studied both in vivo in pig skin, and in vitro in human fibroblasts and keratinocytes, Three and 6h after irradiation, the Fos and Jun proteins and their binding activity to an AP-1 consensus sequence were strongly induced by high doses of gamma-rays, c-Fos, c-Jun and JunB proteins were found to be present in gel-shift complexes by probing with specific antibodies, Both keratinocytes and fibroblasts exhibited heightened AP-1 activity following irradiation, As we previously found that TGF-beta 1 is involved in the development of skin lesions induced by radiation, TGF-beta 1 gene expression was also examined, Two and 6h after irradiation, the levels of TGF-beta 1 transcripts were increased in skin, By immunostaining, TGF-beta 1 protein levels were found to be increased in fibroblasts, keratinocytes and endothelial cells, As promoter contains AP-1 binding sites, between AP-1 activity and TGF-beta 1 induction was addressed, The -365 TGF-beta 1 promoter fragment, which contains a high affinity AP-1 site, exhibited increased binding to Jun and Fos proteins following irradiation, These results suggest that stress-inducible TGF-beta 1 expression is mediated by the activation of AP-1 transcription factor.	INST PASTEUR,UNITE VIRUS ONCOGENES,CNRS,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Martin, M (corresponding author), CEA,LAB RADIOBIOL & ETUDE GENOME,DVS,F-91191 GIF SUR YVETTE,FRANCE.		Martin, Michele T/C-5554-2008; Vozenin, Marie-Catherine/AAR-2268-2021; Pfarr, Curt/HHD-1410-2022	Martin, Michele T/0000-0003-0530-6466; Vozenin, Marie-Catherine/0000-0002-2109-8073; Gault, Nathalie/0000-0001-6233-1946				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASIEDU CK, 1994, BBA-GENE STRUCT EXPR, V1219, P55, DOI 10.1016/0167-4781(94)90246-1; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; COLLART FR, 1995, RADIAT RES, V142, P18; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Fan GS, 1996, ONCOGENE, V12, P1909; FINKELSTEIN JN, 1994, INT J RADIAT ONCOL, V28, P621, DOI 10.1016/0360-3016(94)90187-2; GILLARDON F, 1995, NEUROREPORT, V6, P1766, DOI 10.1097/00001756-199509000-00014; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GUBITS RM, 1993, INT J RADIAT ONCOL, V27, P637, DOI 10.1016/0360-3016(93)90390-H; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hsing AY, 1996, CANCER RES, V56, P5146; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P7041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1995, J BIOL CHEM, V270, P28790, DOI 10.1074/jbc.270.48.28790; LEFAIX JL, 1993, BRIT J RADIOL, V66, P537, DOI 10.1259/0007-1285-66-786-537; MARTIN M, 1993, CANCER RES, V53, P3246; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; MARTIN M, 1989, J INVEST DERMATOL, V93, P497, DOI 10.1111/1523-1747.ep12284053; MASSAGUE J, 1990, CELL BIOL, V6, P597; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RANDALL K, 1995, INT J RADIAT BIOL, V68, P301, DOI 10.1080/09553009514551231; RAYNAL S, 1995, INT J ONCOL, V7, P337; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RUBIN P, 1995, INT J RADIAT ONCOL, V33, P99, DOI 10.1016/0360-3016(95)00095-G; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; VOZENIN MC, 1997, IN PRESS CYTOTECHNOL; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEICHSELBAUM R, 1993, MOL BIOL ONCOLOGISTS, P213; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Welter JF, 1995, ONCOGENE, V11, P2681; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	42	96	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					981	989		10.1038/sj.onc.1201433	http://dx.doi.org/10.1038/sj.onc.1201433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285693				2022-12-25	WOS:A1997XR76700011
J	Jisaka, M; Kim, RB; Boeglin, WE; Nanney, LB; Brash, AR				Jisaka, M; Kim, RB; Boeglin, WE; Nanney, LB; Brash, AR			Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; CDNA CLONING; LINOLEIC-ACID; LIPOXYGENASE; SENCAR; GENE; 5-LIPOXYGENASE; 8-LIPOXYGENASE; CHROMATOGRAPHY; LOCALIZATION	One of the effects of topical application of phorbol ester to mouse skin is the induction of all 8S-lipoxygenase in association with the inflammatory response, Here we report the molecular cloning and characterization of this enzyme. The cDNA was isolated by polymerase chain reaction from mouse epidermis and subsequently from a mouse epidermal cDNA library, The cDNA encodes a protein of 677 amino acids with a calculated molecular mass of 76 kDa, The amino acid sequence has 78% identity to a 15S-lipoxygenase cloned recently from human skin and approximately 40% identity to other mammalian lipoxygenases. When expressed in vaccinia virus-infected Hela cells, the mouse enzyme converts arachidonic acid exclusively to 8S-hydroperoxyeicosatetraenoic acid while linoleic acid is converted to 9S-hydroperoxy-linoleic acid in lower efficiency, Phorbol ester treatment of mouse skin is associated with strong induction of 8S-lipoxygenase mRNA and protein, Ey Northern analysis, expression of 8S-Lipoxygenase mRNA was also detected in brain. Immunohistochemical analysis of phorbol ester-treated mouse skill showed the strongest reaction to 8S-lipoxygenase in the differentiated epidermal layer, the stratum granulosum. The inducibility may be a characteristic feature of the mouse 8S-lipoxygenase and its human 15S-lipoxygenase homologue.	VANDERBILT UNIV, DEPT PHARMACOL, SCH MED, DIV CLIN PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT PLAST SURG & CELL BIOL, SCH MED, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University			Kim, Richard/D-6971-2011	Kim, Richard/0000-0001-8148-1632	NIEHS NIH HHS [ES000267] Funding Source: Medline; NIGMS NIH HHS [GM-53638, GM-49502] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053638, R01GM049502] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; BRASH AR, 1990, METHOD ENZYMOL, V187, P187; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; FISCHER SM, 1988, CANCER RES, V48, P658; FISCHER SM, 1987, CANCER RES, V47, P3174; FISCHER SM, 1987, CARCINOGENESIS, V8, P421, DOI 10.1093/carcin/8.3.421; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; HAMBERG M, 1980, BIOCHIM BIOPHYS ACTA, V617, P545, DOI 10.1016/0005-2760(80)90022-3; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; LEHMANN WD, 1992, ANAL BIOCHEM, V204, P158, DOI 10.1016/0003-2697(92)90156-2; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; NUGTEREN DH, 1987, BIOCHIM BIOPHYS ACTA, V921, P135, DOI 10.1016/0005-2760(87)90179-2; Oesterling JE, 1996, PROSTATE, P67; SUN D, 1996, J BIOL CHEM, V271, P20455; VANDIJK KW, 1995, BBA-LIPID LIPID MET, V1259, P4, DOI 10.1016/0005-2760(95)00158-9; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZIBOH VA, 1988, PROG LIPID RES, V27, P81, DOI 10.1016/0163-7827(88)90006-9	26	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24410	24416		10.1074/jbc.272.39.24410	http://dx.doi.org/10.1074/jbc.272.39.24410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305900	hybrid			2022-12-25	WOS:A1997XY51500051
J	Kurosu, H; Maehama, T; Okada, T; Yamamoto, T; Hoshino, S; Fukui, Y; Ui, M; Hazeki, O; Katada, T				Kurosu, H; Maehama, T; Okada, T; Yamamoto, T; Hoshino, S; Fukui, Y; Ui, M; Hazeki, O; Katada, T			Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110 beta is synergistically activated by the beta gamma subunits of G proteins and phosphotyrosyl peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHOSPHATIDYLINOSITOL 3-KINASE; MYELOID-DERIVED CELLS; GTP-BINDING PROTEINS; BOVINE BRAIN; RAT-LIVER; KINASE; IDENTIFICATION; CLONING; 3'-KINASE; ALPHA	Phosphoinositide 3-kinase (PI 3-kinase) is a key signaling enzyme implicated in variety of receptor-stimulated cell responses, Receptors with intrinsic or associated tyrosine kinase activity recruit heterodimeric PI 3-kinases consisting of a 110-kDa catalytic subunit (p110) and an 85-kDa regulatory subunit (p85). We separated a PI 3-kinase that could be stimulated by the beta gamma subunits of G protein (G beta gamma) from rack liver, The G beta gamma-sensitive PI 3-kinase appeared to be a heterodimer consisting of p110 beta and p85 (or their related subunits), The stimulation by G beta gamma was inhibited by the GDP-bound alpha subunit of the inhibitory GTP-binding protein, Moreover, the stimulatory action of G beta gamma was markedly enhanced by the simultaneous addition of a phosphotyrosyl peptide synthesized according to the amino acid sequence of the insulin receptor substrate-1, Such enzymic properties could be observed with a recombinant p110 beta/p85 alpha expressed in COS-7 cells with their cDNAs, In contrast, another heterodimeric PI 3-kinase consisting of p110 alpha and p85 in the same rat liver, together with a recombinant p110 alpha/p85 alpha, was mot activated by G beta gamma, although their activities were stimulated by the phosphotyrosyl peptide. These results indicate khat p110 beta/p85 PI 3-kinase may be regulated in a cooperative manner by two different types of membrane receptors, one possessing tyrosine kinase activity and the other activating GTP-binding proteins.	UNIV TOKYO,GRAD SCH PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,LAB BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,UI LAB,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; University of Tokyo; RIKEN			Maehama, Tomohiko/HGB-4896-2022; Maehama, Tomohiko/AAX-8926-2020	Maehama, Tomohiko/0000-0002-9685-2317; Hoshino, Shinichi/0000-0001-6135-7896				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KONTANI K, 1992, ARCH BIOCHEM BIOPHYS, V294, P527, DOI 10.1016/0003-9861(92)90720-H; KUROSU H, 1995, BIOCHEM BIOPH RES CO, V216, P655, DOI 10.1006/bbrc.1995.2672; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; NISHINA H, 1995, J BIOCHEM-TOKYO, V118, P1083, DOI 10.1093/jb/118.5.1083; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOKER A, 1994, J BIOL CHEM, V269, P32358; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589	30	227	231	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24252	24256		10.1074/jbc.272.39.24252	http://dx.doi.org/10.1074/jbc.272.39.24252			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305878	hybrid			2022-12-25	WOS:A1997XY51500029
J	Marfatia, SM; MoraisCabral, JH; Kim, AC; Byron, O; Chishti, AH				Marfatia, SM; MoraisCabral, JH; Kim, AC; Byron, O; Chishti, AH			The PDZ domain of human erythrocyte p55 mediates its binding to the cytoplasmic carboxyl terminus of glycophorin C - Analysis of the binding interface by in vitro mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NITRIC-OXIDE SYNTHASE; RED-BLOOD-CELLS; MEMBRANE SIALOGLYCOPROTEINS; MONOCLONAL-ANTIBODIES; GUANYLATE KINASES; MOLECULAR-BASIS; HUMAN HOMOLOG; IDENTIFICATION; ORGANIZATION	The PDZ domain, also known as the GLGF repeat/DHR domain, is an similar to 90-amino acid motif discovered in a recently identified family of proteins termed MAGUKs (membrane-associated guanylate kinase homologues), Sequence comparison analysis has since identified PDZ domains in over 50 proteins, Like SH2 and SH3 domains, the PDZ domains mediate specific protein protein interactions, whose specificities appear to be dictated by the primary structure of the PDZ domain as well as its binding target, Using recombinant fusion proteins and a blot overlay assay, we show that a single copy of the PDZ domain in human erythrocyte p55 binds to the carboxyl terminus of the cytoplasmic domain of human erythroid glycophorin C. Deletion mutagenesis of 21 amino acids at the amino terminus of the p55 PDZ domain completely abrogates its binding activity for glycophorin C. Using an alanine scan and surface plasmon resonance technique, we identify residues in the cytoplasmic domain of glycophorin C that are critical for its interaction with the PDZ domain, The recognition specificity of the p55 PDZ domain appears to be unique, since the three PDZ domains of hDlg (human lymphocyte homologue of the Drosophila discs large tumor suppressor) do not bind the cytoplasmic domain of glycophorin C. Taken together with our previous studies, these results complete the identification of interacting domains in the ternary complex between p55, glycophorin C, and protein 4.1, Implications of these findings are discussed in terms of binding specificity and the regulation of cytoskeleton-membrane interactions.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV INFECT & IMMUN,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Leicester; University of Glasgow	Marfatia, SM (corresponding author), TUFTS UNIV,ACH 4 BMR,ST ELIZABETHS MED CTR,SCH MED,LAB TUMOR CELL BIOL,736 CAMBRIDGE ST,BOSTON,MA 02135, USA.		Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716; Byron, Olwyn/0000-0001-7857-4520	NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL051445, P01HL037462, R01HL051445] Funding Source: NIH RePORTER; NCI NIH HHS [CA66263] Funding Source: Medline; NHLBI NIH HHS [HL37462, HL51445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; ANSTEE DJ, 1986, BRIT J HAEMATOL, V64, P211, DOI 10.1111/j.1365-2141.1986.tb04113.x; ANSTEE DJ, 1984, BIOCHEM J, V218, P615, DOI 10.1042/bj2180615; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHANG S, 1991, BLOOD, V77, P644; CHASIS JA, 1992, BLOOD, V80, P1869; Chishti AH, 1996, BLOOD, V87, P3462, DOI 10.1182/blood.V87.8.3462.bloodjournal8783462; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; DISCHER D, 1993, J BIOL CHEM, V268, P7186; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Hata Y, 1996, J NEUROSCI, V16, P2488; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; Hoskins R, 1996, DEVELOPMENT, V122, P97; Kim AC, 1996, GENOMICS, V31, P223, DOI 10.1006/geno.1996.0035; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KING MJ, 1995, BRIT J HAEMATOL, V89, P440, DOI 10.1111/j.1365-2141.1995.tb08347.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; LOIRAT MJ, 1994, TRANSFUSION MED, V4, P147, DOI 10.1111/j.1365-3148.1994.tb00256.x; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MAZOYER S, 1995, GENOMICS, V28, P25, DOI 10.1006/geno.1995.1101; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; REID ME, 1987, BLOOD, V69, P1068; REID ME, 1990, BLOOD, V75, P2229; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; SMYTHE J, 1994, BLOOD, V83, P1668; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TELEN MJ, 1991, BLOOD, V78, P1603; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	46	82	84	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24191	24197		10.1074/jbc.272.39.24191	http://dx.doi.org/10.1074/jbc.272.39.24191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305870	hybrid			2022-12-25	WOS:A1997XY51500021
J	Hipfner, DR; Almquist, KC; Leslie, EM; Gerlach, JH; Grant, CE; Deeley, RG; Cole, SPC				Hipfner, DR; Almquist, KC; Leslie, EM; Gerlach, JH; Grant, CE; Deeley, RG; Cole, SPC			Membrane topology of the multidrug resistance protein (MRP) - A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; AFFINITY SULFONYLUREA RECEPTOR; BINDING CASSETTE TRANSPORTER; HUMAN TUMOR-CELLS; P-GLYCOPROTEIN; CONDUCTANCE REGULATOR; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; LEUKOTRIENE C-4	Multidrug resistance protein, MRP, is a 190-kDa integral membrane phosphoglycoprotein that belongs to the ATP-binding cassette superfamily of transport proteins and is capable of conferring resistance to multiple chemotherapeutic agents. Previous studies have indicated that MRP consists of two membrane spanning domains (MSD) each followed by a nucleotide binding domain, plus an additional extremely hydrophobic NH2-terminal MSD, Computer-assisted hydropathy analyses and multiple sequence alignments suggest several topological models for MRP. To aid in determining the topology most likely to be correct, we have identified which of the 14 N-glycosylation sequons in this protein are utilized. Limited proteolysis of MRP-enriched membranes and deglycosylation of intact MRP and its tryptic fragments with PNGase F was carried out followed by immunoblotting with antibodies known to react with specific regions of MRP. The results obtained indicated that the sequon at Asn(354) in the middle MSD is not utilized and suggested approximate sites of N-glycosylation, Subsequent site-directed mutagenesis studies established that Asn(19) and Asn(23) in the NH2-terminal MSD and Asn(1006) in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides. N-Glycosylation of Asn(19) and Asn(23) provides the first direct experimental evidence that MRP has an extracytosolic NH2 terminus. This finding, together with those of previous studies, strongly suggests that the NH2-terminal MSD of MRP contains an odd number of transmembrane helices. These results may have important implications for the further understanding of the interaction of drugs with MRP.	QUEENS UNIV, CANC RES LABS, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PHARMACOL & TOXICOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada			Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Leslie, Elaine/0000-0003-1825-348X				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ALMQUIST KC, 1995, CANCER RES, V55, P102; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; BEJA O, 1995, J BIOL CHEM, V270, P12351; BOLES E, 1995, CURR GENET, V28, P197, DOI 10.1007/BF00315788; CHANG XB, 1994, J BIOL CHEM, V269, P18572; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLE SPC, 1996, DRUG RESISTANCE, P89; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GRANT CE, 1994, CANCER RES, V54, P357; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; HOE MH, 1992, J BIOL CHEM, V267, P4916; Jedlitschky G, 1996, CANCER RES, V56, P988; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nelson DA, 1996, BIOCHEMISTRY-US, V35, P14793, DOI 10.1021/bi960777y; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Shapiro AB, 1996, INT J CANCER, V67, P256, DOI 10.1002/(SICI)1097-0215(19960717)67:2<256::AID-IJC17>3.0.CO;2-9; SKACH WR, 1993, J BIOL CHEM, V268, P6903; Stride BD, 1996, MOL PHARMACOL, V49, P962; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; vanKuijck MA, 1996, P NATL ACAD SCI USA, V93, P5401, DOI 10.1073/pnas.93.11.5401; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	49	195	201	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23623	23630		10.1074/jbc.272.38.23623	http://dx.doi.org/10.1074/jbc.272.38.23623			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295302	hybrid			2022-12-25	WOS:A1997XX38100027
J	Lindvall, MK; Pihko, PM; Koskinen, AMP				Lindvall, MK; Pihko, PM; Koskinen, AMP			The binding mode of calyculin A to protein phosphatase-1 - A novel spiroketal vector model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT	The catalytic subunits of serine/threonine protein phosphatases 1 and 2A are subject to inhibition by various toxins such as the microcyst ins, the nodularins, okadaic acid, tautomycin, and the calyculins. A recent paper (Bagu, J. R., Sykes, B. D, Craig, M. M., and Holmes, C. F. B. (1997) J. Biol. Chem. 272, 5087-5097) reported the successful docking of the crystal structure of calyculin A to the crystal structure of protein phosphatase-1. Unfortunately, the model presented there is based on the structure of the unnatural enantiomer of calyculin A and must therefore be incorrect. We have developed a spiroketal vector model which appears to account for the spatial orientation of the hydrophobic and basic chains extending from the spiroketal-phosphate core of calyculin A. The model also clearly demonstrates why the unnatural enantiomer of calyculin A does not fit properly into the pocket of the active site. Based on our model, we present a possible open binding mode for calyculin A in the enzyme, This open structure is conceptually similar to the predicted binding mode of the peptide inhibitor DARPP-32 to the enzyme; the hydrophobic, metal-binding, and electrostatic interactions are all retained in this model.	UNIV OULU,DEPT CHEM,FIN-90570 OULU,FINLAND	University of Oulu			Koskinen, Ari M.P./B-2230-2010; Koskinen, Ari M P/D-2593-2015	Koskinen, Ari M P/0000-0002-5325-2899				Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; Chu YF, 1996, J BIOL CHEM, V271, P2574, DOI 10.1074/jbc.271.5.2574; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HAMADA Y, 1991, TETRAHEDRON LETT, V32, P5605; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; HOOPS SC, 1991, J AM CHEM SOC, V113, P8262, DOI 10.1021/ja00022a010; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KATO Y, 1986, J AM CHEM SOC, V108, P2780, DOI 10.1021/ja00270a061; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	12	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23312	23316		10.1074/jbc.272.37.23312	http://dx.doi.org/10.1074/jbc.272.37.23312			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287341	hybrid			2022-12-25	WOS:A1997XV74400052
J	Parry, RJ; Li, WY				Parry, RJ; Li, WY			An NADPH:FAD oxidoreductase from the valanimycin producer, Streptomyces viridifaciens - Cloning, analysis, and overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIBRIO-HARVEYI; BIOSYNTHESIS; PURIFICATION; ENZYME; GENES; NITRILOTRIACETATE; IDENTIFICATION; MONOOXYGENASE; ANTIBIOTICS; ATCC-29600	The valanimycin producer Streptomyces uilidifaciens contains a two-component enzyme system that catalyzes the oxidation of isobutylamine to isobutylhydroxylamine, One component of this enzyme system is isobutylamine hydroxylase, and the other component is a flavin reductase, The gene (vlmR) encoding the flavin reductase required by isobutylamine hydroxylase has been cloned from S. viridifaciens by chromosome walking, The gene codes for a protein of 194 amino acids with a calculated mass of 21,265 Da and a calculated pI of 10.2, Overexpression of the vlmR gene in Escherichia coli as an N-terminal His-tag derivative yielded a soluble protein that was purified to homogeneity. Removal of the N-terminal His-tag from the overexpressed protein by thrombin cleavage also produced a soluble protein, Both forms of the protein exhibited a high degree of flavin reductase activity, and the thrombin-cleaved form functioned in combination with isobutylamine hydroxylase to catalyze the conversion of isobutylamine to isobutylhydroxylamine, Kinetic data indicate that the overexpressed protein utilizes FAD and NADPH in preference to FMN, riboflavin, and NADH. The deduced amino acid sequence of the VlmR protein exhibited similarity to several other flavin reductases that may constitute a new family of flavin reductases.			Parry, RJ (corresponding author), RICE UNIV, DEPT CHEM, 6100 MAIN ST, MS-60, HOUSTON, TX 77005 USA.				NIGMS NIH HHS [GM53818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053818] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRIO JR, 1973, P NATL ACAD SCI USA, V70, P941, DOI 10.1073/pnas.70.3.941; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chater K. F., 1993, P83; DOLGANOV N, 1993, J BACTERIOL, V175, P7644, DOI 10.1128/JB.175.23.7644-7651.1993; IMAMURA N, 1989, J ANTIBIOT, V42, P156, DOI 10.7164/antibiotics.42.156; IZUMOTO Y, 1994, BBA-BIOENERGETICS, V1185, P243, DOI 10.1016/0005-2728(94)90216-X; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Knobel HR, 1996, J BACTERIOL, V178, P6123, DOI 10.1128/jb.178.21.6123-6132.1996; KORSCH BH, 1964, TETRAHEDRON LETT, P523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY BW, 1951, CHEM IND-LONDON, P75; LARUE TA, 1977, LLOYDIA, V40, P307; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; LYTHGOE B, 1949, J CHEM SOC, P2716, DOI 10.1039/jr9490002716; PARRY RJ, 1994, J CHEM SOC CHEM COMM, P995, DOI 10.1039/c39940000995; Parry RJ, 1997, J BACTERIOL, V179, P409, DOI 10.1128/jb.179.2.409-416.1997; PARRY RJ, 1992, J AM CHEM SOC, V114, P10062, DOI 10.1021/ja00051a049; Parry RJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P47, DOI 10.1006/abbi.1996.9857; PRIETO MA, 1994, J BIOL CHEM, V269, P22823; RIGGS NV, 1956, CHEM IND-LONDON, P926; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; STEVENS CL, 1958, J AM CHEM SOC, V80, P6088, DOI 10.1021/ja01555a048; STEVENS CL, 1959, J AM CHEM SOC, V81, P1435, DOI 10.1021/ja01515a037; STEVENS CL, 1956, J AM CHEM SOC, V78, P3229, DOI 10.1021/ja01594a078; TAKAHASHI Y, 1989, J ANTIBIOT, V42, P1541, DOI 10.7164/antibiotics.42.1541; UETZ T, 1992, J BACTERIOL, V174, P1179, DOI 10.1128/jb.174.4.1179-1188.1992; Worthington V, 1993, WORTHINGTON ENZYME M, P293; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; Xu YR, 1997, J BACTERIOL, V179, P1112, DOI 10.1128/jb.179.4.1112-1116.1997; YAMATO M, 1986, J ANTIBIOT, V39, P184; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994	34	74	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23303	23311		10.1074/jbc.272.37.23303	http://dx.doi.org/10.1074/jbc.272.37.23303			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287340	hybrid			2022-12-25	WOS:A1997XV74400051
J	Beziat, F; Touraille, S; Debise, R; Morel, F; Petit, N; Lecher, P; Alziari, S				Beziat, F; Touraille, S; Debise, R; Morel, F; Petit, N; Lecher, P; Alziari, S			Biochemical and molecular consequences of massive mitochondrial gene loss in different tissues of a mutant strain of Drosophila subobscura	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEARNS-SAYRE SYNDROME; MULTIPLE DELETIONS; DNA; HETEROPLASMY; DISEASE; GENOME; PODOSPORA; PROTEIN; REGION; CELLS	In the studied mutant strain of Drosophila subobscura, 78% of the mitochondrial genomes lost > 30% of the coding region by deletion, The mutations was genetically stable, Despite this massive loss of mitochondrial genes, the mutant did not seem to be affected, Distribution of the two genome types, cell levels of mitochondrial DNA, steady-state concentrations of the mitochondrial gene transcripts, mitochondrial enzymatic activities, and ATP synthesis capacities were measured in the head, thorax, and abdomen fractions of the mutant strain in comparison with a wild type strain, Results indicate that the deleted genomes are detected in all fractions but to a lesser extent in the male and female abdomen, In all fractions, there is a 50% increase in cellular mitochondrial DNA content, Although there is a decrease in steady-state concentrations of mitochondrial transcripts of genes affected by deletion, this is smaller than expected, The variations in mitochondrial biochemical activities in the different fractions of the wild strain are upheld in the mutant strain, Activity of complex I (involved in mutation) nevertheless shows a decrease in all fractions; activity of complex III (likewise involved) shows little or no change; finally, mitochondrial ATP synthesis capacity is identical to that observed in the wild strain, This latter finding possibly accounts for the lack of phenotype, This mutant is a good model for studying mitochondrial genome alterations and the role of the nuclear genome in these phenomena.	UNIV CLERMONT FERRAND,UMR CNRS 6547,EQUIPE GENOME MITOCHONDRIAL,F-63177 AUBIERE,FRANCE									ALZIARI S, 1981, BIOCHEM BIOPH RES CO, V99, P1, DOI 10.1016/0006-291X(81)91704-6; ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BEZIAT F, 1993, NUCLEIC ACIDS RES, V21, P387, DOI 10.1093/nar/21.3.387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN X, 1995, AM J HUM GENET, V57, P239; DEBISE R, 1993, BIOCHEM BIOPH RES CO, V196, P355, DOI 10.1006/bbrc.1993.2256; DELUCA M, 1976, ADV ENZYMOL RAMB, V44, P37; DEQUARDCHABLAT M, 1994, J BIOL CHEM, V269, P14951; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; Errede B, 1978, Methods Enzymol, V53, P40; GARDNER RS, 1974, ANAL BIOCHEM, V59, P272, DOI 10.1016/0003-2697(74)90033-5; Hatefi Y, 1978, Methods Enzymol, V53, P11; Hatefi Y, 1978, Methods Enzymol, V53, P35; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOHORST HJ, 1971, METHOD ENZYMAT AN, P215; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; Kaukonen JA, 1996, AM J HUM GENET, V58, P763; LECHER P, 1994, BIOL CELL, V80, P25, DOI 10.1016/0248-4900(94)90013-2; Lecher P, 1996, EUR J CELL BIOL, V71, P423; LESTIENNE P, 1988, LANCET, V1, P885; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; Moraes CT, 1995, PROG CELL R, V5, P209; PONZETTO C, 1990, J NEUROL SCI, V96, P207, DOI 10.1016/0022-510X(90)90133-8; Sacktor B, 1974, PHYSIOL INSECT, V4, P271; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; VOLZLINGENHOHL A, 1992, P NATL ACAD SCI USA, V89, P11528, DOI 10.1073/pnas.89.23.11528; WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WIBOM R, 1991, J BIOLUM CHEMILUM, V6, P123, DOI 10.1002/bio.1170060210; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22583	22590		10.1074/jbc.272.36.22583	http://dx.doi.org/10.1074/jbc.272.36.22583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278413	hybrid			2022-12-25	WOS:A1997XV49200033
J	Kuo, CL; Vaz, ADN; Coon, MJ				Kuo, CL; Vaz, ADN; Coon, MJ			Metabolic activation of trans-4-hydroxy-2-nonenal, a toxic product of membrane lipid peroxidation and inhibitor of P450 cytochromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ASCITES TUMOR-CELLS; OXYGEN ACTIVATION; OLEFIN FORMATION; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; DEHYDROGENASE; DEFORMYLATION; INACTIVATION; PURIFICATION; HISTIDINE	Lipid peroxidation in biological membranes is known to yield reactive aldehydes, of which trans-4-hydroxy-2-nonenal (HNE) is particularly cytotoxic. This laboratory previously reported that purified liver microsomal P450 cytochromes are directly inactivated to varying extents by HNE. We have now found a mechanism-based reaction in which P450s are inactivated by HNE in the presence of molecular oxygen, NADPH, and NADPH-cytochrome P450 reductase. The sensitivity of the various isozymes in the two pathways is different as follows: P450 2B4 and the orthologous 2B1 are inactivated to the greatest extent and 2C3, 1A2, 2E1, and 1A1 to a somewhat lesser extent by the pathway in which HNE undergoes metabolic activation, In contrast, 2B4 and 2B1 are insensitive to direct inactivation, and the reductase is unaffected by HNE by either route, Recent studies on the catalytic activities of the T302A mutant of P450 2B4 have shown that the rate of oxidation of a variety of xenobiotic aldehydes to carboxylic acids is decreased, but the rates of aldehyde deformylation and mechanism-based inactivation of the cytochrome are stimulated over those of the wild-type enzyme (Raner, G. M., Vaz, A. D. N., and Coon, M. J. (1997) Biochemistry 36, 4895-4902). Inactivation by those aldehydes apparently occurs by homolytic cleavage of a peroxyhemiacetal intermediate to yield formate and an alkyl radical that reacts with the heme. In sharp contrast, the rate of mechanism-based inactivation by HNE is decreased with the T302A. mutant relative to that of the wild-type P450 2B4, and mass spectral analysis of the heme adduct formed shows that deformylation does not occur. We therefore propose that the metabolic activation of HNE involves formation of an acyl carbon radical that leads to the carboxylic acid or alternatively reacts with the heme.	UNIV MICHIGAN,DEPT BIOL CHEM,SCH MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006221] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-06221] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BESTERVELT LL, 1995, P NATL ACAD SCI USA, V92, P3764, DOI 10.1073/pnas.92.9.3764; COLE PA, 1990, J MED CHEM, V33, P2933, DOI 10.1021/jm00173a001; Coon M J, 1978, Methods Enzymol, V52, P109; COON MJ, 1991, OXIDATIVE DAMAGE & REPAIR, P726; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; DING XX, 1991, ARCH BIOCHEM BIOPHYS, V291, P270, DOI 10.1016/0003-9861(91)90134-5; ESTERBAUER H, 1989, FREE RADICAL BIO MED, V7, P197, DOI 10.1016/0891-5849(89)90015-4; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GROVES JT, 1986, ANN NY ACAD SCI, V471, P99, DOI 10.1111/j.1749-6632.1986.tb48029.x; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; GUO Z, 1994, ARCH BIOCHEM BIOPHYS, V312, P59; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HOCHSTEIN P, 1963, BIOCHEM BIOPH RES CO, V12, P388, DOI 10.1016/0006-291X(63)90111-6; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KOOP DR, 1985, P NATL ACAD SCI USA, V82, P4065, DOI 10.1073/pnas.82.12.4065; Mariano P, 1993, ADV ELECT T, V3, P191; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MORGAN ET, 1983, BIOCHEM BIOPH RES CO, V112, P8, DOI 10.1016/0006-291X(83)91789-8; NADKARNI DV, 1995, CHEM RES TOXICOL, V8, P284, DOI 10.1021/tx00044a014; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1994, J BIOL CHEM, V269, P15481; PENG HM, 1993, J BIOL CHEM, V268, P17253; RANER GM, 1997, BIOCHEMISTRY-US, V34, P4905; ROBERTS ES, 1991, P NATL ACAD SCI USA, V88, P8963, DOI 10.1073/pnas.88.20.8963; SCHAUENSTEIN E, 1971, MONATSH CHEM, V102, P517, DOI 10.1007/BF00909348; Schauenstein E., 1979, CIBA F S, V67, P225; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; ULLRICH V, 1968, 19 C GES BIOL CHEM B, P229; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P13651, DOI 10.1021/bi00250a015; VAZ ADN, 1990, P NATL ACAD SCI USA, V87, P5499, DOI 10.1073/pnas.87.14.5499; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P6442, DOI 10.1021/bi00187a008; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P232, DOI 10.1016/0005-2760(84)90122-X; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P226, DOI 10.1016/0005-2760(84)90121-8	41	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22611	22616		10.1074/jbc.272.36.22611	http://dx.doi.org/10.1074/jbc.272.36.22611			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278417	hybrid			2022-12-25	WOS:A1997XV49200037
J	Kuramochi, S; Moriguchi, T; Kuida, K; Endo, J; Semba, K; Nishida, E; Karasuyama, H				Kuramochi, S; Moriguchi, T; Kuida, K; Endo, J; Semba, K; Nishida, E; Karasuyama, H			LOK is a novel mouse STE20-like protein kinase that is expressed predominantly in lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; CELL DEVELOPMENT; ADAPTER PROTEIN; LIGHT-CHAIN; MITOGEN; PATHWAY; CLONING; BINDING; STRESS; FAMILY	We have identified a new gene, designated lok (lymphocyte-oriented kinase), that encodes a 966-amino acid protein kinase whose catalytic domain at the N terminus shows homology to that of the STE20 family members involved in mitogen-activated protein (MAP) kinase cascades, The non-catalytic domain of LOK does not have any similarity to that of other known members of the family, There is a proline-rich motif with Src homology region 3 binding potential, followed by a long coiled-coil structure at the C terminus. LOK is expressed as a 130-kDa protein, which was detected predominantly in lymphoid organs such as spleen, thymus, and bone marrow, in contrast to other mammalian members of the STE20 family, LOK phosphorylated itself as well as substrates such as myelin basic protein and histone IIA on serine and threonine residues but not on tyrosine residues, establishing LOK as a novel serine/threonine kinase, When coexpressed in COS7 cells with the known MAP kinase isoforms (ERK, JNK, and p38), LOK activated none of them in contrast to PAK-and GCK-related kinases, These results suggest that LOK could be involved in a novel signaling pathway in lymphocytes, which is distinct from the known MAP kinase cascades.	TOKYO METROPOLITAN INST MED SCI, DEPT IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 60601, JAPAN; UNIV TOKYO, INST MED SCI, DEPT CELLULAR & MOL BIOL, MINATO KU, TOKYO 108, JAPAN	Tokyo Metropolitan Institute of Medical Science; Kyoto University; University of Tokyo			Moriguchi, Tetsuo/D-7061-2012; Karasuyama, Hajime/A-7966-2011	Moriguchi, Tetsuo/0000-0002-9598-4991; Karasuyama, Hajime/0000-0003-0689-0836				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Borst J, 1996, CURR OPIN IMMUNOL, V8, P181, DOI 10.1016/S0952-7915(96)80056-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Earle WR, 1943, J NATL CANCER I, V4, P165; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDY RR, 1986, P NATL ACAD SCI USA, V83, P1438, DOI 10.1073/pnas.83.5.1438; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAW CL, 1994, CURR OPIN IMMUNOL, V6, P238, DOI 10.1016/0952-7915(94)90097-3; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE SC, 1993, J BIOL CHEM, V268, P12164; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; Owen MJ, 1996, CURR OPIN IMMUNOL, V8, P191, DOI 10.1016/S0952-7915(96)80057-4; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Schaar DG, 1996, BRAIN RES, V721, P217, DOI 10.1016/0006-8993(96)00176-X; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHEVACH EM, 1972, J IMMUNOL, V108, P1146; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; WARNER NL, 1979, IMMUNOL REV, V48, P197, DOI 10.1111/j.1600-065X.1979.tb00304.x; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZLOTNIK A, 1995, CURR OPIN IMMUNOL, V7, P206, DOI 10.1016/0952-7915(95)80005-0	48	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22679	22684		10.1074/jbc.272.36.22679	http://dx.doi.org/10.1074/jbc.272.36.22679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278426	hybrid			2022-12-25	WOS:A1997XV49200046
J	Wang, WF; Zhou, GS; Hu, MCT; Yao, ZB; Tan, TH				Wang, WF; Zhou, GS; Hu, MCT; Yao, ZB; Tan, TH			Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator of TGF beta signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GAMMA-RADIATION; CARCINOMA-CELLS; RETINOIC-ACID; APOPTOSIS; CASCADE; DOMAIN; AP-1; PHOSPHORYLATES; IDENTIFICATION	Transforming growth factor beta (TGF-beta)-activated kinase (TAK1) is known for its involvement in TGF-beta signaling and its ability to activate the p38-mitogen-activated protein kinase (MAPK) pathway, This report shows that TAK1 is also a strong activator of c-Jun N-terminal kinase (JNK). Both the wild-type and a constitutively active mutant of TAK1 stimulated JNK in transient transfection assays, Mitogen-activated protein kinase kinase 4 (MKK4)/stress-activated protein kinase/extracellular signal-regulated kinase (SEK1), a dual-specificity kinase that phosphorylates and activates JNK, synergized with TAK1 in activating JNK. Conversely, a dominant-negative (MKK4/SEK1 mutant inhibited TAK1-induced JNK activation. A kinase-defective mutant of TAK1 effectively suppressed hematopoietic progenitor kinase-1 (HPK1)-induced JNK activity but had little effect on germinal center kinase activation of JNK. There are two additional MAPK kinase kinases, MEKK1 and mixed lineage kinase 3 (MLK3), that are also downstream of HPK1 and upstream of MKK4/SEK mutant, However, because the dominant-negative mutants of MEKK1 and MLK3 did not inhibit TAK1-induced JNK activity, we conclude that activation of JNK1 by TAK1 is independent of MEKK1 and MLK3. In addition to TAK1, TGF-beta also stimulated JNK activity, Taken together, these results identify TAK1 as a regulator in the HPK1 --> TAK1 --> MKK4/SEK1 --> JNK kinase cascade and indicate the involvement of JNK in the TGF-beta signaling pathway, Our results also suggest the potential roles of TAK1 not only in the TGF-beta pathway but also in the other HPK1/JNK1-mediated pathways.	AMGEN INC,DEPT EXPT HEMATOL,THOUSAND OAKS,CA 91320; AMGEN INC,DEPT BIOL,BOULDER,CO 80301	Amgen; Amgen	Wang, WF (corresponding author), BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,M929,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hirai S, 1996, ONCOGENE, V12, P641; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798	29	165	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22771	22775		10.1074/jbc.272.36.22771	http://dx.doi.org/10.1074/jbc.272.36.22771			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278437	hybrid			2022-12-25	WOS:A1997XV49200058
J	Golubovskaya, VM; Presnell, SC; Hooth, MJ; Smith, GJ; Kaufmann, WK				Golubovskaya, VM; Presnell, SC; Hooth, MJ; Smith, GJ; Kaufmann, WK			Expression of telomerase in normal and malignant rat hepatic epithelia	ONCOGENE			English	Article						telomerase; rat liver; hepatocyte; stem cell; hepatocarcinogenesis	STEM-LIKE CELLS; IMMORTAL CELLS; RNA COMPONENT; CANCER; LIVER; TISSUES; HEPATOCARCINOGENESIS; DIFFERENTIATION; PROLIFERATION; PROGRESSION	Telomerase is a ribonucleoprotein that synthesizes telomeric DNA repeats onto the ends of chromosomes. More than 85% of human cancers express telomerase activity and a large proportion of human hepatocellular carcinomas are positive, To study the role of telomerase expression in rat hepatocarcinogenesis, telomerase activity was assayed in various rat tissues and in two types of liver epithelial cells: hepatocytes and hepatic epithelial stem-like cells. In the present study, we demonstrate that telomerase activity in rats is tissue-specific and stable with animal aging. Liver and testis were found to be telomerase positive, spleen had low or no activity, and kidney was negative, Telomerase activity did not change significantly in 18 month-old rats compared to 2 month-old rats, but was moderately (twofold) increased during liver regeneration induced by a 2/3's partial hepatectomy. Telomerase activity was detected in isolated rat hepatocytes and low passage hepatic epithelial stem-like cells (WB-F344). Telomerase activity displayed significant variations in a propagable clone of WB-F344 cells. At low passage levels after establishment in vitro (passages 4-9) non-tumorigenic WB-F344 cells expressed telomerase activity. During further in vitro passaging these cells lost expression of telomerase. Expression of telomerase in the tumor-derived lines of WB-F344 cells but not in the selectively cycled, parental lineages of these cells suggests that there may be a role for telomerase in hepatocarcinogenesis.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM TOXICOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA 59486, CA 59495, CA 64340] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064340, R01CA059486] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACCHETTI S, 1995, INT J ONCOL, V7, P423; BIESSMANN H, 1992, ADV GENET, V30, P185, DOI 10.1016/S0065-2660(08)60321-1; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CAYAMA E, 1978, NATURE, V275, P60, DOI 10.1038/275060a0; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHIAO C, 1995, AM J PATHOL, V146, P1248; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gilley D, 1996, MOL CELL BIOL, V16, P66; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRISHAM JW, 1993, P SOC EXP BIOL MED, V204, P270; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HEALY KC, 1995, ONCOL RES, V7, P121; HUFF J, 1991, ENVIRON HEALTH PERSP, V93, P247, DOI 10.2307/3431195; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KAUFMANN WK, 1981, CANCER RES, V41, P4653; KAUFMANN WK, 1986, CARCINOGENESIS, V7, P669, DOI 10.1093/carcin/7.4.669; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; Kyo S, 1997, CANCER RES, V57, P610; LEE LW, 1989, AM J PATHOL, V135, P63; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; McClintock B, 1941, GENETICS, V26, P234; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; PROWSE K, 1995, P NATL ACAD SCI USA, V201, P4818; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Strahl C, 1996, MOL CELL BIOL, V16, P53; TAHARA H, 1995, CANCER RES, V55, P2734; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; Yoshimi N, 1996, MOL CARCINOGEN, V16, P1, DOI 10.1002/(SICI)1098-2744(199605)16:1<1::AID-MC1>3.0.CO;2-N; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHANG Y, 1995, LIVER REGENERATION C, P179	45	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1233	1240		10.1038/sj.onc.1201278	http://dx.doi.org/10.1038/sj.onc.1201278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294617				2022-12-25	WOS:A1997XU99100013
J	Hesterkamp, T; Deuerling, E; Bukau, B				Hesterkamp, T; Deuerling, E; Bukau, B			The amino-terminal 118 amino acids of Escherichia coli trigger factor constitute a domain that is necessary and sufficient for binding to ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE; MEMBRANE; PROTEIN; RECOGNITION; FOLDS; OMPA	Escherichia coli trigger factor has prolyl-isomerase and chaperone activities and associates with nascent polypeptide chains. Trigger factor has a binding site on ribosomes, which is a prerequisite for its efficient association with nascent chains and its proposed function as a cotranslational folding catalyst. We set out to identify the domain of trigger factor that mediates ribosome binding. Of a series of recombinant fragments, the amino-terminal fragments, TF (1-144) and TF (1-247), cofractionated with ribosomes from cell extracts and rebound to isolated ribosomes in vitro. They competed efficiently with full-length trigger factor for stoichio metric binding to a single site on the large ribosomal subunit. However, TF (1-144) and TF (1-247) differed from full-length trigger factor in that their association with ribosomes was not strengthened by the presence of nascent chains, indicating a role for carboxyl-terminal trigger factor segment in sensing the translational status, The domain responsible for ribosome binding was further investigated by limited proteolysis of recombinant fragments. A stable domain comprising the aminoterminal 118 residues was identified that was still capable of ribosome binding and thus represents a novel structural and functional element of trigger factor.	UNIV HEIDELBERG,ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg				Bukau, Bernd/0000-0003-0521-7199				CALLEBAUT I, 1995, FEBS LETT, V374, P211, DOI 10.1016/0014-5793(95)01109-R; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; Hesterkamp T, 1996, FEBS LETT, V385, P67, DOI 10.1016/0014-5793(96)00351-1; Hesterkamp T, 1996, FEBS LETT, V389, P32, DOI 10.1016/0014-5793(96)00582-0; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; LANZER M, 1988, THESIS U HEIDELBERG; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Stoller G, 1996, FEBS LETT, V384, P117, DOI 10.1016/0014-5793(96)00282-7; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x	17	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21865	21871		10.1074/jbc.272.35.21865	http://dx.doi.org/10.1074/jbc.272.35.21865			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268318	Green Published, hybrid			2022-12-25	WOS:A1997XT85000030
J	Nathan, CA; Carter, P; Liu, L; Li, BD; Abreo, F; Tudor, A; Zimmer, SG; DeBenedetti, A				Nathan, CA; Carter, P; Liu, L; Li, BD; Abreo, F; Tudor, A; Zimmer, SG; DeBenedetti, A			Elevated expression of eIT4E and FGF-2 isoforms during vascularization of breast carcinomas	ONCOGENE			English	Article						eIF4E oncogene; FGF-2 isoforms; tumor vascularization; translation initiation; breast cancer progression; immunohistology	FIBROBLAST GROWTH-FACTOR; RAT EMBRYO FIBROBLASTS; MESSENGER-RNA; INITIATION FACTOR-4E; TRANSLATION; CELLS; TRANSFORMATION; AMPLIFICATION; CANCER	The translation initiation factor eIF4E is a novel protooncogene found over expressed in most breast carcinomas (Kerekatte et al., 1995), but the pathology where this elevation is initially manifested and its possible role in cancer progression are unknown, We report that eIF4E is markedly increased in vascularized malignant ductules of invasive carcinomas, whereas necrotic and avascular ductal carcinomas lit situ display significantly lower levels, eIF4E facilitates the synthesis of FGF-2, a powerful tumor angiogenic factor, Conversely, reducing eIF4E with antisense RNA in MDA-435 cells suppresses their tumorigenic and angiogenic properties, consistent with loss of FGF-2 synthesis, These findings suggest a causal role for eIF4E in tumor vascularization.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM, SHREVEPORT, LA 71105 USA; LOUISIANA STATE UNIV, MED CTR, DEPT OTOLARYNGOL, SHREVEPORT, LA USA; LOUISIANA STATE UNIV, MED CTR, DEPT SURG, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT PATHOL, SHREVEPORT, LA 71130 USA; UNIV KENTUCKY, MED CTR, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Kentucky				de benedetti, arrigo/0000-0002-4198-8647	NCI NIH HHS [CA69148-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; ASCHER NL, 1979, TRANSPLANTATION, V27, P254, DOI 10.1097/00007890-197904000-00010; CHAMPEME MH, 1994, MODERN PATHOL, V7, P900; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; EDGINGTON TS, 1995, FASEB J, V9, P841, DOI 10.1096/fasebj.9.10.7615153; FOLKMAN J, 1986, CANCER RES, V46, P467; FRYKBERG ER, 1994, WORLD J SURG, V18, P45, DOI 10.1007/BF00348191; GABRA N, 1994, BIOCHEM BIOPH RES CO, V205, P1423, DOI 10.1006/bbrc.1994.2824; GRAFF JR, 1995, INT J CANCER, V60, P255; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARLOW E, 1988, ANTIBODIES LABORATOR, P403; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; LI BDL, 1997, IN PRESS CANCER; LIPPMAN M, 1996, 19 ANN SAN ANT BREAS, V41, P191; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MORRISON RS, 1990, CANCER RES, V50, P2524; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Souttou B, 1996, INT J CANCER, V68, P675, DOI 10.1002/(SICI)1097-0215(19961127)68:5<675::AID-IJC19>3.0.CO;2-0; SU ZZ, 1993, ONCOGENE, V8, P1211; TAKEI Y, 1993, J CLIN BIOCHEM NUTR, V15, P57; THEILLET C, 1989, ONCOGENE, V4, P915; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VISSCHER DW, 1995, MODERN PATHOL, V8, P665; WELLSTEIN A, 1991, MOL F ONCOLOGY, P403; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	38	111	114	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1087	1094		10.1038/sj.onc.1201272	http://dx.doi.org/10.1038/sj.onc.1201272			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285563				2022-12-25	WOS:A1997XT16100010
J	Baldassarre, G; Romano, A; Armenante, F; Rambaldi, M; Paoletti, I; Sandomenico, C; Pepe, S; Staibano, S; Salvatore, G; DeRosa, G; Persico, MG; Viglietto, G				Baldassarre, G; Romano, A; Armenante, F; Rambaldi, M; Paoletti, I; Sandomenico, C; Pepe, S; Staibano, S; Salvatore, G; DeRosa, G; Persico, MG; Viglietto, G			Expression of teratocarcinoma-derived growth factor-1 (TDGF-1) in testis germ cell tumors and its effects on growth and differentiation of embryonal carcinoma cell line NTERA2/D1	ONCOGENE			English	Article						TDGF-1; teratocarcinoma; seminoma; cell differentiation	HEXAMETHYLENE BISACETAMIDE HMBA; FACTOR-RELATED PROTEIN; RETINOIC ACID; FACTOR-ALPHA; COLORECTAL TUMORS; TGF-ALPHA; CANCER; CRIPTO; GENE; AMPHIREGULIN	The teratocarcinoma-derived growth factor-1 (TDGF-1) gene codes for a 188-aminoacid glycoprotein that shares structural homology with the epidermal growth factor (EGF) family of growth factors, TDGF-1 is highly expressed in the undifferentiated embryonal carcinoma stem cell line NTERA2 clone D1 (NT2/D1) and its expression is downregulated in response to differentiating agents such as retinoic acid (RA) and hexamethylen-bisacetamide (HMBA), To assess the role of TDGF-1 in the onset and/or progression of human germ cell tumors, we analysed TDGF-1 expression by Northern blot and immunostaining in a panel of 59 human germ cell tumors of different histological origins, We show that TDGF-1 expression is markedly elevated in a subset of human testicular germ cell tumors as compared to normal testes, TDGF-1 overexpression occurs in about 100% of tumors with non-seminomatous phenotype, such as embryonal carcinomas and malignant undifferentiated teratocarcinomas, To address the questions of how TDGF-1 (previously called CRIPTO) may affect the growth and/or the differentiation of embryonal carcinoma cells, we have characterized the effects of exogenous recombinant TDGF-1 protein on the proliferation rate and differentiation potential of NT2/D1, Exogenous TDGF-1 protein stimulated DNA synthesis and cell proliferation in both undifferentiated and differentiated NT2/D1 cells, However, TDGF-1 protein treatment was unable to block differentiation induced by both RA and HMBA, These results suggest that TDGF-1 growth factor may represent an autocrine growth factor that may be involved in the process of development of testicular neoplasms.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; FDN SENATORE PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO ENDOCRINOL & ONCOL SPERIMENTALE & CL,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,IST PATOL,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II			Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; DE ROSA, Gaetano/0000-0002-3635-5853; Sandomenico, Claudia/0000-0003-3709-0807				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; BOS JL, 1989, CANCER RES, V49, P4682; BRANDT R, 1994, J BIOL CHEM, V269, P17320; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DMITROVSKY E, 1990, ONCOGENE, V5, P534; DONO R, 1993, DEVELOPMENT, V118, P1157; KURIE JM, 1993, DIFFERENTIATION, V54, P115; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MURTY VVV, 1994, ONCOGENE, V9, P3228; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 1995, CURRENT OPINION ENDO, V2, P500; Sambrook J., 2002, MOL CLONING LAB MANU; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPORN MB, 1992, ANN INTERN MED, V117, P408, DOI 10.7326/0003-4819-117-5-408; TIENARI J, 1995, DIFFERENTIATION, V59, P193, DOI 10.1046/j.1432-0436.1995.5930193.x; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; ULBRIGHT TM, 1994, DIAGNOSTIC SURG PATH, V46, P1885	38	54	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					927	936		10.1038/sj.onc.1201260	http://dx.doi.org/10.1038/sj.onc.1201260			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285688				2022-12-25	WOS:A1997XR76700006
J	Tedone, T; Correale, M; Barbarossa, G; Casavola, V; Paradiso, A; Reshkin, SJ				Tedone, T; Correale, M; Barbarossa, G; Casavola, V; Paradiso, A; Reshkin, SJ			Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion	FASEB JOURNAL			English	Article						protease; proliferation; MCF-7	TRANSFORMED-CELLS; EXTRACELLULAR-MATRIX; GROWTH-FACTORS; TUMOR-CELLS; ACID; PH; INVITRO; DEGRADATION; METASTASIS; INHIBITION	Data concerning the hormone sensitivity of the release and role of the aspartyl protease cathepsin D in tumor proliferative and invasive processes have been contradictory. To clarify the mechanisms of its release and role we first studied the contribution of estradiol and stripped serum to the time course and kinetics of cathepsin D release, proliferation, and invasion in parallel in the MCF-7 in vitro breast cancer cell culture model. Both estradiol and stripped serum independently stimulated both proliferation and cathepsin D release. However, the dose-response of estradiol and stripped serum-dependent stimulated release were similar to those for invasion and differed from those for proliferation: cathepsin D release and invasion were first stimulated at a stripped serum concentration more than 10-fold lower than that which initiated proliferation and had half stimulation constants almost 10-fold lower than those for proliferation. These results demonstrate that cathepsin D release is not related in any direct way to proliferation. The effect of the reduction of cathepsin D activity or release on in vitro invasion was also measured: both the inhibition of secreted cathepsin D activity by a specific inhibitor, diazoacetyl-DL-Nle-OMe, and the reduction of cathepsin D release by antisense oligonucleotides against its translation start site reduced cellular in vitro invasion without affecting proliferation. Cathepsin D release and activity are concluded to be directly involved in the process of invasion.	UNIV BARI,INST GEN PHYSIOL,I-70126 BARI,ITALY; INST ONCOL,EXPT ONCOL LAB,I-70126 BARI,ITALY	Universita degli Studi di Bari Aldo Moro			Reshkin, Stephan/AAI-6680-2020; paradiso, angelo V/J-9457-2018	Reshkin, Stephan/0000-0001-9757-5908; CASAVOLA, Valeria/0000-0003-4471-4948				ALBINI A, 1987, CANCER RES, V47, P3239; AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BRIOZZO P, 1988, CANCER RES, V48, P3688; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CONOVER CA, 1994, J BIOL CHEM, V269, P7076; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GARCIA M, 1990, ONCOGENE, V5, P1809; *GEN COMP GROUP, 1994, PROGR MAN GSG PACK; GILLIES RJ, 1994, AM J PHYSIOL, V267, pC195, DOI 10.1152/ajpcell.1994.267.1.C195; HELSETH DL, 1984, P NATL ACAD SCI-BIOL, V81, P3302, DOI 10.1073/pnas.81.11.3302; Isidoro C, 1995, INT J CANCER, V63, P866, DOI 10.1002/ijc.2910630619; JOHNSON MD, 1993, CANCER RES, V53, P873; LOCKWOOD TD, 1977, NATURE, V267, P252, DOI 10.1038/267252a0; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; PAGLIACCI MC, 1991, ENDOCRINOLOGY, V129, P2555, DOI 10.1210/endo-129-5-2555; RAVDIN PM, 1993, BREAST CANCER RES TR, V24, P219, DOI 10.1007/BF01833262; RICHARDSON JM, 1988, J CELL BIOL, V107, P2097, DOI 10.1083/jcb.107.6.2097; ROCHEFORT H, 1992, ACTA ONCOL, V31, P125, DOI 10.3109/02841869209088891; ROZHIN J, 1994, CANCER RES, V54, P6517; SCHULTZ DC, 1994, CANCER RES, V54, P48; SLONE BF, 1990, SEMINARS CANC BIOL, V1, P137; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TANAKA K, 1976, EXP CELL RES, V99, P1, DOI 10.1016/0014-4827(76)90672-8; TANNOCK IF, 1989, CANCER RES, V49, P4373; Tedone T, 1996, EUR J CANCER, V32A, P849, DOI 10.1016/0959-8049(95)00660-5; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; VETVICKA V, 1994, CANCER LETT, V79, P131; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WESTLEY B, 1979, BIOCHEM BIOPH RES CO, V90, P410, DOI 10.1016/0006-291X(79)91250-6; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7	36	44	46	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					785	792		10.1096/fasebj.11.10.9271363	http://dx.doi.org/10.1096/fasebj.11.10.9271363			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271363				2022-12-25	WOS:A1997XR10500008
J	Chu, G				Chu, G			Double strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DEPENDENT PROTEIN-KINASE; END BINDING-ACTIVITY; X-RAY RESISTANCE; RNA-POLYMERASE-I; V(D)J RECOMBINATION; KU AUTOANTIGEN; DNA-REPAIR; MAMMALIAN-CELLS; SCID MUTATION; CATALYTIC SUBUNIT		STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University; Stanford University								ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; Beall EL, 1996, GENE DEV, V10, P921, DOI 10.1101/gad.10.8.921; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN DJ, 1994, GENOMICS, V21, P423, DOI 10.1006/geno.1994.1287; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; DANSKA J, 1996, MOL CELL BIOL, V10, P6472; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FALZON M, 1993, J BIOL CHEM, V268, P10546; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P555; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GFACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRZESIUK E, 1987, NUCLEIC ACIDS RES, V15, P971, DOI 10.1093/nar/15.3.971; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; He DM, 1996, MUTAT RES-DNA REPAIR, V363, P43, DOI 10.1016/0921-8777(95)00060-7; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; JEONGYU SJ, 1992, MOL CELL BIOL, V12, P112, DOI 10.1128/MCB.12.1.112; JOHNSON A, 1996, MUTAT RES, V3642, P103; King JS, 1996, J BIOL CHEM, V271, P20450, DOI 10.1074/jbc.271.34.20450; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1996, J BIOL CHEM, V271, P14405, DOI 10.1074/jbc.271.24.14405; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LUKACSOVICH T, 1994, NUCLEIC ACIDS RES, V22, P5649, DOI 10.1093/nar/22.25.5649; Mason RM, 1996, NUCLEIC ACIDS RES, V24, P4946, DOI 10.1093/nar/24.24.4946; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Rathmell WK, 1997, CANCER RES, V57, P68; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Shakespeare William, 1998, JULIUS CAESAR; Siede W, 1996, GENETICS, V142, P91; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; THOMPSON D, 1995, FEM PSYCHOL, V5, P531, DOI 10.1177/0959353595054012; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	73	208	211	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24097	24100		10.1074/jbc.272.39.24097	http://dx.doi.org/10.1074/jbc.272.39.24097			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305850	hybrid			2022-12-25	WOS:A1997XY51500001
J	Filoteo, AG; Elwess, NL; Enyedi, A; Caride, A; Aung, HH; Penniston, JT				Filoteo, AG; Elwess, NL; Enyedi, A; Caride, A; Aung, HH; Penniston, JT			Plasma membrane Ca2+ pump in rat brain - Patterns of alternative splices seen by isoform-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAINS; CALCIUM-PUMP; MESSENGER-RNAS; CA2+-ATPASE; EXPRESSION; REGION; 4B	The expression at the protein level of plasma membrane calcium pump (PMCA) isoforms in rat brain was detected by new antibodies that distinguished the four gene products and their alternatively spliced variants. All four gene products were distributed throughout hippocampus, cortex, and cerebellum, but the alternate splices showed more distinct distribution patterns. The b splice of isoform 1 was not detectable in any of the brain regions, which makes it unlikely that this isoform performs an essential housekeeping role as is frequently proposed. The b splices of isoforms 3 and 4, although expressed in all three regions, showed evidence of proteolysis, which removed a portion of the carboxyl terminus, In contrast, isoform 2b retained its full length, indicating that PMCA2b is more resistant to proteolysis than the other b forms, Whereas substantial amounts of isoforms 1a, 2a, and 3a were expressed in all regions, 4a was found only in frontal cortex. The distinct patterns of expression of the PMCA isoforms in brain suggest that some of them play a special role in intracellular Ca regulation.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; NATL INST HAEMATOL & IMMUNOL,H-1113 BUDAPEST,HUNGARY	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDT P, 1992, J NEUROCHEM, V59, P1566, DOI 10.1111/j.1471-4159.1992.tb08476.x; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; EAKIN TJ, 1995, MOL BRAIN RES, V29, P71, DOI 10.1016/0169-328X(94)00231-3; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FLECHA FLG, 1993, BIOCHEM J, V293, P369; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; KEETON TP, 1993, J BIOL CHEM, V268, P2740; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK DJ, 1987, J IMMUNOL, V139, P2615; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Varadi A, 1996, BIOCHEM J, V314, P663, DOI 10.1042/bj3140663; Verma AK, 1996, J BIOL CHEM, V271, P3714; VERMA AK, 1994, J BIOL CHEM, V269, P1687; WANG KKW, 1991, J BIOL CHEM, V266, P9078; ZACHARIAS DA, 1995, MOL BRAIN RES, V28, P263, DOI 10.1016/0169-328X(94)00215-Z	19	129	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23741	23747		10.1074/jbc.272.38.23741	http://dx.doi.org/10.1074/jbc.272.38.23741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295318	hybrid			2022-12-25	WOS:A1997XX38100043
J	Lin, ECK; Ratnikov, BI; Tsai, PM; Carron, CP; Myers, DM; Barbas, CF; Smith, JW				Lin, ECK; Ratnikov, BI; Tsai, PM; Carron, CP; Myers, DM; Barbas, CF; Smith, JW			Identification of a region in the integrin beta 3 subunit that confers ligand binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; VITRONECTIN RECEPTOR; ENDOTHELIAL-CELLS; BETA(3) SUBUNIT; CROSS-LINKING; IIB-IIIA; SITE; FIBRINOGEN; RECOGNITION; FIBRONECTIN	Many integrin adhesion receptors bind ligands containing the Arg-Gly-Asp (RGD) peptide motif, Most integrins exhibit considerable specificity for particular ligands and can distinguish among the many conformations of RGD. In this study we identify the domain of the integrin beta subunit involved in determining ligand binding specificity, Chimeras of beta 3 and beta 5, the most homologous integrin beta subunits, were expressed with alpha v on the surface of human 293 cells, The ligand binding phenotype of each chimera was assessed using the ligands Fab-9 and fibrinogen, both of which have a binding preference for alpha v beta 3. The results of the study show that when exons C and D of the beta 3 subunit (residues 95-233) are substituted into beta 5, the chimera gained the ability to bind Fab-9 with an affinity close to that of wild-type alpha v beta 3. This chimera was able to mediate cell adhesion to fibrinogen. Furthermore, the swap of only a 39-residue segment of this larger domain, beta 3 residues 164-202, into the backbone of beta 5 enabled the chimeric integrin to bind soluble Fab-9. This small domain is highly divergent among the integrin beta subunits, suggesting that it may play a role in determining ligand selection by all integrins.	LA JOLLA CANC RES CTR, BURNHAM INST, PROGRAM CELL ADHES & EXTRACELLULAR MATRIX, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; MONSANTO CO, GD SEARLE RES & DEV, ST LOUIS, MO 63198 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute; Monsanto					NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NCI NIH HHS [CA56483] Funding Source: Medline; NIAMS NIH HHS [AR42750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Alemany M, 1996, BLOOD, V87, P592, DOI 10.1182/blood.V87.2.592.bloodjournal872592; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Brooks PC, 1996, CANCER METAST REV, V15, P187, DOI 10.1007/BF00437471; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1995, P SOC EXP BIOL MED, V208, P346; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; Filardo EJ, 1996, J CELL SCI, V109, P1615; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GRINNELL F, 1992, J CELL SCI, V101, P1; HORTON MA, 1989, J BONE MINER RES, V4, P803; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P243; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LANZA F, 1990, J BIOL CHEM, V265, P18098; LIAW L, 1995, CIRC RES, V77, P665, DOI 10.1161/01.RES.77.4.665; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RECHLER MM, 1977, J BIOL CHEM, V252, P3898; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schulz G.E., 1979, PRINCIPLES PROTEIN S, P28; SEGEL IH, 1976, BIOCH CALCULATIONS, P152; Smith J.W., 1994, INTEGRINS MOL BIOL R, P1; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1994, J BIOL CHEM, V269, P960; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	55	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23912	23920		10.1074/jbc.272.38.23912	http://dx.doi.org/10.1074/jbc.272.38.23912			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295341	hybrid			2022-12-25	WOS:A1997XX38100066
J	Norris, FA; Atkins, RC; Majerus, PW				Norris, FA; Atkins, RC; Majerus, PW			The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II - Evidence for conserved alternative splicing in the 4-phosphatase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTIVATION; HYDROLYSIS; 3-KINASE; INTEGRIN; AKT	Inositol polyphosphate 4-phosphatase (4-phosphatase) is a Mg2+-independent enzyme that catalyzes the hydrolysis of the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate, inositol 1,3,4-trisphosphate, and inositol 3,4-bisphosphate. We have isolated cDNA encoding a 105,257-Da protein that is 37% identical to the previously cloned 4-phosphatase, Recombinant protein was expressed in Escherichia coli and shown to hydrolyze all three 4-phosphatase substrates with enzymatic properties similar to the original enzyme. We designate the original 4-phosphatase and the new isozyme as inositol polyphosphate 4-phosphatase types I and II, respectively. 4-Phosphatase II is highly conserved with the human and rat enzymes having 90% amino acid identity, A conserved motif between 4-phosphatase I and II is the sequence CKSAKDRT that contains the Cys-Xaa(5)-Arg active site consensus sequence identified for other Mg2+-independent phosphatases. Northern blot analysis indicated that 4-phosphatase II is widely expressed with the highest levels occurring in the skeletal muscle and heart. In addition, cDNA encoding alternatively spliced forms of human 4-phosphatase I (107,309 Da) and rat 4-phosphatase II (106,497 Da) were also isolated that encode proteins with a putative transmembrane domain near their C termini. These alternatively spliced forms were expressed as recombinant proteins in E. coli and SF9 insect cells and found to possess no detectable enzymatic activity suggesting that additional factors and/or processing may be required for these alternatively spliced isozymes.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,DIV HEMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOPHYS,DIV HEMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	Norris, FA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 16634, HL 55672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016634, R01HL055672, R01HL016634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANSAL VS, 1991, J BIOL CHEM, V265, P1806; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Norris FA, 1997, J BIOL CHEM, V272, P10987; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	19	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23859	23864		10.1074/jbc.272.38.23859	http://dx.doi.org/10.1074/jbc.272.38.23859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295334	hybrid			2022-12-25	WOS:A1997XX38100059
J	Orita, T; Shimozaki, K; Murakami, H; Nagata, S				Orita, T; Shimozaki, K; Murakami, H; Nagata, S			Binding of NF-Y transcription factor to one of the cis-elements in the myeloperoxidase gene promoter that responds to granulocyte colony-stimulating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-RECEPTOR; DNA-BINDING; CCAAT BINDING; MYELOID DIFFERENTIATION; MURINE MYELOPEROXIDASE; SIGNAL-TRANSDUCTION; MESSENGER-RNA; CDNA CLONING; CLASS-II; EXPRESSION	The expression of the myeloperoxidase (MPO) gene is restricted to cells of the myeloid cell lineage and is induced by granulocyte colony stimulating factor (G-CSF). In this study, a series of deletion mutations was introduced in the promoter of the human MPO gene, which was then fused to the chloramphenicol acetyltransferase gene. The G-CSF-induced promoter activity was examined in mouse myeloid precursor FDC-P1 transformants that constitutively express the G-CSF receptor. A G-CSF-responsive element (GRE) in the MPO gene was found approximately 800 base pairs upstream from the transcription initiation site. When the 5'-flanking region of the human MPO gene contained this element, it yielded promoter activity in cells cultured with G-CSF but not in cells cultured with interleukin 3. Gel shift assays with the element showed that a specific nuclear factor(s) (NF/G-CSF) binds to the element. The NF/G-CSF was purified by affinity chromatography using an oligonucleotide of GRE. Protein sequence analysis of the purified NF/G-CSF indicated that NF/G-CSF is a ubiquitous transcription factor, NF-Y, which is composed of three subunits. The recombinant, NF-Y was then shown to bind to GRE in a combination of the three subunits.	OSAKA UNIV, SCH MED, DEPT GENET, SUITA, OSAKA 565, JAPAN; OSAKA BIOSCI INST, SUITA, OSAKA 565, JAPAN	Osaka University			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASAKURA A, 1993, MOL CELL BIOL, V13, P7153, DOI 10.1128/MCB.13.11.7153; CHANG KS, 1991, LEUKEMIA, V5, P205; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDGAR S, 1989, NUCLEIC ACIDS RES, V17, P6419; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; ITOH N, 1993, J IMMUNOL, V151, P621; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; JORGENSON KF, 1991, BLOOD, V77, P159; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KUN SC, 1986, BLOOD, V68, P1411; LIWEBER M, 1994, J IMMUNOL, V153, P4122; LUBBERT M, 1991, BLOOD, V78, P345; Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; NAGATA S, 1994, CYTOKINE HDB, P371; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; SACS L, 1982, J CELL PHYSIOL, V1, P151; SCHEOMECLER C, 1995, BLOOD, V11, P4115; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TOBLER A, 1988, J CELL PHYSIOL, V136, P215, DOI 10.1002/jcp.1041360203; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WEIL SC, 1987, P NATL ACAD SCI USA, V84, P2057, DOI 10.1073/pnas.84.7.2057; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; YAMADA M, 1993, J BIOL CHEM, V268, P13479; YAMADA M, 1987, ARCH BIOCHEM BIOPHYS, V255, P147, DOI 10.1016/0003-9861(87)90304-3; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x	51	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23216	23223		10.1074/jbc.272.37.23216	http://dx.doi.org/10.1074/jbc.272.37.23216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287329	hybrid			2022-12-25	WOS:A1997XV74400040
J	Cao, YH; Chen, A; An, SSA; Ji, RWD; Davidson, D; Cao, YM; Llinas, M				Cao, YH; Chen, A; An, SSA; Ji, RWD; Davidson, D; Cao, YM; Llinas, M			Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWIS-LUNG-CARCINOMA; ANGIOGENESIS INHIBITOR; POTENT INHIBITOR; PURIFICATION; FRAGMENT; THROMBOSPONDIN-1; PROLIFERATION; SUPPRESSION; ANGIOSTATIN; CHEMOKINE	Angiostatin is a potent angiogenesis inhibitor which has been identified as an internal fragment of plasminogen that includes its first four kringle modules. We have recently demonstrated that the anti-endothelial cell proliferative activity of angiostatin is also displayed by the first three kringle structures of plasminogen and marginally so by kringle 4 (Cao, Y., Ji, R.-W., Davidson, D., Schaller, J., Marti, D., Sohndel, S., McCance, S. G., O'Reilly, M. S., Llinas, M., and Folkman, J. (1996) J. Biol. Chem. 271, 29461-29467). We now report that the kringle 5 fragment of human plasminogen is a specific inhibitor for endothelial cell proliferation. Kringle 5 obtained as a proteolytic fragment of human plasminogen displays potent inhibitory effect on bovine capillary endothelial cells with a half-maximal concentration (ED50) of approximately 50 nM. Thus, kringle 5 would appear to be more potent than angiostatin on inhibition of basic fibroblast growth factor-stimulated capillary endothelial cell proliferation. Appropriately folded recombinant mouse kringle 5 protein, expressed in Escherichia coli, exhibits a comparable inhibitory effect as the proteolytic kringle 5 fragment. Thus, kringle 5 domain of human plasminogen is a novel endothelial inhibitor that is sufficiently potent to block the growth factor-stimulated endothelial cell growth.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CARNEGIE MELLON UNIV,DEPT CHEM,PITTSBURGH,PA 15213; ABBOTT LABS,DIV PHARMACEUT PROD,AGING & DEGENERAT DIS RES,ABBOTT PK,IL 60064; UNIV BERN,INSELSPITAL,INST PHARMACOL,CH-3010 BERN,SWITZERLAND	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Carnegie Mellon University; Abbott Laboratories; University of Bern; University Hospital of Bern	Cao, YH (corresponding author), KAROLINSKA INST,DEPT CELL & MOL BIOL,LAB ANGIOGENESIS RES,S-17177 STOCKHOLM,SWEDEN.			Davidson, Donald/0000-0002-8669-9814	NATIONAL CANCER INSTITUTE [R01CA064481] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029409] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64481] Funding Source: Medline; NHLBI NIH HHS [HL-29409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CAO Y, 1990, Technique (Philadelphia), V2, P109; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHEN C, 1995, CANCER RES, V55, P4230; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; COX M, 1994, CHEM PHYS LIPIDS, V67-8, P43, DOI 10.1016/0009-3084(94)90123-6; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gately S, 1996, CANCER RES, V56, P4887; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HORI A, 1991, CANCER RES, V51, P6180; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OREILLY MS, 1997, CELL, V88, P1; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SENGER DR, 1990, CANCER RES, V50, P1774; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; THEWES T, 1987, BIOCHIM BIOPHYS ACTA, V912, P254, DOI 10.1016/0167-4838(87)90096-3; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497	39	256	346	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22924	22928		10.1074/jbc.272.36.22924	http://dx.doi.org/10.1074/jbc.272.36.22924			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278456	hybrid			2022-12-25	WOS:A1997XV49200077
J	Spiess, C; Happersberger, HP; Glocker, MO; Spiess, E; Rippe, K; Ehrmann, M				Spiess, C; Happersberger, HP; Glocker, MO; Spiess, E; Rippe, K; Ehrmann, M			Biochemical characterization and mass spectrometric disulfide bond mapping of periplasmic alpha-amylase MalS of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ASSISTED LASER-DESORPTION; MOLECULAR-STRUCTURE; CLOSTRIDIUM-THERMOSACCHAROLYTICUM; ALKALINE-PHOSPHATASE; NUCLEOTIDE-SEQUENCE; ANGSTROM RESOLUTION; SIGNAL SEQUENCE; OUTER-MEMBRANE; PROTEINS	Periplasmic alpha-amylase of Escherichia coli, the malS gene product, hydrolyzes linear maltodextrins. The purified enzyme exhibited a K-m of 49 mu M and a V-max of 0.36 mu mol of p-nitrophenylhexaoside hydrolyzed per min per mg of protein. Amylase activity was optimal at pH 8 and was dependent on divalent cations such as Ca2+. MalS exhibited altered migration on SDS polyacrylamide gel electrophoresis under nonreducing conditions, Analytical ultracentrifugation and electrospray mass spectrometry indicated that MalS is monomeric, The four cysteine residues are involved in intramolecular disulfide bonds, To map disulfide bonds, MalS was proteolytically digested, The resulting peptides were separated by reverse phase-high performance liquid chromatography, and matrix-assisted laser desorption/ionization mass spectrometry analysis indicated the presence of two disulfide bonds, i.e. Cys(40-58) and Cys(104-520). The disulfide bond at Cys(40-58) is located in an N-terminal extension of about 160 amino acids which has no homology to other amylases but to the proposed peptide binding domain of GroEL, the Hsp60 of E. coli. The N-terminal extension is linked to the C-terminal amylase domain via disulfide bond Cys(104-520). Reduction of disulfide bonds by dithiothreitol treatment led to aggregation suggesting that the N terminus of MalS may represent an internal chaperone domain.	UNIV KONSTANZ, FAK BIOL, D-78457 CONSTANCE, GERMANY; UNIV KONSTANZ, FAK CHEM, D-78457 CONSTANCE, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY	University of Konstanz; University of Konstanz; Helmholtz Association; German Cancer Research Center (DKFZ)			Rippe, Karsten/A-3562-2012; Ehrmann, Michael/A-7307-2012	Rippe, Karsten/0000-0001-9951-9395; Ehrmann, Michael/0000-0002-1927-260X; Spiess, Christoph/0000-0002-0570-9700				ARAKAWA T, 1992, J PROTEIN CHEM, V11, P111, DOI 10.1007/BF01025216; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BOOS W, 1996, CELLULAR MOL BIOL, P1175; BRAYER GD, 1995, PROTEIN SCI, V4, P1730, DOI 10.1002/pro.5560040908; CARR SA, 1990, BIOLOGICAL MASS SPECTROMETRY /, P621; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; CRIMMINS DL, 1995, ANAL BIOCHEM, V226, P355, DOI 10.1006/abio.1995.1236; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FELLER G, 1992, J BIOL CHEM, V267, P5217; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; Gehrig PM, 1996, PEPTIDE RES, V9, P308; GLOCKER MO, 1995, J AM SOC MASS SPECTR, V6, P638, DOI 10.1016/1044-0305(95)00250-H; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; Glocker MO, 1996, BIOCHEMISTRY-US, V35, P14625, DOI 10.1021/bi961199o; GLOCKER O, 1994, P NATL ACAD SCI USA, V91, P5868; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; Hatada Y, 1996, J BIOL CHEM, V271, P24075, DOI 10.1074/jbc.271.39.24075; ITOH T, 1987, FEBS LETT, V219, P339, DOI 10.1016/0014-5793(87)80248-X; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; LUCKEY M, 1991, J BIOL CHEM, V266, P1866; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J. H., 1972, EXPT MOL GENETICS, P431; MORRIS HR, 1985, BIOCHEM BIOPH RES CO, V126, P1122, DOI 10.1016/0006-291X(85)90302-X; MORRIS HR, 1988, TRENDS BIOTECHNOL, V6, P140, DOI 10.1016/0167-7799(88)90083-2; NEU HC, 1965, J BIOL CHEM, V240, P3685; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; SCHNEIDER E, 1992, J BIOL CHEM, V267, P5148; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; SCHWARTZ M, 1967, EUR J BIOCHEM, V2, P132, DOI 10.1111/j.1432-1033.1967.tb00117.x; SCHWARTZ M, 1987, CELLULAR MOL BIOL, P1482; SHIBUYA I, 1992, BIOSCI BIOTECH BIOCH, V56, P174, DOI 10.1271/bbb.56.174; SMITH DL, 1990, METHOD ENZYMOL, V193, P374, DOI 10.1016/0076-6879(90)93428-N; SORENSEN HH, 1990, BIOMED ENVIRON MASS, V19, P713, DOI 10.1002/bms.1200191110; SPECKA U, 1993, ARCH MICROBIOL, V160, P284, DOI 10.1007/BF00292078; SPECKA U, 1991, APPL ENVIRON MICROB, V57, P2317, DOI 10.1128/AEM.57.8.2317-2323.1991; STRASSER AWM, 1989, EUR J BIOCHEM, V184, P699, DOI 10.1111/j.1432-1033.1989.tb15069.x; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; TAPIO S, 1991, J BIOL CHEM, V266, P19450; TOTSUKA A, 1994, EUR J BIOCHEM, V221, P649, DOI 10.1111/j.1432-1033.1994.tb18777.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESMEYER H, 1960, BIOCHIM BIOPHYS ACTA, V39, P427, DOI 10.1016/0006-3002(60)90195-5; YAZDANPARAST R, 1987, J BIOL CHEM, V262, P2507; ZHOU J, 1993, INT J MASS SPECTROM, V126, P115, DOI 10.1016/0168-1176(93)80076-Q	62	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22125	22133		10.1074/jbc.272.35.22125	http://dx.doi.org/10.1074/jbc.272.35.22125			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268356	Green Submitted, hybrid			2022-12-25	WOS:A1997XT85000068
J	Sun, J; Xu, Q; Chitnis, VP; Jin, P; Chitnis, PR				Sun, J; Xu, Q; Chitnis, VP; Jin, P; Chitnis, PR			Topography of the photosystem I core proteins of the cyanobacterium Synechocystis sp. PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; ENCODING SUBUNIT-II; SP PCC-6803; MUTATIONAL ANALYSIS; TARGETED INACTIVATION; MOLECULAR-CLONING; ELECTRON-TRANSFER; POLYPEPTIDES; ORGANIZATION; FERREDOXIN	PsaA and PsaB are homologous integral membrane proteins that form the heterodimeric core of photosystem I. Domain-specific antibodies were generated to examine the topography of PsaA and PsaB, The purified photosystem I complexes from the wild type strain of Synechocystis sp, PCC 6803 were treated with eight proteases to study the accessibility of cleavage sites in PsaA and PsaB. Proteolytic fragments were identified using the information from N-terminal amino acid sequencing, reactivity to antibodies, apparent mass, and specificity of proteases. The extramembrane loops of PsaA and PsaB differed in their accessibility to proteases, which indicated the folded structure of the loops or their shielding by the small subunits of photosystem I, NaI-treated and mutant photosystem I complexes were used to identify the extramembrane loops that were exposed in the absence of specific small subunits. The absence of PsaD exposed additional proteolytic sites in PsaB, whereas the absence of PsaE exposed sites in PsaA. These studies distinguish PsaA and PsaB in the structural model for photosystem I that has been proposed on the basis of x-ray diffraction studies (KrauB, N,, Schubert, W,-D,, Klukas, O., Fromme, P., Witt, H. T,, and Saenger, W, (1996) Nat. Struct. Biol, 3, 965-973), Using osmotically shocked cells for protease treatments, the N terminus of PsaA was determined to be on the n side of the photosynthetic membranes. Based on these data and available published information, we propose a topological model for PsaA and PsaB.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053104] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armbrust TS, 1996, PLANT PHYSIOL, V111, P1307, DOI 10.1104/pp.111.4.1307; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; Chitnis PR, 1996, PLANT PHYSIOL, V111, P661, DOI 10.1104/pp.111.3.661; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHITNIS PR, 1992, PLANT PHYSIOL, V99, P239, DOI 10.1104/pp.99.1.239; CHITNIS PR, 1995, PHOT LIGHT BIOSPH, P17; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; COHEN Y, 1993, PLANT MOL BIOL, V23, P895, DOI 10.1007/BF00021544; FISH LE, 1985, J BIOL CHEM, V260, P1413; Fromme P, 1996, CURR OPIN STRUC BIOL, V6, P473, DOI 10.1016/S0959-440X(96)80112-6; GOLBECK JH, 1994, MOL BIOL CYANOBACTER, P179; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HENRY RL, 1992, PLANT PHYSIOL BIOCH, V30, P357; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KRUIP J, 1997, J BIOL CHEM, V271, P10761; KUHN M, 1994, TRENDS BIOCHEM SCI, V19, P401, DOI 10.1016/0968-0004(94)90085-X; LELONG C, 1994, J BIOL CHEM, V269, P10034; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V34, P339, DOI 10.1016/0003-9861(51)90012-4; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V33, P65, DOI 10.1016/0003-9861(51)90082-3; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; STROTMANN H, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204; TAE GS, 1994, BIOCHEMISTRY-US, V33, P10060, DOI 10.1021/bi00199a033; VALLON O, 1993, EUR J BIOCHEM, V214, P907, DOI 10.1111/j.1432-1033.1993.tb17994.x; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; WYNN RM, 1989, PLANT PHYSIOL, V91, P445, DOI 10.1104/pp.91.1.445; XU Q, 1994, PLANT PHYSIOL, V106, P1057, DOI 10.1104/pp.106.3.1057; XU Q, 1994, PLANT MOL BIOL, V26, P291, DOI 10.1007/BF00039540; XU Q, 1994, J BIOL CHEM, V269, P21512; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU Q, 1995, PLANT PHYSIOL, V108, P1067, DOI 10.1104/pp.108.3.1067; XU Q, 1995, PHOTOSYNTHESIS LIGHT, V2, P87; XU QA, 1994, J BIOL CHEM, V269, P3205; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	49	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21793	21802		10.1074/jbc.272.35.21793	http://dx.doi.org/10.1074/jbc.272.35.21793			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268309	hybrid			2022-12-25	WOS:A1997XT85000021
J	Wang, JW; Dong, ZH; Bell, LR				Wang, JW; Dong, ZH; Bell, LR			Sex-lethal interactions with protein and RNA - Roles of glycine-rich and RNA binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICING FACTOR U2AF; CIS-ACTING ELEMENTS; POLYPYRIMIDINE TRACT; DROSOPHILA-MELANOGASTER; PREMESSENGER RNA; SNRNP PROTEIN; HNRNP PROTEIN; MALE EXON; IN-VITRO	Sex-lethal (Sxl) is an RNA-binding protein, containing two conserved RNA binding domains (RBDs) and a glycine-rich region, which functions as a regulator of alternative splicing in Drosophila sex determination, Previous work demonstrated that Sxl monomers interact cooperatively upon binding to target RNAs and that the cooperativity depends on the glycine-rich N terminus, Here we use band shift experiments to show that RNA binding patterns are altered when Sxl is combined with other proteins having similar glycine-rich domains, including mammalian heterogeneous nuclear (hn) RNP L and Drosophila Hrb87F (an hnRNP A/B homolog). Direct involvement of the Sxl glycine-rich region in protein interactions was verified by Far-Western analysis, Two interaction domains, the Sxl N terminus and the Sxl first RNA binding domain, were suggested by the yeast two-hybrid assay, In a systematic examination of the RNA binding properties of Sxl domains, it was found that the Sxl termini as well as the RBDs influence RNA binding specificity, Finally, selection of the Sxl optimal binding site (SELEX) confirms the importance of U-runs in the Sxl binding site and suggests a second type of non-U-run target that may be associated with RNA secondary structure.	UNIV SO CALIF,DEPT BIOL SCI,PROGRAM MOL BIOL,LOS ANGELES,CA 90089	University of Southern California								BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CALVIO C, 1995, RNA, V1, P724; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FLICKINGER TW, 1994, GENE DEV, V8, P914, DOI 10.1101/gad.8.8.914; FU XD, 1995, RNA, V1, P663; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GRANADINO B, 1992, GENETICS, V130, P597; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARPER DS, 1992, NUCLEIC ACIDS RES, V20, P3645, DOI 10.1093/nar/20.14.3645; HAYNES SR, 1990, MOL CELL BIOL, V10, P316, DOI 10.1128/MCB.10.1.316; HAYNES SR, 1991, NUCLEIC ACIDS RES, V19, P25; Hilfiker A, 1995, DEVELOPMENT, V121, P4017; HORABIN JI, 1993, MOL CELL BIOL, V13, P1408, DOI 10.1128/MCB.13.3.1408; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LIU XD, 1995, GENE DEV, V9, P1766, DOI 10.1101/gad.9.14.1766; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1993, MOL CELL BIOL, V13, P2992; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; NEITFELD W, 1990, EMBO, V9, P3699; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	54	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22227	22235		10.1074/jbc.272.35.22227	http://dx.doi.org/10.1074/jbc.272.35.22227			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268369	hybrid			2022-12-25	WOS:A1997XT85000081
J	Zhen, RG; Kim, EJ; Rea, PA				Zhen, RG; Kim, EJ; Rea, PA			Acidic residues necessary for pyrophosphate-energized pumping and inhibition of the vacuolar H+-pyrophosphatase by N,N'-dicyclohexylcarbodiimide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN STRUCTURE; SITE-SPECIFIC MUTAGENESIS; INORGANIC PYROPHOSPHATASE; PHENOTYPIC SELECTION; ATP SYNTHASE; SUBUNIT; SEQUENCE; TOPOLOGY; GENE; BACTERIORHODOPSIN	On the basis of a revised topological model of the vacuolar H+-pyrophosphatase (V-PPase; EC 3.6.1.1) derived from the analysis of four published sequences using two structure-predicting programs, TopPred II and MEMSAT, eight acidic amino acid residues located near or within transmembrane alpha-helices were identified, The codons specifying these amino acids in the cDNA encoding the V-PPase from Arabidopsis thaliana were singly mutated to examine their involvement in pyrophosphate (PPi) hydrolysis and PPi-dependent H+ translocation and the functional significance of the similarities between the sequences encompassing GlU(229) (227-245) of the V-PPase and the N,N'-dicyclohexylcarbodiimide (DCCD)-binding transmembrane alpha-helix of the c-subunits of F-ATPases (Nyren, P., Sakai-Nore, Y., and Strid, A. (1993) Plant Cell Physiol. 34, 375-378). Three functional classes were identified after heterologous expression of mutated enzyme in Saccharomyces cerevisiae, Class I (E119Q, E229Q, D573N, E667Q, and E751Q) mutants exhibited PPi hydrolytic and H+ translocation activities and DCCD sensitivities similar to wild type. The one class II mutant obtained (E427Q) was preferentially impaired for H+ translocation over PPi hydrolysis but retained sensitivity to DCCD, Class III (E305Q and D504N) mutants exhibited a near complete abolition of both PPi hydrolysis and H+ translocation and residual activities with decreased DCCD sensitivity, In none of the mutants was diminished insertion of the V-PPase into the membrane or an increase in the background conductance of the membrane to H+ evident, The decoupled character of E427Q mutants and the enhancement of H+ pumping in E427D mutants by comparison with wild type, in conjunction with the retention of DCCD inhibitability in both E427Q and E427D mutants, implicate a role for Glu(427) in DCCD-insensitive H+ translocation by the V-PPase, The proportionate diminution of PPi hydrolytic and H+ translocation activity and con servation of wild type DCCD sensitivity in E229Q mutants refute the notion that Glu(229) is the residue whose covalent modification by DCCD is responsible for the abolition of PPi-dependent H+ translocation. Instead, the diminished sensitivity of the residual activities of E305Q and D504N mutants, but not E305D or D504E mutants, to inhibition by DCCD is consistent with the involvement of acidic residues at these positions in inhibitory DCCD binding, The results are discussed with regard to the possible involvement of Glu(427) in coupling PPi hydrolysis with transmembrane H+ translocation and earlier interpretations of the susceptibility of the V-PPase to inhibition by carbodiimides.	UNIV PENN, DEPT BIOL, INST PLANT SCI, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								BALTSCHEFFSKY M, 1993, MOL MECH BIOENERGETI, P331; BAYKOV AA, 1993, FEBS LETT, V327, P199, DOI 10.1016/0014-5793(93)80169-U; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; FALK G, 1988, BIOCHEM J, V254, P109, DOI 10.1042/bj2540109; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; GordonWeeks R, 1996, PLANT PHYSIOL, V111, P195, DOI 10.1104/pp.111.1.195; HARLOWE E, 1988, ANTIBODIES LAB MANUA; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HASSINEN IE, 1993, BIOCHIM BIOPHYS ACTA, V1144, P107, DOI 10.1016/0005-2728(93)90164-B; HEBERLE J, 1993, EMBO J, V12, P3721, DOI 10.1002/j.1460-2075.1993.tb06049.x; HUTTLY AK, 1990, GENE, V90, P227, DOI 10.1016/0378-1119(90)90184-S; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; KIM YC, 1994, PLANT PHYSIOL, V106, P375, DOI 10.1104/pp.106.1.375; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEIGH RA, 1992, PLANT PHYSIOL, V100, P1698, DOI 10.1104/pp.100.4.1698; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MORIKAMI A, 1987, NUCLEIC ACIDS RES, V15, P4692, DOI 10.1093/nar/15.11.4692; NYREN P, 1993, PLANT CELL PHYSIOL, V34, P375; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rea P.A., 1990, METHODS PLANT BIOCH, V3, P385, DOI DOI 10.1016/B978-0-12-461013-2.50035-6; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; TANAKA Y, 1993, BIOCH BIOPHYSICAL RE, V190, P962; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; ZHEN RG, 1994, J BIOL CHEM, V269, P23342; Zhen RG, 1997, ADV BOT RES, V25, P297, DOI 10.1016/S0065-2296(08)60156-1	40	83	91	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22340	22348		10.1074/jbc.272.35.22340	http://dx.doi.org/10.1074/jbc.272.35.22340			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268385	hybrid			2022-12-25	WOS:A1997XT85000097
J	Endo, F; Kubo, S; Awata, H; Kiwaki, K; Katoh, H; Kanegae, Y; Saito, I; Miyazaki, J; Yamamoto, T; Jakobs, C; Hattori, S; Matsuda, I				Endo, F; Kubo, S; Awata, H; Kiwaki, K; Katoh, H; Kanegae, Y; Saito, I; Miyazaki, J; Yamamoto, T; Jakobs, C; Hattori, S; Matsuda, I			Complete rescue of lethal albino c(14CoS) mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY TYROSINEMIA; ACID DIOXYGENASE; MURINE MODEL; RECOMBINANT ADENOVIRUS; MOUSE STRAIN; GENE HPD; LIVER; EXPRESSION; ENZYME; HYPERTYROSINEMIA	Hereditary tyrosinemia 1 (HT1) is characterized by progressive liver damage, hom infancy, and by a high risk for hepatocellular carcinoma. HT1 is due to mutations in the fumarylacetoacetate hydrolase gene Fah, encoding the last enzyme in the tyrosine catabolic pathway. Lethal albino deletion c(14CoS) mice and mice with target-disrupted Fah are models for HT1, but they die ill the perinatal period, albeit with a different phenotype from that seen in HT1 in humans, We-first asked whether homozygous null mutation of the 4-hydroxy-phenylpyruvate dioxygenase gene Hpd could rescue the homozygous c(14CoS) mice (c(14CoS)/c(14CoS) or Fah(-/-)), The double mutant Fah(-/-) Hpd(-/-) mice appeared normal, at least until age 18 months, and there was no evidence of liver disease, findings that facilitated examination of the effect of Fah(-/-) on mature and unmodified hepatocytes in vivo. The hepatocytes of Fah(-/-) undergo rapid apoptosis, and acute death follows. Essentially the same phenomena were observed when Fah(-/-) Hpd(-/-) mice were administered homogentisate intraperitoneally. These changes in liver pathology in Fah(-/-) Hpd(-/-) mice after the administration of homogentisate were associated with massive urinary excretion of succinylacetone, These results suggest that accumulation of fumarylacetoacetate, maleylacetoacetate, or succinylacetone seems to trigger the endogenous process of apoptosis in hepatocytes that lack fumarylacetoacetate hydrolase activity. This apoptosis may be related to the development of hepatocellular carcinomas seen in HT1 patients and pharmaceutically treated fumarylacetoacetate hydrolase-deficient mice.	KUMAMOTO UNIV,SCH MED,GRAD SCH MED SCI,DIV MOL PATHOL,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,COLL MED SCI,KUMAMOTO 860,JAPAN; CENT INST EXPT ANIM,DEPT GENET,KAWASAKI,KANAGAWA 216,JAPAN; UNIV TOKYO,INST MED SCI,GENET MOL LAB,MINATO KU,TOKYO 108,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; FREE UNIV AMSTERDAM HOSP,DEPT PEDIAT & CLIN CHEM,NL-1018 HV AMSTERDAM,NETHERLANDS	Kumamoto University; Kumamoto University; University of Tokyo; Tohoku University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Endo, F (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT PEDIAT,HONJO 1-1-1,KUMAMOTO 860,JAPAN.		Miyazaki, Jun-ichi/N-1976-2015; Kubo, Shuji/Q-3868-2019	Miyazaki, Jun-ichi/0000-0003-2475-589X; Kubo, Shuji/0000-0001-7384-4835				AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; ANDREW HW, 1995, CURR OPIN GENE DEV, V5, P97; AWATA H, 1994, GENOMICS, V23, P534, DOI 10.1006/geno.1994.1540; AWATA H, 1994, BBA-MOL BASIS DIS, V1226, P168, DOI 10.1016/0925-4439(94)90025-6; EDWARDS SW, 1956, J BIOL CHEM, V220, P79; ENDO F, 1992, J BIOL CHEM, V267, P24235; ENDO F, 1983, PEDIATR RES, V17, P92, DOI 10.1203/00006450-198302000-00002; ENDO F, 1991, AM J HUM GENET, V48, P704; ENDO F, 1995, GENOMICS, V25, P164, DOI 10.1016/0888-7543(95)80122-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLUECKSOHNWAELSCH S, 1979, CELL, V16, P225, DOI 10.1016/0092-8674(79)90001-1; GROMPE M, 1995, NAT GENET, V10, P453, DOI 10.1038/ng0895-453; GROMPE M, 1993, GENE DEV, V7, P298; JAKOBS C, 1988, CLIN CHIM ACTA, V223, P223; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KASTAN MB, 1993, NAT GENET, V5, P207, DOI 10.1038/ng1193-207; Katoh H., 1991, Mouse Genome, V89, P572; KELSEY G, 1993, GENE DEV, V7, P2285, DOI 10.1101/gad.7.12a.2285; KELSEY G, 1992, J CELL SCI S, V16, P117; Kiwaki K, 1996, HUM GENE THER, V7, P821, DOI 10.1089/hum.1996.7.7-821; KLEBIG ML, 1992, P NATL ACAD SCI USA, V89, P1363, DOI 10.1073/pnas.89.4.1363; Kubo S, 1997, HUM GENE THER, V8, P65, DOI 10.1089/hum.1997.8.1-65; KVITTINGEN EA, 1993, J CLIN INVEST, V91, P1816, DOI 10.1172/JCI116393; La Du BN, 1995, METABOLIC MOL BASES, P1371; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1992, LANCET, V340, P813, DOI 10.1016/0140-6736(92)92685-9; Mitchell G, 1995, METABOLIC MOL BASES, P1077; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PHANEUF D, 1992, J CLIN INVEST, V90, P1185, DOI 10.1172/JCI115979; RUPPERT S, 1992, GENE DEV, V6, P1430, DOI 10.1101/gad.6.8.1430; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; RUSSO P, 1990, AM J HUM GENET, V47, P317; TONJES RR, 1992, EMBO J, V11, P127, DOI 10.1002/j.1460-2075.1992.tb05035.x	36	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24426	24432		10.1074/jbc.272.39.24426	http://dx.doi.org/10.1074/jbc.272.39.24426			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305902	hybrid			2022-12-25	WOS:A1997XY51500053
J	Spink, J; Evans, T				Spink, J; Evans, T			Binding of the transcription factor interferon regulatory factor-1 to the inducible nitric-oxide synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA-GENE; NF-KAPPA-B; FACTOR-I; VIRUS INDUCTION; RELAXING FACTOR; NUCLEAR FACTOR; FACTOR IRF-1; DNA; ELEMENTS; EXPRESSION	Nitric oxide production in a variety of inflammatory conditions is dependent on the synthesis of the enzyme, inducible nitric-oxide synthase (iNOS). The gene for this enzyme is regulated by a number of inflammatory cytokines, including interferon-gamma. Transcriptional activation of the gene is dependent on the interferon-gamma-induced transcription factor, interferon regulatory factor-1 (IRF-1). Using a 99-base pair segment of the iNOS gene promoter encompassing nucleotides -979 to -881, a region essential for gene activation by cytokines, we show that with increasing concentrations of added IRF-1, a monomeric then a dimeric complex form. Molecular footprinting analysis shows that the factor binds initially to a canonical IRF-1 site as a monomer. The region of binding is then extended both in a 5' and 3' direction on formation of the dimeric complex, with additional contacts in the minor groove of DNA, Binding of the second molecule of IRF-1 is dependent on the presence of the initial bound protein, Sequential binding of IRF-1 to form a dimeric complex has not been described previously, and we show that formation of this dimeric complex is essential for full activation of the iNOS gene by cytokines in vascular smooth muscle cells.	ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND	Imperial College London								BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; LEE LYYH, 1990, MOL CELL BIOL, V10, P3087; LIN RT, 1994, J BIOL CHEM, V269, P17542; LUSTER AD, 1987, MOL CELL BIOL, V7, P3723, DOI 10.1128/MCB.7.10.3723; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; OHNO S, 1983, NUCLEIC ACIDS RES, V11, P5403, DOI 10.1093/nar/11.16.5403; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; UEGAKI K, 1995, FEBS LETT, V359, P184, DOI 10.1016/0014-5793(95)00040-G; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	39	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24417	24425		10.1074/jbc.272.39.24417	http://dx.doi.org/10.1074/jbc.272.39.24417			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305901	hybrid			2022-12-25	WOS:A1997XY51500052
J	Swaroop, M; Moussalli, M; Pipe, SW; Kaufman, RJ				Swaroop, M; Moussalli, M; Pipe, SW; Kaufman, RJ			Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-V; MAMMALIAN-CELLS; EXPRESSION; CDNA; CERULOPLASMIN; DISSOCIATION; SEQUENCE; CLONING	Coagulation factor VIII (FVIII) and factor V are homologous glycoproteins that have a domain structure of A1-A2-B-A3-C1-C2, FVIII is a heterodimer of the heavy chain (domains A1-A2-B) and the light chain (domains A3-C1-C2) in a metal ion-dependent association between the Al-and A3 domains. Previous studies identified a 110-amino acid region within the FVIII Al-domain that inhibits its secretion and contains multiple short peptide sequences that have potential to bind immunoglobulin-binding protein (BiP), FVIII secretion requires high levels of intracellular ATP, consistent with an ATP-dependent release from BiP, Site-directed mutagenesis was used to elucidate the importance of the potential BiP binding sites in FVIII secretion, Mutation of Phe at position 309 to Ser or Ala enhanced the secretion of functional FVIII and reduced its ATP dependence. The F309S FVIII had a specific activity, thrombin activation profile, and heat inactivation properties similar to those of wild-type FVIII, However, F309S FVIII displayed increased sensitivity to EDTA-mediated inactivation that is known to occur through metal ion chelation-induced dissociation of the heavy and light chains of FVIII. The results support that Phe(309) is important in high affinity heavy and light chain interaction, and this correlates with a high affinity BiP-binding site, Introduction of the F309S mutation into other secretion defective FVIII mu mutants rescued their secretion, demonstrating the ability of the this mutation to improve secretion of mutant FVIII proteins retained in the cell.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PEDIAT,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Pipe, Steven W./ABC-3843-2020	Pipe, Steven W./0000-0003-2558-2089; Swaroop, Manju/0000-0002-0576-1664	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173, R01HL053777] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52173, HL53777] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIHOREAU N, 1994, EUR J BIOCHEM, V222, P41, DOI 10.1111/j.1432-1033.1994.tb18839.x; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KAUFMAN RJ, 1989, METHOD ENZYMOL, V135, P537; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; TAGLIAVACCA L, 1997, IN PRESS J BIOL CHEM, V272; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; ZATLOUKAL K, 1994, P NATL ACAD SCI USA, V91, P5148, DOI 10.1073/pnas.91.11.5148	25	82	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24121	24124		10.1074/jbc.272.39.24121	http://dx.doi.org/10.1074/jbc.272.39.24121			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305856	hybrid			2022-12-25	WOS:A1997XY51500007
J	Mounier, C; Chen, WZ; Klautky, SA; Goodridge, AG				Mounier, C; Chen, WZ; Klautky, SA; Goodridge, AG			Cyclic AMP-mediated inhibition of transcription of the malic enzyme gene in chick embryo hepatocytes in culture - Characterization of a cis-acting element far upstream of the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE GENE; THYROID-HORMONE; RESPONSE ELEMENTS; BINDING PROTEIN; MAMMALIAN-CELLS; V-ERBA; CAMP; JUN; FOS; TRIIODOTHYRONINE	Glucagon, acting via cAMP, inhibits transcription of the malic enzyme gene in chick embryo hepatocytes. In transiently transfected hepatocytes, fragments from the 5'-flanking DNA of the malic enzyme gene confer cAMP responsiveness to linked reporter genes, The major inhibitory cAMP response element at -3180/-3114 base pairs (bp) is similar to the consensus binding site for AP1. DNA fragments from -3134/-3115, -1713/-944, and -413/-147 bp also contain inhibitory cAMP response elements. The negative action of cAMP is mimicked by overexpression of the catalytic subunit of protein kinase A, inhibited by overexpression of a specific inhibitor of protein kinase A, and inhibited by overexpression of the T3 receptor; these results indicate involvement of the classical eukaryotic pathway for cAMP action and suggest interaction between the T3 and cAMP pathways. Sequence-specific complexes form between nuclear proteins and a DNA fragment containing -3192/-3158 bp of 5'-flanking DNA. In nuclear extracts prepared from cells treated with chlorophenylthio-cyclic AMP and T3, the complexes have different masses than those formed with extracts from cells treated with T3 alone. Antibodies to c-Fos or ATF-2 inhibit formation of the complex formed by proteins from cells treated with chlorophenylthio-cyclic AMP and T3 but not by those from cells treated with T3 alone. These results suggest an important role for c-Fos and ATF-2 in glucagon-nediated inhibition of transcription of the malic enzyme gene.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Mounier, Catherine/D-3690-2011	Mounier, Catherine/0000-0003-3608-4229	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021594, P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25295, DK 21594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAILLIE RB, 1992, J NUTR BIOCH, V4, P431; BARBER JR, 1978, MOL CELL BIOL, V77, P2201; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BORRELLI E, 1992, CRIT REV ONCOGEN, V3, P312; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; Carlisle TL, 1996, J LIPID RES, V37, P2088; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DELMAS V, 1994, REV PHYSIOL BIOCH P, V124, P1, DOI 10.1007/BFb0031030; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROVE JR, 1987, SCIENCE, V238, P530; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; LUCKOW B, 1987, NUCLEIC ACIDS RES, V17, P2365; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MECHTA F, 1989, New Biologist, V1, P297; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RONCERO C, 1992, ARCH BIOCHEM BIOPHYS, V295, P258, DOI 10.1016/0003-9861(92)90516-Y; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SIKORSKA M, 1988, J BIOL CHEM, V263, P3005; TAMIR A, 1994, J IMMUNOL, V152, P3391; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	41	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23606	23615		10.1074/jbc.272.38.23606	http://dx.doi.org/10.1074/jbc.272.38.23606			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295300	hybrid			2022-12-25	WOS:A1997XX38100025
J	Nakajima, Y; Tsuji, Y; Homma, K; Natori, S				Nakajima, Y; Tsuji, Y; Homma, K; Natori, S			A novel protease in the pupal yellow body of Sarcophaga peregrina (flesh fly) - Its purification and cDNA cloning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							29-KDA HEMOCYTE PROTEINASE; SARCOTOXIN IA; FAT-BODY; MOLECULAR-CLONING; METAMORPHOSIS; EXPRESSION; GENE	We purified a novel serine protease with a molecular mass of 26 kDa from Sarcophaga pupae. This protease appeared almost exclusively in the yellow body, an organ that develops temporarily in the pupae of dipteran insects and expands to form the adult midgut by engulfing the larval midgut. cDNA analysis revealed that this protease consists of 239 amino acid residues and has significant structural similarity with bovine trypsin (about 40% sequence identity). The 26-kDa protease gene was transiently activated in 1-day-old pupae. The protease was found to cross-react immunologically with antibody against sarcotoxin IA, an antibacterial protein produced by this insect. It is suggested that this protease participates in the decomposition of the larval midgut in the yellow body during metamorphosis.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Tsuji, Yumiko/AAV-9817-2020					Bodenstein D., 1950, BIOL DROSOPHILA, P275; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLYG C, 1987, INSECT BIOCHEM, V17, P153, DOI 10.1016/0020-1790(87)90155-7; KUBO T, 1991, International Journal of Developmental Biology, V35, P83; KURATA S, 1992, DEV BIOL, V153, P115, DOI 10.1016/0012-1606(92)90096-Y; KURATA S, 1992, EUR J BIOCHEM, V204, P911, DOI 10.1111/j.1432-1033.1992.tb16711.x; KURATA S, 1990, INSECT BIOCHEM, V20, P461, DOI 10.1016/0020-1790(90)90027-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKSHIN RA, 1985, COMPREHENSIVE INSECT, V2, P301; MATSUMOTO N, 1986, BIOCHEM J, V239, P717, DOI 10.1042/bj2390717; NANBU R, 1988, BIOCHEM BIOPH RES CO, V150, P540, DOI 10.1016/0006-291X(88)90427-5; OHTAKI T, 1966, JPN J MED SCI BIOL, V19, P97, DOI 10.7883/yoken1952.19.97; OKADA M, 1983, BIOCHEM J, V211, P727, DOI 10.1042/bj2110727; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TAKAHASHI N, 1993, FEBS LETT, V334, P153, DOI 10.1016/0014-5793(93)81702-2; YAMADA K, 1990, BIOCHEM J, V272, P633, DOI 10.1042/bj2720633; YANO T, 1995, EUR J BIOCHEM, V234, P39, DOI 10.1111/j.1432-1033.1995.039_c.x	19	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23805	23810		10.1074/jbc.272.38.23805	http://dx.doi.org/10.1074/jbc.272.38.23805			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295327	hybrid			2022-12-25	WOS:A1997XX38100052
J	Plummer, NW; McBurney, MW; Meisler, MH				Plummer, NW; McBurney, MW; Meisler, MH			Alternative splicing of the sodium channel SCN8A predicts a truncated two-domain protein in fetal brain and non-neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; GROWTH-FACTOR RECEPTOR; SKELETAL-MUSCLE; ION CHANNELS; GENOMIC ORGANIZATION; ALPHA-SUBUNIT; SECRETED FORM; RAT-BRAIN; GENE; CLONING	The voltage gated sodium channel alpha subunit SCN8A is one of the most abundant sodium channels in neurons from brain and spinal cord. We have identified two alternatively spliced exons, 18N and 18A, that encode transmembrane segments S3 and S4 in domain III. Exon 18N is expressed in fetal brain and non-neuronal tissues. Transcripts with exon 18N have a conserved in-frame stop codon that predicts the synthesis of a truncated, two-domain protein similar to the fetal form of the muscle calcium channel. The proportion of transcripts containing exon 18N is highest in mouse fetal brain between E12.5 and P1.5; at later ages transcripts containing exon 18A predominate. This developmental program is recapitulated in P19 cells during retinoic acid-induced neuronal differentiation. Non-neuronal tissues contain a low level of SCN8A transcripts containing exon 18N. SCN8A thus provides a new model of differentiation specific splicing. Genomic analysis of SCN8A from human, mouse, and fish demonstrated a conserved structure in which exon 18N is located 300-500 bp upstream of exon 18A. Duplication of exon 18 thus preceded the divergence of fish and mammals. The genomic organization, developmental regulation, and coding content of exons 18N and 18A closely resemble the previously described alternate exons 5N and 5A of the neuronal sodium channel genes. Our proposal that the evolutionary origin of exons 18N and 18A was by duplication of exons 5N and 5A is consistent with other evidence that the four-domain cation channels arose by two rounds of duplication from a single-domain ancestral channel.	UNIV OTTAWA,DEPT MED,OTTAWA,ON K1H 8M5,CANADA	University of Ottawa	Plummer, NW (corresponding author), UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109, USA.			/0000-0003-2971-814X	NIGMS NIH HHS [T32 GM 07544] Funding Source: Medline; NINDS NIH HHS [NS34509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARREOLA J, 1993, J PHYSIOL-LONDON, V472, P289, DOI 10.1113/jphysiol.1993.sp019947; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BELCHER SM, 1995, P NATL ACAD SCI USA, V92, P11034, DOI 10.1073/pnas.92.24.11034; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHEUN JE, 1991, INT J DEV NEUROSCI, V9, P391, DOI 10.1016/0736-5748(91)90061-P; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; GEORGE AL, 1993, GENOMICS, V15, P598, DOI 10.1006/geno.1993.1113; GUSTAFSON TA, 1993, J BIOL CHEM, V268, P18648; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HARRIS JB, 1986, J NEUROL SCI, V76, P239, DOI 10.1016/0022-510X(86)90172-3; HILLE B, 1992, ION CHANNELS EXCITAB, P538; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kohrman DC, 1996, J NEUROSCI, V16, P5993; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; Kozak CA, 1996, MAMM GENOME, V7, P787, DOI 10.1007/s003359900235; KUBO Y, 1989, J PHYSIOL-LONDON, V409, P497, DOI 10.1113/jphysiol.1989.sp017510; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MAGNUSON DSK, 1995, DEV BRAIN RES, V84, P130, DOI 10.1016/0165-3806(94)00166-W; MALOUF NN, 1992, NEURON, V8, P899, DOI 10.1016/0896-6273(92)90204-Q; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; MORASSUTTI DJ, 1994, NEUROSCIENCE, V58, P753, DOI 10.1016/0306-4522(94)90452-9; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Peixoto AA, 1997, GENETICS, V145, P1003; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; SCHALLER KL, 1995, J NEUROSCI, V15, P3231; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STRONG M, 1993, MOL BIOL EVOL, V10, P221; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SWAROOP A, 1993, CYTOGENET CELL GENET, V64, P292, DOI 10.1159/000133595; THACKERAY JR, 1995, GENETICS, V141, P203; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236	47	125	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24008	24015		10.1074/jbc.272.38.24008	http://dx.doi.org/10.1074/jbc.272.38.24008			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295353	hybrid			2022-12-25	WOS:A1997XX38100078
J	Li, JY; English, MA; Ball, HJ; Yeyati, PL; Waxman, S; Licht, JD				Li, JY; English, MA; Ball, HJ; Yeyati, PL; Waxman, S; Licht, JD			Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR-ALPHA; TRANS-RETINOIC ACID; GLUTATHIONE-S-TRANSFERASE; TUMOR GENE-PRODUCT; RAR-ALPHA; FUSION PROTEINS; T(15-17) TRANSLOCATION; PLZF GENE; PML; DIFFERENTIATION	Chromosomal translocation t(11;17)(q23;21) is associated with a retinoic acid-resistant form of acute promyelocytic leukemia. The translocation fuses the RAR alpha gene to the PLZF gene, resulting in the formation of reciprocal fusion proteins, hypothesized to play prominent roles in leukemogenesis. Promyelocytic leukemia zinc finger (PLZF) encodes a transcription factor with nine Kruppel-like zinc fingers, seven of which are retained in the t(11;17) fusion protein RAR alpha-PLZF. We identified a specific DNA-binding site for the PLZF protein and showed that PLZF binds to this site through its most carboxyl seven zinc fingers, In co-transfection experiments, PLZF repressed transcription through its cognate binding site, This repression function of PLZF was mapped to two regions on the protein, including the evolutionarily conserved POZ domain, In contrast, the RAR alpha-PLZF protein activated transcription of a promoter containing a PLZF response element, These results suggest that RAR alpha-PLZF, generated in acute promyelocytic leukemia, is an aberrant transcription factor that can deregulate the expression of PLZF target genes and contribute to leukemogenesis.	MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai			Ball, Helen J/A-4242-2010; Licht, Jonathan/L-4239-2019	Ball, Helen J/0000-0003-3733-9748; Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; BALL HJ, 1996, BLOOD S1, V88, P555; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANG CC, 1996, BIOCHEMISTRY-US, V93, P6947; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DUONG S, 1996, P NATL ACAD SCI USA, V93, P3624; FAINSOD A, 1991, NUCLEIC ACIDS RES, V19, P4005, DOI 10.1093/nar/19.14.4005; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Fenaux P, 1997, SEMIN ONCOL, V24, P92; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1991, CR SOC BIOL, V185, P391; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; McBryant SJ, 1996, NUCLEIC ACIDS RES, V24, P2567, DOI 10.1093/nar/24.13.2567; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Seyfert VL, 1996, ONCOGENE, V12, P2331; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SITTERLIN S, 1997, ONCOGENE, V14, P1067; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TESTA U, 1994, CANCER RES, V54, P4508; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YEYATI PL, 1996, BLOOD S1, V88, P291; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x	57	150	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22447	22455		10.1074/jbc.272.36.22447	http://dx.doi.org/10.1074/jbc.272.36.22447			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278395	hybrid			2022-12-25	WOS:A1997XV49200015
J	Pedersen, WA; Guo, Q; Hartman, BK; Mattson, MP				Pedersen, WA; Guo, Q; Hartman, BK; Mattson, MP			Nerve growth factor-independent reduction in choline acetyltransferase activity in PC12 cells expressing mutant presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BASAL FOREBRAIN; IN-VITRO; PROTEIN; NEURONS; ACETYLCHOLINE; MUTATIONS; APOPTOSIS; DEMENTIA; MEMORY	Mutations in the presenilin genes (PS-l and PS-2) are linked to early onset familial Alzheimer's disease (AD), but the mechanisms by which these mutations cause the cognitive impairment characteristic of AD are unknown. Basal forebrain cholinergic neurons are involved in learning and memory processes, and reductions in choline acetyl-transferase (ChAT) activity are a characteristic feature of AD brain. We therefore hypothesized that presenilin mutations suppress expression of the cholinergic phenotype. In rat PC12 cells stably transfected with the human PS-I gene containing the Leu --> Val mutation at codon 286 (L286V), we observed a drastic reduction (>90%) in basal ChAT activity compared with cells transfected with vector alone. By immunocytochemistry, a similar decrease in ChAT protein levels was found in the mutant transfectants. In cells differentiated with nerve growth factor, ChAT activity was again markedly lower in L286V-expressing cells than in control cells. We also observed reductions in ChAT activity in PC12 cells expressing the wild-type human PS-I gene but to a lesser extent than in L286V-expressing cells. The viability of cells transfected with either the wild-type or the mutant PS-I gene was not compromised. Our results suggest that PS-I mutations may contribute to the cognitive impairment in AD by causing a nontoxic suppression of the cholinergic phenotype.	UNIV KENTUCKY,SANDERS BROWN CTR AGING,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536; UNIV MINNESOTA,DEPT PSYCHIAT,MINNEAPOLIS,MN 55455	University of Kentucky; University of Kentucky; University of Minnesota System; University of Minnesota Twin Cities			Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005144] Funding Source: NIH RePORTER; NIA NIH HHS [AG05119, AG05144] Funding Source: Medline; NINDS NIH HHS [NS30583] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BIERER LM, 1995, J NEUROCHEM, V64, P749; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; DUTAR P, 1995, PHYSIOL REV, V75, P393, DOI 10.1152/physrev.1995.75.2.393; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HARKANY T, 1995, BRAIN RES, V698, P270, DOI 10.1016/0006-8993(95)01013-L; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; IVERSEN LL, 1995, BIOCHEM J, V311, P1; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; Kar S, 1996, J NEUROSCI, V16, P1034; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XH, 1996, J NEUROSCI, V16, P5914; Mattson M.P., 1996, MOL MECH DEMENTIA, P103; MATTSON MP, 1992, J NEUROSCI, V12, P375; OAKMAN SA, 1995, J NEUROSCI, V15, P5859; Pedersen WA, 1996, P NATL ACAD SCI USA, V93, P8068, DOI 10.1073/pnas.93.15.8068; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; WU DH, 1994, J NEUROCHEM, V62, P1653; YAMADA M, 1994, BRAIN RES, V661, P137, DOI 10.1016/0006-8993(94)91190-8; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	31	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22397	22400		10.1074/jbc.272.36.22397	http://dx.doi.org/10.1074/jbc.272.36.22397			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278388	hybrid			2022-12-25	WOS:A1997XV49200007
J	Schumacher, MA; Glasfeld, A; Zalkin, H; Brennan, RG				Schumacher, MA; Glasfeld, A; Zalkin, H; Brennan, RG			The X-ray structure of the PurR-guanine-purF operator complex reveals the contributions of complementary electrostatic surfaces and a water-mediated hydrogen bond to corepressor specificity and binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PURINE REPRESSOR; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MET REPRESSOR; DNA-BINDING; PROTEIN; AUTOREGULATION; RECOGNITION; RESOLUTION; FAMILY	The purine repressor, PurR, is the master regulatory protein of de novo purine nucleotide biosynthesis in Escherichia coli. This dimeric transcription factor is activated to bind to cognate DNA operator sites by initially binding either of its physiologically relevant, high affinity corepressors, hypoxanthine (K-d = 9.3 mu M) or guanine (K-d = 1.5 mu M). Here, we report the 2.5-Angstrom crystal structure of the PurR-guanine-purF operator ternary complex and complete the atomic description of 6-oxopurine-induced repression by PurR. As anticipated, the structure of the PurR-guanine-purF operator complex is isomorphous to the PurR-hypoxanthine-purF operator complex, and their protein-DNA and protein-corepressor interactions are nearly identical. The former finding confirms the use of an identical allosteric DNA-binding mechanism whereby corepressor binding 40 Angstrom from the DNA-binding domain juxtaposes the hinge regions of each monomer, thus favoring the formation and insertion of the critical minor groove-binding hinge helices. Strikingly, the higher binding affinity of guanine for PurR and the ability of PurR to discriminate against 2-oxopurines do not result from direct protein-ligand interactions, but rather from a water-mediated contact with the exocyclic N-2 of guanine, which dictates the presence of a donor group on the corepressor, and the better electrostatic complementarity of the guanine base and the corepressor-binding pocket.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA; REED COLL, DEPT CHEM, PORTLAND, OR 97202 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Oregon Health & Science University; Reed College - Oregon; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049244, R01GM024658, R37GM024658] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24658, GM49244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIN H, 1993, J BACTERIOL, V175, P3598, DOI 10.1128/jb.175.11.3598-3606.1993; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; Glasfeld A, 1996, J AM CHEM SOC, V118, P13073, DOI 10.1021/ja962416b; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JOACHIMIAK A, 1994, EMBO J, V13, P367, DOI 10.1002/j.1460-2075.1994.tb06270.x; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVORY R, 1990, J BIOMOL STRUCT DYN, V6, P215; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; Nguyen CC, 1995, FEBS LETT, V377, P98, DOI 10.1016/0014-5793(95)01344-X; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PHILLIPS K, 1994, STRUCTURE, V2, P309, DOI 10.1016/S0969-2126(00)00032-0; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SCHUMACHER MA, 1994, J MOL BIOL, V242, P302, DOI 10.1006/jmbi.1994.1580; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEIERT JG, 1990, J BACTERIOL, V172, P3799, DOI 10.1128/jb.172.7.3799-3803.1990; Tame JRH, 1996, NAT STRUCT BIOL, V3, P998, DOI 10.1038/nsb1296-998; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	40	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22648	22653		10.1074/jbc.272.36.22648	http://dx.doi.org/10.1074/jbc.272.36.22648			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278422	hybrid			2022-12-25	WOS:A1997XV49200042
J	Tran, H; VanDusen, WJ; Argraves, WS				Tran, H; VanDusen, WJ; Argraves, WS			The self-association and fibronectin-binding sites of fibulin-1 map to calcium-binding epidermal growth factor-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; BETA-HYDROXYASPARTIC ACID; EGF-LIKE DOMAIN; HUMAN FACTOR-IX; EXTRACELLULAR-MATRIX; MARFAN-SYNDROME; DEPENDENT BINDING; FACTOR-X; PROTEIN; GLYCOPROTEIN	Fibulin-1 is a modular glycoprotein with amino-terminal anaphylatoxin-like modules followed by nine epidermal growth factor (EGF)-like modules and, depending on alternative splicing, four possible carboxyl termini. Fibulin-1 has been shown to self-associate as well as to bind calcium, fibronectin (FN), laminin, nidogen, and fibrinogen. To map ligand-binding sites within fibulin-1, polypeptides corresponding to various regions of fibulin-1 were expressed recombinantly and evaluated for their capacity to bind calcium, FN, or fibulin-1. A calcium-binding site(s) was mapped to EGF-like modules 5-9. A fibulin-1 self-association site was localized to EGF-like modules 5 and 6 (amino acid residues 356-440), as was a binding site for FN. The self-association interaction mediated by this pair of modules involved calcium since divalent cation chelators reduced the binding affinity of the interaction. By contrast, FN binding to EGF-like modules 5 and 6 was unaffected by the presence of divalent cation chelators. It can be concluded that EGF-like modules 5 and 6 bind calcium and mediate homotypic interaction between EGF-like modules 5 and 6 present in different fibulin-1 molecules and heterotypic interaction between EGF-like modules 5 and 6 and type III repeats 13 and 14 in FN. While additional binding sites for calcium or FN were not detected, another fibulin-1 self-association site was found within amino acid residues 30-173. However, unlike the self-association site in EGF-like modules 5 and 6, which was functional in the native protein, the amino-terminal site was cryptic and revealed only after the protein was denatured.	MED UNIV S CAROLINA,DEPT ANAT & CELL BIOL,CHARLESTON,SC 29425; AMER RED CROSS,DEPT BIOCHEM,ROCKVILLE,MD 20855; MERCK RES LABS,W POINT,PA 19486	Medical University of South Carolina; American Red Cross; Merck & Company					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL052813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52813] Funding Source: Medline; NIGMS NIH HHS [GM 42912] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BROWN JC, 1994, J CELL SCI, V107, P329; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; GODYNA S, 1994, MATRIX BIOL, V14, P467; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V353, P395, DOI 10.1038/353395a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Miosge N, 1996, HISTOCHEM J, V28, P109, DOI 10.1007/BF02331415; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; SUGO T, 1984, J BIOL CHEM, V259, P5705; TRAN H, 1995, J BIOL CHEM, V270, P19458, DOI 10.1074/jbc.270.33.19458; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; ZHANG HY, 1993, DIFFERENTIATION, V52, P211, DOI 10.1111/j.1432-0436.1993.tb00633.x	42	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22600	22606		10.1074/jbc.272.36.22600	http://dx.doi.org/10.1074/jbc.272.36.22600			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278415	hybrid			2022-12-25	WOS:A1997XV49200035
J	Dreier, B; Fritz, S; Volkert, G; Brachvogel, B; Lottspeich, F; Fey, GH				Dreier, B; Fritz, S; Volkert, G; Brachvogel, B; Lottspeich, F; Fey, GH			A 32-kDa proteolytic fragment of transcription factor Stat3 is capable of specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-6 RESPONSE ELEMENT; ACUTE-PHASE RESPONSE; RAT ALPHA-2-MACROGLOBULIN GENE; EPIDERMAL GROWTH-FACTOR; GEL-ELECTROPHORESIS; SIGNAL TRANSDUCER; PROTEINS; ACTIVATION; DOMAIN; PHOSPHORYLATION	Fragments of characteristic size retaining the ability of sequence-specific DNA binding were generated by partial proteolysis of transcription factor Stat3 with trypsin, chymotrypsin, or Staphylococcus V8 proteinase, The molecular masses of the smallest DNA-binding fragments were 75, 48, and 32 kDa after digestion with V8 proteinase, chymotrypsin, and trypsin, respectively, The fragments contained major parts of the domain controlling the sequence specificity of DNA binding (amino acids 406-514), the SH3 and SH2 domains, and the phosphorylated tyrosine residue Tyr-705, but not the C-terminal 20 amino acids, The N terminus of the 32-kDa tryptic fragment (ANCDASLIV) matched the sequence of amino acids 424-432 deduced from cDNA. The fragments were observed after proteolytic treatment of preformed complexes between DNA and native factors eluted from rat liver nuclei or recombinant, tyrosine-phosphorylated rat Stat3 from insect cells. It was possible to elute all three minimal fragments from their complexes with DNA and to obtain specific re-binding, The minimal fragments eluted from complexes with DNA still contained the phosphorylated Tyr-705 and the SH2 domain suggesting that they were probably bound to DNA as dimers, The DNA-binding domain of Stat3 identified by these experiments overlapped the domain previously identified by genetic experiments as the domain controlling the sequence specificity of DNA binding, The DNA-binding domain defined here by partial proteolysis probably represents an autonomously folding portion of Stat3.	UNIV ERLANGEN NURNBERG,CHAIR GENET,D-91058 ERLANGEN,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	University of Erlangen Nuremberg; Max Planck Society				Brachvogel, Bent/0000-0002-3923-0554				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BRECHNER T, 1991, MOL BIOL MED, V8, P267; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; Leung S, 1996, SCIENCE, V273, P750, DOI 10.1126/science.273.5276.750; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Schneider K, 1995, ANN NY ACAD SCI, V762, P502; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	34	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22118	22124		10.1074/jbc.272.35.22118	http://dx.doi.org/10.1074/jbc.272.35.22118			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268355	hybrid			2022-12-25	WOS:A1997XT85000067
J	Serebriiskii, I; Estojak, J; Sonoda, G; Testa, JR; Golemis, EA				Serebriiskii, I; Estojak, J; Sonoda, G; Testa, JR; Golemis, EA			Association of Krev-1/rapla with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22	ONCOGENE			English	Article						Krit1; Krev-1/Rapla; 7q21-22; ankyrin repeat; interaction	BUD-SITE-SELECTION; GTP-BINDING PROTEINS; RAS-RELATED GENE; SACCHAROMYCES-CEREVISIAE; CHILDHOOD MONOSOMY-7; SUPPRESSOR ACTIVITY; ACTIVATING PROTEIN; HUMAN-NEUTROPHILS; TUMOR-SUPPRESSOR; SIGNAL PATHWAY	Krev-1/rap1A is an evolutionarily conserved Ras-family GTPase whose cellular function remains unclear, hut which has been proposed to function as a tumor suppressor gene, and may act as a Ras antagonist, To elucidate Krev-1 activity, we have used LexA-Krev-1 in a two-hybrid screen of a HeLa cell cDNA library, Of the two cDNA classes isolated, one contained a single isolate encoding the known Krev-1 interactor Raf, while the second contained multiple isolates coding for a previously undescribed protein which we have designated Krit1 (for Krev Interaction Trapped 1), The full length Krit1 cDNA encodes a protein of 529 amino acids, with an amino-terminal ankyrin repeat domain and a novel carboxy-terminal domain required for association with Krit1, Krit1 interacted strongly with Krev-1 but only weakly with Ras, suggesting it might specifically regulate Krev-1 activities, Krit1 mRNA and protein are expressed endogenously at low levels, with tissue specific variation, Intriguingly, the Krit cDNA has been mapped by FISH to chromosome 7q21-22, a region known to be frequently deleted or amplified in multiple forms of cancer.	FOX CHASE CANC CTR,DIV BASIC SCI,PHILADELPHIA,PA 19111; FOX CHASE CANC CTR,DIV MED SCI,PHILADELPHIA,PA 19111	Fox Chase Cancer Center; Fox Chase Cancer Center				Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [R29CA063366, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, R29 CA63366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; *CONS I GEN RES, 1995, NATURE, V377, P3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JELINEK MA, 1992, ONCOGENE, V7, P1687; KERE J, 1987, BLOOD, V70, P1349; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Law SF, 1996, MOL CELL BIOL, V16, P3327; LUNAFINEMAN S, 1995, BLOOD, V85, P1985, DOI 10.1182/blood.V85.8.1985.bloodjournal8581985; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Moult J, 1996, CURR OPIN BIOTECH, V7, P422, DOI 10.1016/S0958-1669(96)80118-2; NASSAR N, 1995, NATURE, V375, P554; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PEDERSENBJERGAARD J, 1982, BLOOD, V60, P172; PIZON V, 1988, ONCOGENE, V3, P201; PIZON V, 1994, J CELL SCI, V107, P1661; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; QUINN MT, 1992, BLOOD, V79, P1563; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; SAKODA T, 1992, ONCOGENE, V7, P1705; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SATO KY, 1994, CANCER RES, V54, P552; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WEISS K, 1987, LEUKEMIA, V1, P97; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WOJTASZEK PA, 1993, ONCOGENE, V8, P755; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMADA T, 1990, GENE CHROMOSOME CANC, V2, P88, DOI 10.1002/gcc.2870020203; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; [No title captured]	62	168	175	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1043	1049		10.1038/sj.onc.1201268	http://dx.doi.org/10.1038/sj.onc.1201268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285558				2022-12-25	WOS:A1997XT16100005
J	Candau, R; Scolnick, DM; Darpino, P; Ying, CY; Halazonetis, TD; Berger, SL				Candau, R; Scolnick, DM; Darpino, P; Ying, CY; Halazonetis, TD; Berger, SL			Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity	ONCOGENE			English	Article						adaptor; genetics; mdm-2; p53; transcription	WILD-TYPE P53; TATA-BINDING PROTEIN; PUTATIVE TRANSCRIPTIONAL ADAPTER; TUMOR-SUPPRESSOR GENE; DNA-BINDING; OLIGOMERIZATION DOMAIN; TETRAMERIZATION DOMAIN; REPRESSION FUNCTIONS; BASAL TRANSCRIPTION; OVERLAPPING DOMAINS	The ability of p53 to function as a tumor suppressor is linked to its function as a transcriptional activator, since p53 mutants that do not transactivate are unable to suppress tumor cell growth, Previous studies identified an activation domain in the amino terminal 40 residues of the protein, a region that binds to several general transcription factors and to some oncogene products, For example, mdm-2, a cellular oncoprotein, binds to this region and represses p53 transactivation, Here we describe a new activation domain within the amino terminus of p53 that maps between amino acids 40-83, and whose residues trp-53 and phe-54 are critical for function both in yeast and in mammalian cells, In vivo studies in yeast show that the new activation subdomain, unlike the previously described, is mdm-2 independent, Both p53 activation subdomains (1-40 and 40-83) require the yeast adaptor complex ADA2/ADA3/GCN5 for transcriptional activation, Moreover, since activation by p53 requires GCN5's enzymatic histone acetyltransferase domain, p53 may regulate gene expression by influencing chromatin modification.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute			Halazonetis, Thanos/D-7923-2011	Berger, Shelley/0000-0001-5398-4400				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BLAIR WS, 1994, J VIROL, V68, P3803, DOI 10.1128/JVI.68.6.3803-3808.1994; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1996, MOL CELL BIOL, V16, P593; CANDAU R, IN PRESS EMBO J; CANDAU R, 1996, J BIOL CHEM, V271, P527; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GILL G, 1988, NATURE, V334, P4721; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEONARDO AD, 1994, GENE DEV, V8, P2540; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIENHARDSCHMITZ M, 1994, J BIOL CHEM, V41, P25613; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOIDL P, 1994, CHROMOSOMA, V103, P441; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OHASHI Y, 1994, MOL CELL BIOL, V14, P2731, DOI 10.1128/MCB.14.4.2731; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROSE MD, 1988, METHODS YEAST GENETI; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU L, 1996, NATURE GENTE, V14, P429; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	91	121	125	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					807	816		10.1038/sj.onc.1201244	http://dx.doi.org/10.1038/sj.onc.1201244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266967				2022-12-25	WOS:A1997XQ11700007
J	Ruchaud, S; Seite, P; Foulkes, NS; SassoneCorsi, P; Lanotte, M				Ruchaud, S; Seite, P; Foulkes, NS; SassoneCorsi, P; Lanotte, M			The transcriptional repressor ICER and cAMP-induced programmed cell death	ONCOGENE			English	Article						apoptosis; leukaemia; cAMP-signalling; transcription factors; CREM; ICER	LONG-TERM DESENSITIZATION; DNA FRAGMENTATION; RETINOIC ACID; CREM GENE; RESPONSIVE-ELEMENT; CYCLIC-NUCLEOTIDES; CHOLERA-TOXIN; KINASE-I; APOPTOSIS; EXPRESSION	The cAMP pathway plays a central role in the response to hormonal signals for cell proliferation, differentiation and apoptosis, In IPC-81 leukaemia cells, activation of the cAMP pathway by prostaglandin E1 treatment, or other cAMP-elevating agents, induces apoptosis within 4-6 h. Inhibition of mRNA or protein synthesis during the first 2h of cAMP induction protects cells from apoptosis, suggesting a requirement for early gene expression. cAMP-dependent protein kinase phosphorylates a class of nuclear factors and thereby regulates the transcription of a specific set of genes. Here we show that CREM (cAMP Responsive Element Modulator) expression is induced rapidly upon prostaglandin E1 treatment of IPC-81 cells. The induced transcripts correspond to the early product ICER (Inducible cAMP Early Repressor), ICER expression remains elevated until the burst of cell death, Protein synthesis inhibitors which prevent cAMP-induced apoptosis also block de novo ICER synthesis, Transfected IPC-81 cell lines, constitutively expressing high level of ICER are resistant to cAMP-induced cell death, In these transfected cells, cAMP fails to upregulate the ICER transcripts demonstrating that ICER exerts strongly its repressor function on CRE-containing genes. That an early expression of ICER blocks apoptosis, suggests that gene repression by endogenous ICER in IPC-81 is unsufficient or occurs too late to protect cells against death. ICER transfected cells rescued from cAMP-induced apoptosis are growth arrested, It shows for the first time that CREM activation directly participates to the decision of the cell to die. ICER, by sequentially repressing distinct sets of CRE-containing genes could modulate cell fate.	HOP ST LOUIS,CTR G HAYEM,INSERM U301,F-75010 PARIS,FRANCE; INST GENET BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Ruchaud, Sandrine/AAJ-2179-2021; Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891; Seite, Paule/0000-0002-7809-7610				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRAUMANN TJ, 1995, J CHROMATOGR, V350, P105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUPREZ E, 1993, J BIOL CHEM, V268, P8332; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRIEDMAN DL, 1976, PHYSIOL REV, V56, P652, DOI 10.1152/physrev.1976.56.4.652; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Green DR, 1996, CELL DEATH DIFFER, V3, P339; GROUL DJ, 1993, MOL ENDOCRINOL, V7, P104; HAWLEY RG, 1994, GENE THER, V1, P136; HAYARI Y, 1985, EUR J IMMUNOL, V15, P43, DOI 10.1002/eji.1830150109; HITTELMAN KJ, 1973, PROSTAGLANDINS, P151; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOMNA V, 1978, BIOCHEM BIOPH RES CO, V82, P1246; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; HOUGE G, 1993, FEBS LETT, V315, P16, DOI 10.1016/0014-5793(93)81123-H; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LANOTTE M, 1986, LEUKEMIA RES, V10, P1319, DOI 10.1016/0145-2126(86)90340-1; LANOTTE M, 1986, EXP HEMATOL, V14, P724; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McConkey D J, 1992, Semin Immunol, V4, P371; MCCONKEY DJ, 1993, FASEB J, V7, P580, DOI 10.1096/fasebj.7.6.8386120; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORI K, 1989, BIOCHEM BIOPH RES CO, V162, P1535, DOI 10.1016/0006-291X(89)90849-8; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLSSON IL, 1982, CANCER RES, V42, P3922; POTTEN CS, 1988, CELL, V53, P676; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; ROSSI GB, 1980, BLOOD, V56, P74; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; Ruchaud S., 1995, Cellular Pharmacology, V2, P127; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUSUKI K, 1990, BIOCHEM BIOPH RES CO, V171, P827; TAETLE R, 1980, CANCER RES, V40, P1223; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TORTORA G, 1988, BLOOD, V71, P230; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1987, GENE, V53, P121, DOI 10.1016/0378-1119(87)90099-0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	70	38	39	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					827	836		10.1038/sj.onc.1201248	http://dx.doi.org/10.1038/sj.onc.1201248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266969				2022-12-25	WOS:A1997XQ11700009
J	Maghazachi, AA; Skalhegg, BS; Rolstad, B; AlAoukaty, A				Maghazachi, AA; Skalhegg, BS; Rolstad, B; AlAoukaty, A			Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins	FASEB JOURNAL			English	Article						NK cells; lymphotactin; CHAK; chemokine	RECEPTORS; ALPHA	We show here that interferon-inducible protein-10 (IP-10), an ELR lacking CXC chemokine, and the C chemokine lymphotactin (Ltn) induce the chemotaxis and calcium mobilization in IL-2-activated NK (IANK) and CC chemokine-activated NK (CHAK) cells. Cross-desensitization experiments show that IP-10 or Ltn use receptors not shared by other C, CC, or CXC chemokines. The chemotaxis induced by either IP-10 or Ltn for both cell types is inhibited upon pretreatment of these cells with pertussis toxin (PT), Also, Ltn-induced [Ca2+](i) in IANK but not in CHAK cells is inhibited upon pretreatment with PT, whereas IP-10-induced [Ca2+](i) in IANK and CHAK cells is inhibited upon pretreatment with this toxin, These results suggest important roles for PT-sensitive and -insensitive G-proteins in IP-10-induced and Ltn-induced chemotaxis and calcium fluxes in activated NK cells, This was further implicated after streptolysin O permeabilization of CHAK and IANK cells and after introduction of inhibitory antibodies to the PT-sensitive G(i) and G(o) or the PT-insensitive G(q). Our results suggest that IP-10 and Ltn receptors are coupled to G(i), G(o), and G(q) in IANK cells and to G(i) and G(q) in CHAX cells, with a possible low coupling of IP-10, but not of Ltn, receptors to G(o) in these cells, Together, these results show that IP-10 and Ltn-dependent chemotaxis and calcium mobilization may differentiate at the level of receptor coupling to the heterotrimeric G-proteins.	UNIV OSLO,DEPT BIOCHEM,INST BASIC MED SCI,N-0317 OSLO,NORWAY	University of Oslo	Maghazachi, AA (corresponding author), UNIV OSLO,DEPT ANAT,INST BASIC MED SCI,POSTBOKS 1105,N-0317 OSLO,NORWAY.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Maghazachi, Azzam/0000-0002-3310-678X				AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; BIANCHI G, 1996, EUR J IMMUNOL, V26, P3238; Bluman EM, 1996, J CLIN INVEST, V97, P2722, DOI 10.1172/JCI118726; BYGRAVE FL, 1995, FASEB J, V9, P1297, DOI 10.1096/fasebj.9.13.7557019; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dilloo D, 1996, NAT MED, V2, P1090, DOI 10.1038/nm1096-1090; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; Hedrick JA, 1997, J IMMUNOL, V158, P1533; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1996, J IMMUNOL, V156, P322; LUSTER AD, 1993, J EXP MED, V178, P1809; Maghazachi AA, 1996, EUR J IMMUNOL, V26, P315, DOI 10.1002/eji.1830260207; MAGHAZACHI AA, 1994, J IMMUNOL, V153, P4969; MAGHAZACHI AA, 1991, J LEUKOCYTE BIOL, V49, P302, DOI 10.1002/jlb.49.3.302; MAGHAZACHI AA, 1994, J BIOL CHEM, V269, P6796; MAGHAZACHI AA, 1993, INT IMMUNOL, V5, P825, DOI 10.1093/intimm/5.8.825; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SEBOK K, 1993, J IMMUNOL, V150, P1524; Sgadari C, 1996, BLOOD, V87, P3877, DOI 10.1182/blood.V87.9.3877.bloodjournal8793877; TAUB DD, 1995, J IMMUNOL, V155, P3877; Taub DD, 1996, BLOOD, V87, P1423, DOI 10.1182/blood.V87.4.1423.bloodjournal8741423; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	33	84	101	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					765	774		10.1096/fasebj.11.10.9271361	http://dx.doi.org/10.1096/fasebj.11.10.9271361			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271361				2022-12-25	WOS:A1997XR10500006
J	Jiang, M; TsengCrank, J; Tseng, GN				Jiang, M; TsengCrank, J; Tseng, GN			Suppression of slow delayed rectifier current by a truncated isoform of KvLQT1 cloned from normal human heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; I-KS; VENTRICULAR MUSCLE; CLONING; EXPRESSION; MUTATIONS; K(V)LQT1; PROTEINS; DOMAIN; FORM	It has been suggested that the cardiac slow delayed rectifier channel is formed by the association of two subunits: IsK (also called minK) and KvLQT1. N-terminal splice variants of the human KvLQT1 gene have been identified, but the functional roles of different KvLQT1 isoforms are not clear, Using the nested 5'-rapid amplification of cDNA ends technique, we obtained a truncated isoform of KvLQT1 (termed tKvLQT1) that lacks the N-terminal cytoplasmic domain and the initial one-third of the first transmembrane domain, The function of tKvLQT1 was tested by oocyte expression, alone or together with the full-length KvLQT1 or a human IsK clone (hIsK). tKvLQT1 alone did not generate functional channels, However, it suppressed the KvLQT1 current when coexpressed with the full-length isoform, It also suppressed the slow delayed rectifier current induced by hIsK, probably by competing with the KvLQT1 subunit endogenous to Xenopus oocytes in coassembly with the hIsK subunit, On the other hand, tKvLQT1 did not suppress the expression of Kv1.4, Kv4.3, or hERG, Using the reverse transcription-polymerase chain reaction technique, we further show that the truncated and full-length isoforms are coexpressed in different regions of human heart, Therefore, tKvLQT1 may modulate the function of IKs in human cardiac myocytes.	WYETH AYERST RES,PRINCETON,NJ 08543	Pfizer	Jiang, M (corresponding author), COLUMBIA UNIV,DEPT PHARMACOL,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046451, P01HL030557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30557, HL46451] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU DW, 1995, CIRC RES, V76, P351, DOI 10.1161/01.RES.76.3.351; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Russell MW, 1996, HUM MOL GENET, V5, P1319, DOI 10.1093/hmg/5.9.1319; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SICOURI S, 1993, J CARDIOVASC ELECTR, V4, P48, DOI 10.1111/j.1540-8167.1993.tb01211.x; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tanaka T, 1997, CIRCULATION, V95, P565, DOI 10.1161/01.CIR.95.3.565; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017	20	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24109	24112		10.1074/jbc.272.39.24109	http://dx.doi.org/10.1074/jbc.272.39.24109			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305853	hybrid			2022-12-25	WOS:A1997XY51500004
J	Mitchelhill, KI; Michell, BJ; House, CM; Stapleton, D; Dyck, J; Gamble, J; Ullrich, C; Witters, LA; Kemp, BE				Mitchelhill, KI; Michell, BJ; House, CM; Stapleton, D; Dyck, J; Gamble, J; Ullrich, C; Witters, LA; Kemp, BE			Posttranslational modifications of the 5'-AMP-activated protein kinase beta(1) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; RAT-LIVER; MEMBRANE PHOSPHOLIPIDS; ATP DEPLETION; FATTY-ACID; PHOSPHORYLATION; ACTIVATION; MYRISTOYLATION; MYRISTYLATION; PURIFICATION	The AMP-activated protein kinase (AMPK) consists of catalytic Lu and noncatalytic beta and gamma subunits and is responsible for acting as a metabolic sensor for AMP levels, There are multiple genes for each subunit and the rat liver AMPK alpha(1) and alpha(2), catalytic subunits are associated with beta(1) and gamma(1) noncatalytic subunits. We find that the isolated gamma(1) subunit is N-terminally acetylated with no other posttranslational modification, The isolated beta(1) subunit is N-terminally myristoylated, Transfection of COS cells with AMPK subunit cDNAs containing a non-myristoylatable beta(1) reduces, but does not eliminate, membrane binding of AMPK heterotrimer, The isolated beta(1) subunit is partially phosphorylated at three sites, Ser(24/25), Ser(182), and Ser(108). The Ser(24/25) and Ser(108) sites are substoichiometrically phosphorylated and can be autophosphorylated in vitro. The Ser-Pro site in the se quence LSSS(182)PPGP is stoichiometrically phosphorylated, and no additional phosphate is incorporated into this site with autophosphorylation, Based on labeling studies in transfected cells, we conclude that alpha(1) Thr(172) is a major, although not exclusive, site of both basal and stimulated alpha(1) phosphorylation by an upstream AMPK kinase.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; DARTMOUTH COLL SCH MED,DEPT MED,ENDOCRINE METAB DIV,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	St. Vincent's Institute of Medical Research; Dartmouth College; Dartmouth College			Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Dyck, Jason/0000-0002-7045-2884	NIDDK NIH HHS [DK35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1992, LIPID MODIFICATION P, P3; BERI RK, 1994, FEBS LETT, V356, P117, DOI 10.1016/0014-5793(94)01247-4; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DESJARDINS PR, 1972, CAN J BIOCHEM CELL B, V50, P1249, DOI 10.1139/o72-170; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stapleton D, 1997, FEBS LETT, V409, P452, DOI 10.1016/S0014-5793(97)00569-3; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; WANG JH, 1976, J BIOL CHEM, V251, P4521; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831	32	120	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24475	24479		10.1074/jbc.272.39.24475	http://dx.doi.org/10.1074/jbc.272.39.24475			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305909	hybrid			2022-12-25	WOS:A1997XY51500060
J	Saras, J; Franzen, P; Aspenstrom, P; Hellman, U; Gonez, LJ; Heldin, CH				Saras, J; Franzen, P; Aspenstrom, P; Hellman, U; Gonez, LJ; Heldin, CH			A novel GTPase-activating protein for Rho interacts with a PDZ domain of the protein-tyrosine phosphatase PTPL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; ACTIN STRESS FIBERS; KINASE-C; SIGNAL-TRANSDUCTION; GUANYLATE KINASES; FAMILY GTPASES; CLONING; RAC; CHIMAERIN; BAND-4.1	PTPL1 is an intracellular protein-tyrosine phosphatase that contains five PDZ domains. Here, we present the cloning of a novel 150-kDa protein, the four most C-terminal amino acid residues of which specifically interact with the fourth PDZ domain of PTPL1. The molecule contains a GTPase-activating protein (GAP) domain, a cysteine-rich, putative Zn2+- and diacylglycerol-binding domain, and a region of sequence homology to the product of the Caenorhabditis elegans gene ZK669.1a. The GAP domain is active on Rho, Pac, and Cdc42 in vitro but with a clear preference for Rho; we refer to the molecule as PTPL1-associated RhoGAP 1, PARG1, Rho is inactivated by GAPs, and protein-tyrosine phosphorylation has been implicated in Rho signaling. Therefore, a complex between PTPL1 and PARG1 may function as a powerful negative regulator of Rho signaling, acting both on Rho itself and on tyrosine phosphorylated components in the Rho signal transduction pathway.			Saras, J (corresponding author), LUDWIG INST CANC RES,CTR BIOMED,BOX 595,S-75124 UPPSALA,SWEDEN.							AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Sambrook J., 2002, MOL CLONING LAB MANU; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	39	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24333	24338		10.1074/jbc.272.39.24333	http://dx.doi.org/10.1074/jbc.272.39.24333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305890	hybrid			2022-12-25	WOS:A1997XY51500041
J	Sun, GS; Alexson, SEH; Harrison, EH				Sun, GS; Alexson, SEH; Harrison, EH			Purification and characterization of a neutral, bile salt-independent retinyl ester hydrolase from rat liver microsomes - Relationship to rat carboxylesterase ES-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM CARBOXYLESTERASE; ENDOPLASMIC-RETICULUM; PALMITATE HYDROLYSIS; NUCLEOTIDE-SEQUENCE; MEMBRANE; PROTEIN; ACID; IDENTIFICATION; METABOLISM; EXPRESSION	A neutral, bile salt-independent retinyl ester hydrolase (NREH) has been purified from a rat liver microsomal fraction, The purification procedure involved detergent extraction, DEAE-Sepharose ion exchange, Phenyl-Sepharose hydrophobic interaction, Sephadex G-100 and Sephacryl S-200 gel filtration chromatographies, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The isolated enzyme has an apparent molecular mass of approximately 66 kDa under denaturing conditions on SDS-PAGE, Analysis of the amino acid sequences of four peptides isolated after proteolytic digestion revealed that the enzyme is highly homologous with other rat liver carboxylesterases, In particular, the sequences of the four peptides of the NREH (60 amino acids total) were identical to those of a rat carboxylesterase expressed in the liver (Alexson, S. E. H., Finlay, T. H., Hellman, U., Svensson, L. T., Diczfalusy, U., and Eggertsen, G. (1994) J. Biol. Chem. 269, 17118-17124), Antibodies against this enzyme also react with the purified NREH, Purified NREH shows a substrate preference for retinyl palmitate over triolein and did not catalyze the hydrolysis of cholesteryl oleate, With retinyl palmitate as substrate, the enzyme had a pH optimum of 7 and showed apparent saturation kinetics, with half-maximal activity achieved at substrate concentrations (K-m) of approximately 70 mu M.	ALLEGHENY UNIV HLTH SCI,MED COLL PENN HAHNEMANN SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19129; HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Drexel University; Karolinska Institutet			Harrison, Earl H/AAN-5378-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044498] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443] Funding Source: Medline; NIDDK NIH HHS [R01 DK044498, DK44498] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXSON SEH, 1993, EUR J BIOCHEM, V214, P719, DOI 10.1111/j.1432-1033.1993.tb17973.x; ALEXSON SEH, 1994, J BIOL CHEM, V269, P17118; AMARCOSTESEC A, 1974, J CELL BIOL, V61, P201, DOI 10.1083/jcb.61.1.201; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; ERLANSON C, 1968, BIOCHIM BIOPHYS ACTA, V167, P629, DOI 10.1016/0005-2744(68)90059-4; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; GAD MZ, 1991, J LIPID RES, V32, P685; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; HARRISON EH, 1993, BIOCHIM BIOPHYS ACTA, V1170, P99, DOI 10.1016/0005-2760(93)90058-H; HARRISON EH, 1995, J LIPID RES, V36, P1498; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; KADNER SS, 1992, ARCH BIOCHEM BIOPHYS, V296, P435, DOI 10.1016/0003-9861(92)90594-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P147, DOI 10.1016/0005-2744(80)90050-9; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1987, BIOCHEM J, V245, P863, DOI 10.1042/bj2450863; NAPOLI JL, 1984, ARCH BIOCHEM BIOPHYS, V230, P194, DOI 10.1016/0003-9861(84)90100-0; NAPOLI JL, 1989, ARCH BIOCHEM BIOPHYS, V274, P192, DOI 10.1016/0003-9861(89)90430-X; PRYSTOWSKY JH, 1981, J BIOL CHEM, V256, P4498; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151; YAN BF, 1995, J BIOL CHEM, V270, P19128, DOI 10.1074/jbc.270.32.19128	26	31	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24488	24493		10.1074/jbc.272.39.24488	http://dx.doi.org/10.1074/jbc.272.39.24488			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305911	hybrid			2022-12-25	WOS:A1997XY51500062
J	Winkler, DG; Johnson, JC; Cooper, JA; Vojtek, AB				Winkler, DG; Johnson, JC; Cooper, JA; Vojtek, AB			Identification and characterization of mutations in Ha-Ras that selectively decrease binding to cRaf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PHOSPHOTYROSINE-CONTAINING PROTEINS; GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-TRANSFORMATION; SIGNAL TRANSDUCTION; KINASE ACTIVATION; CRYSTAL-STRUCTURE; FOCAL ADHESIONS; R-RAS	The oncoprotein Ras transforms cells by binding to one or more effector proteins, Effector proteins have been identified by their ability to bind to Bas in the GTP but not GDP form, and by their requirement for the Ras effector domain for binding, The best understood Ras effectors are serine/threonine kinases of the Raf family, but other candidate Ras effecters, including a Ral guanine nucleotide dissociation stimulator and phosphatidylinositol 3-kinase (PI3 kinase) have also been identified, To investigate the mechanism of binding of cRaf-1 to Ras, and to investigate the roles of other candidate Ras effectors in transformation, we have isolated and characterized mutants of activated Ras with decreased binding to cRaf-1 relative to other candidate effecters, Examination of these mutants indicates that surface-exposed residues of Res outside the minimal effector domain interact differentially with cRaf-1 and other Ras-binding proteins, and that fibroblast transformation correlates with cRaf-1 binding and mitogen-activated protein (MAP) kinase activation, Furthermore, activation of PI3 kinase can occur in the absence of significant MAP kinase activation, suggesting that PI3 kinase activation is a primary effect of Ras.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98109	Fred Hutchinson Cancer Center					NCI NIH HHS [CA54786, CA66281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054786, F32CA066281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Leung DW, 1989, TECHNIQUE, V1, P11; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P2850; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SHIROUZU M, 1992, ONCOGENE, V7, P475; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	71	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24402	24409		10.1074/jbc.272.39.24402	http://dx.doi.org/10.1074/jbc.272.39.24402			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305899	hybrid			2022-12-25	WOS:A1997XY51500050
J	Chen, DN; Patrick, JW				Chen, DN; Patrick, JW			The alpha-bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the alpha 7 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; PHARMACOLOGICAL PROPERTIES; H-3 ACETYLCHOLINE; CELL-LINE; CHANNEL; PROTEIN; PURIFICATION; EXPRESSION; SITES; SUBTYPES	When expressed in Xenopus oocytes, the rat alpha 7 subunit forms homo-oligomeric nicotinic acetylcholine receptors, which are blocked by alpha-bungarotoxin. Since the pharmacological and physiological properties of the alpha 7 receptor expressed in oocytes are similar to those of the alpha-bungarotoxin-sensitive nicotinic currents recorded from neuronal preparations and the distribution patterns of alpha 7 mRNA and alpha-bungarotoxin-binding sites in the rat brain are very similar, alpha 7 is thought to be the main component of the alpha-bungarotoxin-binding nicotinic receptor in the mammalian brain. However, while alpha 7 is found in purified alpha-bungarotoxin-binding complexes from rat brain or PC12 cells, other proteins copurify with it. Therefore, the question whether alpha 7 forms a homo-oligomeric alpha-bungarotoxin-binding nicotinic receptor in the mammalian brain remains. We have developed and characterized affinity-purified polyclonal antibodies and used these antibodies in Western blot analyses of alpha-bungarotoxin-binding proteins purified from rat brains. We report here that our experimental data support the current working hypothesis that the alpha-bungarotoxin-binding nicotinic receptor is a homo-oligomer of alpha 7 subunits in the rat brain.	BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine					NIDA NIH HHS [DA04077] Funding Source: Medline; NINDS NIH HHS [NS13546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004077, R37DA004077] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBUQUERQUE EX, 1995, ANN NY ACAD SCI, V757, P48, DOI 10.1111/j.1749-6632.1995.tb17464.x; ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; BROIDE RS, 1995, NEUROSCIENCE, V67, P83, DOI 10.1016/0306-4522(94)00623-D; Chen D., 1993, Society for Neuroscience Abstracts, V19, P466; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P1046, DOI 10.1021/bi00456a029; CONTITRONCONI BM, 1985, P NATL ACAD SCI USA, V82, P5208, DOI 10.1073/pnas.82.15.5208; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FUCHS JL, 1989, BRAIN RES, V501, P223, DOI 10.1016/0006-8993(89)90640-9; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; GOTTI C, 1989, NEUROSCIENCE, V32, P759, DOI 10.1016/0306-4522(89)90296-0; GOTTI C, 1995, EUR J NEUROSCI, V7, P2083, DOI 10.1111/j.1460-9568.1995.tb00630.x; GOTTI C, 1994, EUR J NEUROSCI, V6, P1281, DOI 10.1111/j.1460-9568.1994.tb00318.x; GOTTI C, 1992, NEUROSCIENCE, V50, P117, DOI 10.1016/0306-4522(92)90386-G; GOTTI C, 1991, P NATL ACAD SCI USA, V88, P3258, DOI 10.1073/pnas.88.8.3258; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; KELLIS JT, 1991, BIO-TECHNOL, V9, P994, DOI 10.1038/nbt1091-994; KEMP G, 1985, BRAIN RES, V347, P274, DOI 10.1016/0006-8993(85)90187-8; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LUKAS RJ, 1990, J PHARMACOL EXP THER, V253, P51; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; NEFF S, 1995, J NEUROCHEM, V64, P332; PATRICK J, 1977, J BIOL CHEM, V252, P8629; PATRICK J, 1977, P NATL ACAD SCI USA, V74, P4689, DOI 10.1073/pnas.74.10.4689; Radcliffe K. A., 1996, Society for Neuroscience Abstracts, V22, P1264; ROGERS SW, 1992, J NEUROSCI, V12, P4611; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SEGUELA P, 1993, J NEUROSCI, V13, P596; SINE SM, 1981, J BIOL CHEM, V256, P6692; STALLCUP WB, 1979, J PHYSIOL-LONDON, V286, P525, DOI 10.1113/jphysiol.1979.sp012635; TZARTOS SJ, 1991, MOL NEUROBIOL, V5, P1, DOI 10.1007/BF02935610; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595; WHITING PJ, 1987, NATURE, V327, P515, DOI 10.1038/327515a0; WONNACOTT S, 1986, J NEUROCHEM, V47, P1706, DOI 10.1111/j.1471-4159.1986.tb13078.x	40	185	188	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24024	24029		10.1074/jbc.272.38.24024	http://dx.doi.org/10.1074/jbc.272.38.24024			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295355	hybrid			2022-12-25	WOS:A1997XX38100080
J	MacPhee, IJ; Barker, PA				MacPhee, IJ; Barker, PA			Brain-derived neurotrophic factor binding to the p75 neurotrophin receptor reduces TrkA signaling while increasing serine phosphorylation in the TrkA intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; INDUCED TYROSINE PHOSPHORYLATION; INSULIN-RECEPTOR; TARGETED DISRUPTION; KINASE-ACTIVITY; CELLS; GENE; NGF; SUBSTRATE-1; DIFFERENTIATION	We have examined whether the low affinity neurotrophin receptor p75NTR modulates TrkA function by intracellular signaling. Using ligands that selectively bind p75NTR or TrkA, we found that a p75NTR-derived signal reduces TrkA activation. Short term treatment of PC12 cells with ceramide analogues also resulted in reduced NGF-stimulated TrkA activation, suggesting that p75-mediated increases in sphingomyelinase activity may contribute to this modulatory effect. Phosphoamino acid analysis was performed to determine if brain derived neurotrophic factor- or ceramide-mediated phosphorylation of the TrkA intracellular domain correlated with a reduction in its ligand-induced activation. A specific increase in TrkA phosphoserine content was observed in response to both C-2-ceramide and brain-derived neurotrophic factor. These results suggest that ligand binding of p75NTR can activate a signaling cascade that results in reduced TrkA activity through phosphorylation of its intracellular domain.	MCGILL UNIV,MONTREAL NEUROL INST,CTR NEURONAL SURVIVAL,MONTREAL,PQ H3A 2B4,CANADA	McGill University								BARKER PA, 1993, J BIOL CHEM, V268, P15150; BARKER PA, 1994, J BIOL CHEM, V269, P30645; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BracciLaudiero L, 1996, NEUROREPORT, V7, P485, DOI 10.1097/00001756-199601310-00026; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; OLSON JE, 1990, J BIOL CHEM, V265, P1847; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; THEROUX SJ, 1992, J BIOL CHEM, V267, P16620; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1	38	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23547	23551		10.1074/jbc.272.38.23547	http://dx.doi.org/10.1074/jbc.272.38.23547			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295291	hybrid			2022-12-25	WOS:A1997XX38100016
J	Quinn, KA; Grimsley, PG; Dai, YP; Tapner, M; Chesterman, CN; Owensby, DA				Quinn, KA; Grimsley, PG; Dai, YP; Tapner, M; Chesterman, CN; Owensby, DA			Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCANS; PLASMINOGEN-ACTIVATOR; ALPHA-2-MACROGLOBULIN RECEPTOR; BINDING-PROTEIN; IDENTIFICATION; LINE; PURIFICATION; COMPARTMENT; CATABOLISM; EXPRESSION	Our studies have identified a soluble molecule in normal human plasma and serum with the characteristics of the alpha-chain of the low density lipoprotein receptor-related protein (LRP). LRP is a large multifunctional receptor mediating the clearance of diverse ligands, including selected lipoproteins, various protease inhibitor complexes, and thrombospondin. A soluble molecule (sLRP) has been isolated from plasma using an affinity matrix coupled with methylamine-activated alpha(2)-macroglobulin, the ligand uniquely recognized by LRP, and eluted with EDTA. This eluate contains a protein that co-migrates on SDS-polyacrylamide gel electrophoresis with authentic human placental LRP alpha-chain, is recognized by anti-LRP alpha-chain monoclonal antibodies, and binds the 39-kDa receptor-associated protein (RAP) and tissue plasminogen activator-inhibitor complexes. A similar RAP-binding molecule was detected in medium conditioned for 24 h by primary cultures of rat hepatocytes, suggesting that the liver may be the in vivo source of sLRP. In contrast, immunoprecipitation experiments failed to detect, the production of sLRP by cultured HepG2 hepatoma and primary human fibroblast cells. Addition of a soluble form of LRP to cultured HepG2 cells resulted in a significant inhibition of capacity of these cells to degrade tPA, a process that has been demonstrated to be mediated by cell surface LRP. Preliminary data indicate that the concentration of sLRP is altered in the plasma of patients with liver disease. Increased levels of sLRP may antagonize the clearance of ligands by cell bound LRP perturbing diverse processes including lipid metabolism, cell migration and extracellular proteinase activity.	UNIV NEW S WALES,SCH PATHOL,CTR THROMBOSIS & VASC RES,KENSINGTON,NSW 2052,AUSTRALIA; UNIV SYDNEY,WESTMEAD HOSP,DEPT MED,STORR LIVER UNIT,WESTMEAD,NSW 2145,AUSTRALIA; ILLAWARRA REG HOSP,WOLLONGONG,NSW 2500,AUSTRALIA	University of New South Wales Sydney; University of Sydney								ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; Goodwin B, 1996, BIOCHEM PHARMACOL, V52, P219, DOI 10.1016/0006-2952(96)00179-7; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; REBECK GW, 1993, NEURON, V11, P575; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; RUTLEDGE EA, 1994, J BIOL CHEM, V269, P31864; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SCHEUTZ EG, 1988, J CELL PHYSL, V134, P309; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401	31	114	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23946	23951		10.1074/jbc.272.38.23946	http://dx.doi.org/10.1074/jbc.272.38.23946			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295345				2022-12-25	WOS:A1997XX38100070
J	Yuan, ZM; Utsugisawa, T; Huang, YY; Ishiko, T; Nakada, S; Kharbanda, S; Weichselbaum, R; Kufe, D				Yuan, ZM; Utsugisawa, T; Huang, YY; Ishiko, T; Nakada, S; Kharbanda, S; Weichselbaum, R; Kufe, D			Inhibition of phosphatidylinositol 3-kinase by c-Abl in the genotoxic stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; IONIZING-RADIATION; SH3 DOMAINS; DNA-DAMAGE; GROWTH; CELLS; PHOSPHORYLATION; RECOMBINATION; PROTOONCOGENE	Activation of phosphatidylinositol (PI) 3-kinase by growth factors results in phosphorylation of phosphatidylinositol lipids at the D3 position. Although PI 3-kinase is essential to cell survival, little is known about mechanisms that negatively regulate this activity. Here we show that the c-Abl tyrosine kinase interacts directly with the p85 subunit of PI 3-kinase. Activation of c-Abl by ionizing radiation exposure is associated with c-Abl-dependent phosphorylation of PI 3-kinase. We also show that phosphorylation of p85 by c-Abl inhibits PI 3-kinase activity in vitro and in irradiated cells. These findings indicate that c-Abl negatively regulates PI 3-kinase in the stress response to DNA damage.	UNIV CHICAGO, DEPT RADIAT & CELLULAR ONCOL, CHICAGO, IL 60637 USA	University of Chicago	Yuan, ZM (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, 44 BINNEY ST, BOSTON, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	43	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23485	23488		10.1074/jbc.272.38.23485	http://dx.doi.org/10.1074/jbc.272.38.23485			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295282	hybrid			2022-12-25	WOS:A1997XX38100007
J	Racke, FK; Lewandowska, K; Goueli, S; Goldfarb, AN				Racke, FK; Lewandowska, K; Goueli, S; Goldfarb, AN			Sustained activation of the extracellular signal-regulated kinase mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; INTEGRIN GENE; C ISOTYPES; MAP; CASCADE; TRANSFORMATION; PROLIFERATION; SPECIFICITY	The extracellular signal-regulated kinase (ERK), originally identified as a participant in mitogenic signaling, has recently been implicated in the signaling of cellular differentiation. To examine the role of the ERK/MAP kinase pathway in megakaryocytic differentiation of K562 cells, the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) and bryostatin on ERK activation were determined. Both TPA and bryostatin are known to activate PBC but paradoxically have opposing effects on megakaryocytic differentiation, TPA, a differentiation inducer, caused sustained activation of ERK (>24 h), whereas bryostatin, a differentiation blocker, only transiently activated ERK (similar to 6 h) and attenuated the activation of ERK by TPA, To confirm a requirement for sustained ERK activation for megakaryocytic differentiation, PD098059, a synthetic inhibitor of the MAP kinase kinase 1 (MEK1) was employed. Introduction of PD098059 at any time during the first 18 h of TPA treatment completely abrogated megakaryocytic differentiation of K562 cells, After 24 h of TPA treatment, introduction of PD098059 failed to block differentiation. Differentiation blockade by PD098059 occurred via inhibition of MEK because transfection of a constitutively active mutant of MEK2 could override the PD098059 blockade. Experiments with conditioned media suggested that sustained activation of the ERK/MAP kinase pathway promoted the autocrine secretion of megakaryocytic lineage determination factors.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,INST PATHOL,CLEVELAND,OH 44106; PROMEGA CORP,SIGNAL TRANSDUCT DIV,MADISON,WI 53711	Case Western Reserve University; Promega Corporation								ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FONG AM, 1994, J BIOL CHEM, V269, P18441; GOLDFARB AN, 1992, BLOOD, V80, P2858; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOCEVAR BA, 1992, J CELL SCI, V101, P671; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; TABILIO A, 1983, CANCER RES, V43, P4569; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VILLAGARCIA M, 1994, BLOOD, V83, P668, DOI 10.1182/blood.V83.3.668.bloodjournal833668	22	162	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23366	23370		10.1074/jbc.272.37.23366	http://dx.doi.org/10.1074/jbc.272.37.23366			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287350	hybrid			2022-12-25	WOS:A1997XV74400061
J	Yamauchi, E; Titani, K; Taniguchi, H				Yamauchi, E; Titani, K; Taniguchi, H			Specific binding of acidic phospholipids to microtubule-associated protein MAP1B regulates its interaction with tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; ALZHEIMERS-DISEASE; RAT-BRAIN; MEMBRANE PHOSPHOLIPIDS; MESSENGER-RNA; PHOSPHORYLATION; TAU; IDENTIFICATION; DOMAIN; CELLS	Microtubule-associated protein MAP1B, a major neuronal cytoskeletal protein, is expressed highly during the early stage of brain development and is thought to play an important role in brain development. Although it has been shown that MAP1B localizes both in cytosol and particulate fractions, the underlying molecular mechanism in the membrane localization has yet to be elucidated. In the present study, we show that MAP1B purified from young rat brain can bind to acidic phospholipids, such as phosphatidylserine, but not to a neutral phospholipid, phosphatidylcholine. Furthermore, the binding of MAP1B to taxol-stabilized microtubules was inhibited by the addition of phosphatidylserine or phosphatidylinositol. The addition of phosphatidylcholine showed no effect on the binding of MAP1B to the microtubules. A 120-kDa microtubule-binding fragment of MAP1B was also released from microtubules by the addition of acidic phospholipids. Synthetic peptides derived from the C-terminal half of the tubulin-binding domain, but not that corresponding to the N-terminal half, bound to acidic phospholipids specifically. These results suggest that MAP1B binds to biological membranes through its tubulin-binding site, and the binding may play a regulatory role in MAP1B-microtubule interaction.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DEPT BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN; NAGOYA CITY UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,MIZUHO KU,NAGOYA,AICHI 467,JAPAN	Fujita Health University; Nagoya City University			Taniguchi, Hisaaki/I-9171-2012					AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; ANDERSON PJ, 1979, J BIOL CHEM, V254, P2168; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUZMAN L, 1994, MOL CELL BIOCHEM, V131, P105, DOI 10.1007/BF00925946; HASEGAWA M, 1990, NEURON, V4, P909, DOI 10.1016/0896-6273(90)90144-5; HAYACHI N, 1997, IN PRESS TECHNIQUES, V3; Hayashi N, 1997, J BIOL CHEM, V272, P7639, DOI 10.1074/jbc.272.12.7639; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Lee VMY, 1996, ANN NY ACAD SCI, V777, P107, DOI 10.1111/j.1749-6632.1996.tb34408.x; Liu D, 1996, GENE, V171, P307, DOI 10.1016/0378-1119(95)00061-5; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V205, P1467, DOI 10.1006/bbrc.1994.2830; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Pedrotti B, 1996, FEBS LETT, V388, P131, DOI 10.1016/0014-5793(96)00520-0; PEDROTTI B, 1995, CELL MOTIL CYTOSKEL, V30, P301, DOI 10.1002/cm.970300407; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROCHA MG, 1995, DEV BRAIN RES, V89, P47, DOI 10.1016/0165-3806(95)00105-M; SAFAEI R, 1989, J NEUROCHEM, V52, P1871, DOI 10.1111/j.1471-4159.1989.tb07270.x; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SURRIDGE CD, 1992, BIOCHEMISTRY-US, V31, P6140, DOI 10.1021/bi00141a026; SURRIDGE CD, 1994, BIOCHEMISTRY-US, V33, P8051, DOI 10.1021/bi00192a009; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; ULLOA L, 1993, J NEUROCHEM, V61, P961, DOI 10.1111/j.1471-4159.1993.tb03609.x; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; YAMAUCHI PS, 1987, J BIOL CHEM, V262, P3369; ZAUNER W, 1992, EUR J CELL BIOL, V57, P66	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22948	22953		10.1074/jbc.272.36.22948	http://dx.doi.org/10.1074/jbc.272.36.22948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278459	hybrid			2022-12-25	WOS:A1997XV49200081
J	Dessauer, CW; Scully, TT; Gilman, AG				Dessauer, CW; Scully, TT; Gilman, AG			Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALPHA-SUBUNITS; P-GLYCOPROTEIN; BINDING; KINETICS; PURIFICATION; ACTIVATION; INHIBITION; ADENOSINE; FORM	Fragments of the two cytoplasmic domains of mammalian adenylyl cyclases can be synthesized independently (and abundantly) as soluble proteins; G(s alpha)- and forskolin-stimulated enzymatic activity is restored upon their mixture. We have utilized this system to characterize the interactions of adenylyl cyclase with forskolin and its substrate, ATP, In the presence of G(s alpha), adenylyl cyclase is activated in response to occupation of only one forskolin-binding site, A single binding site for forskolin was identified by equilibrium dialysis; its K-d (0.1 mu M) corresponds to the EC50 for enzyme activation, The affinity of forskolin for adenylyl cyclase is greatly reduced in the absence of G(s alpha) (similar to 40 mu M). Binding of forskolin to the individual cytoplasmic domains of the enzyme was not detected. A single binding site for the ATP analog, alpha,beta-methylene ATP (Ap(CH2)pp), was also detected by equilibrium dialysis, Such binding was not observed with the individual domains, Binding of Ap(CH2)pp was unaffected by P-site inhibitors of adenylyl cyclase, A modified P-loop sequence located near the carboxyl terminus of adenylyl cyclase has been implicated in ATP binding, Mutation of the conserved, non-glycine residues within this region caused no significant changes in the K-m for ATP or the K-i for Ap(CH2)pp. It thus seems unlikely that this region is part of the active site, However, a mutation in the C-1 domain (E518A) cause a 10-fold decrease in the binding affinity for Ap(CH2)pp, This residue and the active site of the enzyme may lie at the interface between the two cytosolic domains.			Dessauer, CW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.		Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34497, GM16905] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Droste M, 1996, FEBS LETT, V391, P209, DOI 10.1016/0014-5793(96)00735-1; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FLORIO VA, 1983, THESIS U VIRGINIA; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEWIN LR, 1995, J BIOL CHEM, V270, P7573; LONDOS C, 1977, J BIOL CHEM, V252, P5957; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Sutkowski EM, 1996, MOL PHARMACOL, V50, P299; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELTON AF, 1980, BIOCHIM BIOPHYS ACTA, V615, P252, DOI 10.1016/0005-2744(80)90028-5; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; YEE R, 1978, J BIOL CHEM, V253, P8902; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	31	103	103	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22272	22277		10.1074/jbc.272.35.22272	http://dx.doi.org/10.1074/jbc.272.35.22272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268376	hybrid			2022-12-25	WOS:A1997XT85000088
J	Vacca, RA; Giannattasio, S; Graber, R; Sandmeier, E; Marra, E; Christen, P				Vacca, RA; Giannattasio, S; Graber, R; Sandmeier, E; Marra, E; Christen, P			Active-site Arg->Lys substitutions alter reaction and substrate specificity of aspartate aminotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ASPARTATE; AMINO-ACIDS; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURES; MECHANISM; RESIDUE; MUTANT; ENZYME; RECOGNITION; HISTIDINE	Arg(386) and Arg(292) of aspartate aminotransferase bind the alpha and the distal carboxylate group, respectively, of dicarboxylic substrates. Their substitution with lysine residues markedly decreased aminotransferase activity. The k(cat) values with L-aspartate and 2-oxoglutarate as substrates under steady-state conditions at 25 degrees C were 0.5, 2.0, and 0.03 s(-1) for the R292K, R386K, and R292K/R386K mutations, respectively, k(cat) of the wild-type enzyme being 220 s(-1). Longer dicarboxylic substrates did not compensate for the shorter side chain of the lysine residues. Consistent with the different roles of Arg(292) and Arg(386);, substrate binding, the effects of their substitution on the activity toward long chain monocarboxylic (norleucine/2-oxocaproic acid) and aromatic substrates diverged. Whereas the R292K mutation did not impair the aminotransferase activity toward these substrates, the effect of the R386K substitution was similar to that on the activity toward dicarboxylic substrates. All three mutant enzymes catalyzed as side reactions the beta-decarboxylation of L-aspartate and the racemization of amino acids at faster rates than the wild-type enzyme. The changes in reaction specificity were most pronounced in aspartate aminotransferase R292K, which decarboxylated L-aspartate to L-alanine 15 times faster (k(cat) = 0.002 s(-1)) than the wild-type enzyme. The rates of racemization of L-aspartate, L-glutamate, and L-alanine were 3, 5, and 2 times, respectively, faster than with the wild-type enzyme. Thus, Arg --> Lys substitutions in the active site of aspartate aminotransferase decrease aminotransferase activity but increase other pyridoxal 5'-phosphate-dependent catalytic activities. Apparently, the reaction specificity of pyridoxal 5'-phosphate-dependent enzymes is not only achieved by accelerating the specific reaction but also by preventing potential side reactions of the coenzyme substrate adduct.	UNIV ZURICH, INST BIOCHEM, CH-8057 ZURICH, SWITZERLAND; CNR, CTR STUDIO MITOCONDRI & METAB ENERGET, I-70126 BARI, ITALY; CNR, CTR STUDIO MITOCONDRI & METAB ENERGET, TRANI, ITALY; UNIV ZURICH, INST BIOCHEM, CH-8057 ZURICH, SWITZERLAND	University of Zurich; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Zurich			Vacca, Rosa Anna/AAX-1388-2020	Vacca, Rosa Anna/0000-0003-2438-6449; Giannattasio, Sergio/0000-0001-5559-5556				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ALMO SC, 1994, PROTEIN ENG, V7, P405, DOI 10.1093/protein/7.3.405; Arnone A, 1985, TRANSAMINASES, P138; CRONIN CN, 1988, BIOCHEMISTRY-US, V27, P4572, DOI 10.1021/bi00412a052; DANISHEFSKY AT, 1991, BIOCHEMISTRY-US, V30, P1980, DOI 10.1021/bi00221a035; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; FONDA ML, 1970, J BIOL CHEM, V245, P2709; FRATTE SD, 1994, EUR J BIOCHEM, V225, P395, DOI 10.1111/j.1432-1033.1994.00395.x; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; GRABER R, 1995, EUR J BIOCHEM, V232, P686, DOI 10.1111/j.1432-1033.1995.tb20861.x; HART KW, 1987, BIOCHIM BIOPHYS ACTA, V914, P294, DOI 10.1016/0167-4838(87)90289-5; HAYASHI H, 1989, BIOCHEM BIOPH RES CO, V159, P337, DOI 10.1016/0006-291X(89)92443-1; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; INOUE Y, 1989, J BIOL CHEM, V264, P9673; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; KAMITORI S, 1987, J BIOCHEM, V101, P813, DOI 10.1093/jb/101.3.813; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KOCHHAR S, 1992, EUR J BIOCHEM, V203, P563, DOI 10.1111/j.1432-1033.1992.tb16584.x; KOCHHAR S, 1988, EUR J BIOCHEM, V175, P433, DOI 10.1111/j.1432-1033.1988.tb14213.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; MALASHKEVICH VN, 1993, BIOCHEMISTRY-US, V32, P13451, DOI 10.1021/bi00212a010; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MITCHELL JBO, 1992, J MOL BIOL, V226, P251, DOI 10.1016/0022-2836(92)90137-9; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1743, DOI 10.1002/pro.5560040909; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; TONEY MD, 1991, BIOCHEMISTRY-US, V30, P7456, DOI 10.1021/bi00244a013; VACCA RA, 1995, EUR J BIOCHEM, V227, P481, DOI 10.1111/j.1432-1033.1995.tb20413.x; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007; YANO T, 1991, J BIOL CHEM, V266, P6079; YANO T, 1993, J MOL BIOL, V234, P1218, DOI 10.1006/jmbi.1993.1672; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	38	39	41	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21932	21937		10.1074/jbc.272.35.21932	http://dx.doi.org/10.1074/jbc.272.35.21932			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268327	hybrid			2022-12-25	WOS:A1997XT85000039
J	ChotteauLelievre, A; Desbiens, X; Pelczar, H; Defossez, PA; deLaunoit, Y				ChotteauLelievre, A; Desbiens, X; Pelczar, H; Defossez, PA; deLaunoit, Y			Differential expression patterns of the PEA3 group transcription factors through murine embryonic development	ONCOGENE			English	Article						murine embryogenesis; ets genes; PEA3 group; transcription factor	ETS GENE FAMILY; DNA-BINDING DOMAIN; CHICK-EMBRYO; CHROMOSOMAL TRANSLOCATION; MOLECULAR-CLONING; ONCOGENE FAMILY; MESSENGER-RNAS; V-MYB; CELLS; LEUKEMIA	ERM, ER81 and PEA3 are three highly related transcription factors belonging to the ETS family. Together they form the PEA3 group within this family. Little data is yet available regarding the roles of these three genes during embryonic development. A prerequisite to investigations in this field is to obtain an accurate spatio-temporal expression map for the erm, er81 and pea3 genes. To this end, we have used in situ hybridization to compare their expression patterns during critical stages of murine embryogenesis. We report that all three genes are expressed in numerous developing organs coming from different embryonic tissues. The three genes appeared co-expressed in different organs but presented specific sites of expression, so that the resultant expression pattern could in fact reveal several distinct functions depending upon isolated and/or various combinations of the PEA3 member expression. These results suggest that erm, er81 and pea3 genes are differentially regulated, probably to serve important functions as cell proliferation control, tissue interaction mediator or cell differentiation, all over successive steps of the mouse organogenesis.	INST BIOL LILLE,UMR 319 CNRS,INST PASTEUR,F-59021 LILLE,FRANCE; USTL,CTR BIOL CELLULAIRE,UNITE DYNAM CELLULES EMBRYONNAIRES & CANCEREUSES,VILLENEUVE DASCQ,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille				Defossez, Pierre-Antoine/0000-0002-6463-9263				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buttice G, 1996, ONCOGENE, V13, P2297; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; FAFEUR V, 1997, IN PRESS CELL GROWTH; Ganan Y, 1996, DEVELOPMENT, V122, P2349; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, ONCOGENE, V13, P1745; JANKNECHT R, 1996, MOL CELL BIOL, V16, P1551; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Laget MP, 1996, ONCOGENE, V12, P1325; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; QUEVA C, 1993, ONCOGENE, V8, P2511; QUEVA C, 1992, DEVELOPMENT, V114, P125; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; SATO H, 1993, ONCOGENE, V8, P395; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Shindoh M, 1996, AM J PATHOL, V148, P693; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; VANBENBUNDER B, 1989, DEVELOPMENT, V109, P265; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	63	126	130	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					937	952		10.1038/sj.onc.1201261	http://dx.doi.org/10.1038/sj.onc.1201261			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285689				2022-12-25	WOS:A1997XR76700007
J	Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO				Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO			Ultraviolet light-induced G2 phase cell cycle checkpoint blocks cdc25-dependent progression into mitosis	ONCOGENE			English	Article						cdc25; cell cycle checkpoint; UV	MATURATION-PROMOTING FACTOR; CDK2 PROTEIN-KINASE; IONIZING-RADIATION; HUMAN FIBROBLASTS; HELA-CELLS; DEPENDENT KINASES; NITROGEN-MUSTARD; DNA-REPLICATION; B IRRADIATION; G1 ARREST	In response to low doses of ultraviolet (U.V.) radiation, cells undergo a G2 delay. In this study we have shown that the G2 delay results in the accumulation of inactive forms of cyclin B1/cdc2 and both the G2 and mitotic complexes of cyclin A/cdk. This appears to be through a block in the cdc25-dependent activation of these complexes. The expression and localisation of cyclin A and cyclin B1/cdk complexes are similar in U.V.-induced G2 delay and normal early G2 phase cells, Cdc25B and cdc25C also accumulate to normal G2 levels in U.V. irradiated cells, but the mitotic phosphorylation associated with increased activity of both cdc25B and cdc25C is absent. The cdc25B accumulates in the nucleus of U.V. irradiated cells and in normal G2 phase cells. Thus the block in cyclin B/cdc2 activation is in part due to the physical separation of cyclin B/cdc2, localised in the cytoplasm, from the cdc25B and cdc25C phosphatases localised in the nucleus, The data positions the U.V.-induced G2 checkpoint at either the S/G2 transition or early G2 phase, prior to the activation of cyclin A/cdk2.			Gabrielli, BG (corresponding author), ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,JOINT ONCOL PROGRAM,QUEENSLAND CANC FUND RES LAB,HERSTON,QLD 4029,AUSTRALIA.		Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAILLY E, 1992, J CELL SCI, V101, P529; BARKER D, 1995, CANCER RES, V55, P4041; Barth H, 1996, CANCER RES, V56, P2268; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GABRIELLI B, 1994, ADV PROT PHOSPHATASE, V8, P209; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NAGATA A, 1991, NEW BIOL, V3, P959; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Petrocelli T, 1996, ONCOGENE, V12, P1387; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Wang XQ, 1996, CANCER RES, V56, P2510	49	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					749	758		10.1038/sj.onc.1201254	http://dx.doi.org/10.1038/sj.onc.1201254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266961				2022-12-25	WOS:A1997XQ11700001
J	Sachs, LM; Abdallah, B; Hassan, A; Levi, G; DeLuze, A; Reed, JC; Demeneix, BA				Sachs, LM; Abdallah, B; Hassan, A; Levi, G; DeLuze, A; Reed, JC; Demeneix, BA			Apoptosis in Xenopus tadpole tail muscles involves Bax-dependent pathways	FASEB JOURNAL			English	Article						thyroid hormone; metamorphosis; in vivo gene transfer	PROGRAMMED CELL-DEATH; THYROID-HORMONE; IN-VIVO; AMPHIBIAN METAMORPHOSIS; GENE-EXPRESSION; BCL-2; SURVIVAL; CLONING; INSITU; P53	Apoptosis is a fundamental mechanism implicated in normal development. One of the most spectacular developmental events involving apoptosis is tail regression during amphibian metamorphosis. We analyzed how thyroid hormone (3, 5, 3'-triiodothyronine, T-3), the orchestrator of metamorphosis, affects expression and function of the proapoptotic gene Bax in the tail muscle of free-living Xenopus tadpoles. During natural metamorphosis Bax mRNA was expressed in tail muscles and was spatially correlated with apoptosis, Precocious treatment of tadpoles with T-3 induced Bax expression and apoptosis. To verify that Bax expression was causally related to apoptosis we used a naked DNA gene transfer method to express Bax in the dorsal tail muscle. This induced apoptosis, and the process was exacerbated by T-3 treatment. To determine whether T-3 effects on Bax expression involved transcriptional regulation, we injected a Bax promoter sequence into dorsal and caudal tail muscles. In the dorsal muscle, T-3 treatment did not affect transcription from the Bax promoter. However, in the caudal muscle, T-3 treatment significantly increased Bax transcription. We conclude that T-3-induced apoptosis in Xenopus tadpole tail muscles involves Bax-activating and Bax-synergistic mechanisms, These programs are induced in spatially and temporally distinct manners.	MUSEUM NATL HIST NAT, LAB PHYSIOL GEN & COMPAREE, URA CNRS 90, F-75231 PARIS 5, FRANCE; IST, CBA, MOL BIOL LAB, GENOA, ITALY; BURNHAM INST, LA JOLLA, CA 92037 USA	Museum National d'Histoire Naturelle (MNHN); Sanford Burnham Prebys Medical Discovery Institute			Levi, Giovanni/B-4416-2013; Sachs, Laurent/AAE-1504-2020	Levi, Giovanni/0000-0002-7041-6787				CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CRUZREYES J, 1995, GENE, V158, P171, DOI 10.1016/0378-1119(95)00159-4; DELUZE A, 1993, P NATL ACAD SCI USA, V90, P7322, DOI 10.1073/pnas.90.15.7322; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; KERR JFR, 1974, J CELL SCI, V14, P571; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MACHUCA I, 1992, MOL CELL ENDOCRINOL, V87, P105, DOI 10.1016/0303-7207(92)90238-2; Middleton G, 1996, DEVELOPMENT, V122, P695; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; NIEUKOOP PD, 1975, NORMAL TABLE XENOPUS; NIKI K, 1982, DEV BIOL, V94, P116, DOI 10.1016/0012-1606(82)90074-4; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SACHS L, 1996, ENDOCRINOLOGY, V137, P1291; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; Shi YB, 1996, BIOESSAYS, V18, P391, DOI 10.1002/bies.950180509; SOUSSI T, 1987, ONCOGENE, V1, P71; TATA JR, 1994, BIOCHEM CELL BIOL, V72, P581, DOI 10.1139/o94-077; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; WANG Z, 1993, J BIOL CHEM, V268, P16270; Werner MH, 1996, STRUCTURE, V4, P879, DOI 10.1016/S0969-2126(96)00094-9; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yaoita Y, 1997, J BIOL CHEM, V272, P5122, DOI 10.1074/jbc.272.8.5122	33	48	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					801	808		10.1096/fasebj.11.10.9271365	http://dx.doi.org/10.1096/fasebj.11.10.9271365			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271365				2022-12-25	WOS:A1997XR10500010
J	Elangovan, B; Chinnadurai, G				Elangovan, B; Chinnadurai, G			Functional dissection of the pro-apoptotic protein Bik - Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 HOMOLOG BAK; E1B 19K; ENZYME; INHIBITION; INTERACTS; DISTINCT; DOMAIN; SYSTEM; GENE; BH1	Bik is a potent pro-apoptotic protein, which complexes with various anti-apoptotic proteins such as Bcl-2, Bcl-x(L), 19-kDa adenovirus E1B, and EBV-BHRF1, The mechanism by which Bik promotes cell death is not known, It shares a conserved domain, BH3, with other pro-apoptotic proteins, Bar, Bah, Bid, and Hrk, and certain anti-apoptosis proteins such as Bcl-2 and Bcl-x(L). Mutations within the BH3 domain of Bik abrogate its ability to induce cell death and to complex with anti-apoptosis proteins, This result is consistent with the hypothesis that Bik may promote cell death by complexing with and antagonizing the activity of endogenous cellular anti-apoptosis proteins such as Bcl-2 and Bcl-x(L). To elucidate the relationship between protein complex formation and induction of cell death, we have identified the minimal sequences of Bik, from a library of N-terminal and C-terminal deletion mutants, required for interaction with Bcl-2 and Bcl-x, and for inducing efficient cell death, Two-hybrid analysis ill yeast and immunoprecipitation analysis of proteins expressed in mammalian cells indicate that a 52-amino acid region (amino acids 43-94) of Bik, encompassing the BH3 domain, is sufficient for efficient heterodimerization with Bcl-2 and Bcl-x(L) Protein interaction studies further reveal that an 18-amino acid region, encompassing the BH3 domain (residues 57-74), constitutes the core heterodimerization domain. Functional analysis indicates that a Bik deletion mutant expressing residues 43-120, which efficiently heterodimerizes with the anti-apoptosis proteins Bcl-2 and Bel-x(L), is defective in eliciting cell death. In contrast, a mutant expressing additional C-terminal sequences (amino acids 43-134) interacts with the survival proteins and elicits efficient cell death. Our results suggest that for Bik-mediated cell death, the heterodimerization activity encoded by the BH3 domain alone is insufficient and raise the possibility-that Bik may induce cell death autonomous of heterodimerization with survival proteins such as Bcl-2 and Bcl-x(L).	ST LOUIS UNIV,MED CTR,INST MOL VIROL,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, R01 CA033616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Han J, 1996, MOL CELL BIOL, V16, P5857; INOHARA N, 1997, EMBO J, V16, P1638; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1995, J CELL BIOL, V124, P1; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	24	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24494	24498		10.1074/jbc.272.39.24494	http://dx.doi.org/10.1074/jbc.272.39.24494			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305912	hybrid			2022-12-25	WOS:A1997XY51500063
J	Jenkins, TD; Nakagawa, H; Rustgi, AK				Jenkins, TD; Nakagawa, H; Rustgi, AK			The keratinocyte-specific Epstein-Barr virus ED-L2 promoter is regulated by phorbol 12-myristate 13-acetate through two cis-regulatory elements containing E-box and Kruppel-like factor motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN PROMOTER; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR USF; TERMINAL DIFFERENTIATION; GENE-EXPRESSION; GROWTH-FACTOR; KINASE-C; MOUSE KERATINOCYTES; EPITHELIAL-CELLS; MULTIGENE FAMILY	We previously employed 782 base pairs of the Epstein-Barr virus ED-LP early lytic cycle promoter in a transgenic mouse model to target cyclin D1 to the stratified squamous epithelium of the tongue and esophagus, This promoter is located 5' to the transcriptional start site of a short open reading frame BNLF-2A and is immediately 3' to the BNLF-1 (LMP-1 oncogene) open reading frame. We studied transcriptional regulation of the ED-LB promoter by phorbol 12-myristate 13-acetate (PMA) as a means of understanding the tissue specificity of this promoter. The transcriptional activity of the ED-LS promoter was stimulated 40-fold by PMA and could be blocked with the compound H7 through antagonism of protein kinase C. 5' deletion analysis of the 782-base pair promoter demonstrated that the sequences necessary for PMA-stimulated trans-activation were located in two separate cis-regulatory regions of the promoter: -187 to -164 and -144 to -114 base pairs from the transcription start site of BNLF-2A. Importantly, mutation of critical base pairs in each region was sufficient to abolish PMA-stimulated trans-activation in the native ED-L2 promoter. Region -187 to -164 contains a CACACCC (E-box) motif, and region -144 to -114 contains a CACACCC motif. Both of these motifs are necessary for trans-activation by PMA. These regions do not, however, demonstrate enhancer characteristics when tested in a heterologous minimal promoter system. Variations of the CACACCC motif are found in other keratinocyte-specific promoters, as well as in the DNA binding motifs of the Kruppel-like family of transcription factors. Electrophoretic mobility shift assays with specific competitors and factor-specific antibody supershift assays demon strated that one complex binding the -187 to -164 region containing the CACCTG nucleotides has characteristics of the helix loop-helix protein upstream stimulatory factor, whereas a factor binding the CACACCC motif may be a member of the Kruppel-like family, These experiments show how ubiquitous and tissue-specific transcription factors induced by PMA regulate the ED-LP promoter in squamous epithelial cells.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, T32DK007191, P30DK043351] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 T32 DK07191 D22, DK40561, DK43351] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BYRNE C, 1993, DEVELOPMENT, V94, P2369; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; COHEN JI, 1993, ANN INTERN MED, V118, P45; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FARRELL PJ, 1983, EMBO J, V2, P1331, DOI 10.1002/j.1460-2075.1983.tb01588.x; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Jenkins TD, 1996, ONCOGENE, V13, P1809; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kieff E, 1996, VIROLOGY, P2343; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LIN Q, 1994, J BIOL CHEM, V269, P23894; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; Nakagawa H, 1997, J BIOL CHEM, V272, P16688, DOI 10.1074/jbc.272.26.16688; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OKAN I, 1995, ONCOGENE, V11, P1027; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RIEGER E, 1994, J INVEST DERMATOL, V103, P341, DOI 10.1111/1523-1747.ep12394888; Rutberg SE, 1996, ONCOGENE, V13, P167; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHOSHAN MC, 1994, J CELL BIOCHEM, V55, P496, DOI 10.1002/jcb.240550409; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SNOEK GT, 1987, EXP CELL RES, V172, P146, DOI 10.1016/0014-4827(87)90101-7; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; Stanwell C, 1996, CARCINOGENESIS, V17, P1259, DOI 10.1093/carcin/17.6.1259; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; TSENG H, 1992, P NATL ACAD SCI USA, V89, P10311, DOI 10.1073/pnas.89.21.10311; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang S, 1996, CANCER RES, V56, P4610; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WU RL, 1994, J BIOL CHEM, V269, P28450; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	62	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24433	24442		10.1074/jbc.272.39.24433	http://dx.doi.org/10.1074/jbc.272.39.24433			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305903	hybrid			2022-12-25	WOS:A1997XY51500054
J	Jho, EH; Malbon, CC				Jho, EH; Malbon, CC			G alpha(12) and G alpha(13) mediate differentiation of P19 mouse embryonal carcinoma cells in response to retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+/H+ EXCHANGER; ALPHA-SUBUNITS; NEURONAL DIFFERENTIATION; GENE; TRANSFORMATION; MUTANT; OLIGODEOXYNUCLEOTIDES; TRANSCRIPTION; FIBROBLASTS	P19 mouse embryonal carcinoma cells can be stimulated to differentiate into endodermal-like, mesodermal-like, and neuronal-like phenotypes in response to specific morphogens. At low concentrations, retinoic acid stimulates P19 embryonal cells to differentiate to cells displaying an endodermal phenotype, whereas at higher concentrations it stimulates differentiation to neuroectoderm, The G alpha(12) and G alpha(13) subunits of heterotrimeric G-proteins are expressed in the embryonal P19 cells and stimulated in response to retinoic acid as the cells differentiate to endodermal or neuroectodermal phenotypes, Suppression of the expression of either G alpha(12) or G alpha(13) by antisense RNA is shown to promote cell detachment from substratum and apoptosis, Expression of the constitutively active, mutant form of Ga-12 (Q229L), in contrast, stimulates loss of the embryonal phenotype, Expression of the constitutively active form of G alpha(13) (Q226L) stimulates differentiation of the cells from embryonal to endodermal, in the absence of retinoic acid. Thus, both Ga-12 and Ga-13 are essential to stimulation of cell differentiation by retinoic acid, Deficiency of either G alpha(12) or G alpha(13) increases programmed cell death.	SUNY STONY BROOK,MED CTR,DEPT MOL PHARMACOL,SCH MED,DIABET & METAB DIS RES CTR,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020	Jho, Eek-hoon/0000-0003-2414-6234	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DYCK JRB, 1995, J BIOL CHEM, V270, P10420, DOI 10.1074/jbc.270.18.10420; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HORIE S, 1992, P NATL ACAD SCI USA, V89, P5236, DOI 10.1073/pnas.89.12.5236; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; KOLYADA AY, 1994, BBA-GENE STRUCT EXPR, V1217, P54; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Sambrook J., 2002, MOL CLONING LAB MANU; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAPSCOTT SJ, 1981, NATURE, V292, P836, DOI 10.1038/292836a0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Zhang YH, 1996, ONCOGENE, V12, P2377	36	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24461	24467		10.1074/jbc.272.39.24461	http://dx.doi.org/10.1074/jbc.272.39.24461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305907	hybrid			2022-12-25	WOS:A1997XY51500058
J	KallooHosein, HE; Whitehead, JP; Soos, M; Tavare, JM; Siddle, K; ORahilly, S				KallooHosein, HE; Whitehead, JP; Soos, M; Tavare, JM; Siddle, K; ORahilly, S			Differential signaling to glycogen synthesis by the intracellular domain of the insulin versus the insulin-like growth factor-1 receptor - Evidence from studies of TrkC-chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3'-KINASE; MONOCLONAL-ANTIBODY; SYNTHASE KINASE-3; MITOGENIC SIGNAL; TERMINAL DOMAIN; BINDING; IRS-1; SHC	Insulin and insulin-like growth factor-1 (IGF-1) have similar cell-surface receptors yet subserve different physiological functions, To examine whether these differences relate to intrinsic signaling properties of the intracellular domains of their respective receptors, chimeric receptors were constructed using the extracellular domain of the neurotrophin-3 (NT-3) receptor, TrkC, and the intracellular domain of either the insulin receptor or the IGF-1 receptor, TrkC-IR (TIR) and TrkC-IGF-1R (TIGR) were stably expressed in 3T3-L1 cells, While TIR and TIGR cell lines expressing similar numbers of chimeric receptors showed a similar dose-response relationship in NT-3 stimulated DNA synthesis, NT-3 stimulated glycogen synthesis was greater in TIR than in TIGR cells (maximum TIGR response was 35% of maximum TIR response), Additionally, the concentration of NT-3 at which significant stimulation of glycogen synthesis was seen was 0.1 ng/ml in TIR and 1 ng/ml in TIGR cells, Basal levels of thymidine incorporation but not glycogen synthesis were consistently higher in TIR than in TIGR expressing cells, No detectable basal autophosphorylation of chimeric receptors was seen in any of the cell lines, However, exposure of cell lines to the phosphatase inhibitor bisperoxovanadate resulted in greater basal autophosphorylation of the TIR and endogenous murine IR than the TIGR and endogenous murine IGF-1R. Thus, in this system, the intracellular domain of the IR appears to couple more effectively to glycogen synthesis than that of the IGF-1R, whereas the intracellular domains of both receptors have a similar capacity to stimulate DNA synthesis.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE CB2 2QR, ENGLAND; UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Bristol			Whitehead, Jonathan/F-5022-2014; O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Whitehead, Jonathan/0000-0003-3978-3148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMO M, 1992, BIOFACTORS, V3, P151; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUANG L, 1990, P NATL ACAD SCI USA, V90, P5172; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; GUITON M, 1994, J BIOL CHEM, V269, P30370; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; Hansen BF, 1996, BIOCHEM J, V315, P271; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAHN CR, 1985, ANNU REV MED, V36, P429; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; MAMOUNAS M, 1989, P NATL ACAD SCI USA, V86, P9294, DOI 10.1073/pnas.86.23.9294; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MOTHE I, 1995, EUR J BIOCHEM, V228, P842, DOI 10.1111/j.1432-1033.1995.0842m.x; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POGGI C, 1979, ENDOCRINOLOGY, V105, P723, DOI 10.1210/endo-105-3-723; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RANDAZZO PA, 1990, EXP CELL RES, V190, P31, DOI 10.1016/0014-4827(90)90140-6; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; TARTARE S, 1994, J BIOL CHEM, V269, P11449; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VERSPOHL EJ, 1984, J CLIN INVEST, V74, P1436, DOI 10.1172/JCI111555; WHITE MF, 1994, J BIOL CHEM, V269, P1; XU B, 1995, J BIOL CHEM, V270, P29825; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	50	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24325	24332		10.1074/jbc.272.39.24325	http://dx.doi.org/10.1074/jbc.272.39.24325			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305889	hybrid			2022-12-25	WOS:A1997XY51500040
J	Lopez, F; Esteve, JP; Buscail, L; Delesque, N; SaintLaurent, N; Theveniau, M; Nahmias, C; Vaysse, N; Susini, C				Lopez, F; Esteve, JP; Buscail, L; Delesque, N; SaintLaurent, N; Theveniau, M; Nahmias, C; Vaysse, N; Susini, C			The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; HUMAN TUMOR-CELLS; PHOSPHOTYROSINE PHOSPHATASE; SH2 DOMAIN; G-PROTEIN; MOLECULAR-CLONING; PANCREATIC-CANCER; MOTH-EATEN; PHOSPHORYLATION	Activation of the somatostatin receptor sst2, a member of the G(i) protein-coupled receptor family, results in the stimulation of a protein-tyrosine phosphatase activity involved in the sstZ-mediated growth inhibitory signal, Here, we report that SHP-1, a cytoplasmic protein-tyrosine phosphatase containing two Src homology 2 domains constitutively associated with sst2 as evidence by coprecipitation of SHP-1 pro-rein with sst2, in Chinese hamster ovary cells coexpressing sst2 and SHP-1. Activation of sst2 by somatostatin resulted in a rapid dissociation of SHP-1 from sst2 accompanied by an increase of SHP-1 activity, SHP-1 was phosphorylated on tyrosine in control cells and somatostatin induced a rapid and transient dephosphorylation on tyrosine residues of She enzyme. Stimulation of SIIP-I activity by somatostatin was abolished by pertussis toxin pretreatment of cells, G(i alpha 3) was specifically immunoprecipitated by anti-sst2 and anti-SHP-1 antibodies, and somatostatin induced a rapid dissociation of G(i alpha 3) from sst2, suggesting that G(i alpha 3) may be involved in the sst2-SHP-1 complexes, Finally, somatostatin inhibited the proliferation of cells coexpressing sst2 and SHP-1, and this effect was suppressed in cells coexpressing sst2 and the catalytic inactive SHP-1 (C453S mutant). Our data identify SHP-1 as the tyrosine phosphatase associated with sst2 and demonstrate that this enzyme may be an initial key transducer of the antimitogenic signaling mediated by sst2.	CHU RANGUEIL,INST LOUIS BUGNARD,INSERM UNITE 151,F-31403 TOULOUSE,FRANCE; LAB GENET & PHYSIOL DEV,LUMINY CASE 907,F-13288 MARSEILLE 9,FRANCE; INST COCHIN GENET MOL,F-75014 PARIS,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Theveniau-Ruissy, Magali/N-3563-2018	Theveniau-Ruissy, Magali/0000-0002-7346-7096				Barr AJ, 1997, J BIOL CHEM, V272, P2223; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CAMBILLAU C, 1995, ENDOCRINOLOGY, V136, P5476, DOI 10.1210/en.136.12.5476; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; COSTA T, 1992, MOL PHARMACOL, V41, P549; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; Gaits F, 1996, J BIOL CHEM, V271, P20151; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; LAW SF, 1993, J BIOL CHEM, V268, P10721; LEWIN MJM, 1992, ANNU REV PHYSIOL, V54, P455, DOI 10.1146/annurev.physiol.54.1.455; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NAHMIAS C, 1995, BIOCHEM J, V306, P87, DOI 10.1042/bj3060087; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Reardon DB, 1996, BIOCHEM J, V314, P401, DOI 10.1042/bj3140401; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; THEVENIAU MA, 1994, J NEUROCHEM, V63, P447; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VIDAL C, 1994, MOL PHARMACOL, V45, P97; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Yamada T, 1989, HDB PHYSL 6, P431; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZEGGARI M, 1994, BIOCHEM J, V303, P441, DOI 10.1042/bj3030441	51	143	144	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24448	24454		10.1074/jbc.272.39.24448	http://dx.doi.org/10.1074/jbc.272.39.24448			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305905	hybrid			2022-12-25	WOS:A1997XY51500056
J	Servent, D; WincklerDietrich, V; Hu, HY; Kessler, P; Drevet, P; Bertrand, D; Menez, A				Servent, D; WincklerDietrich, V; Hu, HY; Kessler, P; Drevet, P; Bertrand, D; Menez, A			Only snake curaremimetic toxins with a fifth disulfide bond have high affinity for the neuronal alpha 7 nicotinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CHICK OPTIC LOBE; ACETYLCHOLINE-RECEPTORS; SKELETAL-MUSCLE; 3-DIMENSIONAL STRUCTURE; BUNGAROTOXIN; BINDING; NEUROTOXIN; VENOM; METHYLLYCACONITINE	Long chain and short chain curaremimetic toxins from snakes possess 66-74 residues with five disulfide bonds and 60-62 residues with four disulfide bonds, respectively, Despite their structural differences all of these toxins bind with high affinity to the peripheral nicotinic acetylcholine receptors (AChR), Binding experiments have now revealed that long chain toxins only, like the neuronal K-bungarotoxin, have a high affinity for a chimeric form of the neuronal alpha 7 receptor, with K-d values ranging from about 1 to 12 nM, In contrast, all other toxins bind to the chimeric alpha 7 receptor with a low affinity, with K-d values ranging between 3 and 22 mu M. These results are supported by electrophysiological recordings on both the wild-type and chimeric alpha 7 receptors. Amino acid sequence analyses have suggested that high affinities for the neuronal receptor are associated with the presence of the fifth disulfide at the tip of the toxin second loop, In agreement with this conclusion, we show that a long chain toxin whose fifth disulfide is reduced and then dithiopyridylated has a low affinity (K-d = 12 mu M) for the neuronal alpha 7 receptor, whereas it retains a high affinity (K-d = 0.35 nM) for the peripheral AChR, Thus, a long chain curaremimetic toxin having a reduced fifth disulfide bond behaves like a short chain toxin toward both the peripheral and neuronal AChR, Therefore, functional classification of toxins that bind to AChRs should probably be done by considering their activities on both peripheral and neuronal receptors.	CTR MED UNIV GENEVA, DEPT PHYSIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	Servent, D (corresponding author), CEA SACLAY, DEPT INGN & ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE.			Servent, Denis/0000-0002-0774-1691				ALBUQUERQUE EX, 1979, HDB EXP PHARM, V52, P377; ALKONDON M, 1992, MOL PHARMACOL, V41, P802; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiappinelli V., 1991, SNAKE TOXINS, P223; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DREVET P, 1997, IN PRESS PROT EXP PU, V10; Ducancel F., 1991, P385; EAKER DL, 1967, JPN J MICROBIOL, V11, P353, DOI 10.1111/j.1348-0421.1967.tb00356.x; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; ENDO T, 1991, SNAKE TOXINS, P259; FIORDALISI JJ, 1994, TECHNIQUES PROTEIN C, V5, P269; GOTTI C, 1994, EUR J NEUROSCI, V6, P1281, DOI 10.1111/j.1460-9568.1994.tb00318.x; ISHIKAWA Y, 1977, TOXICON, V15, P477, DOI 10.1016/0041-0101(77)90098-8; ISHIKAWA Y, 1985, BRAIN RES, V346, P82, DOI 10.1016/0006-8993(85)91097-2; JERUSALINSKY D, 1994, TRENDS PHARMACOL SCI, V15, P424, DOI 10.1016/0165-6147(94)90092-2; KIM HS, 1982, BIOCHEM J, V207, P215, DOI 10.1042/bj2070215; Lamthanh H, 1995, PEPTIDE RES, V8, P316; LEE CY, 1972, ANNU REV PHARMACOL, V12, P84; LORING RH, 1986, BRAIN RES, V385, P30, DOI 10.1016/0006-8993(86)91543-X; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; LUKAS RJ, 1981, BIOCHEMISTRY-US, V20, P7373, DOI 10.1021/bi00529a008; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; PENG X, 1994, MOL PHARMACOL, V45, P546; PILLET L, 1993, J BIOL CHEM, V268, P909; ROSENTHAL JA, 1994, J BIOL CHEM, V269, P11178; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSERNOGLOU D, 1977, P NATL ACAD SCI USA, V74, P971, DOI 10.1073/pnas.74.3.971; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WARD JM, 1990, FEBS LETT, V270, P45, DOI 10.1016/0014-5793(90)81231-C; WEBER M, 1974, MOL PHARMACOL, V10, P1; WOLF KM, 1988, BRAIN RES, V439, P249, DOI 10.1016/0006-8993(88)91481-3; Wonnacott S., 1993, METHODS NEUROSCI, P263; Zamudio F, 1996, BIOCHEMISTRY-US, V35, P7910, DOI 10.1021/bi9600761; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	41	133	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24279	24286		10.1074/jbc.272.39.24279	http://dx.doi.org/10.1074/jbc.272.39.24279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305882	hybrid			2022-12-25	WOS:A1997XY51500033
J	McDonough, PM; Hanford, DS; Sprenkle, AB; Mellon, NR; Glembotski, CC				McDonough, PM; Hanford, DS; Sprenkle, AB; Mellon, NR; Glembotski, CC			Collaborative roles for c-Jun N-terminal kinase, c-Jun, serum response factor, and Sp1 in calcium-regulated myocardial gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NEONATAL CARDIAC MYOCYTES; ATRIAL-NATRIURETIC-FACTOR; CULTURED VENTRICULAR MYOCYTES; RAT SYMPATHETIC NEURONS; ALPHA-ACTIN PROMOTER; BOX-BINDING-PROTEINS; GROWTH-FACTOR; MEMBRANE DEPOLARIZATION; DNA-BINDING	Electrical stimulation of contractions (pacing) of primary neonatal rat ventricular myocytes increases intracellular calcium and activates a hypertrophic growth program that includes expression of the cardiac-specific gene, atrial natriuretic factor (ANF). To investigate the mechanism whereby pacing increases ANF, pacing was tested for its ability to regulate mitogen-activated protein kinase family members, ANF promoter activity, and the trans-activation domain of the transcription factor, Sp1. Pacing and the calcium channel agonist BAYK 8644 activated c-Jun N-terminal kinase (JNK) but not extracellular signal-regulated kinase. Pacing stimulated ANF-promoter activity approximately 10-fold. Furthermore, transfection with an expression vector for c-Jun, a substrate for JNK, also activated the ANF promoter, and the combination of pacing and c-Jun was synergystic, consistent with roles for JNK and c-Jun in calcium-activated ANF expression. Proximal serum response factor and Sp1 binding sites were required for the effects of pacing or c-Jun on the ANF promoter. Pacing and c-Jun activated a GAL4-Sp1 fusion protein by 3- and 12-fold, respectively, whereas the two stimuli together activated GAL4-Sp1 synergistically, similar to their effect on the ANF promoter. Transfection with an expression vector for c-Fos inhibited the effects of c-Jun, suggesting that c-Jun acts independently of AP-1. These results demonstrate an interaction between c-Jun and Sp1 and are consistent with a novel mechanism of calcium-mediated transcriptional activation involving the collaborative actions of JNK, c-Jun, serum response factor, and Sp1.	SAN DIEGO STATE UNIV, INST MOL BIOL, SAN DIEGO, CA 92182 USA; UNIV VIRGINIA, HLTH SCI CTR, CHARLOTTESVILLE, VA 22908 USA	California State University System; San Diego State University; University of Virginia	McDonough, PM (corresponding author), SAN DIEGO STATE UNIV, DEPT BIOL, 5300 CAMPANILE DR, SAN DIEGO, CA 92182 USA.				NHLBI NIH HHS [HL-56861, HL-54030] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054030, R01HL056861] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; BARRY WH, 1993, CIRCULATION, V87, P1806, DOI 10.1161/01.CIR.87.6.1806; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BRAND T, 1993, J MOL CELL CARDIOL, V25, P1325, DOI 10.1006/jmcc.1993.1145; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; DESNOS C, 1990, DEV BRAIN RES, V52, P161, DOI 10.1016/0165-3806(90)90231-M; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIU F, 1993, J BIOL CHEM, V268, P6714; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MCDERMOTT P, 1985, AM J PHYSIOL, V249, pH763, DOI 10.1152/ajpheart.1985.249.4.H763; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; POLAK KA, 1991, J NEUROSCI, V11, P534; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; SPIEGEL K, 1989, MOL BRAIN RES, V5, P23, DOI 10.1016/0169-328X(89)90014-4; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANBILSEN M, 1993, CARDIOVASC RES, V27, P1140; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WIER WG, 1995, CIBA F SYMP, V188, P146; WU RL, 1994, J BIOL CHEM, V269, P28450; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; Zheng JS, 1996, CIRC RES, V78, P525, DOI 10.1161/01.RES.78.4.525; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	76	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24046	24053		10.1074/jbc.272.38.24046	http://dx.doi.org/10.1074/jbc.272.38.24046			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295358	hybrid			2022-12-25	WOS:A1997XX38100083
J	Piotrowski, J; Beal, R; Hoffman, L; Wilkinson, KD; Cohen, RE; Pickart, CM				Piotrowski, J; Beal, R; Hoffman, L; Wilkinson, KD; Cohen, RE; Pickart, CM			Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN CARRIER PROTEINS; MULTIUBIQUITIN-CHAIN; PROTEOLYTIC PATHWAY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ALPHA-GLOBIN; DEGRADATION; ENZYME; PURIFICATION; RESOLUTION	Ubiquitin is a covalent signal that targets cellular proteins to the 26 S proteasome. Multiple ubiquitins can be ligated together through the formation of isopeptide bonds between Lys(48) and Gly(76) of successive ubiquitins. Such a polyubiquitin chain constitutes a highly effective proteolytic targeting signal, but its made of interaction with the proteasome is not well understood. Experiments to address this issue have been limited by difficulties in preparing useful quantities of polyubiquitin chains of uniform length. We report a simple method for large scale synthesis of Lys(48)-linked polyubiquitin chains of defined length. In the first round of synthesis, two ubiquitin derivatives (K48C-ubiquitin and Asp(77)-ubiquitin) were eased as substrates for the well characterized ubiquitin-conjugating enzyme E2-25K. Diubiquitin blocked at the nascent proximal and distal chain. termini was obtained in qualitative yield. Appropriately deblocked chains were then combined to synthesize higher order chains (tetramer and octamer in the present study). Deblocking was achieved either enzymatically (proximal terminus) or by chemical alkylation (distal terminus), Chains synthesized by this method were used to obtain the Fu st quantitative information concerning the influence of polyubiquitin chain length on binding to the 26 S proteasome; this was done through comparison of different length (unanchored) polyubiquitin chains as inhibitors of ubiquitin-conjugate degradation. K-0.5 was found to decrease similar to 90-fold, from 430 to 4.8 mu M, as the chain was lengthened from two to eight ubiquitins. The implications of these results for the molecular basis of chain recognition are discussed.	JOHNS HOPKINS UNIV, DEPT BIOCHEM, SCH PUBL HLTH, BALTIMORE, MD 21205 USA; SUNY BUFFALO, DEPT BIOCHEM, SCH MED, BUFFALO, NY 14214 USA; UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Utah System of Higher Education; University of Utah; Emory University; University of Iowa					NIDDK NIH HHS [DK46984] Funding Source: Medline; NIGMS NIH HHS [GM30308, GM37666] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308, R01GM037666] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cole R.D., 1967, METHOD ENZYMOL, V11, P315; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; COX MJ, 1986, ARCH BIOCHEM BIOPHYS, V250, P400, DOI 10.1016/0003-9861(86)90742-3; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HALDEMAN MT, 1997, IN PRESS BIOCHEMISTR, V36; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; SHAEFFER JR, 1994, J BIOL CHEM, V269, P29530; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TANAKA K, 1986, J BIOL CHEM, V261, P5197; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; WEFES I, 1995, GENE, V163, P321, DOI 10.1016/0378-1119(95)00374-F	54	176	177	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23712	23721		10.1074/jbc.272.38.23712	http://dx.doi.org/10.1074/jbc.272.38.23712			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295315	hybrid			2022-12-25	WOS:A1997XX38100040
J	Berhanu, P; Anderson, C; Hickman, M; Ciaraldi, TP				Berhanu, P; Anderson, C; Hickman, M; Ciaraldi, TP			Insulin signal transduction by a mutant human insulin receptor lacking the NPEY sequence - Evidence for an alternate mitogenic signalling pathway that is independent of Shc phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR-I; JUXTAMEMBRANE REGION; PHOSPHATIDYLINOSITOL 3-KINASE; NPXY MOTIF; CHO CELLS; DOMAIN; SUBSTRATE-1; ENDOCYTOSIS; PROTEINS	The cytoplasmic juxtamembrane domain of the human insulin receptor (hIR) contains a single copy of the tetrameric amino acid sequence Asn-Pro-Glu-Tyr (NPEY) (residues 969-972 in the exon 11-containing B-isoform), which exists in the context of NPXY, In this study, we examined the role of NPEY972 in mediating insulin signal transduction and cellular biological effects. Transfected Chinese hamster ovary cell lines expressing either the wild-type hIR-B isoform (hIR.WT) or a mutant receptor lacking the NPEY972 sequence (hIR Delta NPEY) and control Chinese hamster ovary Neo cells were used to comparatively analyze the following insulin effects: in vivo receptor tyrosine autophosphorylation and kinase activity, signal transduction to downstream signaling molecules, and stimulation of glycogen and DNA synthesis, The results showed that in comparison to hIR.WT, the hIR Delta NPEY mutant demonstrated the following: (a) normal insulin-mediated receptor tyrosine phosphorylation, but similar to 50% reduction in phosphorylation of p185-(insulin receptor substrate-1) and binding of the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase), (b) an enhanced stimulation of PI 3-kinase enzymatic activity, (c) a complete inability to phosphorylate Shc, (d) minimal impairment of insulin sensitivity for glycogen synthesis, and (e) an augmented response to insulin-stimulated DNA synthesis via a high capacity, low sensitivity pathway. These results demonstrate the following: 1) the NPEY972 sequence is important but not absolutely essential for coupling of hIR kinase to insulin receptor substrate-1 and p85 or for mediating insulin's metabolic and mitogenic effects, 2) the NPEY972 sequence is necessary for She phosphorylation, and 3) the absence of Shc phosphorylation releases the constraints on maximal insulin-stimulated mitogenic response, thus indicating that alternate signaling pathway(s) exist for this insulin action, This alternate pathway appears to be associated with enhanced activation of PI 3-kinase and is of high capacity and low sensitivity.	UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92093	University of California System; University of California San Diego	Berhanu, P (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED,B151,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032880] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32880] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; BERHANU P, 1994, MOL BIOL DIABETES, V2, P321; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CIARALDI TP, 1992, DIABETES, V41, P975, DOI 10.2337/diabetes.41.8.975; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KABURAGI Y, 1995, ENDOCRINOLOGY, V136, P3437, DOI 10.1210/en.136.8.3437; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; THIES RS, 1990, J BIOL CHEM, V265, P10132; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1995, J CELL PHYSIOL, V163, P9, DOI 10.1002/jcp.1041630103; WONG EHA, 1995, ENDOCRINOLOGY, V136, P1459, DOI 10.1210/en.136.4.1459; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	37	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22884	22890		10.1074/jbc.272.36.22884	http://dx.doi.org/10.1074/jbc.272.36.22884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278451	hybrid			2022-12-25	WOS:A1997XV49200072
J	Hoylaerts, MF; Manes, T; Millan, JL				Hoylaerts, MF; Manes, T; Millan, JL			Mammalian alkaline phosphatases are allosteric enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; UNCOMPETITIVE INHIBITION; CELLS; EXPRESSION; MECHANISM; SUBSTRATE; P-31; NMR	Mammalian alkaline phosphatases (APs) are zinc-containing metalloenzymes encoded by a multigene family and functional as dimeric molecules, Using human placental AP (FLAP) as a paradigm, we have investigated whether the monomers in a given FLAP dimer are subject to cooperativity during catalysis following an allosteric model or act via a half-of-sites model, in which at any time only one single monomer is operative. Wild type and mutant FLAP homodimers and heterodimers were produced by stably transfecting Chinese hamster ovary cells with mutagenized FLAP cDNAs followed by enzyme extraction, purification, and characterization [Gly(429)]PLAP manifested negative cooperativity when partially metalated as a consequence of the reduced affinity of the incompletely metalated AP monomers for the substrate, Upon full metalation with Zn2+, however the negative cooperativity disappeared, To distinguish between an allosteric and a half-of-sites model, a [Gly(429)]PLAP-[Ser(84)]PLAP heterodimer was produced by combining monomers displaying high and low sensitivity to the uncompetitive inhibitor L-Leu as well as a [Gly(429)]PLAP-[Ala(92)]PLAP heterodimer combining a catalytically active and inactive monomer, respectively. The L-Leu inhibition profile of the [Gly(429)]PLAP-[Ser(84)]PLAP heterodimer was intermediate to that for each homodimer as predicted by the allosteric model. Likewise, the [Gly(429)]PLAP-[Ala(92)]PLAP heterodimer was catalytically active, confirming that AP monomers act independently of each other, Although heterodimers are structurally asymmetrical, they migrate in starch gels with a smaller than expected weighted electrophoretic mobility, are more stable to heat denaturation than expected, and are more sensitive to L-Leu inhibition than predicted by a strict noncooperative model, We conclude that fully metalated mammalian APs: are noncooperative allosteric enzymes but that the stability and catalytic properties of each monomer are controlled by the conformation of the second AP subunit.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037; KATHOLIEKE UNIV LEUVEN,CTR MOL & VASC BIOL,B-3001 LOUVAIN,BELGIUM; UMEA UNIV,DEPT MED GENET,S-90185 UMEA,SWEDEN	Sanford Burnham Prebys Medical Discovery Institute; KU Leuven; Umea University			Millan, Jose Luis/B-6580-2008	Hoylaerts, Marc/0000-0002-6474-3933	NCI NIH HHS [CA42595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BLOCH W, 1974, J BIOL CHEM, V249, P1760; BOSSI M, 1993, J BIOL CHEM, V268, P25409; BYERS DA, 1972, EUR J BIOCHEM, V29, P197, DOI 10.1111/j.1432-1033.1972.tb01975.x; CHLEBOWSKI JF, 1976, J BIOL CHEM, V251, P1207; CIONI P, 1989, EUR J BIOCHEM, V185, P573, DOI 10.1111/j.1432-1033.1989.tb15152.x; COLEMAN JE, 1986, PROGR INORGANIC BIOC, V1, P77; COLEMAN JE, 1983, METAL IONS BIOL, V5, P153; GETTINS P, 1984, J BIOL CHEM, V259, P4991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARRIS H, 1989, CLIN CHIM ACTA, V186, P133; HARRIS MI, 1968, J BIOL CHEM, V243, P5063; HENDRIX PG, 1990, CLIN CHEM, V36, P1793; HOYLAERTS MF, 1992, BIOCHEM J, V286, P23, DOI 10.1042/bj2860023; HOYLAERTS MF, 1992, CLIN CHEM, V38, P2493; HOYLAERTS MF, 1991, EUR J BIOCHEM, V202, P605, DOI 10.1111/j.1432-1033.1991.tb16414.x; HUMMER C, 1991, BIOCHEM J, V274, P91, DOI 10.1042/bj2740091; ITO F, 1984, J BIOL CHEM, V259, P2526; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; McComb Jr RB, 1979, ALKALINE PHOSPHATASE, DOI 10.1007/978-1-4613-2970-1_4; MEIGHEN E, 1975, BIOCHIM BIOPHYS ACTA, V412, P262, DOI 10.1016/0005-2795(75)90040-9; MILLAN JL, 1988, ANTICANCER RES, V8, P995; OLAFSDOTTIR S, 1989, J BIOL CHEM, V264, P4529; RAO NM, 1991, J BIOL CHEM, V266, P5018; Segel I.H., 1975, ENZYME KINETICS; SIMPSON RT, 1970, BIOCHEMISTRY-US, V9, P953, DOI 10.1021/bi00806a035; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; TSONIS PA, 1988, BIOCHEM J, V254, P623, DOI 10.1042/bj2540623; WATANABE S, 1989, J BIOL CHEM, V264, P12611; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	31	99	101	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22781	22787		10.1074/jbc.272.36.22781	http://dx.doi.org/10.1074/jbc.272.36.22781			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278439	hybrid			2022-12-25	WOS:A1997XV49200060
J	Mathupala, SP; Heese, C; Pedersen, PL				Mathupala, SP; Heese, C; Pedersen, PL			Glucose catabolism in cancer cells - The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BOUND HEXOKINASE; WILD-TYPE P53; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; GENE; SEQUENCES; PROTEINS; PHOSPHORYLATION; EXPRESSION; METABOLISM	The p53 tumor suppressor is found to be mutated and abundant in a wide variety of tumors. Within tumors showing rapid growth, the Type II isoform of hexokinase is also highly expressed to facilitate high rates of glucose catabolism, which in turn promote their rapid proliferation. We previously reported isolation of the proximal promoter of the Type II hexokinase gene from the highly glycolytic hepatoma AS-30D (Mathupala, S. P., Rempel, A., and Pedersen, P. L. (1995) J. Biol. Chem. 270, 16918-16925). Here, we show that a p53 protein, exhibiting two point mutations in its cDNA, is abundantly expressed in the AS-30D hepatoma. Co-expression studies showed that p53 overexpression significantly and reproducibly activated the Type II hexokinase promoter. Two functional p53 motifs were identified within this promoter by footprint and gel retardation analyses. Presence of functional p53 response elements on the Type II hexokinase promoter and the positive regulatory effect on the promoter by the mutant p53 indicates that in rapidly growing liver tumors, and perhaps in many other tumors as well, this highly abundant p53 protein plays a role in maintaining a high glycolytic rate. This is the first report of a possible link between less of cell cycle control in rapidly growing cancer cells and their high glycolytic phenotype.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA032742] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARORA KK, 1988, J BIOL CHEM, V263, P17422; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CHEN JY, 1993, ONCOGENE, V8, P2159; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DEVEREUX J, 1994, GCG ANAL SOFTWARE PA; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P264; FUNK WD, 1992, MOL CELL BIOL, V12, P2966; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HULLA JE, 1993, NUCLEIC ACIDS RES, V21, P713, DOI 10.1093/nar/21.3.713; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; MUKHOPADHYAY T, 1995, SUPPRESSOR GENE; NAKASHIMA RA, 1984, CANCER RES, V44, P5702; NAKASHIMA RA, 1988, CANCER RES, V48, P913; PARK DJ, 1994, ONCOGENE, V9, P1899; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAULSKY G, 1991, CANCER RES, V51, P5232; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINSTEIN IB, 1975, CANCER RES, V35, P253; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	34	185	194	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22776	22780		10.1074/jbc.272.36.22776	http://dx.doi.org/10.1074/jbc.272.36.22776			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278438	hybrid			2022-12-25	WOS:A1997XV49200059
J	Matsui, I; Svensson, B				Matsui, I; Svensson, B			Improved activity and modulated action pattern obtained by random mutagenesis at the fourth beta-alpha loop involved in substrate binding to the catalytic (beta/alpha)(8)-barrel domain of barley alpha-amylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; TAKA-AMYLASE; AMYLASE/SUBTILISIN INHIBITOR; SACCHAROMYCES-CEREVISIAE; SUBSITE AFFINITIES; SECRETED PROTEINS; MASS-SPECTROMETRY; RATE PARAMETERS; CDNA CLONE; YEAST	The functionality of the sequence Arg(183)-Gly(184)-Tyr(185) of the substrate binding fourth beta-alpha loop in the (beta/alpha)(8)-barrel of barley alpha-amylase isozyme 1 (AMY1) was studied by random mutagenesis. A motif of polar Gly(184) hydrophobic residues was present in active mutants, selected by starch plate screening of yeast transformants. Gly(184) was important, probably due to the carbonyl group binding to Ca2+ and the spatial proximity of Phe(181). Mutation of both flanking residues as in Ser(183)-Gly(184)-Met(185) (SGM-) and TGL-AMY1 decreased the Ca2+ affinity. SGM-AMY1 has 2-fold increased activity for amylose but reduced activity on maltooligosaccharides, whereas KGY-AMY1 has up to 3-fold elevated activity toward the oligosaccharides. TGL-AMY1 has modest activity on all substrates. Shifted action pattern on maltooligosaccharides for NGY-, SGM-, and TGL-AMY1 support that Arg(183) in wild type is located at subsites +1 and +2, accommodating two sugar rings toward the reducing end from the site of cleavage. In the crystal structure of barley alpha-amylase 2 (AMY2), Lys(182) (equivalent to AMY1 Arg(183)) is hydrogen-bonded with sugar OH-3 in subsite +2. Higher K-i app for acarbose inhibition of KGY-AMY1 and parent AMY1 compared with the other mutants suggests favorable substrate interactions for Arg/Lys(183). KGY-AMY1 was not inhibited by the AMY2-specific proteinaceous barley alpha-amylase/subtilisin inhibitor, although Lys(182) Of AMY2 is salt-linked to the inhibitor.	CARLSBERG LAB, DEPT CHEM, DK-2500 COPENHAGEN, DENMARK					Svensson, Birte/0000-0002-2993-8196				ABE J, 1993, BIOCHEM J, V293, P151, DOI 10.1042/bj2930151; AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; ALLEN JD, 1976, BIOCHEM J, V159, P121, DOI 10.1042/bj1590121; ANDERSEN JS, 1994, BIOL MASS SPECTROM, V23, P547, DOI 10.1002/bms.1200230904; BAULCOMBE DC, 1987, MOL GEN GENET, V209, P33, DOI 10.1007/BF00329833; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERTOFT E, 1984, J I BREWING, V90, P298, DOI 10.1002/j.2050-0416.1984.tb04278.x; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BUSH DS, 1989, J BIOL CHEM, V264, P19392; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; GIBSON RM, 1986, CARLSBERG RES COMMUN, V51, P295, DOI 10.1007/BF02907163; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIROMI K, 1970, BIOCHEM BIOPH RES CO, V40, P1, DOI 10.1016/0006-291X(70)91037-5; HOLM L, 1990, PROTEIN ENG, V3, P181, DOI 10.1093/protein/3.3.181; HUANG N, 1992, GENE, V111, P223, DOI 10.1016/0378-1119(92)90690-Q; ISHIKAWA K, 1989, ARCH BIOCHEM BIOPHYS, V272, P356, DOI 10.1016/0003-9861(89)90229-4; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6259, DOI 10.1021/bi00075a020; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V183, P286, DOI 10.1016/0006-291X(92)91641-3; IWASA S, 1974, J BIOCHEM-TOKYO, V75, P969, DOI 10.1093/oxfordjournals.jbchem.a130499; JANECEK S, 1994, FEBS LETT, V353, P119, DOI 10.1016/0014-5793(94)01019-6; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; JONES RL, 1991, INT REV CYTOL, V126, P49; Juge N, 1996, PROTEIN EXPRES PURIF, V8, P204, DOI 10.1006/prep.1996.0093; JUGE N, 1995, FEBS LETT, V363, P299, DOI 10.1016/0014-5793(95)00291-G; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; KADZIOLA A, 1993, THESIS U COPENHAGEN; KOIZUKA N, 1990, PLANT PHYSIOL, V94, P1488, DOI 10.1104/pp.94.3.1488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LACKS SA, 1982, CELL, V31, P327, DOI 10.1016/0092-8674(82)90126-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACGREGOR AW, 1986, CEREAL FOOD WORLD, V31, P688; MACGREGOR AW, 1978, CEREAL CHEM, V55, P754; MACGREGOR AW, 1992, CARBOHYD RES, V227, P301, DOI 10.1016/0008-6215(92)85080-J; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; MATSUI I, 1992, FEBS LETT, V310, P216, DOI 10.1016/0014-5793(92)81335-J; MATSUI I, 1990, AGR BIOL CHEM TOKYO, V54, P2009, DOI 10.1080/00021369.1990.10870246; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MATSUI I, 1992, BIOCHEMISTRY-US, V31, P5232, DOI 10.1021/bi00137a019; MATSUI I, 1994, BIOCHEMISTRY-US, V33, P451, DOI 10.1021/bi00168a009; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MATSUURA Y, 1991, DENPUN KAGAKU, V38, P137; MCELROY D, 1995, BIO-TECHNOL, V13, P245, DOI 10.1038/nbt0395-245; MUNDY J, 1983, CARLSBERG RES COMMUN, V48, P81, DOI 10.1007/BF02906171; NAGASHIMA T, 1992, BIOSCI BIOTECH BIOCH, V56, P207, DOI 10.1271/bbb.56.207; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; RODENBURG KW, 1994, EUR J BIOCHEM, V221, P277, DOI 10.1111/j.1432-1033.1994.tb18739.x; ROGERS JC, 1983, J BIOL CHEM, V258, P8169; ROGERS JC, 1985, J BIOL CHEM, V260, P3731; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; SOGAARD M, 1993, BIO-TECHNOL, V11, P1162, DOI 10.1038/nbt1093-1162; SOGAARD M, 1993, J BIOL CHEM, V268, P22480; SOGAARD M, 1991, P NATL ACAD SCI USA, V88, P8140, DOI 10.1073/pnas.88.18.8140; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; SVENSSON B, 1991, ACS SYM SER, V458, P28; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; SVENSSON B, 1991, DENPUN KAGAKU, V38, P125; TAKAHA T, 1993, J BIOL CHEM, V268, P1391; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; TRUSCHEIT E, 1981, REGULATORS INTESTINA, V2, P157; TSUKAMOTO A, 1988, BIOCHEM BIOPH RES CO, V151, P25, DOI 10.1016/0006-291X(88)90554-2; VALLEE F, 1994, J MOL BIOL, V236, P368, DOI 10.1006/jmbi.1994.1141; WESELAKE RJ, 1983, PLANT PHYSIOL, V72, P809, DOI 10.1104/pp.72.3.809; YAMANE K, 1992, BIOSCIENCE IND, V50, P13; YAMAUCHI D, 1994, PLANT CELL PHYSIOL, V35, P705, DOI 10.1093/oxfordjournals.pcp.a078647; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU JH, 1989, FEBS LETT, V255, P37, DOI 10.1016/0014-5793(89)81056-7	71	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22456	22463		10.1074/jbc.272.36.22456	http://dx.doi.org/10.1074/jbc.272.36.22456			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278396	hybrid			2022-12-25	WOS:A1997XV49200016
J	Nagaoka, I; TsutsumiIshii, Y; Yomogida, S; Yamashita, T				Nagaoka, I; TsutsumiIshii, Y; Yomogida, S; Yamashita, T			Isolation of cDNA encoding guinea pig neutrophil cationic antibacterial polypeptide of 11 kDa (CAP11) and evaluation of CAP11 mRNA expression during neutrophil maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; BONE-MARROW CELLS; MOLECULAR-CLONING; MESSENGER-RNA; CHEMICAL SYNTHESIS; PEPTIDE; SEQUENCE; LEUKOCYTES; GELATINASE; CYSTEINE	Neutrophils contain various antibacterial polypeptides and proteins in the granules that contribute to the killing of microorganisms. Recently, we have purified a cationic antibacterial polypeptide of 11 kDa (CAP11) from guinea pig neutrophil granules. CAP11 is a homodimer of G(1)LRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI(48) joined with one disulfide bond. In this study, to understand the regulation of CAP11 expression, we isolated and analyzed cDNA encoding CAP11. Furthermore, we investigated the expression of CAP11 mRNA during neutrophil maturation and localization of CAP11 among neutrophil granule subsets. Sequence analysis of CAP11 cDNA isolated from guinea pig bone marrow cells using rapid amplification of cDNA ends technique indicated that CAP11 is synthesized as a precursor comprising 178 amino acid residues, which is composed of a signal peptide (N-terminal 29 residues), a propeptide (106 residues), and a C-terminal mature peptide (43 residues). Interestingly, the predicted CAP11 precursor displayed the characteristic features of cathelicidins, a novel protein family of antibacterial polypeptides with a conserved cathelin-like pro-region and a variable C-terminal antibacterial domain. Northern blot and Western blot analyses using neutrophils, macrophages, eosinophils, mononuclear cells, and bone marrow cells revealed that only neutrophils and bone marrow cells expressed CAP11 mRNA and contained CAP11, suggesting that expression of CAP11 is neutrophil lineage-specific. Furthermore, Northern blot analysis using bone marrow cells separated according to their maturation stages showed that CAP11 mRNA was predominantly expressed in the cells at later stages of neutrophil maturation. Consistent with this, in situ hybridization using CAP11-specific cRNA probe demonstrated that CAP11 mRNA was primarily expressed at metamyelocyte stage. In addition, extracellular release assay revealed that CAP11 was readily released from neutrophils accompanied with gelatinase by low concentrations of N-formyl-Met-Leu-Phe without release of specific and azurophil granule components, and CAP11 was found to be exclusively present in the fraction containing gelatinase granules, prepared by Percoll density gradient centrifugation. Together these observations indicate that CAP11 is a member of cathelicidin family and its mRNA is preferentially expressed at the later stage of neutrophil maturation (i.e. metamyelocyte stage). Furthermore, CAP11 may be stored in the granule subset, possibly the gelatinase granule.			Nagaoka, I (corresponding author), JUNTENDO UNIV, SCH MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN.							AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; BAINTON DF, 1992, INFLAMMATION BASIC P, P303; Borregaard N, 1996, Curr Opin Hematol, V3, P11; BORREGAARD N, 1995, BLOOD, V85, P812, DOI 10.1182/blood.V85.3.812.bloodjournal853812; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; DELSAL G, 1992, BIOCHEM BIOPH RES CO, V187, P467, DOI 10.1016/S0006-291X(05)81517-7; ELSBACH P, 1990, TRENDS BIOTECHNOL, V8, P26, DOI 10.1016/0167-7799(90)90127-J; Elsbach P, 1992, INFLAMMATION BASIC P, P603; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GALLIN JI, 1992, INFLAMMATION BASIC P, P859; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIRATA M, 1994, INFECT IMMUN, V62, P1421, DOI 10.1128/IAI.62.4.1421-1426.1994; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; JOHNSTON JJ, 1992, BLOOD, V79, P2998; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P, P541; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LARRICK JW, 1991, BIOCHEM BIOPH RES CO, V179, P170, DOI 10.1016/0006-291X(91)91350-L; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LEVY O, 1993, J BIOL CHEM, V268, P6058; NAGAOKA I, 1985, BIOCHIM BIOPHYS ACTA, V847, P67, DOI 10.1016/0167-4889(85)90154-5; NAGAOKA I, 1984, COMP BIOCHEM PHYS B, V79, P147, DOI 10.1016/0305-0491(84)90005-1; NAGAOKA I, 1991, FEBS LETT, V280, P287, DOI 10.1016/0014-5793(91)80314-S; NAGAOKA I, 1992, FEBS LETT, V302, P279, DOI 10.1016/0014-5793(92)80459-T; NAGAOKA I, 1994, FEBS LETT, V356, P33, DOI 10.1016/0014-5793(94)01229-6; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; PUNGERCAR J, 1993, FEBS LETT, V336, P284, DOI 10.1016/0014-5793(93)80821-B; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCOCCHI M, 1994, FEBS LETT, V352, P197, DOI 10.1016/0014-5793(94)00954-6; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SRIKANTH S, 1994, J BIOL CHEM, V269, P32626; STORICI P, 1994, FEBS LETT, V337, P303, DOI 10.1016/0014-5793(94)80214-9; STORICI P, 1992, FEBS LETT, V314, P187, DOI 10.1016/0014-5793(92)80971-I; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; TOSSI A, 1994, FEBS LETT, V339, P108, DOI 10.1016/0014-5793(94)80395-1; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; Yomogida S, 1996, ARCH BIOCHEM BIOPHYS, V328, P219, DOI 10.1006/abbi.1996.0166; ZANETTI M, 1993, J BIOL CHEM, V268, P522; ZANETTI M, 1994, J BIOL CHEM, V269, P7855; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHAO CQ, 1994, FEBS LETT, V346, P285, DOI 10.1016/0014-5793(94)00493-5	52	51	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22742	22750		10.1074/jbc.272.36.22742	http://dx.doi.org/10.1074/jbc.272.36.22742			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278433	hybrid			2022-12-25	WOS:A1997XV49200054
J	Gu, J; Shumyatsky, G; Makan, N; Reddy, R				Gu, J; Shumyatsky, G; Makan, N; Reddy, R			Formation of 2',3'-cyclic phosphates at the 3' end of human U6 small nuclear RNA in vitro - Identification of 2',3'-cyclic phosphates at the 3' ends of human signal recognition particle and mitochondrial RNA processing RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; MESSENGER-RNA; RIBOSE METHYLATION; SELF-CLEAVAGE; CELL EXTRACT; TRANSCRIPTION; SEQUENCES; ELEMENTS; EXCISION; GENES	Approximately 90% of human U6 small nuclear RNA (snRNA) contains uridine cyclic phosphate (U > p) at its 3'-end (Lund, E., and Dahlberg, J. E. (1992) Science 255, 327-330). We studied the formation of U > p at the 3' end of human U6 snRNA using an in vitro system where uridylic acid residues are added from UTP precursor and U > p is formed. Analysis of U6 snRNAs with varying number of uridylic acid residues showed that each of these species contains U > p where the phosphate originated from cx-phosphate of UTP precursor, The cyclic phosphate formation occurred on U6 snRNA in extracts where essential spliceosomal snRNAs were specifically degraded, thereby indicating that U > p formation is not coupled to pre-mRNA splicing, A subpopulation of human signal recognition particle and mitochondrial RNA processing RNAs isolated from HeLa cells also contained cyclic phosphates at their 3' ends. These data suggest that U > p in U6 snRNA is unlikely to be related to its participation in splicing of pre-mRNAs, It appears that cyclic phosphate is an intermediate product in the metabolism of these small RNAs.	BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030	Baylor College of Medicine			Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	NIGMS NIH HHS [GM52901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; CLAYTON DA, 1994, P NATL ACAD SCI USA, V91, P4615, DOI 10.1073/pnas.91.11.4615; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; EDMONDS M, 1990, METHOD ENZYMOL, V181, P161; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; Forne T, 1996, BIOCHIMIE, V78, P436, DOI 10.1016/0300-9084(96)84750-X; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; HIRAI H, 1988, J BIOCHEM-TOKYO, V104, P991, DOI 10.1093/oxfordjournals.jbchem.a122597; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; REDDY R, 1981, J BIOL CHEM, V256, P8452; Reddy R., 1991, Progress in Molecular and Subcellular Biology, V12, P1; REDDY R, 1983, J BIOL CHEM, V258, P1383; REDDY R, 1987, J BIOL CHEM, V262, P75; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHUMYATSKY GP, 1990, NUCLEIC ACIDS RES, V18, P6347, DOI 10.1093/nar/18.21.6347; Silberklang M, 1979, Methods Enzymol, V59, P58; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; TAZI J, 1993, MOL CELL BIOL, V13, P1641, DOI 10.1128/MCB.13.3.1641; Umen JG, 1995, RNA, V1, P869; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; Weber U, 1996, NUCLEIC ACIDS RES, V24, P2212, DOI 10.1093/nar/24.12.2212	41	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21989	21993		10.1074/jbc.272.35.21989	http://dx.doi.org/10.1074/jbc.272.35.21989			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268336	hybrid			2022-12-25	WOS:A1997XT85000048
J	Sakamuro, D; Sabbatini, P; White, E; Prendergast, GC				Sakamuro, D; Sabbatini, P; White, E; Prendergast, GC			The polyproline region of p53 is required to activate apoptosis but not growth arrest	ONCOGENE			English	Article						p53; apoptosis; transformation; cell cycle	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; NUCLEAR TYROSINE KINASE; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; E1A-INDUCED APOPTOSIS; EMBRYO FIBROBLASTS	p53 is a pivotal regulator of apoptosis but its mechanism of action is obscure. We report that the polyproline (PP) region located between p53's transactivation and DNA binding domains is necessary to induce apoptosis but not cell growth arrest. The PP region was dispensable for DNA binding, inhibition of SAOS-2 tumor cell growth, suppression of E1A+RAS cell transformation, and cell cycle inhibition. A temperature-sensitive dominant inhibitory p53 mutant lacking PP (p53ts Delta PP) retained its ability to cooperate with adenovirus E1A in transformation of primary BRK cells. However, while activation of wt p53 induced apoptosis in E1A+p53ts-transformed cells, activation of p53 Delta PP induced cell cycle arrest but not apoptosis in E1A+p53ts Delta PP-transformed cells. Similarly, PP deletion abolished apoptosis in LoVo colon carcinoma cells, which are killed by wt p53 overexpression. Transactivation was largely unaffected by PP deletion, Significantly, BAX induction was intact, indicating that additional events are required for p53 to induce apoptosis. As a recently described site for familial mutation in at least one breast cancer family, the PP region represents a domain that may be altered in human tumors. We concluded that p53's ability to induce apoptosis is dispensable for inhibiting cell growth and transformation and that the PP region plays a crucial role in apoptotic signaling.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08854; CANC INST NEW JERSEY,PISCATAWAY,NJ 08854	The Wistar Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CRAVEN RJ, 1995, CANCER RES, V55, P3969; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOGA A, 1995, ONCOGENE, V11, P791; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hansen R, 1995, ONCOGENE, V11, P2535; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HULBOY DL, 1994, CELL GROWTH DIFFER, V5, P1023; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1995, ONCOGENE, V11, P2311; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STEWART N, 1995, ONCOGENE, V10, P109; Sun XF, 1996, ONCOGENE, V13, P407; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197	74	246	253	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					887	898		10.1038/sj.onc.1201263	http://dx.doi.org/10.1038/sj.onc.1201263			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285684				2022-12-25	WOS:A1997XR76700002
J	Xie, KP; Wang, YF; Huang, SY; Xu, L; Bielenberg, D; Salas, T; McConkey, DJ; Jiang, WD; Fidler, IJ				Xie, KP; Wang, YF; Huang, SY; Xu, L; Bielenberg, D; Salas, T; McConkey, DJ; Jiang, WD; Fidler, IJ			Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2	ONCOGENE			English	Article						metastasis; nitric oxide; Bcl-2; apoptosis	VASCULAR ENDOTHELIAL-CELLS; L-ARGININE; CANCER METASTASIS; HUMAN PLATELETS; B-LYMPHOCYTES; TUMOR-CELLS; DEATH; MACROPHAGES; INDUCTION; PATHWAY	Recent studies have shown that the treatment of nonmetastatic K-1735 murine melanoma cells with cytokines induces the production of nitric oxide (NO) and hence cell death, The purpose of this study was to determine the mechanism of this cytokine-induced NO-mediated apoptosis. Incubation of nonmetastatic K-1735 cells with interleukin-1 alpha (IL-1 alpha) and interferon-gamma (IFN-gamma) induced high NO production, Bcl-2 downregulation, and apoptotic cell death, In contrast, incubation of metastatic K-1735 cells with IL-1 alpha. and IFN-gamma did not induce significant production of NO, downregulation of Bcl-2, or cell death. The exposure to exogenous NO derived from the NO donors, sodium nitroprusside (SNP), or GEA5024 produced a dose-dependent apoptotic cell death in both the metastatic and nonmetastatic K-1735 cells, which was associated with downregulation of Bcl-2 at the mRNA level and, to a lesser extent, at the protein level, Nonmetastatic and metastatic K-1735 cells transfected with the Bcl-2 gene were more resistant to apoptosis mediated by both endogenous and exogenous NO, Subsequent to intravenous injection, the tumor cells transfected with the Bcl-2 gene had an increased survival rate in the lungs of nude mice and produced a higher number of experimental lung metastases, These data suggest that NO-induced apoptosis in K-1735 melanoma cells is associated with downregulation of Bcl-2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Xu, Lei/GRR-9174-2022		NCI NIH HHS [CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKERMAN SL, 1986, JNCI-J NATL CANCER I, V77, P915; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BERGELSON S, 1994, CANCER RES, V54, P36; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brune B, 1995, TOXICOL LETT, V82-3, P233, DOI 10.1016/0378-4274(95)03481-1; CHUN SY, 1995, ENDOCRINOLOGY, V136, P2121; CORRALIZA IM, 1993, BIOCHEM BIOPH RES CO, V196, P342, DOI 10.1006/bbrc.1993.2254; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DING AH, 1988, J IMMUNOL, V141, P2407; DONG ZY, 1994, CANCER RES, V54, P789; ELMORE L, 1996, P AACR ANN M, V37, pA119; FANG W, 1995, J IMMUNOL, V155, P66; FIDLER IJ, 1985, CANCER RES, V45, P4714; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FIDLER IJ, 1986, CANCER RES, V46, P5167; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Geng YJ, 1996, CANCER RES, V56, P866; GLAVES D, 1986, INVAS METAST, V6, P101; HANNA N, 1980, J NATL CANCER I, V65, P801, DOI 10.1093/jnci/65.4.801; Herberman R B, 1989, Prog Clin Biol Res, V288, P161; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; Hockenbery D M, 1992, Semin Immunol, V4, P413; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFMANN M, 1991, CANCER RES, V51, P5292; Huang SY, 1996, ONCOGENE, V13, P2339; IGNARRO LJ, 1990, P NATL ACAD SCI USA, V87, P5193; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEWISMOLOCK Y, 1994, AM J RESP CELL MOL, V10, P133, DOI 10.1165/ajrcmb.10.2.8110468; LI L, 1991, CANCER RES, V51, P245; LI LM, 1991, CANCER RES, V51, P2531; LIN JK, 1992, CANCER RES, V52, P385; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MartinSanz P, 1996, HEPATOLOGY, V23, P1200; McConkey DJ, 1996, J IMMUNOL, V156, P2624; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PRICE JE, 1986, CANCER RES, V46, P5172; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RADINSKY R, 1994, ONCOGENE, V9, P1977; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RADOMSKI MW, 1990, BRIT J PHARMACOL, V101, P325, DOI 10.1111/j.1476-5381.1990.tb12709.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Sato H., 1976, FUNDAMENTAL ASPECTS, V11, P311; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SUGIMOTO Y, 1987, CANCER RES, V47, P4396; TALMADGE JE, 1982, SCIENCE, V217, P361, DOI 10.1126/science.6953592; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSURUO T, 1986, CLIN EXP METASTAS, V7, P25; WEISS L, 1986, Cancer Reviews, V3, P1; WEISS L, 1986, J THEOR BIOL, V121, P307, DOI 10.1016/S0022-5193(86)80110-2; WHITWORTH PW, 1990, CANCER METAST REV, V8, P319, DOI 10.1007/BF00052607; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILTROUT RH, 1979, CANCER RES, V39, P4034; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Xie KP, 1997, J NATL CANCER I, V89, P421, DOI 10.1093/jnci/89.6.421; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1996, J LEUKOCYTE BIOL, V59, P797, DOI 10.1002/jlb.59.6.797; XIE KP, 1993, INT J ONCOL, V3, P1043; Xie KP, 1996, CANCER IMMUNOL IMMUN, V43, P109, DOI 10.1007/s002620050310; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	70	77	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					771	779		10.1038/sj.onc.1201239	http://dx.doi.org/10.1038/sj.onc.1201239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266963				2022-12-25	WOS:A1997XQ11700003
J	Ollagnier, S; Mulliez, E; Schmidt, PP; Eliasson, R; Gaillard, J; Deronzier, C; Bergman, T; Graslund, A; Reichard, P; Fontecave, M				Ollagnier, S; Mulliez, E; Schmidt, PP; Eliasson, R; Gaillard, J; Deronzier, C; Bergman, T; Graslund, A; Reichard, P; Fontecave, M			Activation of the anaerobic ribonucleotide reductase from Escherichia coli - The essential role of the iron-sulfur center for S-adenosylmethionine reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME; SUBUNIT; SPECTROSCOPY; MECHANISM; CLUSTERS; PROTEIN; FORMATE; BINDING; SYSTEM; MODEL	The anaerobic ribonucleotide reductase of Escherichia coli catalyzes the synthesis of the deoxyribonucleotides required for anaerobic DNA synthesis. The enzyme is an alpha(2) beta(2) heterotetramer. in its active form, the large cu,subunit contains are oxygen-sensitive glycyl radical, whereas the beta(2) small protein harbors a [4Fe-4S] cluster that joins its two polypeptide chains, Formation of the glycyl radical in the inactive enzyme requires S-adenosylmethionine (AdoMet), dithiothreitol, K+, and either an enzymatic (reduced flavodoxin) or chemical (dithionite or 5-deazaflavin plus light) reducing system. Here, eve demonstrate that AdoMet is directly reduced by the Fe-S center of beta(2) during the activation of the enzyme, resulting in methionine and glycyl radical formation, Direct binding experiments showed that AdoMet binds to beta(2) with a K-d of 10 mu M and a 1:1 stoichiometry Binding was confirmed by EPR spectroscopy that demonstrated the formation of a complex between AdoMet and the [4Fe-4S] center of beta 2. Dithiothreitol triggered the cleavage of AdoMet, leading to an EPR-silent form of beta(2) and, in the case of alpha(2) beta(2), to glycyl radical formation, In both instances, 3 methionines were formed per mol of protein, Our results indicate that the Fe-S center of beta(2) is directly involved in the reductive cleavage of AdoMet and suggest a mew biological function for an iron-sulfur center, i.e redox catalysis, as recently proposed by others (Staples, R, C,, Ameyibor, E., Fu, W., Gardet-Salvi, L,, Stritt-Etter, A. L,, Schurmann, P,, Knaff D, B,, and Johnson, M, K, (1996) Biochemistry 35, 11425-11434).	UNIV GRENOBLE 1, ETUD DYNAM & STRUCT SELECT LAB, CNRS UMR 5616, F-38041 GRENOBLE 09, FRANCE; KAROLINSKA INST, MBB, MED NOBEL INST, DEPT BIOCHEM 1, S-17177 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT MOL BIOL & BIOPHYS, S-10691 STOCKHOLM, SWEDEN; CEA, DEPT RECH FONDAMENTALE MAT CONDENSEE, SESAM, SCPM, F-38054 GRENOBLE 09, FRANCE; KAROLINSKA INST, DEPT CHEM 1, MBB, S-17177 STOCKHOLM, SWEDEN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Karolinska Institutet; Stockholm University; CEA; Karolinska Institutet				Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; ELIASSON R, 1994, J BIOL CHEM, V269, P26116; ELIASSON R, 1995, BIOCHEM BIOPH RES CO, V214, P28, DOI 10.1006/bbrc.1995.2252; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; FREY M, 1994, J BIOL CHEM, V269, P12432; GEORGIADIS MM, 1992, SCIENCE, V92, P2499; Grimshaw J., 1981, CHEM SULPHONIUM GROU, P141; HARDER J, 1992, J BIOL CHEM, V267, P25548; Johnson DA, 1996, BIOCHEMISTRY-US, V35, P15846, DOI 10.1021/bi961370w; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MOSS ML, 1990, J BIOL CHEM, V265, P18112; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SODERMAN K, 1986, ANAL BIOCHEM, V152, P89, DOI 10.1016/0003-2697(86)90124-7; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577	32	131	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24216	24223		10.1074/jbc.272.39.24216	http://dx.doi.org/10.1074/jbc.272.39.24216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305874	hybrid			2022-12-25	WOS:A1997XY51500025
J	Benoist, F; Lau, P; McDonnell, M; Doelle, H; Milne, R; McPherson, R				Benoist, F; Lau, P; McDonnell, M; Doelle, H; Milne, R; McPherson, R			Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE PLASMA-MEMBRANES; HUMAN FAT-CELLS; APOPROTEIN-A-I; SCAVENGER RECEPTOR; SR-BI; MONOCLONAL-ANTIBODIES; REGIONAL VARIATION; ADRENAL-CELLS; MESSENGER-RNA; RAT	We have determined the role of cholesteryl ester transfer protein (CETP) in selective uptake of high density lipoprotein (HDL)-derived cholesteryl esters (CE) by human adipose tissue, using organ culture or collagenase-digested adipocytes, Incubation of the fresh tissue fragments with HDL containing [H-3]CE or I-125-apoprotein (apo) A-I resulted in significant uptake of HDL-CE-derived label. Addition of recombinant CETP (rCETP) increased CE uptake in a dose-response fashion, In contrast, little association of I-125-apoA-I with adipose tissue was noted, and addition of rCETP did not alter apoA-I uptake or degradation. Incubation of adipose tissue with TP2, an anti-CETP monoclonal antibody, which inhibits neutral lipid transfer, markedly reduced selective uptake of HDL-CE. Studies using human adipocytes isolated by collagenase digestion also demonstrated selective uptake of HDL-CE and enhancement of this process by rCETP. To confirm that the association of HDL-CE-derived radioactivity with adipose tissue was not due to neutral lipid exchange between adipocytes and HDL, we measured changes in HDL composition following incubation of HDL and rCETP with isolated adipocytes. A decreases in HDL-CE concentration in the medium was observed, an effect which was markedly attenuated when incubations were carried out in the presence of monoclonal antibody TP2. Furthermore, the decrease in HDL-CE was accompanied by an increase in HDL free cholesterol, likely representing efflux of adipocyte cholesterol to HDL. There were no significant changes in phospholipid, apoA-I, or apoA-II in the medium following incubation with adipocytes. These data demonstrate a novel and important role for CETP in selective uptake of HDL-cholesteryl esters by human adipocytes and suggest that this pathway may be of quantitative physiological significance in HDL remodeling and adipocyte cholesterol accumulation.	UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; University of Ottawa Heart Institute								Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANGEL A, 1979, CAN J BIOCHEM CELL B, V57, P578, DOI 10.1139/o79-073; ANGEL A, 1987, RECENT ADV OBES RES, P222; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONIFACINO JS, 1987, CURRENT PROTOCOLS MO, V3; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; DESPRES JP, 1988, AM J PHYSIOL, V254, pE667, DOI 10.1152/ajpendo.1988.254.5.E667; DESPRES JP, 1987, AM J PHYSIOL, V252, pE654, DOI 10.1152/ajpendo.1987.252.5.E654; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; FOLCH J, 1957, J BIOL CHEM, V226, P497; FONG BS, 1985, J CLIN INVEST, V75, P1804, DOI 10.1172/JCI111893; FONG BS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P53, DOI 10.1016/0005-2760(89)90212-9; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; HESLER CB, 1988, J BIOL CHEM, V263, P5020; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KRAEMER FB, 1994, J LIPID RES, V35, P1760; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72, DOI 10.1016/0005-2760(84)90240-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACALA LJ, 1983, J LIPID RES, V24, P1243; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MISRA KB, 1994, J BIOL CHEM, V269, P23838; Niemeier A, 1996, J LIPID RES, V37, P1733; PARKES JG, 1989, BIOCH CELL BIOL, V68, P870; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Radeau T, 1995, J LIPID RES, V36, P2552; RAJAN VP, 1988, BIOCHIM BIOPHYS ACTA, V959, P206, DOI 10.1016/0005-2760(88)90192-0; RINNINGER F, 1989, J BIOL CHEM, V264, P6111; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; Roy P, 1996, J LIPID RES, V37, P22; SALTER AM, 1987, EUR J CLIN INVEST, V17, P16, DOI 10.1111/j.1365-2362.1987.tb01220.x; Shen G. X., 1994, International Journal of Obesity, V18, P50; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Woollett LA, 1997, J CLIN INVEST, V99, P1704, DOI 10.1172/JCI119334; ZECHNER R, 1991, J BIOL CHEM, V266, P10583	44	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23572	23577		10.1074/jbc.272.38.23572	http://dx.doi.org/10.1074/jbc.272.38.23572			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295295	hybrid			2022-12-25	WOS:A1997XX38100020
J	Malkov, VA; Biswas, I; CameriniOtero, RD; Hsieh, P				Malkov, VA; Biswas, I; CameriniOtero, RD; Hsieh, P			Photocross-linking of the NH2-terminal region of Taq MutS protein to the major groove of a heteroduplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; ESCHERICHIA-COLI; MISMATCH REPAIR; MUTATION; HOMOLOG; IDENTIFICATION; CONTACT; RNA	The MutS DNA mismatch repair protein recognizes heteroduplex DNAs containing mispaired or unpaired bases, To identify regions of MutS protein in close proximity to the heteroduplex DNA, we have utilized the photoactivated cross-linking moiety 5-iododeoxyuridine (5-IdUrd), Nucleoprotein complexes of Thermus aquaticus MutS protein bound to monosubstituted 5-IdUrd-containing heteroduplex DNAs were cross-linked with long-wavelength ultraviolet light, Positioning of the 5-IdUrd moiety at one of three positions within the DNA bulge, two nucleotides upstream or three nucleotides downstream of the unpaired base, resulted in an identical subset of cross-linked peptides as determined by proteolytic fingerprinting, The tryptic peptide cross linked to an unpaired 5-IdUrd residue was determined by peptide sequencing to correspond to a highly conserved region spanning residues 25-49. Cross-linking to the bulge nucleotide occurred at Phe-39, indicating that this residue contacts, or is in close proximity to, the unpaired base of a heteroduplex DNA. Site-directed mutagenesis resulting in the substitution of Ala for Phe-39 reduced the affinity of the mutant protein for heteroduplex DNA by roughly 3 orders of magnitude, but had no apparent effect on its ability to dimerize, its thermostability, or its ATPase activity, These results implicate the region in the vicinity of Phe-39 as being crucial for heteroduplex DNA binding by Tag MutS protein.	NIDDK,GENET & BIOCHEM BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Biswas I, 1996, J BIOL CHEM, V271, P5040; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P311; CHODOSH LA, 1996, CURRENT PROTOCOLS MO, V12; Drapeau G R, 1976, Methods Enzymol, V45, P469; HICKE BJ, 1994, BIOCHEMISTRY-US, V33, P3364, DOI 10.1021/bi00177a030; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P2675, DOI 10.1093/nar/17.7.2675; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SU SS, 1988, J BIOL CHEM, V263, P6829; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369	21	86	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23811	23817		10.1074/jbc.272.38.23811	http://dx.doi.org/10.1074/jbc.272.38.23811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295328	hybrid			2022-12-25	WOS:A1997XX38100053
J	Misumi, Y; Sohda, M; Yano, A; Fujiwara, T; Ikehara, Y				Misumi, Y; Sohda, M; Yano, A; Fujiwara, T; Ikehara, Y			Molecular characterization of GCP170, a 170-kDa protein associated with the cytoplasmic face of the Golgi membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; BREFELDIN-A; SECRETORY PROTEINS; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GUANINE-NUCLEOTIDE; COATED VESICLES; COMPLEX; FUSION; CELLS	We have isolated a cDNA clone encoding a protein (designated GCP170) of 1530 amino acid residues with a calculated molecular mass of 170 kDa that is localized to the Golgi complex, Hydropathy analysis shows that GCP170 contains no NH2-terminal signal sequence nor a hydrophobic domain sufficient for participating in membrane localization. It is also predicted that GCP170 has characteristic secondary structures including an extremely long alpha-helical domain that likely forms a coiled-coil between non-coil domains at the NH2 and COOH termini, suggesting that the protein is organized as a globular head, a stalk, and a tail. Immunocytochemical observations revealed that GCP170 was localized to the Golgi complex and the cytoplasm, consistent with biochemical data indicating that the protein exits as a membrane-associated form and a soluble form. GCP170 was dissociated from the Golgi membrane in response to brefeldin A as rapidly as a coat protein complex of non-clathrin-coated vesicles (beta-COP, a subunit of coatomer), but did not co-localize with beta-COP on the Golgi membrane when examined by immunoelectron microscopy. The protein was detected as phosphorylated and unphosphorylated forms, of which the unphosphorylated form was more tightly associated with the Golgi membrane, When cells were extracted with 1% Triton X-100 under microtubule-stabilizing conditions, GCP170 remained in the cells in association with the Golgi complex. These results indicate that GCP170 is a peripheral membrane protein with a long coiled-coil domain that may be involved in the structural organization or stabilization of the Golgi complex.	FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,JONAN KU,FUKUOKA 81480,JAPAN	Fukuoka University								ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DEALMEIDA JB, 1993, J CELL SCI, V106, P1239; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; Funaki T, 1996, CELL STRUCT FUNCT, V21, P63, DOI 10.1247/csf.21.63; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1990, J BIOCHEM-TOKYO, V108, P230, DOI 10.1093/oxfordjournals.jbchem.a123185; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MISUMI Y, 1988, BIOCHEM J, V249, P661, DOI 10.1042/bj2490661; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	49	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23851	23858		10.1074/jbc.272.38.23851	http://dx.doi.org/10.1074/jbc.272.38.23851			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295333	hybrid			2022-12-25	WOS:A1997XX38100058
J	Pregel, MJ; Storer, AC				Pregel, MJ; Storer, AC			Active site titration of the tyrosine phosphatases SHP-1 and PTP1B using aromatic disulfides - Reaction with the essential cysteine residue in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; PHENYLARSINE OXIDE; SULFHYDRYL-GROUPS; PROTEIN; PURIFICATION; THIOL; PHOSPHORYLATION; INACTIVATION; EXCHANGE	Aromatic disulfides were found to inactivate truncated forms of the SHP-1 and PTP1B phosphatases by reaction with the essential active site cysteine residue. For truncated SHP-1 at pH 5.0, the reaction proceeded through an initial burst phase followed by a slower secondary phase. Our experiments demonstrated that the burst phase corresponded to the reaction of the aromatic disulfide with the active site cysteine. The magnitude of the burst phase was found to measure the active enzyme concentration, and the rate of the burst reflected the reactivity of the active site cysteine. The data were consistent with a mechanism in which an intramolecular disulfide is formed between the active site cysteine and a proximal cysteine during the burst reaction. Aromatic disulfides were found to react with the active site cysteines of full-length SHP-1 and truncated PTP1B also. Using vanadate to mask the active site cysteine, the active enzyme concentration could be assayed by comparing product yields for the reaction with aromatic disulfides in the presence and absence of vanadate at pH 8.0. These findings demonstrate the utility of aromatic disulfides as active site titrants and reactivity probes or tyrosine phosphatases.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,PHARMACEUT BIOTECHNOL SECTOR,MONTREAL,PQ H4P 2R2,CANADA	National Research Council Canada								BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Brocklehurst K., 1987, HYDROLYTIC ENZYMES, P39; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CASELLI A, 1994, J BIOL CHEM, V269, P24878; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FERSHT A, 1985, ENZYME STRUCTURE MEC, P143; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLASHNER M, 1972, J BIOL CHEM, V247, P8114; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; JOSHI S, 1981, J BIOL CHEM, V256, P1112; KORODI I, 1986, BIOCHEMISTRY-US, V25, P6895, DOI 10.1021/bi00370a024; KUSSMANN M, 1995, METHOD ENZYMOL, V251, P430, DOI 10.1016/0076-6879(95)51146-6; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; LI B, 1994, BIOCHEMISTRY-US, V33, P8594, DOI 10.1021/bi00194a026; LI J, 1995, BIOCHEMISTRY-US, V34, P15829, DOI 10.1021/bi00048a028; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1991, J BIOL CHEM, V266, P19688; Pregel MJ, 1995, PROTEIN ENG, V8, P1309, DOI 10.1093/protein/8.12.1309; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RIPPA M, 1978, ARCH BIOCHEM BIOPHYS, V186, P406, DOI 10.1016/0003-9861(78)90452-6; SEEHRA JS, 1981, EUR J BIOCHEM, V114, P263, DOI 10.1111/j.1432-1033.1981.tb05145.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Singh R, 1993, CHEM SULPHUR CONTAIN, P633; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TSOU C, 1962, SCI SINICA, V11, P1535; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	38	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23552	23558		10.1074/jbc.272.38.23552	http://dx.doi.org/10.1074/jbc.272.38.23552			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295292	hybrid			2022-12-25	WOS:A1997XX38100017
J	Mabuchi, K; Li, B; Ip, W; Tao, T				Mabuchi, K; Li, B; Ip, W; Tao, T			Association of calponin with desmin intermediate filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; CHICKEN GIZZARD; THIN-FILAMENTS; ACTIN-BINDING; CALMODULIN; CELLS; ACTOMYOSIN; PROTEINS; MYOSIN	Our previous immunoelectron microscopy studies of chicken gizzard smooth muscle cells showed that in certain areas the distribution of anti-calponin exhibits a high degree of overlap with beta-actin, filamin, and in particular, desmin, suggesting that in situ a fraction of calponin may be associated with intermediate filaments of the cytoskeleton. In this work we further explore this idea by studying the interaction between calponin and desmin. We found that at physiological salt concentrations, calponin bound only weakly to synthetic desmin intermediate filaments. On the other hand, calponin bound strongly to nonfilamentous desmin tetramers and was incorporated into intermediate filaments when the two proteins were mixed in a buffer containing 6 M urea and dialyzed into a buffer containing 0.15 M NaCl. Anti-calponin was found to label a portion of intermediate filaments and dense bodies isolated from gizzard tissues. Our findings suggest that in chicken gizzard smooth muscle cells, calponin may be an integral component of desmin intermediate filaments in the vicinity of dense bodies. Since calponin is also known to bind actin, we hypothesize that one of the functions of calponin might be to bridge intermediate filaments with actin in dense bodies.	UNIV CINCINNATI,COLL MED,DEPT ANAT CELL BIOL & NEUROBIOL,CINCINNATI,OH 45267; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	University System of Ohio; University of Cincinnati; Harvard University; Harvard Medical School; Tufts University	Mabuchi, K (corresponding author), BOSTON BIOMED RES INST,MUSCLE RES GRP,BOSTON,MA 02114, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR41637] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; BAGBY RM, 1990, ULTRASTRUCTURE SMOOT, P23; GIMONA M, 1996, BIOCH SMOOTH MUSCLE, P91; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LEHMAN W, 1989, BIOCHIM BIOPHYS ACTA, V996, P57, DOI 10.1016/0167-4838(89)90094-0; LI H, 1994, J CELL BIOL, V124, P287; MABUCHI H, 1996, J MUSCLE RES CELL M, V17, P243; MABUCHI K, 1990, J STRUCT BIOL, V103, P249, DOI 10.1016/1047-8477(90)90043-C; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; NAKA M, 1990, BIOCHEM BIOPH RES CO, V171, P933, DOI 10.1016/0006-291X(90)90773-G; NORTH AJ, 1994, J CELL SCI, V107, P445; NORTH AJ, 1994, J CELL SCI, V107, P437; SMALL JV, 1995, BIOESSAYS, V17, P785, DOI 10.1002/bies.950170908; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SOBIESZEK A, 1975, EUR J BIOCHEM, V55, P49, DOI 10.1111/j.1432-1033.1975.tb02137.x; STAFFORD WF, 1995, J BIOL CHEM, V270, P10576, DOI 10.1074/jbc.270.18.10576; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TSUKITA S, 1983, CELL TISSUE RES, V229, P233, DOI 10.1007/BF00214972; Wang PY, 1996, FEBS LETT, V392, P255, DOI 10.1016/0014-5793(96)00824-1; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1993, BIOCHEMISTRY-US, V32, P13327, DOI 10.1021/bi00211a046	27	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22662	22666		10.1074/jbc.272.36.22662	http://dx.doi.org/10.1074/jbc.272.36.22662			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278424	hybrid			2022-12-25	WOS:A1997XV49200044
J	Orchansky, PL; Ayres, SD; Hilton, DJ; Schrader, JW				Orchansky, PL; Ayres, SD; Hilton, DJ; Schrader, JW			An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; ALPHA-CHAIN; STIMULATING FACTOR; T-CELLS; HEMATOPOIETIC-CELLS; KINASE ACTIVATION; BINDING SUBUNIT; JANUS KINASE; BETA-SUBUNIT; B-CELLS	Interleukin (IL)-13 is a pleiotropic immunoregulatory cytokine that shares many, although not all, of the biological activities of IL-4. The overlapping biological properties of IL-4 and IL-13 appear to be due to the existence of shared components of the receptors, and we and others showed that the IL-4 receptor-alpha is involved in signal transduction paths activated by both. We show here that expression of the IL-13 receptor-alpha in two factor-dependent cell lines, the premyeloid FD5 and the T lymphoid CT4.S, conferred the ability to grow continuously in response to IL-13; to respond to IL-13 with tyrosine phosphorylation of JAK1, Tyk2, IL-4R alpha, IRS-2, and STAT6; and to respond to IL-4 with tyrosine phosphorylation of Tyk2 in addition to those induced in parental cell lines. Expression of a truncated IL-13 receptor-alpha that lacked the cytoplasmic domain demonstrated that this domain was essential for IL-13-dependent growth and phosphorylation of the above substrates. Expression of this truncated IL-13 receptor also resulted in an inhibition of biochemical and biological responses to IL-4 that was exacerbated by the presence of IL-13. These dominant inhibitory effects indicate that the extracellular domain of the truncated IL-13 receptor competes with gamma c for complexes of IL-4 and the IL-4 receptor-alpha, or, when itself bound to IL-13, competes with IL-4 for the IL-4 receptor-alpha.	ROYAL MELBOURNE HOSP,COOPERAT RES CTR CELLULAR GROWTH FACTORS,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Orchansky, PL (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER,BC V6T 1Z3,CANADA.		Hilton, Douglas J/C-7250-2013	Hilton, Douglas J/0000-0002-7698-2392				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; deGroot RP, 1997, J BIOL CHEM, V272, P2319; FOLTZ IN, 1997, BLOOD, V272, P3296; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; Hilton CJ, 1995, GROWTH FACTORS, V12, P263, DOI 10.3109/08977199509028965; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HU LJ, 1989, J IMMUNOL, V142, P800; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Jiang N, 1996, J BIOL CHEM, V271, P16472, DOI 10.1074/jbc.271.28.16472; KAMMER, 1996, J BIOL CHEM, V271, P23634; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; KUORO T, 1996, INT IMMUNOL, V8, P237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai SY, 1996, EMBO J, V15, P4506, DOI 10.1002/j.1460-2075.1996.tb00828.x; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Murata T, 1996, J IMMUNOL, V156, P2972; MURATA T, 1996, J BIOL CHEM, V270, P30829; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHRADER JW, 1986, P NATL ACAD SCI USA, V83, P2458, DOI 10.1073/pnas.83.8.2458; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	67	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22940	22947		10.1074/jbc.272.36.22940	http://dx.doi.org/10.1074/jbc.272.36.22940			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278458	hybrid			2022-12-25	WOS:A1997XV49200080
J	Sunahara, RK; Dessauer, CW; Whisnant, RE; Kleuss, C; Gilman, AG				Sunahara, RK; Dessauer, CW; Whisnant, RE; Kleuss, C; Gilman, AG			Interaction of G(s alpha) with the cytosolic domains of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PURIFICATION; FORSKOLIN; FORM	Forskolin-and G(s alpha)-stimulated adenylyl cyclase activity is observed after mixture of two independently-synthesized similar to 25-kDa cytosolic fragments derived from mammalian adenylyl cyclases (native M-r similar to 120,000), The C-1a domain from type V adenylyl cyclase (VC1) and the C-2 domain from type II adenylyl cyclase (IIC2) can both be expressed in large quantities and purified to homogeneity, When mixed, their maximally stimulated specific activity, 150 mu mol/min/mg protein, substantially exceeds values observed previously with the intact enzyme, A soluble, high-affinity complex containing one molecule each of VC1, IIC2, and guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S)-G(s alpha) is responsible for the observed enzymatic activity and can be isolated, In addition, GTP gamma S-G(s alpha) interacts with homodimers of IIC2 to form a heterodimeric complex (one molecule each of G(s alpha) and IIC2) but not detectably with homodimers of VC1, Nevertheless, G(s alpha) can be cross-linked to VC1 in the activated heterotrimeric complex of VC1, IIC2, and G(s alpha), indicating its proximity to both components of the enzyme that are required for efficient catalysis, These results and those in the accompanying report (Dessauer, C. W., Scully, T. T., and Gilman, A. G. (1997) J. Biol. Chem. 272, 22272-22277) suggest that activators of adenylyl cyclase facilitate formation of a single, high-activity catalytic site at the interface between C-1 and C-2.			Sunahara, RK (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.		Sunahara, Roger/AAJ-8667-2020; Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497, GM16905] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; LEE E, 1994, METHOD ENZYMOL, V237, P146; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; POLLET RJ, 1985, METHOD ENZYMOL, V117, P3; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941	16	149	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22265	22271		10.1074/jbc.272.35.22265	http://dx.doi.org/10.1074/jbc.272.35.22265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268375	hybrid			2022-12-25	WOS:A1997XT85000087
J	Witte, S; Krawinkel, U				Witte, S; Krawinkel, U			Specific interactions of the autoantigen L7 with multi-zinc finger protein ZNF7 and ribosomal protein S7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; CELL BIOLOGY; LOCALIZATION; SUBUNIT; SURFACE; IDENTIFICATION; AUTOANTIBODIES; EXPRESSION; ANTIBODIES; GENE	The eucaryotic protein L7, which associates with the large subunit of ribosomes, has been shown to be a major autoantigen in systemic autoimmune arthritis, The N terminus carries a sequence motif that is similar to the leucine zipper domain of eucaryotic transcription factors. This domain promotes the homodimerization of protein L7 through alpha helical coiled-coil formation and binds to distinct mRNAs, thereby inhibiting their cell-free translation, Using a yeast two-hybrid selection, we have identified from a Jurkat T lymphoma cDNA library ribosomal protein S7 and the multi-zinc finger protein ZNF7 as proteins that interact with protein L7, A fragment of L7 carrying the leucine zipper-like domain is fully sufficient to mediate these interactions, Their potential biological significance is indicated by low apparent dissociation constants of S7-L7 (15 x 10(-9) M) and, respectively, ZNF7-L7 (2 x 10(-9) M) complexes and co-immunoprecipitation of proteins S7, ZNF7, and L7 from a cell lysate with an anti-L7 antibody. We also show that ZNF7-like L7 and S7 can exist in a ribosome-bound form, This study provides further evidence suggesting that L7 is involved in translational regulation through interactions with components of the translational apparatus.			Witte, S (corresponding author), UNIV KONSTANZ, FAK BIOL, POSTFACH 5560, D-78434 CONSTANCE, GERMANY.							ANNILO T, 1995, GENE, V165, P297, DOI 10.1016/0378-1119(95)00576-R; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLEMIS EA, 1993, CURRENT PROTOCOLS MO, V3; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HADJIOLOV AA, 1985, CELL BIOL MONOGRAPH, V12; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMMERICH P, 1993, NUCLEIC ACIDS RES, V21, P223, DOI 10.1093/nar/21.2.223; Hemmerich P, 1997, EUR J BIOCHEM, V245, P549, DOI 10.1111/j.1432-1033.1997.00549.x; KISILEVSKY R, 1987, BIOCHIM BIOPHYS ACTA, V910, P282, DOI 10.1016/0167-4781(87)90121-7; LANIA L, 1990, GENOMICS, V6, P333, DOI 10.1016/0888-7543(90)90574-E; LIN A, 1987, J BIOL CHEM, V262, P12665; LIN A, 1991, FEBS LETT, V287, P121, DOI 10.1016/0014-5793(91)80030-7; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MARION MJ, 1987, BIOCHEM BIOPH RES CO, V149, P1077, DOI 10.1016/0006-291X(87)90518-3; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MUNDUS DA, 1993, MOL BIOL+, V27, P91; NEU E, 1995, CLIN EXP IMMUNOL, V100, P198; NEU E, 1997, IN PRESS ARTHRITIS R; Neumann F, 1997, EXP CELL RES, V230, P252, DOI 10.1006/excr.1996.3417; NEUMANN F, 1995, NUCLEIC ACIDS RES, V23, P195, DOI 10.1093/nar/23.2.195; NYGARD O, 1982, EMBO J, V1, P357, DOI 10.1002/j.1460-2075.1982.tb01174.x; STULTZ CM, 1993, PROTEIN SCI, V2, P305; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TSURUGI K, 1976, J BIOL CHEM, V251, P7940; VONMIKECZ A, 1994, IMMUNOBIOLOGY, V192, P137, DOI 10.1016/S0171-2985(11)80413-4; VONMIKECZ AH, 1995, CLIN EXP IMMUNOL, V100, P205; Witte S, 1996, J BIOL CHEM, V271, P18171, DOI 10.1074/jbc.271.30.18171; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101	38	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22243	22247		10.1074/jbc.272.35.22243	http://dx.doi.org/10.1074/jbc.272.35.22243			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268371	hybrid			2022-12-25	WOS:A1997XT85000083
J	Agarwal, ML; Agarwal, A; Taylor, WR; Wang, ZQ; Wagner, EF; Stark, GR				Agarwal, ML; Agarwal, A; Taylor, WR; Wang, ZQ; Wagner, EF; Stark, GR			Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase	ONCOGENE			English	Article						growth arrest; DNA damage; N-(phosphonacetyl)-L-aspartate; spindle checkpoint; mouse embryo fibroblasts	WILD-TYPE P53; DNA-BINDING FUNCTION; ANTISENSE RNA EXPRESSION; TUMOR-SUPPRESSOR PROTEIN; POLY(ADP-RIBOSE) POLYMERASE; GENE AMPLIFICATION; CYCLE CHECKPOINT; ATAXIA-TELANGIECTASIA; CELLULAR-RESPONSE; GENOMIC STABILITY	Poly-ADP-ribose polymerase (PARP) and p53 are bath induced by DNA damage and each has been proposed to mediate the normal cellular response to damage, We find that embryo fibroblasts from PARP-null mice have a similar to twofold lower basal level of p53 and that the induction of p53 in response to DNA damage or nucleotide depletion is more than twofold less than in normal mouse cells, These factors combine to decrease the induced level of the p53 protein in PARP-deficient cells by 4-5-fold, compared to normal cells, However, there is virtually no decrease in the induction of p53 activity in PARP-deficient cells, as assayed with a p53-responsive promoter, Furthermore, cells lacking PARP arrest normally in G(1) after DNA damage, in contrast to cells lacking p53, where this checkpoint is absent, Other p53-dependent properties, such as the mitotic spindle checkpoint and permissivity for gene amplification, are also normal in PARP-deficient cells, We conclude that the induced level of the p53 protein is governed by a combination of PARP-dependent and PARP-independent pathways and that the activation of p53 is largely PARP-independent, The results are consistent with a model in which the regulation of gene expression by p53 involves both increases in the amount of the protein and activation of p53 as a transcription factor.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195; INT AGCY RES CANC,F-69372 LYON 08,FRANCE; RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Cleveland Clinic Foundation; World Health Organization; International Agency for Research on Cancer (IARC); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Wagner, Erwin F/0000-0001-7872-0196	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DURKACZ BW, 1980, NATURE, V283, P595; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Harlow E., 1988, ANTIBODIES LAB MANUA; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; STEWART N, 1995, ONCOGENE, V10, P109; STRAIN AJ, 1985, EXP CELL RES, V159, P531, DOI 10.1016/S0014-4827(85)80026-4; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITACRE CM, 1995, CANCER RES, V55, P3697; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	54	84	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1035	1041		10.1038/sj.onc.1201274	http://dx.doi.org/10.1038/sj.onc.1201274			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285557				2022-12-25	WOS:A1997XT16100004
J	Leung, HY; Mehta, P; Gray, LB; Collins, AT; Robson, CN; Neal, DE				Leung, HY; Mehta, P; Gray, LB; Collins, AT; Robson, CN; Neal, DE			Keratinocyte growth factor expression in hormone insensitive prostate cancer	ONCOGENE			English	Article						kGF; FGF; FGFR isoform; alternative splicing; prostate cancer; paracrine loop	FACTOR RECEPTOR-1; FGF-RECEPTOR; CELLS; BINDING; ACTIVATION; ANDROGEN; CLONING	Cellular interactions between stroma and epithelium are important in the growth and proliferation of prostate cancer, Peptide growth factors may facilitate the progression of prostate cancer as autocrine and/or paracrine factors, Keratinocyte Growth Factor (KGF or FGF7) has a differentiative and proliferative effect on the epithelium of the developing rat prostate, We investigated if KGF may act as a paracrine agent in human prostate cancer and examined the expression of KGF and Fibroblast Growth Factor Receptors (FGFRs) (IIIb and IIIc isoforms of the FGFR1 and FGFR2 genes), Sixty-five percent (11 out of 17 informative cases) of prostate cancers (CaP) expressed KGF mRNA by RT-PCR, while KGF expression was not detected in benign prostatic hyperplasia (BPH) (n = 6), Upregulation of KGF expression was related to hormone insensitive tumours (P<0.05), Tumour grade and stage were not associated with KGF expression, The source of KGF expression was further characterised using an in vitro primary culture model, showing its restriction to the prostatic stroma, The FGFR1IIIb isoform was expressed in all cases of prostate cancer (n = 17), and FGFR1IIIc mRNA was not detected, In the BPH group, FGFR1IIIb transcripts were detected in four out of six cases, FGFR2IIIb expression was detected in five of six cases of BPH and twelve out of seventeen (71%) cases of prostate cancer, In CaP, though not reaching statistical significance, the persistence of FGFR2IIIb expression appeared to be associated with hormone insensitive tumours (P=0.052), FGFR2IIIc expression was present in eleven of seventeen tumours but was absent in all six cases of BPH. Functional assessment of recombinant KGF in a proliferation assay demonstrated a mitogenic effect of up to 100% on cultured prostatic epithelial cells.			Leung, HY (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Collins, Anne/A-8243-2008	Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086; Collins, Anne/0000-0002-2991-2703				Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; COLLINS AT, 1994, J ENDOCRINOL, V143, P269, DOI 10.1677/joe.0.1430269; CRUMLEY G, 1991, ONCOGENE, V6, P2255; CUNHA GR, 1983, RECENT PROG HORM RES, V39, P559; EISEMANN A, 1991, ONCOGENE, V6, P2379; EISEMANN A, 1991, ONCOGENE, V6, P1195; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HAMAGUCHI A, 1995, PROSTATE, V27, P141, DOI 10.1002/pros.2990270304; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LEUNG HY, 1994, INT J ONCOL, V4, P1219; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; Peehl DM, 1996, GROWTH REGULAT, V6, P22; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STORY MT, 1994, GROWTH FACTORS, V10, P269, DOI 10.3109/08977199409010993; Sugimura Y, 1996, INT J DEV BIOL, V40, P941; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	26	70	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1115	1120		10.1038/sj.onc.1201256	http://dx.doi.org/10.1038/sj.onc.1201256			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285567				2022-12-25	WOS:A1997XT16100014
J	Cuisset, L; Tichonicky, L; Jaffray, P; Delpech, M				Cuisset, L; Tichonicky, L; Jaffray, P; Delpech, M			The effects of sodium butyrate on transcription are mediated through activation of a protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; FLOW CYTOMETRIC DETECTION; OKADAIC ACID; HISTONE H1-DEGREES; MESSENGER-RNA; ANNEXIN-V; PHOSPHATIDYLSERINE EXPRESSION; CULTURED-CELLS; HEPATOMA-CELLS; TUMOR-CELLS	In this study we have investigated the molecular mechanism by which sodium butyrate modulates gene expression when added to cultured cells, As a model system we used hepatoma tissue culture cells in which sodium butyrate treatment increases histone H1 degrees mRNA level and decreases c-myc mRNA level. Because we observed that stimulation of histone H1 degrees gene expression could take place in the absence of protein neosynthesis, we hypothesized that sodium butyrate induced a posttranslational modification of a factor involved in the transcription process. Using different types Of well known kinase and phosphatase inhibitors, we studied the implication of kinase or phosphatase activity in this pathway. Interestingly, cell treatment with patent serine-threonine-phosphatase inhibitors, calyculin A or okadaic acid, prevented the regulation of both histone H1 degrees and c-myc gene expressions by sodium butyrate, On the other hand, the tyrosine phosphatase inhibitor, vanadate, or the protein kinase C inhibitor, staurosporine, did not significantly modify sodium butyrate effects. Using protein phosphatase I and 2A for in vitro assays, we found a 45% increase of phosphatase activity after cell treatment by sodium butyrate, possibly due to a protein phosphatase I-type protein phosphatase. These data strongly suggest that signaling pathway(s) triggered by sodium butyrate to modulate gene expression involve(s) a serine-threonine-phosphatase activity.	UNIV PARIS 05, ICGM,EA 1501,FAC MED COCHIN PORT ROYAL, LAB BIOL MOL CELLULES EUCARYOTES, F-75014 PARIS, FRANCE; HOP COCHIN, BIOCHIM LAB A, F-75014 PARIS, FRANCE	UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite								ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; BOHAN C, 1987, BIOCHEM BIOPH RES CO, V148, P899, DOI 10.1016/S0006-291X(87)80217-6; BOIX J, 1992, EXP CELL RES, V201, P531, DOI 10.1016/0014-4827(92)90306-S; BROCARD MP, 1994, EUR J BIOCHEM, V221, P421, DOI 10.1111/j.1432-1033.1994.tb18754.x; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DEXTER DL, 1981, DIFFERENTIATION, V18, P115, DOI 10.1111/j.1432-0436.1981.tb01111.x; DYSON JED, 1992, BRIT J CANCER, V65, P803, DOI 10.1038/bjc.1992.172; FRIEND C, 1987, CANCER RES, V47, P378; GIRARDOT V, 1994, EUR J BIOCHEM, V224, P885, DOI 10.1111/j.1432-1033.1994.00885.x; GOLUB EI, 1991, AIDS, V5, P663, DOI 10.1097/00002030-199106000-00004; GOPE R, 1993, CELL MOL BIOL, V39, P589; GORKA C, 1995, EXP CELL RES, V217, P528, DOI 10.1006/excr.1995.1118; GUPTA S, 1994, GROWTH FACTORS, V10, P171, DOI 10.3109/08977199409000235; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HENNEBERRY RC, 1976, EXP CELL RES, V103, P55, DOI 10.1016/0014-4827(76)90240-8; HERSHKO A, 1971, J BIOL CHEM, V246, P710; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; HERZ F, 1990, EXP CELL RES, V188, P50, DOI 10.1016/0014-4827(90)90276-G; HOCHHUTH C, 1990, DIFFERENTIATION, V43, P212, DOI 10.1111/j.1432-0436.1990.tb00448.x; HOCHHUTH C, 1992, J CELL BIOCHEM, V50, P316, DOI 10.1002/jcb.240500312; HOMBURG CHE, 1995, BLOOD, V85, P532; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KHOCHBIN S, 1993, GENE, V128, P173, DOI 10.1016/0378-1119(93)90560-P; KLUMPP S, 1990, EMBO J, V9, P685, DOI 10.1002/j.1460-2075.1990.tb08160.x; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KRESS H, 1986, NUCLEIC ACIDS RES, V14, P7189, DOI 10.1093/nar/14.18.7189; Kruh J., 1995, P275; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LEIBOVITCH MP, 1979, BIOCHEM BIOPH RES CO, V87, P896, DOI 10.1016/0006-291X(79)92042-4; MULLINS TD, 1991, PANCREAS, V6, P578, DOI 10.1097/00006676-199109000-00012; PANYIM S, 1969, BIOCHEM BIOPH RES CO, V37, P1042, DOI 10.1016/0006-291X(69)90237-X; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; ROUSSEAU D, 1992, EUR J BIOCHEM, V208, P775, DOI 10.1111/j.1432-1033.1992.tb17247.x; SADAIE MR, 1994, VIROLOGY, V202, P513, DOI 10.1006/viro.1994.1372; SAEMUNDSEN AK, 1980, VIROLOGY, V107, P557, DOI 10.1016/0042-6822(80)90326-8; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; THOMPSON EB, 1966, P NATL ACAD SCI USA, V56, P296, DOI 10.1073/pnas.56.1.296; TICHONICKY L, 1990, BIOL CELL, V69, P65, DOI 10.1016/0248-4900(90)90329-2; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VANWIJK R, 1981, IN VITRO CELL DEV B, V17, P859; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WRIGHT JA, 1973, EXP CELL RES, V78, P456, DOI 10.1016/0014-4827(73)90091-8; WRIGHT PS, 1986, ARCH BIOCHEM BIOPHYS, V248, P243, DOI 10.1016/0003-9861(86)90422-4; ZLATANOVA J, 1994, FASEB J, V8, P1260, DOI 10.1096/fasebj.8.15.8001738	50	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24148	24153		10.1074/jbc.272.39.24148	http://dx.doi.org/10.1074/jbc.272.39.24148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305863	hybrid			2022-12-25	WOS:A1997XY51500014
J	Gavva, NR; Gavva, R; Ermekova, K; Sudol, M; Shen, CKJ				Gavva, NR; Gavva, R; Ermekova, K; Sudol, M; Shen, CKJ			Interaction of WW domains with hematopoietic transcription factor p45/NF-E2 and RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE-EXPRESSION; PORPHOBILINOGEN DEAMINASE GENE; LOCUS-CONTROL REGION; FACTOR NF-E2; CHROMATIN STRUCTURE; ERYTHROID PROMOTER; IN-VIVO; PROTEIN; CELLS; PURIFICATION	NF-E2 is an erythroid-specific transcription factor required for expression of several erythroid-specific genes. By Far-Western blotting and yeast two-hybrid assay, we demonstrate that p45, the large subunit of NF-ES, is capable of binding to a specific set of WW domain containing proteins, including the ubiquitin ligase hRPF1. This binding is mediated through the interaction between the WW domains and a PY motif located within the amino-terminal region of p45. Interestingly, the carboxyl-terminal domain of mammalian RNA polymerase II binds a similar set of WW domains to which p45 interacts with. We discuss the data in terms of possible new pathways through which the processes of transcriptional regulation by NF-EB could be regulated in erythroid and megakaryote cells.	UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN	University of California System; University of California Davis; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Academia Sinica - Taiwan					NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NCI NIH HHS [CA01605, CA45757] Funding Source: Medline; NIDDK NIH HHS [DK29800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; ZHANG QY, 1995, J BIOL CHEM, V270, P8501, DOI 10.1074/jbc.270.15.8501; [No title captured]	42	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24105	24108		10.1074/jbc.272.39.24105	http://dx.doi.org/10.1074/jbc.272.39.24105			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305852	hybrid			2022-12-25	WOS:A1997XY51500003
J	Jho, EH; Davis, RJ; Malbon, CC				Jho, EH; Davis, RJ; Malbon, CC			c-Jun amino-terminal kinase is regulated by G alpha(12)/G alpha(13) and obligate for differentiation of P19 embryonal carcinoma cells by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; SIGNAL-TRANSDUCTION PATHWAY; MAMMALIAN-CELLS; DROSOPHILA; APOPTOSIS; JNK; TRANSFORMATION; MORPHOGENESIS; G-ALPHA(12); CASCADE	Retinoic acid induces P19 mouse embryonal carcinoma cells to differentiate to endoderm and increases expression of the heterotrimeric G-protein subunits G alpha(12) and G alpha(13). Retinoic acid was found to induce differentiation and sustained activation of c-Jun amino-terminal kinase, but not of ERK1,S or of p38 mitogen-activated protein kinases. Much like retinoic acid, expression of constitutively active forms of G alpha(12) and G alpha(13) induced differentiation and constitutive activation of c-Jun amino-terminal kinase. Expression of the dominant negative form of c-Jun amino-terminal kinase 1 blocked both the activation of c-Jun amino-terminal kinase and the induction of endodermal differentiation in the presence of retinoic acid. These data implicate c-Jun amino-terminal kinase as a downstream element of activation of G alpha(12) or G alpha(13) obligate for re0inoie acid-induced differentiation.	SUNY STONY BROOK, MED CTR,DEPT MOL PHARMACOL,SCH MED, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA; UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, WORCESTER, MA 01605 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			malbon, craig/ABF-3604-2020	Jho, Eek-hoon/0000-0003-2414-6234	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; GRAHAM CF, 1978, NATURE, V272, P355; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Heasley LE, 1996, MOL CELL BIOL, V16, P648; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malbon CC, 1997, BIOCHEM PHARMACOL, V53, P1, DOI 10.1016/S0006-2952(96)00662-4; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RINCON M, 1997, GENES FUNCT, V1, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	47	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24468	24474		10.1074/jbc.272.39.24468	http://dx.doi.org/10.1074/jbc.272.39.24468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305908	hybrid			2022-12-25	WOS:A1997XY51500059
J	Lin, BZ; Pilch, PF; Kandror, KV				Lin, BZ; Pilch, PF; Kandror, KV			Sortilin is a major protein component of Glut4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED PROTEIN; GLUCOSE-TRANSPORT; 3T3-L1 PREADIPOCYTES; CELL-SURFACE; AMINOPEPTIDASE; TRAFFICKING; COMPARTMENT; EXPRESSION; INDUCTION; TISSUES	In fat and skeletal muscle cells, glucose transporter isoform 4 (Glut4) is translocated to the cell surface in response to insulin via a system of specialized recycling vesicles, Besides Glut4, these vesicles include the novel insulin-regulatable aminopeptidase, receptors for insulin-like growth factor-II/Man-6-phosphate and transferrin, and a glycoprotein with the molecular mass of 110 kDa. We report here by the criteria of the partial protein sequencing and subsequent cDNA cloning that glycoprotein 110, the last unidentified major protein component of Glut4-containing vesicles, is sortilin, a novel type I receptor-like protein recently cloned from human brain (Petersen, C, M,, Nielsen, M. S., Nykjar, A., Jacobsen, L,, Tommerup, N,, Rasmussen, H, H,, Roigaard, H,, Gliemann, J,, Madsen, P,, and Moestrup, S. K, (1997) J, Biol, Chen, 272, 3599-3605), This protein is highly expressed in fat, brain, and lung and is dramatically up-regulated during differentiation of adipocytes in vitro.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Pilch, Paul/0000-0003-1997-0499; Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036424, R01DK030425] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30425, R29DK52057, DK 36424] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kandror KV, 1996, SEMIN CELL DEV BIOL, V7, P269, DOI 10.1006/scdb.1996.0035; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	21	99	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24145	24147		10.1074/jbc.272.39.24145	http://dx.doi.org/10.1074/jbc.272.39.24145			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305862	hybrid			2022-12-25	WOS:A1997XY51500013
J	Schechter, NM; Plotnick, M; Selwood, T; Walter, M; Rubin, H				Schechter, NM; Plotnick, M; Selwood, T; Walter, M; Rubin, H			Diverse effects of pH on the inhibition of human chymase by serpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; PLASMA PROTEINASE-INHIBITORS; 2-STEP REACTION-MECHANISM; ALPHA-1-PROTEINASE INHIBITOR; NEUTROPHIL ELASTASE; ALPHA-CHYMOTRYPSIN; ANTITHROMBIN-III; CENTER LOOP; THROMBIN; HEPARIN	Inhibition of human chymase by the serpins alpha(1)-antichymotrypsin (ACT) and alpha(1)-proteinase inhibitor (PI) at pH 8.0 produces a complex stable to dissociation by SDS/dithiothreitol and a second product, hydrolyzed/inactivated serpin, The first product is the presumed trapped acyl-enzyme complex typical of serpin inhibition, and the second is the result of a concurrent substrate-like reaction, As a result of the hydrolytic reaction, stoichiometries of inhibition (SI) appear greater than 1; values of 4 and 6.0 are observed for the chymase-ACT and -PI reactions, In this study the effect of pH on the inhibition rate constant (k(inh)) and the SI of each reaction were evaluated to better define the rate-limiting steps of the inhibitory and hydrolytic reaction pathways associated with chymase inhibition, Reactions were evaluated over a pH range to correlate k(inh) and SI with the ionizations (pK values of 7 and 9) that typically regulate serine protease catalytic activity, The results show that the effects of pH on SI and k(?inh), differ for each inhibitor, On reducing the pH from 8.0 to 5.5, the chymase-ACT reaction exhibited a decrease in SI (to about 1) and little change in k(inh) whereas the chymase PI reaction revealed an increase in SI and a marked decrease in k(inh). On increasing the pH from 8.0 to 10.0, the chymase-ACT reaction exhibited little change in SI and a marked decrease in k(inh) whereas the chymase-PI reaction revealed a decrease in SI and a marked increase in k(inh). Chymase catalytic properties determined for a peptide substrate were atypical over the high pH range exhibiting increases for k(cat)/K-m and k(cat) and decreases for K-m. This behavior suggests the presence of a high pH enzyme form with enhanced hydrolytic activity. From these results and others involving analyses of ACT/PI reactive loop chimeras and ACT point variants exhibiting a range of SI values, we suggest that the diverse pH effects on k(inh) and SI are caused largely by a difference in the abilities of ACT and PI to interact with low (catalytically inactive) and high (catalytically enhanced) pH forms of chymase, The constancy of k(inh) for the chymase-ACT reaction over the low pH range suggests that the rate-limiting step for inhibition is pH insensitive and not reflective of diminished chymase hydrolytic activity, Low pH did not appear to affect the rate of SDS-stable complex formation as complex accumulation, assessed qualitatively by SDS-PAGE, correlated with the loss of chymase enzymatic activity.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Schechter, NM (corresponding author), UNIV PENN,DEPT DERMATOL,CLIN RES BLDG,415 CURIE BLVD,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL50523] Funding Source: Medline; NIAMS NIH HHS [AR42931] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042931] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BJORK I, 1982, J BIOL CHEM, V257, P9487; BOSWELL DR, 1983, BIOCHIM BIOPHYS ACTA, V744, P212, DOI 10.1016/0167-4838(83)90093-6; BRUCH M, 1989, BIOCHEM J, V259, P929, DOI 10.1042/bj2590929; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; CARRELL RW, 1986, RES MONOGRAPHS CELL, V12, P403; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; ELLIOT PR, 1996, NAT STRUCT BIOL, V8, P676; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P33; KNIGHT CG, 1986, RES MONOGR CELL TISS, V12, P23; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIJNEN HR, 1991, J BIOL CHEM, V266, P4041; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MCCONN J, 1969, J MOL BIOL, V39, P551, DOI 10.1016/0022-2836(69)90145-4; MORII M, 1979, J BIOCHEM, V86, P915, DOI 10.1093/oxfordjournals.jbchem.a132623; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; POLGAR L, 1989, MECHANISMS PROTEASE, P87; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHECHTER NM, 1995, CL ALLER IM, V6, P47; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WANG ZM, 1995, BIOL CHEM H-S, V376, P681; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652	44	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24499	24507		10.1074/jbc.272.39.24499	http://dx.doi.org/10.1074/jbc.272.39.24499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305913	hybrid			2022-12-25	WOS:A1997XY51500064
J	Modarress, KJ; Opoku, J; Xu, M; Sarlis, NJ; Simons, SS				Modarress, KJ; Opoku, J; Xu, M; Sarlis, NJ; Simons, SS			Steroid-induced conformational changes at ends of the hormone-binding domain in the rat glucocorticoid receptor are independent of agonist versus antagonist activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; RETINOIC ACID RECEPTOR; LONG TERMINAL REPEAT; HEPATOMA-CELL LINES; ESTROGEN-RECEPTOR; DEXAMETHASONE 21-MESYLATE; NUCLEAR RECEPTORS; GENE-EXPRESSION; MODULATORY ELEMENT; FUNCTIONAL-GROUP	The underlying molecular mechanism for the expression of agonist versus antagonist activity for a given receptor-steroid complex is still not known. One attractive hypothesis, based on data from progesterone receptors, is that agonist versus antagonist binding induces unique conformations at the C terminus of receptors, which can be detected by the different fragments produced by partial proteolysis. We now report that the determinants of glucocorticoid receptor (GR)-antagonist complex activity are more complex, Steroid binding did cause a conformational change in the GR that was detected by partial trypsin digestion, as described previously (Simons, S. S., Jr., Sistare, F. D., and Chakraborti, P. K. (1989) J. Biol. Chem. 264, 14493-14497). However, there was no uniformity in the digestion patterns of unactivated or activated receptors bound by a series of six structurally different antagonists including the affinity labeling antiglucocorticoid dexamethasone 21-mesylate, A total of four resistant bands were observed on SDS-polyacrylamide gels in the range of 30-27 kDa. Using a series of point mutations and epitope-specific antibodies, it was determined that the 30-kDa species represented the entire C-terminal sequence of amino acids 518-795, whereas the other bands arose from additional N-terminal and/or C-terminal cleavages, Bioassays with GRs containing various point and deletion mutations failed to reveal any C-terminal alterations that could convert antagonists into biologically active agonists, Thus, the presence or absence of C-terminal amino acids of the GR did not uniquely determine either the appearance of smaller trypsin-resistant fragments or the nature of the biological response of receptor-bound antisteroids. When compared with the current model of the ligand-binding domain, which is based on the x-ray structures of the comparable region of thyroid and retinoic acid receptors, the present results suggest that sequences outside of the model structure are relevant for the binding and biological activity of GRs.	NIDDK,STEROID HORMONES SECT,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sarlis, Nicholas/AAN-9444-2020					ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Allan GF, 1996, MOL ENDOCRINOL, V10, P1206, DOI 10.1210/me.10.10.1206; Arnold SF, 1996, SCIENCE, V272, P1489, DOI 10.1126/science.272.5267.1489; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BOEQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; Collier CD, 1996, MOL ENDOCRINOL, V10, P463, DOI 10.1210/me.10.5.463; DECASTRO M, 1996, MOL MED, V2, P567; DELABRE K, 1993, P NATL ACAD SCI USA, V90, P4421, DOI 10.1073/pnas.90.10.4421; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FLACH H, 1992, J STEROID BIOCHEM, V42, P467, DOI 10.1016/0960-0760(92)90258-K; GRAVANIS A, 1985, J CLIN ENDOCR METAB, V60, P156, DOI 10.1210/jcem-60-1-156; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; HOECK W, 1989, J BIOL CHEM, V264, P14396; KASPER CB, 1975, MOL BIOL BIOCH BIOPH, V8, P114; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; LAMONTAGNE N, 1984, ENDOCRINOLOGY, V114, P2252, DOI 10.1210/endo-114-6-2252; Lamour FPY, 1996, MOL CELL BIOL, V16, P5386; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Martinez E, 1997, NUCLEIC ACIDS RES, V25, P163, DOI 10.1093/nar/25.1.163; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MILLER PA, 1988, ENDOCRINOLOGY, V122, P2990, DOI 10.1210/endo-122-6-2990; MILLER PA, 1984, BIOCHEMISTRY-US, V23, P6883, DOI 10.1021/bi00321a093; MODARRESS KJ, 1994, J BIOL CHEM, V269, P25621; Newling DWW, 1996, BRIT J UROL, V77, P776, DOI 10.1046/j.1464-410X.1996.00052.x; OJASOO T, 1988, J MED CHEM, V31, P1160, DOI 10.1021/jm00401a015; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; Parczyk K, 1996, J CANCER RES CLIN, V122, P383, DOI 10.1007/BF01212877; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; PRATT WB, 1997, IN PRESS ENDOCR REV; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1979, BIOCHEM BIOPH RES CO, V86, P793, DOI 10.1016/0006-291X(79)91782-0; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; Simons SS, 1996, SCIENCE, V272, P1451, DOI 10.1126/science.272.5267.1451; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1987, STEROID STEROL HORMO, P251; SIMONS SS, 1997, IN PRESS MOL BIOL ST; SIMONS SS, 1994, VITAM HORM, V48, P49; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SUNDSTROM SA, 1990, ENDOCRINOLOGY, V126, P1449, DOI 10.1210/endo-126-3-1449; SVEC F, 1989, ENDOCRINOLOGY, V125, P3103, DOI 10.1210/endo-125-6-3103; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; TRAPP T, 1995, BIOCHEM BIOPH RES CO, V215, P286, DOI 10.1006/bbrc.1995.2464; TUNG L, 1993, MOL ENDOCRINOL, V7, P1257; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Wagner BL, 1996, P NATL ACAD SCI USA, V93, P8739, DOI 10.1073/pnas.93.16.8739; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; WEAVER CA, 1988, MOL ENDOCRINOL, V2, P936, DOI 10.1210/mend-2-10-936; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P1585, DOI 10.1210/me.6.10.1585; WILSON JD, 1996, GOODMAN GILMANS PHAR, P1441; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; ZENG ZM, 1994, ENDOCRINOLOGY, V135, P248, DOI 10.1210/en.135.1.248; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	74	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23986	23994		10.1074/jbc.272.38.23986	http://dx.doi.org/10.1074/jbc.272.38.23986			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295350	hybrid			2022-12-25	WOS:A1997XX38100075
J	Thyagarajan, B; Campbell, C				Thyagarajan, B; Campbell, C			Elevated homologous recombination activity in Fanconi anemia fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; DNA-REPAIR; PLASMID RECOMBINATION; RAD51 PROTEIN; SOMATIC-CELLS; CROSS-LINKS; COMPLEMENTATION	It is widely believed that Fanconi anemia cells possess a reduced ability to repair inter-strand DNA cross-links. While the mechanism through which inter-strand DNA cross-links are removed from mammalian chromosomes is unknown, these lesions ape repaired via homologous recombination in lower eukaryotes and bacteria. Based on the hypothesis that a similar mechanism of DNA repair functions in mammalian somatic cells, we measured homologous recombination activity in diploid fibroblasts from healthy donors, and Fanconi anemia patients. Somewhat surprisingly, homologous recombination levels in nuclear protein extracts prepared from Fanconi anemia cells were nearly 100-fold higher than in extracts prepared from control cells. We observed a similar increase in the activity of a 100-kDa homologous DNA pairing protein in extracts from Fanconi anemia cells. Transfection studies confirmed that plasmid homologous recombination levels in intact Fanconi anemia cells were substantially elevated, compared with control cells. These results suggest that inappropriately elevated levels of homologous recombination activity may contribute to the genomic instability and cancer predisposition that characterize Fanconi anemia.	UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [R29CA061906] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1970, J VIROL, V6, P470, DOI 10.1128/JVI.6.4.470-475.1970; AARONSON SA, 1968, VIROLOGY, V36, P253; ABE H, 1994, ANTICANCER RES, V14, P1807; AKHMEDOV AT, 1995, P NATL ACAD SCI USA, V92, P1729, DOI 10.1073/pnas.92.5.1729; AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; BENDIXEN C, 1994, GENOMICS, V23, P300, DOI 10.1006/geno.1994.1503; BERTRAND P, 1993, NUCLEIC ACIDS RES, V21, P3653, DOI 10.1093/nar/21.16.3653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EMERIT I, 1995, HUM GENET, V96, P14, DOI 10.1007/BF00214180; *FANC AN BREAST CA, 1996, NAT GENET, V14, P324; FINN GK, 1989, MOL CELL BIOL, V9, P4009, DOI 10.1128/MCB.9.9.4009; GLANZ A, 1982, J MED GENET, V19, P412, DOI 10.1136/jmg.19.6.412; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HANG B, 1993, NUCLEIC ACIDS RES, V21, P4187, DOI 10.1093/nar/21.18.4187; HELLGREN D, 1992, MUTAT RES, V284, P37, DOI 10.1016/0027-5107(92)90023-U; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; JEONGYU SJ, 1992, MOL CELL BIOL, V12, P112, DOI 10.1128/MCB.12.1.112; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Johnson BL, 1996, MUTAT RES-DNA REPAIR, V363, P179, DOI 10.1016/0921-8777(96)00007-9; KEOWN W, 1989, METHOD ENZYMOL, V185, P527; KUCHERLAPATI R, 1988, BIOCH ASPECTS HOMOLO, P575; KUCHERLAPATI RS, 1984, P NATL ACAD SCI-BIOL, V81, P3153, DOI 10.1073/pnas.81.10.3153; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LIN FLM, 1990, MOL CELL BIOL, V10, P113, DOI 10.1128/MCB.10.1.113; Liu JM, 1996, BIOCHEM BIOPH RES CO, V223, P685, DOI 10.1006/bbrc.1996.0956; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; McANulty MM, 1996, MUTAT RES-DNA REPAIR, V362, P75, DOI 10.1016/0921-8777(95)00037-2; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PAPADOPOULO D, 1987, MUTAT RES, V184, P271, DOI 10.1016/0167-8817(87)90026-5; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RAUTH S, 1986, P NATL ACAD SCI USA, V83, P5587, DOI 10.1073/pnas.83.15.5587; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; ROUSSET S, 1990, CANCER RES, V50, P2443; SALLES B, 1994, TOXICOLOGY, V93, P235, DOI 10.1016/0300-483X(94)90081-7; SEIDMAN MM, 1987, MOL CELL BIOL, V7, P3561, DOI 10.1128/MCB.7.10.3561; SHEN ZY, 1995, GENOMICS, V25, P199, DOI 10.1016/0888-7543(95)80126-7; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SINDEN RR, 1978, P NATL ACAD SCI USA, V75, P2373, DOI 10.1073/pnas.75.5.2373; SINDEN RR, 1978, J BACTERIOL, V136, P538, DOI 10.1128/JB.136.2.538-547.1978; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SYMINGTON LS, 1983, CELL, V35, P805, DOI 10.1016/0092-8674(83)90113-7; Thyagarajan B, 1996, NUCLEIC ACIDS RES, V24, P4084, DOI 10.1093/nar/24.20.4084; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; Thyagarajan B, 1996, SOMAT CELL MOLEC GEN, V22, P31, DOI 10.1007/BF02374374; TIMME TL, 1989, PLASMID, V22, P1, DOI 10.1016/0147-619X(89)90030-9; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; YOUNG D, 1971, LANCET, V1, P294	55	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23328	23333		10.1074/jbc.272.37.23328	http://dx.doi.org/10.1074/jbc.272.37.23328			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287344	hybrid			2022-12-25	WOS:A1997XV74400055
J	McKinsey, TA; Chu, ZL; Ballard, DW				McKinsey, TA; Chu, ZL; Ballard, DW			Phosphorylation of the PEST domain of I kappa B beta regulates the function of NF-kappa B/I kappa B beta complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1; C-FOS; EXPRESSION; ACTIVATION; PROTEINS; ENCODES; IDENTIFICATION; SUBUNIT; PRODUCT; CLONING	Activation of transcription factor NF-kappa B involves the signal-dependent degradation of basally phosphorylated inhibitors such as I kappa B alpha and I kappa B beta. The gene encoding I kappa B alpha is under NF-kappa B control, which provides a negative feedback loop to terminate the induced NF-kappa B response, However, recent studies have identified a hypophosphorylated pool of I kappa B beta that shields nuclear NF-kappa B from inhibition by newly synthesized I kappa B alpha. In the present work, we provide three lines of evidence indicating that this protection mechanism is regulated by the C-terminal PEST domain of I kappa B beta. First, disruption of two basal phosphoacceptors present in the I kappa B beta PEST domain (Ser-313 and Ser-315) yields a mutant that forms ternary complexes with NF-kappa B and its target DNA-binding site. Second, based on in vitro mixing experiments, these ternary complexes are resistant to the inhibitory action of I kappa B alpha. Third, mutants of I kappa B beta that are defective for phosphorylation at Ser-313 and Ser-315 fail to efficiently block NF-kappa B-directed transcription in vivo, whereas replacement of these two I kappa B beta residues with a phosphoserine mimetic generates a fully functional repressor, Taken together, our findings suggest that the functional fate of NF-kappa B when bound to I kappa B beta is critically dependent on the phosphorylation status of the I kappa B beta PEST domain.	VANDERBILT UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033839] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33839] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LINK E, 1992, J BIOL CHEM, V267, P239; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1	25	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22377	22380		10.1074/jbc.272.36.22377	http://dx.doi.org/10.1074/jbc.272.36.22377			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278383	hybrid			2022-12-25	WOS:A1997XV49200002
J	Nakagawa, N; Masui, R; Kato, R; Kuramitsu, S				Nakagawa, N; Masui, R; Kato, R; Kuramitsu, S			Domain structure of Thermus thermophilus UvrB protein - Similarity in domain structure to helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI UVRB; CRYSTAL-STRUCTURE; ATPASE ACTIVITY; RECA PROTEIN; PREINCISION COMPLEX; UVRABC ENDONUCLEASE; MICROCOCCUS-LUTEUS; EXCISION-REPAIR; DNA; GENE	UvrB protein plays an essential role in the prokaryotic excision repair system. UvrB protein shows cryptic ATPase activity, DNA binding, helicase-like activity, and incision activity by interacting with UvrA or UvrC proteins. To reveal the Structure-function relationship of this multifunctional protein, the domain structure of Thermus thermophilus UvrB protein (ttUvrB) was studied by limited proteolysis and denaturation experiments. Proteolytic profiles indicated that ttUvrB consists of four domains: the N domain (residues 2-105), M domain (106-455), C1 domain (456-590), and C2 domain (591-665). The properties of the proteolytic fragments indicated the involvement of the respective domains in the functions of the protein as follows: the N and C1 domains are necessary for ATPase activity, the C1 domain is indispensable for DNA binding, and the N and/or M domains are involved in UvrA binding. The structural stability of the C1 and C2 domains was higher than that of the N and M domains, which supports the proposed domain nature of ttUvrB. Based on these results and the crystal structure of PcrA helicase (Subramanya, H. S., Bird, L. E., Brannigan, J. A., and Wigley, D. B. (1996) Nature 384, 379-383), the domain organization of ttUvrB was proposed.	OSAKA UNIV, DEPT BIOL, GRAD SCH SCI, TOYONAKA, OSAKA 560, JAPAN	Osaka University				Kato, Ryuichi/0000-0003-2087-2896				ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BLACK CG, 1995, J BACTERIOL, V177, P1952, DOI 10.1128/jb.177.8.1952-1958.1995; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10903, DOI 10.1093/nar/16.22.10903; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRIEDBERG EC, 1995, DNA REPAIR; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; KATO R, 1993, J BIOCHEM-TOKYO, V114, P926, DOI 10.1093/oxfordjournals.jbchem.a124278; Kato R, 1996, J BIOL CHEM, V271, P9612, DOI 10.1074/jbc.271.16.9612; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATSUBARA H, 1966, ARCH BIOCHEM BIOPHYS, V115, P324, DOI 10.1016/0003-9861(66)90282-7; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; Ptitsyn Oleg B., 1992, P243; PUGH BF, 1988, J BIOL CHEM, V263, P76; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SHIOTA S, 1988, MOL GEN GENET, V213, P21, DOI 10.1007/BF00333393; SICARD N, 1992, J BACTERIOL, V174, P2412, DOI 10.1128/JB.174.7.2412-2415.1992; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; Yamamoto N, 1996, GENE, V171, P103, DOI 10.1016/0378-1119(96)00052-2; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22703	22713		10.1074/jbc.272.36.22703	http://dx.doi.org/10.1074/jbc.272.36.22703			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278428	hybrid			2022-12-25	WOS:A1997XV49200049
J	Booher, RN; Holman, PS; Fattaey, A				Booher, RN; Holman, PS; Fattaey, A			Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DEPENDENT KINASES; FISSION YEAST; HELA-CELLS; G2 ARREST; ACTIVATION; P34CDC2; PROTEIN; WEE1; THREONINE-14	Activation of the Cdc2.cyclin B kinase is a pivotal step of mitotic initiation. This step is mediated principally by the dephosphorylation of residues threonine 14 (Thr(14)) and tyrosine 15 (Tyr(15)) on the Cdc2 catalytic subunit, In several organisms homologs of the Wee1 kinase have been shown to be the major activity responsible for phosphorylating the Tyr(15) inhibitory site, A membrane-bound kinase capable of phosphorylating residue Thr(14), the Myt1 kinase, has been identified in the frog Xenopus laevis and more recently in human. In this study, we have examined the substrate specificity and cell cycle regulation of the human Myt1 kinase, We find that human Myt1 phosphorylates and inactivates Cdc2-containing cyclin complexes but not complexes containing Cdk2 or Cdk4. Analysis of endogenous Myt1 demonstrates that it remains membrane-bound throughout the cell cycle, but its kinase activity decreased during M phase arrest, when Myt1 became hyperphosphorylated, Further, Cdc2.cyclin B1 was capable of phosphorylating Myt1 in vitro, but this phosphorylation did not affect Myt1 kinase activity, These findings suggest that human Myt1 is negatively regulated by an M phase-activated kinase and that Myt1 inhibits mitosis due to its specificity for Cdc2.cyclin complexes.			Booher, RN (corresponding author), ONYX PHARMACEUT, 3031 RES DR, RICHMOND, CA 94806 USA.							ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CAMPBELL SD, 1995, MOL BIOL CELL, V6, P1333, DOI 10.1091/mbc.6.10.1333; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HONDA R, 1995, CHROMOSOME RES, V3, P300, DOI 10.1007/BF00713068; Iavarone A, 1997, NATURE, V387, P417; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LOCK RB, 1990, CANCER RES, V50, P3761; Matsuura I, 1996, J BIOL CHEM, V271, P5443, DOI 10.1074/jbc.271.10.5443; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	39	218	224	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22300	22306		10.1074/jbc.272.35.22300	http://dx.doi.org/10.1074/jbc.272.35.22300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268380	hybrid			2022-12-25	WOS:A1997XT85000092
J	Boronat, S; RichardFoy, H; Pina, B				Boronat, S; RichardFoy, H; Pina, B			Specific deactivation of the mouse mammary tumor virus long terminal repeat promoter upon continuous hormone treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; RECEPTOR MESSENGER-RNA; DOWN-REGULATION; CHROMATIN STRUCTURE; MMTV PROMOTER; IN-VIVO; GLUCOCORTICOID RESPONSIVENESS; POSITIONED NUCLEOSOMES; METALLOTHIONEIN-I; DNA	We have studied the transcriptional behavior of the mouse mammary tumor virus long repeat (MMTV-LTR) promoter during a prolonged exposure to glucocorticoids. When integrated into XC derived cells, MMTV-LTR expression reached its maximum during the first day of dexamethasone treatment, but longer exposure to the hormone resulted in the deactivation of the promoter. In contrast, glucocorticoid-responsive resident genes or MMTV-based transiently transfected plasmids maintained or even increased their mRNA levels during the same period of hormone treatment. An integrated chimeric construct containing the hormone-responsive elements from MMTV-LTR but in different sequence context became also deactivated after a prolonged hormone treatment but with a deactivation kinetics significantly slower than constructs containing the entire, chromatin-positioning MMTV-LTR sequence. The decrease on MMTV-LTR-driven transcription was concomitant with a parallel closure of the MMTV LTR chromatin and with a decrease in glucocorticoid receptor (GR) concentration in the cell. We concluded that the chromatin-organized MMTV-LTR promoter is particularly sensitive to any decrease on GR levels. We propose that chromatin structure may contribute decisively to the differential expression of MMTV-LTR by two mechanisms: limiting MMTV-LTR accessibility to activating transcription factors and accelerating its shutting down upon a decrease on GR levels.	CSIC,CID,DEPT MOL & CELLULAR BIOL,ES-08034 BARCELONA,SPAIN; CNRS,UPR 9006,LAB BIOL MOL EUCARYOTES,F-31062 TOULOUSE,FRANCE	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); Centre National de la Recherche Scientifique (CNRS)			Boronat, Susanna/H-5428-2015; Piña, Benjamin/A-1671-2011	Boronat, Susanna/0000-0003-1745-1556; Piña, Benjamin/0000-0001-9216-2768				ADOM J, 1991, J STEROID BIOCHEM, V40, P325, DOI 10.1016/0960-0760(91)90198-E; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; ARCHER TK, 1995, J STEROID BIOCHEM, V53, P421, DOI 10.1016/0960-0760(95)00088-H; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1753; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BEATO M, 1990, MOL ASPECTS CELLULAR, P287; BELLINGHAM DL, 1992, MOL ENDOCRINOL, V6, P2090, DOI 10.1210/me.6.12.2090; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KIMURA G, 1972, VIROLOGY, V49, P394, DOI 10.1016/0042-6822(72)90492-8; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAYO KE, 1981, J BIOL CHEM, V256, P2621; MCINTYRE WR, 1985, J BIOL CHEM, V260, P418; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; SRINIVASAN AN, 1994, DNA CELL BIOL, V13, P651, DOI 10.1089/dna.1994.13.651; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	40	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21803	21810		10.1074/jbc.272.35.21803	http://dx.doi.org/10.1074/jbc.272.35.21803			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268310	hybrid			2022-12-25	WOS:A1997XT85000022
J	Namiki, M; Akiyama, S; Katagiri, T; Suzuki, A; Ueno, N; Yamaji, N; Rosen, V; Wozney, JM; Suda, T				Namiki, M; Akiyama, S; Katagiri, T; Suzuki, A; Ueno, N; Yamaji, N; Rosen, V; Wozney, JM; Suda, T			A kinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-SUPERFAMILY; GROWTH-FACTOR-BETA; DIFFERENTIATION PATHWAY; OSTEOGENIC PROTEIN-1; VENTRAL MESODERM; MOUSE; ACTIVATION; CLONING; MEMBER; IDENTIFICATION	Members of the transforming growth factor (TGF)-beta superfamily bind the transmembrane serine/threonine kinase complex consisting of type I and type II receptors. Their intracellular signals are propagated via respective type I receptors. Bone morphogenetic protein (BMP)-2, a member of the TGF-beta superfamily, induces ectopic bone formation when implanted into muscular tissues. Two type I receptors (BMPR-IA and BMPR-IB) have been identified for BMP-2. We have reported that BMP-2 inhibits the terminal differentiation of C2C12 myoblasts and converts their differentiation pathway into that of osteoblast lineage cells (Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., Rosen, V., Wozney, J. M., Fujisawa-Sehara, A. and Suda, T. (1994) J. Cell Biol. 127, 1755-1766). In the present study, we examined the involvement of functional BMP-2 type I receptors in signal transduction in C2C12 cells, which expressed mRNA for BMPR-IA, but not for BMPR-IB in Northern blotting. TGF-beta type I receptor (T beta R-I) mRNA was also expressed in C2C12 cells. Subclonal cell lines of C2C12 that stably expressed a kinase domain-truncated BMPR-IA (Delta BMPR-IA) differentiated into myosin heavy chain-expressing myotubes but not into alkaline phosphatase (ALP)-positive cells, even in the presence of BMP-2. In contrast, the differentiation of the Delta BMPR-IA-transfected C2C12 cells into myotubes was suppressed by TGF-beta 1, as in the parental C2C12 cells. BMP-2 did not efficiently suppress the mRNA expression of muscle-specific genes such as muscle creatine kinase, MyoD, and myogenin, nor did it induce the expression of ALP mRNA in the Delta BMPR-IA-transfected C2C12 cells. In contrast, TGF-beta 1 inhibited mRNA expression of the muscle-specific genes in those cells. When wild-type BMPR-IA was transiently transfected into the Delta BMPR-IA-transfected C2C12 cells, a number of ALP-positive cells appeared in the presence of BMP-2. Transfection of wild-type BMPR-IB or T beta R-I failed to increase the number of ALP-positive cells. These results suggest that the BMP-2-induced signals, which inhibit myogenic differentiation and induce osteoblast differentiation, are transduced via BMPR-IA in C2C12 myoblasts.	SHOWA UNIV,SCH DENT,DEPT BIOCHEM,SHINAGAWA KU,TOKYO 142,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN; YAMANOUCHI PHARMACEUT CO LTD,TOKYO 103,JAPAN; GENET INST INC,CAMBRIDGE,MA 02140	Showa University; Hokkaido University; Astellas Pharmaceuticals				Ueno, Naoto/0000-0002-8375-2317				AKIYAMA S, 1997, IN PRESS EXP CELL RE; Attisano L, 1996, MOL CELL BIOL, V16, P1066; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; FROLIK CA, 1984, J BIOL CHEM, V259, P995; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Komaki M, 1996, CELL TISSUE RES, V284, P9, DOI 10.1007/s004410050562; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; RAFTERY LA, 1995, GENETICS, V139, P241; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SEKELSKY JJ, 1995, GENETICS, V139, P1347; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; SUZUKI A, 1994, BIOCHEM BIOPH RES CO, V198, P1063, DOI 10.1006/bbrc.1994.1151; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TERAO M, 1987, P NATL ACAD SCI USA, V84, P7051, DOI 10.1073/pnas.84.20.7051; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; YAMAJI N, 1994, BIOCHEM BIOPH RES CO, V205, P1944, DOI 10.1006/bbrc.1994.2898; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217	54	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22046	22052		10.1074/jbc.272.35.22046	http://dx.doi.org/10.1074/jbc.272.35.22046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268344	hybrid			2022-12-25	WOS:A1997XT85000056
J	Roman, RM; Wang, Y; Lidofsky, SD; Feranchak, AP; Lomri, N; Scharschmidt, BF; Fitz, JG				Roman, RM; Wang, Y; Lidofsky, SD; Feranchak, AP; Lomri, N; Scharschmidt, BF; Fitz, JG			Hepatocellular ATP-binding cassette protein expression enhances ATP release and autocrine regulation of cell volume	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MDR1 P-GLYCOPROTEIN; PERFUSED-RAT-LIVER; MULTIDRUG-RESISTANCE; DEPENDENT TRANSPORT; CHLORIDE CHANNELS; CYCLOSPORINE-A; HEPATOCYTES; INHIBITION; MECHANISM	In a model liver cell line, recovery from swelling is mediated by a sensitive autocrine pathway involving conductive release of ATP, P-2 receptor stimulation, and opening of membrane Cl- channels (Wang, Y,, Roman, R. M., Lidofsky, S. D., and Fitz, J. G. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 12020-12025), However, the mechanisms coupling changes in cell volume to ATP release are not known. Based on evidence that certain ATP binding cassette (ABC) proteins may function as ATP channels or channel regulators, we evaluated the potential role of ABC proteins by comparing ATP release and volume regulation in rat HTC and HTC-R hepatoma cells, the latter of which overexpress Mdr proteins, In both cell types, Cl- current activation (ICl-swell) and volume recovery following swelling were dependent on conductive ATP efflux, The rate of volume recovery was similar to 6-fold faster in HTC-R cells compared with HTC cells, This effect is likely due to enhanced ABC protein-dependent ATP release since (i) ICl-swell and cell volume recovery were eliminated by inhibition of P-glycoprotein transport (20 mu M verapamil and 15 mu M cyclosporin A); (ii) swelling-induced Cl- current density was similar in both cell types (approximately -50 pA/pF; not significant); and (iii) ATP conductance measured by whole-cell techniques was increased similar to 3-fold in HTC-R cells compared with HTC cells, Moreover, HTC R cells exhibited enhanced survival during hypotonic stress, By modulating ATP release, hepatic ABC proteins may play a key role in the cellular pathways coupling changes in cell volume to ion permeability and secretion.	UNIV CALIF SAN FRANCISCO, DEPT MED, DIV GASTROENTEROL, SAN FRANCISCO, CA 94143 USA; DUKE UNIV, MED CTR, DEPT MED, DIV GASTROENTEROL, DURHAM, NC 27710 USA	University of California System; University of California San Francisco; Duke University	Roman, RM (corresponding author), UNIV COLORADO, HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL, CAMPUS BOX B-158,RM 6412, 4200 E 9TH AVE, DENVER, CO 80262 USA.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALHABORI M, 1994, INT J BIOCHEM, V26, P319, DOI 10.1016/0020-711X(94)90052-3; Bodily K, 1997, HEPATOLOGY, V25, P403; BOHME M, 1994, ADV ENZYME REGUL, V34, P371, DOI 10.1016/0065-2571(94)90023-X; Bosch I, 1996, AM J PHYSIOL-CELL PH, V271, pC1527, DOI 10.1152/ajpcell.1996.271.5.C1527; BROWN RS, 1995, P NATL ACAD SCI USA, V92, P5421, DOI 10.1073/pnas.92.12.5421; Carini R, 1996, HEPATOLOGY, V24, P446; CARINI R, 1995, BIOCHEM BIOPH RES CO, V206, P180, DOI 10.1006/bbrc.1995.1025; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; Chari RS, 1996, AM J PHYSIOL-GASTR L, V270, pG246; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; CROMER B, 1992, BIOCHEM PHARMACOL, V44, P1214; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GASBARRINI A, 1992, J BIOL CHEM, V267, P6654; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GOSLAND M, 1993, CANCER RES, V53, P5382; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HAUSSINGER D, 1995, J HEPATOL, V22, P94, DOI 10.1016/0168-8278(95)80266-5; HAUSSINGER D, 1987, EUR J BIOCHEM, V167, P65; KADMON M, 1993, GASTROENTEROLOGY, V104, P1507, DOI 10.1016/0016-5085(93)90363-H; KEPPENS S, 1991, BRIT J PHARMACOL, V104, P301, DOI 10.1111/j.1476-5381.1991.tb12426.x; LEBOT MA, 1994, CANCER CHEMOTH PHARM, V35, P53, DOI 10.1007/BF00686284; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; Lomri N, 1996, SEMIN LIVER DIS, V16, P201, DOI 10.1055/s-2007-1007232; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; MULLER M, 1994, FEBS LETT, V343, P168, DOI 10.1016/0014-5793(94)80312-9; NUKINA S, 1994, AM J PHYSIOL, V266, pG99, DOI 10.1152/ajpgi.1994.266.1.G99; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; REISIN IL, 1994, J BIOL CHEM, V269, P20584; Ribeiro RCJ, 1996, J BIOL CHEM, V271, P17147, DOI 10.1074/jbc.271.29.17147; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; Schlenker T, 1996, HEPATOLOGY, V24, P514; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SMELAND E, 1995, ANTICANCER RES, V15, P1221; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STAPF V, 1994, ANTICANCER RES, V14, P581; STRIGGOW F, 1993, FEBS LETT, V318, P341, DOI 10.1016/0014-5793(93)80542-3; TAKEGUCHI N, 1993, TRANSPLANTATION, V55, P646, DOI 10.1097/00007890-199303000-00033; Wang Y, 1996, J BIOL CHEM, V271, P18107, DOI 10.1074/jbc.271.30.18107; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; WATANABE T, 1992, J HEPATOL, V16, P77, DOI 10.1016/S0168-8278(05)80098-4	44	138	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21970	21976		10.1074/jbc.272.35.21970	http://dx.doi.org/10.1074/jbc.272.35.21970			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268333	hybrid			2022-12-25	WOS:A1997XT85000045
J	Yuan, YP; Dopheide, SM; Ivanidis, C; Salem, HH; Jackson, SP				Yuan, YP; Dopheide, SM; Ivanidis, C; Salem, HH; Jackson, SP			Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets - Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alpha(IIb)beta(3)) in von Willebrand factor-induced signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; VONWILLEBRAND-FACTOR BINDING; HUMAN BLOOD-PLATELETS; MU-CALPAIN; CYTOPLASMIC DOMAIN; MEMBRANE SKELETON; CALCIUM INFLUX; CELL-ADHESION; ACTIVATION; AGGREGATION	The adhesion of platelets to sites of vascular injury is critically dependent on the binding of subendothelial bound von Willebrand factor (vWf) to the platelet surface glycoprotein complexes, GP Ib-V-IX and GP IIb-IIIa (integrin alpha(IIb)beta(3)). There is growing evidence that the binding of vWf to these receptors is not only essential for stable platelet adhesion but is also important for the transduction of activation signals required for changes in platelet morphology, granule secretion, and platelet aggregation. In this study we have investigated signaling events induced by vWf binding to GP Ib-V-IX in both spreading and aggregated platelets. The adhesion of platelets to vWf resulted in dramatic actin filament reorganization, as assessed by immunofluorescence with fluorescein isothiocyanate-conjugated phalloidin, and the cytoskeletal recruitment of various structural proteins (talin and integrin alpha(IIb)beta(3)) and signaling enzymes (pp60(c-src), focal adhesion kinase (FAK), phosphatidylinositol 3-kinase (PI 3-kinase), and protein-tyrosine phosphatase (PTP)-1B). Time course experiments in both spreading and aggregated platelets revealed that talin, FAK, and PTP-1B were proteolyzed after translocation to the cytoskeleton. The proteolysis of these proteins was dependent on the presence of extracellular calcium and was specifically inhibited by pretreating platelets with the membrane-permeable calpain inhibitors calpeptin, E64d, and MDL 28,170, but not with the membrane-impermeable inhibitors leupeptin, E64, and calpastatin. The cytoskeletal translocation of signaling enzymes in vWf-stimulated platelets was abolished by pretreating platelets with an anti-GP Ib-V-IX antibody but was unaffected by blocking ligand binding to integrin alpha(IIb)beta(3). In contrast, calpain activation in vWf-stimulated platelets required ligand binding to both GP Ib-V-IX and integrin alpha(IIb)beta(3). The activation of calpain in both spreading and aggregated platelets resulted in a substantial decrease in the level of tyrosine phosphorylation of multiple platelet proteins and was associated with a 50-80% reduction in the amount of cytoskeletal associated talin, integrin alpha(IIb)beta(3), PI 3-kinase, FAK, pp60(c-src), and PTP-1B. These studies suggest a potentially important role for calpain in regulating the formation and/or stability of cytoskeletal signaling complexes in vWf-stimulated platelets. Furthermore, they demonstrate distinct roles for GP Ib-V-IX and integrin alpha(IIb)beta(3) in vWf-induced signal transduction.	BOX HILL HOSP,DEPT MED,MONASH MED SCH,BOX HILL,VIC 3128,AUSTRALIA; BOX HILL HOSP,AUSTRALIAN CTR BLOOD DIS,BOX HILL,VIC 3128,AUSTRALIA; BOX HILL HOSP,DEPT PATHOL,BOX HILL,VIC 3128,AUSTRALIA	Box Hill Hospital; Monash University; Box Hill Hospital; Box Hill Hospital				Jackson, Shaun/0000-0002-4750-1991				ARIYOSHI H, 1995, ARTERIOSCL THROM VAS, V15, P511, DOI 10.1161/01.ATV.15.4.511; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BERTOLINO G, 1995, THROMB HAEMOSTASIS, V73, P689; CHOW TW, 1992, BLOOD, V80, P113; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, J CLIN INVEST, V75, P198; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1995, THROMB HAEMOSTASIS, V72, P987; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; ODA A, 1993, J BIOL CHEM, V268, P12603; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; ROTH GJ, 1991, BLOOD, V77, P5; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SMITH CM, 1992, BLOOD, V80, P2774; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WEISS HJ, 1973, J CLIN INVEST, V52, P2697, DOI 10.1172/JCI107464; WHITE GC, 1980, BIOCHIM BIOPHYS ACTA, V631, P130, DOI 10.1016/0304-4165(80)90061-6; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHANG J, 1992, J BIOL CHEM, V267, P4686	49	92	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21847	21854		10.1074/jbc.272.35.21847	http://dx.doi.org/10.1074/jbc.272.35.21847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268316	hybrid			2022-12-25	WOS:A1997XT85000028
J	Zhou, X; Cahoon, M; Rosa, P; Hedstrom, L				Zhou, X; Cahoon, M; Rosa, P; Hedstrom, L			Expression, purification, and characterization of inosine 5'-monophosphate dehydrogenase from Borrelia burgdorferi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMP DEHYDROGENASE; MYCOPHENOLIC-ACID; SALMONELLA-TYPHIMURIUM; INHIBITION; VIRULENCE; MECHANISM; CELLS	Inosine 5'-monophosphate dehydrogenase (IMPDH) is the rate limiting enzyme in de novo guanine nucleotide biosynthesis, IMPDH converts IMP to xanthosine 5'-monophosphate with concomitant conversion of NAD(+) to NADH, All IMPDHs characterized to date contain a 130-residue ''subdomain'' that extends from an N-terminal loop of the alpha/beta barrel domain, The role of this subdomain is unknown, An IMPDH homolog has been cloned from Borrelia burgdorferi, the causative agent of Lyme disease (Margolis, N., Hogan, D., Tilly, K., and Rosa, P. A. (1994) J. Bacteriol. 176, 6427-6432), This homolog has replaced the subdomain with a 50-residue segment of unrelated sequence, We have expressed and characterized the B. burgdorferi IMPDH homolog, This protein has IMPDH activity, which unequivocally demonstrates that the subdomain is not required for catalytic activity, The monovalent cation and dinucleotide binding sites of B. burgdorferi IMPDH are significantly different from those of human IMPDH, Therefore, these sites are targets for the design of specific inhibitors for B. burgdorferi IMPDH. Such inhibitors might be new treatments for Lyme disease.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA; NIAID, MICROBIAL STRUCT & FUNCT LAB, ROCKY MT LABS, NIH, HAMILTON, MT 59840 USA	Brandeis University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ANDREWS SC, 1988, BIOCHEM J, V255, P35, DOI 10.1042/bj2550035; ATKINS CA, 1985, ARCH BIOCHEM BIOPHYS, V236, P807, DOI 10.1016/0003-9861(85)90687-3; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; CARR SF, 1993, J BIOL CHEM, V268, P27286; Farazi T, 1997, J BIOL CHEM, V272, P961, DOI 10.1074/jbc.272.2.961; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FLOREY HW, 1946, LANCET, V250, P46; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P635, DOI 10.1016/0005-2744(76)90313-2; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P645, DOI 10.1016/0005-2744(76)90314-4; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; HUPE DJ, 1986, J BIOL CHEM, V261, P8363; KRISHNAIAH KV, 1975, ARCH BIOCHEM BIOPHYS, V170, P567, DOI 10.1016/0003-9861(75)90152-6; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MARGOLIS N, 1994, J BACTERIOL, V176, P6427, DOI 10.1128/JB.176.21.6427-6432.1994; MARQUEZ VE, 1986, J MED CHEM, V29, P1726, DOI 10.1021/jm00159a027; MCFARLAND WC, 1987, MICROB PATHOGENESIS, V3, P129, DOI 10.1016/0882-4010(87)90071-4; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NIJKAMP HJJ, 1967, BIOCHIM BIOPHYS ACTA, V145, P31, DOI 10.1016/0005-2787(67)90651-X; Noriega FR, 1996, INFECT IMMUN, V64, P3055, DOI 10.1128/IAI.64.8.3055-3061.1996; ROBINS RK, 1982, NUCLEOS NUCLEOT, V1, P35, DOI 10.1080/07328318208079400; SAKAGUCHI K, 1975, CANCER RES, V35, P1643; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; SMITH RA, 1980, DEV ANTIVIRAL THERAP, P133; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; Wang W, 1996, BIOCHEMISTRY-US, V35, P95, DOI 10.1021/bi951499q; WANG W, 1997, IN PRESS BIOCHEMISTR; WEBER G, 1983, CANCER RES, V43, P3466; Wu John C., 1994, Perspectives in Drug Discovery and Design, V2, P185, DOI 10.1007/BF02171743; WU TW, 1973, CAN J BIOCHEM CELL B, V51, P1391, DOI 10.1139/o73-182; Xiang BS, 1996, J BIOL CHEM, V271, P1435, DOI 10.1074/jbc.271.3.1435; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057	36	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21977	21981		10.1074/jbc.272.35.21977	http://dx.doi.org/10.1074/jbc.272.35.21977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268334	hybrid			2022-12-25	WOS:A1997XT85000046
J	Keeling, SL; Gad, JM; Cooper, HM				Keeling, SL; Gad, JM; Cooper, HM			Mouse Neogenin, a DCC-like molecule, has four splice variants and is expressed widely in the adult mouse and during embryogenesis	ONCOGENE			English	Article						neogenin; sequence; tumorigenesis; cell adhesion molecule; embryogenesis	TUMOR-SUPPRESSOR GENE; MESSENGER-RNA; FREQUENT LOSS; COLORECTAL-CARCINOMA; N-CAM; HETEROZYGOSITY; CANCERS; NCAM; DIFFERENTIATION; CADHERIN	Neogenin is a member of the N-CAM family of cell adhesion molecules and is closely related to the DCC tumor suppressor gene product, Recently, it has been demonstrated that the DCC/Neogenin subfamily plays a key role in axonal guidance within the embryonic nervous system, however little is known about the function of DCC or Neogenin in non-neuronal tissues in vertebrates. To gain an understanding of Neogenin function outside of the nervous system we have cloned and sequenced the mouse homologue of Neogenin. We describe three alternatively spliced exons within the extracellular domain of Neogenin and a fourth alternatively spliced exon within the cytoplasmic domain, We further demonstrate that three of these alternatively spliced exons are developmentally regulated, Analysis of Neogenin mRNA expression showed that two distinct Neogenin transcripts are expressed at significant levels in a broad spectrum of adult mouse tissues and throughout the mid to late stages of embryogenesis. In situ hybridization studies on day 15.5 mouse embryos revealed that Neogenin is expressed widely throughout the developing mouse embryo, in both neuronal and nonneuronal tissues, These observations suggests that Neogenin may play an integral role in regulating differentiation programmes and/or cell migration events within many embryonic and adult tissues.			Keeling, SL (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, POB 2008, PARKVILLE, VIC 3050, AUSTRALIA.		Cooper, Helen/G-3505-2010; Cooper, Helen M/AAA-2182-2019	Cooper, Helen M/0000-0001-9838-5743				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BOLAM JP, 1992, EXPT NEUROANATOMY PR, P6; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; Cooper HM, 1995, ONCOGENE, V11, P2243; DEVILEE P, 1991, ONCOGENE, V6, P311; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG Y, 1992, CANCER RES, V52, P6525; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Kaufman M.H., 1992, ATLAS MOUSE DEV; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MIYAKE K, 1993, BLOOD, V82, P927; OLEARY DDM, 1993, NEURON, V10, P991, DOI 10.1016/0896-6273(93)90049-W; PORFIRI E, 1993, BLOOD, V81, P2696; REALE MA, 1994, CANCER RES, V54, P4493; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAFFELL JL, 1994, J CELL BIOL, V125, P427, DOI 10.1083/jcb.125.2.427; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; UCHINO S, 1992, CANCER RES, V52, P3099; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Walsh FS, 1996, CURR OPIN CELL BIOL, V8, P707, DOI 10.1016/S0955-0674(96)80113-X; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; ZORN AM, 1992, DEV BIOL, V149, P197, DOI 10.1016/0012-1606(92)90276-M	46	78	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					691	700		10.1038/sj.onc.1201225	http://dx.doi.org/10.1038/sj.onc.1201225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264410	Bronze			2022-12-25	WOS:A1997XP68300009
J	Li, WQ; Zhang, JC; Bottaro, DP; Li, W; Pierce, JH				Li, WQ; Zhang, JC; Bottaro, DP; Li, W; Pierce, JH			Identification of serine 643 of protein kinase C-delta as an important autophosphorylation site for its enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP BINDING MUTANT; TYROSINE PHOSPHORYLATION; IN-VIVO; ACTIVATION; CELLS; PATHWAY; PKC; DIFFERENTIATION; TRANSFORMATION; STIMULATION	To investigate the role of serine/threonine autophosphorylation of protein kinase C-delta (PMC-delta), we mutated serine 643 of PKC-delta to an alanine residue (PKC-delta S643A). Two different expression vectors containing PKC-delta S643A mutant cDNAs were transfected and expressed in 32D myeloid progenitor cells. In vitro autophosphorylation assays demonstrated 65-83% reduction in autophosphorylation of PKC-delta S643A in comparison to wild type PKC-delta (PKC-delta WT). The enzymatic activity of PKC-delta S643A mutant as measured by phosphorylating the PKC-delta pseudosubstrate region-derived substrate was also reduced more than 70% in comparison to that of PRC-delta WT. In vivo labeling and subsequent two-dimensional phosphopeptide analysis demonstrated that at least one phosphopeptide was absent in PKC-delta S643A when compared with PRC-delta WT, further substantiating that serine 643 is phosphorylated in vivo, Localization and 12-O-tetradecanoylphorbol-13-acetate-dependent translocation and tyrosine phosphorylation of PKC-delta S643A were not altered in comparison to PRC-delta WT, indicating that mutagenesis did not affect the structural integrity of the mutant protein, 12-O-Tetradecanoylphorbol-13-acetate-mediated monocytic differentiation of 32D cells overexpressing PKC-delta S643A mutant protein was impaired in comparison to that of PRC-delta WT transfectant, Taken together, oar results demonstrate that serine 643 of PRC-delta is a major autophosphorylation site, and phosphorylation of this site plays an important role in controlling its enzymatic activity and biological function.	UNIV CHICAGO, BEN MAY INST CANC RES, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	Li, WQ (corresponding author), NCI, MOL & CELLULAR BIOL LAB,NIH,BLDG 37,RM 1E24, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HUANG KP, 1986, J BIOL CHEM, V261, P2134; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Li WQ, 1996, ONCOGENE, V13, P731; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOLINA CA, 1991, CANCER RES, V51, P4624; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ORR JW, 1994, J BIOL CHEM, V269, P27715; SMITH H, 1995, P NATL ACAD SCI USA, V92, P9112; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	31	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24550	24555		10.1074/jbc.272.39.24550	http://dx.doi.org/10.1074/jbc.272.39.24550			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305920	Green Submitted, hybrid			2022-12-25	WOS:A1997XY51500071
J	Sato, MH; Nakamura, N; Ohsumi, Y; Kouchi, H; Kondo, M; HaraNishimura, I; Nishimura, M; Wada, Y				Sato, MH; Nakamura, N; Ohsumi, Y; Kouchi, H; Kondo, M; HaraNishimura, I; Nishimura, M; Wada, Y			The AtVAM3 encodes a syntaxin-related molecule implicated in the vacuolar assembly in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; YEAST VACUOLE; BARLEY LECTIN; PLANT-CELLS; PROTEIN; MEMBRANE; MORPHOGENESIS; GENES; TRANSFORMATION	The vacuole constitutes a large compartment in plant and fungal cells, The VAM3 gene of Saccharomyces cerevisiae encodes a syntaxin-related protein required far vacuolar assembly, An Arabidopsis thaliana cDNA library, designed for expression iu S. cerevisiae, was screened for cDNAs able to complement defective vacuolar assembly of the Delta vam3 mutation, One cDNA, encoding a 33-kDa protein with structural similarities to the other syntaxins, was identified, The product of AtVAM3 (AtVam3p) was expressed in various tissues including roots, leaves, inflorescence stems, flower buds, and young siliques. The AtVAM3 transcripts were abundant; in undifferentiated cells in the meristematic region, AtVam3p fractionated predominantly to an 8,000 x g pellet fraction where a vacuolar membrane protein H+-translocating inorganic pyrophosphatase (H+-PPase) also fractionated. Immunoelectron microscopy showed that AtVam3p was localized to restricted regions on the vacuolar membranes, The propose that AtVam3p provides the t-SNARE function in the vacuolar assembly in A. thaliana.	UNIV TOKYO,DEPT BIOL,GRAD SCH ARTS & SCI,TOKYO 153,JAPAN; NATL INST AGROBIOL RESOURCES,DEPT APPL PHYSIOL,TSUKUBA,IBARAKI 305,JAPAN; NATL INST BASIC BIOL,DEPT CELL BIOL,OKAZAKI,AICHI 444,JAPAN	University of Tokyo; National Institute of Agrobiological Sciences - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)			Sato, Masa/P-6487-2019; Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166; Nishimura, Mikio/0000-0001-7960-9721; Sato, Masa H./0000-0001-5794-4545				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BEDNAREK SY, 1994, PLANT PHYSIOL, V104, P591, DOI 10.1104/pp.104.2.591; BEDNAREK SY, 1990, PLANT CELL, V2, P1145, DOI 10.1105/tpc.2.12.1145; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CONCEICAO AD, 1997, PLANT CELL, V9, P1; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DOMBROWSKI JE, 1993, PLANT CELL, V5, P587, DOI 10.1105/tpc.5.5.587; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HOH B, 1995, J CELL SCI, V108, P299; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOUCHI H, 1993, MOL GEN GENET, V238, P106, DOI 10.1007/BF00279537; LEE HI, 1993, P NATL ACAD SCI USA, V90, P11433, DOI 10.1073/pnas.90.23.11433; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Maeshima M, 1996, J PLANT RES, V109, P119, DOI 10.1007/BF02344297; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; Nakamura N, 1997, J BIOL CHEM, V272, P11344; NISHIMURA M, 1993, PROTOPLASMA, V175, P131, DOI 10.1007/BF01385011; Paris N, 1996, CELL, V85, P563, DOI 10.1016/S0092-8674(00)81256-8; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STRZALKA K, 1995, BBA-BIOMEMBRANES, V1239, P103, DOI 10.1016/0005-2736(95)00141-O; TAGUE BW, 1990, PLANT CELL, V2, P533, DOI 10.1105/tpc.2.6.533; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wada Y, 1996, PROTOPLASMA, V191, P126, DOI 10.1007/BF01281810; WADA Y, 1992, J BIOL CHEM, V267, P18671; Wada Y, 1997, J CELL SCI, V110, P1299; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539	41	102	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24530	24535		10.1074/jbc.272.39.24530	http://dx.doi.org/10.1074/jbc.272.39.24530			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305917	hybrid			2022-12-25	WOS:A1997XY51500068
J	James, PF; Lake, AC; Hajra, AK; Larkins, LK; Buchanan, FG; Zoeller, RA				James, PF; Lake, AC; Hajra, AK; Larkins, LK; Buchanan, FG; Zoeller, RA			An animal cell mutant with a deficiency in acyl/alkyl-dihydroxyacetone-phosphate reductase activity - Effects on the biosynthesis of ether-linked and diacyl glycerolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER PEROXISOMES; PLASMALOGEN BIOSYNTHESIS; ZELLWEGER SYNDROME; PHOSPHATIDYLSERINE; ACYLTRANSFERASE; ENZYMES; KINASE; TRIACYLGLYCEROL; METABOLISM; GROWTH	In the accompanying paper (James, P. F., and Zoeller, R. A. (1997) J. Biol. Chem. 272, 23532-23539), we reported the isolation of st series of mutants from the fibroblast-like cell line, CHO-K1, that are deficient in the incorporation of the long chain fatty alcohol, hexadecanol, into complex lipids. All but one of these mutants, FAA.K1B, were deficient; in long-chain-fatty alcohol oxidase (FAO) activity. We have further characterized this FAO(+) isolate. FAA.K1B cells displayed a 40% decrease in [9,10-H-3]hexadecanol uptake when compared with the parent strain. Although incorporation of hexadacanol into the phospholipid fraction was decreased by 52%, She cells accumulated label in alkylglycerol (20-fold over wild type). The increase in 1-alkylglycerol labeling corresponded to a 4-fold increase in alkylglycerol mass. Short term labeling with P-32(i) showed a 45-50% decrease in overall phospholipid biosynthesis in FAA.K1B. Both diacyl- and ether-linked species were affected, suggesting a general defect in phospholipid biosynthesis. Mutant cells were able to partially compensate for the decreased. biosynthesis by decreasing the turnover of the phospholipid pools. The primary lesion in FAA.K1B was identified as a 95% reduction in acyl/alkyl-dihydroxyacetone-phosphate reductase activity. Whole cell homogenates from FAA.K1B were unable to reduce either acyl-dihydroxyacetone phosphate (DHAP) or alkyl-DHAP, supporting the notion that the reduction of these two compounds is catalyzed by a single enzyme. These data suggest that the biosynthesis of diacyl phospholipids, in Chinese hamster ovary cells, begins with the acylation of dihydroxyacetone phosphate as well as glycero-3-phosphate and that the ''DHAP pathway'' contributes significantly to diacyl glycerolipid biosynthesis. Also, the severe reduction in acyl/alkyl-DHAP reductase activity in FAA.K1B resulted in only a moderate decrease in ether lipid biosynthesis. These latter data together with the observed increase in alkylglycerol levels support the existence of a shunt pathway that is able to partially bypass the enzymatic lesion.	BOSTON UNIV, SCH MED, DEPT BIOPHYS, CTR ADV BIOMED RES, BOSTON, MA 02118 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MENTAL HLTH INST, ANN ARBOR, MI 48109 USA; E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, DEPT BIOCHEM, JOHNSON CITY, TN 37614 USA	Boston University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; East Tennessee State University				Zoeller, Raphael/0000-0002-6560-0993	NCI NIH HHS [CA 59981] Funding Source: Medline; NIGMS NIH HHS [GM 50571] Funding Source: Medline; NINDS NIH HHS [NS 15747] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R15CA059981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015747] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COREY EJ, 1975, TETRAHEDRON LETT, V31, P2647; DATTA NS, 1984, NEW ENGL J MED, V311, P1080, DOI 10.1056/NEJM198410253111704; DATTA SC, 1990, J BIOL CHEM, V265, P8268; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FORD DA, 1990, J BIOL CHEM, V265, P12280; GHOSH MK, 1986, ARCH BIOCHEM BIOPHYS, V245, P523, DOI 10.1016/0003-9861(86)90245-6; GREENSPAN MD, 1982, BIOCHIM BIOPHYS ACTA, V710, P15, DOI 10.1016/0005-2760(82)90184-9; HAJRA AK, 1992, METHOD ENZYMOL, V209, P402; Hajra AK, 1995, PROG LIPID RES, V34, P343, DOI 10.1016/0163-7827(95)00013-5; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; HAJRA AK, 1983, CHEM PHYS LIPIDS, V33, P179, DOI 10.1016/0009-3084(83)90020-8; HAJRA AK, 1979, J BIOL CHEM, V254, P896; James PF, 1997, J BIOL CHEM, V272, P23532, DOI 10.1074/jbc.272.38.23532; JONES CL, 1980, J BIOL CHEM, V255, P8289; KUGE O, 1991, J BIOL CHEM, V266, P24184; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; LABELLE EF, 1974, J BIOL CHEM, V249, P6936; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING R, 1972, BIOCHEM J, V130, P1003, DOI 10.1042/bj1301003; Martonosi, 1985, ENZYMES BIOL MEMBR, V2, P1; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; MYHER JJ, 1989, J CHROMATOGR, V471, P187, DOI 10.1016/S0021-9673(00)94167-0; Nagan N, 1997, P NATL ACAD SCI USA, V94, P4475, DOI 10.1073/pnas.94.9.4475; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; OWENS K, 1966, BIOCHEM J, V100, P354, DOI 10.1042/bj1000354; POLLOCK RJ, 1975, BIOCHIM BIOPHYS ACTA, V380, P421, DOI 10.1016/0005-2760(75)90110-1; POLOKOFF MA, 1981, J BIOL CHEM, V256, P7687; ROCK CO, 1974, J BIOL CHEM, V249, P5382; ROGNSTAD R, 1974, BIOCHEM J, V140, P249, DOI 10.1042/bj1400249; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; WARNE TR, 1995, J BIOL CHEM, V270, P11147, DOI 10.1074/jbc.270.19.11147; WEBBER KO, 1987, ARCH BIOCHEM BIOPHYS, V254, P611, DOI 10.1016/0003-9861(87)90144-5; WYKLE RL, 1970, J BIOL CHEM, V245, P3047; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1992, J BIOL CHEM, V267, P8299	43	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23540	23546		10.1074/jbc.272.38.23540	http://dx.doi.org/10.1074/jbc.272.38.23540			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295290	hybrid			2022-12-25	WOS:A1997XX38100015
J	Richards, OC; Ehrenfeld, E				Richards, OC; Ehrenfeld, E			One of two NTP binding sites in poliovirus RNA polymerase required for RNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; DNA; IDENTIFICATION; RESOLUTION; MUTATION; RESIDUES; BETA	The poliovirus RNA-dependent RNA polymerase (3D(pol)) has been shown to contain two NTP binding: sites by chemical cross-linking of oxidized nucleotide to the intact protein. Only one site (Lys-61) was shown to be essential for RNA chain elongation activity by purified enzyme; however, a full-length viral RNA, coding for an altered lysine residue (K276L) in the second site, generated virus with a minute plaque phenotype that rapidly reverted to a wild-type phenotype with Arg-276 replacing Leu-276 in 3D. Viruses with lysine to leucine substitutions in other positions of the second binding site of their polymerase proteins grew with wild-type phenotype, To test the significance of the second binding site, poliovirus 3D(pol) was generated with lysine (wild type), leucine, or arginine at residue 276 and tested for NTP cross-linking using P-32-oxidized GTP. Analysis of cyanogen bromide peptides of each 3D preparation showed that the second NTP binding site had severely reduced NTP binding in mu 276(Leu) but not in the revertant mu 276(Arg), despite the reported requirement for lysine in the cross-linking reaction. To eliminate the possibility that P-32-oxidized GTP cross-linked to Arg at residue 276, a model system was designed with unmodified amino acid or acetylated (alpha-amino) amino acid and P-32-oxidized GTP. Cross-linking to lysine, but not leucine or arginine, was observed thus eliminating the possibility that NTP could be cross-linked to residue 276 in 3D, We conclude that NTP binding at the second site in poliovirus 3D is at lysine residues at positions other than 276 (278 or 283), and nucleotide binding at these sites has no bearing on elongation activity or replication of the virus, Nucleotide binding only at the site including Lys-61 is essential for RNA replication.			Richards, OC (corresponding author), UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,3205 BIOL SCI 2,IRVINE,CA 92697, USA.				NIAID NIH HHS [AI17386] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017386, R37AI017386] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; EASTERBROOKSMITH SB, 1976, EUR J BIOCHEM, V62, P125, DOI 10.1111/j.1432-1033.1976.tb10105.x; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; JABLONSKI SA, 1995, J VIROL, V69, P1532, DOI 10.1128/JVI.69.3.1532-1539.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; MORAS D, 1993, NATURE, V364, P572, DOI 10.1038/364572a0; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; PATA JD, 1995, RNA, V1, P466; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Richards OC, 1996, J VIROL, V70, P8564, DOI 10.1128/JVI.70.12.8564-8570.1996; RICHARDS OC, 1992, J BIOL CHEM, V267, P17141; RICHARDS OC, 1995, BIOCHEMISTRY-US, V34, P6288, DOI 10.1021/bi00019a005; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445	16	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23261	23264		10.1074/jbc.272.37.23261	http://dx.doi.org/10.1074/jbc.272.37.23261			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287335	hybrid			2022-12-25	WOS:A1997XV74400046
J	Sciorati, C; Rovere, P; Ferrarini, M; Heltai, S; Manfredi, AA; Clementi, E				Sciorati, C; Rovere, P; Ferrarini, M; Heltai, S; Manfredi, AA; Clementi, E			Autocrine nitric oxide modulates CD95-induced apoptosis in gamma delta T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INTRACELLULAR STORES; SIGNAL-TRANSDUCTION; SPHINGOSINE KINASE; CELL-DEATH; ACTIVATION; RECEPTOR; SPHINGOMYELINASE; INHIBITION; TRANSPORT	gamma delta T lymphocytes play an important early role in the defense against pathogens. Their function is terminated by acquisition of susceptibility to CD95-triggered apoptosis. Here we show that the regulation of this process depends on the activity of the endothelial NO synthase expressed by gamma delta T lymphocytes, which is modulated in an activation-dependent way. The effects of nitric oxide thus generated, mediated via cGMP generation, are exerted at at least two sites along the CD95 signaling cascade: one at, or upstream, and the other downstream of ceramide generation. At either site, nitric oxide/cGMP action is sufficient for protection from apoptosis. The effect of NO is selective for apoptosis induced by CD95 cross-linking, since it does not affect apoptotic program triggered by other stimuli. The evidence here reported demonstrates a new physiological role for nitric oxide, acting as a survival factor for T lymphocytes.	SAN RAFFAELE SCI INST,DIPARTIMENTO FARMACOL,DIBIT,I-20132 MILAN,ITALY; SCI INST OSPED SAN RAFFAELE,LAB CANC IMMUNOL,DEPT MED 2,I-88021 CATANZARO,ITALY; UNIV REGGIO CALABRIA,SCH PHARM,DEPT PHARMACOL,CNR,IBAF,I-88021 CATANZARO,ITALY; CNR,CELLULAR & MOL PHARMACOL CTR,I-20132 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Agroambientale e Forestale (IBAF-CNR); Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR)			Heltai, Silvia/AAN-4078-2020; Rovere-Querini, Patrizia/J-2340-2012; Ferrarini, Marina/AAO-1548-2020; Manfredi, Angelo A./C-7018-2014; sciorati, clara/K-4823-2016	Heltai, Silvia/0000-0002-3842-5595; Manfredi, Angelo A./0000-0001-8370-6970; Ferrarini, Marina/0000-0003-1015-9632; sciorati, clara/0000-0003-2030-9366				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Choi OH, 1996, NATURE, V380, P634; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CIFONE MG, 1993, J EXP MED, V177, P1547; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ferrarini M, 1996, JNCI-J NATL CANCER I, V88, P436, DOI 10.1093/jnci/88.7.436; FERRARINI M, 1995, J IMMUNOL, V154, P3704; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; Mao CG, 1996, P NATL ACAD SCI USA, V93, P1993, DOI 10.1073/pnas.93.5.1993; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Reiling N, 1996, EUR J IMMUNOL, V26, P511, DOI 10.1002/eji.1830260302; ROONEY E, 1996, J BIOL CHEM, V270, P29304; Rovere P, 1996, J IMMUNOL, V156, P4631; Skowronski EW, 1996, CELL DEATH DIFFER, V3, P171; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509	29	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23211	23215		10.1074/jbc.272.37.23211	http://dx.doi.org/10.1074/jbc.272.37.23211			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287328	hybrid			2022-12-25	WOS:A1997XV74400039
J	Chen, CD; Doray, B; Kemper, B				Chen, CD; Doray, B; Kemper, B			Efficient assembly of functional cytochrome P450 2C2 requires a spacer sequence between the N-terminal signal anchor and catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; PROLINE-RICH REGION; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; MEMBRANE; PROTEINS; IDENTIFICATION; GLYCOSYLATION; ORIENTATION; EXPRESSION	Cytochromes P450 (P450) are anchored to the endoplasmic reticulum membrane by an N-terminal transmembrane sequence with the catalytic domain facing the cytoplasmic side, Within the peptide sequence linking these two domains in P450 2C2 is a glycine-rich region from residues 22 to 28, To examine the role of this region, deletion and substitution mutations were constructed, and the activities and spectral properties were determined for the mutant proteins expressed in COS-1 cells, insect cells, and bacteria, Deletion of residues 22 to 28 or substitution of 7 valines for this region inactivated the proteins in COS-1 cells, and no P450 species was detected for these mutations in bacteria or insect cells, Substitution of the three glycine residues with alanine or proline or the entire sequence from 22 to 28 with 7 alanines did not reduce lauric acid hydroxylase activity of the proteins expressed in COS-1 cells, Reducing the number of alanines substituted to 4, 3, and 2 progressively decreased activity in COS-1 cells to undetectable levels when 2 alanines were substituted, The loss of activity in COS-1 cells correlated with decreased expression of hemoprotein with a reduced difference spectrum of 450 nm (P450 species) and a corresponding increase in the inactive P420 species in insect cells and bacteria, The activities expressed per nanomole of P450 in insect microsomes were similar for P450 2C2 and the alanine substitution mutants, including the mutant with 2 alanines which was inactive in COS-1 cells, The rates of conversion of P450 to P420 resulting from incubation at 48 degrees C in vitro were not changed sufficiently to explain the increase in expressed P420 observed for the mutants with 3 or 7 alanines substituted, These data are consistent with a role for the residue 22-28 region as a linker that facilitates the folding of P450; however, once the protein is properly folded into the functional P450 species, this region has little influence on the stability and activity of the enzyme.	UNIV ILLINOIS, COLL MED, DEPT MOL & INTEGRAT PHYSIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, COLL MED, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Doray, Balraj/0000-0003-3347-5013	NIGMS NIH HHS [GM35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Chen CD, 1996, J BIOL CHEM, V271, P28607, DOI 10.1074/jbc.271.45.28607; CHOU KC, 1995, PROTEINS, V21, P319, DOI 10.1002/prot.340210406; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Deisenhofer, 1990, CURRENT TOPICS MEMBR, V36, P53; Dong MS, 1996, BIOCHEMISTRY-US, V35, P10031, DOI 10.1021/bi960873z; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; KING RD, 1990, J MOL BIOL, V216, P441, DOI 10.1016/S0022-2836(05)80333-X; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LEVIN JM, 1988, BIOCHIM BIOPHYS ACTA, V955, P283, DOI 10.1016/0167-4838(88)90206-3; MAO BY, 1994, PROTEIN ENG, V7, P319, DOI 10.1093/protein/7.3.319; Martinis SA, 1996, BIOCHEMISTRY-US, V35, P14530, DOI 10.1021/bi961511u; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pernecky SJ, 1996, METHOD ENZYMOL, V272, P25, DOI 10.1016/S0076-6879(96)72005-0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; STRAUB P, 1993, J BIOL CHEM, V268, P21997; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V304, P170, DOI 10.1006/abbi.1993.1335; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; Von Wachenfeldt Claes, 1995, P183; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; YAMAZAKI S, 1993, J BIOCHEM-TOKYO, V114, P652, DOI 10.1093/oxfordjournals.jbchem.a124232; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	38	19	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22891	22897		10.1074/jbc.272.36.22891	http://dx.doi.org/10.1074/jbc.272.36.22891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278452	hybrid			2022-12-25	WOS:A1997XV49200073
J	Mertens, PR; Harendza, S; Pollock, AS; Lovett, DH				Mertens, PR; Harendza, S; Pollock, AS; Lovett, DH			Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; IV COLLAGENASE; MOLECULAR-CLONING; Y-BOX; ENHANCED EXPRESSION; PROMOTER; ELEMENT; GENES; SECRETE; ALPHA	Mesangial cell (MC) activation plays a pivotal role in the development of the end stage sclerotic lesion characteristic of most forms of chronic glomerular disease. We have previously demonstrated that RLC activation is directly linked to high level expression of the matrix metalloproteinase-2 (MMP-2) enzyme (Turck, J., Pollock, A. S., Lee, L., Marti, H.-P., and Lovett, D. H. (1996) J. Biol. Chem. 25, 15074-15083), the transcription of which is regulated in a tissue-specific fashion. Recent studies (Harendza, S., Pollock, A. Mertens, P. R., and Lovett, D. H. (1995) J. Biol. Chem. 270, 18786-18796) delineated a strong cis-acting enhancer element, designated MMP-2 RE1, within the 5'-flanking region of the rat MMP-2 gene. Gel shift, DNA footprint, and transcriptional analyses mapped the enhancer element to a unique 40-base pair (bp) sequence located at -1322 to -1282 bp relative to the translational start site. Bromodeoxyuridine-substituted UV cross-linking of the 40-bp enhancer element with MC nuclear extracts yielded a single protein of 52 kDa, while Southwestern blot analysis with MMP-2 RE1 demonstrated three hybridizing nuclear proteins of 52, 62, and 86 kDa size. Screening of a human MC cDNA expression library with MMP-2 RE1 exclusively yielded clones with the identical sequence of the transcription factor YB-1. Western blot and supershift gel analysis of MC nuclear extracts with an anti-YB-1 antibody confirmed the presence of YB-1 within the shifted complex. Examination of the MMP-2 RE1 sequence revealed an incomplete Y-box sequence (CTGCTGGGCAAG), which specifically interacted with recombinant YB-1 on DMS protection footprinting analysis. YB-1 protein preferentially bound the single-stranded components of the 40-bp MMP-2 RE1 and, with increasing concentrations, formed multimeric complexes. Co-transfection of YB-1 in MC increased the enhancer activity within the context of the native MMP-2 promoter, while transfection of non-MMP-2-synthesizing glomerular epithelial cells with YB-1 led to transcriptional suppression. This study indicates that YB-1 is a major, cell type-specific transactivator of MMP-2 transcription by glomerular mesangial cells.	UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,DEPT MED 111J,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Mertens, Peter/AAI-7310-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031398, R01DK039776, R56DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39776, DK 31398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CAROME MA, 1994, J AM SOC NEPHROL, V5, P1391; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; COHEN I, 1991, NUCLEIC ACIDS RES, V19, P4753, DOI 10.1093/nar/19.17.4753; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; JOHNSON R, 1992, J AM SOC NEPHROL, V2, P1388; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LOVETT DH, 1992, AM J PATHOL, V141, P85; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; McMillan JI, 1996, J CLIN INVEST, V97, P1094, DOI 10.1172/JCI118502; Ohga T, 1996, CANCER RES, V56, P4224; OZER J, 1990, J BIOL CHEM, V265, P22143; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAKURA H, 1988, GENE, V73, P499; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SREENATH T, 1992, CANCER RES, V52, P4942; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YAN C, 1991, P NATL ACAD SCI USA, V88, P144, DOI 10.1073/pnas.88.1.144; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	37	135	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22905	22912		10.1074/jbc.272.36.22905	http://dx.doi.org/10.1074/jbc.272.36.22905			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278454	hybrid			2022-12-25	WOS:A1997XV49200075
J	Mihara, H; Kurihara, T; Yoshimura, T; Soda, K; Esaki, N				Mihara, H; Kurihara, T; Yoshimura, T; Soda, K; Esaki, N			Cysteine sulfinate desulfinase, a NIFS-like protein of Escherichia coli with selenocysteine lyase and cysteine desulfurase activities - Gene cloning, purification, and characterization of a novel pyridoxal enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXY-ACID DEHYDRATASE; BETA-SUBSTITUTED ALANINES; ACTIVE-SITE PEPTIDE; FE-S CLUSTER; NUCLEOTIDE-SEQUENCE; NITROGEN-FIXATION; AZOTOBACTER-VINELANDII; AMINO-ACID; D-ISOMERS; IN-VITRO	Selenocysteine lyase (EC 4.4.1.16) exclusively decomposes selenocysteine to alanine and elemental selenium, whereas cysteine desulfurase (NIFS protein) of Azotobacter vinelandii acts indiscriminately on both cysteine and selenocysteine to produce elemental sulfur and selenium respectively, and alanine. These proteins exhibit some sequence homology, The Escherichia coli genome contains three genes with sequence homology to nifS. We have cloned the gene mapped at 63.4 min in the chromosome and have expressed, purified to homogeneity, and characterized the gene product, The enzyme comprises two identical subunits with 401 amino acid residues (M-r 43,238) and contains pyridoxal 5'-phosphate as a coenzyme. The enzyme catalyzes the removal of elemental sulfur and selenium atoms from L-cysteine, L-cystine, L-selenocysteine, and L-selenocystine to produce L-alanine, Because L-cysteine sulfinic acid was desulfinated to form L-alanine as the preferred substrate, we have named this new enzyme cysteine sulfinate desulfinase. Mutant enzymes having alanine substituted for each of the four cysteinyl residues (Cys-100, Cys-176, Cys-323, and Cys-358) were all active, Cys-358 corresponds to Cys-325 of A. vinelandii NIFS, which is conserved among all NIFS-like proteins and catalytically essential (Zheng, L., White, R. H., Cash, V. L., and Dean, D. R. (1994) Biochemistry 33, 4714-4720), is not required for cysteine sulfinate desulfinase. Thus, the enzyme is distinct from A. vinelandii NIFS in this respect.	KYOTO UNIV, INST CHEM RES, MICROBIAL BIOCHEM LAB, UJI, KYOTO 611, JAPAN; KANSAI UNIV, FAC ENGN, DEPT BIOTECHNOL, SUITA, OSAKA 564, JAPAN	Kyoto University; Kansai University			Mihara, Hisaaki/F-2172-2010	Mihara, Hisaaki/0000-0002-5153-4403				Aiba H, 1996, DNA Res, V3, P363, DOI 10.1093/dnares/3.6.363; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BADET B, 1984, BIOCHEMISTRY-US, V23, P5188, DOI 10.1021/bi00317a016; BEYNON J, 1987, J BACTERIOL, V169, P4024, DOI 10.1128/jb.169.9.4024-4029.1987; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRAUNSTEIN AE, 1969, BIOCHIM BIOPHYS ACTA, V171, P366, DOI 10.1016/0005-2744(69)90173-9; CHOCAT P, 1983, J BACTERIOL, V156, P455, DOI 10.1128/JB.156.1.455-457.1983; CHOCAT P, 1985, J BACTERIOL, V163, P669, DOI 10.1128/JB.163.2.669-676.1985; ESAKI N, 1982, J BIOL CHEM, V257, P4386; ESAKI N, 1988, METALLOPROTEINS, P429; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flint DH, 1996, J BIOL CHEM, V271, P16068; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P232, DOI 10.1073/pnas.91.1.232; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HEIDER J, 1993, ADV MICROB PHYSIOL, V35, P71, DOI 10.1016/S0065-2911(08)60097-1; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HOSOKAWA Y, 1990, BIOCHEM BIOPH RES CO, V168, P473, DOI 10.1016/0006-291X(90)92345-Z; JACKMAN DM, 1995, MICROBIOL-UK, V141, P2235, DOI 10.1099/13500872-141-9-2235; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KISHORE GM, 1984, J BIOL CHEM, V259, P669; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINWEBER FJ, 1987, METHOD ENZYMOL, V143, P15; LEONGMORGENTHALER P, 1994, BIOCHIMIE, V76, P45, DOI 10.1016/0300-9084(94)90061-2; LYONS EM, 1995, J BACTERIOL, V177, P1570, DOI 10.1128/jb.177.6.1570-1575.1995; MASEPOHL B, 1993, MOL GEN GENET, V238, P369, DOI 10.1007/BF00291996; MEHTA PK, 1993, EUR J BIOCHEM, V211, P373, DOI 10.1111/j.1432-1033.1993.tb19907.x; MEIJER WG, 1992, J BACTERIOL, V174, P3855, DOI 10.1128/jb.174.12.3855-3866.1992; MULLIGAN ME, 1989, J BIOL CHEM, V264, P19200; Neuhierl B, 1996, EUR J BIOCHEM, V239, P235, DOI 10.1111/j.1432-1033.1996.0235u.x; OBrien C, 1997, NATURE, V385, P472, DOI 10.1038/385472a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RECASENS M, 1980, BIOCHEMISTRY-US, V19, P4583, DOI 10.1021/bi00561a007; Reymond I, 1996, BBA-GENE STRUCT EXPR, V1307, P152, DOI 10.1016/0167-4781(96)00068-1; ROISE D, 1984, BIOCHEMISTRY-US, V23, P5195, DOI 10.1021/bi00317a017; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SINGH M, 1989, MOL GEN GENET, V219, P235, DOI 10.1007/BF00261182; SODA K, 1964, BIOCHEMISTRY-US, V3, P1450, DOI 10.1021/bi00898a010; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; TATE SS, 1969, BIOCHEMISTRY-US, V8, P5016, DOI 10.1021/bi00840a051; THIEL T, 1995, P NATL ACAD SCI USA, V92, P9358, DOI 10.1073/pnas.92.20.9358; UENO H, 1982, BIOCHEMISTRY-US, V21, P4387, DOI 10.1021/bi00261a030; VERES Z, 1994, J BIOL CHEM, V269, P10597; WALSH CT, 1986, VITAMIN B6 PYRIDOXAL, P43; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO Y, 1977, DNA RES, V4, P91; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	61	142	150	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22417	22424		10.1074/jbc.272.36.22417	http://dx.doi.org/10.1074/jbc.272.36.22417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278392	Green Submitted, hybrid			2022-12-25	WOS:A1997XV49200011
J	Guo, WT; Baluda, MA; Park, NH				Guo, WT; Baluda, MA; Park, NH			Ethanol upregulates the expression of p21(WAF1/CIP1) and prolongs G(1) transition via a p53-independent pathway in human epithelial cells	ONCOGENE			English	Article						ethanol; p53; p21(WAF1/CIP1); cell cycle	HUMAN ORAL KERATINOCYTES; WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; ALCOHOL-CONSUMPTION; HUMAN PAPILLOMAVIRUS; SIGNAL-TRANSDUCTION; HUMAN-LYMPHOCYTES; LEUKEMIC-CELLS; DNA-DAMAGE; APOPTOSIS	The control of cell cycle progression is necessary for accuracy in the replication of DNA and the distribution of genetic information to daughter cells, Disturbances in progression of the cell cycle may result in the loss of genomic integrity, a 'hallmark' of cancer cells, Extensive consumption of alcoholic beverages is a risk with the development of various associated epidermoid cancer including oral and pharyngeal squamous cell carcinomas, However, effects of ethanol on cell cycle progression and on the expression of genes associated with the cell cycle have not been studied. We report here that exposure of human epithelial cells to ethanol, at concentrations (100-200 mM) that do not cause cell death, (a) does not affect or only reduces slightly the cellular level of p53 protein, (b) upregulates the transcription of the WAF1/CIP1 gene, (c) inhibits the Cdk2 activity, and (d) reduces the rate of cellular proliferation by inducing a delay in G(1) phase transition, The results also indicate that, at these non-cytotoxic concentrations, ethanol exhibits its effects through a p53-independent mechanism.	UNIV CALIF LOS ANGELES, DENT RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH DENT, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P20DE010598, P50DE010598] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10598] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHLUWALIA BS, 1995, ALCOHOL, V12, P589, DOI 10.1016/0741-8329(95)02008-X; ANDERSON LM, 1995, ALCOHOL, V12, P97, DOI 10.1016/0741-8329(94)00089-1; BAEK JH, 1994, INT J ONCOL, V5, P1023; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BLOT WJ, 1994, CANCER SURV, V20, P23; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Deleyiannis FWB, 1996, JNCI-J NATL CANCER I, V88, P542, DOI 10.1093/jnci/88.8.542; DEPETRILLO PB, 1993, ALCOHOL CLIN EXP RES, V17, P351, DOI 10.1111/j.1530-0277.1993.tb00774.x; DIAMOND I, 1994, EXS, V71, P175; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELMORE JG, 1995, OTOLARYNG HEAD NECK, V113, P253, DOI 10.1016/S0194-5998(95)70114-1; EWALD SJ, 1993, ALCOHOL CLIN EXP RES, V17, P359, DOI 10.1111/j.1530-0277.1993.tb00776.x; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; Hsieh KP, 1996, J BIOL CHEM, V271, P2709, DOI 10.1074/jbc.271.5.2709; KASTAN MB, 1991, CANCER RES, V51, P6304; KO YC, 1995, J ORAL PATHOL MED, V24, P450, DOI 10.1111/j.1600-0714.1995.tb01132.x; Kobayashi T, 1995, ONCOGENE, V11, P2311; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LONGNECKER MP, 1995, ALCOHOL, V12, P87, DOI 10.1016/0741-8329(94)00088-3; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAIER H, 1994, ALCOHOL CLIN EXP RES, V18, P387, DOI 10.1111/j.1530-0277.1994.tb00030.x; MILES MF, 1991, J BIOL CHEM, V266, P2409; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUFTI SI, 1992, CANCER DETECT PREV, V16, P157; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; RABIN RA, 1983, J PHARMACOL EXP THER, V227, P551; Seitz H K, 1992, Eur J Cancer Prev, V1 Suppl 3, P5, DOI 10.1097/00008469-199210003-00002; SHAO H, 1995, CELL IMMUNOL, V164, P11, DOI 10.1006/cimm.1995.1137; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPINOZZI F, 1993, GASTROENTEROLOGY, V105, P1490, DOI 10.1016/0016-5085(93)90156-7; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILKE N, 1994, EXS, V71, P49; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1995, CANCER RES, V55, P668	43	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1143	1149		10.1038/sj.onc.1201287	http://dx.doi.org/10.1038/sj.onc.1201287			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294607				2022-12-25	WOS:A1997XU99100003
J	Sundfors, CH; Collan, YUI				Sundfors, CH; Collan, YUI			Target length and primer concentration affect the gain of c-erbB2 and p53 amplicons	FASEB JOURNAL			English	Article						quantitative polymerase chain reaction; primer; DNA synthesis; optical density; target sequence	POLYMERASE CHAIN-REACTION; AQUATICUS DNA-POLYMERASE; THERMUS-AQUATICUS; PCR; QUANTITATION; PRODUCTS; BASICS	Although quantitative polymerase chain reaction (PCR) using internal standards may perform reproducibly, the calibration of the normal level is problematic, Three test sequences (171, 213, and 260 base pairs [bp]) from the c-erbB2 oncogene were separately coamplified with a 133 bp control sequence from the single copy gene p53 in differential PCR, Sequence length differences between the oncogene and control sequences influenced the ratio estimates, obviously because of less efficient synthesis of the longer sequence, Increase in primer concentration of the longer oncogene sequences adjusted this imbalance, and the expected ratio of 1.0 could be reached, The primer or target sequence also influenced the ratio estimate, since the 171 bp oncogene sequence was as efficiently synthesized as the 133 bp control sequence but with lower primer concentration, The 260 bp oncogene sequence produced the most stable results, probably because of clear band separation in polyacrylamide gel electrophoresis. A ratio estimate of 1.0 was produced by oncogene and control gene printer concentrations of 3.5 pmol/ mu 1 and 0.6 pmol/mu 1, respectively. Calibrated quantitative PCR methodology is applicable to many areas and offers an excellent tool for screening allele deletions, supernumerary alleles, or chromosomes associated with familial diseases or disease syndromes.			Sundfors, CH (corresponding author), UNIV TURKU, DEPT PATHOL, BIOCITY 6TH FLOOR, TYKISTOKATU 6B, FIN-20520 TURKU, FINLAND.							BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRISCOE WT, 1993, BREAST CANCER RES TR, V28, P45, DOI 10.1007/BF00666355; CHIEN A, 1976, J BACTERIOL, V127, P1550, DOI 10.1128/JB.127.3.1550-1557.1976; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; FRYE RA, 1989, ONCOGENE, V4, P1153; KARP C, 1996, CELL MOL BIOL CONCEP, P573; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; SUNDFORS C, 1995, CELL MOL BIOL, V41, P671; Sundfors C, 1996, ELECTROPHORESIS, V17, P44, DOI 10.1002/elps.1150170108; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Zimmermann K, 1996, BIOTECHNIQUES, V21, P480	12	4	4	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1997	11	11					897	903		10.1096/fasebj.11.11.9285488	http://dx.doi.org/10.1096/fasebj.11.11.9285488			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285488				2022-12-25	WOS:A1997XT79000009
J	Pierre, Y; Breyton, C; Lemoine, Y; Robert, B; Vernotte, C; Popot, JL				Pierre, Y; Breyton, C; Lemoine, Y; Robert, B; Vernotte, C; Popot, JL			On the presence and role of a molecule of chlorophyll a in the cytochrome b(6)f complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTERS; ELECTRON-TRANSFER; CHLAMYDOMONAS-REINHARDTII; GLYCOGEN-PHOSPHORYLASE; BF COMPLEX; EVOLUTION; PROTEINS; POLYPEPTIDES; METABOLISM; SPECTRA	Highly purified preparations of cytochrome b(6)f complex from the unicellar freshwater alga Chlamydomonas reinhardtii contain about 1 molecule of chlorophyll a/cytochrome f. Several lines of evidence indicate that the chlorophyll is an authentic component of the complex rather than a contaminant. In particular, (i) the stoichiometry is constant; (ii) the chlorophyll is associated with the complex at a specific binding site, as evidenced by resonance Raman spectroscopy; (iii) it does not originate from free chlorophyll released from thylakoid membranes upon solubilization; and (iv) its rate of exchange with free, radioactive chlorophyll a is extremely slow (weeks). Some of the putative functional roles for a chlorophyll in the b(6)f complex are experimentally ruled out, and its possible evolutionary origin is briefly discussed.	INST BIOL PHYSICOCHIM, F-75005 PARIS, FRANCE; UNIV PARIS 07, CNRS UPR 9052, F-75005 PARIS, FRANCE; UNIV LILLE, F-75005 PARIS, FRANCE; ECOLE NORMALE SUPER, CNRS URA 1810, F-75005 PARIS, FRANCE; CTR ETUD SACLAY, CEA, CNRS URA 2096, F-91191 GIF SUR YVETTE, FRANCE; CNRS, UPR 9061, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; Universite de Lille; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Robert, Bruno/D-1264-2012	Robert, Bruno/0000-0001-5999-4538				AJLANI G, 1995, BBA-BIOENERGETICS, V1231, P189, DOI 10.1016/0005-2728(95)00086-X; ATTEIA A, 1992, J BIOL CHEM, V267, P226; Bald D., 1992, RES PHOTOSYNTHESIS, VI, P629; Barr R, 1971, METHOD ENZYMOL, V23, P372; BENNOUN P, 1995, P NATL ACAD SCI USA, V92, P10202, DOI 10.1073/pnas.92.22.10202; BLANKENSHIP RE, 1992, PHOTOSYNTH RES, V33, P91, DOI 10.1007/BF00039173; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; BRITTON G, 1985, METHOD ENZYMOL, V111, P113, DOI 10.1016/S0076-6879(85)11007-4; CASTRESANA J, 1995, J MOL BIOL, V250, P202, DOI 10.1006/jmbi.1995.0371; CASTRESANA J, 1995, TRENDS BIOCHEM SCI, V20, P443, DOI 10.1016/S0968-0004(00)89098-2; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; Dawson R.M.C., 1986, DATA BIOCH RES, V3rd, P232; EICHENBERGER W, 1962, HELV CHIM ACTA, V45, P974, DOI 10.1002/hlca.19620450325; FEILER U, 1994, J RAMAN SPECTROSC, V25, P365, DOI 10.1002/jrs.1250250513; FUJIWARA M, 1986, J PHYS CHEM-US, V90, P5646, DOI 10.1021/j100280a033; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Hauska G., 1996, OXYGENIC PHOTOSYNTHE, P377; HOLM L, 1995, EMBO J, V14, P1287, DOI 10.1002/j.1460-2075.1995.tb07114.x; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; Joliot A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P615; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1984, BIOCHIM BIOPHYS ACTA, V765, P210, DOI 10.1016/0005-2728(84)90015-X; Kaneko T, 1996, DNA Res, V3, P109; KOK B, 1956, BIOCHIM BIOPHYS ACTA, V22, P399, DOI 10.1016/0006-3002(56)90172-X; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LUTZ M, 1988, BIOL APPLICATIONS RA, V3, P347; Lutz M., 1991, CHLOROPHYLLS, P855; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MARCUS RA, 1993, ANGEW CHEM INT EDIT, V32, P1111, DOI 10.1002/anie.199311113; MEYER TE, 1994, BIOSYSTEMS, V33, P167, DOI 10.1016/0303-2647(94)90002-7; NAVEKE A, 1997, IN PRESS J RAMAN SPE; NITSCHKE W, 1997, PHOTOSYNTHESIS COMPR; OLSON JM, 1987, ORIGINS LIFE EVOL B, V17, P419, DOI 10.1007/BF02386479; PALM D, 1990, BIOCHEMISTRY-US, V29, P1099, DOI 10.1021/bi00457a001; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; POPOT JL, 1995, PHOTOSYNTHESIS LIGHT, V2, P507; RICH PR, 1987, BIOCHIM BIOPHYS ACTA, V892, P138, DOI 10.1016/0005-2728(87)90256-8; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Watanabe T., 1991, CHLOROPHYLLS, P287; Woodbury NW, 1995, ANOXYGENIC PHOTOSYNT, P527, DOI [DOI 10.1007/0-306-47954-0_24, 10.1007/0-306-47954-0_24]	43	87	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21901	21908		10.1074/jbc.272.35.21901	http://dx.doi.org/10.1074/jbc.272.35.21901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268323	hybrid			2022-12-25	WOS:A1997XT85000035
J	Schwemmle, M; De, B; Shi, LC; Banerjee, A; Lipkin, WI				Schwemmle, M; De, B; Shi, LC; Banerjee, A; Lipkin, WI			Borna disease virus P-protein is phosphorylated by protein kinase C epsilon and casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; STRAND RNA VIRUS; BLOOD MONONUCLEAR-CELLS; VIRAL PHOSPHOPROTEIN-P; TRANSCRIPTIONAL ACTIVITY; PSYCHIATRIC-PATIENTS; INFECTED-CELLS; RAT-BRAIN; EXPRESSION; BDV	Borna disease virus (BDV) is a newly classified nonsegmented negative-strand RNA virus (order of Mononegavirales) that persistently infects specific brain regions and circuits of warm-blooded animals to cause behavioral disturbances. Viruses within the order of Mononegavirales have phosphoproteins that typically serve as transcription factors and are modulated in functional activity through phosphorylation. To identify the kinases involved in BDV phosphoprotein (BDV-P) phosphorylation, in vitro phosphorylation as says were performed using recombinant phosphoprotein produced in Escherichia coli as substrate and cytoplasmic extracts from a rat glioma cell line (C6) or rat brain extracts as sources of kinase activity. These experiments revealed that BDV-P was phosphorylated predominantly by protein kinase C (PKC) and to a lesser extent by casein kinase II. Partial purification of the PKC from rat brain extract suggested that the BDV-P phosphorylating kinase is PKC epsilon. A role for PKC phosphorylation in vivo was confirmed by using the PKC-specific inhibitor GF109203X. Furthermore, peptide mapping studies indicated that BDV-P is phosphorylated at the same sites in vitro as it is in vivo. Mutational analysis identified Ser(26) and Ser(28) as sites for PKC phosphorylation and Ser(70) and Ser(86) as sites for casein kinase II phosphorylation. The anatomic distribution of PKC epsilon in the central nervous system may have implications for BDV neurotropism and pathogenesis.	UNIV CALIF IRVINE, DEPT NEUROL ANAT & NEUROBIOL & MICROBIOL & MOL GE, LAB NEUROVIROL, IRVINE, CA 92697 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOL BIOL, CLEVELAND, OH 44195 USA	University of California System; University of California Irvine; Cleveland Clinic Foundation			Lipkin, W. Ian/ABE-6216-2020	Lipkin, W. Ian/0000-0002-8768-9386	NIAID NIH HHS [AI32027] Funding Source: Medline; NINDS NIH HHS [NS29425] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029425] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEE AK, 1991, PHARMACOL THERAPEUT, V51, P47, DOI 10.1016/0163-7258(91)90041-J; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARIK S, 1995, VIROLOGY, V213, P405, DOI 10.1006/viro.1995.0013; BODE L, 1995, NAT MED, V1, P232, DOI 10.1038/nm0395-232; Bode L, 1996, MOL PSYCHIATR, V1, P200; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRIESE T, 1994, P NATL ACAD SCI USA, V91, P4362, DOI 10.1073/pnas.91.10.4362; BRIESE T, 1992, P NATL ACAD SCI USA, V89, P11486, DOI 10.1073/pnas.89.23.11486; CARBONE KM, 1993, J VIROL, V67, P1453, DOI 10.1128/JVI.67.3.1453-1460.1993; CUBITT B, 1994, VIRUS RES, V34, P69, DOI 10.1016/0168-1702(94)90120-1; CUBITT B, 1994, J VIROL, V68, P1371, DOI 10.1128/JVI.68.3.1371-1381.1994; DAS T, 1995, J BIOL CHEM, V270, P24100, DOI 10.1074/jbc.270.41.24100; DAS T, 1995, VIROLOGY, V211, P218, DOI 10.1006/viro.1995.1394; DE BP, 1995, P NATL ACAD SCI USA, V92, P5204, DOI 10.1073/pnas.92.11.5204; DelaTorre JC, 1996, VIROLOGY, V223, P272, DOI 10.1006/viro.1996.0479; DELATORRE JC, 1994, J VIROL, V68, P7669, DOI 10.1128/JVI.68.12.7669-7675.1994; GAO Y, 1995, EMBO J, V14, P1240, DOI 10.1002/j.1460-2075.1995.tb07107.x; GOSZTONYI G, 1995, BORNA DIS, P39; IgataYi R, 1996, NAT MED, V2, P948, DOI 10.1038/nm0996-948b; KISHI M, 1995, FEBS LETT, V364, P293, DOI 10.1016/0014-5793(95)00406-Y; Kliche S, 1996, J VIROL, V70, P8133, DOI 10.1128/JVI.70.11.8133-8137.1996; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LUDWIG H, 1988, PROG MED VIROL, V35, P107; MAZUMDER B, 1994, VIROLOGY, V205, P104, DOI 10.1006/viro.1994.1624; MAZUMDER B, 1994, VIROLOGY, V205, P93, DOI 10.1006/viro.1994.1623; MEEK DW, 1992, BIOCHEM J, V287, P1; Nakaya T, 1996, FEBS LETT, V378, P145, DOI 10.1016/0014-5793(95)01439-X; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1990, J NATL CANCER I, V82, P1734, DOI 10.1093/jnci/82.22.1734; RICHT JA, 1992, CLIN INFECT DIS, V14, P1240, DOI 10.1093/clinids/14.6.1240; SAITO N, 1993, BRAIN RES, V607, P241, DOI 10.1016/0006-8993(93)91512-Q; Sauder C, 1996, J VIROL, V70, P7713, DOI 10.1128/JVI.70.11.7713-7724.1996; SCHNEEMANN A, 1995, VIROLOGY, V210, P1, DOI 10.1006/viro.1995.1311; SCHNEIDER PA, 1994, J VIROL, V68, P5007, DOI 10.1128/JVI.68.8.5007-5012.1994; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; TAKACS AM, 1995, VIROLOGY, V208, P821, DOI 10.1006/viro.1995.1219; THIEDEMANN N, 1992, J GEN VIROL, V73, P1057, DOI 10.1099/0022-1317-73-5-1057; TOULLEC D, 1991, J BIOL CHEM, V266, P15771	39	52	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21818	21823		10.1074/jbc.272.35.21818	http://dx.doi.org/10.1074/jbc.272.35.21818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268312	hybrid			2022-12-25	WOS:A1997XT85000024
J	Doubeikovski, A; Uzan, G; Doubeikovski, Z; Prandini, MH; Porteu, F; Gisselbrecht, S; DusanterFourt, I				Doubeikovski, A; Uzan, G; Doubeikovski, Z; Prandini, MH; Porteu, F; Gisselbrecht, S; DusanterFourt, I			Thrombopoietin-induced expression of the glycoprotein IIb gene involves the transcription factor PU.1/Spi-1 in UT7-Mpl cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MEGAKARYOCYTIC FEATURES; ACTIVATION PROPERTIES; PLATELET ACTIVATION; HEMATOPOIETIC-CELLS; 5'-FLANKING REGION; RECEPTOR MPL; ETS ONCOGENE; FACTOR PU.1; GPIIB GENE	Thrombopoietin (TPO) is the major regulator of proliferation and differentiation of megakaryocytes and their progenitors. These actions can be reproduced in the human megakaryoblastic cell line UT7 into which the murine TPO receptor, c-Mpl, was introduced, In these cells, TPO enhanced the expression of the specific megakaryocytic marker integrin glycoprotein (GP) IIb-IIIa while decreasing the expression of erythroid genes (Porteu, F,, Rouyez, M.-C., Cocault, L,, Benit, L,, Charon, M., Picard, F., Gisselbrecht, S,, Souyri, M., and Dusanter-Fourt I, (1996) Mol Cell. Biol 16, 2473-2482. We have now analyzed the effect of TPO on the transcriptional activity of the GPIIb promoter in these cells, Using transient transfection assays of a series of human GPIIb promoter fragments, we delineated a TPO-responsive element within the previously reported enhancer region of the promoter. Although this enhancer included GATA- and Ets-binding sites (EBSs), we found that only EBS -514 was important for TPO response, We identified PU.1/Spi-1 as the endogenous Ets transcription factor that strongly and preferentially interacted with this enhancer EBS. This factor did not interact with other proximal EBSs in the GPIIb promoter. We next showed that TPO) induced a strong and selective increase of PU.1/Spi-1 expression and DNA binding activity in UT7-Mpl cells, in contrast, TPO did not affect the expression of Ets-1/2 while weakly increasing the levels of Fli-1. Overexpression of PU.1/Spi-1 was further shown to enhance GPIIb promoter activity in the absence and presence of TPO. Overall, our data indicated that, in UT7-Mpl cells, TPO increased the transcriptional activity of a GPIIb gene in part due to an enhanced expression of an unexpected transcription factor, the Eb family PU.1/Spi-1 factor, To our knowledge, this is the first evidence of a role for the PU.1/Spi-1 factor in the regulation of megakaryocytic genes.	HOP COCHIN, INSERM U363, INST COCHIN GENET MOL, F-75014 PARIS, FRANCE; HOP PAUL BROUSSE, INSERM U268, F-94807 VILLEJUIF, FRANCE; CEA, F-38054 GRENOBLE 9, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA			PORTEU, Françoise/I-8445-2016; Dusanter-Fourt, Isabelle/P-4558-2017; Uzan, Georges/M-8199-2018	PORTEU, Françoise/0000-0002-2403-4163; Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Uzan, Georges/0000-0002-0178-5386				Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BLOCK KL, 1994, BLOOD, V84, P3385; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; CarverMoore K, 1996, BLOOD, V88, P803; CHEN JC, 1995, BLOOD, V86, P4054, DOI 10.1182/blood.V86.11.4054.bloodjournal86114054; DELGADO MD, 1994, ONCOGENE, V9, P1723; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; FONG AM, 1994, J BIOL CHEM, V269, P18441; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GEGONNE A, 1992, NEW BIOL, V4, P512; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; HROMAS R, 1993, BLOOD, V82, P2998; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMATSU N, 1991, CANCER RES, V51, P341; LANZA F, 1993, J BIOL CHEM, V268, P20801; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MARTIN F, 1993, J BIOL CHEM, V268, P21606; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PAOLETTI F, 1995, BLOOD, V86, P2624; Porteu F, 1996, MOL CELL BIOL, V16, P2473; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TRONIKLEROUX D, 1995, J EXP MED, V181, P2141, DOI 10.1084/jem.181.6.2141; UZAN G, 1991, J BIOL CHEM, V266, P8932; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZUTTER MM, 1995, BLOOD, V86, P3006	43	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24300	24307		10.1074/jbc.272.39.24300	http://dx.doi.org/10.1074/jbc.272.39.24300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305885	hybrid			2022-12-25	WOS:A1997XY51500036
J	Gho, YS; Chae, CB				Gho, YS; Chae, CB			Anti-angiogenin activity of the peptides complementary to the receptor-binding site of angiogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; TUMOR-GROWTH; PROTEIN; RIBONUCLEASE; RECOGNITION; FIBRONECTIN; SEQUENCE; ADHESION; INHIBIT	Angiogenesis promotes growth and metastasis of tumor cells, In this study, we have developed two peptide antagonists of human angiogenin by deducing the codes from the antisense RNA sequence. corresponding to the receptor-binding site of angiogenin in either 5' --> 3' (chANG) or 3' --> 5' (chGNA) direction. chANG and chGNA peptides bind to angiogenin with specificity and high affinity (K-d approximate to 44 nM) and inhibit the interaction of angiogenin with actin, which is regarded as the angiogenin-binding protein on the surface of endothelial cells. The peptides inhibit the neovascularization induced by angiogenin in the chick chorioallantoic membrane assay. The anti angiogenic activity of the peptides is specific for angiogenin, and the peptides do not have any apparent effect on embryonic angiogenesis or the preexisting blood vessels. chANG and chGNA also inhibit She angiogenesis induced by the angiogenin-secreting PC 3 human prostate adenocarcinoma cells and have no direct effect on the proliferation as well as the adhesion of PC 3 cells to angiogenin. Therefore, the inhibition of the tumor-induced angiogenesis by the peptides is most likely caused by neutralization of the extracellular angiogenin secreted by PC 3 cells, Based on our results, chANG and chGNA peptides may be effective for treatment of various human tumors which secrete angiogenin.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27514	Pohang University of Science & Technology (POSTECH); University of North Carolina; University of North Carolina Chapel Hill								ACHARYA KR, 1995, P NATL ACAD SCI USA, V92, P2949, DOI 10.1073/pnas.92.7.2949; ACHARYA KR, 1994, P NATL ACAD SCI USA, V91, P2915, DOI 10.1073/pnas.91.8.2915; BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BARSHAVIT R, 1991, J CELL BIOL, V12, P335; BEINTEMA JJ, 1984, ANAL BIOCHEM, V136, P48, DOI 10.1016/0003-2697(84)90306-3; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRENTANI RR, 1988, P NATL ACAD SCI USA, V85, P364, DOI 10.1073/pnas.85.2.364; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Folkman J, 1976, Int Rev Exp Pathol, V16, P207; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; KNUTSON VP, 1988, J BIOL CHEM, V263, P14146; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOENNER M, 1994, EUR J BIOCHEM, V226, P483, DOI 10.1111/j.1432-1033.1994.tb20073.x; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; OLSON KA, 1994, CANCER RES, V54, P4576; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; PASQUALINI R, 1989, J BIOL CHEM, V264, P14566; RAINES RT, 1995, J BIOL CHEM, V270, P17180, DOI 10.1074/jbc.270.29.17180; RYBAK SM, 1989, BIOCHEM BIOPH RES CO, V162, P535, DOI 10.1016/0006-291X(89)92030-5; SHAI Y, 1987, BIOCHEMISTRY-US, V26, P669, DOI 10.1021/bi00377a002; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; SONCIN F, 1992, P NATL ACAD SCI USA, V89, P2232, DOI 10.1073/pnas.89.6.2232; SONCIN F, 1994, J BIOL CHEM, V269, P8999	33	37	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24294	24299		10.1074/jbc.272.39.24294	http://dx.doi.org/10.1074/jbc.272.39.24294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305884	hybrid			2022-12-25	WOS:A1997XY51500035
J	Guttridge, DC; Lau, A; Tran, L; Cunningham, DD				Guttridge, DC; Lau, A; Tran, L; Cunningham, DD			Thrombin causes a marked delay in skeletal myogenesis that correlates with the delayed expression of myogenin and p21(CIP1/WAF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE WITHDRAWAL; PROTEASE NEXIN-I; RECEPTOR ACTIVATION; PLASMINOGEN ACTIVATORS; MUSCLE DIFFERENTIATION; NEUROMUSCULAR SYSTEM; MOLECULAR-CLONING; NERVOUS-SYSTEM; INHIBITOR; BINDING	Thrombin is a multifunctional serine protease whose activity is regulated in the extravasculature by an extracellular inhibitor, protease nexin-l. Because protease nexin-l expression has been shown to be regulated during skeletal muscle cell differentiation, we reasoned that thrombin inactivation may be an important requirement for this developmental process, To test this hypothesis, we examined the effects of thrombin on differentiating C2C12 myoblasts. We report here that myogenesis, as scored by myotube formation, is considerably delayed by thrombin, This regulation correlated with delayed expression of myogenin and p21(CIP1/WAF1), both considered critical components of the skeletal muscle cell differentiation program, Regulation occurred at the RNA level, indicating that the effect of thrombin is either transcriptional or post-transcriptional. Further more, we present evidence suggesting that this regulation is mediated by the thrombin receptor. Although thrombin is mitogenic for certain cell types, we found that delay of myogenesis in C2C12 cells did not involve a mitogenic signal, Taken together, these results imply that inhibition of the serine protease thrombin may be required for proper progression through the myogenic differentiation program, The data point to potentially important roles that thrombin and protease nexin-l may play during skeletal muscle development.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOL GENET,IRVINE,CA 92697	University of California System; University of California Irvine				Guttridge, Denis/0000-0002-7276-6609	NIA NIH HHS [AG 10598, AG 00538] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG000538, R01AG010598] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; CARNEY DH, 1978, J CELL PHYSIOL, V95, P13, DOI 10.1002/jcp.1040950103; CHEN J, 1994, J BIOL CHEM, V269, P16041; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FESTOFF BW, 1991, J CELL PHYSIOL, V147, P76, DOI 10.1002/jcp.1041470111; FESTOFF BW, 1990, J CELL PHYSIOL, V144, P272, DOI 10.1002/jcp.1041440213; GLOOR S, 1986, CELL, V47, P687; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; GUTTRIDGE DC, 1993, J BIOL CHEM, V268, P18966; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HOUENOU LJ, 1995, P NATL ACAD SCI USA, V92, P895, DOI 10.1073/pnas.92.3.895; HUPPI K, 1994, ONCOGENE, V9, P3017; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PERRAUD F, 1987, INT J DEV NEUROSCI, V5, P181, DOI 10.1016/0736-5748(87)90028-1; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VAUGHAN PJ, 1994, BRAIN RES, V668, P160, DOI 10.1016/0006-8993(94)90521-5; VerdiereSahuque M, 1996, EXP CELL RES, V222, P70, DOI 10.1006/excr.1996.0009; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WAGNER SL, 1989, J BIOL CHEM, V264, P611; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	31	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24117	24120		10.1074/jbc.272.39.24117	http://dx.doi.org/10.1074/jbc.272.39.24117			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305855	hybrid			2022-12-25	WOS:A1997XY51500006
J	Ratovitski, T; Slunt, HH; Thinakaran, G; Price, DL; Sisodia, SS; Borchelt, DR				Ratovitski, T; Slunt, HH; Thinakaran, G; Price, DL; Sisodia, SS; Borchelt, DR			Endoproteolytic processing and stabilization of wild-type and mutant presenilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; IN-VIVO; GENE; CELLS	Presenilin 1 (PS1), mutated in pedigrees of early-onset familial Alzheimer's disease, is a polytopic integral membrane protein that is endoproteolytically cleaved into 27-kDa N-terminal and 17-kDa C-terminal fragments, Although these fragments are the principal PSI species found in normal mammalian brain, the role of endoproteolysis in the maturation of PS1 has been unclear. The present study, which uses stably transfected mouse neuroblastoma N2a cells, demonstrates that full-length polypeptides, derived from either wild-type or A246E FAD-mutant human (hu) PSII, are relatively short-lived (t(1/2), 1.5 h) proteins that give rise to the N- and C-terminal PS1 fragments, which are more stable (t(1/2) similar to 24 h), N-terminal fragments, generated artificially by engineering a stop codon at amino acid 306 (PS1-306) of wild-type huPS1, were short-lived, whereas an FAD-linked variant that lacked exon 9 (Delta E9) and was not endoproteolytically cleaved exhibited a long half-life. These observations suggest that endoproteolytic cleavage and stability are not linked, leading us to propose a model ill which wild-type full-length huPS1 molecules are first stabilized then subsequently endoproteolytically cleaved to generate the N- and C-terminal fragments, These fragments appear to represent the mature and functional Terms of wild-type huPS1.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV NEUROPATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NIA NIH HHS [AG05146, AG07914] Funding Source: Medline; NINDS NIH HHS [NS10580] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005146, R35AG007914] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; LO ACY, 1994, J BIOL CHEM, V269, P30966; LO ACY, 1995, J BIOL CHEM, V270, P12641, DOI 10.1074/jbc.270.21.12641; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SLUNT HH, 1995, AMYLOID, V2, P188, DOI 10.3109/13506129509036925; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652	24	192	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24536	24541		10.1074/jbc.272.39.24536	http://dx.doi.org/10.1074/jbc.272.39.24536			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305918	hybrid			2022-12-25	WOS:A1997XY51500069
J	Jervis, EJ; Haynes, CA; Kilburn, DG				Jervis, EJ; Haynes, CA; Kilburn, DG			Surface diffusion of cellulases and their isolated binding domains on cellulose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; CRYSTALLINE CELLULOSE; BACTERIAL CELLULASE; MEMBRANE-PROTEINS; FIMI; EXOGLUCANASE; ADSORPTION; RESIDUES; MOBILITY; CENA	The surface diffusion rate of bacterial cellulases from Cellulomonas fimi on cellulose was quantified using fluorescence recovery after photobleaching analysis. Studies were performed on an exo-beta-1-4-glycanase (Cex), an endo-beta-1-4-glucanase (CenA), and their respective isolated cellulose-binding domains (CBDs). Although these cellulose-binding domains hind irreversibly to microcrystalline cellulose, greater than 70% of bound molecules are mobile on the cellulose surface. Surface diffusion rates are dependent on surface coverage and range from a low of 2 x 10(-11) to a maximum of 1.2 x 10(-10) cm(2)/s. The fraction of mobile molecules increases only slightly with increasing fractional surface coverage density. Results demonstrate that the packing of C. fimi cellulases and their isolated binding domains onto the cellulose surface is a dynamic process. This suggests that the exclusion of potential CBD binding sites on the cellulose due to steric effects of neighboring bound CBDs may not fully explain the apparent negative cooperativity exhibited in CBD adsorption isotherms. Comparison with the kinetics of cellulase hydrolysis of crystalline substrate suggests that surface diffusion rates do not limit cellulase activity.	UNIV BRITISH COLUMBIA, BIOTECHNOL LAB, PROT ENGN NETWORK CTR EXCELLENCE, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT CHEM ENGN, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ABNEY JR, 1989, BIOPHYS J, V55, P817, DOI 10.1016/S0006-3495(89)82882-6; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BLONK JCG, 1993, J MICROSC-OXFORD, V169, P363, DOI 10.1111/j.1365-2818.1993.tb03312.x; BRINKLEY M, 1993, PERSPECTIVES BIOCONJ, P59; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; DAMUDE HG, 1995, BIOCHEMISTRY-US, V34, P2220, DOI 10.1021/bi00007a016; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; GARDNER KH, 1974, BIOPOLYMERS, V13, P1975, DOI 10.1002/bip.1974.360131005; GASPERS PB, 1994, LANGMUIR, V10, P2699, DOI 10.1021/la00020a032; GILKES NR, 1992, J BIOL CHEM, V267, P6743; GILKES NR, 1993, INT J BIOL MACROMOL, V15, P347, DOI 10.1016/0141-8130(93)90052-N; GREENWOOD JM, 1994, BIOTECHNOL BIOENG, V44, P1295, DOI 10.1002/bit.260441105; HENIS YI, 1988, BIOPOLYMERS, V27, P123, DOI 10.1002/bip.360270110; KATCHALSKIKATZIR E, 1985, BIOPOLYMERS, V24, P257, DOI 10.1002/bip.360240120; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; MINTON AP, 1989, BIOPHYS J, V55, P805, DOI 10.1016/S0006-3495(89)82880-2; ONG E, 1993, BIOTECHNOL BIOENG, V42, P401, DOI 10.1002/bit.260420402; ONG E, 1991, ENZYME MICROB TECH, V13, P59, DOI 10.1016/0141-0229(91)90189-H; PETERS R, 1974, BIOCHIM BIOPHYS ACTA, V367, P282, DOI 10.1016/0005-2736(74)90085-6; Revol JF, 1982, CARBOHYD POLYM, V2, P123; SCALETTAR BA, 1988, P NATL ACAD SCI USA, V85, P6726, DOI 10.1073/pnas.85.18.6726; STOUT AL, 1995, PHOTOCHEM PHOTOBIOL, V62, P239, DOI 10.1111/j.1751-1097.1995.tb05264.x; TILTON RD, 1990, BIOPHYS J, V58, P1321, DOI 10.1016/S0006-3495(90)82473-5; Tomme P, 1995, ACS SYM SER, V618, P142; TOMME P, 1995, J BACTERIOL, V177, P4356, DOI 10.1128/jb.177.15.4356-4363.1995; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	28	164	168	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24016	24023		10.1074/jbc.272.38.24016	http://dx.doi.org/10.1074/jbc.272.38.24016			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295354	hybrid			2022-12-25	WOS:A1997XX38100079
J	PalsRylaarsdam, R; Gurevich, VV; Lee, KB; Ptasienski, JA; Benovic, JL; Hosey, MM				PalsRylaarsdam, R; Gurevich, VV; Lee, KB; Ptasienski, JA; Benovic, JL; Hosey, MM			Internalization of the m2 muscarinic acetylcholine receptor - Arrestin-independent and -dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; CHOLINERGIC RECEPTORS; PROTEIN; AGONIST; DYNAMIN; CELLS; DESENSITIZATION; IDENTIFICATION; ENDOCYTOSIS; MECHANISMS	Recent studies have identified agonist-dependent phosphorylation as a critical event in the rapid uncoupling of the m2 muscarinic cholinergic receptors (mAChR) rom G-proteins and sequestration of the receptors away hom the cell surface, However, mutant m2 mAChRs were identified that were phosphorylated but unable to desensitize in adenylyl cyclase assays, while they internalized like wild type (WT) mAChRs, Ne have tested whether these properties might stem from differences in the abilities of the WT and mutant mAChR to bind arrestins, proteins implicated in both receptor-/G-protein uncoupling and internalization, We have de determined that arresting binding requires phosphorylation at a cluster of Ser/Thr residues ia amino acids 307-311 in the m2 mAChR, A strong correlation was found between the ability of WT and mutant receptors to bind arrestins in vitro or in vivo and to desensitize in adenylyl cyclase assays, However, the phosphorylation dependent internalization of the m2 mAChR in HEK-tsA201 cells did not require arrestins and did not proceed via clathrin-mediated endocytosis, While the m2 mAChR was able to enter a clathrin-and arrestin-dependent pathway when arrestin 2 or arrestin 3 was significantly overexpressed, the preferred pathway al internalization of WT and certain mutant m2 mAChR in HEK-tsA201 cells did not involve participation of arrestins. The results suggest that the phosphorylation-mediated regulation of the m2 mAChR may involve arrestin-dependent and -independent events.	NORTHWESTERN UNIV,SCH MED,DEPT MOL PHARMACOL & BIOL CHEM,CHICAGO,IL 60614; SUN HLTH RES INST,SUN CITY,AZ 85372; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107	Northwestern University; Banner Research; Banner Health; Banner Sun Health Research Institute; Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500] Funding Source: Medline; NHLBI NIH HHS [HL50121] Funding Source: Medline; NIGMS NIH HHS [GM4494] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUAN XM, 1992, J BIOL CHEM, V267, P21995; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LIGGETT SB, 1994, REGULATION SIGNAL TR, P25; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MORO O, 1993, J BIOL CHEM, V268, P6862; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	28	151	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23682	23689		10.1074/jbc.272.38.23682	http://dx.doi.org/10.1074/jbc.272.38.23682			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295310	hybrid			2022-12-25	WOS:A1997XX38100035
J	Arteaga, CL; Ramsey, TT; Shawver, LK; Guyer, CA				Arteaga, CL; Ramsey, TT; Shawver, LK; Guyer, CA			Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EGF-RECEPTOR; SIGNAL-TRANSDUCTION; POINT MUTATION; TRANSMEMBRANE DOMAIN; CARCINOMA-CELLS; NUCLEOTIDE-BINDING; INDUCED ACTIVATION; MEMBRANE-VESICLES; EXTERNAL DOMAIN	Receptor dimerization is critical for signaling by the epidermal growth factor receptor (EGFR) tyrosine kinase, This occurs after binding of the receptor's extracellular domain by ligand or bivalent antibodies, The role of other receptor domains in dimerization is less clear, and there are no examples of dimers induced by direct perturbation of the EGFR kinase domain, Submicromolar concentrations of AG-1478 and AG-1517, quinazolines specific for inhibition of the EGFR kinase, induced reversible receptor dimerization in vitro and in intact A431 cells, Consistent with the inhibitory effect of quinazolines on receptor kinase activity, the dimers formed lacked a detectable Tyr(P) signal. Quinazoline-induced EGFR dimerization was abrogated in vitro by ATP and the ATP analog adenyl-5'-yl imidodiphosphate, Receptors with a single-point mutation in the ATP binding site as well as wild-type EGFR with a covalent modification of the ATP site failed to dimerize in response to AG-1478 and AG-1517, These data suggest that EGFR dimerization can be induced by the interaction of quinazolines at the ATP site in the absence of receptor ligand binding, In SKBR-3 cells, the quinazolines induced the formation of inactive EGFR/ ErbB-2 heterodimers, potentially sequestering ErbB-2 from interacting with other coreceptors of the ErbB family, Structural studies of the quinazoline interaction with the EGFR tyrosine kinase domain should allow for an analysis of receptor-specific chemical features required for binding to the ATP site and disruption of signaling, a strategy that can be perhaps applied to other tumor cell receptor systems.	VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; SUGEN INC,REDWOOD CITY,CA 94063; VANDERBILT UNIV,DEPT MOL BIOL,NASHVILLE,TN 37235	Vanderbilt University; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), VANDERBILT UNIV,SCH MED,DIV MED ONCOL,VANDERBILT CANC CTR,DEP MED,1161 22ND AVE S,1956 TVC,NASHVILLE,TN 37232, USA.				NATIONAL CANCER INSTITUTE [R55CA065943, R01CA062212] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA62212, R55 CA65943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ARTEAGA CL, 1994, CANCER RES, V54, P4703; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASU M, 1986, J BIOL CHEM, V261, P2879; BUHROW SA, 1982, J BIOL CHEM, V257, P4019; BUHROW SA, 1983, J BIOL CHEM, V258, P7824; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1993, FORUM, V3, P616; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Cheng KR, 1996, J BIOL CHEM, V271, P311, DOI 10.1074/jbc.271.1.311; COCHET C, 1988, J BIOL CHEM, V263, P3290; COHEN S, 1982, J BIOL CHEM, V257, P1523; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1994, J BIOL CHEM, V269, P27595; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; GUYER CA, 1994, ARCH BIOCHEM BIOPHYS, V312, P573, DOI 10.1006/abbi.1994.1347; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; IMAI Y, 1982, CANCER RES, V42, P4394; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KWATRA MM, 1992, BIOCHIM BIOPHYS ACTA, V1134, P178, DOI 10.1016/0167-4889(92)90042-A; LANGTON BC, 1991, CANCER RES, V51, P2593; LAX I, 1991, J BIOL CHEM, V266, P13828; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; QIAN XL, 1994, ONCOGENE, V9, P1507; RUSSO MW, 1985, J BIOL CHEM, V260, P5205; SELVA E, 1993, J BIOL CHEM, V268, P2250; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STOSCHECK CM, 1983, ARCH BIOCHEM BIOPHYS, V227, P457, DOI 10.1016/0003-9861(83)90476-9; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Zhang K, 1996, J BIOL CHEM, V271, P3884	61	125	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23247	23254		10.1074/jbc.272.37.23247	http://dx.doi.org/10.1074/jbc.272.37.23247			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287333	hybrid			2022-12-25	WOS:A1997XV74400044
J	Bailly, V; Lauder, S; Prakash, S; Prakash, L				Bailly, V; Lauder, S; Prakash, S; Prakash, L			Yeast DNA repair proteins Rad6 and Rad18 form a heterodimer that has ubiquitin conjugating, DNA binding, and ATP hydrolytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MUTAGENESIS; SEQUENCE; UV; MUTATIONS; ENCODES; ENZYME	The RAD6 and RAD18 genes of Saccharomyces cerevisiae are required far postreplicative bypass of ultraviolet (UV)-damaged DNA and for UV mutagenesis. The RAD6 encoded protein is a ubiquitin conjugating enzyme, and RAD18 encodes a protein containing a RING finger motif and a nucleotide binding motif, Rad18 can be co-immunoprecipitated with Rad6, indicating that the two proteins exist in a complex in vivo. Here, we co-overproduce the two proteins using a yeast multicopy plasmid, purify the Rad6-Rad18 complex to near homogeneity, and show that the complex is heterodimeric. The Rad6-Rad18 heterodimer has ubiquitin conjugating activity, binds single-stranded DNA, and possesses single-stranded DNA-dependent ATPase activity. The Rad6-Rad18 complex provides the first example wherein a ubiquitin conjugating activity is physically associated with DNA binding and ATPase activities provided by an associated protein factor, The co-existence of these activities should provide the complex with the ability to recognize single-stranded DNA resulting from stalling of the replication machinery at DNA damage sites and to recognize the components of the DNA replication machinery for ubiquitination by Rad6.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG JD, 1994, MUTAT RES-DNA REPAIR, V315, P281, DOI 10.1016/0921-8777(94)90039-6; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; FRIEDBERG EC, 1995, DNA REPAIR; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAWRENCE CW, 1982, ADV GENET, V21, P173, DOI 10.1016/S0065-2660(08)60299-0; LAWRENCE CW, 1985, MOL GEN GENET, V200, P86, DOI 10.1007/BF00383317; LEMONTT JF, 1970, GENETICS, V68, P21; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023	22	245	253	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23360	23365		10.1074/jbc.272.37.23360	http://dx.doi.org/10.1074/jbc.272.37.23360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287349	hybrid			2022-12-25	WOS:A1997XV74400060
J	Adeli, K; Macri, J; Mohammadi, A; Kito, M; Urade, R; Cavallo, D				Adeli, K; Macri, J; Mohammadi, A; Kito, M; Urade, R; Cavallo, D			Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOPLASMIC-RETICULUM; G2 CELLS; HEP-G2 CELLS; RAT-LIVER; DEGRADATION; SECRETION; TRANSLOCATION; LIPOPROTEINS; MEMBRANE; GOLGI	Two ALLN (N-acetyl-leucyl-leucyl-norleucinal)-sensitive endoplasmic reticulum (ER)-localized proteases (ER-60 and ER-72) were recently purified from rat liver, We used an antibody to rat ER-60 to investigate the possible role of this protease in apolipoprotein B (apoB) degradation, First, immunoprecipitation and immunoblotting experiments with the anti-rat ER-60 antibody suggested that HepG2 cells contain a homologue of ER-60 with an approximate molecular mass of 58-60 kDa. The ER-60 homologue was mostly associated with the luminal contents of HepG2 microsomes, Evidence from co-immunoprecipitation and cross-linking experiments appear to suggest that the ER-60 homologue in HepG2 cells is associated with apoB intracellularly. A small pool of apoB was recovered when HepG2 lysates were subjected to immunoprecipitation with anti-rat ER-60 antibody followed by a second immunoprecipitation with anti-apoB antibody, Furthermore, cross-linking of permeabilized cells with dithiobis(succinimidylpropionate) further demonstrated association of apoB with the ER-60 homologue in HepG2 cells, Three polypeptides with molecular masses of 78, 66, and 50 kDa were consistently found to be associated with apoB as well as the 58-kDa ER-60 homologue, The 78-kDa protein associated with both apoB and ER-60 appeared to represent immunoglobulin heavy chain-binding protein (BiP) based on immunoprecipitation with a monoclonal antibody, Cross-linking and immunoblotting experiments suggested the association of the 78-kDa BiP with both the 58-kDa ER-60 homologue as well as the 550-kDa apoB. In summary, the data suggests that HepG2 cells contain a 58-kDa protein which is homologous to the rat liver ER-60 in size, antigenecity, and intracellular localization, The ER-60 homologue in HepG2 cells appears to be closely associated with apoB, as well as other proteins possibly representing ER chaperones such as BiP, We hypothesize that the ER-60 homologue may be involved in the degradation of apoB in the ER lumen of HepG2 cells.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University	Adeli, K (corresponding author), UNIV WINDSOR,DEPT CHEM & BIOCHEM,401 SUNSET AVE,WINDSOR,ON N9B 3P4,CANADA.			Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1994, J BIOL CHEM, V269, P9166; Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; ADELI K, 1990, FEBS LETT, V2, P345; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DU EZ, 1994, J BIOL CHEM, V269, P24169; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; HJELMELAND LM, 1980, P NATL ACAD SCI-BIOL, V77, P6368, DOI 10.1073/pnas.77.11.6368; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macri J, 1997, J BIOL CHEM, V272, P7328, DOI 10.1074/jbc.272.11.7328; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALLACH SM, 1995, BBA-MOL CELL RES, V1265, P29, DOI 10.1016/0167-4889(95)00239-O; SATO R, 1990, J BIOL CHEM, V265, P11880; Sparks Janet D., 1993, Current Opinion in Lipidology, V4, P177, DOI 10.1097/00041433-199306000-00002; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; URADE R, 1993, J BIOL CHEM, V268, P22004; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	30	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22489	22494		10.1074/jbc.272.36.22489	http://dx.doi.org/10.1074/jbc.272.36.22489			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278400	hybrid			2022-12-25	WOS:A1997XV49200020
J	Brenner, B; Koppenhoefer, U; Weinstock, C; Linderkamp, O; Lang, F; Gulbins, E				Brenner, B; Koppenhoefer, U; Weinstock, C; Linderkamp, O; Lang, F; Gulbins, E			Fas- or ceramide-induced apoptosis is mediated by a rad-regulated activation of jun N-terminal kinase p38 kinases and GADD153	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CHOP; CELL-SURFACE ANTIGEN; ICE-LIKE PROTEASE; HUMAN T-CELLS; SIGNALING PATHWAY; ACIDIC SPHINGOMYELINASE; MAP KINASE; LYMPHOPROLIFERATIVE SYNDROME; RECEPTOR SUPERFAMILY; FAS/APO-1 CD95	In the present study, we show that Fas receptor ligation or cellular treatment with synthetic C-6-ceramide results in activation or phosphorylation, respectively, of the small G-protein Rac1, Jun N-terminal kinase (JNK)/ p38 kinases (p38-K), and the transcription factor GADD153. A signaling cascade from the Fas receptor via ceramide, Ras, Rad, and JNK/p38-K to GADD153 is demonstrated employing transfection of transdominant inhibitory N17Ras, N17Rac1, c-Jun, or treatment with a specific p38-K inhibitor. The critical function of this signaling cascade is indicated by prevention of Fas-or C-6-ceramide-induced apoptosis after inhibition of Ras,Rac1, or JNK/p38-K.	UNIV TUBINGEN,DEPT PHYSIOL,D-72076 TUBINGEN,GERMANY; UNIV HEIDELBERG,DEPT PEDIAT,INF 150,D-69120 HEIDELBERG,GERMANY; UNIV TUBINGEN,DEPT TRANSFUS MED,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen; Ruprecht Karls University Heidelberg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital			Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COLLINS M, 1995, AM J RESP CRIT CARE, V152, pS20, DOI 10.1164/ajrccm/152.4_Pt_2.S20; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLING GJ, 1994, PHILOS T ROY SOC B, V345, P257, DOI 10.1098/rstb.1994.0103; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J IMMUNOL, V157, P2844; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HANNUN YA, 1996, ASCIENCE, V274, P1855; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; LIU ZG, 1996, CELL, V87, P566; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LUCIANI MF, 1994, PHILOS T R SOC B, V345, P303, DOI 10.1098/rstb.1994.0110; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MERCEP M, 1989, J IMMUNOL, V142, P4058; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nunes JA, 1996, MOL IMMUNOL, V33, P63, DOI 10.1016/0161-5890(95)00121-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OEHM A, 1992, J BIOL CHEM, V267, P10709; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STEVENSON MA, 1994, CANCER RES, V54, P12; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	78	294	300	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22173	22181		10.1074/jbc.272.35.22173	http://dx.doi.org/10.1074/jbc.272.35.22173			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268362	hybrid			2022-12-25	WOS:A1997XT85000074
J	Cornet, F; Hallet, B; Sherratt, DJ				Cornet, F; Hallet, B; Sherratt, DJ			Xer recombination in Escherichia coli - Site-specific DNA topoisomerase activity of the XerC and XerD recombinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINUS REGION; FLP RECOMBINASE; INTEGRASE FAMILY; GENE-PRODUCT; IN-VITRO; CHROMOSOME; DIF; MECHANISM; CER; IDENTIFICATION	Xer site-specific recombination functions in maintaining circular replicons in the monomeric state in Escherichia coli. Two recombinases of the bacteriophage A integrase family, XerC and XerD, are required for recombination at the chromosomal site, dif, and at a range of plasmid-borne sites. Xer recombination core sites contain the 11-base pair binding sites for each recombinase separated by a 6 to 8-base pair central region. We report that both XerC and XerD act as site-specific type I topoisomerases by relaxing supercoiled plasmids containing a dif site. Relaxation by either XerC or XerD occurs in the absence of the partner recombinase and requires only a single recombination core site, XerC or XerD relaxation activities are completely inhibited by the addition of the partner recombinase, providing that the DNA recognition sequence for the inhibiting partner is present.	UNIV OXFORD,DEPT BIOCHEM,MICROBIOL UNIT,OXFORD OX1 3QU,ENGLAND	University of Oxford			Cornet, Francois/A-9201-2008	Cornet, Francois/0000-0001-8576-7451	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1986, J BIOL CHEM, V261, P391; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Arciszewska L, 1997, EMBO J, V16, P3731, DOI 10.1093/emboj/16.12.3731; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; Blakely G, 1996, GENE DEV, V10, P762, DOI 10.1101/gad.10.6.762; BLAKELY G, 1991, NEW BIOL, V3, P789; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; CLERGET M, 1991, NEW BIOL, V3, P780; COLLOMS SD, 1990, J BACTERIOL, V172, P6973, DOI 10.1128/jb.172.12.6973-6980.1990; Colloms SD, 1996, EMBO J, V15, P1172, DOI 10.1002/j.1460-2075.1996.tb00456.x; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; EVANS BR, 1990, J BIOL CHEM, V265, P18504; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LESLIE NR, 1995, EMBO J, V14, P1561, DOI 10.1002/j.1460-2075.1995.tb07142.x; LOVETT ST, 1991, J BACTERIOL, V173, P353, DOI 10.1128/jb.173.1.353-364.1991; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NUNESDUBY, 1995, EMBO J, V13, P4421; PAN GH, 1992, J BIOL CHEM, V267, P12397; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; ROCCA J, 1995, TRENDS BIOCHEM SCI, V20, P156; Sambrook J., 2002, MOL CLONING LAB MANU; SHERRATT DJ, 1995, PHILOS T ROY SOC B, V347, P37, DOI 10.1098/rstb.1995.0006; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SUMMERS DK, 1989, EMBO J, V8, P309, DOI 10.1002/j.1460-2075.1989.tb03378.x; TECKLENBURG M, 1995, P NATL ACAD SCI USA, V92, P1352, DOI 10.1073/pnas.92.5.1352; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	31	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21927	21931		10.1074/jbc.272.35.21927	http://dx.doi.org/10.1074/jbc.272.35.21927			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268326	hybrid			2022-12-25	WOS:A1997XT85000038
J	Holden, M; Mayhew, M; Bunk, D; Roitberg, A; Vilker, V				Holden, M; Mayhew, M; Bunk, D; Roitberg, A; Vilker, V			Probing the interactions of putidaredoxin with redox partners in camphor p450 5-monooxygenase by mutagenesis of surface residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; ELECTRON-TRANSFER; REDUCED PUTIDAREDOXIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OXIDIZED PUTIDAREDOXIN; AFFECT BINDING; REDUCTASE; IDENTIFICATION; EXPRESSION	The role of surface amino acid residues in the interaction of putidaredoxin (Pdx) with its redox partners in the cytochrome P450(cam) (CYP101) system was investigated by site-directed mutagenesis. The mutated Pdx genes were expressed in Escherichia coli, and the proteins were purified and studied in vitro. Activity of the complete reconstituted P450(cam) system was measured, and kinetic parameters were determined, Partial assays were also conducted to determine the effect of the mutations on interactions with each redox partner. Some mutations altered interactions of Pdx with one redox partner but not the other, Other mutations affected interactions with both redox partners, suggesting some overlap in the binding sites on Pdx for putidaredoxin reductase and CYP101. Cysteine 73 of Pdx was identified as important in the interaction of Pdx with putidaredoxin reductase, whereas aspartate 38 serves a critical role in the subunit binding and electron transfer to CYP101.	NIST, CHEM SCI & TECHNOL LAB, DIV ANALYT CHEM, GAITHERSBURG, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Holden, M (corresponding author), NIST, CHEM SCI & TECHNOL LAB, DIV BIOTECHNOL, GAITHERSBURG, MD 20899 USA.		Roitberg, Adrian E/A-2378-2009					BECKERT V, 1994, J BIOL CHEM, V269, P2568; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; DAVIES MD, 1992, BIOCHEMISTRY-US, V31, P11383, DOI 10.1021/bi00161a016; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; GERBER NC, 1990, BIOCHEM BIOPH RES CO, V169, P1016, DOI 10.1016/0006-291X(90)91995-5; GEREN L, 1986, J BIOL CHEM, V261, P5491; Grayson DA, 1996, ARCH BIOCHEM BIOPHYS, V332, P239, DOI 10.1006/abbi.1996.0338; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; KOGA H, 1985, BIOCHEM BIOPH RES CO, V130, P412, DOI 10.1016/0006-291X(85)90432-2; KOGA H, 1989, J BIOCHEM-TOKYO, V106, P831, DOI 10.1093/oxfordjournals.jbchem.a122939; KOGA H, 1993, FEBS LETT, V331, P109, DOI 10.1016/0014-5793(93)80307-G; MOSELEY MA, 1991, ANAL CHEM, V63, P1467, DOI 10.1021/ac00014a023; Mueller Ernest J., 1995, P83; NAKAMURA K, 1994, BBA-PROTEIN STRUCT M, V1207, P40, DOI 10.1016/0167-4838(94)90049-3; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6433, DOI 10.1021/bi00187a007; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; ROOME PW, 1983, J BIOL CHEM, V258, P2593; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sibbesen O, 1996, J BIOL CHEM, V271, P22462, DOI 10.1074/jbc.271.37.22462; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869; WADA A, 1992, J BIOL CHEM, V267, P22877; YE XM, 1992, BIOCHEMISTRY-US, V31, P1961, DOI 10.1021/bi00122a009	29	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21720	21725		10.1074/jbc.272.35.21720	http://dx.doi.org/10.1074/jbc.272.35.21720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268300	hybrid			2022-12-25	WOS:A1997XT85000012
J	Salet, C; Moreno, G; Ricchelli, F; Bernardi, P				Salet, C; Moreno, G; Ricchelli, F; Bernardi, P			Singlet oxygen produced by photodynamic action causes inactivation of the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; HEMATOPORPHYRIN DERIVATIVE PHOTOFRIN; CYCLOSPORINE-A; II PHOTOSENSITIZATION; MEMBRANE; INHIBITION; AGENTS; CA2+; TRANSLOCATOR; CYCLOPHILIN	We have studied the effects of singlet oxygen produced by photodynamic action on the cyclosporin A-sensitive permeability transition (PT) in isolated rat liver mitochondria. Mitochondria were incubated with 3 mu M hematoporphyrin and irradiated at 365 nm with a fluence rate of 25 watts/m(2). For short durations of irradiation (60 s) the adenine nucleotide translocase was inactivated, but mitochondria retained their ability to form a proton electrochemical gradient and accumulated Ca2+ and P-i at the same rate as non-irradiated controls, Strikingly, however, the oxidative effects of photodynamic action prevented opening of the PT pore which is normally induced by Ca2+ plus P-i or by treatment with diethyl pyrocarbonate (a histidine reagent) or diamide (a thiol oxidant), We show that the most likely targets for photodynamic action are critical histidines that undergo degradation. Irradiated, hematoporphyrin-loaded mitochondria treated with diethyl pyrocarbonate or diamide still undergo the PT when treated with phenylarsine oxide, which reacts with a critical dithiol involved in pore modulation (Petronilli, V,, Costantini, P,, Scorrano, L., Colonna, R,, Passamonti, S,, and Pernardi, P, (1994) J, Biol. Chem. 269, 16638-16642), These data suggest (i) that the dithiol cysteines are not oxidized by photodynamic action, but rather became inaccessible to oxidants; and (ii) that irradiation of hematoporphyrin-loaded mitochondria does not lead to pore denaturation, but rather to site-selective inactivation of discrete pore functional domains.	UNIV PADUA,CNR,CTR METALLOPROT,DIPARTIMENTO BIOL,I-35121 PADUA,ITALY; UNIV PADUA,CTR BIOMEMBRANE,DIPARTIMENTO SCI BIOMED SPERIMENTALI,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Salet, C (corresponding author), MUSEUM NATL HIST NAT,LABS BIOPHYS & PHOTOBIOL,CNRS URA 481,INSERM,U201,43 RUE CUVIER,F-75231 PARIS 05,FRANCE.		Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736				ATLANTE A, 1989, J PHOTOCH PHOTOBIO B, V4, P35, DOI 10.1016/1011-1344(89)80100-9; ATLANTE A, 1990, J PHOTOCH PHOTOBIO B, V7, P21, DOI 10.1016/1011-1344(90)85140-R; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BRAGADIN M, 1980, BIOCHEMISTRY-US, V18, P5972; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; CHAPPEL GB, 1967, BIOCH MITOCHONDRIA, P75; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; DOUGHERTY TJ, 1993, PHOTOCHEM PHOTOBIOL, V58, P895, DOI 10.1111/j.1751-1097.1993.tb04990.x; HARIHARAN PV, 1980, INT J RADIAT BIOL, V37, P691, DOI 10.1080/713857576; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PASSARELLA S, 1988, BIOCHEM BIOPH RES CO, V156, P978, DOI 10.1016/S0006-291X(88)80940-9; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; RICCHELLI F, 1993, PHOTOCHEM PHOTOBIOL, V58, P53, DOI 10.1111/j.1751-1097.1993.tb04903.x; RICCHELLI F, 1995, EUR J BIOCHEM, V233, P165, DOI 10.1111/j.1432-1033.1995.165_1.x; SALET C, 1990, J PHOTOCH PHOTOBIO B, V5, P133, DOI 10.1016/1011-1344(90)80002-F; Salet C, 1997, FREE RADICAL RES, V26, P201, DOI 10.3109/10715769709097800; SALET C, 1983, BIOCHEM BIOPH RES CO, V115, P76, DOI 10.1016/0006-291X(83)90970-1; SALET C, 1991, PHOTOCHEM PHOTOBIOL, V53, P391; SALET C, 1982, PHOTOCHEM PHOTOBIOL, V36, P291, DOI 10.1111/j.1751-1097.1982.tb04377.x; SALET C, 1981, INT J RADIAT BIOL, V399, P227; SANDBERG S, 1980, BIOCHIM BIOPHYS ACTA, V593, P187, DOI 10.1016/0005-2728(80)90056-0; STRAIGHT RC, 1985, SINGLET O2, V4, P92; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; TOMITA M, 1969, BIOCHEMISTRY-US, V8, P5149, DOI 10.1021/bi00840a069; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	35	77	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21938	21943		10.1074/jbc.272.35.21938	http://dx.doi.org/10.1074/jbc.272.35.21938			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268328	hybrid			2022-12-25	WOS:A1997XT85000040
J	Zhao, WN; McAlisterHenn, L				Zhao, WN; McAlisterHenn, L			Affinity purification and kinetic analysis of mutant forms of yeast NAD(+)-specific isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE; PHOSPHORYLATION; CLONING; BINDING; ENZYME; EXPRESSION; SEQUENCE; SUBUNITS	Polyhistidine tags were added to the carboxyl termini of the two homologous subunits of yeast NAD(+)-specific isocitrate dehydrogenase (IDH). The tag in either the IDH1 or IDH2 subunit permits one step affinity purification from yeast cellular extracts of catalytically active and allosterically responsive holoenzyme. This expression system was used to investigate subunit-specific contributions of residues with putative functions in adenine nucleotide binding, The primary effect of simultaneous replacement of the adjacent Asp-279 and Ile-280 residues in IDH1 with alanines is a dramatic loss of activation by AMP. In contrast, alanine replacement of the homologous Asp-286 and Ile-287 residues in IDH2 does not alter the allosteric response to AMP, but produces a 160-fold reduction in V-max due to a 70-fold increase in the S-0.5 value for NAD(+), These results suggest that the targeted aspartate/isoleucine residues may con tribute to regulator binding in IDH1 and to cofactor binding in IDHS, i.e. that these homologous residues are located in regions that have evolved for binding the adenine nucleotide components of different ligands, In other mutant enzymes, an alanine replacement of Asp 191 in IDH1 eliminates measurable catalytic activity, and a similar substitution of the homologous Asp-197 in IDH2 produces pleiotropic catalytic effects, A model is presented for the primary function of IDH2 in catalysis and of IDH1 in regulation, with crucial roles for these single aspartate residues in the communication and functional interdependence of the two subunits.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BARNES LD, 1972, BIOCHEMISTRY-US, V11, P4322, DOI 10.1021/bi00773a019; BOTSTEIN D, 1979, GENE, V9, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DEAN AM, 1989, J BIOL CHEM, V264, P20482; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; HENGEN PN, 1995, TRENDS BIOCHEM SCI, V20, P285, DOI 10.1016/S0968-0004(00)89045-3; HUANG Y, 1986, J BIOL CHEM, V261, P14100; HUANG YC, 1989, J BIOL CHEM, V264, P12208; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; ILLINGWORTH JA, 1972, BIOCHEM J, V129, P1119, DOI 10.1042/bj1291119; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KUEHN GD, 1971, BIOCHEMISTRY-US, V10, P3945, DOI 10.1021/bi00797a023; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; NICHOLS BJ, 1993, BIOCHEM J, V295, P347, DOI 10.1042/bj2950347; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIKORSKI RS, 1989, GENETICS, V122, P19; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Zhao WN, 1996, J BIOL CHEM, V271, P10347, DOI 10.1074/jbc.271.17.10347	32	33	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21811	21817		10.1074/jbc.272.35.21811	http://dx.doi.org/10.1074/jbc.272.35.21811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268311	hybrid			2022-12-25	WOS:A1997XT85000023
J	Hurd, C; Khattree, N; Dinda, S; Alban, P; Moudgil, VK				Hurd, C; Khattree, N; Dinda, S; Alban, P; Moudgil, VK			Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells	ONCOGENE			English	Article						breast cancer; tumor suppressors; p53; retinoblastoma; estrogens; antiestrogens	GENE-MUTATIONS; RECEPTOR; PHOSPHORYLATION; PROGRESSION; PROLIFERATION; INHIBITION; TAMOXIFEN; PRODUCT; TAXOL; LINES	We have utilized the estrogen receptor (ER)-positive human breast carcinoma cell line, T47D, to determine the role of ER in regulating cell proliferation, the level of expression of p53 and the state of phosphorylation of retinoblastoma protein (pRB) by 17 beta-estradiol (E-2) and antiestrogens. T47D cells cultured for 7 days proliferated rapidly expressing maximal levels of p53 in medium containing 5% fetal bovine (whole) serum, Exogenously added E-2 had no effect on either of the above parameters, The antiestrogen, ICI 164,384 (ICI, 1 mu M), decreased cell number and p53 level to nearly 20% of the control, Comparatively, a treatment of the tells with 100 nM 4OH-tamoxifen (OHT) decreased cell number to 40% of the control without a concomitant decrease in the p53 levels suggesting a differential ability of these antiestrogens to regulate p53 levels in cells cultured in whole serum, When cells were cultured in medium containing serum depleted of endogenous steroids (charcoal stripped serum), cell number and p53 levels declined, Treatment with exogenous E-2 (1 nM) increased cell proliferation, p53 expression and phosphorylation of pRB. The antiestrogens ICI and OHT blocked these E-2 effects, demonstrating a direct antagonism of ER by ICI and OHT, These results indicate an ER-mediated mechanism for coordinate expression of p53 and hyperphosphorylation of pRB during E-2-induced proliferation of T47D cells.	OAKLAND UNIV,DEPT BIOL SCI,ROCHESTER,MI 48309; OAKLAND UNIV,INST BIOCHEM & BIOTECHNOL,ROCHESTER,MI 48309	Oakland University; Oakland University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARDON S, 1987, CANCER RES, V47, P1441; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Guillot C, 1996, CLIN CANCER RES, V2, P1439; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; KASTAN MB, 1991, CANCER RES, V51, P6304; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; KUSHNER PJ, 1990, MOL ENDOCRINOL, V4, P1465, DOI 10.1210/mend-4-10-1465; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; SCHUCHARD M, 1993, ENDOCR REV, V14, P659, DOI 10.1210/er.14.6.659; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THOMPSON EW, 1989, CANCER RES, V49, P6929; WAFIK S, 1994, CANCER RES, V54, P1169; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	69	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					991	995		10.1038/sj.onc.1201233	http://dx.doi.org/10.1038/sj.onc.1201233			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285694				2022-12-25	WOS:A1997XR76700012
J	Erickson, JW; Cerione, RA; Hart, MJ				Erickson, JW; Cerione, RA; Hart, MJ			Identification of an actin cytoskeletal complex that includes IQGAP and the Cdc42 GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RASGAP-RELATED PROTEIN; BINDING PROTEIN; DOMAIN; RHO; PHALLOIDIN; FILOPODIA; EFFECTOR; CELLS; RAC	The Rho subfamily of low molecular weight GTPases have been implicated in a variety of cellular functions that include reorganization of the actin cytoskeleton and stress-induced activation of the c-Jun kinase. The downstream targets that mediate the effects of Cdc42 on the actin cytoskeleton have yet to be fully identified, We have used the transient transfection of COS-7 cells with epitope tagged Cdc42 to identify candidate signaling partners for this GTPase and identified the IQGAP protein as a major in. vivo target for activated Cdc42. Epidermal growth factor stimulation of serum-starved COS-7 cells promoted the formation of a Cdc42-IQGAP complex, indicating that growth factors can increase the pool of activated Cdc42, Activated HA-Cdc42 co-localized with IQGAP or F-actin in vivo, whereas cells transfected with dominant-negative forms of Cdc42 (CdC42(T17N)) showed predominantly dispersed distributions for both HA-Cdc42 and endogenous IQGAP, In detergent lysates from COS-7 cells transiently transfected with different forms of Cdc42, or from stably transfected CHO cells, the induction of actin polymerization by phalloidin resulted in the incorporation of both IQGAP and Cdc42 into actin containing complexes. Taken together, these findings are consistent with a model whereby IQGAP serves as a target for GTP-bound Cdc42 providing a direct link between the activated GTPase and the actin cytoskeleton.	CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853; ONYX PHARMACEUT,RICHMOND,CA 94806	Cornell University				Hart, Matthew/0000-0002-2683-480X	NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Boivin D, 1996, CAN J PHYSIOL PHARM, V74, P801, DOI 10.1139/cjpp-74-7-801; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LEBART MC, 1994, J BIOL CHEM, V269, P4279; LEBIHAN T, 1991, BIOCHEM BIOPH RES CO, V181, P542; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WIELAND T, 1986, PHALLOTOXINS, P69; WINDER SJ, 1995, J CELL SCI, V108, P63	20	109	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24443	24447		10.1074/jbc.272.39.24443	http://dx.doi.org/10.1074/jbc.272.39.24443			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305904	hybrid			2022-12-25	WOS:A1997XY51500055
J	Oka, T; Yamamoto, R; Futai, M				Oka, T; Yamamoto, R; Futai, M			Three vha genes encode proteolipids of Caenorhabditis elegans vacuolar-type ATPase - Gene structures and preferential expression in an H-shaped excretory cell and rectal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; V-ATPASE; MOLECULAR-CLONING; PLASMA-MEMBRANE; B-SUBUNIT; CDNA; ACIDIFICATION; SEQUENCE; PROTEIN; TRANSPORT	The proteolipids of the vacuolar-type H+-ATPase (V-ATPase) are major components of the integral membrane sector. The vha-l and vha-2 (vacuolar type H+-ATPase) genes in Caenorhabditis elegans encode putative 16-kDa proteolipids and are tandemly localized on chromosome III. The vha-2 gene has three exons, whereas vha-l has no introns, The deduced amino acid sequences of the two genes exhibit about 60% identity with the homologues from yeast, mouse, and cow. The mRNAs of both vha genes are trans-spliced to spliced leaders, suggesting that these genes constitute a polycistronic transcriptional unit. The vha-4 gene consists of four exons and is very similar to the yeast VMA16 gene that codes for the 23-kDa proteolipid. This is the first example of three distinct V-ATPase proteolipids being identified in higher eukaryotes. Northern blot and transgenic analyses show that the three vha genes may be highly expressed in the II-shaped excretory cell, rectum, and a pair of cells posterior to the anus, These results suggest that the V-ATPase activity may be important for exporting toxic compounds or metabolic wastes in this organism.	OSAKA UNIV,INST SCI & IND RES,DIV BIOL SCI,DEPT MOL CELL BIOL,OSAKA 567,JAPAN	Osaka University								ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; BROEKS A, 1995, EMBO J, V14, P1858, DOI 10.1002/j.1460-2075.1995.tb07178.x; BROWN D, 1992, J EXP BIOL, V172, P231; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; GLUCK S, 1992, J EXP BIOL, V172, P29; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HARVEY WR, 1992, J EXP BIOL, V172, P1; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HESEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; KLEIN U, 1992, J EXP BIOL, V172, P345; KLINNSKY DJ, 1992, J EXP BIOL, V172, P83; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P6712, DOI 10.1093/nar/18.22.6712; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Moriyama Y, 1996, BIOL CHEM H-S, V377, P155; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J EXP BIOL, V172, P19; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STEVENS TH, 1992, J EXP BIOL, V172, P47; Sulston J., 1988, NEMATODE CAENORHABDI, P587; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	38	57	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24387	24392		10.1074/jbc.272.39.24387	http://dx.doi.org/10.1074/jbc.272.39.24387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305897	hybrid			2022-12-25	WOS:A1997XY51500048
J	Grenert, JP; Sullivan, WP; Fadden, P; Haystead, TAJ; Clark, J; Mimnaugh, E; Krutzsch, H; Ochel, HJ; Schulte, TW; Sausville, E; Neckers, LM; Toft, DO				Grenert, JP; Sullivan, WP; Fadden, P; Haystead, TAJ; Clark, J; Mimnaugh, E; Krutzsch, H; Ochel, HJ; Schulte, TW; Sausville, E; Neckers, LM; Toft, DO			The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROGESTERONE-RECEPTOR; IN-VIVO; GLUCOCORTICOID RECEPTOR; RETICULOCYTE LYSATE; TYROSINE KINASE; COMPLEX; HETEROCOMPLEX; ASSOCIATION; RAF	Many functions of the chaperone, heat shock protein 90 (hsp90), are inhibited by the drug geldanamycin that specifically binds hsp90, We have studied an amino-terminal domain of hsp90 whose crystal structure has recently been solved and determined to contain a geldanamycin binding site. We demonstrate that, in solution, drug binding is exclusive to this domain. This domain also binds ATP linked to Sepharose through the gamma-phosphate. Binding is specific for ATP and ADP and is inhibited by geldanamycin, Mutation of four glycine residues within two proposed ATP binding motifs diminishes both geldanamycin binding and the ATP-dependent conversion of hsp90 to a conformation capable of binding the co-chaperone p23, Since p23 binding requires regions outside the 1-221 domain of hsp90, these results indicate a common site for nucleotides and geldanamycin that regulates the conformation of other hsp90 domains.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; NCI,NIH,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia					NHLBI NIH HHS [HL 19242] Funding Source: Medline; NICHD NIH HHS [HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK 46249] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Chavany C, 1996, J BIOL CHEM, V271, P4974; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Gerloff DL, 1997, PROTEINS, V27, P450, DOI 10.1002/(SICI)1097-0134(199703)27:3<450::AID-PROT12>3.3.CO;2-9; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P371; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; McGuire J, 1995, J BIOL CHEM, V270, P31353, DOI 10.1074/jbc.270.52.31353; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHNUR RC, 1994, J LABELLED COMPD RAD, V34, P529, DOI 10.1002/jlcr.2580340606; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532	57	478	498	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23843	23850		10.1074/jbc.272.38.23843	http://dx.doi.org/10.1074/jbc.272.38.23843			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295332	hybrid			2022-12-25	WOS:A1997XX38100057
J	Murayama, T; Ogawa, Y				Murayama, T; Ogawa, Y			Characterization of type 3 ryanodine receptor (RyR3) of sarcoplasmic reticulum from rabbit skeletal muscles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; BINDING-PROTEIN ISOFORMS; CA2+ RELEASE; MICE LACKING; MOLECULAR-CLONING; FIBER TYPES; BRAIN-TYPE; EXPRESSION; CDNA; CA-2+	We investigated type 3 isoform (RyR3) of ryanodine receptor in rabbit skeletal muscles using an antibody specific for RyR3. By Western blot analysis and by immunoprecipitation, a single polypeptide for RyR3 was detected in sarcoplasmic reticulum vesicles from rabbit diaphragm but not in those from back muscle. The molecular mass was slightly smaller than that of RyR1, the major isoform in skeletal muscles. Each of RyR1 and RyR3 formed a homotetramer in rabbit diaphragm. RyR3 had a single class of [H-3]ryanodine binding sites of high affinity (K-D = 1.6 nM). From the B-max of the binding, the content of RyR3 was estimated to be only 0.6% of RyR1 in rabbit diaphragm, [H-3]Ryanodine binding to RyR3 was biphasically dependent on Ca2+, as is true of RyR1, and was stimulated further by adenine nucleotide, caffeine, or high. salt concentration. Procaine and ruthenium red inhibited the binding. RyR3 was more resistant to Mg2+ inhibition than RyR1. interestingly, RyR3 showed about a 7-fold lower Ca2+ sensitivity for activation than RyR1. Comparison with the counterparts in bullfrog skeletal muscles indicates that the Ca2+ sensitivities of RyR3 homologs are similar to each other, whereas those of RyR1 homologs are species-specific.	JUNTENDO UNIV,SCH MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN	Juntendo University								AIREY JA, 1990, J BIOL CHEM, V265, P14187; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GREEN HJ, 1984, HISTOCHEMISTRY, V81, P67, DOI 10.1007/BF00495403; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KILARSKI W, 1990, J ANAT, V168, P13; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Miyatake R, 1996, FEBS LETT, V395, P123, DOI 10.1016/0014-5793(96)01022-8; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MOORE GE, 1985, J MUSCLE RES CELL M, V6, P513, DOI 10.1007/BF00712587; MURAYAMA T, 1994, J BIOCHEM-TOKYO, V116, P1117, DOI 10.1093/oxfordjournals.jbchem.a124636; Murayama T, 1996, FEBS LETT, V380, P267, DOI 10.1016/0014-5793(96)00053-1; Murayama T, 1996, J BIOL CHEM, V271, P5079; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1305, DOI 10.1093/oxfordjournals.jbchem.a121837; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OTSU K, 1990, J BIOL CHEM, V265, P13472; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; WEBER A, 1968, J GEN PHYSIOL, V52, P750, DOI 10.1085/jgp.52.5.750; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	45	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24030	24037		10.1074/jbc.272.38.24030	http://dx.doi.org/10.1074/jbc.272.38.24030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295356	hybrid			2022-12-25	WOS:A1997XX38100081
J	Ragolia, L; Cherpalis, B; Srinivasan, M; Begum, N				Ragolia, L; Cherpalis, B; Srinivasan, M; Begum, N			Role of serine/threonine protein phosphatases in insulin regulation of Na+/K+-ATPase activity in cultured rat skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; KINASE-C; PHOSPHOSERINE PHOSPHATASE; CATALYTIC SUBUNIT; PHOSPHORYLATION; NA+,K+-ATPASE; STIMULATION; INHIBITION; IDENTIFICATION; ACTIVATION	In this study, we examined the potential role of serine/threonine protein phosphatase-1 (PP-1) and PP-2A in the mechanism of Na+/K+-ATPase activation by insulin in the rat skeletal muscle cell line L6. Incubation of L6 cells with insulin caused a time-and dose-dependent stimulation of ouabain-sensitive plasma membrane Na+/K+-ATPase activity, Pretreatment with okadaic acid (OA; 0.1-1 mu M) or calyculin A (1 mu M) blocked insulin's effect on Na+/K+-ATPase activation, Low concentrations of OA that specifically inhibit PP-2A were ineffective, Immunoprecipitation of the enzyme from P-32-labeled cells with an antibody directed against the alpha-1 subunit of the enzyme revealed a 60% decrease in 110 kDa protein phosphorylation in insulin-treated cells. The presence of calyculin A blocked insulin-mediated dephosphorylation of Na+/K+-ATPase, whereas low concentrations of OA were ineffective, To further confirm the role of PP-1, we used L6 cell lines that overexpress the glycogen/SR-associated regulatory subunit of PP-1, PP-1(G). Overexpression of PP-1(G) resulted in a 3-fold increase in insulin-stimulated PP-1 catalytic activity. This was accompanied by a 30% increase in basal Na+/K+-ATPase activity and a > 2-fold increase in insulin's effect on pump activity, Inhibition of phosphatidylinositol-3 kinase with wortmannin blocked insulin-stimulated PP-1 activation as well as the dephosphorylation and activation of Na+/K+-ATPase. We conclude that insulin regulates the activity of Na+/K+ ATPase by promoting dephosphorylation of the alpha subunit via an insulin-stimulated PP-1 and that phosphatidylinositol 3 kinase-generated signals may mediate insulin activation of PP-1 and Na+/K+-ATPase.	WINTHROP UNIV HOSP,DIABET RES LAB,MINEOLA,NY 11501; SUNY STONY BROOK,SCH MED,STONY BROOK,NY 11704	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Ragolia, Louis/AAW-2383-2021	Ragolia, Louis/0000-0002-8292-5159				APERIA A, 1991, P NATL ACAD SCI USA, V88, P2798, DOI 10.1073/pnas.88.7.2798; BARNETT RE, 1970, BIOCHEMISTRY-US, V9, P4644, DOI 10.1021/bi00826a004; BEGUM N, 1992, J BIOL CHEM, V267, P5959; BEGUM N, 1991, DIABETES, V40, P1620, DOI 10.2337/diabetes.40.12.1620; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BERTORELLO AM, 1993, AM J PHYSIOL, V265, pF743, DOI 10.1152/ajprenal.1993.265.6.F743; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DRAZNIN B, 1991, EXCERPTA MED INT C S, V980, P225; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; FAVRE B, 1996, J BIOL CHEM, V272, P13856; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI DL, 1995, AM J PHYSIOL-RENAL, V269, pF673, DOI 10.1152/ajprenal.1995.269.5.F673; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MARETTE A, 1993, AM J PHYSIOL, V265, pC1716, DOI 10.1152/ajpcell.1993.265.6.C1716; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MOORE RD, 1983, J PHYSIOL-LONDON, V338, P277, DOI 10.1113/jphysiol.1983.sp014673; NISHIDA K, 1992, METABOLISM, V41, P56, DOI 10.1016/0026-0495(92)90191-C; OGUCHI A, 1993, AM J PHYSIOL, V265, pH1167, DOI 10.1152/ajpheart.1993.265.4.H1167; OHARA T, 1991, DIABETES, V40, P1560, DOI 10.2337/diabetes.40.11.1560; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ragolia L, 1997, ENDOCRINOLOGY, V138, P2398, DOI 10.1210/en.138.6.2398; SAMPSON SR, 1994, AM J PHYSIOL, V266, pC751, DOI 10.1152/ajpcell.1994.266.3.C751; SATOH T, 1992, J CLIN INVEST, V89, P1496, DOI 10.1172/JCI115740; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; XIA P, 1995, J CLIN INVEST, V96, P733, DOI 10.1172/JCI118117	33	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23653	23658		10.1074/jbc.272.38.23653	http://dx.doi.org/10.1074/jbc.272.38.23653			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295306	hybrid			2022-12-25	WOS:A1997XX38100031
J	Elefteriou, F; Exposito, JY; Garrone, R; Lethias, C				Elefteriou, F; Exposito, JY; Garrone, R; Lethias, C			Characterization of the bovine tenascin-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; CLASS-III REGION; GENE; EXPRESSION; DOMAIN; FIBRONECTIN; FRAGMENTS; MOLECULE; COLLAGEN; SEQUENCE	The primary structure of flexilin, an extracellular matrix glycoprotein previously identified in bovine tissues (Lethias, e., Descollonges, Y., Boutillon, M.-M., and Garrone, R. (1996) Matrix: Biol. 15, 11-19) was determined by cDNA cloning. The deduced amino acid sequence (4135 residues) reveals that this protein is composed of a succession of peptide motifs characteristic of the tenascin family: an amino-terminal domain containing cysteine residues and heptads of hydrophobic amino acids, 18.5 epidermal growth factor-like repeats, 30 fibronectin type III-like (FNIII) domains, and a carboxyl-terminal fibrinogen-like motif. Sequence analysis indicated that this protein is the bovine orthologue of human tenascin-X. By rotary shadowing, bovine tenascin-X was identified as monomers with a flexible aspect, which are ended by a globule. More FNIII motifs were characterized in the bovine protein than in human tenascin-X The main difference between the human and bovine tenascin-X is found in the arrangement of the three classes of highly similar FNIII repeat types in the central region of tenascin-X. The bovine FNIII motif b10 exhibits an RGD putative cell attachment site. The functional role of this sequence is corroborated by cell adhesion on purified tenascin-X, which is inhibited by RGD peptides. Moreover, we demonstrate that this RGD site is conserved at the same location in the human molecule.	UNIV LYON 1,CNRS,UPR 412,IBCP,F-69367 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1			Elefteriou, Florent/P-2586-2017; Elefteriou, Florent/GMW-8429-2022	Elefteriou, Florent/0000-0002-2972-5633; Elefteriou, Florent/0000-0002-2972-5633; Exposito, Jean-Yves/0000-0002-4926-4942				BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8; BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; BURCH GH, 1995, DEV DYNAM, V203, P491, DOI 10.1002/aja.1002030411; CHIQUET M, 1991, EUR J BIOCHEM, V199, P379, DOI 10.1111/j.1432-1033.1991.tb16134.x; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; CHIQUETEHRISMANN R, 1995, BIOESSAYS, V17, P873, DOI 10.1002/bies.950171009; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DARDEL F, 1988, COMPUT APPL BIOSCI, V4, P483; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; EXPOSITO JY, 1990, EUR J BIOCHEM, V190, P401, DOI 10.1111/j.1432-1033.1990.tb15589.x; GEFFROTIN C, 1995, EUR J BIOCHEM, V231, P83, DOI 10.1111/j.1432-1033.1995.0083f.x; GOODWIN AE, 1995, J IMMUNOL METHODS, V187, P213, DOI 10.1016/0022-1759(95)00187-6; Hagios C, 1996, J CELL BIOL, V134, P1499, DOI 10.1083/jcb.134.6.1499; HUMBERTDAVID N, 1993, EUR J BIOCHEM, V216, P255, DOI 10.1111/j.1432-1033.1993.tb18140.x; JOSHI P, 1993, J CELL SCI, V106, P389; Lethias C, 1996, MATRIX BIOL, V15, P11, DOI 10.1016/S0945-053X(96)90122-5; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; MATSUDANAKAGAWA LM, 1991, PHILOS T R SOC LON B, V331, P323; MATSUMOTO K, 1992, IMMUNOGENETICS, V36, P400; MATSUMOTO K, 1994, J CELL BIOL, V125, P483, DOI 10.1083/jcb.125.2.483; MATSUMOTO K, 1992, GENOMICS, V12, P485, DOI 10.1016/0888-7543(92)90438-X; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; NIES DE, 1991, J BIOL CHEM, V266, P2818; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Sakai T, 1996, J CELL SCI, V109, P2069; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; Speek M, 1996, HUM MOL GENET, V5, P1749, DOI 10.1093/hmg/5.11.1749; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	35	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22866	22874		10.1074/jbc.272.36.22866	http://dx.doi.org/10.1074/jbc.272.36.22866			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278449	hybrid			2022-12-25	WOS:A1997XV49200070
J	Hauser, PJ; Agrawal, D; Chu, BK; Pledger, WJ				Hauser, PJ; Agrawal, D; Chu, BK; Pledger, WJ			p107 and p130 associated cyclin A has altered substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CELL-CYCLE; GROWTH SUPPRESSION; TRANSCRIPTION FACTORS; FAMILY MEMBERS; CDK COMPLEXES; PROTEIN P107; E2F; INTERACTS; BINDING	We demonstrate that p107 and p130 immune complexes exhibit kinase activity. We have tested such immune complexes with four substrates commonly utilized to assay Cdk activity, including all three known members of the retinoblastoma family. Immunodepletion revealed this kinase activity could be abolished by removal of either cyclin A or Cdk2 but was unaffected by removal of Cdk4 or any D-type cyclin. The appearance of p101 associated activity followed the accumulation of p107 protein. In contrast, the kinase activity associated with p130 immune complexes became apparent after mid-G(1), coincident with p130 hyperphosphorylation. GST-Rb, GST-p107, and GST-p130 (where GST indicates glutathione S-transferase) were equally suitable substrates in p107 and p130 immune complex kinase assays, yielding activity equal to 25% of the cyclin A activity present. The p107 and p130 associated activity was unable to phosphorylate histone H1, suggesting the p107 and p130 associated cyclin A/Cdk2 may represent a distinct pool with a distinct substrate specificity. The p107 and p130 associated activity was released from the immune complexes upon incubation with ATP and Mg2+ and exhibited the same substrate preference observed with the untreated immune complex. Our data suggest that p107 and p130 recognize, or form by association, a distinct pool of cyclin A/Cdk2 that preferentially phosphorylates retinoblastoma family members.	UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR,TAMPA,FL 33612; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37240; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT MED MICROBIOL,TAMPA,FL 33612	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Vanderbilt University; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida					NATIONAL CANCER INSTITUTE [R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BEIJERSHERGEN R, 1994, EMBO J, V17, P4080; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; NEVINS JR, 1992, SCIENCE, V258, P424; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22954	22959		10.1074/jbc.272.36.22954	http://dx.doi.org/10.1074/jbc.272.36.22954			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278460	hybrid			2022-12-25	WOS:A1997XV49200082
J	Kanemitsu, MY; Loo, LWM; Simon, S; Lau, AF; Eckhart, W				Kanemitsu, MY; Loo, LWM; Simon, S; Lau, AF; Eckhart, W			Tyrosine phosphorylation of connexin 43 by v-Src is mediated by SH2 and SH3 domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; GAP-JUNCTION PROTEIN; TEMPERATURE-SENSITIVE MUTANT; TO-CELL COMMUNICATION; FOCAL ADHESION KINASE; AMINO-TERMINAL DOMAIN; INTERCELLULAR COMMUNICATION; C-SRC; TRANSFORMED-CELLS; GENE-PRODUCT	Reduction of gap junctional communication in v-src transformed cells is accompanied by tyrosine phosphorylation of the gap junction protein, connexin 43 (Cx43). Cx43 is phosphorylated on tyrosine by v-Src. The Src homology 3 (SH3) and Src homology 2 (SH2) domains of v-Src mediate interactions with substrate proteins. SH3 domains interact with proline-rich peptide motifs. SH2 domains associate with short amino acid sequences containing phosphotyrosine. We present evidence that the SH3 and SH2 domains of v-Src bind to proline-rich motifs and a phosphorylated tyrosine residue in the C-terminal tail of Cx43. Cx43 bound to the SH3 domain of v-Src, but not c-Src, in vitro. Tyrosine-phosphorylated Cx43 bound to the SH2 domain of v-Src in vitro. v-Src coprecipitated with Cx43 from v-src-transformed Rat-1 fibroblasts. Mutations in the SH3 and SH2 domains of v-Src, and in the proline-rich region or tyrosine 265 of Cx43, reduced interactions between v-Src and Cx43 in vivo. Tyrosine phosphorylation of Cx43 was dependent on the association of v-Src and Cx43. These results provide further evidence for the direct involvement of v-Src in tyrosine phosphorylation of Cx43 and inhibition of gap junctional communication in v-src-transformed cells.	SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV HAWAII, CANC RES CTR HAWAII, HONOLULU, HI 96813 USA	Salk Institute; Cancer Research Center of Hawaii; University of Hawaii System					NCI NIH HHS [CA13884, CA09370, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, T32CA009370, R37CA013884, R01CA013884] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; ATKINSON MM, 1988, AM J PHYSIOL, V255, pC674, DOI 10.1152/ajpcell.1988.255.5.C674; AZARNIA R, 1989, ONCOGENE, V4, P1161; AZARNIA R, 1987, MOL CELL BIOL, V7, P946, DOI 10.1128/MCB.7.2.946; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P213, DOI 10.1007/BF01871631; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; DEFEIJTER AW, 1990, MOL CARCINOGEN, V3, P54, DOI 10.1002/mc.2940030203; ELFOULY MH, 1989, MOL CARCINOGEN, V2, P131, DOI 10.1002/mc.2940020305; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KLAUNIG JE, 1990, LAB INVEST, V62, P135; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURATA WE, 1994, ONCOGENE, V9, P329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LEVINSON AD, 1980, J BIOL CHEM, V255, P1973; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS JT, 1984, CANCER CELLS ONCOGEN, P36; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TRAUB O, 1987, EUR J CELL BIOL, V43, P48; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	100	160	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22824	22831		10.1074/jbc.272.36.22824	http://dx.doi.org/10.1074/jbc.272.36.22824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278444	hybrid			2022-12-25	WOS:A1997XV49200065
J	Niswender, KD; Shiota, M; Postic, C; Cherrington, AD; Magnuson, MA				Niswender, KD; Shiota, M; Postic, C; Cherrington, AD; Magnuson, MA			Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; DEPENDENT DIABETES-MELLITUS; ACID-SYNTHASE GENE; INSULIN-SECRETION; TRANSCRIPTIONAL CONTROL; REGULATORY PROTEIN; LIVER GLUCOKINASE; TRANSGENIC MICE; RAT HEPATOCYTES; EXPRESSION	The relationship between glucokinase (GK) gene copy number and glucose homeostasis was studied in transgenic mice with additional copies of the entire GK gene locus (Niswender, K. D., Postic, C., Jetton, T. L., Bennett, B. D., Piston, D. W., Efrat, S., and Magnuson, M. A. (1997) J. Biol. Chem. 272, 22564-22569). The plasma glucose concentration was reduced by 25 +/- 3% and 37 +/- 4% in mice with one or two extra copies of the gene locus, respectively. The basis for the hypoglycemic phenotype was determined using metabolic tracer techniques in chronically cannulated, conscious mice with one extra GK gene copy. Under basal conditions (6-h fasted) transgenic mice had a lower blood glucose concentration (-12 +/- 1%) and a slightly higher glucose turnover rate (+8 +/- 3%), resulting in a significantly higher glucose clearance rate (+21 +/- 2%). Plasma insulin levels were not different, suggesting that increased glucose clearance was due to augmented hepatic, not islet, GK gene expression. Under hyperglycemic clamp conditions the transgenic mice had glucose turnover and clearance rates similar to the controls, but showed a lower plasma insulin response (-48 +/- 5%). Net hepatic glycogen synthesis was markedly elevated (+360%), whereas skeletal muscle glycogen synthesis was decreased (-40%). These results indicate that increased GK gene dosage leads to increased hepatic glucose metabolism and, consequently, a lower plasma glucose concentration. Increased insulin secretion was not observed, even though the transgene is expressed in islets, because hypoglycemia causes a down-regulation in islet GK content (Niswender, K. D., Postic, C., Jetton, T. L., Bennett, B. D., Piston, D. W., Efrat, S., and Magnuson, M. A. (1997) J. Biol. Chem. 272, in press).	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University			Postic, Catherine/P-2271-2017; Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Postic, Catherine/0000-0002-1875-6960; Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499	NIDDK NIH HHS [DK42612, DK43706, DK42502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612, R01DK043706, R56DK043706] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Bell GI, 1996, ANNU REV PHYSIOL, V58, P171, DOI 10.1146/annurev.physiol.58.1.171; CUIF MH, 1993, J BIOL CHEM, V268, P13769; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; HERS HG, 1990, J INHERIT METAB DIS, V13, P395, DOI 10.1007/BF01799497; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LIANG Y, 1994, DIABETES, V43, P1138, DOI 10.2337/diabetes.43.9.1138; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEDOYA FJ, 1996, J BIOL CHEM, V261, P10760; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; Niswender KD, 1997, J BIOL CHEM, V272, P22564, DOI 10.1074/jbc.272.36.22564; NOLL F, 1984, METHOD ENZYMAT AN, V6, P582; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Pagliassotti M, 1994, ROLE LIVER MAINTAINI, P45; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; SCOTT D, 1997, DIABETES S1, V46, pA21; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SHIOTA M, 1984, BIOCHEM J, V222, P281, DOI 10.1042/bj2220281; STURIS J, 1994, DIABETES, V43, P718, DOI 10.2337/diabetes.43.5.718; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; Towle HC, 1996, BIOCHEM SOC T, V24, P364, DOI 10.1042/bst0240364; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1992, ADV ENZYME REGUL, V32, P133; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; YIN L, 1992, DIABETES, V41, P792	49	124	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22570	22575		10.1074/jbc.272.36.22570	http://dx.doi.org/10.1074/jbc.272.36.22570			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278411	hybrid			2022-12-25	WOS:A1997XV49200031
J	Salceda, S; Caro, J				Salceda, S; Caro, J			Hypoxia-inducible factor 1 alpha (HIF-1 alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions - Its stabilization by hypoxia depends on redox-induced changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; TRANSCRIPTIONAL REGULATION; ENHANCER ELEMENT; EXPRESSION; PROTEOLYSIS; ACTIVATION; INHIBITORS; SEQUENCES; CELLS	The hypoxia-inducible factor 1 transcriptional activator complex (HIF-1) is involved in the activation of the erythropoietin and several other hypoxia-responsive genes, The HIF-1 complex is composed of two protein subunits: HIF-1 beta/ARNT (aryl hydrocarbon receptor nuclear translocator), which is constitutively expressed, and HIF-1 alpha, which is not present in normal cells but induced under hypoxic conditions. The HIF-1 alpha subunit is continuously synthesized and degraded under normoxic conditions, while it accumulates rapidly following exposure to low oxygen tensions. The involvement of the ubiquitin-proteasome system in the proteolytic destruction of HIF-1 in normoxia was studied by the use of specific inhibitors of the proteasome system. Lactacystin and MG-132 were found to protect the degradation of the HIF-1 complex in cells transferred from hypoxia to normoxia. The same inhibitors were able to induce HIF-1 complex formation when added to normoxic cells. Final confirmation of the involvement of the ubiquitin-proteasome system in the regulated degradation of HIF-1 alpha was obtained by the use of ts20TG(R) cells, which contain a temperature-sensitive mutant of E1, the ubiquitin-activating enzyme, Exposure of ts20 cells, under normoxic conditions, to the non-permissive temperature induced a rapid and progressive accumulation of HIF-1. The effect of proteasome inhibitors on the normoxic induction of HIF-1 binding activity was mimicked by the thiol reducing agent N-(2-mercaptopropionyl)glycine and by the oxygen radical scavenger 2-acetamidoacrylic acid. Furthermore, N-(2-mercaptopropionyl)-glycine induced gene expression as measured by the stimulation of a HIF-1-luciferase expression vector and by the induction of erythropoietin mRNA in normoxic Hep 3B cells. These last findings strongly suggest that the hypoxia induced changes in HIF-1 alpha stability and subsequent gene activation are mediated by redox-induced changes.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107	Jefferson University					NHLBI NIH HHS [1 F32 HL 09247] Funding Source: Medline; NIDDK NIH HHS [DK-34642] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034642] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dick LR, 1997, J BIOL CHEM, V272, P182; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HUNAG LE, 1996, J BIOL CHEM, V271, P32253; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Ratcliffe PJ, 1997, KIDNEY INT, V51, P514, DOI 10.1038/ki.1997.72; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robertson NM, 1997, CANCER RES, V57, P43; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SIPE HJ, 1993, CHEM-BIOL INTERACT, V86, P93, DOI 10.1016/0009-2797(93)90114-E; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	30	1341	1382	6	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22642	22647		10.1074/jbc.272.36.22642	http://dx.doi.org/10.1074/jbc.272.36.22642			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278421	hybrid			2022-12-25	WOS:A1997XV49200041
J	Zimmermann, AG; Wright, KL; Ting, JPY; Mitchell, BS				Zimmermann, AG; Wright, KL; Ting, JPY; Mitchell, BS			Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells - Role for a novel 5' palindromic octamer sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE 5'-PHOSPHATE DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; HUMAN IMP DEHYDROGENASE; LEUKEMIA-CELLS; MYCOPHENOLATE MOFETIL; INVIVO FOOTPRINT; UP-REGULATION; IN-VIVO; TRANSCRIPTION; PROMOTER	Expression of the gene encoding human inosine-5'-monophosphate dehydrogenase (IMPDH) type II, an enzyme catalyzing the rate-limiting step in the generation of guanine nucleotides, is increased more than 10-fold in activated peripheral blood T lymphocytes and is required for T cell activation, We have examined the 5'-regulatory sequences that are important for the transcriptional regulation of this gene in T cells, DNase I mapping of genomic DNA identified a hypersensitive element near the transcription initiation site, Fine mapping by in vivo footprinting demonstrated five transcription factor binding sites that are occupied in. both resting and activated peripheral blood T lymphocytes; these are tandem CRE motifs, a Sp1 site, an overlapping Egr-1/Sp1 site, and a novel palindromic octamer sequence (POS). The tandem CRE and POS sites are of major functional importance as judged by mutational and electrophoretic mobility shift analyses. These data provide evidence that expression of the human IMPDH type II gene is predominantly regulated by the nuclear factors ATF-2 and an as yet unidentified POS-binding protein. Additional major protein-DNA interactions do not occur within the promoter region after T lymphocyte activation, indicating a requirement for additional protein-protein interactions and/or post-translational modifications of pre-bound transcription factors to account for the observed increase in IMPDH type II gene expression.	UNIV N CAROLINA, SCH MED, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT INTERNAL MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Zimmermann, AG (corresponding author), UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, 1106 FLOB CB 7365, CHAPEL HILL, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA064192, R01CA034085] Funding Source: NIH RePORTER; NCI NIH HHS [CA64192, CA34085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRUNVAND MW, 1993, NUCLEIC ACIDS RES, V21, P4824, DOI 10.1093/nar/21.20.4824; CARR SF, 1993, J BIOL CHEM, V268, P27286; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Danovitch G, 1996, TRANSPLANTATION, V61, P722; DAYTON JS, 1994, J IMMUNOL, V152, P984; DAYTON JS, 1992, MOL PHARMACOL, V41, P671; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GLESNE D, 1993, GENOMICS, V16, P274, DOI 10.1006/geno.1993.1177; GU JJ, 1994, GENOMICS, V24, P179, DOI 10.1006/geno.1994.1597; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; JONES DH, 1991, BIOTECHNIQUES, V10, P62; KIGUCHI K, 1990, EXP CELL RES, V187, P47, DOI 10.1016/0014-4827(90)90114-P; KIGUCHI K, 1990, CELL GROWTH DIFFER, V1, P259; KONNO Y, 1991, J BIOL CHEM, V266, P506; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; OLAH E, 1988, P NATL ACAD SCI USA, V85, P6533, DOI 10.1073/pnas.85.17.6533; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SOKOLOSKI JA, 1986, CANCER RES, V46, P2314; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; TIEDEMAN AA, 1991, GENE, V97, P289, DOI 10.1016/0378-1119(91)90065-J; TRICOT GJ, 1989, CANCER RES, V49, P3696; Tsai EY, 1996, MOL CELL BIOL, V16, P459; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; WEBER G, 1983, CANCER RES, V43, P3466; WEISS A, 1984, J IMMUNOL, V133, P123; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; ZIMMERMANN AG, 1995, J BIOL CHEM, V270, P6808, DOI 10.1074/jbc.270.12.6808	48	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22913	22923		10.1074/jbc.272.36.22913	http://dx.doi.org/10.1074/jbc.272.36.22913			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278455	hybrid			2022-12-25	WOS:A1997XV49200076
J	Adachi, S; Cross, AR; Babior, BM; Gottlieb, RA				Adachi, S; Cross, AR; Babior, BM; Gottlieb, RA			Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SUPEROXIDE-DISMUTASE; PROTEASE ACTIVATION; JURKAT CELLS; ACIDIFICATION; REQUIREMENT; EXTRACTS	Fas-driven apoptosis in Jurkat cells results in the inactivation of cytochrome c with cessation of oxygen consumption, Overexpression of Bcl-2 was found to protect against acidification and apoptosis mediated by Fas ligation in these cells. Bcl-2 is present in the outer mitochondrial membrane, but the molecular mechanism by which it protects cells is unknown. Because Bcl-2 projects into the mitochondrial intermembrane space and cytochrome c is located in the intermembrane space, we considered the possibility that Bcl-2 might protect cytochrome c from inactivation during Fas-mediated apoptosis. The present study shows that 1) in Jurkat cells, cytochrome c inactivation during Fas-driven apoptosis requires the permeabilization of the outer mitochondrial membrane; and 2) the post-mitochondrial fraction from CEM cells that overexpress Bcl-2 both prevents and reverses cytochrome c inactivation.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01345] Funding Source: Medline; NIA NIH HHS [AG-13501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; KIZAKI M, 1993, BLOOD, V82, P1142; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	21	162	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21878	21882		10.1074/jbc.272.35.21878	http://dx.doi.org/10.1074/jbc.272.35.21878			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268320	hybrid			2022-12-25	WOS:A1997XT85000032
J	Lee, CK; Bluyssen, HAR; Levy, DE				Lee, CK; Bluyssen, HAR; Levy, DE			Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GUANYLATE-BINDING PROTEIN; GAMMA-INTERFERON; TYROSINE-PHOSPHATASE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; MESSENGER-RNA; ACTIVATION; GENE; STAT1	Daudi B lymphoblastoid cells are highly sensitive to the anti-growth and anti-viral effects of interferon (IFN). Unlike many cell lines, these cells show prolonged transcription of IFN-stimulated genes following treatment with IFN-alpha. This prolonged response correlated with the continued presence of the activated transcription factor, IFN-stimulated gene factor 3 (ISGF3). Pulse-chase labeling experiments indicated that the half life of the phosphorylation of signal transducers and activators of transcription (Stat)1 and Stat2 was short (<2 h) although the turnover of the proteins themselves was slow (>24 h), indicative of a constitutive phosphatase activity. The administration of protein-tyrosine kinase inhibitors at any time point during IFN stimulation led to rapid inhibition of the response, indicating that tyrosine kinase activity was continuously required. Catalytic activity of Jak1 and Tyk2 kinases remained elevated for prolonged periods following stimulation. Continuous presence of IFN-alpha was necessary for maintaining prolonged activation of ISGF3 and of Janus kinases, an activity that was blocked by antibodies to IFN-alpha or by cycloheximide. Conditioned medium of IFN-alpha-stimulated cells was capable of stimulating STAT activation in naive cells. Taken together, these results suggest that the response to IFN-alpha is controlled by the duration of stimulated Janus kinase activity over the background of constitutive dephosphorylation and that this response can be sustained by autocrine secretion of IFN-alpha.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Levy, David/AAG-6202-2019; Lee, Chien-Kuo/AAZ-1039-2020; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; Lee, Chien-Kuo/0000-0001-8189-6045; Bluyssen, Hans/0000-0002-4568-6259	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DRON M, 1993, J INTERFERON RES, V13, P377, DOI 10.1089/jir.1993.13.377; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LAMB P, 1994, J INTERFERON RES, V14, P365, DOI 10.1089/jir.1994.14.365; LARNER AC, 1986, J BIOL CHEM, V261, P453; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; TONKS NK, 1994, TRENDS BIOCHEM SCI, V19, P480; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038	32	77	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21872	21877		10.1074/jbc.272.35.21872	http://dx.doi.org/10.1074/jbc.272.35.21872			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268319	hybrid			2022-12-25	WOS:A1997XT85000031
J	Paris, S; BeraudDufour, S; Robineau, S; Bigay, J; Antonny, B; Chabre, M; Chardin, P				Paris, S; BeraudDufour, S; Robineau, S; Bigay, J; Antonny, B; Chabre, M; Chardin, P			Role of protein-phospholipid interactions in the activation of ARF1 by the guanine nucleotide exchange factor Arno	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; PLECKSTRIN-HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ESCHERICHIA-COLI; BINDING; MYRISTOYLATION; TRANSPORT; MEMBRANE; VESICLES; KINASE	Arno is a 47-kDa human protein recently identified as a guanine nucleotide exchange factor for ADP ribosylation factor 1 (ARF1) with a central Sec7 domain responsible for the exchange activity and a carboxyl-terminal pleckstrin homology (PH) domain (Chardin, P., Paris, S., Antonny, B., Robineau, S., Beraud-Dufour, S., Jackson, C. L., and Chabre, M. (1996) Nature 384, 481-484), Binding of the PH domain to phosphatidylinositol 4,5-bisphosphate (PIP2) greatly enhances Arno-mediated activation of myristoylated ARF1, We show here that in the absence of phospholipids, Arno promotes nucleotide exchange on [Delta 17]ARF1, a soluble mutant of ARF1 lacking the first 17 amino acids, This reaction is unaffected by PIP2, which suggests that the PIP2-PH domain interaction does not directly regulate the catalytic activity of Arno but rather serves to recruit Arno to membranes, Arno catalyzes the release of GDP more efficiently than that of GTP from [Delta 17]ARF1, and a stable complex between Arno Sec7 domain and nucleotide-free [Delta 17]ARF1 can be isolated, In contrast to [Delta 17]ARF1, full-length unmyristoylated ARF1 is not readily activated by Arno in solution, Its activation requires the presence of phospholipids and a reduction of ionic strength and Mg2+ concentration, PIP2 is strongly stimulatory, indicating that binding of Arno to phospholipids is involved, but in addition, electrostatic interactions between phospholipids and the amino-terminal portion of unmyristoylated ARF1(GDP) seem to be important. We conclude that efficient activation of full-length ARF1 by Arno requires a membrane surface and two distinct protein-phospholipid interactions: one between the PH domain of Arno and PIP2, add the other between amino-terminal cationic residues of ARF1 and anionic phospholipids. The latter interaction is normally induced by insertion of the amino-terminal myristate into the bilayer but can also be artificially facilitated by decreasing Mg2+ and salt concentrations.			Paris, S (corresponding author), CNRS, INST PHARMACOL MOL & CELLULAIRE, 660 ROUTE LUCIOLES, F-06560 VALBONNE, FRANCE.		Antonny, Bruno/ABH-7434-2020; BERAUD-DUFOUR, Sophie/M-4641-2016	Antonny, Bruno/0000-0002-9166-8668; Joelle, BIGAY/0000-0002-7487-3416; BERAUD-DUFOUR, Sophie/0000-0002-0062-6842				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Harter C, 1996, BBA-REV BIOMEMBRANES, V1286, P75, DOI 10.1016/0304-4157(96)00003-2; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; KAHN RA, 1992, J BIOL CHEM, V267, P13039; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	34	137	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22221	22226		10.1074/jbc.272.35.22221	http://dx.doi.org/10.1074/jbc.272.35.22221			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268368	hybrid			2022-12-25	WOS:A1997XT85000080
J	Vallet, VS; Henrion, AA; Bucchini, D; Casado, M; Raymondjean, M; Kahn, A; Vaulont, S				Vallet, VS; Henrion, AA; Bucchini, D; Casado, M; Raymondjean, M; Kahn, A; Vaulont, S			Glucose-dependent liver gene expression in upstream stimulatory factor 2 -/- mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; TRANSCRIPTION FACTOR USF; PYRUVATE-KINASE; METABOLIC-REGULATION; TRANSGENIC MICE; RAT; PROMOTER; ORGANIZATION; SPECIFICITY; DEFINITION	Upstream stimulatory factors (USF) 1 and 2 belong to the Myc family of transcription factors characterized by a basic/helix loop helix/leucine zipper domain responsible for dimerization and DNA binding, These ubiquitous factors form homo- and heterodimers and recognize in vitro a CACGTG core sequence termed E box, Through binding to E boxes of target genes, USF factors have been demonstrated to activate gene transcription and to enhance expression of some genes in response to various stimuli. In particular, in the liver USF1 and USF2 have been shown to bind in vitro glucose/carbohydrate response elements of glycolytic and lipogenic genes and have been proposed, from ex vivo experiments, to be involved in their transcriptional activation by glucose, However, the direct involvement of these factors in gene expression and nutrient gene regulation in vivo has not yet been demonstrated, Therefore, to gain insight into the specific role of USF1 and USF2 in vivo, and in particular to determine whether the USF products are required for the response of genes to glucose, we have created, by homologous recombination, USF2 -/- mice, In this paper, we provide the first evidence that USF2 proteins are required in vivo for a normal transcriptional response of L-type pyruvate kinase and Spot 14 genes to glucose in the liver.	INSERM, INST COCHIN GENET MOL, U129, UNITE RECH PHYSIOL & PATHOL GENET & MOL, F-75014 PARIS, FRANCE; UNIV PARIS 05, INSERM, U257, LAB GENET CELLULAIRE & MOL, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Casado, Marta/L-2078-2014; Vaulont, Sophie/O-6732-2017; Caude, Alexandra A Henrion/I-2778-2016	Casado, Marta/0000-0001-6457-4650; Caude, Alexandra A Henrion/0000-0002-8170-2260				Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Joyner AL, 1993, GENE TARGETING PRACT; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIAW CW, 1984, J BIOL CHEM, V259, P7253; LIN Q, 1994, J BIOL CHEM, V269, P23894; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MARIE J, 1976, BIOCHIM BIOPHYS ACTA, V438, P393, DOI 10.1016/0005-2744(76)90256-4; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCOTT RJ, 1983, DIFFERENTIATION, V25, P64; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405	30	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21944	21949		10.1074/jbc.272.35.21944	http://dx.doi.org/10.1074/jbc.272.35.21944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268329	hybrid			2022-12-25	WOS:A1997XT85000041
J	Alkema, MJ; Jacobs, H; vanLohuizen, M; Berns, A				Alkema, MJ; Jacobs, H; vanLohuizen, M; Berns, A			Perturbation of B and T cell development and predisposition to lymphomagenesis in E mu Bmi1 transgenic mice require the Bmi1 RING finger	ONCOGENE			English	Article						Bmi1; lymphoid development; lymphomagenesis; provirus tagging	E-MU-MYC; POLYCOMB GROUP GENES; C-MYC; ZINC-FINGER; LEUKEMIA-VIRUS; HOMEOBOX GENE; PROVIRAL INSERTION; AXIAL SKELETON; DROSOPHILA; EXPRESSION	Proviral activation of the Bmi1 gene has implicated Bmi1 as a collaborator of c-Myc in lymphomagenesis. To determine the effect of Bmi1 overexpression on hematopoiesis and lymphomagenesis transgenic mice were generated that overexpress different forms of the Bmi1 protein in their lymphoid compartment. E mu Bmi1 transgenic mice, overexpressing the wild type Bmi1 protein showed a perturbed lymphoid development and were highly susceptible to B and T cell lymphomagenesis. Mutational analysis of the Bmi1 protein demonstrated that the conserved N-terminal RING finger and central part of Bmi1 are essential for its oncogenic potential whereas the C-terminal Pro-Ser rich region is not required. We have used provirus tagging in the E mu Bmi1 mice to identify genes that cooperate with Bmi1 in lymphomagenesis. MoMLV infection in E mu Bmi1 transgenic mice accelerated Lymphoma development. Proviral activation of the Pim and Myc genes but not the Gfi1 gene were frequently observed in these tumors. These results demonstrate that Bmi1 is a potent oncogene and suggest that it plays an important role in early lymphoid development.	NETHERLANDS CANC INST, DIV MOL GENET, NL-1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOL CARCINOGENESIS, NL-1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute				Jacobs, Heinz/0000-0001-6227-9850				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; DUBE ID, 1991, BLOOD, V78, P2996; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVERETT R, 1995, J VIROL, V69, P7339, DOI 10.1128/JVI.69.11.7339-7344.1995; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEVY LS, 1993, VIROLOGY, V196, P892, DOI 10.1006/viro.1993.1553; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; MCKEON J, 1994, MOL GEN GENET, V244, P474, DOI 10.1007/BF00583898; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NOMURA M, 1994, DIFFERENTIATION, V57, P39, DOI 10.1046/j.1432-0436.1994.5710039.x; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; PELEGRI F, 1994, GENETICS, V136, P1341; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zornig M, 1996, ONCOGENE, V12, P1789	56	109	114	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	1997	15	8					899	910		10.1038/sj.onc.1201262	http://dx.doi.org/10.1038/sj.onc.1201262			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285685				2022-12-25	WOS:A1997XR76700003
J	Gong, DW; He, YF; Karas, M; Reitman, M				Gong, DW; He, YF; Karas, M; Reitman, M			Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta 3-adrenergic agonists, and leptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; PROTON TRANSPORT; FAT; EXPRESSION; CLONING; OBESITY; MICE; GENE; MECHANISM; C57BL/6J	Mitochondrial uncoupling proteins (UCPs) are transporters that are important for thermogenesis, The net result of their activity is the exothermic movement of protons through the inner mitochondrial membrane, uncoupled from ATP synthesis, We have cloned a third member of the UCP family, UCP3. UCP3 is expressed at high levels in muscle and rodent brown adipose tissue, Overexpression in yeast reduced the mitochondrial membrane potential, showing that UCP3 is a functional uncoupling protein, UCP3 RNA levels are regulated by hormonal and dietary manipulations, In contrast, levels of UCP2, a widely expressed UCP family member, showed little hormonal regulation, In particular, muscle UCP3 levels were decreased 3-fold in hypothyroid rats and increased B-fold in hyperthyroid rats, Thus UCP3 is a strong candidate to explain the effects of thyroid hormone on thermogenesis. White adipose UCP3 levels were greatly increased by treatment with the beta 3-adrenergic agonist, CL214613, suggesting another pathway for increasing thermogenesis, UCP3 mRNA levels were also regulated by dexamethasone, leptin, and starvation, albeit differently in muscle and brown adipose tissue. Starvation caused increased muscle and decreased BAT UCP3, suggesting that muscle assumes a larger role in thermoregulation during starvation, The UCP3 gene is located close to that encoding UCP2, in a chromosomal region implicated in previous linkage studies as contributing to obesity.			Gong, DW (corresponding author), NIDDK,DIABET BRANCH,NIH,BLDG 10,RM 8N-250,10 CTR DR,MSC 1770,BETHESDA,MD 20892, USA.		Reitman, Marc/B-4448-2013; Gong, Dawei/AAB-4283-2020	Reitman, Marc/0000-0002-0426-9475; 				Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLAUD F, 1985, P NATL ACAD SCI USA, V82, P445, DOI 10.1073/pnas.82.2.445; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; DAWSON AG, 1979, TRENDS BIOCHEM SCI, V4, P171, DOI 10.1016/0968-0004(79)90417-1; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Lowell BB, 1997, ANNU REV MED, V48, P307; MIROUX B, 1993, EMBO J, V12, P3739, DOI 10.1002/j.1460-2075.1993.tb06051.x; Nagase I, 1996, J CLIN INVEST, V97, P2898, DOI 10.1172/JCI118748; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; SHAPIRO HM, 1994, METHOD CELL BIOL, V41, P121; Silva JE, 1995, THYROID, V5, P481, DOI 10.1089/thy.1995.5.481; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Soloveva V, 1997, MOL ENDOCRINOL, V11, P27, DOI 10.1210/me.11.1.27; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; WESTERTERP KR, 1986, J APPL PHYSIOL, V61, P2162, DOI 10.1152/jappl.1986.61.6.2162; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	36	700	744	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24129	24132		10.1074/jbc.272.39.24129	http://dx.doi.org/10.1074/jbc.272.39.24129			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305858	hybrid			2022-12-25	WOS:A1997XY51500009
J	Isenring, P; Forbush, B				Isenring, P; Forbush, B			Ion and bumetanide binding by the Na-K-Cl cotransporter - Importance of transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CHLORIDE COTRANSPORTER; CYTOPLASMIC DOMAIN; PROTEIN; PHOSPHORYLATION; LOCALIZATION; TRANSPORT; EXCHANGER	The Na-K-CI cotransporter (NKCC) plays a key role in electrolyte secretion and absorption across polarized epithelia, The structure of the Na-R-Cl cotransporter transport protein is not known, but from analysis of the primary amino acid sequence and biochemical studies, it has been inferred that the protein has large cytoplasmic N and C termini and a hydrophobic central domain containing 12 transmembrane helices, Both the central domain and the C-terminal domain are highly conserved within the cation-chloride cotransporter family, This paper examines the role of these three domains in interacting with the transported ions and with the inhibitor bumetanide. We have used a chimera approach, exploiting the functional differences between the structurally similar shark and human secretory Na-R-Cl cotransporters (sNKCC1 and hNKCC1). These transporters are 74% identical to one another and have similar transport and regulatory behaviors; however, sNKCCI differs markedly from hNRCC1 with regard to apparent affinities for the cotransported ions and for bumetanide. We prepared six sNKCC1-hNKCC1 chimeras in which N and C termini were interchanged between species, When transfected in HEK-293 cells, each chimera carried out bumetanide-sensitive Rb-86 influx, demonstrating transporter synthesis and cell surface delivery, Monoclonal antibodies J3 and J7 were used to detect the chimeric proteins, and the epitopes for these antibodies were localized to residues 49-196 and 1050-1168, respectively, in the shark sequence, For each of tyro chimeras that were examined, the time course of activation in low Cl- medium was the same as for the parent proteins; activation was found to proceed through a change in V-max rather than K-m. For the six chimeras, the apparent affinities for Na+, K+, Cl-, and bumetanide segregated exactly according-to whether the large hydrophobic central domain was derived from sNKCCI or hNKCCl, Significantly, the well-conserved C terminus does not appear to contain residues involved in She shark-human affinity differences, These results demonstrate that residues involved with ion translocation and inhibitor binding are within the large central domain that contains the 12 predicted transmembrane helices.			Isenring, P (corresponding author), YALE UNIV,DEPT CELLULAR & MOL PHYSIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47661] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Brill S., 1995, B MT DESERT ISL BIOL, V34, P53; COLLINS JF, 1993, P NATL ACAD SCI USA, V90, P3938, DOI 10.1073/pnas.90.9.3938; DELPIRE E, 1994, J BIOL CHEM, V269, P26677; FISCHBARG J, 1994, MOL CELL BIOCHEM, V140, P147, DOI 10.1007/BF00926753; FORBUSH B, 1995, INT SOC NEPHR AM PHY; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GILLEN CM, 1996, BIOPHYS J, V70, P204; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HEDGE RS, 1992, J MEMBRANE BIOL, V126, P27; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; ISENRING P, 1995, J AM SOC NEPHROL, V6, P341; Isenring Paul, 1996, Journal of the American Society of Nephrology, V7, P1282; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUF PK, 1984, J MEMBRANE BIOL, V77, P57, DOI 10.1007/BF01871100; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	31	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24556	24562		10.1074/jbc.272.39.24556	http://dx.doi.org/10.1074/jbc.272.39.24556			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305921	hybrid			2022-12-25	WOS:A1997XY51500072
J	Ishimi, Y				Ishimi, Y			A DNA helicase activity is associated with an MCM4, -6, and -7 protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; REPLICATION LICENSING SYSTEM; HUMAN NUCLEAR-PROTEIN; S-PHASE; YEAST; XENOPUS; INITIATION; CHROMATIN; COMPONENT; ENZYMES	All six minichromosome maintenance (MCM) proteins have DNA-dependent ATPase motifs in the central domain which is conserved from yeast to mammals. Our group purified MCM protein complexes consisting of MCM2, -4 (Cdc21), -6 (Mis5), and -7 (CDC47) proteins from HeLa cells by using histone-Sepharose column chromatography (Ishimi, Y., Ichinose, S., Omori, A., Sato K., and Kimura, H. (1996) J. Biol. Chem. 271, 24115-24122). The present study revealed that both ATPase activity and DNA helicase activity that displaces oligonucleotides annealed to single-stranded circular DNA are associated with an MCM protein complex, Both ATPase and DNA helicase activities were co-purified with a 600-kDa protein complex that is consisted of equal amounts of MCM4, -6, and -7 proteins, An immunodepletion of the MCM protein complex from the purified fraction using anti-MCM4 antibody resulted in the severe reduction of the DNA helicase activity. Displacement of DNA fragments by the DNA helicase suggested that it migrated along single-stranded DNA in the 3' to 5' direction, and the DNA helicase activity was detected only in the presence of hydrolyzable ATP or bATP. These results suggest that this helicase may be involved in the initiation of DNA replication as a DNA unwinding enzyme.			Ishimi, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P9642; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DEAN FB, 1992, J BIOL CHEM, V267, P14129; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Fujita M, 1997, J BIOL CHEM, V272, P10928; GOETZ GS, 1988, J BIOL CHEM, V263, P383; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Holthoff HP, 1996, GENOMICS, V37, P131, DOI 10.1006/geno.1996.0530; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MARIORANO D, 1996, EMBO J, V15, P861; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Matson SW, 1995, METHOD ENZYMOL, V262, P389; MATSUMOTO K, 1995, BIOCHEMISTRY-US, V34, P7913, DOI 10.1021/bi00024a016; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; SEKI M, 1995, MOL CELL BIOL, V15, P165, DOI 10.1128/MCB.15.1.165; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; STARBORG M, 1995, J CELL SCI, V108, P927; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	51	462	472	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24508	24513		10.1074/jbc.272.39.24508	http://dx.doi.org/10.1074/jbc.272.39.24508			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305914	hybrid			2022-12-25	WOS:A1997XY51500065
J	Laudanna, C; Campbell, JJ; Butcher, EC				Laudanna, C; Campbell, JJ; Butcher, EC			Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL ADHERENCE; SIGNALING PATHWAY; CYCLIC-AMP; PROTEIN; ENDOTHELIUM; LYMPHOCYTES; RECEPTORS; INFILTRATION; CHEMOTAXIS; MODULATION	Chemoattractant receptors of the serpentine, heterotrimeric G alpha(i) protein-linked family can activate leukocyte integrins and in this role regulate leukocyte traffic and cell-cell interactions in immune and inflammatory responses. Using a mouse lymphoid cell line transfected with human formyl peptide or interleukin-8 receptors and normal human neutrophils as models, we show that cAMP functions as a gating element on the chemoattractant-induced rho-dependent signaling pathway leading to leukocyte integrin activation and adhesion. cAMP, acting through protein kinase A, inhibits chemoattractant-triggered integrin-dependent leukocyte adhesion. cAMP also prevents guanine nucleotide exchange on RhoA, a small GTP-binding protein of the rho subfamily, which is activated in seconds by chemoattractants. In contrast, chemoattractant-triggered intracellular calcium elevation is unaffected by cAMP, and cAMP has no effect on rho-dependent adhesion and RhoA guanine nucleotide exchange triggered through the independent protein kinase C pathway. These data suggest that cAMP-induced inhibition of rho activation may be responsible for the anti-adhesive effect of cAMP and may contribute to the anti-inflammatory activity of cAMP elevating agonists and drugs, Moreover, the findings extend the concept of cyclic nucleotide gating as a broadly important mechanism in the regulation of intracellular signaling pathways and the cellular activities they control.	STANFORD UNIV,DEPT PATHOL,LAB IMMUNOL & VASC BIOL,STANFORD,CA 94305; STANFORD UNIV,DEPT MED,CTR DIGEST DIS,STANFORD,CA 94305; VET AFFAIRS HLTH CARE SYST,CTR MOL BIOL & MED,PALO ALTO,CA 94304	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Campbell, James/0000-0003-4252-5182	NHLBI NIH HHS [HL48638] Funding Source: Medline; NIAID NIH HHS [AI37832, AI37319] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037832, R01AI037319] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURKEY TH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P312, DOI 10.1016/0167-4889(93)90223-C; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CONDINONETO A, 1991, BRIT J CLIN PHARMACO, V32, P557, DOI 10.1111/j.1365-2125.1991.tb03951.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GRISTWOOD RW, 1991, INT ARCH ALLER A IMM, V94, P293, DOI 10.1159/000235388; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARVATH L, 1991, J IMMUNOL, V146, P224; HONDA S, 1994, J IMMUNOL, V152, P4026; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; MATSUMOTO T, 1994, J PHARMACOL EXP THER, V269, P1236; Milligan G, 1995, Adv Pharmacol, V32, P1, DOI 10.1016/S1054-3589(08)61010-8; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; OPPENHEIMERMARKS N, 1994, J IMMUNOL, V152, P5703; RAVI L, 1996, SCIENCE, V271, P461; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VALITUTTI S, 1993, EUR J IMMUNOL, V23, P790, DOI 10.1002/eji.1830230403; VANEPPS DE, 1981, INFLAMMATION, V5, P81, DOI 10.1007/BF00910782; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	27	178	180	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24141	24144		10.1074/jbc.272.39.24141	http://dx.doi.org/10.1074/jbc.272.39.24141			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305861	hybrid			2022-12-25	WOS:A1997XY51500012
J	Lazarowski, ER; Homolya, L; Boucher, RC; Harden, TK				Lazarowski, ER; Homolya, L; Boucher, RC; Harden, TK			Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL SELECTIVITY; FUNCTIONAL EXPRESSION; PHOSPHOLIPASE-C; ATP RECEPTOR; CELLS; CLONING; IDENTIFICATION; ASTROCYTES; SIGNAL; PURINE	ATP is released from most cell types and functions as an extracellular signaling molecule through activation of members of the two large families of P2X and P2Y receptors. Although three mammalian P2Y receptors have been cloned that are selectively activated by uridine nucleotides, direct demonstration of the release of cellular UTP has not, been reported, Pharmacological studies of the P2Y, receptor expressed in 1321N1 human astrocytoma cells indicated that this receptor is activated by UTP but mot by ATP. Mechanical stimulation of 1321N1 cells also resulted in release of a molecule that markedly activated the expressed P2Y(4) receptor. This nucleotide was shown to be UTP by two means, First, high performance liquid chromatography analysis of the medium from [P-33]H3PO4-loaded 1321N1 cells illustrated that mechanical stimulation resulted in a large increase in a radioactive species that co-eluted with authentic UTP. This species was degraded by incubation with the nonspecific pyrophosphohydrolase apyrase or with hexokinase and was specifically lost by incubation with the UTP-specific enzyme UDP-glucose pyrophosphorylase. Second, a sensitive assay that quantitates UTP mass at low nanomolar concentrations was devised Based on the nucleotide specificity of UDP-glucose pyrophosphorylase. Using this assay, mechanical stimulation of 1321N1 cells was shown to result in an increase of medium UTP levels from 2.6 to 36.4 pmol/10(6) cells within a min, This increase was paralleled by a similar augmentation of extracellular ATP levels, Pn calcein-based fluorescence quenching method was utilized to confirm that none of the increases in medium nucleotide levels could be accounted for by cell lysis, Taken together, these results directly demonstrate the mechanically induced release of UTP and illustrate the efficient coupling of this release to activation of P2Y(4) receptors.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; HUNGARIAN ACAD SCI,MEMBRANE RES GRP,H-1113 BUDAPEST,HUNGARY	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Hungarian Academy of Sciences			Homolya, Laszlo/N-1154-2016	Homolya, Laszlo/0000-0003-1639-8140	NHLBI NIH HHS [HL32322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbracchio MP, 1996, CIBA F SYMP, V198, P142; ANDERSSON M, 1988, INT J BIOCHEM, V20, P1039, DOI 10.1016/0020-711X(88)90248-0; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Charlton SJ, 1996, BRIT J PHARMACOL, V118, P704, DOI 10.1111/j.1476-5381.1996.tb15457.x; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ENOMOTO K, 1994, PFLUG ARCH EUR J PHY, V427, P533, DOI 10.1007/BF00374271; FREDHOLM BB, 1997, DRUG DEVELOP RES, V39, P461; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HO C, 1995, BRIT J PHARMACOL, V116, P2909, DOI 10.1111/j.1476-5381.1995.tb15944.x; KEPPLER D, 1970, ANAL BIOCHEM, V38, P105, DOI 10.1016/0003-2697(70)90160-0; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; Neary JT, 1996, CIBA F SYMP, V198, P130; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PEARCE B, 1994, BRAIN RES, V660, P329, DOI 10.1016/0006-8993(94)91307-2; PLESNER L, 1995, INT REV CYTOL, V158, P141; Saiag B, 1995, ENDOTHELIUM, V2, P279, DOI 10.3109/10623329509024644; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; STEELMAN VS, 1966, BIOCHIM BIOPHYS ACTA, V128, P92, DOI 10.1016/0926-6593(66)90145-7; WATT WC, 1996, PEDIAT PULMONAL S, V13, P26; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I	33	254	257	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24348	24354		10.1074/jbc.272.39.24348	http://dx.doi.org/10.1074/jbc.272.39.24348			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305892	Green Published, hybrid			2022-12-25	WOS:A1997XY51500043
J	Choi, HS; Chung, MR; Tzameli, I; Simha, D; Lee, YK; Seol, W; Moore, DD				Choi, HS; Chung, MR; Tzameli, I; Simha, D; Lee, YK; Seol, W; Moore, DD			Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; THYROID-HORMONE; GENE-EXPRESSION; GROWTH-HORMONE; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE ELEMENT; CRYSTAL-STRUCTURE; CONSERVED REGION; X-RECEPTOR	We have identified a new murine orphan member of the nuclear hormone receptor superfamily, termed mCAR, that is closely related to the previously described human orphan MB67, referred to here as hCAR. Like hCAR, mCAR expression is highest in liver, In addition to the most abundant mCAR1 isoform, the mCAR gene expresses a truncated mCAR2 variant that is missing the C-terminal portion of the ligand binding/dimerization domain. The mCAR gene has 8 introns, and this mCAR2 variant is generated by a splicing event that skips the 8th exon. mCAR1, like hCAR, binds as a heterodimer with the retinoid X receptor to the retinoic acid response element from the promoter of the retinoic acid receptor beta 2 isoform, Consistent with its lack of a critical heterodimerization interface, the mCAR2 variant does not bind this site, Both mCAR1 and hCAR are apparently constitutive transcriptional activators, This activity is dependent on the presence of the conserved C terminal AF-2 transcriptional activation motif, As expected from its inability to bind DNA, the mCAR2 variant neither transactivates by itself nor inhibits transactivation by hCAR or mCAR1.	MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital					NIDDK NIH HHS [DK46546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRENT GA, 1989, J BIOL CHEM, V264, P178; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Malik S, 1996, MOL CELL BIOL, V16, P1824; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TONE Y, 1994, J BIOL CHEM, V269, P31157; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	232	250	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23565	23571		10.1074/jbc.272.38.23565	http://dx.doi.org/10.1074/jbc.272.38.23565			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295294	hybrid			2022-12-25	WOS:A1997XX38100019
J	Elhabazi, A; Lang, V; Herold, C; Freemann, GJ; Bensussan, A; Boumsell, L; Bismuth, G				Elhabazi, A; Lang, V; Herold, C; Freemann, GJ; Bensussan, A; Boumsell, L; Bismuth, G			The human semaphorin-like leukocyte cell surface molecule CD100 associates with a serine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH CONE GUIDANCE; HUMAN LYMPHOCYTES-T; SELECTIVE INHIBITOR; TYROSINE PHOSPHORYLATION; AXON GUIDANCE; CD45; ACTIVATION; COMPLEX; FAMILY	CD100 is a 150-kDa homodimeric glycoprotein broadly expressed on the surface of human hematopoietic cells. CD100 has been recently identified as the first lymphoid gene that belongs to the semaphorin gene family. Semaphorins function as chemorepellent molecules in the nervous system, but the function of CD100 remains poorly understood. In lymphoid cells, it has been suggested to play a role in homotypic cell adhesion and in T cell activation. We demonstrate that in T cells and natural killer cells a serine kinase activity is immunoprecipitated with CD100. Distinct epitopes of CD100 have been defined with specific monoclonal antibodies, mediating opposite effects at the functional level, especially in T cells. The kinase activity is retained only with an antibody against a particular epitope of CD100. Additionally, a fusion protein containing the cytoplasmic domain of the molecule retains the kinase activity in cellular lysates, and CD100 itself is presumably a favorite substrate of the kinase, These findings suggest that a serine kinase pathway may participate in the different functional effects triggered through the distinct epitopes of CD100 and is likely involved in the biological effects of this semaphorin-like leukocyte cell surface molecule.	CTR HOSP PITIE SALPETRIERE,CERVI,CNRS,URA 625,LAB IMMUNOL CELLULAIRE,F-75013 PARIS,FRANCE; HARVARD UNIV,SCH MED,DEPT MED,DIV HEMATOL MALIGNANCIES,DANA FARBER CANC INST,BOSTON,MA 02115; FAC MED CRETEIL,IMMUNOL LAB,INSERM,U448,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)			Bensussan, Armand/E-5434-2017	Bensussan, Armand/0000-0002-0409-2497				ALBEROLAILA J, 1993, J IMMUNOL, V151, P4423; BOUGERET C, 1992, J IMMUNOL, V148, P318; BOUMSELL L, 1990, J IMMUNOL, V145, P2797; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CARDINE AM, 1994, EUR J IMMUNOL, V124, P1255; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; DAVID V, 1990, J IMMUNOL, V144, P1; DEANS JP, 1993, J IMMUNOL, V151, P4494; Frearson JA, 1996, IMMUNOL TODAY, V17, P385, DOI 10.1016/0167-5699(96)10026-8; Furuyama T, 1996, J BIOL CHEM, V271, P33376, DOI 10.1074/jbc.271.52.33376; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; HEROLD C, 1995, INT IMMUNOL, V7, P1, DOI 10.1093/intimm/7.1.1; Herold C, 1996, J IMMUNOL, V157, P5262; HEROLD C, 1995, LEUKOCYTE TYPING, V5, P290; HEROLD C, 1995, LEUCOCYTE TYPING, V5, P288; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LOH C, 1994, J BIOL CHEM, V269, P8817; MUSTELIN T, 1995, EUR J IMMUNOL, V25, P942, DOI 10.1002/eji.1830250413; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PINTO A, 1994, LEUKEMIA, V8, P347; PRASAD KVS, 1992, MOL CELL BIOL, V12, P5260, DOI 10.1128/MCB.12.11.5260; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHRAVEN B, 1993, EUR J IMMUNOL, V23, P119, DOI 10.1002/eji.1830230119; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474	41	47	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23515	23520		10.1074/jbc.272.38.23515	http://dx.doi.org/10.1074/jbc.272.38.23515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295286	hybrid			2022-12-25	WOS:A1997XX38100011
J	Garabedian, EM; Roberts, LJJ; McNevin, MS; Gordon, JI				Garabedian, EM; Roberts, LJJ; McNevin, MS; Gordon, JI			Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; SEGMENTED FILAMENTOUS BACTERIA; GASTROINTESTINAL-TRACT; EPITHELIAL-CELLS; CELLULAR-DIFFERENTIATION; PEPTIDE COMPONENTS; FORCED EXPRESSION; ENHANCING FACTOR; MAJOR MODIFIER; HOST-DEFENSE	The Paneth cell lineage is one of four epithelial lineages derived from the adult mouse small intestine's multipotent stem cell. Mature Paneth cells secrete antimicrobial peptides (cryptdins), growth factors, as well as two gene products, a secreted phospholipase A, and matrilysin, that has been implicated as modifiers of adenoma formation in mice containing a mutation in the tumor suppressor Apc. Immature Paneth cells are located just above and below the cell layer, in intestinal crypts, that has been proposed to contain the multipotent stem cell. Paneth cells differentiate during a downward migration to the crypt base. The location and direction of Paneth cell migration, their high density and long residency time at the crypt base, and the nature of their secreted gene products, suggest that they may influence the structure and/or function of the stem cell niche. Paneth cell ablation can therefore be viewed as an experimental manipulation of the cellular microenvironment that purportedly contains the stem cell and its immediate descendants. Two types of ablation experiments were performed in transgenic mice. Nucleotides -6500 to +34 of the mouse cryptdin-2 gene (CR2) were used to express an attenuated diphtheria toxin A fragment. Light and electron microscopic immunohistochemical analyses of several pedigrees of postnatal day 28 to 180 animals established that ablation of Paneth cells is accompanied by an increase in the proportion of undifferentiated crypt base columnar cells. These cells normally co-exist with Paneth cells. The ablation does not produce a detectable effect on the proliferation or terminal differentiation programs of the other three lineages or on host-microbial interactions. The last conclusion is based on the ability of crypts to remain free of microbes detectable by Gram and Warthin-Starry stains and by retention of the normal crypt-villus distribution of components of the diffuse gut-associated lymphoid tissue. CR2-directed expression of simian virus 40 large T antigen also results in a loss of mature Paneth cells but produces a marked amplification of crypt cells having a morphology intermediate between Paneth and granule goblet cells, EM immunohistochemical analyses suggest that intermediate cells can differentiate to mature goblet cells but not to Paneth cells, as they migrate up the crypt-villus axis. Our findings suggest that (i) stemness in the crypt is not defined by instructive interactions involving the Paneth cell; (ii) expressing a Paneth cell fate may require that precursors migrate to the crypt base; (iii) antimicrobial factors produced by Paneth cells are not required to prevent colonization of small intestinal crypts; and (iv) this lineage does not function to maintain the asymmetric crypt-villus distribution of components of the diffuse gut-associated lymphoid tissue.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIDDK NIH HHS [DK 37960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037960] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P65, DOI 10.1002/aja.1001600106; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; CALVERT R, 1988, ANAT REC, V220, P291, DOI 10.1002/ar.1092200310; CASTRO NM, 1959, LIN ACTA ANAT, V38, P345; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1969, AM J ANAT, V126, P507, DOI 10.1002/aja.1001260409; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; COHN SM, 1984, J BIOL CHEM, V259, P2456; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; DAVIS CP, 1974, INFECT IMMUN, V10, P948, DOI 10.1128/IAI.10.4.948-956.1974; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dove WF, 1997, CANCER RES, V57, P812; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOOS Y, 1971, Histochemical Journal, V3, P175, DOI 10.1007/BF01002560; Gould KA, 1996, GENETICS, V144, P1769; Gould KA, 1996, GENETICS, V144, P1777; GUSTAFSSON BE, 1982, SCAND J GASTROENTERO, V17, P117; HALL PA, 1994, J CELL SCI, V107, P3569; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; Hertzog AJ, 1937, AM J PATHOL, V13, P351; Hunyady B, 1996, HISTOCHEM CELL BIOL, V106, P447, DOI 10.1007/BF02473306; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JEPSON MA, 1993, INFECT IMMUN, V61, P4001, DOI 10.1128/IAI.61.9.4001-4004.1993; KLAASEN HLBM, 1991, ARCH MICROBIOL, V156, P148, DOI 10.1007/BF00290989; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MERZEL J, 1969, AM J ANAT, V124, P281, DOI 10.1002/aja.1001240303; MONTERO C, 1978, ANAT REC, V190, P127, DOI 10.1002/ar.1091900111; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POULSEN SS, 1986, HISTOCHEMISTRY, V85, P389, DOI 10.1007/BF00982668; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; SNEL J, 1995, INT J SYST BACTERIOL, V45, P780, DOI 10.1099/00207713-45-4-780; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TAN XD, 1993, AM J PATHOL, V142, P1858; TROUGHTON WD, 1969, J CELL BIOL, V41, P251, DOI 10.1083/jcb.41.1.251; TUCCARI G, 1984, BASIC APPL HISTOCHEM, V28, P177; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wyllie A H, 1980, Int Rev Cytol, V68, P251	72	192	204	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23729	23740		10.1074/jbc.272.38.23729	http://dx.doi.org/10.1074/jbc.272.38.23729			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295317	hybrid			2022-12-25	WOS:A1997XX38100042
J	Liang, GS; Hai, T				Liang, GS; Hai, T			Characterization of human activating transcription factor 4, a transcriptional activator that interacts with multiple domains of cAMP-responsive element-binding protein (CREB)-binding protein (CBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; LARGE T-ANTIGEN; COACTIVATOR CBP; ADENOVIRUS E1A; LEUCINE ZIPPER; FACTOR ATF; INDUCED STIMULATION; MOLECULAR-CLONING; NUCLEAR FACTOR; BZIP PROTEIN	We demonstrate that human activating transcription factor 4 (hATF4), a member of the activating transcription factor/cAMP-responsive element-binding protein (ATF/CREB) family of transcription factors, is a potent transcriptional activator in both mammalian cells and yeast. The N-terminal 113 amino acids of hATF4 activate transcription efficiently, and unexpectedly, the C-terminal bZip DNA binding domain of hATF4 also activates transcription, albeit weakly. Our results indicate that hATF4 interacts with several general transcription factors: TATA-binding protein, TFIIB, and the RAP30 subunit of TFIIF. In addition, hATF4 interacts with the coactivator CREB-binding protein (CBP) at four regions: 1) the KIX domain, 2) a region that contains the third zinc finger and the E1A-interacting domain, 3) a C-terminal region that contains the p160/SRC-1-interacting domain, and 4) the recently identified histone acetyltransferase domain. Interestingly, both the N-terminal and C-terminal regions of hATF4 interact with the above general transcription factors and CBP, providing a mechanistic explanation for their ability to activate transcription. Consistent, with its role as a coactivator, CBP potentiates the ability of hATF4 to activate transcription. The potential significance of the interaction between hATF4 and multiple factors is discussed.	OHIO STATE UNIV,BIOCHEM PROGRAM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210; OHIO STATE UNIV,NEUROBIOTECHNOL CTR,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NIGMS NIH HHS [GM46218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BRANDL CJ, 1989, P NATL ACAD SCI USA, V86, P2652, DOI 10.1073/pnas.86.8.2652; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHEN BPC, 1994, GENE, V139, P73, DOI 10.1016/0378-1119(94)90525-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARPER JW, 1993, CELL, V75, P805; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JONES RH, 1989, P NATL ACAD SCI USA, V86, P2176, DOI 10.1073/pnas.86.7.2176; JOSEPH CK, 1993, J BIOL CHEM, V268, P2002; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MIELNICKI LM, 1991, NUCLEIC ACIDS RES, V19, P6332, DOI 10.1093/nar/19.22.6332; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; NOJIMA H, 1994, NUCLEIC ACIDS RES, V22, P5279, DOI 10.1093/nar/22.24.5279; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; Rose MD., 1990, METHODS YEAST GENETI; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; VULLIET R, 1992, J BIOL CHEM, V267, P22570; Willems L, 1991, DNA Seq, V1, P415, DOI 10.3109/10425179109020800; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	77	100	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24088	24095		10.1074/jbc.272.38.24088	http://dx.doi.org/10.1074/jbc.272.38.24088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295363	hybrid			2022-12-25	WOS:A1997XX38100088
J	Spizz, G; Blackshear, PJ				Spizz, G; Blackshear, PJ			Identification and characterization of cathepsin B as the cellular MARCKS cleaving enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SUBSTRATE MARCKS; MEMBRANE ASSOCIATION; MOLECULAR-CLONING; TISSUE DISTRIBUTION; CHROMOSOMAL LOCALIZATION; MEDIATED PHOSPHORYLATION; EPOXYSUCCINYL PEPTIDES; LYSOSOMAL PROTEOLYSIS; MAJOR SUBSTRATE	The importance of regulating the cellular concentrations of the myristoylated alanine-rich C kinase substrate (MARCKS), a major cellular substrate of protein kinase C, is indicated by the fact that mice lacking MARCKS exhibit gross abnormalities of central nervous system development and die shortly after birth, We previously identified a novel means of regulating cellular MARCKS concentrations that involved a specific proteolytic cleavage of the protein and implicated a cysteine protease in this process (Spizz, G., and Blackshear, P. J. (1996) J. Biol. Chem. 271, 553-562). Here we show that p40, the carboxyl-terminal fragment resulting from this cleavage of MARCKS, was associated with the mitochondrial/lysosomal pellet fraction of human diploid fibroblasts and that its generation in cells was sensitive to treatment with NH4Cl. These data suggest the involve ment of lysosomes in the generation and/or stability of p40, The MARCKS-cleaving enzyme (MCE) activity was peripherally associated with a 10,000 x g pellet fraction from bovine liver, and it co-purified with the activity and immunoreactivity of a lysosomal protease, cathepsin B, Cathepsin B catalyzed the generation of p40 from MARCKS in a cell-free system and behaved similarly to the MCE with respect to mutants of MARCKS previously shown to be poor substrates for the MCE, Treatment of fibroblasts with a cell-permeable, specific inhibitor of cathepsin B, CA074-Me, resulted in parallel time-and concentration-dependent inhibition off cathepsin B and MCE activity, Incubation of a synthetic MARCKS phosphorylation site domain peptide with purified cathepsin B resulted in cleavage of the peptide at sites consistent with preferred cathepsin B substrate sites, These data provide evidence for the identity of the MCE as cathepsin B and suggest that this cleavage most likely takes place within lysosomes, perhaps as a result of specific lysosomal targeting sequences within the MARCKS primary sequence, The data also suggest a direct interaction between MARCKS and cathepsin B in cells and leave open the possibility that MARCKS may in some way regulate the protease for which it is a substrate.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & NUTR,SECT DIABET & METAB,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AGARWAL SK, 1987, BIOCHEM INT, V15, P785; ALDRED AR, 1995, COMP BIOCHEM PHYS B, V111, P1, DOI 10.1016/0305-0491(94)00229-N; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; AMESS B, 1992, FEBS LETT, V297, P285; BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Blackshear PJ, 1997, EXP NEUROL, V145, P46, DOI 10.1006/exnr.1997.6475; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; CARDOZO C, 1992, J LAB CLIN MED, V119, P169; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; COOPER JA, 1983, J BIOL CHEM, V258, P1108; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DEAN RT, 1984, BIOCHEM J, V217, P27, DOI 10.1042/bj2170027; DEVAL C, 1990, BIOCHEM CELL BIOL, V68, P822, DOI 10.1139/o90-121; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HASNAIN S, 1993, J BIOL CHEM, V268, P235; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JOHNSON GVW, 1993, J NEUROSCI RES, V34, P642, DOI 10.1002/jnr.490340607; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; KOGA H, 1991, J BIOCHEM-TOKYO, V110, P179, DOI 10.1093/oxfordjournals.jbchem.a123554; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; LINDNER D, 1992, J BIOL CHEM, V267, P24; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MUNGER JS, 1995, BIOCHEM J, V311, P299, DOI 10.1042/bj3110299; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NAKAOKA T, 1995, J BIOL CHEM, V270, P12147, DOI 10.1074/jbc.270.20.12147; OTSUKA M, 1991, BIOCHEM BIOPH RES CO, V178, P494, DOI 10.1016/0006-291X(91)90134-S; PAGE AE, 1992, BIOCHIM BIOPHYS ACTA, V1116, P57, DOI 10.1016/0304-4165(92)90128-H; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; ROWAN AD, 1992, BIOL CHEM H-S, V373, P427, DOI 10.1515/bchm3.1992.373.2.427; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SHI GP, 1994, J BIOL CHEM, V269, P11530; Spizz G, 1996, J BIOL CHEM, V271, P553, DOI 10.1074/jbc.271.1.553; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1994, EXPERIENTIA, V50, P1021, DOI 10.1007/BF01923456; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; TU GF, 1992, AM J PHYSIOL, V263, pR195, DOI 10.1152/ajpregu.1992.263.1.R195; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WOJTASZEK PA, 1993, ONCOGENE, V8, P755; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YASUHARA O, 1993, BRAIN RES, V628, P85, DOI 10.1016/0006-8993(93)90941-F	79	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23833	23842		10.1074/jbc.272.38.23833	http://dx.doi.org/10.1074/jbc.272.38.23833			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295331	hybrid			2022-12-25	WOS:A1997XX38100056
J	Yoon, SO; Soltoff, SP; Chao, MV				Yoon, SO; Soltoff, SP; Chao, MV			A dominant role of the juxtamembrane region of the TrkA nerve growth factor receptor during neuronal cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE INTERACTION DOMAIN; TYROSINE KINASE-ACTIVITY; PC12 CELLS; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITES; MAP KINASE; PHEOCHROMOCYTOMA CELLS; SUSTAINED ACTIVATION; SIGNAL-TRANSDUCTION	All receptor tyrosine kinases share a common intracellular signaling machinery, including ras activation, whereas cellular responses vary from mitogenesis to cell differentiation. To investigate the structural basis for receptor tyrosine kinase action for nerve growth factor, the juxtamembrane region of TrkA was transferred to a corresponding region of the epidermal growth factor (EGF) receptor. The resulting chimeric receptor contains an additional She site, Tyr(490), in the juxtamembrane region. In transfected PC12 cell lines, neuronal differentiation was observed with EGF treatment, as evidenced by increased neurite extension. The action of the chimeric receptor was correlated with prolonged activation of MAP kinases and a 3-4-fold increase in phosphatidylinositol 3-kinase activity. The effect of the juxtamembrane chimera was dependent upon the She site at Tyr(490), because expression of a chimeric receptor containing a Y490F mutation resulted in a complete loss of neuritogenesis by EGF treatment. These findings indicate that the juxtamembrane region of the TrkA receptor serves as a key functional domain that can confer a dominant effect upon neuronal differentiation.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; BETH ISRAEL DEACONESS MED CTR,DIV SIGNAL TRANSDUCT,DEPT MED,BOSTON,MA 02115	Cornell University; Harvard University; Beth Israel Deaconess Medical Center			Yoon, Sung Ok/C-5992-2012	Chao, Moses/0000-0002-6969-3744				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BERG MM, 1992, J BIOL CHEM, V267, P13; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; Mandiyan V, 1996, J BIOL CHEM, V271, P4770; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P278; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23231	23238		10.1074/jbc.272.37.23231	http://dx.doi.org/10.1074/jbc.272.37.23231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287331	hybrid			2022-12-25	WOS:A1997XV74400042
J	Zollner, S; Haseloff, RF; Kirilyuk, IA; Blasig, IE; Rubanyi, GM				Zollner, S; Haseloff, RF; Kirilyuk, IA; Blasig, IE; Rubanyi, GM			Nitroxides increase the detectable amount of nitric bride released from endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE MIMICS; HYDROXYL RADICAL PRODUCTION; OXYGEN RADICALS; RELAXING FACTOR; OXIDE; PEROXYNITRITE; KINETICS; IRON; CYTOTOXICITY; DERIVATIVES	Nitroxides are known to exert superoxide dismutase-mimetic properties and to decrease O-2(.-)- and H2O2-mediated cytotoxicity. However, the effect of nitroxides on (NO)-N-. homeostasis has not been studied yet. The present study investigates the effect of nitroxides on the detectable amount of (NO)-N-. released by 3-morpholinosydnonimine (SIN-1) and cultured endothelial cells. Cultured bovine aortic and atrial endothelial cells stimulated with 10 mu m A23187 released a stable flux of (NO)-N-., as detected by (NO)-N-. chemiluminescence. Addition of 100 units/ml SOD or 10 mu M of the nitroxides 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL), 3-carboxy-proxyl, and 3-ethoxycarbonyl-proxyl, increased the chemiluminescence signal. The effect of these nitroxides on the amount of (NO)-N-. released from cell monolayers was dose-dependent, with the highest efficacy between 30 and 100 mu M. EPR spin trapping in SIN-1 solutions revealed the formation of (OH)-O-. adducts from spontaneous dismutation of O-2(.-) and concomitant reaction with H2O2. Both SOD and TEMPOL increased the signal intensity of the (OH)-O-. adduct by accelerating the dismutation of O-2(.-). The results of this study demonstrate that the SOD-mimetic activity of nitroxides increases the amount of bioavailable (NO)-N-. in vitro.	BERLEX BIOSCI,CARDIOVASC DEPT,RICHMOND,CA 94804; INST MOL PHARMACOL,D-10315 BERLIN,GERMANY; RUSSIAN ACAD SCI,INST ORGAN CHEM,NOVOSIBIRSK 630090,RUSSIA	Russian Academy of Sciences; Vorozhtsov Novosibirsk Institute of Organic Chemistry			Kirilyuk, Igor/R-1688-2016; Kirilyuk, Igor/AAR-1400-2021	Kirilyuk, Igor/0000-0001-6033-0368; 				ANKEL EG, 1987, LIFE SCI, V40, P495, DOI 10.1016/0024-3205(87)90116-0; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BEHAR D, 1970, J PHYS CHEM-US, V74, P3209, DOI 10.1021/j100711a009; CHAN PH, 1994, BRAIN PATHOL, V4, P59; COSENTINO F, 1994, HYPERTENSION, V23, P229, DOI 10.1161/01.HYP.23.2.229; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; DEGRAFF WG, 1992, ENVIRON MOL MUTAGEN, V19, P21, DOI 10.1002/em.2850190105; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GADZHEVA V, 1994, FREE RADICAL RES, V21, P177, DOI 10.3109/10715769409056568; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAHN SM, 1994, CANCER RES, V54, pS2006; HALLE W, 1984, PHARMAZIE, V39, P77; HALLIWELL B, 1993, BRIT MED J, V307, P885, DOI 10.1136/bmj.307.6909.885; Haseloff RF, 1997, FREE RADICAL RES, V26, P7, DOI 10.3109/10715769709097780; HASELOFF RF, 1992, J BIOLUM CHEMILUM, V7, P171, DOI 10.1002/bio.1170070303; HASELOFF RF, 1990, FREE RADICAL BIO MED, V9, P111, DOI 10.1016/0891-5849(90)90113-W; JOSEPH J, 1993, BIOCHEM BIOPH RES CO, V192, P926, DOI 10.1006/bbrc.1993.1504; Katusic ZS, 1996, FREE RADICAL BIO MED, V20, P443, DOI 10.1016/0891-5849(96)02116-8; Koppenol W.H., 1981, OXYGEN OXYRADICALS C, P671; Krishna MC, 1996, J BIOL CHEM, V271, P26026, DOI 10.1074/jbc.271.42.26026; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAGANO T, 1989, J BIOL CHEM, V264, P9243; NOACK E, 1989, J CARDIOVASC PHARM, V14, pS1, DOI 10.1097/00005344-198914110-00002; RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199304000-00002; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH815, DOI 10.1152/ajpheart.1986.250.5.H815; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; RUBANYI GM, 1988, FREE RADICAL BIO MED, V4, P107, DOI 10.1016/0891-5849(88)90071-8; RYAN US, 1980, TISSUE CELL, V12, P619, DOI 10.1016/0040-8166(80)90017-8; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1991, FREE RADICAL RES COM, V12-3, P187, DOI 10.3109/10715769109145785; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SHI XL, 1994, BIOCHEM BIOPH RES CO, V203, P1515, DOI 10.1006/bbrc.1994.2357; SHIMIZU S, 1994, RES COMMUN CHEM PATH, V84, P301; SHUFF ST, 1992, BIOCHEM PHARMACOL, V43, P1601, DOI 10.1016/0006-2952(92)90219-9; SOSNOVSKY G, 1995, J ORG CHEM, V60, P3414, DOI 10.1021/jo00116a029; THOMAS JP, 1993, J LIPID RES, V34, P479; WEISS RH, 1993, J BIOL CHEM, V268, P23049; ZHANG RL, 1994, ARCH BIOCHEM BIOPHYS, V312, P385, DOI 10.1006/abbi.1994.1323	48	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23076	23080		10.1074/jbc.272.37.23076	http://dx.doi.org/10.1074/jbc.272.37.23076			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287307	hybrid			2022-12-25	WOS:A1997XV74400018
J	Jeyaseelan, R; Poizat, C; Baker, RK; Abdishoo, S; Isterabadi, LB; Lyons, GE; Kedes, L				Jeyaseelan, R; Poizat, C; Baker, RK; Abdishoo, S; Isterabadi, LB; Lyons, GE; Kedes, L			A novel cardiac-restricted target for doxorubicin - CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING; DEVELOPING HEART; MUSCLE; TRANSCRIPTION; PROTEIN; EMBRYOGENESIS; PROMOTER; NKX-2.5; FAMILY	Doxorubicin (Dox), a cardiotoxic antineoplastic drug, disrupts the cardiac-specific program of gene expression (Kurabayashi, M., Dutta, S., Jeyaseelan, R., and Kedes, L. (1995) Mel. Cell. Biol. 15, 6386-6397; Jeyaseelan, R., Poizat, C., Wu, H. Y., and Kedes, L. (1997) J. Biol. Chem. 272, 5828-5832). To determine whether this drug might interfere with the function of cardiac-specific regulatory pathways, we used a differential display strategy to clone from neonatal rat cardiomyocyte candidate mRNAs that were rapidly sensitive to Box. We report here the identification of a constitutively expressed, cardiac-restricted, nuclear protein whose mRNA level is exquisitely sensitive to Box Hence we have named this protein cardiac adriamycin-responsive protein (CARP). CARP mRNA is present at the earliest stages of cardiac morphogenesis. It was detected by in situ hybridization within the cardiogenic plate of 7.5-day post coitum (p.c.) embryos, and in 8.5-day p.c. embryos CARP transcripts are present in uniformly high levels in the myocardium. Throughout cardiac development, GARP expression is specific for the myocardium; endocardial cushions and valves exhibit only background levels of signal. Transcript levels persist but gradually decrease in neonatal, 2-week-old, and adult hearts. There were no stages when CARP mRNA could not be detected. The pattern and timing of CARP mRNA expression, including transient expression in the tongue at 14.5 days p.c., coincides with that of Nkx2.5/Csx (a putative homolog of tinman, the Drosophila melanogaster gene responsible for cardiac development). The cloned full-length 1749 nucleotide CARP cDNA encodes a 319-amino acid 40-kDa polypeptide containing five tandem ankyrin repeats. CARP appears to be the rat homolog of a previously reported human single-copy gene (C-193; Chu, W., Burns, D. K., Swerlick, R. A., and Presky, D. H. (1995) J. Biol. Chem. 270, 10236-10245), whose mRNA is inducible by cytokines only in human endothelial cells. CARP appears to function as a negative regulator of cardiac-specific gene expression. Over-expression of CARP in cardiomyocytes suppresses cardiac troponin C and atrial natriuretic factor transcription. Cotransfection experiments in HeLa cells indicate that CARP inhibits Nkx2.5 transactivation of atrial natriuretic factor promoter. When fused to a GAL4 DNA-binding domain, CARP has transcriptional inhibitory properties in noncardiac cells. CARP thus represents the first example of a cardiac-restricted transcriptional regulatory protein that is sensitive to Dox.	UNIV SO CALIF,SCH MED,INST GENET MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033; UNIV WISCONSIN,SCH MED,DEPT ANAT,MADISON,WI 53706	University of Southern California; University of Southern California; University of Southern California; University of Wisconsin System; University of Wisconsin Madison								BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BODMER R, 1993, DEVELOPMENT, V118, P719; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Jeyaseelan R, 1997, J BIOL CHEM, V272, P5828, DOI 10.1074/jbc.272.9.5828; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; KURABAYASHI M, 1995, MOL CELL BIOL, V15, P6386; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LIANG P, 1992, CANCER RES, V52, P6966; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; Lyons GE, 1996, CURR OPIN GENET DEV, V6, P454, DOI 10.1016/S0959-437X(96)80067-0; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MANASEK FJ, 1986, HEART CARDIOVASCULAR, P965; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; RUGH R, 1990, MOUSE ITS REPRODUCTI; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Zou YM, 1997, DEVELOPMENT, V124, P793	39	165	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22800	22808		10.1074/jbc.272.36.22800	http://dx.doi.org/10.1074/jbc.272.36.22800			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278441	hybrid			2022-12-25	WOS:A1997XV49200062
J	Simpson, PB; Mehotra, S; Lange, GD; Russell, JT				Simpson, PB; Mehotra, S; Lange, GD; Russell, JT			High density distribution of endoplasmic reticulum proteins and mitochondria at specialized Ca2+ release sites in oligodendrocyte processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CALCIUM WAVES; SARCOPLASMIC-RETICULUM; CELLS; RAT; CALRETICULIN; ASTROCYTES; STORES; LOCALIZATION; EXPRESSION	In oligodendrocyte processes, methacholine-evoked Ca2+ waves propagate via regions of specialized Ca2+ release kinetics (wave amplification sites) at which the amplitude and rate of rise of local Ca2+ signals are markedly higher than in surrounding areas (Simpson, P. B., and Russell, J. T. (1996) J. Biol. Chem. 271, 33493-33501). In the present study we have examined the effects of other phosphoinositide-coupled agonists on Ca2+ in these cells, and the structural specializations underlying regenerative wave amplification sites, Both bradykinin and norepinephrine evoke Ca2+ waves, which initiate at the same loci and propagate through the cell body and multiple processes via identical wave amplification sites, Antibodies against type 2 inositol 1,4,5-trisphosphate receptors (InsP(3)R2) and calreticulin identify expression of these proteins in oligodendrocyte membranes in Western blots, Immunocytochemistry followed by high resolution fluorescence microscopy revealed that both InsP(3)R2 and calreticulin are expressed in high intensity patches along processes. Cross-correlation analysis of the profiles of local Ca2+ release kinetics during a Ca2+ wave and immunofluorescence for these proteins along cellular processes showed that the domains of high endoplasmic reticulum protein expression correspond closely to wave amplification sites, Staining cells with the mitochondrial dye, MitoTracker(R), showed that mitochondria are only found in intimate association with these sites possessing high density endoplasmic reticulum proteins, and they remain in the same locations over relatively long periods of time. It appears, therefore, that multiple specializations are found at domains of elevated Ca2+ release in oligodendrocyte processes, including high levels of calreticulin, InsP(3)R2 Ca2+ release channels, and mitochondria.	NICHHD, LCMN, NIH, BETHESDA, MD 20892 USA; NINCDS, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Simpson, Peter/0000-0003-0364-2685				BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; Bootman MD, 1996, CURR BIOL, V6, P855, DOI 10.1016/S0960-9822(02)00609-7; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; COHEN RI, 1994, EUR J NEUROSCI, V6, P1213, DOI 10.1111/j.1460-9568.1994.tb00620.x; COHEN RI, 1993, NEUROREPORT, V4, P1115; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; Dent MAR, 1996, DEVELOPMENT, V122, P1029; ENYEDI P, 1993, CELL CALCIUM, V14, P485, DOI 10.1016/0143-4160(93)90007-S; FATATIS A, 1992, GLIA, V5, P95, DOI 10.1002/glia.440050203; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; JAFFE LF, 1993, CELL CALCIUM, V14, P736, DOI 10.1016/0143-4160(93)90099-R; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KASTRITSIS CH, 1993, GLIA, V8, P106, DOI 10.1002/glia.440080206; LIU NG, 1994, J BIOL CHEM, V269, P28635; MARRIOTT DR, 1993, J NEUROCHEM, V61, P826, DOI 10.1111/j.1471-4159.1993.tb03593.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; NIXON GF, 1994, J MUSCLE RES CELL M, V15, P682, DOI 10.1007/BF00121075; NORI A, 1993, BIOCHEM J, V291, P199, DOI 10.1042/bj2910199; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; PRESS WH, 1989, NUMERICAL RECIPES PA, P120; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROTH BJ, 1995, CELL CALCIUM, V17, P53, DOI 10.1016/0143-4160(95)90102-7; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SIMPSON PB, 1994, J NEUROCHEM, V63, P2369; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TAKEI K, 1992, J NEUROSCI, V12, P489; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; YAGODIN S, 1995, MOL CELL BIOCHEM, V149, P137, DOI 10.1007/BF01076572; YAGODIN SV, 1994, J NEUROBIOL, V25, P265, DOI 10.1002/neu.480250307	40	146	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22654	22661		10.1074/jbc.272.36.22654	http://dx.doi.org/10.1074/jbc.272.36.22654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278423	hybrid			2022-12-25	WOS:A1997XV49200043
J	Zanello, LP; Norman, AW				Zanello, LP; Norman, AW			Stimulation by 1 alpha,25(OH)(2)-vitamin D-3 of whole cell chloride currents in osteoblastic ROS 17/2.8 cells - A structure-function study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC BIOLOGICAL RESPONSES; D ENDOCRINE SYSTEM; PARATHYROID-HORMONE; CALCIUM-TRANSPORT; STEROID-HORMONE; RAT OSTEOBLASTS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; OSTEOSARCOMA CELLS; NONGENOMIC ACTIONS; ROS-17/2.8 CELLS	1 alpha,25-Dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) can generate biological responses via genomic and nongenomic mechanisms, This article reports for the first time the effects of 1 alpha,25(OH)(2)D-3 and structurally related analogs on whole cell chloride currents in osteoblastic cells. 1 alpha,25(OH)(2)D-3 promoted the rapid enhancement of outwardly rectifying Cl- currents in 93% of the osteoblasts in a concentration-dependent manner, with a maximal increase of about 4-fold between 0.5 and 5 nM. This effect of 1 alpha,25(OH)(2)D-3 was blocked by 1 nM stereoisomer 1 beta,25(OH)(2)D-3. when added to the bath before 1 alpha,25(OH)(2)D-3. On the other hand, 1 nM of the 6-s-cis locked analog 1 alpha,25(OH)(2)-lumisterol(3) significantly increased by about 2.2-fold outward Cl- currents in the ROS 17/2.8 cells, whereas the increase promoted by same concentration of the 6-s-trans locked analog 1 alpha,25(OH)(2)-tachysterol (0.8-fold) was significantly lower, suggesting that the 6-s-cis locked or steroid-like form was preferred over the extended 6-s-trans conformer to promote these rapid effects of the hormone, We conclude that the agonist effects of 1 alpha,25(OH)(2)D-3 in osteoblasts at the cellular membrane level seem to be determined by some structural, features of the molecule which may be crucial for its interaction with a putative membrane receptor in the cell surface.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside					PHS HHS [OK-09012-033] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARAN DT, 1994, J CELL BIOCHEM, V56, P510, DOI 10.1002/jcb.240560411; BARAN DT, 1994, J CELL BIOCHEM, V56, P303, DOI 10.1002/jcb.240560305; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHESNOYMARCHAIS D, 1994, J MEMBRANE BIOL, V140, P173; CHESNOYMARCHAIS D, 1988, J PHYSIOL-LONDON, V398, P291, DOI 10.1113/jphysiol.1988.sp017043; CHESNOYMARCHAIS D, 1993, BIOCHIM BIOPHYS ACTA, V1148, P239, DOI 10.1016/0005-2736(93)90135-M; CHESNOYMARCHAIS D, 1989, PFLUG ARCH EUR J PHY, V415, P104, DOI 10.1007/BF00373147; DAVIDSON RM, 1990, PFLUG ARCH EUR J PHY, V416, P646, DOI 10.1007/BF00370609; DEBOLAND AR, 1992, J CELL BIOCHEM, V49, P32, DOI 10.1002/jcb.240490107; DEBOLAND AR, 1990, ENDOCRINOLOGY, V127, P2475, DOI 10.1210/endo-127-5-2475; DIXON SJ, 1984, J MEMBRANE BIOL, V80, P49, DOI 10.1007/BF01868689; DUNCAN R, 1989, FEBS LETT, V251, P17, DOI 10.1016/0014-5793(89)81420-6; DUNCAN RL, 1992, FEBS LETT, V307, P219, DOI 10.1016/0014-5793(92)80771-8; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FERRIER J, 1986, J CELL PHYSIOL, V126, P237, DOI 10.1002/jcp.1041260212; FERRIER J, 1987, J CELL PHYSIOL, V130, P344, DOI 10.1002/jcp.1041300306; FRITSCH J, 1987, BONE MINER, V2, P463; GOSLING M, 1995, J PHYSIOL-LONDON, V485, P671, DOI 10.1113/jphysiol.1995.sp020761; Gosling M, 1996, J PHYSIOL-LONDON, V493, P613, DOI 10.1113/jphysiol.1996.sp021408; GUGGINO SE, 1989, P NATL ACAD SCI USA, V86, P2657; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANNAH SS, 1994, NUTR REV, V52, P376, DOI 10.1111/j.1753-4887.1994.tb01368.x; JOELS M, 1995, J NEUROSCI, V15, P4289; LOWE K E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P65; LOZA J, 1994, CALCIFIED TISSUE INT, V55, P128, DOI 10.1007/BF00297188; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1476, DOI 10.1210/endo-115-4-1476; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NEMERE I, 1987, J BONE MINER RES, V2, P99; NEMERE I, 1991, MOL CELL ENDOCRINOL, V80, pC165, DOI 10.1016/0303-7207(91)90132-C; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; NORMAN AW, 1997, IN PRESS MOL ENDOCRI; Takeuchi K, 1996, J BIOL CHEM, V271, P33335, DOI 10.1074/jbc.271.52.33335; TWYMAN RE, 1992, J PHYSIOL-LONDON, V456, P215, DOI 10.1113/jphysiol.1992.sp019334; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P4383; YPEY DL, 1988, J MEMBRANE BIOL, V101, P141, DOI 10.1007/BF01872829; YUKHIRO S, 1994, J BIOL CHEM, V269, P23889; Zanello LP, 1996, BIOCHEM BIOPH RES CO, V225, P551, DOI 10.1006/bbrc.1996.1210; ZHANG SJ, 1994, J NEUROENDOCRINOL, V6, P533, DOI 10.1111/j.1365-2826.1994.tb00616.x	42	91	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22617	22622		10.1074/jbc.272.36.22617	http://dx.doi.org/10.1074/jbc.272.36.22617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278418	hybrid			2022-12-25	WOS:A1997XV49200038
J	Defilippi, P; Venturino, M; Gulino, D; Duperray, A; Boquet, P; Fiorentini, C; Volpe, G; Palmieri, M; Silengo, L; Tarone, G				Defilippi, P; Venturino, M; Gulino, D; Duperray, A; Boquet, P; Fiorentini, C; Volpe, G; Palmieri, M; Silengo, L; Tarone, G			Dissection of pathways implicated in integrin-mediated actin cytoskeleton assembly - Involvement of protein kinase C, Rho GTPase, and tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION PATHWAYS; EXTRACELLULAR-MATRIX; STRESS FIBERS; FIBRONECTIN; ACTIVATION; PP125(FAK); PLATELETS; ALPHA(IIB)BETA(3)	A panel of antibodies to the alpha IIb beta 3 integrin was used to promote adhesion of Chinese hamster ovary cells transfected with the alpha IIb beta 3 fibrinogen receptor. While some alpha IIb beta 3 antibodies were not able to induce p125 focal adhesion kinase (p125FAK) tyrosine phosphorylation, all the antibodies equally support cell adhesion but not spreading and assembly of actin stress fibers, Absence of stress fibers was also obtained by plating on antibodies directed to the hamster beta 1 integrin. In contrast, cells plated on matrix proteins spread organizing actin stress fibers. Treatment with phorbol esters phorbol 12-myristate 13-acetate (PMA) induced cells to spread on antibodies-coated dishes but not to organize actin in stress fibers, The combination of PMA and cytotoxic necrotizing factor 1 (CNF1), a specific Rho activator, induced cell spreading and organization of stress fibers. PMA or the combination of PMA and CNF1 also increases tyrosine phosphorylation of p125FAK in response to antibodies that were otherwise unable to trigger this response, These data show that: 1) matrix proteins and antibodies differ in their ability to induce integrin-dependent actin cytoskeleton organization (while matrix induced stress fibers formation, antibodies did not); 2) p125FAK tyrosine phosphorylation is insufficient per se to trigger actin stress fibers formation since antibodies that activate p125FAK tyrosine phosphorylation did not lead to actin stress fibers assembly; and 3) the inability of anti-integrin antibodies to trigger stress fibers organization is overcome by concomitant activation of the protein kinase C (PKC) and Rho pathways; PKC activation leads to cell spreading and Rho activation is required to organize actin stress fibers.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO PSICOL,ROME,ITALY; INSERM,U217,HEMATOL LAB,GRENOBLE,FRANCE; FAC MED NICE,INSERM,U452,F-06034 NICE,FRANCE; IST SUPER SANITA,ULTRASTRUTTURE LAB,I-00161 ROME,ITALY	Sapienza University Rome; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Istituto Superiore di Sanita (ISS)	Defilippi, P (corresponding author), UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,VIA SANTENA 5 BIS,I-10126 TURIN,ITALY.		Duperray, Alain/E-8428-2012; Fiorentini, Carla/Q-2088-2015; FIORENTINI, CARLA/AAG-8005-2019; DEFILIPPI, Paola/L-2232-2014	Duperray, Alain/0000-0002-2719-252X; Fiorentini, Carla/0000-0003-1707-6282; FIORENTINI, CARLA/0000-0003-1707-6282; Defilippi, Paola/0000-0001-6427-4906; Tarone, Guido/0000-0003-4805-086X				ARCANGELI A, 1993, J CELL BIOL, V122, P1131, DOI 10.1083/jcb.122.5.1131; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; BROWN PJ, 1988, EXP CELL RES, V177, P376; BURRIDGE CA, 1997, ANN REV CELL DEV BIO, V12, P463; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANIELS K, 1991, J CELL SCI, V100, P249; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; FIORENTINI C, 1997, IN PRESS J BIOL CHEM; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Flinn HM, 1996, J CELL SCI, V109, P1133; FRACHET P, 1992, BIOCHEMISTRY-US, V31, P2408, DOI 10.1021/bi00123a028; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GONZALEZRODRIGUEZ J, 1994, BIOCHEMISTRY-US, V33, P266, DOI 10.1021/bi00167a035; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GULINO D, 1990, J BIOL CHEM, V265, P9575; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIRSCH E, 1994, DEV DYNAM, V201, P108, DOI 10.1002/aja.1002010203; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KELLER HU, 1994, J CELL PHYSIOL, V161, P526, DOI 10.1002/jcp.1041610316; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEONG L, 1995, J CELL SCI, V108, P3817; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NIIYA K, 1987, BLOOD, V70, P472; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCONNOR TP, 1993, J CELL BIOL, V123, P1581; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; VUORI K, 1993, J BIOL CHEM, V268, P21459; WOODS A, 1992, J CELL SCI, V101, P277; [No title captured]	53	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21726	21734		10.1074/jbc.272.35.21726	http://dx.doi.org/10.1074/jbc.272.35.21726			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268301	hybrid			2022-12-25	WOS:A1997XT85000013
J	Haghighat, A; Sonenberg, N				Haghighat, A; Sonenberg, N			eIF4G dramatically enhances the binding of eIF4E to the mRNA 5'-cap structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION-FACTORS; PROTEIN-KINASE-C; MESSENGER-RNA; TRANSLATION INITIATION; FACTOR EIF-4E; 4E-BINDING PROTEINS; SECONDARY STRUCTURE; ESCHERICHIA-COLI; CROSS-LINKING; IN-VITRO	The cap structure, m(7)GpppN, is present at the 5'-end of all eukaryotic cellular (except organellar) mRNAs, Initiation of translation is mediated by the multisubunit initiation factor eIF4F, which binds the cap structure via its eIF4E subunit and facilitates the binding of mRNA to ribosomes, Here, we used recombinant proteins to reconstitute the cap recognition activity of eIF4F in vitro, We demonstrate that the interaction of eIF4E with the mRNA 5'-cap structure is dramatically enhanced by eIF4G, as determined by a UV-induced cross-linking assay, Furthermore, assembly of the eIF4F complex at the cap structure, as well as ATP hydrolysis, is shown to be a requisite for the cross-linking of another initiation factor, eIF4B, to the cap structure, In addition, the stimulatory effect of eIF4G on the cap recognition of eIF4E is inhibited by the translational repressor, 4E-BP1, These results suggest that eIF4E initially interacts with the mRNA cap structure as part of the eIF4F complex.	MCGILL UNIV,FAC MED,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University								BELSHAM G J, 1980, Biochemical Society Transactions, V8, P382; BU X, 1993, J BIOL CHEM, V268, P4975; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; EDERY I, 1983, J BIOL CHEM, V258, P1398; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; EDERY I, 1987, TRANSLATIONAL REGULA, P335; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JOSHI B, 1994, J BIOL CHEM, V269, P2048; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LEE KAW, 1985, J VIROL, V54, P515, DOI 10.1128/JVI.54.2.515-524.1985; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Summers MD, 1987, MANUAL METHODS BACUL; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; UEDA H, 1991, J BIOCHEM-TOKYO, V109, P882, DOI 10.1093/oxfordjournals.jbchem.a123475; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	38	197	211	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21677	21680		10.1074/jbc.272.35.21677	http://dx.doi.org/10.1074/jbc.272.35.21677			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268293	hybrid			2022-12-25	WOS:A1997XT85000005
J	Shilatifard, A; Haque, D; Conaway, RC; Conaway, JW				Shilatifard, A; Haque, D; Conaway, RC; Conaway, JW			Structure and function of RNA polymerase II elongation factor ELL - Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-SIII; TUMOR-SUPPRESSOR PROTEIN; PROLINE-RICH PROTEIN; PREINITIATION COMPLEX; ACUTE LEUKEMIAS; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; ABORTIVE INITIATION; GENE-TRANSCRIPTION; MYELOID-LEUKEMIA	The human ELL gene on chromosome 19p13.1 undergoes frequent translocations with the trithorax-like MLL gene on chromosome 11q23 in acute myeloid leukemia, Recently, the human ELL gene was shown to encode an RNA polymerase II elongation factor that activates elongation by suppressing transient pausing by polymerase at many sites along the DNA. In this report, we identify and characterize two overlapping ELL functional domains that govern its interaction with RNA polymerase II and the ternary elongation complex. Our findings reveal that, in addition to its elongation activation domain, ELL contains a novel type of RNA polymerase II interaction domain that is capable of negatively regulating polymerase activity in promoter-specific transcription initiation in vitro. Notably, the MLL-ELL translocation results in deletion of a portion of this functional domain, and ELL mutants lacking sequences deleted by the translocation bind RNA polymerase II and are fully active in elongation, but fail to inhibit initiation. Taken together, these results raise the possibility that the MLL-ELL translocation could alter ELL-RNA polymerase II interactions that are not involved in regulation of elongation.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; ASO T, 1994, J BIOL CHEM, V269, P26575; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; INOSTROZA JA, 1992, CELL, V70, P477; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee G, 1996, P NATL ACAD SCI USA, V93, P2570, DOI 10.1073/pnas.93.6.2570; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PETERSON MG, 1991, NATURE, V354, P369; POEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAMBRIIJ H, 1989, MOL CLONING LAB MANU; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAN SY, 1994, BIOTECHNIQUES, V16, P824; Thirman MJ, 1997, P NATL ACAD SCI USA, V94, P1408, DOI 10.1073/pnas.94.4.1408; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WU J, 1993, J VIROL, V67, P7547, DOI 10.1128/JVI.67.12.7547-7555.1993; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	59	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22355	22363		10.1074/jbc.272.35.22355	http://dx.doi.org/10.1074/jbc.272.35.22355			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268387	hybrid			2022-12-25	WOS:A1997XT85000099
J	Torpey, J; deMontellano, PRO				Torpey, J; deMontellano, PRO			Oxidation of alpha-meso-formylmesoheme by heme oxygenase - Electronic control of the reaction regiospecificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; REGIOISOMERS; MESSENGER; CLEAVAGE	The oxidation of heme to biliverdin Ma by heme oxygenase involves regiospecific alpha-meso hydroxylation followed by extrusion of the alpha-mese-carbon as CO, In an earlier study, enzymatic oxidation of the four meso-methylmesoheme isomers suggested that the reaction regiospecificity is sensitive to the electronic properties of the mesoe-methyl group (Torpey, J. W., and Ortiz de Montellano, P. R. (1996) J. Biol. Chem. 271, 26067-26073), although we could not exclude the possibility that the altered reaction regiochemistry was due to perturbation of the porphyrin structure by the meso substituent. To examine this possibility, we have synthesized the four meso-formylmesoporphyrin isomers and have examined their oxidation by heme oxygenase, The meso-formyl and meso methyl substituents differ in that the former is electron withdrawing and the latter is electron donating. In contrast to alpha-meso-methylmesoheme, which is exclusively oxidized at the methyl-substituted position, alpha-meso-formylmesoheme is exclusively oxidized at a non-formyl-substituted meso-carbon. The finding that the methyl and formyl groups channel the reaction regiospecificity in opposite directions establishes that the regiochemistry of the heme oxygenase reaction is primarily under electronic rather than steric control. It also confirms that the oxidation involves electrophilic addition of the oxygen to the porphyrin ring.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDDK NIH HHS [DK30297, 5 P30 DK26743] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONNETT R, 1973, J CHEM SOC PERK T 1, P881, DOI 10.1039/p19730000881; BROWN SB, 1981, NATURE, V289, P93, DOI 10.1038/289093a0; Hansch C., 1995, EXPLORING QSAR FUNDA, P1; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; LAGARIAS JC, 1982, BIOCHIM BIOPHYS ACTA, V717, P12, DOI 10.1016/0304-4165(82)90373-7; LIGHTNER DA, 1969, ARCH BIOCHEM BIOPHYS, V131, P566, DOI 10.1016/0003-9861(69)90431-7; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; MARKS GS, 1994, CELL MOL BIOL, V40, P863; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; SAITO S, 1982, P NATL ACAD SCI-BIOL, V79, P1393, DOI 10.1073/pnas.79.5.1393; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Torpey J, 1996, J BIOL CHEM, V271, P26067, DOI 10.1074/jbc.271.42.26067; TORPEY J, 1997, THESIS U CALIFORNIA; TORPEY JW, 1995, J ORG CHEM, V60, P2195, DOI 10.1021/jo00112a045; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x	24	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22008	22014		10.1074/jbc.272.35.22008	http://dx.doi.org/10.1074/jbc.272.35.22008			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268339	hybrid			2022-12-25	WOS:A1997XT85000051
J	Goltsev, YV; Kovalenko, AV; Arnold, E; Varfolomeev, EE; Brodianskii, VM; Wallach, D				Goltsev, YV; Kovalenko, AV; Arnold, E; Varfolomeev, EE; Brodianskii, VM; Wallach, D			CASH, a novel caspase homologue with death effector domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CELL-DEATH; CYSTEINE PROTEASE; GENE CED-3; C-ELEGANS; APOPTOSIS; INHIBITION; INTERACTS; ENCODES	CASP-8 and CASP-10, members of a cysteine protease family that participates in apoptosis, interact with MORT1/FADD, an adapter protein in the CD120a (p55 tumor necrosis factor receptor), and CD95 (Fas/Apo-1) death-inducing signaling pathways, through a shared N-terminal sequence motif, the death effector domain. We report cloning of two splice variants of a novel protein, CASH, that contain two N-terminal death effector domains and can bind through them to each other, to MORT1/FADD, to CASP-8, and to CASP-10. The unique C-terminal part of the longer variant shows marked sequence homology to the caspase protease region yet lacks several of the conserved caspase active site residues, suggesting that it is devoid of cysteine protease activity. Overexpression of the short CASH splice variant strongly inhibited cytotoxicity induction by CD120a and CD95. Expression of the longer variant, while inhibiting cytotoxicity in HeLa cells, had a marked cytocidal effect in 293 cells that could be shown to involve its protease homology region. The findings suggest that CASH acts as an attenuator and/or initiator in CD95 and CD120a signaling for cell death.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNANDESALNEMR.T, 1996, P NATL ACAD SCI USA, V93, P7646; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; TEWARI M, 1995, CELL, V81, P1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VanCriekinge W, 1996, J BIOL CHEM, V271, P27245, DOI 10.1074/jbc.271.44.27245; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	32	265	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19641	19644		10.1074/jbc.272.32.19641	http://dx.doi.org/10.1074/jbc.272.32.19641			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9289491	hybrid			2022-12-25	WOS:A1997XQ05900003
J	Pan, GH; Aso, T; Greenblatt, J				Pan, GH; Aso, T; Greenblatt, J			Interaction of elongation factors TFIIS and Elongin A with a human RNA polymerase II holoenzyme capable of promoter-specific initiation and responsive to transcriptional activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; BASAL TRANSCRIPTION; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; NASCENT TRANSCRIPT; TERMINAL DOMAIN; REPEAT DOMAIN; 3 PROTEINS; FACTOR-SII; COMPLEX	Affinity chromatography on columns containing the immobilized monomeric transcriptional elongation factor TFIIS or the essential large subunit, Elongin A, of the trimeric elongation factor, Elongin, was used to purify a human RNA polymerase II holoenzyme from HeLa whole cell extract. This holoenzyme contained near-stoichiometric amounts of all the general transcription factors, TFIIB, TFIID (TBP + TAF(II)s), TFIIE, TFIIF, and TFIIH, required to accurately initiate transcription in vitro at the adenovirus major late promoter. It behaved as a large complex, slightly smaller than 70 S ribosomes, during gelfiltration chromatography, and contained nearly half the, TFIID that was present in the extract used for the affinity chromatography. It also contained the cyclin-dependent kinase CDK8, a human homologue of the Saccharomyces cerevisiae holoenzyme subunit SRB10, and many other polypeptides. Efficient interaction of holoenzyme with TFIIS or Elongin A required only the amino-terminal region of either protein. These regions are similar in amino acid sequence but dispensable for TFIIS or Elongin to regulate elongation in, vitro by highly purified RNA polymerase II. The transcriptional activators GAL4-VP16 and GAL4-Sp1 activated transcription in vitro by purified holoenzyme in the absence of any additional factors.	UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1L6, CANADA; OKLAHOMA MED RES FDN, PROGRAM MOL & CELL BIOL, OKLAHOMA CITY, OK 73104 USA	University of Toronto; University of Toronto; Oklahoma Medical Research Foundation								AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Blau J, 1996, MOL CELL BIOL, V16, P2044; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAVIES CJ, 1990, NATURE, V345, P298, DOI 10.1038/345298a0; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FENG GH, 1994, J BIOL CHEM, V269, P22282; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GU WG, 1993, J BIOL CHEM, V268, P25604; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI Y, 1981, FEBS LETT, V130, P69, DOI 10.1016/0014-5793(81)80667-9; NONET ML, 1989, GENETICS, V123, P715; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAN GH, 1994, J BIOL CHEM, V269, P30101; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SOPTA M, 1985, J BIOL CHEM, V260, P353; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; TAN SY, 1994, J BIOL CHEM, V269, P25684; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	99	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24563	24571		10.1074/jbc.272.39.24563	http://dx.doi.org/10.1074/jbc.272.39.24563			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305922	hybrid			2022-12-25	WOS:A1997XY51500073
J	Merienne, K; Germain, N; ZinnJustin, S; Boulain, JC; Ducancel, F; Menez, A				Merienne, K; Germain, N; ZinnJustin, S; Boulain, JC; Ducancel, F; Menez, A			The functional architecture of an acetylcholine receptor-mimicking antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CROSS-REACTION COMPLEX; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ALKALINE-PHOSPHATASE; CRYSTAL-STRUCTURE; BINDING-SITE; PROTEIN ANTIGENS; FUSION PROTEIN	M alpha 2-3 is a monoclonal antibody that partially mimics the nicotinic acetylcholine receptor (AChR), Its three-dimensional structure has been previously predicted by molecular modeling, suggesting that 29 complementarity determining region (CDR) residues and 2 framework residues are exposed to solvent. To identify the antibody residues that bind to the antigen, i.e. snake toxin that binds specifically to AChR, we (i) produced the scFv form of M alpha 2-3 fused to alkaline phosphatase, in the periplasmic space of Escherichia coli; (ii) submitted approximately 75% of exposed residues of the fused scFv to individual or combined mutations, and (iii) identified the residues whose mutations affect scFv binding to the toxin, using a sensitive enzyme-linked immunosorbent assay. 11 critical residues were identified, including 8 heavy chain residues, 2 framework residues, and 1 light chain residue, They cover a surface of approximately 800 Angstrom(2), with a subset of most critical residues (VHD31, VHY32, and VHG101) and several aromatic residues. This functional architecture not only constitutes a plausible complementary binding surface for the snake toxin but also offers a structural basis to ultimately understand the capacity of the antibody to partially mimic AChR.	CEA, DEPT INGN & ETUD PROT, DIRECT SCI VIVANT, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay				Merienne, Karine/0000-0003-2549-2315				AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AMATI V, 1995, PROTEIN ENG, V8, P403, DOI 10.1093/protein/8.4.403; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARRIER A, 1995, J IMMUNOL METHODS, V181, P177, DOI 10.1016/0022-1759(94)00344-V; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Chanussot C, 1996, J IMMUNOL METHODS, V197, P39, DOI 10.1016/0022-1759(96)00109-3; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DARVEAU RP, 1992, J CLIN IMMUNOASSAY, V15, P25; DAVIES DR, 1993, ACCOUNTS CHEM RES, V26, P421, DOI 10.1021/ar00032a005; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DORING E, 1994, MOL IMMUNOL, V31, P1059, DOI 10.1016/0161-5890(94)90101-5; DUCANCEL F, 1993, BIO-TECHNOL, V11, P601, DOI 10.1038/nbt0593-601; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GILLET D, 1993, ANAL CHEM, V65, P1779, DOI 10.1021/ac00061a023; GILLET D, 1992, PROTEIN ENG, V5, P273, DOI 10.1093/protein/5.3.273; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANON K, 1996, THESIS U PARIS 11 PA; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; LESCAR J, 1995, J BIOL CHEM, V270, P18067, DOI 10.1074/jbc.270.30.18067; MALBY RL, 1994, STRUCTURE, V2, P733, DOI 10.1016/S0969-2126(00)00074-5; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PRASAD L, 1993, J BIOL CHEM, V268, P10705; RIECHMANN L, 1995, J BIOMOL NMR, V6, P141, DOI 10.1007/BF00211778; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Tenette C, 1996, PROTEINS, V26, P9, DOI 10.1002/(SICI)1097-0134(199609)26:1<9::AID-PROT2>3.0.CO;2-E; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WHITLOW M, 1994, PROTEIN ENG, V7, P1017, DOI 10.1093/protein/7.8.1017; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Xiang J, 1996, PROTEIN ENG, V9, P539, DOI 10.1093/protein/9.6.539; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	60	22	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23775	23783		10.1074/jbc.272.38.23775	http://dx.doi.org/10.1074/jbc.272.38.23775			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295323	hybrid			2022-12-25	WOS:A1997XX38100048
J	Ali, MS; Sayeski, PP; Dirksen, LB; Hayzer, DJ; Marrero, MB; Bernstein, KE				Ali, MS; Sayeski, PP; Dirksen, LB; Hayzer, DJ; Marrero, MB; Bernstein, KE			Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; ACTIVATION; BINDING; PROTEIN; TRANSCRIPTION; PATHWAYS; REGION; CELLS	Angiotensin II is the effector molecule of the renin-angiotensin system. Virtually all of its biochemical actions are mediated through a single class of cell-surface receptors called AT(1). These receptors contain the structural features of the seven-transmembrane, G-protein-coupled receptor superfamily. Angiotensin II, acting through the AT(1) receptor, also stimulates the Jak/STAT pathway by inducing ligand-dependent Jak2 tyrosine phosphorylation and activation. Here, we show that a glutathione S-transferase fusion protein containing the carboxyl-terminal 54 amino acids of the rat AT(1A) receptor physically binds to Jak2 in an angiotensin II-dependent manner. Deletional analysis, using both in vitro protocols and cell transfection analysis, showed that this association is dependent on the AT(1A) receptor motif YIPP (amino acids 319-322), The mild-type AT(1A) receptor can induce Jak2 tyrosine phosphorylation, In contrast, an AT(1A) receptor lacking the YIPP motif is unable to induce ligand-dependent phosphorylation of Jak2. Competition experiments with synthetic peptides suggest that each of the YIPP amino acids, including tyrosine 319, is important in Jak2 binding to the AT(1A) receptor. The binding of the AT(1A) receptor to the intracellular tyrosine kinase Jak2 supports the concept that the seven-transmembrane superfamily of receptors can physically associate with enzymatically active intracellular proteins, creating a signaling complex mechanistically similar to that observed with growth factor and cytokine receptors.	EMORY UNIV,DEPT PATHOL & LAB MED,ATLANTA,GA 30322	Emory University				Bernstein, Kenneth/0000-0001-8097-3272	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, R01DK039777, R37DK039777, P50DK045215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39777, DK45215, DK44280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Bernstein KE, 1996, TRENDS CARDIOVAS MED, V6, P179, DOI 10.1016/S1050-1738(96)00053-9; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DINERSTEIN H, 1995, MOL ENDOCRINOL, V9, P1701, DOI 10.1210/me.9.12.1701; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARRERO MB, 1995, CARDIOVASC RES, V30, P530, DOI 10.1016/0008-6363(95)00094-1; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Tian Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE831, DOI 10.1152/ajpendo.1996.270.5.E831; TIMMERMANS PBM, 1993, PHARMACOL REV, V45, P206; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	28	184	190	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23382	23388		10.1074/jbc.272.37.23382	http://dx.doi.org/10.1074/jbc.272.37.23382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287353	hybrid			2022-12-25	WOS:A1997XV74400064
J	Bai, XM; Bame, KJ; Habuchi, H; Kimata, K; Esko, JD				Bai, XM; Bame, KJ; Habuchi, H; Kimata, K; Esko, JD			Turnover of heparan sulfate depends on 2-O-sulfation of uronic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; OVARIAN GRANULOSA-CELLS; INTRACELLULAR DEGRADATIVE PATHWAYS; POLYMER-MODIFICATION REACTIONS; PROTEIN INTERACTIONS; MOUSE MASTOCYTOMA; CORE PROTEIN; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; ENDOGLUCURONIDASE	To study how the pattern of sulfation along a heparan sulfate chain affects its turnover, we examined heparan sulfate catabolism in wild-type Chinese hamster ovary cells and mutant pgsF-17, defective in 2-O-sulfation of uronic acid residues (Bai, X., and Esko, J. D. (1996) J. Biol, Chem. 271, 17711-17717). Heparan sulfate from the mutant contains normal amounts of 6-O-sulfated glucosamine residues and iduronic acid and somewhat higher levels of N-sulfated glucosamine residues but lacks any 2-O-sulfated iduronic or glucuronic acid residues. Pulse-chase experiments showed that both mutant and wild-type cells transport newly synthesized heparan sulfate proteoglycans to the plasma membrane, where they shed into the medium or move into the cell through endocytosis. Internalization of the cell-associated molecules leads to sequential endoglycosidase (heparanase) fragmentation of the chains and eventual lysosomal degradation. In wild-type cells, the chains begin to degrade within 1 h, leading to the accumulation of intermediate (1O-20-kDa) and small (4-7-kDa) oligosaccharides. Mutant cells did not generate these intermediates, although internalization and intracellular trafficking of the heparan sulfate chains appeared normal, and the chains degraded with normal kinetics. This difference was not due to defective heparanase activities in the mutant, since cytoplasmic extracts from mutant cells cleaved wild-type heparan sulfate chains in vitro. instead, the heparan sulfate chains from the mutant ware relatively resistant to degradation by cellular heparanases. These findings suggest that 2-O-sulfated iduronic acid residues in heparan sulfate are important for cleavage by endogenous heparanases but not for the overall catabolism of the chains.	UNIV CALIF SAN DIEGO, CTR CANC, DEPT MED, DIV CELL & MOL BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV MISSOURI, SCH BIOL SCI, DIV MOL BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA; AICHI MED UNIV, INST MOL SCI MED, NAGAKUTE, AICHI 48011, JAPAN	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Missouri System; University of Missouri Kansas City; Aichi Medical University								Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; Bame KJ, 1997, J BIOL CHEM, V272, P2245; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1993, J BIOL CHEM, V268, P19956; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; CZEKAY RP, 1995, J CELL SCI, V108, P1433; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Edgren G, 1997, GLYCOBIOLOGY, V7, P103, DOI 10.1093/glycob/7.1.103; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; ESKO JD, 1986, J BIOL CHEM, V261, P5725; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FREEMAN C, 1992, ADV EXP MED BIOL, V313, P121; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HOOK M, 1975, BIOCHEM BIOPH RES CO, V67, P1422, DOI 10.1016/0006-291X(75)90185-0; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V73, P569, DOI 10.1016/0006-291X(76)90848-2; KLEIN U, 1979, H-S Z PHYSIOL CHEM, V360, P1465, DOI 10.1515/bchm2.1979.360.2.1465; KLEIN U, 1976, FEBS LETT, V71, P266, DOI 10.1016/0014-5793(76)80947-7; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; OGREN S, 1975, J BIOL CHEM, V250, P2690; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; TAKEUCHI Y, 1992, J BIOL CHEM, V267, P14677; THUNBERG L, 1982, J BIOL CHEM, V257, P278; Tumova S, 1997, J BIOL CHEM, V272, P9078; YANAGISHITA M, 1985, J BIOL CHEM, V260, P1075; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	48	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23172	23179		10.1074/jbc.272.37.23172	http://dx.doi.org/10.1074/jbc.272.37.23172			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287321	hybrid			2022-12-25	WOS:A1997XV74400032
J	Emoto, H; Tagashira, S; Mattei, MG; Yamasaki, M; Hashimoto, G; Katsumata, T; Negoro, T; Nakatsuka, M; Birnbaum, D; Coulier, F; Itoh, N				Emoto, H; Tagashira, S; Mattei, MG; Yamasaki, M; Hashimoto, G; Katsumata, T; Negoro, T; Nakatsuka, M; Birnbaum, D; Coulier, F; Itoh, N			Structure and expression of human fibroblast growth factor-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; CHROMOSOME; CLONING; MEMBER; REGION; FGF8	We isolated the cDNA encoding a novel member of the human fibroblast growth factor (FGF) family from the lung. The cDNA encodes a protein of 208 amino acids with high sequence homology (95.6%) to rat FGF-10, in dicating that the protein is human FGF-10. Human FGF-10 as well as rat FGF-10 has a hydrophobic amino terminus (similar to 40 amino acids), which may serve as a signal sequence. The apparent evolutionary relationships of human FGFs indicate that FGF-10 is closest to FGF-7. Chromosomal localization of the human FGF-IO gene was examined by in situ hybridization. The gene was found to map to the 5p12-p13 region. Human FGF-10 (amino acids 40 to 208 with a methionine residue at the amino terminus) was produced in Escherichia coli and purified from the cell lysate. Recombinant human FGF-10 (similar to 19 kDa) showed mitogenic activity for fetal rat keratinizing epidermal cells, but essentially no activity for NIH/3T3 cells, fibroblasts. The specificity of mitogenic activity of FGF-10 is similar to that of FGF-7 but distinct from that of bFGF, In structure and biological activity, FGF-10 is similar to FGF-7.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM GENET, SAKYO KU, KYOTO 60601, JAPAN; SUMITOMO PHARMACEUT CO LTD, RES CTR, OSAKA 554, JAPAN; INSERM, U406, F-13385 MARSEILLE, FRANCE; INSERM, U119, F-13009 MARSEILLE, FRANCE	Kyoto University; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773; Yamasaki, Masahiro/0000-0002-5296-4974; Negoro, Takaharu/0000-0002-4159-6352				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; ARAKAWA T, 1989, BIOCHEM BIOPH RES CO, V161, P335, DOI 10.1016/0006-291X(89)91601-X; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; COULIER F, 1991, ANN NY ACAD SCI, V638, P53, DOI 10.1111/j.1749-6632.1991.tb49017.x; DICKSON C, 1991, ANN NY ACAD SCI, V638, P18, DOI 10.1111/j.1749-6632.1991.tb49014.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; JACSKSON A, 1992, P NATL ACAD SCI USA, V89, P10691; LOVEC H, 1997, IN PRESS CYTOGENET C; MATTEI MG, 1995, GENOMICS, V29, P811, DOI 10.1006/geno.1995.9926; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MATTEI MG, 1995, MAMM GENOME, V6, P196, DOI 10.1007/BF00293012; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; PATRY V, 1986, J VET MED B, V33, P609; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TAGASHIRA S, 1997, IN PRESS GENE; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WHITE RA, 1995, GENOMICS, V30, P109, DOI 10.1006/geno.1995.0020; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YOSHIDA T, 1991, ANN NY ACAD SCI, V638, P27, DOI 10.1111/j.1749-6632.1991.tb49015.x	29	101	127	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23191	23194		10.1074/jbc.272.37.23191	http://dx.doi.org/10.1074/jbc.272.37.23191			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287324	hybrid			2022-12-25	WOS:A1997XV74400035
J	Nocentini, S; Coin, F; Saijo, M; Tanaka, K; Egly, JM				Nocentini, S; Coin, F; Saijo, M; Tanaka, K; Egly, JM			DNA damage recognition by XPA protein promotes efficient recruitment of transcription factor II H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; A XERODERMA-PIGMENTOSUM; RNA-POLYMERASE-II; COMPLEMENTING PROTEIN; CELL-EXTRACTS; ERCC1; GENE; REPLICATION; BTF2/TFIIH; TFIIH	The human basal transcription factor IIH (TFIIH) is an essential component of the nucleotide excision repair machinery. TFIIH is required for reaction steps concomitant with or prior to the formation of dual incisions in the damaged DNA strand. To understand the mechanism underlying the recruitment of TFIIH to DNA damage sites we have analyzed i) the direct affinity of TFIIH for damaged or undamaged DNA and ii) the interaction of TFIIH with XPA.DNA complexes, formed using unirradiated or UV-irradiated DNA. Filter binding assays showed that TFIIH has some affinity for the DNA, but in contrast to XPA, does not show any preference for UV-irradiated DNA. Pull-down experiments demonstrated that TFIIH binds to XPA DNA complexes in an UV damage-dependent manner by a direct protein-protein interaction with XPA. We propose that an enhancement of the affinity of XPA protein for TFIIH could arise from conformational changes of XPA when it binds to UV lesions on the DNA.	INST CURIE,LRC NO 1,CEA,SECT RECH,F-75248 PARIS 05,FRANCE; CU STRASBOURG,INST GENET & BIOL MOL CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; OSAKA UNIV,INST MOL & CELLULAR BIOL,DIV CELLULAR GENET,SUITA,OSAKA 565,JAPAN	CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Osaka University	Nocentini, S (corresponding author), INST CURIE,CNRS,UMR 218,SECT RECH,26 RUE ULM,F-75248 PARIS 05,FRANCE.		Coin, Frédéric/F-5925-2013	Coin, Frédéric/0000-0002-5620-8519				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; CLEAVER JE, 1989, METABOLIC BASIS INHE, P2959; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Kuraoka I, 1996, MUTAT RES-DNA REPAIR, V362, P87, DOI 10.1016/0921-8777(95)00038-0; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P1993; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARKASH S, 1993, ANNU REV GENET, V27, P33; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROY R, 1994, J BIOL CHEM, V269, P9826; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SAIJO M, 1996, NUCLEIC ACIDS RES, V23, P4719; SATOKATA I, 1992, MUTAT RES, V273, P193, DOI 10.1016/0921-8777(92)90080-M; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; ZAVEL L, 1993, PROG NUCLEIC ACID RE, V44, P67	41	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					22991	22994		10.1074/jbc.272.37.22991	http://dx.doi.org/10.1074/jbc.272.37.22991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287294	hybrid			2022-12-25	WOS:A1997XV74400005
J	Haas, H; Angermayr, K; Zadra, I; Stoffler, G				Haas, H; Angermayr, K; Zadra, I; Stoffler, G			Overexpression of nreB, a new GATA factor-encoding gene of Penicillium chrysogenum, leads to repression of the nitrate assimilatory gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN REGULATORY PROTEIN; TRANSCRIPTION FACTOR GATA-1; PUTATIVE ZINC FINGER; DNA-BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; NEUROSPORA-CRASSA; CATABOLITE REPRESSION; METABOLITE REPRESSION; LEUCINE ZIPPER	To investigate the mechanism of nitrogen metabolite repression in the biotechnologically important fungus Penicillium chrysogenum a polymerase chain reaction approach was employed to identify transcription factors involved in this regulatory circuit, leading to the isolation of a new gene (nreB) encoding a 298 amino acid protein. Despite a low overall amino acid sequence identity of approximately 30%, it shares several features with Dal80p/Uga43p and Gzf3p/Nil2p, both repressors in nitrogen metabolism in Saccharomyces cerevisiae. All three proteins contain an N-terminal GATA-type zinc finger motif, displaying 86% amino acid sequence identity, and a putative leucine zipper motif in the C terminus. Northern blot analysis revealed the presence of two nreB transcripts, 1.8 and 1.5 kilobases in length, that differ in polyadenylation sites. The steady state level of both transcripts is subject to nitrogen metabolite repression. The putative DNA binding domain of NREB, expressed as a fusion protein in Escherichia coli, binds in vitro to GATA sites of its own 5'-upstream region as well as in the promoter of the nitrate assimilation gene cluster. Consistent with a role in the regulation of nitrogen metabolism, overexpression of nreB leads to repression of nitrate assimilatory genes. Hence, the simple view of nitrogen regulation by four GATA factors in yeast, but only one key regulator in filamentous ascomycetes seems no longer valid.			Haas, H (corresponding author), UNIV INNSBRUCK, SCH MED, DEPT MICROBIOL, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Caddick Mark X., 1997, Genes and Function, V1, P37; CANTORAL JM, 1987, BIO-TECHNOL, V5, P494, DOI 10.1038/nbt0587-494; CHAE KS, 1995, MOL CELLS, V5, P146; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Cooper TG, 1996, MYCOTA, V3, P139; COORNAERT D, 1992, CURR GENET, V21, P301, DOI 10.1007/BF00351687; CRAWFORD NM, 1993, ANNU REV GENET, V27, P115, DOI 10.1146/annurev.ge.27.120193.000555; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; FENG B, 1993, NUCLEIC ACIDS RES, V21, P3989, DOI 10.1093/nar/21.17.3989; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; Haas H, 1996, BBA-GENE STRUCT EXPR, V1309, P81, DOI 10.1016/S0167-4781(96)00150-9; HAAS H, 1993, GENE, V126, P237, DOI 10.1016/0378-1119(93)90372-A; Haas H, 1997, GENE, V184, P33, DOI 10.1016/S0378-1119(96)00570-7; HAAS H, 1995, CURR GENET, V27, P150, DOI 10.1007/BF00313429; HAAS H, 1995, CURR GENET, V28, P177, DOI 10.1007/BF00315785; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; KOLAR M, 1991, J BIOTECHNOL, V17, P67, DOI 10.1016/0168-1656(91)90027-S; KOLAR M, 1988, GENE, V62, P127, DOI 10.1016/0378-1119(88)90586-0; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LANGDON T, 1995, MOL MICROBIOL, V17, P877, DOI 10.1111/j.1365-2958.1995.mmi_17050877.x; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Martin J. F., 1986, REGULATION SECONDARY, P41; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; PETERS DG, 1994, NUCLEIC ACIDS RES, V22, P5164, DOI 10.1093/nar/22.24.5164; Platt A, 1996, EMBO J, V15, P2791, DOI 10.1002/j.1460-2075.1996.tb00639.x; POLEY SD, 1996, FEBS LETT, V388, P200; RAI R, 1989, MOL CELL BIOL, V9, P602, DOI 10.1128/MCB.9.2.602; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SoussiBoudekou S, 1997, MOL MICROBIOL, V23, P1157, DOI 10.1046/j.1365-2958.1997.3021665.x; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091; XIAO XD, 1995, BIOCHEMISTRY-US, V34, P8861, DOI 10.1021/bi00027a038; YANG HY, 1995, MOL CELL BIOL, V15, P1353; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470	49	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22576	22582		10.1074/jbc.272.36.22576	http://dx.doi.org/10.1074/jbc.272.36.22576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278412	hybrid			2022-12-25	WOS:A1997XV49200032
J	Krejci, E; Thomine, S; Boschetti, N; Legay, C; Sketelj, J; Massoulie, J				Krejci, E; Thomine, S; Boschetti, N; Legay, C; Sketelj, J; Massoulie, J			The mammalian gene of acetylcholinesterase-associated collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-FORMS; TAILED FORMS; CAUDATE-NUCLEUS; SUBUNIT; EXPRESSION; TORPEDO; CELLS; LOCALIZATION; DIAPHRAGM; COMPONENT	The collagen-tailed or asymmetric forms (A) represent a major component of acetylcholinesterase (AChE) in the neuromuscular junction of higher vertebrates. They are hetero-oligomeric molecules, in which tetramers of catalytic subunits of type T (AChE(T)) are attached to the subunits of a triple-stranded collagen ''tail.'' We report the cloning of at rat AChE-associated collagen subunit, Q. We show that collagen tails are encoded by a single gene, COLQ. The ColQ subunits form homotrimers and readily form collagen-tailed AChE, when coexpressed with rat AChE(T). We found that the same ColQ subunits are incorporated, in vivo, in asymmetric forms of both AChE and butyrylcholinesterase. A splice variant from the COLQ gene encodes a proline-rich AChE attachment domain without the collagen domain but does not represent the membrane anchor of the brain tetramer. The COLQ gene is expressed in cholinergic tissues, brain, muscle, and heart, and also in noncholinergic tissues such as lung and testis.	UNIV LJUBLJANA, SCH MED, INST PATHOPHYSIOL, LJUBLJANA 61105, SLOVENIA	University of Ljubljana	Krejci, E (corresponding author), ECOLE NORMALE SUPER, CNRS, URA 1857, NEUROBIOL CELLULAIRE & MOL LAB, 46 RUE ULM, F-75230 PARIS 05, FRANCE.			Thomine, Sebastien/0000-0003-0045-1701				ANGLISTER L, 1991, J CELL BIOL, V115, P755, DOI 10.1083/jcb.115.3.755; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BON S, 1978, EUR J BIOCHEM, V85, P1, DOI 10.1111/j.1432-1033.1978.tb12207.x; BRODBECK U, 1981, MEMBRANE PROTEINS LA, P85; CARTER JL, 1981, J NEUROCHEM, V36, P1018, DOI 10.1111/j.1471-4159.1981.tb01695.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSSEN F, 1995, EUR J CELL BIOL, V67, P254; CRNEFINDERLE N, 1995, J NEUROSCI RES, V41, P745, DOI 10.1002/jnr.490410605; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; KRIEG PA, 1987, P NATL ACAD SCI USA, V84, P2331, DOI 10.1073/pnas.84.8.2331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SL, 1982, J BIOL CHEM, V257, P2292; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; LI Y, 1991, J BIOL CHEM, V266, P23083; LIAO J, 1993, J NEUROCHEM, V61, P1127, DOI 10.1111/j.1471-4159.1993.tb03629.x; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MASSOULIE J, 1991, CHOLINESTERASES, P285; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NYQUISTBATTIE C, 1987, J MOL CELL CARDIOL, V19, P935, DOI 10.1016/S0022-2828(87)80622-3; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; SOREQ H, 1982, P NATL ACAD SCI-BIOL, V79, P830, DOI 10.1073/pnas.79.3.830; TOUTANT JP, 1988, HDB EXP PHARM, V86, P225; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VIGNY M, 1978, P NATL ACAD SCI USA, V75, P2588, DOI 10.1073/pnas.75.6.2588; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	37	140	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22840	22847		10.1074/jbc.272.36.22840	http://dx.doi.org/10.1074/jbc.272.36.22840			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278446	hybrid			2022-12-25	WOS:A1997XV49200067
J	Kume, K; Shimizu, T				Kume, K; Shimizu, T			Platelet-activating factor (PAF) induces growth stimulation, inhibition, and suppression of oncogenic transformation in NRK cells overexpressing the PAF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; PROTEIN-KINASE ACTIVATION; HIGH-AFFINITY RECEPTOR; HAMSTER OVARY CELLS; LYSOPHOSPHATIDIC ACID; FACTOR ACETYLHYDROLASE; SIGNAL TRANSDUCTION; FUNCTIONAL RECEPTOR; MOLECULAR-CLONING; RETINOIC ACID	Platelet-activating factor (PAF) is a phospholipid mediator with various physiological functions, including cellular growth and transformation. PAF exerts biological activities through G-protein-coupled receptors. In normal rat fibroblasts overexpressing a cloned PAF receptor, PAF induced immediate early oncogene expression and mitogenic responses, On the other hand, PAF strongly inhibited the epidermal growth factor-induced mitogenic growth response, growth acceleration, and anchorage-independent cell growth in a soft agar. Furthermore, PAF suppressed v-src-or v-ras-induced oncogenic morphological changes and anchorage-independent growth. Our observations suggest that PAF is a unique growth regulator with apparently diverse functions. Dual actions of PAF may relate to the point of action in the cell cycle; PAF stimulates the mitogenic response in G(0)-arrested cells in a pertussis toxin-sensitive manner, while it inhibits the G(1) to S transition through a pertussis toxin-resistant manner.			Kume, K (corresponding author), UNIV TOKYO,FAC MED,DEPT BIOCHEM & MOL BIOL,HONGO 7-3-1,TOKYO 113,JAPAN.			Kume, Kazuhiko/0000-0003-4232-1657				BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BEHRENS TW, 1990, INT J IMMUNOPHARMACO, V12, P175, DOI 10.1016/0192-0561(90)90051-N; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; CUSS FM, 1986, LANCET, V2, P189; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FILMUS J, 1994, ONCOGENE, V9, P3627; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1991, EUR J PHARMACOL, V196, P169, DOI 10.1016/0014-2999(91)90424-O; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KO TC, 1995, ONCOGENE, V10, P177; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KUME K, 1992, NEW BIOL, V4, P504; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LIU B, 1994, J BIOCHEM-TOKYO, V116, P882, DOI 10.1093/oxfordjournals.jbchem.a124611; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAGGI M, 1994, CANCER RES, V54, P4777; MASUDA A, 1992, NEW BIOL, V4, P489; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Mori M, 1996, J NEUROSCI, V16, P3590; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mutoh H, 1996, P NATL ACAD SCI USA, V93, P774, DOI 10.1073/pnas.93.2.774; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1130, DOI 10.1006/bbrc.1994.2783; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; QIAN NX, 1994, J BIOL CHEM, V269, P17417; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	53	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22898	22904		10.1074/jbc.272.36.22898	http://dx.doi.org/10.1074/jbc.272.36.22898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278453	hybrid			2022-12-25	WOS:A1997XV49200074
J	Leonarduzzi, G; Scavazza, A; Biasi, F; Chiarpotto, E; Camandola, S; Vogl, S; Dargel, R; Poli, G				Leonarduzzi, G; Scavazza, A; Biasi, F; Chiarpotto, E; Camandola, S; Vogl, S; Dargel, R; Poli, G			The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta 1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis	FASEB JOURNAL			English	Article						fibrinogenesis; sclerosis; cytokines; aldehydes; Kupffer cell	I GENE-EXPRESSION; RAT-LIVER; CARBON-TETRACHLORIDE; ALDEHYDIC PRODUCTS; CELLS; ATHEROSCLEROSIS; STIMULATION; ACTIVATION; SEPARATION; CIRRHOSIS	An increasing number of reports underscore the frequent association of fibrosclerotic diseases of lung, liver, arterial wall, brain, etc., with the accumulation of oxidatively modified lipids and proteins. A cause-and-effect relationship has been proposed between cellular oxidative damage and increased fibrogenesis based on the fact that experimental treatment with antioxidants either prevents or quenches the fibrotic process. With some peculiarities in the different organs, fibrosclerosis is essentially the result of the interaction of macrophages and extracellular matrix-producing cells. The cross-talk is mediated by fibrogenic cytokines, among which the most important appears to be transforming growth factor beta 1 (TGF-beta 1). This report describes treatment of different types of macrophage, of both human and murine origin, with 4-hydroxy-2,3-nonenal (HNE) a major aldehyde end product of membrane lipid oxidation found consistently to induce both mRNA expression and synthesis of TGF-beta 1. Since increased HNE levels have been demostrated in the cirrhotic liver and in the oxidatively modified low-density human lipoproteins associated with atherosclerosis, the up-regulation of macrophage TGF-beta 1 by HNE appears to be involved in the pathogenesis of these and similar diseases characterized by fibrosclerosis.	UNIV TURIN,DEPT EXPTL MED & ONCOL,SECT GEN PATHOL,I-10125 TURIN,ITALY; CNR,CTR IMMUNOGENET & EXPTL ONCOL,I-10126 TURIN,ITALY; UNIV JENA,INST PATHOL BIOCHEM,D-07740 JENA,GERMANY	University of Turin; Consiglio Nazionale delle Ricerche (CNR); Friedrich Schiller University of Jena			Leonarduzzi, Gabriella/AAA-6575-2019	LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X				BEDOSSA P, 1994, HEPATOLOGY, V19, P1262, DOI 10.1016/0270-9139(94)90876-1; BELLOMO G, 1996, P 2 INT C LIP OX ATH; CAMANDOLA S, 1997, BIOFACTORS, V9, P1; CARINI R, 1988, ALCOHOL TOXICITY FRE, P61; Davies K.J.A., 1993, FREE RADICALS BASIC, P18; DIANZANI MU, 1993, CRIT REV ONCOL HEMAT, V15, P125, DOI 10.1016/1040-8428(93)90052-6; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; EYHORN S, 1988, J HEPATOL, V6, P23, DOI 10.1016/S0168-8278(88)80459-8; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; KIM SJ, 1989, J BIOL CHEM, V264, P19373; LIU SL, 1995, HEPATOLOGY, V22, P1474, DOI 10.1016/0270-9139(95)90155-8; Massague J., 1990, REV CELL BIOL, V6, P597; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PAROLA M, 1992, HEPATOLOGY, V16, P1014, DOI 10.1002/hep.1840160426; Parola M, 1996, BIOCHEM BIOPH RES CO, V222, P261, DOI 10.1006/bbrc.1996.0732; PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927; PAROLA M, 1992, FEBS LETT, V308, P267, DOI 10.1016/0014-5793(92)81290-3; POLI G, 1987, CHEM PHYS LIPIDS, V45, P117, DOI 10.1016/0009-3084(87)90063-6; POLI G, 1985, BIOCHEM J, V227, P629, DOI 10.1042/bj2270629; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; ROSS R, 1993, AM J PATHOL, V143, P987; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; ZIMMERMANN T, 1986, EXP PATHOL-JENA, V30, P109, DOI 10.1016/S0232-1513(86)80069-X	28	235	250	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					851	857		10.1096/fasebj.11.11.9285483	http://dx.doi.org/10.1096/fasebj.11.11.9285483			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285483				2022-12-25	WOS:A1997XT79000004
J	Mari, B; Guerin, S; Maulon, L; Belhacene, N; Far, DF; Imbert, V; Rossi, B; Peyron, JF; Auberger, P				Mari, B; Guerin, S; Maulon, L; Belhacene, N; Far, DF; Imbert, V; Rossi, B; Peyron, JF; Auberger, P			Endopeptidase 24.11 (CD10/NEP) is required for phorbol ester-induced growth arrest in Jurkat T cells	FASEB JOURNAL			English	Article						diacylglycerol; protein kinase C; PMA; cellular proliferation; transfectant	PROTEIN-KINASE-C; BOMBESIN-LIKE PEPTIDES; EL4 THYMOMA CELLS; NEUTRAL ENDOPEPTIDASE; SIGNAL-TRANSDUCTION; HUMAN-NEUTROPHILS; LEUKEMIA ANTIGEN; DOWN-REGULATION; FETAL LUNG; WILD-TYPE	Jurkat T cells express a functional endopeptidase 24.11 that is involved in the regulation of T cell activation. We have analyzed the effect of ectopic CD10 expression in mutant Jurkat cell clones that fail to express CD10 and, unlike wild-type cells, are resistant to the growth-inhibitory effects of the protein kinase C activator, PMA. No differences in the expression of the mRNA encoding the alpha, beta, gamma, delta epsilon, and zeta isoforms of PKC were found in parental vs. PMA-resistant Jurkat cells, ruling out the possibility that the defect could be accounted for by an altered expression of one of these isoforms. Phorbol ester-induced growth arrest was not due to apoptosis since PMA failed to trigger DNA fragmentation in parental and mutant Jurkat T cells. CD10 mRNA expression and activity were abrogated in four independent PMA-resistant Jurkat T cell clones compared to parental cells, whereas the activities of several other peptidases were unaffected. Transfection of one mutant clone with a functional endopeptidase 24.11 restored in a significant manner PMA-induced growth arrest in all the clones selected and tested, whereas transfection of an inactive form of endopeptidase 24.11 had no effect, demonstrating that the enzymatic activity of CD10 is critical in the mediation of the PMA growth arrest. The data presented here demonstrate that a functional CD10 is required for PMA-induced growth arrest in Jurkat cells and provide further evidence for a role of endopeptidase 24.11 in the regulation of tumor cell proliferation.	FAC MED,CJF INSERM 9605,F-06107 NICE 02,FRANCE; FAC MED,INSERM U364,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Jean-Francois, Peyron/AAA-9496-2022; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/F-8960-2013; Peyron, Jean-Francois/M-5682-2016; Imbert, Véronique/I-6093-2016; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Mari, Bernard P/GVS-3100-2022	Jean-Francois, Peyron/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Peyron, Jean-Francois/0000-0001-6113-916X; Imbert, Véronique/0000-0003-2103-6718; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182				BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BIEMANN HPN, 1990, MOL CELL BIOL, V10, P2122, DOI 10.1128/MCB.10.5.2122; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ERDOS EG, 1989, J BIOL CHEM, V264, P14519; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; GANJU RK, 1994, J CLIN INVEST, V94, P1784, DOI 10.1172/JCI117526; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Guerin S, 1997, CELL IMMUNOL, V175, P85, DOI 10.1006/cimm.1996.1045; Guerin S, 1997, FASEB J, V11, P376, DOI 10.1096/fasebj.11.5.9141505; HOMAN EC, 1990, J BIOL CHEM, V266, P5676; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; ISHIMARU F, 1995, BLOOD, V85, P3199, DOI 10.1182/blood.V85.11.3199.bloodjournal85113199; Ishimaru F, 1996, EXP HEMATOL, V24, P43; JENSEN DE, 1991, ONCOGENE, V6, P1219; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KALLED SL, 1995, EUR J IMMUNOL, V25, P677, DOI 10.1002/eji.1830250308; KEENAN C, 1995, EUR J IMMUNOL, V25, P13, DOI 10.1002/eji.1830250104; KING KA, 1993, J CLIN INVEST, V91, P1969, DOI 10.1172/JCI116417; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, J BIOL CHEM, V269, P8517; MARI B, 1994, IMMUNOLOGY, V82, P433; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MILHIET PE, 1992, BIOCHEM PHARMACOL, V43, P1711, DOI 10.1016/0006-2952(92)90700-S; PAINTER RG, 1988, J BIOL CHEM, V263, P9456; PEYRON JF, 1991, MOL IMMUNOL, V28, P921, DOI 10.1016/0161-5890(91)90177-L; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SALLES G, 1993, P NATL ACAD SCI USA, V90, P7618, DOI 10.1073/pnas.90.16.7618; SALLES G, 1992, BLOOD, V80, P2021; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1991, BLOOD, V78, P1834; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SUNDAY ME, 1992, J CLIN INVEST, V90, P2517, DOI 10.1172/JCI116145; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TCHOUWONG KM, 1992, MOL CELL BIOL, V12, P394, DOI 10.1128/MCB.12.1.394; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WERB Z, 1989, J BIOL CHEM, V264, P9111; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	47	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					869	879		10.1096/fasebj.11.11.9285485	http://dx.doi.org/10.1096/fasebj.11.11.9285485			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285485				2022-12-25	WOS:A1997XT79000006
J	Beaumelle, B; Taupiac, MP; Lord, JM; Roberts, LM				Beaumelle, B; Taupiac, MP; Lord, JM; Roberts, LM			Ricin A chain can transport unfolded dihydrofolate reductase into the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; DIPHTHERIA-TOXIN; PSEUDOMONAS EXOTOXIN; PROTEIN; TRANSLOCATION; MEMBRANE; CYTOTOXICITY; BINDING; IMPORT; CELLS	Ricin is a heterodimeric protein toxin. The ricin A chain is able to cross the membrane of intracellular compartments to reach the cytosol where it catalytically inactivates protein synthesis. It is linked via a disulfide bond to the B chain, a galactose-specific lectin, which allows ricin binding at the cell surface and endocytosis, To examine the potential of ricin A to carry proteins into the cytosol and the requirement for unfolding of the passenger protein, we connected mouse dihydrofolate reductase (DHFR) to ricin A by gene fusion via a spacer peptide, DHFR-ricin A expressed in Escherichia coli displayed the biological activities of the parent proteins and associated quantitatively with ricin B to form DHFR-ricin, The resulting toxin was highly cytotoxic to cells (4-8-fold less than recombinant ricin), DHFR-ricin cytotoxicity was inhibited by methotrexate, a DHFR inhibitor stabilizing DHFR-ricin A in a folded conformation, The DHFR moiety of DHFR ricin bound to the plasma membrane. Although methotrexate prevented this binding, it did not significantly affect DHFR-ricin endocytosis, which proceeded via ricin B chain. Intoxication kinetics data and a cell-free translocation assay demonstrated that protection of cells from DHFR-ricin cytotoxicity resulted from a selective inhibition by methotrexate of DHFR-ricin A translocation. We conclude that ricin A is a potential carrier of proteins to the cytosol, provided that the passenger protein is able to unfold for transmembrane transport.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick	Beaumelle, B (corresponding author), UNIV MONTPELLIER 2,UMR 5539 CNRS,DEPT BIOL SANTE,CASE 107,F-34095 MONTPELLIER 05,FRANCE.			Beaumelle, Bruno/0000-0002-4912-9134				ARGENT RH, 1994, J BIOL CHEM, V269, P26705; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3075, DOI 10.1073/pnas.89.7.3075; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; DONNELLY JJ, 1993, P NATL ACAD SCI USA, V90, P3530, DOI 10.1073/pnas.90.8.3530; EILERS M, 1986, NATURE, V322, P229; FALNES PO, 1994, J BIOL CHEM, V269, P8402; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; Klingenberg O, 1996, BIOCHEM J, V313, P647, DOI 10.1042/bj3130647; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OHARE M, 1990, FEBS LETT, V273, P200, DOI 10.1016/0014-5793(90)81084-2; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; Olsnes S., 1988, IMMUNOTOXINS, P39; Pastore E J, 1974, Methods Enzymol, V34, P281; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Robertus J, 1991, Semin Cell Biol, V2, P23; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1979, EXP CELL RES, V121, P15, DOI 10.1016/0014-4827(79)90439-7; SCHLENSTEDT G, 1994, FEBS LETT, V340, P139, DOI 10.1016/0014-5793(94)80189-4; SHACKELFORD DA, 1986, J BIOL CHEM, V261, P8334; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; STUBER D, 1984, EMBO J, V3, P3143; Walker D, 1996, J BIOL CHEM, V271, P4082; WIELDOCHA A, 1992, EMBO J, V11, P4835; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; YOULE RJ, 1982, J BIOL CHEM, V257, P1598	35	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22097	22102		10.1074/jbc.272.35.22097	http://dx.doi.org/10.1074/jbc.272.35.22097			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268352	Green Published, hybrid			2022-12-25	WOS:A1997XT85000064
J	Dong, BH; Silverman, RH				Dong, BH; Silverman, RH			A bipartite model of 2-5A-dependent RNase L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON ACTION; RIBONUCLEASE-L; CELLS; INFECTION; CLEAVAGE; 2-5A	The 2-5A-dependent RNase (RNase L) is a tightly regulated endoribonuclease of higher vertebrates that is catalytically active only after engaging unusual effector molecules consisting of the 2',5'-linked oligoadenylates, p(1-3)A(2'p5'A)(greater than or equal to 2) (2-5A), Progressive truncations from either terminus have provided insight into the structure, function, and regulation of RNase L, We determined that deletion of the N-terminal 335 amino acids of RNase L, about 45% of the enzyme, produced a constitutively active endoribonuclease, thus effectively eliminating the requirement for 2-5A. The truncated nuclease had 6-fold lower catalytic activity against an oligo(rU) substrate than wild type RNase L, However, the two enzymes showed identical RNA cleavage site preferences with an mRNA as substrate, The repressor function required only the last three of a series of nine ankyrin-like repeats present in the N-terminal part of RNase L, In contrast, the entire ankyrin repeat region was necessary and sufficient for 2-5A binding activity. Deletion of a 10-amino acid sequence near the C terminus of RNase L, between residues 710 and 720, eliminated both the catalytic and RNA substrate binding functions of the enzyme. The ability to bind native RNase L in response to 2-5A required amino acid sequences near both termini of the protein, A bipartite model for the structure of RNase L emerged in which the regulatory functions of the molecule are located in the N-terminal half, while the catalytic domain is present in the C-terminal half.	CLEVELAND CLIN FDN,DEPT CANC BIOL,LERNER RES INST,NN106,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NCI NIH HHS [CA 44059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; Carroll SS, 1996, J BIOL CHEM, V271, P4988; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; Cole JL, 1996, J BIOL CHEM, V271, P3979; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1982, EUR J BIOCHEM, V124, P131, DOI 10.1111/j.1432-1033.1982.tb05915.x; SILVERMAN RH, 1997, RIBONUCLEASES STRUCT, P516; SOBOL RW, 1995, J BIOL CHEM, V270, P5963, DOI 10.1074/jbc.270.11.5963; WILLIAMS BRG, 1979, NATURE, V282, P582, DOI 10.1038/282582a0; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	20	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22236	22242		10.1074/jbc.272.35.22236	http://dx.doi.org/10.1074/jbc.272.35.22236			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268370	hybrid			2022-12-25	WOS:A1997XT85000082
J	Trzepacz, C; Lowy, AM; Kordich, JJ; Groden, J				Trzepacz, C; Lowy, AM; Kordich, JJ; Groden, J			Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34(cdc2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; BETA-CATENIN; COLORECTAL-CANCER; M-PHASE; PROTEIN; ASSOCIATION; IDENTIFICATION; CHROMOSOME-5Q21; MICROTUBULES; MUTATIONS	Mutations in the tumor suppressor gene APC invariably lead to the development of colorectal cancer, The vast majority of these mutations are nonsense or frame-shifts resulting in nonfunctional, truncated APC protein products, Eleven cyclin-dependent kinase (CDK) consensus phosphorylation sites have been identified in the frequently deleted carboxyl-terminal region of APC; loss of these phosphorylation sites by mutation could therefore compromise the ability of APC to inhibit cell growth. This report demonstrates that immunoprecipitates of full-length, but not truncated, APC protein include a mitosis-specific kinase activity in vivo, Biochemical and Western analysis of these immunoprecipitates confirms the presence of the CDK p34(cdc2). We also show that APC is a substrate for recombinant human p34(cdc2)-cyclin B1. Modification of APC by p34(cdc2) implicates phosphorylation as a mechanism for regulating APC function via a link to the cell cycle.	UNIV CINCINNATI, COLL MED, DEPT MOL GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT SURG, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NATIONAL CANCER INSTITUTE [R29CA063507, R01CA063507] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharjee RN, 1996, BIOCHEM BIOPH RES CO, V220, P192, DOI 10.1006/bbrc.1996.0379; BHATTACHARYA G, 1995, BIOCHEM BIOPH RES CO, V208, P103, DOI 10.1006/bbrc.1995.1311; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OOKATA K, 1993, J CELL SCI, V105, P873; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; TOMBES RM, 1991, CELL REGUL, V2, P861, DOI 10.1091/mbc.2.11.861; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x	24	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21681	21684		10.1074/jbc.272.35.21681	http://dx.doi.org/10.1074/jbc.272.35.21681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268294	hybrid			2022-12-25	WOS:A1997XT85000006
J	Porcellini, A; Ruggiano, G; Pannain, S; Ciullo, I; Amabile, G; Fenzi, G; Avvedimento, EV				Porcellini, A; Ruggiano, G; Pannain, S; Ciullo, I; Amabile, G; Fenzi, G; Avvedimento, EV			Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells	ONCOGENE			English	Article						thyrotropin receptor; mutations; cAMP signaling; neoplasm, genetics	SOMATIC MUTATIONS; THYROGLOBULIN GENE; FRTL5 CELLS; EXPRESSION; ADENOSINE-3',5'-MONOPHOSPHATE; ACTIVATION; TRANSFORMATION; IDENTIFICATION; CLONING; HORMONE	TSH receptor mutants in the VI transmembrane segment, found in thyroid autonomously functioning adeonomas, have been expressed in differentiated thyroid cells, All mutant receptors constitutively stimulated adenylyl cyclase, The biological activity, measured as cAMP production relative to the wild type receptor, was specific for each mutant in transient and stable transfection assays. Cells expressing these mutants proliferated in the absence of TSH, The rate of growth in the absence of TSH paralleled basal cAMP production for each mutant receptor, Low TSH concentrations stimulated of mutant receptor-expressing growth of the cells expressing the wild type receptor, Also, the entry in the cell cycle and the plating efficiency were markedly stimulated by the expression of the mutant receptors, These data provide a molecular link between the occurrence of TSH receptor mutations and thyroid autonomously functioning adenomas.	UNIV REGGIO CALABRIA,FAC MED,DIPARTIMENTO MED SPERIMENTALE,I-88100 CATANZARO,ITALY; FDN G PASCALE,SERV ONCOL SPERIMENTALE E,IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,DIPARTIMENTO BIOL & PATOL MOL & CELLULARE L CALIF,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,DEPT ENDOCRINOL,I-80131 NAPLES,ITALY	Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II			Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BIDEY SP, 1988, J ENDOCRINOL, V119, P365, DOI 10.1677/joe.0.1190365; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1995, ONCOGENE, V11, P1089; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P567; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; Sambrook J., 2002, MOL CLONING LAB MANU; SETTE C, 1994, J BIOL CHEM, V269, P9245; SUAREZ HG, 1991, ONCOGENE, V6, P677; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; TRAMONTANO D, 1986, ENDOCRINOLOGY, V118, P1945, DOI 10.1210/endo-118-5-1945; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099	32	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					781	789		10.1038/sj.onc.1201240	http://dx.doi.org/10.1038/sj.onc.1201240			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266964				2022-12-25	WOS:A1997XQ11700004
J	Duncan, RR; Westwood, PK; Boyd, A; Ashley, RH				Duncan, RR; Westwood, PK; Boyd, A; Ashley, RH			Rat brain p64H1, expression of a new member of the p64 chloride channel protein family in endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; CHROMAFFIN GRANULE MEMBRANES; CALCIUM CHANNELS; SARCOPLASMIC-RETICULUM; SELECTIVE CHANNEL; POTASSIUM CURRENT; ANION CHANNELS; MESSENGER-RNAS; ION CHANNELS; M2 PROTEIN	Many plasma membrane Cl- channels have been cloned, including the cystic fibrosis transmembrane conductance regulator and several members of the voltage-gated ClC family, In contrast, very little is known about the molecular identity of intracellular Cl- channels, me used a polymerase chain reaction-based approach to identify candidate genes in mammalian brain and cloned the cDNA. corresponding to rat brain p64H1. This encoded a microsomal membrane protein of predicted M-r 28,635 homologous to the putative intracellular bovine kidney Cl- channel p64. In situ mRNA hybridization histochemistry showed marked expression in hippocampus and cerebellum, and in vitro expression revealed a large cytoplasmic domain, one membrane-spanning segment, and a small nonglycosylated N-terminal luminal domain. The predicted protein contained consensus phosphorylation sites for protein kinase C and protein kinase A, and protein kinase C-mediated phosphorylation increased the M-r of p64H1 to similar to 43,000, characteristic of the native protein in Western blots. Recombinant p64H1 was immunolocalized to the endoplasmic reticulum of human embryonic kidney 293 and HT-4 cells, and incorporation of human embryonic kidney 293 endoplasmic reticulum vesicles into planar lipid bilayers gave rise to intermediate conductance, outwardly rectifying anion channels. Although p64H1 is the first intracellular Cl- channel component or regulator to be identified in brain, Northern blotting revealed transcripts in many other rat tissues. This suggests that p64H1 may contribute widely to intracellular Cl- transport.	UNIV EDINBURGH,DEPT BIOCHEM,EDINBURGH EH8 9XD,MIDLOTHIAN,SCOTLAND	University of Edinburgh				Duncan, Rory/0000-0003-0693-910X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; ARISPE N, 1992, J MEMBRANE BIOL, V130, P191; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; ASHLEY RH, 1994, EUR BIOPHYS J BIOPHY, V23, P263, DOI 10.1007/BF00213576; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark AG, 1997, BIOPHYS J, V73, P168, DOI 10.1016/S0006-3495(97)78057-3; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HAYMAN KA, 1993, J MEMBRANE BIOL, V136, P181, DOI 10.1007/BF02505762; HODGKIN AL, 1949, J PHYSL, V108, P27; Howell S, 1996, FEBS LETT, V390, P207, DOI 10.1016/0014-5793(96)00676-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; MARTIN C, 1993, CELL CALCIUM, V14, P427, DOI 10.1016/0143-4160(93)90002-N; Miller C., 1984, ION CHANNEL RECONSTI; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; MORIER N, 1994, BIOPHYS J, V67, P590, DOI 10.1016/S0006-3495(94)80519-3; MURUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; RAHAMIMOFF R, 1988, P NATL ACAD SCI USA, V85, P5310, DOI 10.1073/pnas.85.14.5310; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SCHMID A, 1988, J MEMBRANE BIOL, V104, P275, DOI 10.1007/BF01872329; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SUKHAREVA M, 1994, BIOPHYS J, V67, P751, DOI 10.1016/S0006-3495(94)80536-3; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TERASAKI M, 1992, J CELL SCI, V101, P315; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; YOUNG WS, 1986, NEUROSCI LETT, V70, P198	47	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23880	23886		10.1074/jbc.272.38.23880	http://dx.doi.org/10.1074/jbc.272.38.23880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295337	hybrid			2022-12-25	WOS:A1997XX38100062
J	Gerber, HP; Condorelli, F; Park, J; Ferrara, N				Gerber, HP; Condorelli, F; Park, J; Ferrara, N			Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes - Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; LACTATE-DEHYDROGENASE-A; HIPPEL-LINDAU PROTEIN; FACTOR MESSENGER-RNA; INDUCIBLE FACTOR-1; TYROSINE KINASE; NITRIC-OXIDE; FACTOR VEGF; EXPRESSION; CELLS	Vascular endothelial growth factor (VEGF) and its two endothelial cell-specific receptor tyrosine kinases, Flk-1/KDR and Flt-1, play a key role in physiological and pathological angiogenesis. Hypoxia has been shown tee be a major mechanism for up-regulation of VEGF and its receptors in vivo. When we exposed human umbilical vein endothelial cells to hypoxic conditions in vitro, we observed increased levels of Flt-1 expression, In contrast, Flk-1/KDR mRNA levels were unchanged or slightly repressed, These findings suggest a differential transcriptional regulation of the two receptors by hypoxia, To identify regulatory elements involved in the hypoxic response, promoter regions of the mouse Flt-1 and Flk-1/KDR genes were isolated and tested in conjunction with luciferase reporter gene. In transient transfection assays, hypoxia led to strong transcriptional activation of the Flt-1 promoter, whereas Flk-1/KDR transcription was essentially unchanged, Promoter deletion analysis demonstrated a 430-bp region of the Flt-1 promoter to be required for transcriptional activation in response to hypoxia, This region includes a heptamer sequence matching the hypoxia-inducible factor-1 (HIF) consensus binding site previously found in other hypoxia-inducible genes such as the VEGF gene and erythropoietin gene, We further narrowed down the element mediating the hypoxia response to a 40-base pair sequence including the putative HIF binding site, We show that this element acts like an enhancer, since it activated transcription irrespective of its location or orientation in the construct, Furthermore, mutations within the putative HIF consensus binding site lead to impaired transcriptional activation by hypoxia, These findings indicate that, unlike the KDR/Flk-1 gene, the Flt-1 receptor gene is directly up-regulated by hypoxia via a hypoxia-inducible enhancer element located at positions -976 to -937 of the Flt-1 promoter.	GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Condorelli, Fabrizio/J-4726-2016	Condorelli, Fabrizio/0000-0002-9943-0857				Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINNERTY H, 1993, ONCOGENE, V8, P2293; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FOLKMAN J, 1987, J NATL CANCER I, V82, P4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; IKEDA T, 1996, GROWTH FACTORS, V13, P1151; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MINCHENKO A, 1994, LAB INVEST, V71, P374; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PHILLIPS HS, 1993, INT J ONCOL, V2, P913; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Sambrook J., 2002, MOL CLONING LAB MANU; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; TERMAN BI, 1991, ONCOGENE, V6, P1677; THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647	52	635	666	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23659	23667		10.1074/jbc.272.38.23659	http://dx.doi.org/10.1074/jbc.272.38.23659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295307	hybrid			2022-12-25	WOS:A1997XX38100032
J	Wandall, HH; Hassan, H; Mirgorodskaya, E; Kristensen, AK; Roepstorff, P; Bennett, EP; Nielsen, PA; Hollingsworth, MA; Burchell, J; TaylorPapadimitriou, J; Clausen, H				Wandall, HH; Hassan, H; Mirgorodskaya, E; Kristensen, AK; Roepstorff, P; Bennett, EP; Nielsen, PA; Hollingsworth, MA; Burchell, J; TaylorPapadimitriou, J; Clausen, H			Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; O-LINKED GLYCOSYLATION; CORE-PROTEIN; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; HUMAN FIBRONECTIN; DONOR SUBSTRATE; CDNA CLONING; IN-VIVO; EXPRESSION	Mucin-type O-glycosylation is initiated by UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases (GalNAc-transferases). The role each GalNAc-transferase plays in O-glycosylation is unclear, In this report we characterized the specificity and kinetic properties of three purified recombinant GalNAc-transferases. GalNAc-T1, -T2, and -T3 were expressed as soluble proteins in insect cells and purified to near homogeneity, The enzymes have distinct but partly overlapping specificities with short peptide acceptor substrates, Peptides specifically utilized by GalNAc-T2 or -T3, or preferentially by GalNAc-T1 were identified. GalNAc-T1 and -T3 showed strict donor substrate specificities for UDP-GalNAc, whereas GalNAc-T2 also utilized UDP-Gal with one peptide acceptor substrate. Glycosylation of peptides based on MUC1 tandem repeat showed that three of five potential sites in the tandem repeat were glycosylated by all three enzymes when one or five repeat peptides were analyzed, However, analysis of enzyme kinetics by capillary electrophoresis and mass spectrometry demonstrated that the three enzymes react at different rates with individual sites in the MUC1 repeat, The results demonstrate that individual GalNAc-transferases have distinct activities and the initiation of O-glycosylation in a cell is regulated by a repertoire of GalNAc-transferases.	UNIV COPENHAGEN, SCH DENT, DK-2200 COPENHAGEN N, DENMARK; ODENSE UNIV, DEPT MOL BIOL, DK-5230 ODENSE, DENMARK; UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	University of Copenhagen; University of Southern Denmark; University of Nebraska System; University of Nebraska Medical Center; Cancer Research UK			Bennett, Eric/AAG-6120-2020; clausen, henrik/AAD-8016-2021; Burchell, Joy/G-4560-2012	Bennett, Eric/0000-0002-4976-0647; Clausen, Henrik/0000-0002-0915-5055; Burchell, Joy/0000-0003-0413-3823; Wandall, Hans H./0000-0003-0240-9232	NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER; NCI NIH HHS [1 RO1 CA66234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V206, P318, DOI 10.1006/bbrc.1995.1044; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; BURCHELL J, 1987, CANCER RES, V47, P5476; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; ELLIOTT S, 1994, BIOCHEMISTRY-US, V33, P11237, DOI 10.1021/bi00203a020; Finck M, 1996, GLYCOBIOLOGY, V6, P313, DOI 10.1093/glycob/6.3.313; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GREENWELL P, 1986, CARBOHYD RES, V149, P149, DOI 10.1016/S0008-6215(00)90375-6; GRUNNET N, 1994, VOX SANG, V67, P210, DOI 10.1111/j.1423-0410.1994.tb01662.x; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HANSEN JE, 1994, PROTEIN STRUCTURE BY DISTANCE ANALYSIS, P247; HennebicqReig S, 1996, CARBOHYD RES, V280, P121, DOI 10.1016/0008-6215(95)00297-9; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HILL HD, 1977, J BIOL CHEM, V252, P3799; HINDSGAUL O, 1994, ALFRED BENZON SYMP S, V36, P104; HOMA FL, 1993, J BIOL CHEM, V268, P12609; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; MANDEL U, 1992, APMIS, V100, P817, DOI 10.1111/j.1699-0463.1992.tb04005.x; MATSUURA H, 1989, J BIOL CHEM, V264, P10472; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NISHIMORI I, 1994, CANCER RES, V54, P3738; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; YATES AD, 1984, BIOCHEM SOC T, V11, P300; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	48	255	271	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23503	23514		10.1074/jbc.272.38.23503	http://dx.doi.org/10.1074/jbc.272.38.23503			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295285	hybrid			2022-12-25	WOS:A1997XX38100010
J	Wang, F; Kan, M; McKeehan, K; Jang, JH; Feng, SJ; McKeehan, WL				Wang, F; Kan, M; McKeehan, K; Jang, JH; Feng, SJ; McKeehan, WL			A homeo-interaction sequence in the ectodomain of the fibroblast growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; THANATOPHORIC DYSPLASIA; CONSTITUTIVE ACTIVATION; STRUCTURAL DOMAINS; BINDING; HEPARIN; MUTATIONS; CELLS; IDENTIFICATION; ACHONDROPLASIA	Interaction of fibroblast growth factor receptors (FGFR) sufficient for a trans-phosphorylation event in which one intracellular domain is substrate for the other is essential for signal transduction. By analysis of the direct interaction of recombinant constructions coexpressed in baculoviral-infected insect cells, we identified a 17-amino acid sequence that is required for the stable interaction between ectodomains of FGFR, The sequence (160)ERSPHRPILQAGLPANK(176) (Glu(160)-Lys(176)) connects immunoglobulin modules II and III. In insect cells, the interaction between Glu(160)-Lys(176) domains occurs independently of intact heparin or FGF binding domains, The sequence is not required for the binding of heparin or FGF-1, but is essential for mitogenic activity of the FGFR kinase in mammalian cells. The results support a model in which the homeo-interaction between Glu(160)-Lys(176) in the ectodomain contributes to the interaction between intracellular domains in mammalian cell membranes (Kan, M., Wang, F., Kan, M., To, B., Gabriel, J. L., and McKeehan, W. L. (1996) J. Biol. Chem. 271, 26143-26148), We propose that the Glu(160)-Lys(176) domain plays a pivotal role in restriction of the interaction between kinases by pericellular matrix heparan sulfate proteoglycan and divalent cations. Restrictions are overcome by FGF or constitutively by diverse gain of function mutations which cause skeletal and craniofacial abnormalities.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, CTR CANC BIOL & NUTR, HOUSTON, TX 77030 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, HOUSTON, TX 77030 USA	Texas A&M University System; Texas A&M University System					NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310, R01DK040739] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310, DK40739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bellus GA, 1996, NAT GENET, V14, P174, DOI 10.1038/ng1096-174; Bonaventure J, 1996, AM J MED GENET, V63, P148, DOI 10.1002/(SICI)1096-8628(19960503)63:1<148::AID-AJMG26>3.0.CO;2-N; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Feng SJ, 1996, BBA-MOL CELL RES, V1310, P67, DOI 10.1016/0167-4889(95)00146-8; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOU JZ, 1992, J BIOL CHEM, V267, P17804; HOU JZ, 1993, PROTEIN SCI, V2, P86; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Luo YD, 1996, J BIOL CHEM, V271, P26876, DOI 10.1074/jbc.271.43.26876; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1996, MOL CELL BIOL, V16, P4081; XU JM, 1992, J BIOL CHEM, V267, P17792; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	33	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23887	23895		10.1074/jbc.272.38.23887	http://dx.doi.org/10.1074/jbc.272.38.23887			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295338	hybrid			2022-12-25	WOS:A1997XX38100063
J	Tomura, H; Itoh, H; Sho, K; Sato, K; Nagao, M; Ui, M; Kondo, Y; Okajima, F				Tomura, H; Itoh, H; Sho, K; Sato, K; Nagao, M; Ui, M; Kondo, Y; Okajima, F			beta gamma Subunits of pertussis toxin-sensitive G proteins mediate A(1) adenosine receptor agonist-induced activation of phospholipase C in collaboration with thyrotropin - A novel stimulatory mechanism through the cross-talk of two types of receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRTL-5 THYROID-CELLS; SIGNAL TRANSDUCTION SYSTEMS; NG 108-15 CELLS; ALPHA-SUBUNITS; ADENYLYL-CYCLASE; INOSITOL 1,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE TURNOVER; ARACHIDONATE RELEASE; BRADYKININ RECEPTORS; CA-2+ MOBILIZATION	COS-7 cells were transiently transfected with human thyrotropin receptor and dog A(1) adenosine receptor cDNAs. An A(1) agonist, N-6-(L-2-phenylisopropyl) adenosine (PIA), which is ineffective alone, enhanced tale thyrotropin (TSH)-induced inositol phosphate production, reflecting phospholipase C (PLC) activation, but inhibited the TSH-induced cAMP accumulation, reflecting adenylyl cyclase inhibition, These PIA-induced actions were completely inhibited by pertussis toxin (PTX) treatment. Moreover, in the cells expressing a PTX-insensitive mutant of G(i)2 alpha or G(i)3 alpha, in which a glycine residue was substituted for a cysteine residue to be ADP-ribosylated by PTX, at the fourth position of the C terminus, PIA effectively exerted both stimulatory and inhibitory effects on the TSH-induced actions although the cells were treated with the toxin. Overexpression of the beta gamma subunits of the G proteins enhanced the TSH-induced inositol phosphate production without any significant effect on the cAMP response; under these conditions, PIA did not further increase the elevated inositol phosphate response to TSH. On the contrary, overexpression of a constitutively active mutant of G(i)2 alpha, in which the guanosine triphosphatase activity is lost, inhibited the TSH-induced cAMP accumulation brat hardly affected the inositol phosphate response; under these conditions, PIA never exerted further inhibitory effects an the cAMP response to TSH. In contrast to the case of the TSH-induced inositol phosphate response, the response to a constitutively active G(11)alpha mutant was not appreciably affected, and that to NaF was rather inhibited by PIA and overexpression of the beta gamma subunits. Taken together, these results suggest that a single type of PTX-sensitive G protein mediates the A(1) adenosine receptor-linked modulation of two signaling pathways in collaboration with an activated thyrotropin receptor; alpha subunits of the PTX-sensitive G proteins mediate the inhibitory action an adenylyl cyclase, and the beta gamma subunits mediate the stimulatory action on PLC, In the case of the latter stimulatory action on PLC, the beta gamma subunits may not directly activate PLC. The possible mechanism by which beta gamma subunits enhance the TSH-induced PLC activation is discussed.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,YOKOHAMA,KANAGAWA 226,JAPAN; TOKYO METROPOLITAN INST MED SCI,TOKYO 113,JAPAN	Tokyo Institute of Technology; Tokyo Metropolitan Institute of Medical Science	Tomura, H (corresponding author), GUNMA UNIV,LAB SIGNAL TRANSDUCT,INST MOL & CELLULAR REGULAT,3-39-15 SHOWA MACHI,MAEBASHI,GUMMA 371,JAPAN.							AKBAR M, 1994, MOL PHARMACOL, V45, P1036; ALI H, 1990, J BIOL CHEM, V265, P745; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; GERWINS P, 1992, P NATL ACAD SCI USA, V89, P7330, DOI 10.1073/pnas.89.16.7330; GERWINS P, 1992, J BIOL CHEM, V267, P16081; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HUNT TW, 1994, J BIOL CHEM, V269, P29565; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; ITOH H, 1988, J BIOL CHEM, V263, P6656; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Laglia G, 1996, ENDOCRINOLOGY, V137, P3170, DOI 10.1210/en.137.8.3170; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; NAZAREA M, 1991, EUR J PHARM-MOLEC PH, V206, P47, DOI 10.1016/0922-4106(91)90145-8; OKAJIMA F, 1990, J BIOL CHEM, V265, P21741; OKAJIMA F, 1995, BIOCHEM J, V306, P709, DOI 10.1042/bj3060709; OKAJIMA F, 1989, FEBS LETT, V248, P145, DOI 10.1016/0014-5793(89)80450-8; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAJIMA F, 1993, BIOCHEM J, V290, P241, DOI 10.1042/bj2900241; OKAJIMA F, 1992, FEBS LETT, V301, P223, DOI 10.1016/0014-5793(92)81252-H; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V281, P298, DOI 10.1016/0003-9861(90)90447-7; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SHO K, 1991, J BIOL CHEM, V266, P12180; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STILES GL, 1992, J BIOL CHEM, V267, P6451; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TOMURA H, 1992, NEUROSCI LETT, V148, P93, DOI 10.1016/0304-3940(92)90812-L; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WATSON S, 1994, G PROTEIN LINKED REC, P296; WEST RE, 1985, J BIOL CHEM, V260, P4428; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; YASUDA K, 1992, J BIOL CHEM, V267, P20422	58	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23130	23137		10.1074/jbc.272.37.23130	http://dx.doi.org/10.1074/jbc.272.37.23130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287315	hybrid			2022-12-25	WOS:A1997XV74400026
J	Huang, DQ; Wilson, WA; Roach, PJ				Huang, DQ; Wilson, WA; Roach, PJ			Glucose-6-P control of glycogen synthase phosphorylation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE TYPE-1; SACCHAROMYCES-CEREVISIAE; 2 FORMS; GENE; PHOSPHOFRUCTOKINASE; METABOLISM; SNF1; SYNTHETASE; DISRUPTION; EXISTENCE	The SNF1 gene encodes a protein kinase necessary for expression of glucose-repressible genes and for the synthesis of the storage polysaccharide glycogen, From a genetic screen, we have found that mutation of the PFK2 gene, which encodes the beta-subunit of 6-phosphofructo-1-kinase, restores glycogen accumulation in snf1 cells. Loss of PFK2 causes elevated levels of metabolites such as glucose-6-P, hyperaccumulation of glycogen, and activation of glycogen synthase, whereas glucose-6-P is reduced in snf1 cells, Other mutations that increase glucose-6-P, deletion of PFK1, which codes for the alpha-subunit of 6-phosphofructo-1-kinase, or of PGI1, the phosphoglucoisomerase gene, had similar effects on glycogen metabolism as did pfk2 mutants. We propose that elevated glucose-g-P mediates the effects of these mutations on glycogen storage. Glycogen synthase kinase activity was reduced in extracts from pfk2 cells but was restored to that of wild type if the extract was gel-filtered to remove small molecules, Also, added glucose-6-P inhibited the glycogen synthase kinase activity in extracts from wild-type cells, half-maximally at similar to 2 mM. We suggest that glucose-6-P controls glycogen synthase activity by two separate mechanisms. First, glucose-6-P is a direct activator of glycogen synthase, and second, it controls the phosphorylation state of glycogen synthase by inhibiting a glycogen synthase kinase.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Wilson, Wayne/0000-0003-2417-5756				BREITENBACHSCHMITT I, 1984, MOL GEN GENET, V195, P536, DOI 10.1007/BF00341459; CANNON JF, 1994, GENETICS, V136, P485; CARLSON M, 1981, GENETICS, V98, P25; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; CHESTER VE, 1967, NATURE, V214, P1237, DOI 10.1038/2141237a0; COROMINAS J, 1992, FEBS LETT, V310, P182, DOI 10.1016/0014-5793(92)81325-G; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; FRANCOIS J, 1997, IN PRESS YEAST SUGAR; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; Guinovart JJ, 1997, BIOCHEM SOC T, V25, P157, DOI 10.1042/bst0250157; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; HEINISCH J, 1989, GENE, V78, P309; HEINISCH J, 1986, MOL GEN GENET, V202, P75, DOI 10.1007/BF00330520; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1996, GENETICS, V143, P119; HUANG KP, 1974, J BIOL CHEM, V249, P3851; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG G, 1974, METHOD ENZYMAT AN, P1235; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; ROECH PJ, 1976, TRENDS BIOCHEM SCI, V1, P110; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; SIKORSKI RS, 1989, GENETICS, V122, P19; Skurat Alexander V., 1996, P213; Stalmans W, 1997, BIOCHEM SOC T, V25, P19, DOI 10.1042/bst0250019; TARUI S, 1965, BIOCHEM BIOPH RES CO, V19, P517, DOI 10.1016/0006-291X(65)90156-7; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; Timblin BK, 1996, GENETICS, V143, P57; WILSON WA, 1995, THESIS U DUNDEE SCOT	37	35	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22495	22501		10.1074/jbc.272.36.22495	http://dx.doi.org/10.1074/jbc.272.36.22495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278401	hybrid			2022-12-25	WOS:A1997XV49200021
J	Guzder, SN; Sung, P; Prakash, L; Prakash, S				Guzder, SN; Sung, P; Prakash, L; Prakash, S			Yeast Rad7-Rad16 complex, specific for the nucleotide excision repair of the nontranscribed DNA strand, is an ATP-dependent DNA damage sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; RECONSTITUTION; NUCLEASE; PROTEINS; SYSTEM; GENE	In eukaryotes, nucleotide excision repair of ultraviolet light-damaged DNA is a highly intricate process that requires a large number of evolutionarily conserved protein factors, Genetic studies in the yeast Saccharomyces cerevisiae have indicated a specific role of the RAD7 and RAD16 genes in the repair of transcriptionally inactive DNA. Here we show that the RAD7- and RAD16-encoded products exist as a complex of 1:1 stoichiometry, exhibiting an apparent dissociation constant (K-d) of <4 x 10(-10) M. The Rad7-Rad16 complex has been purified to near homogeneity in this study and is shown to bind, in an ATP-dependent manner and with high specificity, to DNA damaged by ultraviolet light, Importantly, inclusion of the Rad7-Rad16 complex in the in vitro nucleotide excision repair system that consists entirely of purified components results in a marked stimulation of damage specific incision. Thus, Rad7-Rad16 complex is the ATP-dependent DNA damage sensor that specifically functions with the ensemble of nucleotide excision repair factor (NEF) 1, NEF2, NEF3, and replication protein A in the repair of transcriptionally inactive DNA. We name this novel complex of Rad7 and Rad16 proteins NEF4.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R37CA041261, R37CA035035, R01CA041261, R01CA035035] Funding Source: NIH RePORTER; NCI NIH HHS [CA41261, CA35035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MUELLER JP, 1995, NUCLEIC ACIDS RES, V23, P3457, DOI 10.1093/nar/23.17.3457; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635	15	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21665	21668		10.1074/jbc.272.35.21665	http://dx.doi.org/10.1074/jbc.272.35.21665			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268290	hybrid			2022-12-25	WOS:A1997XT85000002
J	Sherrington, PD; Scott, JL; Jin, BQ; Simmons, D; Dorahy, DJ; Lloyd, J; Brien, JH; Aebersold, RH; Adamson, J; Zuzel, M; Burns, GF				Sherrington, PD; Scott, JL; Jin, BQ; Simmons, D; Dorahy, DJ; Lloyd, J; Brien, JH; Aebersold, RH; Adamson, J; Zuzel, M; Burns, GF			TLiSA1 (PTA1) activation antigen implicated in T cell differentiation and platelet activation is a member of the immunoglobulin superfamily exhibiting distinctive regulation of expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE SURFACE PROTEIN; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; GENE; LYMPHOCYTES; SIGNAL; CLASSIFICATION; SPECIFICITY; INHIBITION; PREDICTION	T lineage-specific activation antigen 1 (TLiSA1) antigen was initially described as a T lineage-specific activation antigen involved in the differentiation of human cytotoxic T cells, Subsequently, the antigen was identified on platelets and was shown to be involved in platelet activation, hence it was renamed platelet and T cell antigen 1 (PTA1), although identity between the two antigens was not established, In the present study we have cloned the cDNA encoding TLiSA1 from Jurkat cells and show it to be a novel member of the immunoglobulin superfamily with the unusual structure of two V domains only, Identity between TLiSA1 and platelet PTA1 is established by immunological criteria, by internal peptide sequences obtained from the purified platelet glycoprotein and by sequencing the platelet transcript after reverse transcriptase-polymerase chain reaction, In Jurkat cells, TLiSA1/PTA1 mRNA and surface protein expression is greatly stimulated by treatment of the cells with phorbol ester, but the T cell proliferative signal of phorbol ester and ionophore combined greatly reduces or abrogates this response, and this suppressive effect of the ionophore is not reversed by incorporating FK506 to inhibit calcineurin. Together with the known signaling role of PTA1, these data substantiate the notion that this molecule is implicated in T cell differentiation, perhaps by engagement of an adhesive ligand.	UNIV NEWCASTLE, CANC RES UNIT, NEWCASTLE, NSW 2300, AUSTRALIA; UNIV OXFORD, INST MOL MED, OXFORD OX3 9DU, ENGLAND; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1W5, CANADA	University of Newcastle; University of Oxford; University of British Columbia	Sherrington, PD (corresponding author), UNIV LIVERPOOL, DEPT HAEMATOL, DUNCAN BLDG, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AEBERSOLD RH, 1986, J BIOL CHEM, V261, P4229; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA, P38; Berke Gideon, 1993, P965; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BURNS GF, 1985, J EXP MED, V161, P1063, DOI 10.1084/jem.161.5.1063; CHEN LK, 1986, EUR J IMMUNOL, V16, P767, DOI 10.1002/eji.1830160709; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; EDISON AM, 1995, J BIOL CHEM, V270, P27112, DOI 10.1074/jbc.270.45.27112; *GEN CLMP GROUP, 1994, PROGR MAN WISC PACK; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JIN B, 1989, IMMUNOLOGY, V66, P570; LENS SMA, 1995, LEUCOCYTE TYPING 5, P357; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; MAKOVER D, 1991, ONCOGENE, V6, P455; Mazurov A V, 1992, Platelets, V3, P181, DOI 10.3109/09537109209013181; MESCHER MF, 1995, IMMUNOL REV, V146, P177, DOI 10.1111/j.1600-065X.1995.tb00689.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNGER WE, 1982, CANCER RES, V42, P5023; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAKAI K, 1996, PSORT PREDICTION PRO; NATHAN CF, 1979, J EXP MED, V149, P84, DOI 10.1084/jem.149.1.84; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991; RIVAS A, 1995, J IMMUNOL, V154, P4423; RUEGG CL, 1995, J IMMUNOL, V154, P4434; RYSAVY FR, 1992, COMPUT APPL BIOSCI, V8, P149; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SCOTT JL, 1994, J CELL BIOCHEM, V54, P135, DOI 10.1002/jcb.240540202; SCOTT JL, 1989, J BIOL CHEM, V264, P13475; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SIMMONS DL, 1992, J IMMUNOL, V148, P267; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG PL, 1992, J IMMUNOL, V148, P2600; Weiss Arthur, 1993, P467; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZUZEL M, 1991, BRIT J HAEMATOL, V79, P466, DOI 10.1111/j.1365-2141.1991.tb08057.x	48	37	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21735	21744		10.1074/jbc.272.35.21735	http://dx.doi.org/10.1074/jbc.272.35.21735			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268302	hybrid			2022-12-25	WOS:A1997XT85000014
J	Blanquet, PR; Lamour, Y				Blanquet, PR; Lamour, Y			Brain-derived neurotrophic factor increases Ca2+/calmodulin-dependent protein kinase 2 activity in hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SYNAPTIC TRANSMISSION; GROWTH-FACTOR; II ACTIVITY; NEURONS; DIFFERENTIATION; MODULATION; ACTIVATION; SIGNALS; CELLS	Here we show that brain-derived neurotrophic factor (BDNF) stimulates both the phosphorylation of the Ca2+/calmodulin-dependent protein kinase 2 (CaMK2) and its kinase activity in rat hippocampal slices. In addition, we find that: (i) the time course of BDNF action is not accompanied by a change in the spectrum of either alpha- and beta-subunits of CaMK2 detected by immunoblotting; (ii) both treatment of solubilized CaMK2 with alkaline phosphatase and treatment of immunoprecipitated CaMK2 with protein phosphatase 1 reverse phosphorylation and activation of the kinase; (iii) phospholipase C inhibitor D609 and intracellular Ca2+ chelation by 1,2-bis-(o-aminophenoxy)ethane-N,N,N '',N',-tetracetic acid tetra(acetoxymethyl) ester or 8-(diethylamino) octyl-3, 4,5-trimethoxybenzoate but not omission of Ca2+ or Ca2+ chelation by EGTA, abolish the stimulatory effect of BDNF on phosphorylation and activation of CaMK2. These results strongly suggest that the conversion of CaMK2 into its active, autophosphorylated form, but not its concentration, is increased by BDNF via stimulation of phospholipase C and subsequent intracellular Ca2+ mobilization.			Blanquet, PR (corresponding author), U161 INSERM,UNITE RECH PHYSIOPHARMACOL SYST NERVEUX,2 RUE ALESIA,F-75014 PARIS,FRANCE.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; Aronowski J, 1996, BRAIN RES, V709, P103, DOI 10.1016/0006-8993(95)01311-3; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; BLANQUET PR, 1995, J CELL PHYSIOL, V165, P358, DOI 10.1002/jcp.1041650217; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Frenguelli BG, 1996, SEMIN NEUROSCI, V8, P301, DOI 10.1006/smns.1996.0037; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; KANG HJ, 1995, J PHYSIOLOGY-PARIS, V89, P11, DOI 10.1016/0928-4257(96)80547-X; Levine ES, 1996, MOL BRAIN RES, V38, P300, DOI 10.1016/0169-328X(96)00025-3; Marsh HN, 1996, J NEUROCHEM, V67, P952; Miyamoto E, 1996, NEUROSCI RES, V24, P117, DOI 10.1016/0168-0102(95)00991-4; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; SchmidtKastner R, 1996, NEUROSCIENCE, V74, P161, DOI 10.1016/0306-4522(96)00093-0; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; Tan SE, 1996, BRAIN RES, V711, P234, DOI 10.1016/0006-8993(95)01411-X; Tsuda M, 1996, NEUROCHEM INT, V29, P443, DOI 10.1016/0197-0186(96)00014-9; Wu K, 1996, MOL BRAIN RES, V43, P286, DOI 10.1016/S0169-328X(96)00211-2	23	58	59	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24133	24136		10.1074/jbc.272.39.24133	http://dx.doi.org/10.1074/jbc.272.39.24133			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305859	hybrid			2022-12-25	WOS:A1997XY51500010
J	Burdick, MD; Harris, A; Reid, CJ; Iwamura, T; Hollingsworth, MA				Burdick, MD; Harris, A; Reid, CJ; Iwamura, T; Hollingsworth, MA			Oligosaccharides expressed an MUC1 produced by pancreatic and colon tumor cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; MOLECULAR-CLONING; GENE-EXPRESSION; O-GLYCOSYLATION; CARCINOMA; CDNA; SELECTIN; ADHESION; PROTEIN; SIALYL-LEWIS(X)	MUC1 is expressed at the apical surface of ductal epithelia of tissues, including breast, pancreas, airway, and the gastrointestinal tract, where its functions include lubrication and protection of the epithelia, In addition, roles for MUC1 have been suggested in both adhesive and antiadhesive properties of tumor cells, and extensive O-glycosylation of the MUC1 tandem repeat domain may contribute to these functions. Little information is available on the specific O-glycosylation of MUC1. One problem in identifying different MUC1 glycoforms has been that monoclonal antibodies raised against the MUC1 core protein recognize epitopes in the tandem repeat domain, which is often glycosylated to an extent that obscures these epitopes, We developed an epitope-tagged form of MUC1 that allowed the detection of multiple MUC1 glycoforms and established the presence of a number of important blood group and tumor-associated carbohydrate antigens on MUC1 expressed by two pancreatic tumor cell lines (Panc-1 and S2-013) and two colon tumor cell Lines (Caco-2 and HT-29). Antigens detected include sialyl-Lewis(a), sialyl-Lewis(c), sialyl-Lewis(x), and sialyl-Tn.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND; MIYAZAKI MED COLL,DEPT SURG 1,MIYAZAKI 88916,JAPAN	University of Nebraska System; University of Nebraska Medical Center; University of Oxford; University of Miyazaki					NCI NIH HHS [CA69234, CA57362] Funding Source: Medline; NIDDK NIH HHS [DK46589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057362, R01CA069234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATRA SK, 1991, J CELL SCI, V100, P841; BATRA SK, 1992, INT J PANCREATOL, V12, P271; BOSHELL M, 1992, BIOCHEM BIOPH RES CO, V185, P1, DOI 10.1016/S0006-291X(05)80946-5; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; HANSKI C, 1993, CANCER RES, V53, P4082; HANSKI C, 1995, CANCER RES, V55, P928; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HO JJL, 1995, CANCER RES, V55, P3659; HO SB, 1993, CANCER RES, V53, P641; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; IWAMURA T, 1992, J GASTROEN HEPATOL, V7, P512, DOI 10.1111/j.1440-1746.1992.tb01030.x; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; PANDEY P, 1995, CANCER RES, V55, P4000; Park H, 1996, AM J RESP CELL MOL, V15, P237, DOI 10.1165/ajrcmb.15.2.8703480; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA T, 1994, INT J CANCER, V57, P901, DOI 10.1002/ijc.2910570621; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; TAKADA A, 1993, CANCER RES, V53, P354; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Woynarowska B, 1996, GLYCOCONJUGATE J, V13, P663, DOI 10.1007/BF00731455; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	33	183	188	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24198	24202		10.1074/jbc.272.39.24198	http://dx.doi.org/10.1074/jbc.272.39.24198			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305871	hybrid			2022-12-25	WOS:A1997XY51500022
J	Francisco, JA; Gawlak, SL; Siegall, CB				Francisco, JA; Gawlak, SL; Siegall, CB			Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL LYMPHOMA; ENDOTHELIAL-CELLS; CD40 ANTIGEN; PHASE-I; PSEUDOMONAS EXOTOXIN; CONTINUOUS-INFUSION; BRYONIA-DIOICA; ACTIVATION; CARCINOMAS	The major limitation to the use of immunotoxins in the clinic is the toxicity associated with the toxin moiety, BD1-G28-5 single-chain Fv (sFv) is a single-chain immunotoxin targeted to human CD40 and consists of bryodin 1 (BD1), a plant ribosome-inactivating protein that is 20-30-fold less toxic in animals than commonly used toxins, fused to the sFv region of the anti-CD40 monoclonal antibody G28-5, This immunotoxin was expressed in Escherichia coli and purified from refolded inclusion bodies. BD1-G28-5 sFv retained the full protein synthesis inhibition activity of recombinant BD1 and specifically bound to CD40 with a binding affinity, k(d), of 1.5 nM, within 10-fold of the bivalent parental monoclonal antibody, BD1-G28-5 sFv was potently cytotoxic against CD40-expressing B lineage non-Hodgkin's lymphoma and multiple myeloma cell lines, with EC50 values in the ng/ml range, but not against a CD40-negative T cell line, Interestingly, BD1-G28-5 sFv was not cytotoxic against CD40-expressing carcinoma cell lines that were sensitive to a BD1-based immunotoxin conjugate targeted to the Le(y) carbohydrate antigen, These data represent the first report indicating that BD1 can be used in the construction of potent single-chain immunotoxins, Additionally, although BD1-G28-5 sFv effectively killed CD40-expressing hematologic malignancies, its lack of activity against CD40-expressing carcinomas suggests that CD40-mediated trafficking of BD1 differs in the two cancer types.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL IMMUNOL,SEATTLE,WA 98121	Bristol-Myers Squibb								ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARIANSEN S, 1993, BIOCHEMISTRY-US, V32, P83, DOI 10.1021/bi00052a012; BETTER M, 1995, J BIOL CHEM, V270, P14951, DOI 10.1074/jbc.270.25.14951; BRINKMANN U, 1994, BBA-REV CANCER, V1198, P27, DOI 10.1016/0304-419X(94)90004-3; CASELLAS P, 1984, J BIOL CHEM, V259, P9359; COOK JP, 1993, BIOCONJUGATE CHEM, V4, P440, DOI 10.1021/bc00024a005; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Francisco JA, 1997, BLOOD, V89, P4493, DOI 10.1182/blood.V89.12.4493; FRANCISCO JA, 1995, CANCER RES, V55, P3099; Francisco JA, 1996, J IMMUNOL, V157, P1652; FRANKEL AE, 1995, SEMIN CANCER BIOL, V6, P307, DOI 10.1006/scbi.1995.0039; FRIEDMAN PN, 1993, CANCER RES, V53, P334; Gawlak SL, 1997, BIOCHEMISTRY-US, V36, P3095, DOI 10.1021/bi962474+; GROSSBARD ML, 1993, J CLIN ONCOL, V11, P726, DOI 10.1200/JCO.1993.11.4.726; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; HONJO T, 1968, J BIOL CHEM, V243, P3553; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OGRADY JT, 1994, AM J PATHOL, V144, P21; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; Pammer J, 1996, AM J PATHOL, V148, P1387; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; PELLATDECEUNYNCK C, 1994, BLOOD, V84, P2597, DOI 10.1182/blood.V84.8.2597.bloodjournal8482597; PRESS OW, 1991, BIOTHERAPY, V3, P65, DOI 10.1007/BF02175100; Przepiorka D, 1995, BONE MARROW TRANSPL, V16, P737; RAMAKRISHNAN S, 1984, SCIENCE, V223, P58, DOI 10.1126/science.6318313; SIEGALL CB, 1995, DRUG DEVELOP RES, V34, P210, DOI 10.1002/ddr.430340210; SIEGALL CB, 1994, BIOCONJUGATE CHEM, V5, P423, DOI 10.1021/bc00029a008; SIEGALL CB, 1991, BIOCHEMISTRY-US, V30, P7154, DOI 10.1021/bi00243a016; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STIRPE F, 1986, BIOCHEM J, V240, P659, DOI 10.1042/bj2400659; Stone MJ, 1996, BLOOD, V88, P1188, DOI 10.1182/blood.V88.4.1188.bloodjournal8841188; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Thomas WD, 1996, INT J CANCER, V68, P795, DOI 10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; UCKUN FM, 1990, BLOOD, V76, P2449; VITETTA ES, 1991, CANCER RES, V51, P4052	38	25	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24165	24169		10.1074/jbc.272.39.24165	http://dx.doi.org/10.1074/jbc.272.39.24165			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305866	hybrid			2022-12-25	WOS:A1997XY51500017
J	Salinas, M; Duprat, F; Heurteaux, C; Hugnot, JP; Lazdunski, M				Salinas, M; Duprat, F; Heurteaux, C; Hugnot, JP; Lazdunski, M			New modulatory alpha subunits for mammalian Shab K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELAYED-RECTIFIER PROPERTIES; GATED POTASSIUM CHANNELS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; XENOPUS-OOCYTES; MESSENGER-RNA; MOUSE-BRAIN; RAT-BRAIN; CATION CHANNEL; GENE	Two novel K+ channel alpha subunits, named Kv9,1 and Kv9,2, have been cloned, The Kv9,2 gene is situated in the 8q22 region of the chromosome, mRNAs for these two subunits are highly and selectively expressed in the nervous system, High levels of expressions are found in the olfactory bulb, cerebral cortex, hippocampal formation, habenula, basolateral amygdaloid nuclei, and cerebellum, Interestingly Kv9.1 and Kv9,2 colocalized with Kv2,1 and/or Kv2,2 alpha subunits in several regions of the brain, Neither Kv9,1 nor Kv9,2 have K+ channel activity by themselves, but both modulate the activity of Kv2,1 and Kv2,2 channels by changing kinetics and levels of expression and by shifting the half-inactivation potential to more polarized values, This report also analyzes the changes in electrophysiological properties of Kv2 subunits induced by Kv5,1 and Kv6,1, two other modulatory subunits, Each modulatory subunit has its own specific properties of regulation of the functional Kv2 subunits, and they can lead to extensive inhibitions, to large changes in kinetics, and/or to large shifts in the voltage dependencies of the inactivation process, The increasing number of modulatory subunits for Kv2,1 and Kv2,2 provides an amazingly new capacity of functional diversity.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			SALINAS, Miguel/N-6380-2016; HEURTEAUX, Catherine/M-4947-2016; Duprat, Fabrice/D-1221-2013	SALINAS, Miguel/0000-0002-7445-123X; HEURTEAUX, Catherine/0000-0002-9741-9777; Duprat, Fabrice/0000-0001-8774-1220				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATTALI B, 1992, J BIOL CHEM, V267, P8650; ATTALI B, 1993, J BIOL CHEM, V268, P24283; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CHANDY KG, 1995, VOLTAGE GATES K PLUS; Chen ML, 1996, NEURON, V17, P535, DOI 10.1016/S0896-6273(00)80185-3; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; CHRISTIE MJ, 1990, NEURON, V2, P405; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEMIERA EV, 1992, P ROY SOC LOND B BIO, V248, P9, DOI [DOI 10.1098/RSPB.1992.0036, 10.1098/rspb.1992.0036]; DREWE JA, 1992, J NEUROSCI, V12, P538; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEURTEAUX C, 1993, MOL BRAIN RES, V18, P17, DOI 10.1016/0169-328X(93)90169-P; Hille B., 1992, IONIC CHANNELS EXCIT; Hille Bertil, 1994, P75; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; HWANG PM, 1993, NEUROSCIENCE, V55, P613, DOI 10.1016/0306-4522(93)90427-H; HWANG PM, 1992, NEURON, V8, P473, DOI 10.1016/0896-6273(92)90275-I; Jegla T, 1997, J NEUROSCI, V17, P32, DOI 10.1523/JNEUROSCI.17-01-00032.1997; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, EUR J BIOCHEM, V216, P679, DOI 10.1111/j.1432-1033.1993.tb18188.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOPATIN AN, 1993, J PHARMACOL EXP THER, V265, P1011; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; PAK MD, 1991, J NEUROSCI, V11, P869; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; Post MA, 1996, FEBS LETT, V399, P177, DOI 10.1016/S0014-5793(96)01316-6; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SHAHIDULLAH M, 1995, FEBS LETT, V371, P307, DOI 10.1016/0014-5793(95)00928-3; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WILSON GG, 1994, PFLUG ARCH EUR J PHY, V428, P186, DOI 10.1007/BF00374857; Wood S, 1993, Cytogenet Cell Genet, V64, P134; ZHAO B, 1994, NEURON, V13, P1205, DOI 10.1016/0896-6273(94)90058-2	56	163	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24371	24379		10.1074/jbc.272.39.24371	http://dx.doi.org/10.1074/jbc.272.39.24371			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305895	hybrid			2022-12-25	WOS:A1997XY51500046
J	January, B; Seibold, A; Whaley, B; Hipkin, RW; Lin, D; Schonbrunn, A; Barber, R; Clark, RB				January, B; Seibold, A; Whaley, B; Hipkin, RW; Lin, D; Schonbrunn, A; Barber, R; Clark, RB			beta(2)-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DEPENDENT PROTEIN-KINASE; ADENYLATE-CYCLASE; HETEROLOGOUS DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR; S49-LYMPHOMA CELLS; COUPLED RECEPTORS; LYMPHOMA-CELLS; WILD-TYPE; STIMULATION	Previous studies indicated that partial agonists cause less desensitization of the beta(2)-adrenergic receptor (beta AR) than full agonists; however, the molecular basis for this in intact cells has not been investigated, In the present work, we have determined the rates of desensitization, internalization, and phosphorylation caused by a series of beta AR agonists displaying a 95-fold range of coupling efficiencies, These studies were performed with HEK-293 cells overexpressing the beta AR with hemagglutinin and 6-histidine epitopes introduced into the N and C termini, respectively, This modified beta AR behaved identically to the wild type receptor with regard to agonist K-d, coupling efficiency, and desensitization. The coupling efficiencies for beta AR agonist activation of adenylyl cyclase relative to epinephrine (100%) were 4.2% for fenoterol, 4.9% for albuterol, 2.5% for dobutamime, and 1.1% for ephedrine, At concentrations of these agonists yielding >90% receptor occupancy, the rate and extent (0-30 min) of agonist-induced desensitization of beta AR activation of adenylyl cyclase followed the same order as coupling efficiency, i.e. epinephrine greater than or equal to fenoterol > albuterol > dobutamine > ephedrine, The rate of internalization of the beta AR with respect to these agonists also followed the same order as the desensitization and exhibited a slight lag, Like internalization and desensitization, beta AR phosphorylation exhibited a dependence on agonist strength. The two strongest agonists, epinephrine and fenoterol, provoked 11-13-fold increases in the level of beta AR phosphorylation after just 1 min, whereas the weak agonists dobutamine and ephedrine caused only 3-4-fold increases, similar to levels induced by cAMP-dependent protein kinase activation with forskolin. With longer treatment times, the level of beta AR phosphorylation declined with strong agonists, but it progressively increased with the weaker partial agonists, such that after 30 min the -fold elevation with epinephrine (6.2 +/- 0.82) was not appreciably different from ephedrine (5.0 +/- 0.96) and significantly less than that caused by albuterol (10.4 +/- 1.7), In summary, our results demonstrate an excellent proportionality between the agonist strength and agonist-induced desensitization, internalization, and the rapid initial phase of phosphorylation. The data support the hypothesis that increasing agonist-coupling efficiency primarily affects desensitization by increasing the rate of beta ARK phosphorylation of the beta AR.	UNIV TEXAS,SCH MED,DEPT INTEGRAT BIOL PHARMACOL & PHYSIOL,HOUSTON,TX 77225	University of Texas System					NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07710] Funding Source: Medline; NIGMS NIH HHS [GM31208] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; BAROVSKY K, 1980, J CYCLIC NUCL PROT, V6, P297; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEUNG AH, 1988, MOL PHARMACOL, V34, P132; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; Clark RB, 1996, MOL PHARMACOL, V49, P182; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HOYER D, 1984, MOL PHARMACOL, V25, P209; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PROLL MA, 1992, MOL PHARMACOL, V42, P116; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SLOWIEJKO DM, 1994, J NEUROCHEM, V62, P1795; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; SU YF, 1980, J BIOL CHEM, V255, P7410; TOWES ML, 1908, J BIOL CHEM, V259, P2227; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALDO GL, 1983, J BIOL CHEM, V258, P3900; Whaley B. S., 1995, PHARM COMMUN, V6, P203; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; YU SS, 1993, J BIOL CHEM, V268, P337; YUAN NY, 1994, J BIOL CHEM, V269, P23032	38	133	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23871	23879		10.1074/jbc.272.38.23871	http://dx.doi.org/10.1074/jbc.272.38.23871			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295336	hybrid			2022-12-25	WOS:A1997XX38100061
J	Owczarek, CM; Hwang, SY; Holland, KA; Gulluyan, LM; Tavaria, M; Weaver, B; Reich, NC; Kola, I; Hertzog, PJ				Owczarek, CM; Hwang, SY; Holland, KA; Gulluyan, LM; Tavaria, M; Weaver, B; Reich, NC; Kola, I; Hertzog, PJ			Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA RECEPTOR; BINDING; CELLS; EXPRESSION; SUBUNIT; GENE; RESPONSES; SITE	This report describes the cloning of cDNAs encoding transmembrane and soluble isoforms of a novel chain of the murine type I interferon (IFN) receptor and characterization of its capability to bind ligand and transduce signals, The transmembrane receptor (murine IFNAR 2c) has an extracellular domain of 215 amino acids and an intracellular domain of 250 amino acids, with 48% amino acid and 71% nucleotide identity with human IFNAR 2c, The cDNA for the soluble murine receptor (IFNAR 2a) encodes a 221-amino acid polypeptide identical to the first 210 amino acids of IFNAR 2c plus a novel 11 amino acids, Northern blot analyses show that murine IFNAR 2 is expressed as two transcripts of 4 kilobases encoding the transmembrane isoform and 1.5 kilobases encoding the more abundant soluble isoform, Studies using primary murine cells that lack IFNAR 1 show that IFNAR 2 is expressed, and cells bind type I IFN ligand, but do not transduce signals as detected by electrophoretic mobility shift assays of ISGF3 or GAF complexes binding to their cognate oligonucleotides, These cells show no effects on the ability of IFN gamma to activate these complexes, These studies demonstrate that the IFNAR 2 transmembrane (2c) and soluble (2a) isoforms are conserved between the human and mouse and that IFNAR 2c has intrinsic ligand binding activity, but no intrinsic signal transducing activity as measured in this study.	MONASH UNIV, INST REPROD & DEV, MOL GENET & DEV GRP, CLAYTON, VIC 3168, AUSTRALIA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	Monash University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Kola, Ismail/C-5254-2013; Hertzog, Paul J/I-7053-2013; Hertzog, Paul J/G-6734-2013	Hertzog, Paul J/0000-0002-1373-8472; Hertzog, Paul J/0000-0002-1373-8472	NCI NIH HHS [CA50773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050773, R29CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HAMILTON JA, 1996, J IMMUNOL, V156, P2533; HERTZOG PJ, 1991, CLIN IMMUNOL IMMUNOP, V58, P18, DOI 10.1016/0090-1229(91)90145-Z; HERTZOG PJ, 1994, J BIOL CHEM, V269, P14088; Holland KA, 1997, J BIOL CHEM, V272, P21045, DOI 10.1074/jbc.272.34.21045; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Hwang SY, 1996, INT J BIOCHEM CELL B, V28, P911, DOI 10.1016/1357-2725(96)00023-4; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; LUTFALLA G, 1995, EMBO J, V14, P101; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MULLERSMAN JE, 1995, J INTERF CYTOK RES, V15, P815, DOI 10.1089/jir.1995.15.815; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; ROBERTS RM, 1991, SERONO SYMP, P235; RUSSELLHARDE D, 1995, J BIOL CHEM, V270, P26033, DOI 10.1074/jbc.270.44.26033; SOH JM, 1994, J BIOL CHEM, V269, P18102; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERFERON CYTOKIN, V25, P3; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4	29	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23865	23870		10.1074/jbc.272.38.23865	http://dx.doi.org/10.1074/jbc.272.38.23865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295335	hybrid			2022-12-25	WOS:A1997XX38100060
J	Roth, A; Kreienkamp, HJ; Meyerhof, W; Richter, D				Roth, A; Kreienkamp, HJ; Meyerhof, W; Richter, D			Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GASTRIN-RELEASING PEPTIDE; BETA-ADRENERGIC-RECEPTOR; CHOLINERGIC RECEPTORS; PITUITARY-CELLS; ARRESTIN; ENDOCYTOSIS; BINDING; PHOSPHATASE; KINASES	Agonist-dependent internalization of the rat somatostatin receptor subtype 3 (SSTR3) requires four hydroxyl amino acids (Ser(341), Ser(346), Ser(351), and Thr(357)) in the receptor C terminus (Roth, A., Kreienkamp, H.-J., Nehring, R., Roostermann, D., Meyerhof, W. and Richter, D. (1997) DNA Cell Biol. 16, 111-119). Here we report on the molecular mechanism responsible for the endocytotic process by analyzing the agonist-dependent phosphorylation of wild-type and mutant receptors expressed in human embryonic kidney cells, Wild-type SSTR3 is phosphorylated in response to agonist treatment, Phosphorylation is markedly reduced in a S341A/S346A/S351A triple mutant and is also reduced, but to a lesser extent, in the T357A point mutant. Internalization of the wild-type receptor is preceded by a functional desensitization of the receptor; in contrast, the triple serine mutant does not desensitize after treatment with agonists as assayed by its ability to inhibit forskolin-stimulated adenylate cyclase activity, After internalization via a clathrin-coated vesicle mediated endocytotic pathway, SSTR3 efficiently recycles to the cell surface, suggesting that agonist mediated endocytosis is necessary for the functional resensitization of a phosphorylated and desensitized receptor.	UNIV HAMBURG,INST ZELLBIOCHEM & KLIN NEUROBIOL,D-20246 HAMBURG,GERMANY; DEUTSCH INST ERNAHRUNGSFORSCH,ABT MOL GENET,D-14558 POTSDAM,GERMANY	University of Hamburg; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)								BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERELOWITZ M, 1995, ENDOCRINOLOGY, V136, P3695, DOI 10.1210/en.136.9.3695; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HIGUCHI R, 1992, PCR PROTOCOLS GUIDE, P177; HOFLAND LJ, 1995, ENDOCRINOLOGY, V136, P3698, DOI 10.1210/en.136.9.3698; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; John M, 1996, GUT, V38, P33, DOI 10.1136/gut.38.1.33; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; MAYOR F, 1987, J BIOL CHEM, V262, P6468; NEHRING RB, 1995, DNA CELL BIOL, V14, P939, DOI 10.1089/dna.1995.14.939; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; PRESKY DH, 1988, J BIOL CHEM, V263, P714; PRESKY DH, 1986, J CELL BIOL, V102, P878, DOI 10.1083/jcb.102.3.878; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; Roth A., 1996, Society for Neuroscience Abstracts, V22, P1298; YASUDA K, 1992, J BIOL CHEM, V267, P20422; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	31	77	82	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23769	23774		10.1074/jbc.272.38.23769	http://dx.doi.org/10.1074/jbc.272.38.23769			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295322	hybrid			2022-12-25	WOS:A1997XX38100047
J	Wang, ZG; Wu, XH; Friedberg, EC				Wang, ZG; Wu, XH; Friedberg, EC			Molecular mechanism of base excision repair of uracil-containing DNA in yeast cell-free extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASE; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; ESCHERICHIA-COLI; POLYMERASE-BETA; SACCHAROMYCES-CEREVISIAE; BOVINE TESTIS; HOMOLOG; GENE; PURIFICATION; RESIDUES	Base excision repair (BER) constitutes a ubiquitous excision repair mechanism, which is responsible for the removal of multiple types of damaged and inappropriate bases in DNA. We have employed a yeast cell-free system to examine the biochemical mechanism of the BER pathway in lower eukaryotes. Using uracil-containing DNA as a model substrate, we demonstrate that yeast BER requires Apn1 protein, an Escherichia coli endonuclease IV homolog. In extracts of an apn1 deletion mutant, the 5'-incision at AP (apurinic/apyrimidinic) sites is not detectable, supporting the notion that yeast contains only one major 5'-AP endonuclease. The processing of the 5'-deoxyribose phosphate moieties was found to be a rate-limiting step. During BER of uracil-containing DNA, repair patch sizes of 1-5 nucleotides were detected, with single nucleotide repair patches predominant.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,LAB MOL PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, ZG (corresponding author), UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40536, USA.				NATIONAL CANCER INSTITUTE [R55CA067978, R37CA012428, R01CA067978, R01CA012428] Funding Source: NIH RePORTER; NCI NIH HHS [CA67978, CA12428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Budd ME, 1995, METHOD ENZYMOL, V262, P108; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHSON RE, 1995, SCIENCE, V269, P238; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LINDAHL T, 1973, BIOCHEMISTRY-US, V12, P5151, DOI 10.1021/bi00749a020; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Sander M, 1997, BIOCHEMISTRY-US, V36, P6100, DOI 10.1021/bi970048y; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P3694, DOI 10.1021/bi00129a019; Wang Zhigang, 1995, Methods (Orlando), V7, P177, DOI 10.1006/meth.1995.1023	40	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24064	24071		10.1074/jbc.272.38.24064	http://dx.doi.org/10.1074/jbc.272.38.24064			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295360	hybrid			2022-12-25	WOS:A1997XX38100085
J	Gao, EW; Wang, Y; Alcorn, JL; Mendelson, CR				Gao, EW; Wang, Y; Alcorn, JL; Mendelson, CR			The basic helix-loop-helix-zipper transcription factor USF1 regulates expression of the surfactant protein-A gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR USF; MAJOR LATE PROMOTER; BINDING-PROTEINS; DEVELOPMENTAL REGULATION; PULMONARY SURFACTANT; MULTIPLE FORMS; FETAL LUNG; C-MYC; UPSTREAM; ELEMENTS	Expression of the rabbit pulmonary surfactant protein A (SP-A) gene is lung-specific, occurs primarily in type II cells, and is developmentally regulated. We previously identified two E-box-like enhancers, termed the distal binding element (DBE) and proximal binding element (PBE), in the 5'-flanking region of the rabbit SP-A gene. In the present study, the PBE was used to screen a rabbit fetal lung cDNA expression library; a cDNA insert was isolated which is highly similar in sequence to human upstream stimulatory factor 1 (hUSF1). By use of reverse transcription polymerase chain reaction, two isoforms of rabbit USF1 (rUSF1) mRNAs were identified in fetal rabbit lung and other tissues. The levels of rUSF1 mRNAs reach a peak in fetal rabbit lung at 23 days gestation, in concert with the time of initiation of SP-A gene transcription, Binding complexes of nuclear proteins obtained from fetal rabbit lung tissue and isolated type II cells with the DBE and PBE were supershifted by the addition of anti-rUSF1 IgG. Binding activity was enriched in type II cells compared with lung fibroblasts. Overexpression of rUSF1s in A549 adenocarcinoma cells positively regulated SP-A promoter activity of cotransfected reporter gene constructs, It is suggested that rUSF1s, which bind to two E-box elements in the SP-A gene 5'-flanking-region, may serve a key role in the regulation of SP-A gene expression in pulmonary type II cells.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Mendelson, Carole Ruth/0000-0003-1696-9791	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050022] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL50022] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; AUTEN RL, 1990, AM J RESP CELL MOL, V3, P491, DOI 10.1165/ajrcmb/3.5.491; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1988, J BIOL CHEM, V263, P2939; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRESNICK EH, 1994, J BIOL CHEM, V269, P21110; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P937; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GAO E, 1993, J BIOL CHEM, V268, P19697; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; MENDELSON CR, 1993, SEMIN PERINATOL, V17, P223; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MICHAEL LF, 1996, MOL ENDOCRINOL, V10, P8159; Miller J.H., 1972, EXPT MOL GENETICS; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PATERSON JM, 1995, BIOCHEM J, V310, P401, DOI 10.1042/bj3100401; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Rose MD, 1988, LAB COURSE MANUAL ME; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIEH BH, 1993, GENOMICS, V16, P266, DOI 10.1006/geno.1993.1174; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH IS, 1994, MOL ENDOCRINOL, V8, P1163, DOI 10.1210/me.8.9.1163; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082	43	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23398	23406		10.1074/jbc.272.37.23398	http://dx.doi.org/10.1074/jbc.272.37.23398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287355	hybrid			2022-12-25	WOS:A1997XV74400066
J	You, M; Zhao, ZZ				You, M; Zhao, ZZ			Positive effects of SH2 domain-containing tyrosine phosphatase SHP-1 on epidermal growth factor- and interferon-gamma-stimulated activation of STAT transcription factors in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; GENE-EXPRESSION; PHOSPHORYLATION; KINASE; PTP1C; PATHWAY; FAMILY; DEPHOSPHORYLATION; ASSOCIATION	SHP-1 (also known as PTP1C, SHPTP-1, SHP, and HCP) is an SH2 domain-containing protein-tyrosine phosphatase. We have stably overexpressed the native form and a catalytically inactive cysteine to serine mutant of the enzyme, SHP-1-(Cys --> Ser), in human cervical carcinoma HeLa cells, Following stimulation of the cells with epidermal growth factor (EGF) and interferon-gamma (INF-gamma), signal transducers and activators of transcription (STAT) activity was analyzed by using two P-32-labeled DNA probes, namely hSIE which is derived from a high affinity mutant form of the serum-inducible element in the c-fos promotor and GAS which resembles the INF-gamma activation site, EGF induced hSIE binding activity only, and the activity was suppressed by similar to 70% when the inactive mutant. form of SHP-1 was expressed but was essentially unaffected by expression of the native enzyme. INF-gamma treatment resulted in appearance of both hSIE and GAS binding activities. While expression of the inactive mutant reduced the activities by 30-50%, the native enzyme caused a 20-30% increase. Consistent with effects on STAT activation, altered SHP-1 expression also affected EGF-induced activation of the mitogen-activated protein kinase pathway; expression of SHP-1-(Cys --> Ser) inhibited activity of MEK by similar to 25%, whereas expression of SHP-1 resulted in a similar to 25% increase. Further studies revealed that overexpression of SHP-1 caused decreased tyrosine phosphorylation of the EGF receptor and that EGF induced phosphorylation and recruitment of SHP-1. Together, the data suggest that SHP-1 is positively involved in EGF-and INF-gamma-induced STAT activation in non-hematopoietic HeLa cells and that, in the EGF signaling system, SHP-1 functions at least partly by modulating tyrosine phosphorylation of EGF receptor.	VANDERBILT UNIV,DEPT VET AFFAIRS MED CTR,DEPT MED,DIV HEMATOL,NASHVILLE,TN 37232	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University			You, Min/I-4973-2012	You, Min/0000-0003-1977-3479				Adachi M, 1996, CELL, V85, P15; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO Z, 1995, ADV PROT PHOSPHATASE, V9, P297; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23376	23381		10.1074/jbc.272.37.23376	http://dx.doi.org/10.1074/jbc.272.37.23376			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287352	hybrid			2022-12-25	WOS:A1997XV74400063
J	Chen, PQ; Mayne, M; Power, C; Nath, A				Chen, PQ; Mayne, M; Power, C; Nath, A			The Tat protein of HIV-1 induces tumor necrosis factor-alpha production - Implications for HIV-1-associated neurological diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMARY HUMAN ASTROCYTES; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; INCREASED EXPRESSION; GENE-EXPRESSION; CELL-ADHESION; BASIC DOMAIN; GLIAL-CELLS; TNF-ALPHA	Human immunodeficiency virus (HIV) infection may cause a dementing illness. HIV-mediated dementia is clinically and pathologically correlated with the infiltration of activated macrophages and elevated levels of tumor necrosis factor (TNF)-alpha, both of which occur in an environment of small numbers of infected cells. We examined the possibility that HIV protein Tat, which is released extracellularly from infected cells, may induce the production of TNF-alpha. Tat induced TNF-alpha mRNA and protein production dose-dependently, primarily in macrophages but also in astrocytic cells. The TNF-alpha induction was NF-kappa B-dependent and could be eliminated by inhibiting protein kinase A or protein tyrosine kinase activity. In addition, Tat-induced TNF-alpha release was also linked to phospholipase C activation. However, Tat effects were independent of protein kinase C. These observations suggest that Tat may provide an important link between HIV and macrophage/glial cell activation and suggest new therapeutic approaches for HIV dementia.	UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,DEPT MED,NEUROL SECT,WINNIPEG,MB R3E 0W3,CANADA	University of Manitoba; University of Manitoba			Power, Christopher/C-7181-2013	Power, Christopher/0000-0002-5131-9711				ALOISI F, 1992, J IMMUNOL, V149, P3379; Battey, 1986, BASIC METHODS MOL BI; Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; BRISCOE DM, 1992, J IMMUNOL, V149, P2954; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHENG J, 1997, IN PRESS NEUROSCI; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; FURER M, 1993, CELL ADHES COMMUN, V1, P223, DOI 10.3109/15419069309097256; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; Han X, 1996, EUR J CLIN INVEST, V26, P286, DOI 10.1046/j.1365-2362.1996.116271.x; JOVELIN F, 1995, BIOTECHNIQUES, V19, P378; Lafortune L, 1996, J NEUROPATH EXP NEUR, V55, P515, DOI 10.1097/00005072-199605000-00003; LOCARDI C, 1990, J VIROL, V64, P5874, DOI 10.1128/JVI.64.12.5874-5882.1990; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MATHEW TC, 1990, DEV BIOL, V141, P84, DOI 10.1016/0012-1606(90)90103-P; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; NATH A, 1989, ARCH VIROL, V107, P159, DOI 10.1007/BF01313888; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; Power C, 1995, CURR TOP MICROBIOL, V202, P89; RENIER G, 1994, J LIPID RES, V35, P1413; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SIPPY BD, 1995, J ACQ IMMUN DEF SYND, V10, P511; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; VIKTOVIC L, 1994, HIV AIDS BRAIN, P203; VITKOVIC L, 1990, J NEUROIMMUNOL, V30, P153, DOI 10.1016/0165-5728(90)90099-9; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WILT SG, 1995, ANN NEUROL, V37, P381, DOI 10.1002/ana.410370315; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	44	190	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22385	22388		10.1074/jbc.272.36.22385	http://dx.doi.org/10.1074/jbc.272.36.22385			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278385	hybrid			2022-12-25	WOS:A1997XV49200004
J	Hammell, RL; HitchcockDeGregori, SE				Hammell, RL; HitchcockDeGregori, SE			The sequence of the alternatively spliced sixth exon of alpha-tropomyosin is critical for cooperative actin binding but not for interaction with troponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE THIN FILAMENT; LABELED TROPOMYOSIN; FUNCTIONAL DOMAINS; CROSS-LINKING; F-ACTIN; FLUORESCENCE; FRAGMENTS; SURFACE; SITES; MUTAGENESIS	Tropomyosins, a family of highly conserved coiled-coil actin binding proteins, can differ as a consequence of alternative expression of several exons (Lees-Miller, J., and Helfman, D. (1991) BioEssays 13, 429-457). Exon 6, which encodes residues 189-213 in long, 284-residue tropomyosins, has two alternative forms, exon 6a or 6b, both highly conserved throughout evolution, In alpha-tropomyosin, exon 6a or 6b is not specific to any one of the nine isoforms, Exon 6b encodes part of a putative Ca2+-sensitive troponin binding site in striated muscle tropomyosins, suggesting that the exon 6-encoded region may be specialized for certain tropomyosin functions, A series of recombinant, unacetylated , tropomyosin exon 6 deletion and substitution mutants and chimeras was expressed in Escherichia coli to determine the requirements of exon 6 for tropomyosin function, Functional properties of the tropomyosins were defined by actin affinity measured by cosedimentation, troponin T affinity using a newly developed biosensor assay, and regulation of the actomyosin MgATPase. The region of tropomyosin encoded by exon 6 affects actin affinity but not thin filament assembly, troponin T binding, or regulation with troponin, The tropomyosins with exon 6a or 6b function normally whether a striated muscle exon 9a or smooth/non-muscle exon 9d is present, However, the effect of deleting 21 amino acids encoded by exon 6 or replacing it with a GCN4 leucine zipper sequence depends on the COOH-terminal sequence.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT CELL BIOL & NEUROSCI,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [HL35726] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CARR HJ, 1988, J MUSCLE RES CELL M, V9, P384, DOI 10.1007/BF01774065; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CHONG PCS, 1982, J BIOL CHEM, V257, P9152; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; GREENFIELD NJ, 1995, BIOCHEMISTRY-US, V34, P10797; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HAMMELL RL, 1993, MOL BIOL CELL, V4, pS259; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HitchcockDeGregori SE, 1996, J BIOL CHEM, V271, P3600; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P2573; HITCHCOCKDEGREGORI SE, 1988, ARCH BIOCHEM BIOPHYS, V264, P410, DOI 10.1016/0003-9861(88)90306-2; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; Jonsson U., 1992, ADV BIOSENSOR, P291; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMKIN M, 1983, BIOCHEMISTRY-US, V22, P3053, DOI 10.1021/bi00282a005; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; OBRIEN EJ, 1971, PHILOS T ROY SOC B, V261, P201, DOI 10.1098/rstb.1971.0051; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUCK P, 1996, TRENDS BIOCHEM SCI, V21, P458; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZCZESNA D, 1995, BIOCHEMISTRY-US, V34, P3614, DOI 10.1021/bi00011a016; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; UENO H, 1978, J BIOCHEM-TOKYO, V84, P1009, DOI 10.1093/oxfordjournals.jbchem.a132182; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; WATSON MH, 1990, J BIOL CHEM, V265, P18860; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; YANG YZ, 1979, J BIOL CHEM, V254, P7137; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	55	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22409	22416		10.1074/jbc.272.36.22409	http://dx.doi.org/10.1074/jbc.272.36.22409			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278391	hybrid			2022-12-25	WOS:A1997XV49200010
J	Itoh, T; Ikeda, T; Gomi, H; Nakao, S; Suzuki, T; Itohara, S				Itoh, T; Ikeda, T; Gomi, H; Nakao, S; Suzuki, T; Itohara, S			Unaltered secretion of beta-amyloid precursor protein in gelatinase a (matrix metalloproteinase 2)-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; NEXIN-II; CELLS; RAT; LOCALIZATION; SURFACE; DOMAIN; BRAIN; GENE	The beta-amyloid peptide, which forms extracellular cerebral deposits in Alzheimer's disease, is derived from a large membrane-spanning glycoprotein referred to as the beta-amyloid precursor protein (APP). The APP is normally cleaved within the beta-amyloid region by a putative proteinase (alpha-secretase) to generate large soluble amino-terminal derivatives of APP, and this event pre vents the beta-amyloid peptide formation. It has been suggested that the gelatinase A (matrix metalloproteinase 2, a 72-kDa type IV collagenase) may act either as alpha-secretase or as beta-secretase. Mice devoid of gelatinase A generated by gene targeting develop normally, except for a subtle delay in their growth, thus providing a useful system to examine the role of gelatinase A in the cleavage and secretion of APP in vivo. We show here that APP is cleaved within the beta-amyloid region and secreted into the extracellular milieu of brain and cultured fibroblasts without gelatinase A activity. The data suggest that gelatinase A does not play an essential role in the generation and release of soluble derivatives of APP at physiological conditions.	KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; University of Tokyo			Itohara, Shigeyoshi/I-8769-2012; Suzuki, Toshiharu/B-5342-2013	Itohara, Shigeyoshi/0000-0002-2410-9989; 				ARAKI W, 1994, NEUROSCI LETT, V167, P125, DOI 10.1016/0304-3940(94)91043-X; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HILBICH C, 1993, J BIOL CHEM, V268, P26571; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATO Y, 1992, J BIOL CHEM, V267, P11424; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; LePage RN, 1995, FEBS LETT, V377, P267, DOI 10.1016/0014-5793(95)01358-X; LOFFLER J, 1992, J NEUROCHEM, V59, P1316, DOI 10.1111/j.1471-4159.1992.tb08443.x; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MIYAZAKI K, 1994, NATURE, V368, P695, DOI 10.1038/368695b0; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1757; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; VANNOSTRAND WE, 1989, NATURE, V341, P546; WALSH DM, 1994, NATURE, V367, P27, DOI 10.1038/367027a0; XIE B, 1994, J IMMUNOL, V152, P3637; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAMADA T, 1995, ACTA NEUROPATHOL, V89, P199	24	297	303	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22389	22392		10.1074/jbc.272.36.22389	http://dx.doi.org/10.1074/jbc.272.36.22389			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278386	hybrid			2022-12-25	WOS:A1997XV49200005
J	Nadal, F; LevyToledano, S; Grelac, F; Caen, JP; Rosa, JP; Bryckaert, M				Nadal, F; LevyToledano, S; Grelac, F; Caen, JP; Rosa, JP; Bryckaert, M			Negative regulation of mitogen-activated protein kinase activation by integrin alpha(IIb)beta(3) in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; MAP KINASE; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; PHORBOL ESTER; PHOSPHATASE; CELLS; THROMBASTHENIA; RECEPTORS	Activation of the mitogen-activated protein (MAP) kinase pathway in nucleated cells is dependent on both growth factor receptors and integrins engaged in cell adhesion, Human platelets are an interesting model for studying cell adhesion and the involvement of integrin engagement on extracellular signal-regulated kinase (ERK) activation, independently from the nuclear-DNA signal pathway, Maximal phosphorylation and activity of ERK2 occurred late during thrombin-induced platelet aggregation (90 s and later), an alpha(IIb)beta(3) integrin-dependent event, Surprisingly, alpha(IIb)beta(3) inhibition by the RGDS ligand peptide, or (Fab')(2) fragments of the AP-2 monoclonal antibody, resulted in a a-fold enhancement in ERK2 phosphorylation and activity. A similar 2-fold enhancement of ERK2 activation was observed in thrombasthenic platelets which are defective in alpha(IIb)beta(3) and do not aggregate, This suggests that ERK2 activation in thrombin-induced platelet aggregation is dependent on thrombin rather than on alpha(IIb)beta(3) and is down-regulated by alpha(IIb)beta(3) engaged in ligand (fibrinogen) binding and/or aggregation, Finally, in the absence of stirring which allows fibrinogen binding to alpha(IIb)beta(3) but prevents aggregation, ERK2 was again overactivated. This overactivation appears to be consecutive to inhibition of aggregation itself and to alpha(IIb)beta(3) ligand binding, We conclude that in platelets, alpha(IIb)beta(3) engaged in aggregation down-regulates thrombin-induced ERK2 activation, To our knowledge, this is the first report of a down-regulation of the MAP kinase pathway by integrin engagement.	HOP LARIBOISIERE,U348 INSERM,IFR CIRCULAT LARIBOISIERE,F-75475 PARIS 10,FRANCE; HOP LARIBOISIERE,IVS,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite			ROSA, JEAN-PHILIPPE/B-6245-2018	ROSA, JEAN-PHILIPPE/0000-0001-7342-0389; Bryckaert, Marijke/0000-0003-3398-0976				Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; ASHWORTH A, 1992, ONCOGENE, V7, P2555; Berrou E, 1996, BIOCHEM J, V316, P167, DOI 10.1042/bj3160167; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DJAFFAR I, 1993, HUM MOL GENET, V2, P2183, DOI 10.1093/hmg/2.12.2183; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENORMAND P, 1993, ADV SEC MESS PHOSPH, V28, P237; Li RY, 1997, THROMB HAEMOSTASIS, V77, P150; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PIDARD D, 1983, J BIOL CHEM, V258, P2582; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Toyoda H, 1996, THROMB HAEMOSTASIS, V76, P1053; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WHITE GC, 1995, THROMB HAEMOSTASIS, V73, P995; WILLIAMS MJ, 1995, SEMIN CELL BIOL, V6, P305, DOI 10.1006/scel.1995.0040; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22381	22384		10.1074/jbc.272.36.22381	http://dx.doi.org/10.1074/jbc.272.36.22381			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278384	hybrid			2022-12-25	WOS:A1997XV49200003
J	Rumbaugh, JA; Murante, RS; Shi, S; Bambara, RA				Rumbaugh, JA; Murante, RS; Shi, S; Bambara, RA			Creation and removal of embedded ribonucleotides in chromosomal DNA during mammalian Okazaki fragment processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-SPECIFIC ENDONUCLEASE; BLOOMS SYNDROME CELLS; CALF RTH-1 NUCLEASE; LIGASE-I; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; REPLICATION; REPAIR	Mammalian RNase HI has been shown to specifically cleave the initiator RNA of Okazaki fragments at the RNA-DNA junction, leaving a single ribonucleotide attached to the 5'-end of the downstream DNA segment, This monoribonucleotide can then be removed by the mammalian 5'- to 3'-exo-/endonuclease, a RAD2 homolog-1 (RTH-1) class nuclease, also known as flap endonuclease-l (FEN-1), Although FEN-1/RTH-1 nuclease often requires an upstream primer for efficient activity, the presence of an upstream primer is usually inhibitory or neutral for removal of this 5'-monoribonucleotide. Using model Okazaki fragment substrates, we found that DNA ligase I can seal a 5'-monoribonucleotide into DNA. When both ligase and FEN-1/RTH-1 were present simultaneously, some of the 5'-monoribonucleotides were ligated into DNA, while others were released, Thus, a 5'-monoribonucleotide, particularly one that is made resistant to FEN-1/RTH-1-directed cleavage by extension of an inhibitory upstream primer, can be ligated into the chromosome, despite the presence of FEN-1/RTH-1 nuclease, DNA ligase I was able to seal different monoribonucleotides into the DNA for all substrates tested, with an efficiency of 1-13% that of ligating DNA, These embedded monoribonucleotides can be removed by the combined action of RNase HI, cutting on the 5'-side, and FEN-1/RTR-1 nuclease, cleaving on the 3'-side. After FEN-1/RTH-1 action and extension by polymerization, DNA ligase I can join the entirely DNA strands to complete repair.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007356, R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM24441, T32GM07356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1977, BIOCHEMISTRY-US, V16, P4990, DOI 10.1021/bi00642a009; ARRAND JE, 1986, J BIOL CHEM, V261, P9079; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CHAN JYH, 1988, J BIOL CHEM, V263, P18231; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; EDER PS, 1991, J BIOL CHEM, V266, P6472; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P668; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; HUSAIN I, 1995, J BIOL CHEM, V270, P9683, DOI 10.1074/jbc.270.16.9683; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JOHNSTON LH, 1978, NATURE, V274, P891, DOI 10.1038/274891a0; KAUFMANN G, 1977, J MOL BIOL, V116, P549, DOI 10.1016/0022-2836(77)90083-3; Komberg A., 1992, DNA REPLICATION, P307; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LASKO DD, 1990, MUTAT RES, V236, P277, DOI 10.1016/0921-8777(90)90011-S; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LI CJ, 1993, J CELL BIOCHEM, V53, P405, DOI 10.1002/jcb.240530418; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; MALKAS LH, 1990, BIOCHEMISTRY-US, V29, P6362, DOI 10.1021/bi00479a004; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; ROBERTS E, 1994, J BIOL CHEM, V269, P3789; Sambrook J., 2002, MOL CLONING LAB MANU; SODERHALL S, 1975, J BIOL CHEM, V250, P8438; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21726; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; WILLIS AE, 1987, P NATL ACAD SCI USA, V84, P8016, DOI 10.1073/pnas.84.22.8016; YAMAMOTO KF, 1987, CELL TISSUE KINET, V20, P69	52	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22591	22599		10.1074/jbc.272.36.22591	http://dx.doi.org/10.1074/jbc.272.36.22591			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278414	hybrid			2022-12-25	WOS:A1997XV49200034
J	Montero, M; Barrero, MJ; Alvarez, J				Montero, M; Barrero, MJ; Alvarez, J			[Ca2+] microdomains control agonist-induced Ca2+ release in intact HeLa cells	FASEB JOURNAL			English	Article						endoplasmic reticulum; recombinant aequorin; inositol 1,4,5-trisphosphate receptor	ENDOPLASMIC-RETICULUM; INTRACELLULAR STORES; INOSITOL TRISPHOSPHATE; FLUORESCENT INDICATOR; CELLULAR CALCIUM; AEQUORIN; OSCILLATIONS; MOBILIZATION; DEPENDENCE; RECEPTORS	We have monitored specifically the [Ca2+] in the lumen of the endoplasmic reticulum (ER) of intact HeLa cells using-an ER-targeted low Ca2+-affinity aequorin. The steady-state [Ca2+] in the ER was around 600 mu M Histamine induced a concentration-dependent decrease in lumenal [Ca2+], whose rate increased near one order of magnitude and became ''quantal'' when cytosolic [Ca2+] ([Ca2+](c)) was clamped with the Ca2+ chelator BAPTA. This effect was not due to decreased Ca2+ pumping because simultaneous addition of a SERCA inhibitor produced only additive effects, Given that inhibition by [Ca2+](c) of the inositol 1,4,5-trisphosphate-gated channels requires a [Ca2+](c) much higher than that observed in the bulk cytosol after histamine addition, we conclude that local [Ca2+](c) microdomains at the site of release strongly inhibit agonist-induced Ca2+ mobilization in intact cells, This effect should play a key role in the mechanism controlling cytosolic [Ca2+] oscillations and waves, and therefore in the generation of spatio-temporal Ca2+ patterns.	UNIV VALLADOLID, FAC MED, DEPT BIOQUIM & FISIOL, IBGM, E-47002 VALLADOLID, SPAIN; CSIC, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC)			Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN M, 1994, CURR BIOL, V4, P169, DOI 10.1016/S0960-9822(94)00041-2; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; CHATTON JY, 1995, FEBS LETT, V368, P165, DOI 10.1016/0014-5793(95)00632-J; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; HANNAERTMERAH Z, 1995, CELL CALCIUM, V18, P390, DOI 10.1016/0143-4160(95)90054-3; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kendall JM, 1996, BIOCHEM J, V318, P383, DOI 10.1042/bj3180383; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MUALLEM S, 1989, J BIOL CHEM, V264, P205; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; SHIMOMURA O, 1993, CELL CALCIUM, V14, P373, DOI 10.1016/0143-4160(93)90041-4; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; VILLALOBOS C, 1995, FASEB J, V9, P815, DOI 10.1096/fasebj.9.9.7601345	32	65	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1997	11	11					881	885		10.1096/fasebj.11.11.9285486	http://dx.doi.org/10.1096/fasebj.11.11.9285486			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285486				2022-12-25	WOS:A1997XT79000007
J	Smith, RA; Mosesson, MW; Rooney, MM; Lord, ST; Daniels, AU; Gartner, TK				Smith, RA; Mosesson, MW; Rooney, MM; Lord, ST; Daniels, AU; Gartner, TK			The role of putative fibrinogen A alpha-, B beta-, and gamma A-chain integrin binding sites in endothelial cell-mediated clot retraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; MONOCLONAL-ANTIBODY; RECOMBINANT FIBRINOGEN; ADHESION; AGGREGATION; CLEAVAGE; IIIA; FIBRONECTIN; TERMINUS; SEQUENCE	In this study, endothelial cell-mediated clot retraction was supported by fibrin generated from several purified fractions of plasma fibrinogen, purified proteolytic fragments of plasma fibrinogen, recombinant normal fibrinogen, and recombinant variant fibrinogen, These results were surprising because some of these fibrinogens lack domains that are known binding sites for the integrin receptors that support clot retraction. Specifically, fibrinogens lacking A alpha-chain RGD residues at 572-574 or lacking the gamma-chain residues AGDV 408-411 supported endothelial cell-mediated clot retraction as well as intact fibrinogen, Thus, clot retraction mediated by endothelial cells is not dependent on either of these sites, A variety of monoclonal antibodies against the integrin alpha(v) beta(3) partially inhibited the endothelial cell-mediated retraction of clots formed from plasma fibrinogen, As expected, an antibody to the platelet integrin alpha(IIb)beta(3) did not inhibit endothelial cell-mediated clot retraction. These results indicate that this retraction is mediated at least in part by alpha(v) beta(3). These results support the conclusion that (a) neither of the two fibrinogen cell binding sites described above is required to support clot retraction or that (b) either site alone or in conjunction with other fibrin(ogen) region(s) can support clot retraction, Thus, endothelial cell-mediated clot retraction appears to be dependent on fibrinogen cell binding sites other than those required to support adhesion of resting platelets to immobilized fibrinogen and platelet aggregation.	UNIV MEMPHIS,DEPT MICROBIOL & MOL CELL SCI,MEMPHIS,TN 38152; UNIV WISCONSIN,SCH MED,DEPT MED,SINAI SAMARITAN MED CTR,MILWAUKEE,WI 53233; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599	University of Memphis; University of Wisconsin System; University of Wisconsin Milwaukee; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Smith, RA (corresponding author), UNIV TENNESSEE,CAMPBELL CLIN,DEPT ORTHOPAED SURG,956 COURT AVE,ROOM A302,MEMPHIS,TN 38163, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL056369] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56369] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alemany M, 1996, BLOOD, V87, P592, DOI 10.1182/blood.V87.2.592.bloodjournal872592; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BUNCE LA, 1992, J CLIN INVEST, V89, P842, DOI 10.1172/JCI115663; CARR ME, 1995, THROMB HAEMOSTASIS, V73, P499; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DECLERCK R, 1975, BRIT J HAEMATOL, V29, P341; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FRANCIS CW, 1993, BLOOD CELLS, V19, P291; GARTNER TK, 1988, THROMB RES, V49, P43; GARTNER TK, 1993, THROMB RES, V71, P47; GARTNER TK, 1994, BLOOD COAGUL FIBRIN, V5, P747, DOI 10.1097/00001721-199410000-00011; HANTGAN RR, 1988, BIOCHIM BIOPHYS ACTA, V968, P36, DOI 10.1016/0167-4889(88)90041-9; HETTASCH JM, 1992, THROMB HAEMOSTASIS, V68, P701; Holmback K, 1996, EMBO J, V15, P5760, DOI 10.1002/j.1460-2075.1996.tb00962.x; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; MOSESSON MW, 1963, J LAB CLIN MED, V62, P663; NEWMAN PJ, 1985, BLOOD, V65, P227; PANDY BV, 1991, BIOCHEMISTRY-US, V30, P162, DOI 10.1021/bi00215a024; PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010; PANDYA BV, 1985, J BIOL CHEM, V260, P2994; PONCZ M, 1987, J BIOL CHEM, V262, P8476; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAUBENFELD SM, 1995, THROMB HAEMOSTASIS, V74, P923; TUAN TL, 1989, J CELL PHYSIOL, V140, P577, DOI 10.1002/jcp.1041400324; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967	38	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22080	22085		10.1074/jbc.272.35.22080	http://dx.doi.org/10.1074/jbc.272.35.22080			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268349	Green Published, hybrid			2022-12-25	WOS:A1997XT85000061
J	Ponten, F; Berg, C; Ahmadian, A; Ren, ZP; Nister, M; Lundeberg, J; Uhlen, M; Ponten, J				Ponten, F; Berg, C; Ahmadian, A; Ren, ZP; Nister, M; Lundeberg, J; Uhlen, M; Ponten, J			Molecular pathology in basal cell cancer with p53 as a genetic marker	ONCOGENE			English	Article						p53; BCC; mutation; LOH; heterogeneity; clonality	SKIN-CANCER; MUTATIONS; CARCINOMA; SUNLIGHT; EXPOSURE; PATTERN	Human basal cell cancer (BCC) has unique growth characteristics with virtual inability to metastasize, We investigated clonality and genetic progression using p53 mutations as marker. Sampling was done through microdissection of frozen immunohistochemically stained 16 mu m slices of tumors. From 11 BCC tumors 78 samples were analysed. Direct DIVA sequencing of exons 5-8 was performed, haplotypes were determined after cloning of p53 exons and loss of heterozygosity (LOH) ascertained by microsatellite analysis, All tumors had p53 mutations and in a majority both p53 alleles were affected, commonly through missense mutations. Microdissection of small parts (50-100 cells) of individual tumors showed BCC to be composed of a dominant cell clone and prone to genetic progression with appearance of subclones with a second and even third p53 mutation, Samples from normal immunohistochemically negative epidermis always showed wild type sequence, except for a case of previously unknown germline p53 mutation. Our analysis also included p53 immunoreactive patches i.e. morphologically normal epidermis with a compact pattern of p53 immunoreactivity. Mutations within those were never the same as in the adjacent BCC. This detailed study of only one gene thus uncovered a remarkable heterogeneity within a tumor category famous for its benign clinical behavior.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,KTH,S-10044 STOCKHOLM,SWEDEN	Royal Institute of Technology	Ponten, F (corresponding author), UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.		Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016; Williams, Cecilia/A-6677-2009	Uhlen, Mathias/0000-0002-4858-8056; Williams, Cecilia/0000-0002-0602-2062				BERG C, 1995, CLIN CHEM, V41, P1461; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DIFFEY BL, 1979, PHYS MED BIOL, V24, P931, DOI 10.1088/0031-9155/24/5/006; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUTREAL PA, 1992, CANCER RES, V52, P2624; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARRIS CC, 1995, ANN S BIOL SKIN, V1, P115; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; IMAYAMA S, 1987, AM J PATHOL, V128, P497; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KANJILAL S, 1995, CANCER RES, V55, P3604; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRESS S, 1992, CANCER RES, V52, P6400; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; KUBO Y, 1994, J INVEST DERMATOL, V102, P440, DOI 10.1111/1523-1747.ep12373002; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MADSEN A, 1965, ACTA PATHOL MICROB S, V177, P9; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; PONTEN F, 1994, J INVEST DERMATOL, V102, P304, DOI 10.1111/1523-1747.ep12371787; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; RADY P, 1992, CANCER RES, V52, P3804; Ren ZP, 1996, ONCOGENE, V12, P765; REN ZP, 1996, INT J CANCER, V66, P174; REN ZP, 1996, ROLE MUTATIONS P52 G; RUTHER U, 1982, NUCLEIC ACIDS RES, V10, P5765, DOI 10.1093/nar/10.19.5765; VANSCOTT EJV, 1982, J INVEST DERMATOL, V36, P109; VONDOMARUS H, 1984, J AM ACAD DERMATOL, V10, P1043; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	36	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1059	1067		10.1038/sj.onc.1201435	http://dx.doi.org/10.1038/sj.onc.1201435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285560				2022-12-25	WOS:A1997XT16100007
J	Finco, TS; Westwick, JK; Norris, JL; Beg, AA; Der, CJ; Baldwin, AS				Finco, TS; Westwick, JK; Norris, JL; Beg, AA; Der, CJ; Baldwin, AS			Oncogenic Ha-Ras-induced signaling activates NF-kappa B transcriptional activity, which is required for cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE INHIBITION; KINASE ACTIVATION; INDUCED APOPTOSIS; PROTEIN-KINASES; GENE-EXPRESSION; DNA-BINDING; C-JUN; ALPHA; PHOSPHORYLATION; INDUCTION	Ras proteins function in stimulating cell proliferation and differentiation through the activation of Raf-dependent and Raf independent signal transduction pathways and the subsequent activation of specific transcription factors, The transcription factor NF-kappa B has been widely studied as a regulator of genes involved in immune and inflammatory responses, A variety of stimuli activate NF-kappa B through the induced phosphorylation and degradation of the inhibitor I kappa B followed by nuclear translocation of NF-kappa B. We show here that oncogenic forms of Ha-Ras activate NF-kappa B, not through induced nuclear translocation, but rather through the activation of the transcriptional function of the NF-kappa B RelA/p65 subunit, Importantly, RelA/p65 -/- cells are inefficient in the activation of kappa B-dependent gene expression in response to oncogenic Ras expression, Furthermore, I kappa B alpha expression blocks focus formation in NIH3T3 cells induced by oncogenic Ras, These results demonstrate that NF-kappa B is a critical downstream mediator of Ha-Ras signaling and oncogenic potential.	UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Columbia University				Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA069577, R01CA072771] Funding Source: NIH RePORTER; NCI NIH HHS [CA69577, CA72771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OLSEN MF, 1995, SCIENCE, V269, P1270; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; ZHANG JD, 1994, ONCOGENE, V9, P1931	38	320	326	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24113	24116		10.1074/jbc.272.39.24113	http://dx.doi.org/10.1074/jbc.272.39.24113			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305854	Green Published, hybrid			2022-12-25	WOS:A1997XY51500005
J	Hristova, K; Selsted, ME; White, SH				Hristova, K; Selsted, ME; White, SH			Critical role of lipid composition in membrane permeabilization by rabbit neutrophil defensins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE CONTENTS; ANTIMICROBIAL PEPTIDES; GRANULOCYTE PEPTIDES; CANDIDA-ALBICANS; FUSION; BILAYERS; MECHANISM; PHOSPHATIDYLETHANOLAMINE; EXTRUSION; KINETICS	We have examined the interactions of the six known rabbit neutrophil defensin antimicrobial peptides with large unilamellar vesicles (LW) made from various lipid mixtures based an the lipid composition of Escherichia coli membranes. We find that the permeabilization of LUV made from E. coli whole lipid extracts differs dramatically from that of single-component LUV made from palmitoyl-oleoyl-phosphatidylglcerol (POPG). Specifically, defensins NP-1, NP-2, NP-3A, NP-3B, and a natural mixture of the six defensins cause fast nonpreferential leakage of high molecular weight dextrans as well as the low molecular weight fluorophore/ quencher pair 8-aminonapthalene-1,3,6 trisulfonic acid (ANTS)/p-xylene-bis-pyridium bromide (DPX) from E. coli whole lipid LUV through large, transient membrane lesions. In contrast, release of ANTS/DPX form POPG LUV induced by the defensins is slow and graded with preference for DPX (Hristova, K., Selstad, M. E., and White, S. H. (1996) Biochemistty 35, 11888-11894). Interestingly, defensins NP-4 and NP-5 alone do not induce leakage from E. Coli whole lipid LUV, whereas only NP-4 is ineffective with POPG LW, Examination of She sequences of the six defensins suggests that the inactivity of NP-4 and NP-5 may be due to their lower net positive charge and/or the substitution of a Thr for the Arg or Lys that follows the fourth Cys residue. We found the presence of three major lipid components of E. coli whole lipid to be essential for creation of the large lesions observed in LUV: phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin, Cardiolipin appears to play a key role because no leakage can be induced when only phosphatidylglycerol, and phosphatidylethanolamine are present. These results indicate the importance of membrane lipid composition in the permeabilization of cell membranes by rabbit defensins.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT PATHOL,IRVINE,CA 92697	University of California System; University of California Irvine; University of California System; University of California Irvine			White, Stephen H/B-1053-2009; Abrams, William R/A-5782-2008; White, Stephen/N-1507-2019	White, Stephen H/0000-0001-8540-7907; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031696, R37AI022931, R01AI022931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046823] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31696, AI-22931] Funding Source: Medline; NIGMS NIH HHS [GM-46823] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; BACH AC, 1987, BIOCHEMISTRY-US, V26, P4389, DOI 10.1021/bi00388a030; BATENBURG AM, 1987, BIOCHIM BIOPHYS ACTA, V903, P142, DOI 10.1016/0005-2736(87)90164-7; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; ELLENS H, 1984, BIOCHEMISTRY-US, V23, P1532, DOI 10.1021/bi00302a029; FUJII G, 1993, PROTEIN SCI, V2, P1301, DOI 10.1002/pro.5560020813; GANZ T, 1990, EUR J HAEMATOL, V44, P1; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; Jost W., 1960, DIFFUSION SOLIDS LIQ; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KANEMASA Y, 1967, BIOCHIM BIOPHYS ACTA, V144, P382; KANEMASA Y, 1971, ACTA MED OKAYAMA, V25, P255; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; Ladokhin AS, 1997, METHOD ENZYMOL, V278, P474; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; Ladokhin AS, 1995, BIOPHYS J, V69, P1964, DOI 10.1016/S0006-3495(95)80066-4; LAURENT TC, 1967, BIOCHIM BIOPHYS ACTA, V136, P191, DOI 10.1016/0304-4165(67)90063-3; LEHRER RI, 1985, J VIROL, V54, P467, DOI 10.1128/JVI.54.2.467-472.1985; LEHRER RI, 1985, INFECT IMMUN, V49, P207, DOI 10.1128/IAI.49.1.207-211.1985; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEHRER RI, 1986, INFECT IMMUN, V52, P902, DOI 10.1128/IAI.52.3.902-904.1986; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; LIU YP, 1993, J AM CHEM SOC, V115, P708, DOI 10.1021/ja00055a047; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NAGAWA Y, 1991, J AM CHEM SOC, V113, P7237, DOI 10.1021/ja00019a022; NIR S, 1982, BIOCHIM BIOPHYS ACTA, V688, P275, DOI 10.1016/0005-2736(82)90604-6; NIR S, 1980, BIOCHEMISTRY-US, V19, P6030, DOI 10.1021/bi00567a013; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; PARDI A, 1988, J MOL BIOL, V201, P625, DOI 10.1016/0022-2836(88)90643-2; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; RANDLE CL, 1969, BIOCHIM BIOPHYS ACTA, V187, P214, DOI 10.1016/0005-2760(69)90030-7; SCHANCK A, 1993, BIOCHEM BIOPH RES CO, V195, P654, DOI 10.1006/bbrc.1993.2095; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SHIN KH, 1995, BBA-BIOMEMBRANES, V1238, P42, DOI 10.1016/0005-2736(95)00111-F; STRICKLAND KP, 1973, FORM FUNCTION PHOSPH, P9; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TYTLER EM, 1995, BIOCHEMISTRY-US, V34, P4393, DOI 10.1021/bi00013a031; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; WILDE CG, 1989, J BIOL CHEM, V264, P11200; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; WIMLEY WC, 1993, ANAL BIOCHEM, V213, P213, DOI 10.1006/abio.1993.1411	45	125	134	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24224	24233		10.1074/jbc.272.39.24224	http://dx.doi.org/10.1074/jbc.272.39.24224			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305875	hybrid			2022-12-25	WOS:A1997XY51500026
J	Kuroki, DW; Minden, A; Sanchez, I; Wattenberg, EV				Kuroki, DW; Minden, A; Sanchez, I; Wattenberg, EV			Regulation of a c-Jun amino-terminal kinase stress-activated protein kinase cascade by a sodium-dependent signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR PROMOTER; PALYTOXIN; PHOSPHORYLATION; DOMAIN; ERK; ONCOPROTEIN; CYTOKINES; CLONING; BINDS; MAPKS	Palytoxin is a novel skin tumor promoter that does not activate protein kinase C. Previous studies demonstrated that palytoxin stimulates a sodium-dependent signaling pathway that activates the c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK) in Swiss 3T3 fibroblasts. In this study we show that a JNK kinase known as the stress-activated protein kinase/extracellular signal-regulated kinase-1 (SEK1) plays an important role in the regulation of JNK by palytoxin. We found that palytoxin stimulates the sustained activation of both JNK and SEK1 in COS7 and HeLa cells. Transiently expressed SEK1 isolated from palytoxin-treated cells can phosphorylate and activate JNK, which, in turn, can phosphorylate c-Jun, Furthermore, expression of a dominant negative mutant of SEK1 blocks activation of JNK by palytoxin, Sodium appears to play an important role in the regulation of JNK and SEK1 by palytoxin. Activation of JNK and SEK1 by palytoxin, but not anisomycin, requires extracellular sodium, Complementary studies showed that the sodium ionophore gramicidin can mimic palytoxin by regulating JNK and SEK1 through a sodium-dependent mechanism. Collectively, these results demonstrate that palytoxin stimulates a sodium-dependent signaling pathway that activates the SEK1/JNK/c-Jun protein kinase cascade.	UNIV MINNESOTA,DIV ENVIRONM & OCCUPAT HLTH,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	University of Minnesota System; University of Minnesota Twin Cities; Columbia University; Harvard University					NATIONAL CANCER INSTITUTE [R29CA072498] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72498-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CORPUZ GP, 1995, P INT S CIG MAR NAT, P143; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUBOURDIEU DJ, 1992, TOXICOL APPL PHARM, V116, P47, DOI 10.1016/0041-008X(92)90143-G; EAN J, 1996, J BIOL CHEM, V271, P2886; FUJIKI H, 1986, CARCINOGENESIS, V7, P707, DOI 10.1093/carcin/7.5.707; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HABERMANN E, 1989, TOXICON, V27, P1171, DOI 10.1016/0041-0101(89)90026-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kuroki DW, 1996, CANCER RES, V56, P637; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOORE RE, 1971, SCIENCE, V172, P495, DOI 10.1126/science.172.3982.495; MOORE RE, 1985, PROGR CHEM ORGANIC N, V48, P81; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; WATTENBERG EV, 1987, CANCER RES, V47, P4618; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	40	38	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23905	23911		10.1074/jbc.272.38.23905	http://dx.doi.org/10.1074/jbc.272.38.23905			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295340	hybrid			2022-12-25	WOS:A1997XX38100065
J	Nishikawa, T; Lee, ISM; Shiraishi, N; Ishikawa, T; Ohta, Y; Nishikimi, M				Nishikawa, T; Lee, ISM; Shiraishi, N; Ishikawa, T; Ohta, Y; Nishikimi, M			Identification of S100b protein as copper-binding protein and its suppression of copper-induced cell damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; METAL-IONS; DISEASE; ALBUMIN; CERULOPLASMIN; SEQUENCE; INJURY; FLUID; SERUM; ALPHA	We have isolated from bovine brain a protein with a high capacity to inhibit the copper ion-catalyzed oxidation of L-ascorbate and identified it as S100b protein, an EF-hand calcium-binding protein, by sequencing its proteolytic peptides. Copper binding studies showed that this protein has four copper binding sites per dimeric protein molecule with a dissociation constant of 0.46 mu M and that in the presence of L-ascorbate, copper ions bind to a total of six binding sites with a great increase in affinity. Furthermore, we examined whether S100b protein can prevent copper-induced cell damage. Bovine S100b protein was found to suppress dose-dependently the hemolysis of mouse erythrocytes induced by CuCl2. We transformed Escherichia coli cells with pGEX-5X-3 vector containing a cDNA for rat S100b protein, so that this protein could be expressed as a fusion protein with glutathione S-transferase. The transformed cells were demonstrated to be markedly resistant to a treatment with CuCl2 plus H2O2 as compared with the control cells expressing glutathione S-transferase alone. These results indicate that S100b protein does suppress oxidative cell damage by sequestering copper ions.	WAKAYAMA MED COLL,DEPT BIOCHEM,WAKAYAMA 640,JAPAN	Wakayama Medical University								BAUDIER J, 1986, J BIOL CHEM, V261, P8192; Buettner G R, 1986, Free Radic Res Commun, V1, P349, DOI 10.3109/10715768609051638; CAFFREY JM, 1990, BIOL TRACE ELEM RES, V25, P11, DOI 10.1007/BF02990259; CHEVION M, 1993, P NATL ACAD SCI USA, V90, P1102, DOI 10.1073/pnas.90.3.1102; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; EVANS PJ, 1984, FREE RADICAL RES COM, V7, P55; GUTTERIDGE JMC, 1986, BIOCHIM BIOPHYS ACTA, V869, P119, DOI 10.1016/0167-4838(86)90286-4; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1977, BIOCHIM BIOPHYS ACTA, V494, P222, DOI 10.1016/0005-2795(77)90150-7; IYER KS, 1978, BIOCHEM J, V169, P61, DOI 10.1042/bj1690061; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KIMURA S, 1984, NEUROCHEM INT, V6, P513, DOI 10.1016/0197-0186(84)90123-2; KLINGMAN D, 1988, TIBS, V13, P437; KUWANO R, 1984, NUCLEIC ACIDS RES, V12, P7455, DOI 10.1093/nar/12.19.7455; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LVSTAD RA, 1984, INT J BIOCHEM, V16, P155; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; NISHIKIMI M, 1987, BIOCHEM INT, V14, P111; PALL HS, 1987, LANCET, V2, P238; SHAROYAN SG, 1977, BIOCHIM BIOPHYS ACTA, V493, P478, DOI 10.1016/0005-2795(77)90204-5; SIMPSON JA, 1990, FREE RADICAL RES COM, V10, P303, DOI 10.3109/10715769009149899; Yagi K, 1996, BIOCHEM BIOPH RES CO, V219, P486, DOI 10.1006/bbrc.1996.0260	24	76	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23037	23041		10.1074/jbc.272.37.23037	http://dx.doi.org/10.1074/jbc.272.37.23037			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287301	hybrid			2022-12-25	WOS:A1997XV74400012
J	Velasco, M; DiazGuerra, MJM; MartinSanz, P; Alvarez, A; Bosca, L				Velasco, M; DiazGuerra, MJM; MartinSanz, P; Alvarez, A; Bosca, L			Rapid up-regulation of I kappa B beta and abrogation of NF-kappa B activity in peritoneal macrophages stimulated with lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; DNA-BINDING; ACTIVATION; ALPHA; PHOSPHORYLATION; INDUCTION; DEGRADATION; EXPRESSION	Lipopolysaccharide (LPS) administration to mice elicited the activation of nuclear factor kappa B (NF-kappa B) in several tissues including liver and macrophages. Maximal activation was observed 1 h after treatment but declined at 3 and 6 h. The levels of I kappa B alpha and I kappa B beta were analyzed during this period in an attempt to correlate NF-kappa B activity with I kappa B resynthesis. Degradation of I kappa B alpha was very rapid and was followed by recovery 1 h after LPS administration. I kappa B beta degradation, which has been associated with persistent NF-kappa B activation, was complete at 1 h. However, a rapid recovery of I kappa B beta in these tissues was observed at 3 h in parallel with the abrogation of NF-kappa B activity. Immunolocalization of newly synthesized I kappa B beta by confocal microscopy revealed its preferential accumulation in the cytosol. Analysis of I kappa B beta by Western blot using high resolution polyacrylamide gel electrophoresis showed the presence of two bands in cytosolic extracts of LPS-treated macrophages at 3 h, but only one band with the same mobility as the control was detected at 6 h. Moreover, treatment of extracts of resynthesized I kappa B beta with alkaline phosphatase resulted in the accumulation of the protein of slightly higher electrophoretic mobility, indicating the prevalence of a rapid phosphorylation of the newly synthesized I kappa B beta. At the mRNA level, up-regulation of I kappa B beta was observed in macrophages stimulated for 1 h with LPS. When the effect of pro-inflammatory cytokines was investigated, tumor necrosis factor alpha, but not interleukin-1 or interferon-gamma, promoted an important degradation of I kappa B beta followed by an increase in the mRNA at 1 h. These results suggest the existence of LPS and tumor necrosis factor gamma-specific pathways involved in a rapid I kappa B beta degradation and resynthesis and might explain the transient period of activation of NF-kappa B in these tissues upon stimulation with these factors. This rapid control of NF-kappa B function may contribute to the attenuation of the inflammatory response of these cells.	UNIV COMPLUTENSE MADRID,FAC FARM,INST BIOQUIM,CSIC,E-28040 MADRID,SPAIN; UNIV COMPLUTENSE MADRID,FAC FARM,CTR CITOMETRIA FLUJO,E-28040 MADRID,SPAIN	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid			Díaz-Guerra, María José M/M-2855-2014; Bosca, Lisardo/A-2059-2008; Martín-Sanz, Paloma/K-1303-2014; Alvarez-Barrientos, Alberto/L-9299-2014	Díaz-Guerra, María José M/0000-0003-3843-3912; Bosca, Lisardo/0000-0002-0253-5469; Alvarez-Barrientos, Alberto/0000-0003-4761-0212				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOPP E, 1994, ADV IMMUNOL, V58, P1; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Weil R, 1997, J BIOL CHEM, V272, P9942; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; XIE QW, 1994, J BIOL CHEM, V269, P4705	39	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23025	23030		10.1074/jbc.272.37.23025	http://dx.doi.org/10.1074/jbc.272.37.23025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287299	hybrid			2022-12-25	WOS:A1997XV74400010
J	Besancon, M; Simon, A; Sachs, G; Shin, JM				Besancon, M; Simon, A; Sachs, G; Shin, JM			Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SECRETION; ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGES; MEMBRANE TOPOLOGY; ATPASE; OMEPRAZOLE; NA+,K+-ATPASE; H+,K+-ATPASE; INHIBITION	The vesicular gastric H,K-ATPase catalyzes an electroneutral H for K exchange allowing acidification of the intravesicular space, There is a total of 28 cysteines present in the alpha subunit of the gastric H,K-ATPase, of which 10 are found in the predicted transmembrane segments and their connecting loop, and 9 are present in the beta subunit, of which 6 are disulfide-linked, To determine which of these was accessible to extracytoplasmic attack, the enzyme was inhibited by four different substituted 2-pyridylmethylsulfinyl benzimidazoles, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole (omeprazole), 2-[(4-trifluoroethoxy-3-methyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole (lansoprazole), 5-difluoromethoxy-2-[3,4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole (pantoprazole), and 2-[(4-(3-methoxypropoxy)-3-methyl)-2-pyridyl)methylsulfinyl]-1H-benzimidazole (rabeprazole), under acid transporting conditions, All of these compounds are weak bases that accumulate in the acidic space generated by the pump and undergo an acid catalyzed rearrangement to a cationic sulfenamide, which forms disulfides with accessible cysteines, The relative rates of acid activation of these compounds corresponded to the relative rates of inhibition of ATPase activity and acid transport, Fragmentation of the enzyme by trypsin followed by SDS-polyacrylamide gel electrophoresis showed that omeprazole bound covalently to one of the two cysteines in the domains containing the fifth and sixth transmembrane segments and their extracytoplasmic loop and to cysteine 892 in the loop between the seventh and eighth transmembrane segments, but inhibition correlated with the reaction with cysteines in the fifth and sixth domain, Lansoprazole bound to the cysteines in these two domains as well as to cysteine 321 toward the extracytoplasmic end of the third transmembrane segments, Pantoprazole bound only to either cysteine 813 or 822 in the fifth and sixth transmembrane region, The inhibition of Rabeprazole correlated also with its binding to this part of the protein, but this compound continued to bind after full inhibition, eventually binding also to cysteines 321 and 892. No binding was found to any of the cysteines in the seventh to tenth transmembrane segments, Thermolysin digestion of the isolated omeprazole-labeled fifth and sixth transmembrane pair showed that cysteine 813 was the site of labeling. It is concluded that binding of these sided reagents to cysteine 813 in the loop between transmembrane (TM)5 and TM6 is sufficient for inhibition of ATPase activity and acid transport by the gastric acid pump, Of the 10 cysteines present in the membrane and extracytoplasmic domain, only three are exposed sufficiently to allow reactivity with these cationic thiol reagents. The binding to cysteine 813 defines the location of the extracytoplasmic loop between TM5 and TM6 and places the carboxylic acids 820 and 824 conserved between the gastric H,K- and the Na,K-ATPases in TM6, consistent with their assumed role in cation binding.	VET ADM WADSWORTH HOSP CTR, LOS ANGELES, CA 90073 USA; UNIV CALIF LOS ANGELES, DEPT PHYSIOL & MED, LOS ANGELES, CA 90073 USA; BYK GULDEN LOMBERG GMBH, D-78467 CONSTANCE, GERMANY	University of California System; University of California Los Angeles; Altana					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK017294, R01DK040615, R37DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40615, DK41301, DK17294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRANDSTROM A, 1989, ACTA CHEM SCAND, V43, P536, DOI 10.3891/acta.chem.scand.43-0536; ESMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1112, P215, DOI 10.1016/0005-2736(92)90394-2; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FRYKLUND J, 1988, BIOCHEM PHARMACOL, V37, P2543, DOI 10.1016/0006-2952(88)90244-4; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; KAPLAN JH, 1991, SOC GEN PHY, V46, P117; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KEELING DJ, 1987, BIOCHEM PHARMACOL, V36, P339, DOI 10.1016/0006-2952(87)90291-7; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LINDBERG P, 1986, J MED CHEM, V29, P1327, DOI 10.1021/jm00158a001; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LORENTZON P, 1985, BIOCHIM BIOPHYS ACTA, V817, P25, DOI 10.1016/0005-2736(85)90064-1; LORENTZON P, 1987, BIOCHIM BIOPHYS ACTA, V897, P41, DOI 10.1016/0005-2736(87)90313-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSENKO S, 1997, J BIOL CHEM, V272, P5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Mahanty SK, 1996, J BIOL CHEM, V271, P367, DOI 10.1074/jbc.271.1.367; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; Padmanabha K P, 1994, Symp Soc Exp Biol, V48, P33; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; RABON E, 1978, BIOCHEMISTRY-US, V17, P3345, DOI 10.1021/bi00609a027; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RABON EC, 1990, J BIOL CHEM, V265, P19594; Rabon EC, 1996, J BIOL CHEM, V271, P32137, DOI 10.1074/jbc.271.50.32137; RABON EC, 1988, METHOD ENZYMOL, V157, P649; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; ROBINSON JD, 1974, FEBS LETT, V38, P325, DOI 10.1016/0014-5793(74)80083-9; SACHS G, 1977, REV PHYSIOL BIOCH P, V79, P133, DOI 10.1007/BFb0037090; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; Sachs G, 1993, ALIMENT PHARM THER S, V7, P4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONER W, 1971, ANGEW CHEM INT EDIT, V10, P882, DOI 10.1002/anie.197108821; SCOTT DR, 1993, BIOCHIM BIOPHYS ACTA, V1146, P73, DOI 10.1016/0005-2736(93)90340-6; SENNBILFINGER J, 1987, J ORG CHEM, V52, P4582, DOI 10.1021/jo00229a027; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; Singh P, 1991, Drug Des Deliv, V7, P131; SMITH DL, 1993, J BIOL CHEM, V268, P22469; Terauchi H, 1997, J MED CHEM, V40, P313, DOI 10.1021/jm9605593; VANDERHIJDEN HTWM, 1990, J MEMBRANE BIOL, V114, P245, DOI 10.1007/BF01869218; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	47	216	241	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22438	22446		10.1074/jbc.272.36.22438	http://dx.doi.org/10.1074/jbc.272.36.22438			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278394	hybrid			2022-12-25	WOS:A1997XV49200014
J	Chen, LH; Marechal, V; Moreau, J; Levine, AJ; Chen, JD				Chen, LH; Marechal, V; Moreau, J; Levine, AJ; Chen, JD			Proteolytic cleavage of the mdm2 oncoprotein during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-LIKE PROTEASE; DEATH GENE CED-3; CELL-DEATH; TRANSCRIPTIONAL ACTIVATION; P53 PROTEIN; POLY(ADP-RIBOSE) POLYMERASE; P53-ASSOCIATED PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ICE/CED-3 PROTEASE	The mdm2 oncogene encodes a 90-kDa protein that can bind to the p53 tumor suppressor protein and negatively regulate its functions In transcription, cell cycle arrest, and apoptosis. The mdm2 gene is frequently amplified in human sarcomas, which may be responsible for the malignant transformations. We present evidence that the mdm2 oncoprotein is cleaved by an interleukin 1 beta-converting enzyme-like protease (caspase) during p53-mediated apoptosis. The protease that cleaves mdm2 has a specificity similar to that of CPP32 (caspase-3), and recombinant caspase-3 is able to cleave mdma in vitro. The protease cleavage site has been mapped to between residue 361 and 362 of human mdm2. The proteolytic cleavage removes the COOH-terminal RING finger domain of mdm2, resulting in the loss of RNA binding activity. The p53 binding and inhibition functions of mdm2 are not affected by the cleavage. The cleavage site sequence of mdm2 is evolutionarily conserved, suggesting that regulation by caspase cleavage during apoptosis is an important feature of mdm2.	LOUISIANA STATE UNIV,MED CTR,STANLEY S SCOTT CANC CTR,DEPT MICROBIOL IMMUNOL & PARASITOL,NEW ORLEANS,LA 70112; HOP ROTHSCHILD,MICROBIOL SERV,F-75571 PARIS,FRANCE; UNIV DENIS DIDEROT,INST JACQUES MONOD,EQUIPE EMBRYOL MOL,F-75251 PARIS,FRANCE; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Louisiana State University System; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Princeton University			marechal, vincent/P-7719-2017		NATIONAL CANCER INSTITUTE [R01CA072915] Funding Source: NIH RePORTER; NCI NIH HHS [CA72915-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARDONCARDO C, 1994, CANCER RES, V54, P794; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LENG P, 1995, ONCOGENE, V10, P1275; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LUNA RMD, 1995, NATURE, V378, P203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	63	114	115	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22966	22973		10.1074/jbc.272.36.22966	http://dx.doi.org/10.1074/jbc.272.36.22966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278461	hybrid			2022-12-25	WOS:A1997XV49200084
J	Skorey, K; Ly, HD; Kelly, J; Hammond, M; Ramachandran, C; Huang, Z; Gresser, MJ; Wang, QP				Skorey, K; Ly, HD; Kelly, J; Hammond, M; Ramachandran, C; Huang, Z; Gresser, MJ; Wang, QP			How does alendronate inhibit protein-tyrosine phosphatases?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CONTAINING PEPTIDES; FLUOROMETRIC ASSAY; HYDROGEN-PEROXIDE; REDOX REGULATION; BONE; OSTEOPOROSIS; CELLS; BISPHOSPHONATES; DITHIOTHREITOL	Alendronate (4-amino-1-hydroxybutylidene 1,l-bisphosphonate) is a drug used in the treatment of osteoporosis and other bone diseases. The inhibition of protein-tyrosine phosphatases (PTPs) by alendronate suggests that PTPs may be molecular targets, As a clear understanding of the inhibition mechanism is lacking, our aim was to analyze the mechanism to provide further insight into its therapeutic effect. We show here that the inhibition of PTPs by alendronate in the presence of calcium followed first-order kinetic behavior, and kinetic parameters for the process were determined, Evidence is presented that the inhibition by alendronate/calcium is active site-directed. However, this process was very sensitive to assay constituents such as EDTA and dithiothreitol, Furthermore, the inhibition of PTPs by alendronate/calcium was eliminated by the addition of catalase, These observations suggest that a combination of alendronate, metal ions, and hydrogen peroxide is responsible for the inhibition of PTPs, The individual effects of alendronate, calcium, or hydrogen peroxide on the inactivation of CD45 were determined. Electrospray ionization mass spectrometry demonstrated that the mass of PTP1B increased by 34 +/- 2 units after the enzyme was inactivated with alendronate/calcium, due to the oxidization of the catalytic cysteine to sulfinic acid (Cys-SO2H). The inhibited PTP1B could be partially reactivated by treatment with reducing agents such as hydroxylamine (NH2OH) and N,N'-dimethyl-N,N'-bis-(mercaptoacetyl)hydrazine, indicating the presence of other oxidized forms such as sulfenic acid (Cys-SOH). This further confirms that the inhibition is the result of oxidation of the catalytic cysteine, The relevance of this oxidative inhibition mechanism in a biological system is discussed.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOL BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company; Merck & Company								ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; DOWSON RMC, 1987, DATA BIOCH RES, P404; Endo N, 1996, J BONE MINER RES, V11, P535; GALLAGHER KE, 1993, BIOCHEM SOC T, V21, P98; GATTI D, 1994, J BONE MINER RES, V9, P1833; Gresser M. J., 1987, ADV PROTEIN PHOSPHAT, V4, P35; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P115; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KANIS JA, 1995, OSTEOPOROSIS INT, V5, P1, DOI 10.1007/BF01623652; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRIEGER NS, 1983, ENDOCRINOLOGY, V113, P324, DOI 10.1210/endo-113-1-324; LAMSON ML, 1984, INT J PHARM, V21, P143, DOI 10.1016/0378-5173(84)90089-9; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756-3282(96)00182-2; MEVKH AT, 1985, ANAL BIOCHEM, V150, P91, DOI 10.1016/0003-2697(85)90444-0; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NARDELLI M, 1983, INORG CHIM A-BIOINOR, V80, P259, DOI 10.1016/S0020-1693(00)91293-3; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OSTOVIC D, 1993, PHARMACEUT RES, V10, P470, DOI 10.1023/A:1018969112754; PERCIVAL MD, 1992, EUR J BIOCHEM, V210, P109, DOI 10.1111/j.1432-1033.1992.tb17397.x; Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722; RODAN GA, 1994, ANNU REP MED CHEM, V29, P275; SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539; Sawyer DT, 1996, ACCOUNTS CHEM RES, V29, P409, DOI 10.1021/ar950031c; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; SHIBANUMA M, 1988, ONCOGENE, V3, P17; Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961; STANKIEWICZ PJ, 1987, BIOCHEMISTRY-US, V26, P1264, DOI 10.1021/bi00379a010; STONE RL, 1994, J BIOL CHEM, V269, P31323; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Taher MM, 1996, BIOCHEM MOL BIOL INT, V40, P159; TROTTA PP, 1974, J BIOL CHEM, V249, P1915; Vepa S, 1997, FREE RADICAL BIO MED, V22, P25, DOI 10.1016/S0891-5849(96)00241-9; WANG Q, 1997, IN PRESS BIOCH PHARM; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhao F, 1996, PHARMACEUT RES, V13, P931, DOI 10.1023/A:1016021716274	41	63	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22472	22480		10.1074/jbc.272.36.22472	http://dx.doi.org/10.1074/jbc.272.36.22472			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278398	hybrid			2022-12-25	WOS:A1997XV49200018
J	Weiss, JN				Weiss, JN			The Hill equation revisited: uses and misuses	FASEB JOURNAL			English	Review						ligands; receptors; binding; ligand-receptor interaction; ion channels; enzymes		The Hill coefficient is commonly used to estimate the number of ligand molecules that are required to bind to a receptor to produce a functional effect. However, for a receptor dth more than one ligand binding site, the Hill equation does not reflect a physically possible reaction scheme; only under the very specific condition of marked positive cooperativity does the Hill coefficient accurately estimate the number of binding sites. The Hill coefficient is best thought of as an ''interaction'' coefficient, reflecting the extent of cooperativity among multiple ligand binding sites. Several relatively simple, physically plausible reaction schemes are shown here to produce a variety of ligand dose-response curve phenotypes more appropriately suited to modeling ligand-receptor interactions, especially if independent information about the stochiometry of the ligand-receptor interaction is available.			Weiss, JN (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,DEPT MED,3641 MRL BLDG,LOS ANGELES,CA 90095, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052319, R01HL036729] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL52319, R01HL36729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; ENGEL PC, 1996, NONLINEAR KINETICS C; FROMM HJ, 1996, INITIAL RATE ENZYME, P236; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; WALZ D, 1988, CELL BIOPHYS, V12, P13, DOI 10.1007/BF02918348	9	654	664	7	123	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					835	841		10.1096/fasebj.11.11.9285481	http://dx.doi.org/10.1096/fasebj.11.11.9285481			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285481				2022-12-25	WOS:A1997XT79000002
J	Atkin, AL; Schenkman, LR; Eastham, M; Dahlseid, JN; Lelivelt, MJ; Culbertson, MR				Atkin, AL; Schenkman, LR; Eastham, M; Dahlseid, JN; Lelivelt, MJ; Culbertson, MR			Relationship between yeast polyribosomes and Upf proteins required for nonsense mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TURNOVER; TRANSLATIONAL TERMINATION CODON; GENE; IDENTIFICATION; DEGRADATION; STABILITY; COMPONENT; PATHWAY; CELLS; DNA	In yeast, the accelerated rate of decay of nonsense mutant mRNAs, called nonsense-mediated mRNA decay, requires three proteins, Upf1p, Upf2p, and Upf3p. Single, double, and triple disruptions of the UPF genes had nearly identical effects on nonsense mRNA accumulation, suggesting that the encoded proteins function in a common pathway, We examined the distribution of epitope-tagged versions of Upf proteins by sucrose density gradient fractionation of soluble lysates and found that all three proteins co-distributed with 80 S ribosomal particles and polyribosomes. Treatment of lysates with RNase A caused a coincident collapse of polyribosomes and each Upf protein into fractions containing 80 S ribosomal particles, as expected for proteins that are associated with polyribosomes. Mutations in the cysteine-rich (zinc finger) and RNA helicase domains of Upf1p caused loss of function, but the mutant proteins remained polyribosome-associated. Density gradient profiles for Upf1p were unchanged in the absence of Upf3p, and although similar, were modestly shifted to fractions lighter than those containing polyribosomes in the absence of Upf2p. Upf2p shifted toward heavier polyribosome fractions in the absence of Upf1p and into fractions containing 80 S particles and lighter fractions in the absence of Upf3p, Our results suggest that the association of Upf2p with polyribosomes typically found in a wild-type strain depends on the presence and opposing effects of Upf1p and Upf3p.	UNIV WISCONSIN,LAB GENET & MOL BIOL,MADISON,WI 53706; UNIV NEBRASKA,SCH BIOL SCI,LINCOLN,NE 68588	University of Wisconsin System; University of Wisconsin Madison; University of Nebraska System; University of Nebraska Lincoln				Atkin, Audrey/0000-0001-5893-1068	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026217] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26217] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKIN AL, 1995, MOL BIOL CELL, V6, P611; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; CZAPLINSKI K, 1995, RNA, V1, P610; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN LL, 1988, J MOL BIOL, V200, P321, DOI 10.1016/0022-2836(88)90244-6; GREY M, 1992, CURR GENET, V22, P83, DOI 10.1007/BF00351746; He F, 1997, MOL CELL BIOL, V17, P1580, DOI 10.1128/MCB.17.3.1580; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; KAUFER NF, 1983, NUCLEIC ACIDS RES, V11, P3123; KLESSIG DF, 1983, PLANT MOL BIOL REP, V1, P12; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LEE BS, 1995, P NATL ACAD SCI USA, V92, P10354, DOI 10.1073/pnas.92.22.10354; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; Weng YM, 1996, MOL CELL BIOL, V16, P5491, DOI 10.1128/mcb.16.10.5491	27	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22163	22172		10.1074/jbc.272.35.22163	http://dx.doi.org/10.1074/jbc.272.35.22163			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268361	Green Published, hybrid			2022-12-25	WOS:A1997XT85000073
J	Hayflick, JS; Stine, J; Fox, R; Hoekstra, D; Gallatin, WM				Hayflick, JS; Stine, J; Fox, R; Hoekstra, D; Gallatin, WM			Functional mapping of the cytoplasmic region of intercellular adhesion molecule-3 reveals important roles for serine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESENTING B-CELLS; KINASE C-THETA; HELPER T-CELLS; TYROSINE PHOSPHORYLATION; AMINO-ACIDS; I-DOMAIN; PROTEIN; ANTIGEN; ICAM-3; EXPRESSION	Intercellular adhesion molecule-3 (ICAM-3), a ligand for beta(2) integrins, elicits a variety of activation responses in lymphocytes, We describe a functional mapping study that focuses on the 37-residue cytoplasmic region of ICAM-3. Carboxyl-terminal truncations delineated portions involved in T cell antigen receptor costimulation, homotypic aggregation, and cellular spreading, Truncation of the membrane distal 25 residues resulted in loss of T cell antigen receptor costimulation as determined by interleukin 2 secretion, Aggregation and cell spreading were sensitive to truncation of the membrane distal and proximal thirds of the cytoplasmic portion. Phosphoamino acid analysis revealed that ICAM-3 from activated cells contained phosphoserine and phosphopeptide mapping identified Ser(489) as a site of phosphorylation in vivo, Mutation of Ser(489) or Ser(515) to alanine blocked interleukin 2 secretion, aggregation and cell spreading, while mutation of other serine residues affected only a subset of functions, Ser(489) was a phosphorylation site in vitro for recombinant protein kinase C theta. Finally, treatment of Jurkat cells with chelerythrine chloride, a protein kinase C inhibitor, prevented ICAM-3-triggered spreading. This study delineates separable regions and amino acid residues within the cytoplasmic portion of ICAM-3 that are important for T cell function.			Hayflick, JS (corresponding author), ICOS CORP, 22021 20TH AVE SE, BOTHELL, WA 98021 USA.							ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Binnerts ME, 1996, J BIOL CHEM, V271, P9962, DOI 10.1074/jbc.271.17.9962; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CHANG JD, 1993, J BIOL CHEM, V268, P14208; CHIRATHAWORN C, 1995, J IMMUNOL, V155, P5479; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JUAN M, 1994, J EXP MED, V179, P1747, DOI 10.1084/jem.179.6.1747; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; KUPFER A, 1987, J EXP MED, V165, P1565, DOI 10.1084/jem.165.6.1565; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LORENZ HM, 1993, CELL IMMUNOL, V147, P110, DOI 10.1006/cimm.1993.1052; LOZANO F, 1992, EUR J BIOCHEM, V203, P321, DOI 10.1111/j.1432-1033.1992.tb19862.x; MITCHISON A, 1995, IMMUNOLOGIST, V3, P259; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PHATAK PD, 1994, J CELL PHYSIOL, V159, P365, DOI 10.1002/jcp.1041590220; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SKUBITZ KM, 1995, J IMMUNOL, V154, P2888; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VILELLA R, 1990, TISSUE ANTIGENS, V36, P203, DOI 10.1111/j.1399-0039.1990.tb01830.x; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P	38	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22207	22214		10.1074/jbc.272.35.22207	http://dx.doi.org/10.1074/jbc.272.35.22207			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268366	hybrid			2022-12-25	WOS:A1997XT85000078
J	Walsh, DM; Lomakin, A; Benedek, GB; Condron, MM; Teplow, DB				Walsh, DM; Lomakin, A; Benedek, GB; Condron, MM; Teplow, DB			Amyloid beta-protein fibrillogenesis - Detection of a protofibrillar intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL FRAGMENT; ALZHEIMERS-DISEASE; CEREBRAL-HEMORRHAGE; PEPTIDE; AGGREGATION; CONFORMATION; PRECURSOR; GROWTH; ZINC; PURIFICATION	Fibrillogenesis of the amyloid beta-protein (A beta) is a seminal pathogenetic event in Alzheimer's disease, Inhibiting fibrillogenesis is thus one approach toward disease therapy, Rational design of fibrillogenesis inhibitors requires elucidation of the stages and kinetics of A beta fibrillogenesis, We report results of studies designed to examine the initial stages of A beta oligomerization, Size exclusion chromatography, quasielastic light scattering spectroscopy, and electron microscopy were used to characterize fibrillogenesis intermediates, After dissolution in 0.1 M Tris-HCl, pH 7.4, and removal of preexistent seeds, A beta chromatographed almost exclusively as a single peak, The molecules composing the peak had average hydrodynamic radii of 1.8 +/- 0.2 nm, consistent with the predicted size of dimeric A beta. Over time, an additional peak, with a molecular weight >100,000, appeared, This peak contained predominantly curved fibrils, 6-8 nm in diameter and <200 nm in length, which we have termed ''protofibrils.'' The kinetics of protofibril formation and disappearance are consistent with protofibrils being intermediates in the evolution of amyloid fibers, Protofibrils appeared during the polymerization of A beta-(1-40), A beta-(1-42), and A beta-(1-40)-Gln(22), peptides associated with both sporadic and inherited forms of Alzheimer's disease, suggesting that protofibril formation may be a general phenomenon in A beta fibrillogenesis. If so, protofibrils could be attractive targets for fibrillogenesis inhibitors.	BRIGHAM & WOMENS HOSP, BIOPOLYMER LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROL NEUROSCI, BOSTON, MA 02115 USA; MIT, DEPT PHYS, CAMBRIDGE, MA 02139 USA; MIT, CTR MAT SCI & ENGN, CAMBRIDGE, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NEI NIH HHS [5R37EY05127] Funding Source: Medline; NIA NIH HHS [1P01AG14366] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY005127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014366] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, J BIOL CHEM, V269, P12152; Chan W, 1996, BIOCHEMISTRY-US, V35, P7123, DOI 10.1021/bi952852v; Clements A, 1996, J NEUROCHEM, V66, P740; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; COHEN RJ, 1975, IMMUNOCHEMISTRY, V12, P349, DOI 10.1016/0019-2791(75)90188-3; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Esler WP, 1996, J NEUROCHEM, V66, P723; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1994, J BIOL CHEM, V269, P17741; Haass C, 1996, EUR ARCH PSY CLIN N, V246, P118, DOI 10.1007/BF02189111; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IRVINE GB, 1997, IN PRESS ANAL CHEM A; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kametani F, 1995, BRAIN RES, V703, P237, DOI 10.1016/0006-8993(95)01195-1; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; Naslund J, 1996, J NEUROCHEM, V67, P294; Pecora R, 1985, BER BUNSEN PHYS CHEM, DOI DOI 10.1002/BBPC.19870910455; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Soto C, 1996, BIOCHEM J, V314, P701, DOI 10.1042/bj3140701; Teplow DB, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P311; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850	53	916	944	2	89	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22364	22372		10.1074/jbc.272.35.22364	http://dx.doi.org/10.1074/jbc.272.35.22364			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268388	hybrid			2022-12-25	WOS:A1997XT85000100
